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ABSTRACT 
 
Past Endemic Malaria and Adaptive Responses in the Fens and Marshlands of Eastern 
England 
Ross Kendall 
 
 Changes in climate have increased concerns over the return of temperate malaria to 
the United Kingdom. Hence, studies of ancient disease are becoming more relevant for 
future health predictions in areas which are under threat of disease re-emergence. Conditions 
were likely ideal for Plasmodium vivax malaria from at least the Roman period, and recent 
research on Anglo-Saxon Fen populations has suggested an indigenous malarial presence. 
The primary aim of this project was to investigate the presence of English malaria in 
archaeological Fen cemetery populations from the Roman, Anglo-Saxon, and later medieval 
periods (c. AD 40-1600), using biomolecular analyses of human bone, and 
palaeopathological analyses via extant published data. A further aim was to investigate 
Masters’ (1987) hypothesis concerning preferential survival of non-collagenous proteins 
(NCPs) within archaeological bone.  
 Indirect evidence for malaria was sought by reassessing archaeological reports for 
osteological evidence of the genetic anaemia β thalassaemia at 13 cemetery sites (five 
Roman, seven Anglo-Saxon, one late medieval) closely associated with the Fens and 
marshlands of Lincolnshire and Cambridgeshire. A palaeodemographic comparison of 30 
Fen (five Roman, 21 Anglo-Saxon, four late medieval) and 31 non-Fen (nine Roman, 18 
Anglo-Saxon, four late medieval) cemetery populations was also undertaken to assess any 
impact of vivax malaria on mortality. Osteological evidence does not support the presence of 
past thalassaemia, with palaeodemographic analysis suggesting an acquired, rather than 
genetic immunity in the Fens. Possible evidence emerged for ‘healthy adaptation’ to the 
increased stresses of Fenland life, and one population provided tentative evidence of 
intrauterine growth restriction, a condition strongly linked to endemic P. vivax. Direct 
evidence was sought by attempting to extract and test anti-malarial antibodies from human 
bone samples from 13 Fen-associated cemetery sites (five Roman, seven Anglo-Saxon, one 
late medieval), encompassing 24 individuals. Bone preservation was assessed in over 200 
samples to provide a baseline for sample selection for biomolecular analysis. 
 Analysis of bone samples proved unsupportive of Masters’ (1987) hypothesis. 
However, a range of endogenous proteins and a possible pathogenic disease marker were 
revealed, as was a correlation between bone preservation and NCP content. Evaluation of 
extraction protocols failed to yield antibodies which, if present, were consistently masked by 
collagen. Consequently, a novel antibody extraction technique has been developed. If 
successful, this could lead to a replicable technique of ancient, reactive antibody isolation, 
which would offer an invaluable new tool in biomolecular palaeopathology. 
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CHAPTER 1: INTRODUCTION 
 
“Severe agues, which the inhabitants are rarely without, whose complexions from those 
distempers become of a dingy yellow colour, and if they survive, are generally afflicted with 
them till summer, and often for several years, so it is not unusual to see a poor man, his 
wife, and whole family of five or six children, hovering over their fire in their hovel, shaking 
with an ague fit all at the same time” (Hasted, 1797:144). 
 
 Malaria is a protozoan disease caused by inoculation of Plasmodium parasites into 
the bloodstream through the bite of an infected anopheline mosquito (Warrell, 2002). 
Malaria is endemic in many regions of the world, with up to 3.4 billion people living at risk 
of infection (Hay et al., 2004). The disease kills over 600,000 people worldwide per year 
World Health Organization, 2013), and has thus been described as being “one of the top 
three killers among communicable diseases” (Sachs and Malaney, 2002:680). 
 Concerns over the return of temperate malaria to the United Kingdom have recently 
been raised based on a number of ecological and environmental changes. These include an 
increased presence of indigenous mosquito species, particularly in urban settings, a recent 
push for wetland restoration projects (e.g., The Great Fen Project), and the elevated average 
temperatures associated with global warming (Lindsay and Thomas, 2001; Willott, 2004; 
Lindsay et al., 2010; Medlock and Vaux 2011; Townroe and Callagham, 2014). Studies of 
past disease are becoming important to future health predictions in areas under threat of 
disease re-emergence resulting from climatic and environmental changes (Greenblatt and 
Spigelman, 2003). 
 The presence and likely endemicity of temperate English malaria between the 16th 
and 19th centuries is well established (Dobson, 1997; Lindsay and Thomas, 2001), supported 
in part by the increased prevalence of seasonal mortality rates in marshland parishes 
(Dobson, 1997). Plasmodium vivax is the most widely distributed species of human 
temperate malaria, with up to 2.6 billion people living at risk of vivax malaria infection (Hay 
et al., 2004; Baird 2007). In antiquity, prior to the availability of prophylactic and curative 
medications, the disease would have had a profoundly negative impact on the health and 
well-being of affected populations, being chronic, debilitating, and potentially fatal, 
especially when comorbid with other commonly encountered pathogens (Dobson, 1997). 
Despite the reservations of some authors (e.g., Bollet 2004; Pinello, 2008) to the contrary, it 
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is highly likely that P. vivax malaria was present, if not endemic, in the marshes and Fens of 
south east and eastern Britain for many centuries prior to the post-medieval period. It seems 
naïve to assume otherwise, given that the climatic, geographic, epidemiological, and 
demographic conditions were all suitable for the transmission of vivax malaria prior to the 
16th century. This study proposes to investigate a number of sources of indirect and direct 
evidence for malaria in British Fenland populations from the Roman to medieval periods. 
 There has been little traditional palaeopathological research performed on vivax 
malaria. This may be surprising, given the likelihood that the disease undoubtedly affected 
so many people in the past. Yet the reason for this dearth of research is relatively simple: 
although vivax malaria can be a chronic, recurrent condition, the disease elicits no direct 
osseous response. There are, therefore, no macroscopically observable skeletal changes that 
can be unequivocally attributed to malarial infection. Research on putative English malaria 
prior to the 16th century has, therefore, concentrated on identifying either direct evidence of 
infection, such as residual ancient P. vivax DNA in bone (e.g., Pinello, 2008), or on indirect 
evidence of malaria, such as attempts to correlate prevalence rates of non-specific skeletal 
stress markers with likely malarious locations (e.g., Gowland and Western, 2012). Indeed, 
the latter has provided compelling evidence for an indigenous malarial presence in British 
antiquity, as suggested by an increased cribra orbitalia prevalence in Anglo-Saxon Fenland 
populations. This condition, which may result from haemolytic anaemia, is one of the most 
commonly observed sequelae of vivax malaria. The aetiology of cribra orbitalia, however, 
is complex. For instance, megaloblastic anaemia resulting from concurrent parasitic 
infection may also influence its development (Bathurst, 2005; Walker et al., 2009). 
 The lack of malaria-specific skeletal changes forces a reliance on biomolecular 
analysis in the search for direct evidence of past temperate Plasmodium vivax malaria. The 
clinically observed longevity of anti-malarial antibodies in life (Wipasa et al., 2010) and the 
high affinity of antibodies for adherence to, and concentration within bone mineral 
(Omelyanenko et al., 2013), suggests that immunological analysis may be the most likely 
method of successfully detecting the disease in bone. Extraction of endogenous antibodies 
has advantages over the search for exogenous antigens or pathogenic ancient DNA (aDNA), 
since malaria-specific antibodies can circulate for an extended period (Wipasa et al., 2010), 
long after pathogenic biomolecules have been removed from the body. As long as antibodies 
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are retained in the bone, they represent a far more stable target for analysis than pathogenic 
molecules, which are, by nature, transitory. This assumes, of course, that the antibodies are 
indeed extant in the archaeological samples, and that they can be successfully extracted and 
identified.  
 
1.1: Research aims 
 The main aim of this study was to detect direct evidence of malaria by extracting 
immunoreactive antibodies from archaeological human bone of individuals inhabiting likely 
malarious areas. These areas comprise the Lincolnshire and Cambridgeshire Fens and 
associated marshlands from the Roman to late medieval periods (c. AD 40 to 1600). 
Successfully extracted antibodies could then be tested against vivax malaria antigens using 
commercially available immunological tests (e.g., Enzyme-linked Immunosorbent Assay, or 
ELISA) in order to detect the presence of the disease.   
 Reliable and replicable immunological testing of the type proposed in this study 
requires the extraction of well-preserved, immunoreactive archaeological antibodies. This 
represents a considerable challenge, with only a handful of publications reporting successful 
antibody/antigen reactions (e.g., Kolman et al., 1999; Torres et al., 2002; Schmidt-Schultz 
and Schultz, 2004). Each of these used different protein extraction and characterisation 
techniques, demonstrating a clear lack of standardisation in methodologies aimed at 
extracting immunoglobulins from ancient bones. A major problem with utilizing 
archaeological antibodies, which affects all biomolecular techniques, is diagenesis. This is 
the term for the complex set of intrinsic and extrinsic factors which degrade organic material 
(including bone) following the death of an organism. Although advances have been made in 
understanding protein diagenesis, degradation processes in archaeological human bone 
remain unpredictable and often idiosyncratic, dependent upon a multitude of factors. These 
also often result in little correlation between macroscopic and microscopic bone 
preservation. Assessing target bone sample preservation through histological analysis may, 
therefore, aid in screening out those affected by diagenesis, and has been advocated by 
studies as an important precursory step to protein extraction (e.g., Hanson and Buikstra, 
1987; Schoeninger et al., 1989; Schmidt-Schultz and Schultz, 2004). Recent technological 
improvements in protein mass spectrometry (proteomics), which have led to ground-
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breaking and innovative characterisation of the extant protein content (or proteome) of 
ancient bones (e.g., Buckley et al., 2011; Cappellini et al., 2012; Wadsworth and Buckley, 
2014), offer the potential to aid in characterising antibody preservation following extraction. 
 This research will also attempt to investigate the claim that non-collagenous proteins 
(including antibodies) may preferentially survive the diagenetic changes encountered within 
the burial environment, due to their high affinity with bone mineral (after Masters, 1987). 
Analysis of bone samples displaying varied levels of histological preservation may reveal 
different patterns of surviving exogenous and endogenous proteins. This would provide 
important information which may be used to direct future studies into archaeological protein 
survival, or in the targeting of specific proteins for analysis.  
 Research on indirect evidence of putative past English malaria will also be 
conducted to complement the direct biomolecular line of inquiry. This will be attempted by 
two methods. Firstly, published osteoarchaeological reports on populations from likely 
malarious areas will be examined, in order to identify phenotypic evidence of genetic 
responses to the long term presence of endemic malaria. This is in response to the recent 
identification of possible cases of thalassaemia in non-adult skeletons from Poundbury 
Camp, Dorset (Lewis, 2010). Thalassemia is one of the most commonly observed 
polymorphisms in modern populations. High prevalence rates of the condition are seen in 
areas with strong historical ties to endemic malaria, since the condition confers increased 
protection against malaria infection (Duffy and Fried, 2006). Diagnosis of thalassaemia in 
archaeological human remains has been hampered firstly by the non-specific nature of 
possible skeletal sequela resulting from the condition, and secondly, by the unpredictable 
nature of phenotypic expression of the disorder, particularly in heterozygous genotypes. 
Additionally, the severity of thalassaemia in homozygous form would frequently have 
resulted in early infant mortality, often before the development of diagnostic skeletal 
changes (Ortner, 2003; Lagia et al., 2007; Lewis, 2010). Conversely, heterozygous 
thalassaemia may result in no skeletal changes at all. The majority of cases in antiquity 
would, therefore, likely be undetectable in the burial record by traditional palaeopathological 
analysis. However, pathological changes suggestive of thalassaemia at Poundbury (Lewis, 
2010) provide additional diagnostic criteria which may not have been previously recognised 
in palaeopathological reporting. Additionally, since thalassaemia may not be expected to be 
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encountered in British archaeological populations, there is the potential for skeletal changes 
to be misinterpreted. 
 Secondly, a basic analysis of Fen and non-Fen cemetery demographic profiles will 
be attempted. A comparison of the age-at-death profiles of cemetery populations from likely 
malarious and non-malarious areas has not previously been performed, and the analysis of 
demographic differences between locations may prove useful in highlighting possible 
epidemiological influences on mortality. P. vivax infection, for instance, places a 
particularly heavy burden upon the pregnant and the very young, resulting in increased 
morbidity and mortality in these groups (Desai et al., 2007). It is possible that the presence 
of P. vivax malaria in past Fenland environments may have resulted in increased mortality 
rates for these groups. The difficulties and limitations inherent in extrapolating demographic 
trends from skeletal information will also be discussed.    
 
1.2: Research questions 
 The study proposed above can be summarised into the following research questions: 
1. Can direct evidence for malaria infection in past populations be detected through 
extraction and testing of anti-malaria antibodies from archaeological human 
bone? 
2. Do non-collagenous proteins, such as immunoglobulins, preferentially survive 
within archaeological bone due to their high affinity to bone mineral? 
3. Can indirect evidence for past malaria presence be obtained through the 
identification of skeletal changes suggestive of genetic anaemia in skeletal 
populations from potentially malarious areas? 
4. Can the presence of putative malaria be evidenced by comparing mortality and 
survivorship patterns from cemetery populations associated with Fen and non-
Fen/marshland locations? 
 
1.3: Thesis structure 
 The thesis begins with an exploration of the historical and environmental evidence 
pertaining to the presence of malaria vectors and the P. vivax parasite in the British Fens and 
marshlands from the Roman to post-medieval periods. The chapter discusses how climatic 
28 
 
conditions, landscape modification, and resource utilisation may have influenced changing 
human settlement patterns, mosquito habitats, and parasite transmission. The chapter also 
discusses how documentary evidence, usually in the form of symptomatic descriptions, may 
indicate the presence of vivax malaria prior to the post-medieval period, while also 
examining outside perceptions of the Fens and Fen inhabitants. This is followed by a brief 
discussion concerning the eventual withdrawal of malaria from England in the late 18th to 
early 19th centuries. 
 Chapter 3 presents an introduction to malaria in terms of the different vectors and 
parasite species responsible for transmission and infection of human hosts. It then 
concentrates specifically on the temperate malaria species Plasmodium vivax, detailing its 
lifecycle and pathophysiology. Following this is an overview of the human immune system, 
its response to Plasmodium infection, and the status of immunity in temperate areas.  
Finally, the possible implications of the presence of vivax malaria for British populations in 
antiquity is assessed. Chapter 4 introduces the most commonly employed clinical methods 
of detecting malaria in modern settings, before discussing the history of palaeopathological 
attempts at detection. An exploration of potential methods of indirectly observing the 
disease in skeletal material follows. Biomolecular archaeology and the survival and 
interpretation of ancient biomolecules is then discussed, followed by an assessment of how 
clinical techniques may be adapted for the biomolecular detection of the malaria in ancient 
skeletal samples.  
 The material and methods (chapter 5) details and justifies the criteria for the 
selection of sites and individual samples for analyses of indirect and direct evidence of vivax 
malaria. It also discusses reasons for choosing specific methodologies for these analyses, 
before detailing each technique. This is followed by the results (chapter 6), which details the 
data obtained from both the direct and indirect lines of enquiry employed in the search for 
vivax malaria, while highlighting potentially informative patterns in the data. The discussion 
(chapter 7) interprets the results of the aforementioned analyses, taking into account the 
limitations of each chosen methodology. The extent to which each applicable line of 
evidence supports the hypothesis that vivax malaria played a significant epidemiological role 
in the pre-16th century Fens is evaluated. Finally, the conclusion provides a brief summation 
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of the project in relation to the research questions posed in Section 1.2, and addresses 
potential implications of the research. 
 
1.3: Summary and research implications 
 Little palaeoepidemiological research has been conducted on Fenland populations, 
whose lives were intertwined with a unique environment of “…moory soil…watry 
atmosphere, with damp, unhealthy moisture... thick, stinking fogs, and noxious vapours” 
(Anonymous, quoted in Darby, 1940:117). An indigenous malarial presence in British 
antiquity has been strongly suggested by recent research on Anglo-Saxon Fen and 
marshland populations (Gowland and Western 2012), and epidemiological and demographic 
conditions were likely ideal for temperate malaria transmission from at least the Roman 
period (Knotterus, 2002). Despite the likelihood that vivax malaria exerted a significant 
epidemiological burden upon Fen populations for many centuries, evidence for its existence 
prior to the modern period has always been circumstantial. Direct observation of the 
parasite, or parasite products in archaeological contexts has not yet proven possible. This 
study is the first to take a different approach by attempting to identify evidence of the 
natural human biological response to Plasmodium infection, rather than the parasite itself, 
which is less likely to survive in the archaeological record.    
 The potential impact of this research upon the fields of palaeopathology and 
palaeoepidemiology should not be underestimated: a reliable antibody extraction protocol 
would provide a powerful new biomolecular tool for the study of ancient diseases, 
particularly where a disease is suspected, but not confirmable by traditional analyses. The 
identification of latent ancient diseases offers great potential for advancing our 
understanding of their evolution alongside their hosts, as well as for aiding in the 
construction of modern policies aimed at confronting potentially reemerging pathogens, 
such as vivax malaria. This research also has the potential to shed light on the interaction 
between environment and disease in these relatively unstudied ancient Fenland populations. 
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CHAPTER 2: MALARIA AND ENVIRONMENT IN BRITAIN: 
HISTORIC AND PREHISTORIC CONTEXTS 
 
"They live out their brief, miserable existences on the edge of a tomb…Good health is a 
blessing unknown to them. Born among the sources of insalubrity, they suffer its disastrous 
influence from an early age…They live in a state of permanent ill health, and go to sleep 
amid suffering only to wake to their pain…Everything conspires against their health: their 
dwellings, their habits, their rough, unhealthy, insubstantial food and the indifference with 
which they choose their drinking water " (Bossi, 1808, quoted in Goubert, 1989:216). 
 
This chapter will examine the documentary evidence which alludes to the presence 
of malaria in Britain, along with the environmental contexts in which the disease flourished, 
from the prehistoric to post-medieval periods. The majority of the earlier sources, 
particularly the Anglo-Saxon and later medieval documentation, are in the form of medical 
texts which describe treatments for the symptoms of agues and intermittent fevers. 
  There is no definitive answer regarding when malaria first reached British shores 
within its human host(s). Whenever this occurred, a native and highly effective mosquito 
vector was already in place to spread the parasite to the local population. Anopheles 
atroparvus is the only indigenous British mosquito species that “breeds in sufficient 
numbers and in close association with man to be an efficient vector amongst human 
population” (Dobson, 1980:376), and hence was almost certainly the vector that transmitted 
the original Plasmodium parasites. A. atroparvus retains a relatively widespread distribution 
in modern United Kingdom and Ireland (Snow, 1998). There seems to exist a latent 
assumption that the relative dearth of documentary evidence specifically describing English 
malaria means that the disease was not present prior to the 16th century (e.g., Bollet, 2004; 
Pinello, 2008; Neghina et al., 2010). This study will explore the available historical, 
environmental, and physical evidence for the presence of English malaria prior to the post-
medieval period. 
 
2.1: Prehistory and the Roman period to c. AD 400 
 The absence of pre-Roman documentary evidence dictates that attempts to trace the 
presence of British malaria into prehistory must rely either on inference from continental 
sources, or on alternative methodologies, such as the analysis of past environments, the 
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physical remains of the Plasmodium parasite, and its infected hosts. Ancient south Asian 
Vedic and Chinese medical writings, dating from 2700 to 600 BC, contain some of the 
earliest references to malaria-type intermittent fevers and their symptoms, including 
splenomegaly (enlarged spleen, referred to as ‘ague-cake’ in the post-medieval period), a 
condition strongly associated with malaria infection (Carter and Mendis, 2002; Packard, 
2007; Neghina et al., 2010). By at least the fifth century BC Plasmodium vivax is considered 
to have been endemic in China, the Indian sub-continent, and Greece (Carter; 2003). The 
Hippocratic Corpus of medical texts, written between 450 and 350 BC, frequently, though 
somewhat simplistically, describe symptoms of a variety of intermittent fevers and their 
physiological impacts on patients living in proximity to marshland environments (De 
Zulueta, 1973; Grmek, 1989; Sallares, 2002). 
 Malaria in the forms of P. vivax and P. falciparum, quickly established itself in the 
populations of the eastern and southern Mediterranean around the 5th century BC (Carter, 
2003). Anthropophilic falciparum, a relative new-comer in the evolutionary history of 
malaria, likely spread out of west sub-Saharan Africa within the last few thousand years 
(Carter and Mendis, 2002; Hay et al., 2010). Malaria was possibly spread to Italy through 
militaristic contact with Carthaginians and/or immigration from Greece (Sallares, 2002; 
Packard, 2007). P. falciparum malaria became the dominant species in central and southern 
Italy, out-competing P. vivax due to its higher reproduction rates in hot climates (Sallares, 
2002). However, it was the ability of temperate P. vivax to survive at lower temperatures 
and to ‘hibernate’ through cold winters inside the human host, that propagated a migration to 
northern Europe and beyond, eventually reaching the United Kingdom, northern Russia, and 
the New World (Packard, 2007). The mosquito vector A. atroparvus is an opportunistic 
feeder on both livestock and humans (Sinka et al., 2010), and capable of overwintering in 
human habitations (Medlock and Vaux, 2011), close to the blood-meals required for P. vivax 
parasite sporogeny, and infective in temperatures as low as 3ºC (Dobson, 1980). The modern 
day presence of A. atroparvus, along with other anopheline vectors, suggests that the species 
are indigenous to the British Isles (Snow, 1999), and represent the most likely vectors in 
antiquity. 
 Given the understanding of the life-cycle and habitat requirements of P. vivax 
(discussed in sections 3.3 and 3.4), it is almost certain that it was this malaria parasite that 
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first established a foothold in the British Isles, although the exact timing of its arrival 
remains unclear. It has been suggested that the parasite was introduced into Britain around 
the first century AD by the influx of immigrants from the Roman Empire (Sallares, 2002), 
although this remains unsubstantiated (Pinello, 2008). If malaria was introduced into Britain 
from the Roman Empire, it is likely that P. falciparum entered simultaneously. It remains 
unclear whether British anopheline species are capable of transmitting falciparum malaria. 
Many studies have suggested a lack of capability (e.g., James et al., 1932; Schute, 1940; 
Ramsdale and Coluzzi, 1975; Ribeiro et al., 1989), although laboratory tests have confirmed 
the ability of A. atroparvus to transmit a particular Italian strain of P. falciparum (Dobson, 
1997). One species of tree-breeding mosquito, A. plumbeus, is capable of its transmission 
(Marchant, 1997); this indigenous species was the likely vector for a small outbreak in post-
medieval London (Kitching, 1971; Dobson, 1980). The climatic conditions in Britain would 
not, however, have allowed for stable transmission of P. falciparum to occur. Ambient 
temperature, aridity, and suitable vector presence are some of the most important 
determinants in the transmissibility of malaria (Gething et al., 2012); a parasite that requires 
a sustained temperature of over 20°C for more than twenty days for sporogenesis to occur 
(Dobson, 1997), along with the year-round presence of a transmission vector, would struggle 
to maintain a presence, let alone virulent endemicity, in past or present Britain. 
 Malaria may have been present in Scotland by AD 208, when the army of Septimus 
Severus was severely affected by a disease associated with marshlands (Sallares, 2002). It is, 
of course, possible that the parasite was already present in Britain prior to the Roman 
Conquest, perhaps transmitted through contact and trade with continental Europe. Sallares 
(2002) suggests that the recovery of archaeobotanical remains of opium poppies (Papaver 
somniferum) from East Anglian Iron Age sites may provide indirect evidence for the 
treatment of vivax malaria symptoms, since it points to a coordinated effort to cultivate a 
source of medicinal opium. It is, however, unknown whether opium poppies were initially 
cultivated, if at all, in Britain solely for treatment of malarial symptoms. The drug was 
certainly effective for the temporary relief of the symptoms of vivax malaria, although it is 
also known to have been used in later periods for conditions as diverse as insomnia, 
rheumatism, and neuralgia (Bonser, 1963; Dobson, 1997). The cultivation of opium poppies 
dates back to at least the 3rd millennium BC in Mesopotamia and opium was widely traded 
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throughout the Mediterranean and southern Europe by 1000 BC (Kritikos and Papadaki, 
1967; Brownstein, 1993). It is likely that the medicinal properties of opium were known to 
the native British population before the possible Roman timeframe for the introduction of P. 
vivax. Beyond this tentative, indirect link to malaria, evidence for pre-Roman malaria in 
Britain remains elusive.  
 Iron Age settlement distribution on Fenland terraces, such as in the localities of Ely 
and Chatteris in Cambridgeshire, and around the Fen edge margins near Peterborough 
suggests the prevalence of contemporary utilisation of Fen resources (Hooke, 1998; Evans 
and Hodder, 2006). Such settlement is also noted around the Humber Estuary (Creighton, 
1990) and in Romney Marsh, Kent (Eddison, 2000). Archaeological and aerial photographic 
evidence demonstrate that by the middle of the first century AD, the siltlands of 
Lincolnshire, in particular, were heavily colonised (Darby, 1983). Such environs were 
mainly utilised for the seasonal grazing of livestock and for salt production. The latter 
activity has been archaeologically recorded as occurring as early as the late Bronze Age 
(Chowne et al., 2001), and there is extensive evidence (in the form of salterns and 
briquetage) for Iron Age and Roman salt production throughout the coastal Fenlands, 
marshlands, and major estuaries of eastern England (Cracknell, 1959; Darby, 1983; Eddison, 
2000; Rippon, 2000). Salt making evidence strongly suggests that people were working in 
close proximity to brackish marshes, and hence close to ideal anopheline breeding grounds, 
long before the arrival of the Romans. If these mosquitoes carried the Plasmodium parasite, 
then the local workforce would certainly have been frequently exposed, stimulating 
localised endemicity.   
 Fenland occupation intensified during the Roman period (Figure 2.1), partly in 
response to an increasingly favourable climate, which led to a falling water table and the 
exposure of extensive areas of fertile siltlands suitable for summer pasture grazing (Hooke, 
1998). Areas of Romney Marsh in Kent were “sufficiently elevated and well-drained to 
allow Roman settlement to take place” (Cunliffe, 1988:83). Roman settlement has also been 
noted along the south bank of the river Humber (Ellis and Crowther, 1990) and on Canvey 
Island in Essex (Cracknell, 1959). This period saw the first attempts at large-scale Fen 
landscape modification projects (Darby, 1932), including the still-extant 85 mile Carr Dyke, 
which runs from the River Cam in Cambridgeshire to the Witham near Lincoln (Thorpe and 
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Zeffert, 1989). It is likely that the majority of these projects were aimed at providing 
convenient access routes, rather than representing determined attempts at drainage and land 
reclamation, such as occurred in late Anglo-Saxon and Post-medieval periods. The effects of 
improving climate and attempts at landscape management on the potential transmission and 
endemicity of malaria is unknown. On one hand, the increasing population and land 
exploitation would naturally intensify contact between the mosquito vector and its human 
prey, promoting a subsequent increase in parasitism. Conversely, modification of the 
environment, both through natural and human action, may have disturbed some of the 
anopheline breeding grounds, thus reducing the local mosquito population. This is one 
example of the highly complex relationship between environment, vector and human host. 
Towards the end of the Roman period, many sites seem to have been abandoned and 
subsequently buried by flooding events during the late 3rd and early 4th centuries (Darby, 
1932). 
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Figure 2.1: Roman settlement areas in the Lincolnshire, Cambridgeshire, and Norfolk 
Fenlands. L – King’s Lynn; P – Peterborough; W – Wisbech (after Darby, 1983:4). 
 
2.2: The Early Medieval (Anglo-Saxon) period c. AD 400 – 1066 
 If we are to accept the proposal that Plasmodium vivax first entered Britain with the 
conquering Romans and that, by this time, the siltlands and marshlands of eastern England 
were relatively well populated and utilised, then we may also assume that malaria infection 
was probably widespread by the start of the Early Medieval, or Anglo-Saxon period. 
Unfortunately, as with the prehistoric and Roman periods, documentary evidence for the 
presence of malaria in the early and middle Anglo-Saxon periods is virtually non-existent. 
Sallares (2002) suggests that writings by Gregory of Tours provide strong evidence for the 
presence of malaria in 5th century France, but it is not until Bede’s Historia ecclesiastica 
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gentis Anglorum (Ecclesiastical History of the English People), compiled around AD 731, 
that reference to symptoms of putative English malaria is first made. Bede’s accounts 
concern the miraculous healings of a young Lincolnshire boy and the sick of London 
suffering from ‘febricintantes’ (Bonser, 1963). It is uncertain if Bede’s ‘febricintantes’ 
actually represented true malaria, since the word may have been used to refer to any acute 
fever (Howe, 1997).It should be noted, however, that Bede’s original Latin word for fevers 
was replaced in the 9th century Anglo-Saxon translation by a potentially more convincing 
descriptor for malaria, ‘lencten ádl’, or ‘Spring ailment’ (Bonser, 1963; Howe, 1997). A 
progression from Bede’s potentially ambiguous ‘fevers’, ‘lencten ádl’ is also encountered in 
Bald’s famous Leechbook, which was probably compiled no later than the late 9th century 
(Cameron 1993).  
 Numerous types of fevers are mentioned in Anglo-Saxon literature, including 
descriptions of burning fever (bryne-ádl), epidemic fever (drif), and shaking fever (hriõian). 
The Anglo-Saxon authors were clearly attempting to define different fevers by symptom, but 
it remains unclear which (if any) of these terms could refer to true malaria, as the disease 
can be characterised by all of these symptoms. However, Cameron (1993:10) suggests that 
“it seems clear that this name [lencten ádl] most commonly described an endemic form of 
tertian malaria [hence, P. vivax malaria], one in which the parasite remained dormant during 
much of the year, becoming active in spring about the same time as the adult forms of the 
mosquito vector emerged.” It is also likely that the 9th century translator of Bede’s work was 
drawing on knowledge of the different types of fevers when changing ‘febricintantes’ to 
‘lencten ádl’, especially since Bede describes cases of fever occurring in potentially 
malarious areas. 
 Bruce-Chwatt (1976) suggests that ‘lencten ádl’ was the precursory term for ‘ague’, 
which was in common usage by the 14th century. It has long been argued (e.g., by Creighton 
et al., 1965) that ‘ague’ was often used as a catch-all term to describe a number of diseases 
that are symptomatically similar to true malaria. Certain enteric diseases, such as typhoid 
fever, for instance, result in the classic malaria-type symptoms of high fever and swollen 
abdominal organs, which, as with P. vivax malaria, can relapse should the patient survive the 
initial infection. However, it can equally be argued that many of these early periodic fevers 
described as ‘tertian’ were probably true malaria, particularly if manifesting in patients 
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located near marshland environments (Reiter, 2000; Sallares, 2002). Even in modern clinical 
literature, the most commonly observed malarial symptom, febrile paroxysm, is sometimes 
referred to as ‘ague attack’ or ‘ague fit’, such is the longevity and ingrained nature of the 
word (Warrell, 2002).  
 The word ‘mal’aere’ (literally ‘bad air’) likely made its first appearance in 14th 
century Italian writings by Marco Cornaro (Neghina et al., 2010) and was transferred into 
English usage in 1740 by Horace Walpole to refer to the unhealthy summer conditions 
encountered in Rome during his travels (Sallares, 2002). During the 18th century, ‘malaria’ 
quickly became the term of choice for fevers resulting from contact with miasmic 
emanations (Bruce-Chwatt, 1976), although ‘ague’ remained in common usage into the early 
19th century, particularly when discussing fevers associated with marshland environments. It 
was during this period that the two terms were often used interchangeably in both clinical 
and non-clinical literature. It was not until the turn of the 20th century that ‘ague’ was finally 
replaced by ‘malaria’ as the clinically favoured term (Bruce-Chwatt, 1976). 
  If Bald’s Leechbook and Bede’s translator were describing true English malaria, 
rather than conditions exhibiting malaria-type symptoms, what of the status of malaria in the 
intervening centuries since the end of the Roman occupation to the 8th century? As with the 
Roman period, the dearth of documentation for the Early and Middle Anglo-Saxon periods 
forces a reliance on alternate, and often indirect, methodologies of tracing the disease. Even 
working on the assumption that malaria was indeed present, and possibly endemic, in the 
Fens and marshlands of eastern England by the end of the Roman occupation, evidence for 
its presence is as ephemeral as for the people themselves. It is in these periods that possible 
indirect skeletal and environmental evidence (e.g., Gowland and Western, 2012), alongside 
potential biomolecular markers (e.g., Pinello, 2008), must be more heavily relied upon.  
 Environmental evidence from the early first millennium AD suggests deteriorating 
climatic conditions during the late third, fourth, and fifth centuries. Rising sea levels caused 
more frequent marine and fluvial flooding events, resulting in the deposition of silt and 
formation of fresh peat (Hooke, 1998). It has been suggested that the sea level in proximity 
to some areas of East Anglia (including the Fens) rose by as much as four metres during the 
early to mid-first millennium AD (Dark, 2000). The impact of this climatic change on 
Anglo-Saxon settlement patterns in the Fenland is not yet fully understood. Darby (1983:5) 
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suggests that at this time much of the Lincolnshire and Cambridgeshire Fenland “seems to 
have become a land of choked drains and abandoned settlements,” while both Roffe (2005) 
and Rippon (2009) suggest that there was a discontinuity of settlement in the worst affected 
areas as people gradually relocated to higher ground. A comparison of Figures 2.1 and 2.2 
does suggest a shifting Fenland settlement pattern from the Roman to Middle Anglo-Saxon 
periods, encompassing a general movement away from siltland area occupation.  
 By the 8th century, according to Bede, the southern Fen island of Ely in 
Cambridgeshire was both populous and prosperous (Darby, 1983), thus supporting the 
suggestion that the Fen islands were becoming heavily populated at the expense of the lower 
siltlands. The latter may have become largely unsuitable for continuous habitation due to 
poor climatic conditions, although the silt and marshland areas probably dried sufficiently in 
the summer months to allow for activities such as livestock grazing, salt production, and 
resource gathering. Recent archaeological work suggests that exploitation of the rich 
Fenland and marshland resources continued throughout the period (Rippon, 2009), although 
evidence for continuous siltland settlement remains ephemeral. Despite the inherent risks, 
remaining siltland occupation would probably have focused on raised roddons (elevated silt 
ridges), upon which small-scale production of salt-tolerant crops may have taken place 
(Murphy, 2010). 
 Despite the deteriorating climate, the Fenlands and marshlands would have 
continued to provide a rich variety of resources and economic opportunities, certainly 
enough to keep populations from completely abandoning the area. The Tribal Hidage, a 
document describing 7th-9th century areas and their hidage assessments, lists numerous 
communities situated in and around the Lincolnshire Fens, such as the Spaldas and the 
North and South Gyrwe (people of the Fens). Both Bede and the Tribal Hidage seem to 
provide “a clear picture of a peopled landscape” which was “organised into communities 
with recognisable identities” (Roffe, 2005:265) in the 8th century. The enormity of the Fens 
and marshlands of Eastern England, in terms of both scale and economic opportunity 
therein, meant that “the environment was a condition rather than a determinant of land use 
throughout the period” (Roffe, 2005:265).   
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Figure 2.2: Distribution of Early and Middle Anglo-Saxon sites identified by the Fenland 
Survey in the Lincolnshire, Cambridgeshire, and Norfolk Fenlands (adapted from Crowson 
et al., 2005:5). 
 
 It is likely that the changing environmental conditions also impacted the anopheline 
breeding grounds and consequently, in areas which saw sufficient human depopulation, any 
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stable endemicity of malaria would probably have been interrupted. It would seem, 
therefore, advantageous to seek certain physical effects of the disease (e.g., possible 
biomolecular evidence, osteological pathological markers, or genetic resistances in human 
populations) in areas of continuous settlement, and hence, long-term, stable exposure to 
malaria. These areas include the southern Fenland islands and higher silt coastal regions of 
Lincolnshire, Cambridgeshire and Norfolk, the raised islands of southeast England, such as 
the Isles of Canvey, Sheppey, Grain, and Oxney, and the roddons, ridges and margins of 
North and South Kent and Essex marshes.  
   One of the earliest and most famous literary descriptions of the Fenland environment 
dates from the mid-9th century. Felix’s exposition on the life of Saint Guthlac, who relocated 
to the Fen island of Crowland, Lincolnshire, and founded a monastery there in 716, 
describes the general area: 
 “There is a midland district of Britain a most dismal Fen of immense size, which 
 begins  at the banks of the river Granta not far from the camp which is called 
 Cambridge, and stretches from the now south as far north as the sea. It is a very long 
 tract, now consisting of marshes, now of bogs, sometimes of black waters overhung 
 by fog, sometimes studded with wooded islands and traversed by the windings of 
 tortuous streams” (Colgrave, 1956:87, translating Felix). 
 
Felix describes Crowland itself as: 
 “…an island in the middle of the marsh which on account of the wildness of this 
 very remote [spiritual] desert had hitherto remained untilled and known to few. No 
 settler had been able to dwell alone in this place before Guthlac the servant of Christ, 
 on account of the phantoms of demons which haunted it” (Colgrave, 1956:78, 
 translating Felix). 
   
A similar description can be seen dating from the late 7th century, when St. Boltoph arrived 
near Boston in the north Lincolnshire Fens, a place he found to be “infested with devils of 
various kinds” (Darby, 1934:191). Beowulf’s monster, Grendel, also supposedly inhabited 
the Fenlands. 
 These highly illustrative accounts provide fascinating insights into the 8th century 
physical and metaphysical perceptions of the Fenland environments. The Fens and 
marshlands of England represented the interface of land and sea, and were a mysterious, 
remote wilderness supposedly inhabited by demons and mythical creatures (Rippon, 2009). 
The Fens were “spurned and held in fearful contempt” (Darby, 1934:192), particularly by 
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outsiders who would likely have heard and perpetuated tales of the heavy miasmic fogs and 
lurking evil creatures. These early descriptions must, of course, be taken in context. Felix, 
for instance, probably would not have been aware that the island of Crowland was home to 
continuous settlement from as early as the Bronze Age (Cope-Faulkner et al., 2010).   
 Narratives pertaining to the ‘phantoms of demons’ and ‘devils’ which haunted the 
Fens may well have alluded to the ever-present spectres of death and disease which 
permeated the Fenland environs (Dobson, 1997). Anglo-Saxon ideas concerning diseases 
and their effective treatments were based upon a complex amalgamation of “classical texts, 
Judeo-Christian belief and ‘native’ northern European lore…[which] complement each other 
to produce a truly rich and fascinating mélange of herbal plant lore, materia medica, spells, 
charms, rites and superstitions” (Pollington, 2000:27). This is hardly surprising, given the 
complicated, dynamic, and interspersed nature of the formation of the English population 
since the Roman Conquest. A full exploration of the corpus of Anglo-Saxon medicinal 
thought is beyond the scope this study, yet it is pertinent to touch upon these perceptions if 
we are to understand how the Anglo-Saxons viewed and understood the causes, symptoms 
and treatments of malaria. 
 Although the ancient Chinese seemed aware that malaria was contracted through the 
bite of an insect, there is no evidence that the classical Greek and Roman world had made 
this connection (Sallares, 2002). A common perception, witnessed, for example, in the 
construction of a temple to Dea Febris (Fever deity) in Rome and discovery of a Romano-
British inscription from Risingham, Northumberland, dedicated to the same deity, was that 
intermittent fevers were of divine or demonic origin, a concept refuted by earlier 
Hippocratic and later Roman writers (Sallares, 2002; Neghina et al., 2010). Despite these 
refutations, the notions of supernatural causation remained entrenched outside of the 
educated elite for many centuries to follow. It is likely that the Anglo-Saxon understanding 
of malaria was as heavily influenced by classical mythological ideologies as it was by 
indigenous folklore and religion. Indeed, Sallares (2002:54) suggests that, in Rome at least, 
“the shift from pagan religions to Christianity probably made no significant difference to 
popular perceptions of malaria, which was frequently the target of healing miracles in 
Christian literature.” For instance, Felix’s own understanding of disease causes and 
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processes would have been heavily influenced by Christian ideology and native 
traditions/superstitions, as evidenced by his descriptions of the demon-haunted Fens. 
 Early medieval medical understanding was also influenced by the classical Greek 
theory of the four humours: blood, phlegm, red bile, and black bile. These humours worked 
in tandem to keep bodily function in a state of equilibrium. Deficiencies in, or imbalance of 
certain humours would lead to disease, which could only be cured by humoural balancing 
(Cameron, 1993). Strong backing by the Roman physician/philosopher Galen ensured that 
the theory of the four humours remained “a basic tenet of medicine for almost another two 
thousand years; it finally died out in the last half of the nineteenth century” (Cameron, 
1993:160). Due to the fundamental misunderstanding of the causes and processes of malarial 
infection, early medieval treatments would have inevitably been ineffective at parasite 
elimination, although temporary relief of symptoms may, in some cases, have been 
achievable. Such treatments included herbal preparations and, failing this, complex magical 
rites (Bonser, 1963; Cameron, 1993), intended to cast out the underlying demonic influences 
that upset the balance of humours. Despite an intimate understanding of the clinical 
pathophysiology of vivax malaria, even modern treatment of the disease sometimes fails to 
prevent later episodic relapses (Baird et al., 2007). Thus, earlier medieval efforts (if they 
existed) beyond simple symptomatic alleviation would have almost certainly failed, leaving 
the patient to suffer repeated debilitating relapses. 
 Environmental evidence suggests that the late 8th century through to the end of the 
Anglo-Saxon period saw an improvement in climatic conditions. Known as the Medieval 
Warm Period (MWP), the three centuries preceding approximately AD 1250 saw a trend 
towards climatic warming and drying, and falling sea levels (Darby, 1983; Dark, 2000; 
Mann et al., 2009). Increasingly favourable conditions propagated a slow repopulation of the 
siltlands, although the continuity of such activity remains difficult to establish. Settlement 
would probably, at least in the early stages, have continued to be sporadic and very much 
dictated by short-term climatic variability. It is in this period that concerted efforts at 
landscape management within the Fens and marshes, with the general aim of removing 
excess water from the landscape (Rippon, 2009) can be seen. Some of the most impressive 
endeavours were the construction of the Lincolnshire Sea and Fen Banks sometime around 
the 10th century. The former was particularly impressive: this massive earthwork was 
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constructed around the Wash in order to protect siltland settlement, pasture and agriculture 
from marine inundation (Hooke, 1998). The Sea Bank held “the key to future reclamation of 
the Fens…permitting campaigns of drainage and reclamation” (Hall, 2005:xii). The 
introduction of watermills, flood gates, sluices, and the canalisation of major watercourses, 
such as the River Nene, further aided in the control of water (Hooke, 1998; Rippon, 2009).  
 The Cambridgeshire Fens, mostly under monastic ownership by the ninth century, 
were modified by a network of canals, which functioned as drainage and a method of linking 
the Fen-island monastic communities (Hall, 1988). Such improvements in the transport 
network would have been of great benefit to the populace and economy, although they may 
also have facilitated the Danes in their increasingly frequent ninth century raids (Darby, 
1940). Similar contemporary attempts at marshland reclamation were also occurring in 
Romney Marsh (Hooke, 1998), most of which was occupied year round by the end of the 
Anglo-Saxon period (Eddison, 2000). The beginnings of Fenland management, 
reorganisation and subsequent increasing population density can be traced to these Late 
Anglo-Saxon attempts to manipulate and improve their surrounding environment. 
 
2.3: The high and late medieval periods c. AD 1066-1600 
 Reclamation, repopulation, and socio-political organisation of the Fenlands and 
marshlands of eastern England were well underway by the time of the Norman Conquest. 
The Domesday Book, first assembled in 1086, provides the first detailed illustration of the 
settlement and population patterns of the Fenlands and marshlands (see Figure 2.3 for 
Lincolnshire, Cambridgeshire and west Norfolk). The Domesday Book records that by the 
late 11th century the coastal marshlands had been resettled quite extensively, including much 
of Romney Marsh (Eddison, 2000; Rippon, 2009). The importance that the extant 
Lincolnshire Sea Bank played in the increasing number of settlements cannot be 
underestimated, since all of the recorded Fenland Domesday settlements are found on the 
landward side of the Bank (Darby, 1983).  
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Figure 2.3: Distribution of Domesday settlements in the Lincolnshire, Cambridgeshire, and 
Norfolk Fens and marshlands (after Darby 1983:9). 
 
 Siltland settlements were generally well populated and prosperous in 1086, but their 
relative isolation within a flood-threatened environment meant that overall population 
density in the Lincolnshire and Cambridgeshire Fenlands remained moderately low (Figure 
2.4), especially in comparison to some upland communities (Darby, 1983). There can be 
little doubt, however, that these Fenlands were about to experience something of a boom, 
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both in terms of population and economic prosperity. The coastal regions of Sussex, Essex, 
and marshland areas of Kent were already experiencing exponential population increase by 
1086 (Cracknell, 1959; Smith, 1988). Despite the frequent records of disastrous flooding 
events over the following centuries (particularly during the mid-13th century) the Fens and 
marshlands continued to attract an increasing number of inhabitants. The imminent dangers, 
both environmental and epidemiological, of living and working in such habitats must have 
been offset by the attractive economic benefits. 
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Figure 2.4: Lincolnshire, Cambridgeshire, and Norfolk Fenland population densities in 1086 
(adapted from Darby, 1983:10). 
 
 Regional and national demand for salt propagated one of the earliest Fenland post-
Conquest ‘industrial’ booms in the 12th century, which saw intensification of salt making 
activities to supply the North Sea fisheries. This was particularly evident around the Wash 
(Astill and Grant, 1988). Demand for salt rose so high that by the 13th century, continental 
sources of this vital commodity were being imported (Astill and Grant, 1988). Salt and 
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freshwater fishing industries blossomed, and mainstays such as the collection of reeds, 
rushes and sedges for thatching continued apace. Waterfowl represented an important 
commodity and the rearing of large flocks of geese became particularly prevalent in certain 
marshier areas of the Fens, such as around Lincoln and King’s Lynn (Grant, 1988). Peat cut 
from the freshwater areas of the Fens was also becoming increasingly important as a fuel 
source for the growing local populations, particularly given the limited availability of 
alternative fuels (Darby, 1983).  
 The most important economic prospect offered by the siltland environment arguably 
came in the form of extensive pasture lands, which were rendered extremely fertile for 
summer livestock grazing by yearly winter flooding. Sale of much sought-after English wool 
was a driving force behind the Fenland economic and population boom in the three to four 
centuries post-Conquest. Grant (1988) states that during the last two decades of the 13th 
century, the wool from approximately three million sheep was exported from the 
Lincolnshire port of Boston. The number of extravagant Fenland parish churches 
constructed between the 12th and 15th centuries are testament to the wealth of the area 
(Darby 1940) - fortunes derived heavily from the wool trade. Sheep and wool were also 
important commodities in the medieval marshlands of Norfolk and Essex (Cracknell, 1959; 
Rippon, 2000). The boom in Fen exploitation can be seen in late 13th and 14th taxation 
records, which show that the resource-rich siltlands of south Lincolnshire were by this time 
“crammed with people” (Rippon, 2000:198), with population density higher than in the early 
19th century (Hallam, 1961). Increasing 14th century population densities are also evident in 
Norfolk, Suffolk, Essex and Kent (Figure 2.5).  
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Figure 2.5: National population densities from the 1377 poll tax returns (adapted from 
Smith, 1988:199). 
 
 With increasing population levels and interaction within Fenland and marshland 
environments, a subsequent increase in contact with indigenous mosquito species should 
also be expected, yet the extent to which modification and reorganisation of the landscape 
would have affected anopheline breeding grounds, and hence the vector’s general 
distribution, remain unclear. As previously stated, it is likely that any malarial transmission 
continued uninterrupted in those areas which experienced continuous settlement (e.g., the 
raised Fen islands), whilst areas experiencing temporary or fluctuating population levels 
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may not have been able to maintain any endemicity. The climatic data, settlement patterns 
and population densities from 1066 to the mid-13th century, however, suggest that there was 
potential for endemicity over a much wider range than during the middle centuries of the 
first millennium AD. It was not just large-scale land management projects that contributed 
to this; local smaller-scale changes may also have played an important role in facilitating the 
spread of malaria to new populations. Such an example can be found at Sedgeford in 
northwest Norfolk, which saw intentional, controlled flooding through the building of a dam 
(Faulkner, 2001), hence creating potentially new anopheline breeding grounds beyond the 
‘traditionally’ accepted Fen/marshland malarial areas. Improving transport, trade, and 
communication links throughout the Fenlands may have propagated the spread of malaria 
from potentially endemic to non-endemic areas. Further to this, inter-continental trade and 
contact, particularly with southern Europe, an area described as being ‘hyperendemic’ with 
malaria in the medieval period (Gasper 2004), may have repeatedly introduced new strains 
of P. vivax into the existing Fenland populations.  
 It is easy to assume that drainage projects would reduce the mosquito population and 
the subsequent prevalence of malaria. It has, however, been suggested that wetland drainage 
and reclamation efforts lead to an increase in anopheline mosquito populations, at least in 
the short term (Horn, 1987). In a stable marshland environment mosquito population 
numbers are checked by predators. Disruption of the local environment through drainage 
efforts may spur an increase in anopheline numbers through the removal of both predators 
and competing aedes mosquito species which predominate in marshlands (Horn, 1987), but 
may be less adaptable to sudden environmental changes than their anopheline counterparts. 
This may explain the reported increase in biting insects immediately following post-
medieval drainage efforts (Darby, 1956). Smaller scale Anglo-Saxon and medieval attempts 
may, therefore, have propagated an increase, rather than an assumed decrease, in malaria 
transmission.  
 Documentary evidence for malaria in the early centuries of the high medieval period 
remains confined to sparsely-encountered medical descriptions of malaria-type symptoms, 
despite the increasingly favourable environmental and demographic conditions for disease 
transmission. This can be seen as very much carrying on the medical traditions of the Anglo-
Saxon period. Evidence that the theory of the four humours remained at the core of the 
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medieval understanding of malaria-type fevers can be seen in the Ramsey Scientific 
Compendium, which was probably compiled around 1110 (Cameron, 1993). The 
Compendium contains a detailed description of the perceived causes of various 
contemporary malaria-type fevers, each influenced by a humoural imbalance: 
 “Quotidian fever comes from phlegm, tertian from red bile, quarten from 
 melancholic, that is, black bile…Quotidian comes from cold humour, because 
 phlegm is cold and moist. Tertian from hot, because red bile is hot and dry. Quarten 
 from melancholy, because it is dry and cold” (Singer, 1917, quoted in Cameron, 
 1993:54). 
 
 Gasper’s (2004) research on late 11th century letters to and from Anselm of 
Canterbury provides possible evidence of malaria in Romney Marsh. The letters contain a 
detailed description of the symptoms of a patient, Osbern: 
 “First of all a sudden chill violently afflicts his whole head and then his heart and 
 whole body; and soon his heart, pounding uncontrollably, fails along with all the 
 senses and powers of his body…After he appears to have revived from this fainting 
 fit, he immediately burns with heat throughout his whole body, as if becoming 
 feverish. A headache also follows this and great discomfort, as if he had to vomit” 
 (Anselm and Frohlich, 1990, quoted in Gasper, 2004:255). 
 
The condition presented here makes a compelling case for possible ‘benign tertian’ vivax 
malaria, especially since it occurred in close proximity to Romney Marsh, a likely malarious 
area. Gasper goes on to suggest that tentative evidence of 11th century malaria may provide 
an important bridge to later periods and that “there is no reason to think that the situation 
[endemic malarial infection] had changed dramatically between the tenth and fourteenth 
centuries” (2004:258). 
 As previously mentioned, by the 14th century ‘ague’ was in common usage as a 
descriptor for a wide range of illnesses exhibiting febrile symptoms. It is during this time 
that early authors and poets began making relatively frequent references to ague (Bruce-
Chwatt, 1976). Chaucer, for instance, wrote in 1386: 
 “You are so very choleric of complexion, 
  Beware the mounting sun and dejection, 
 Nor get yourself with sudden humours hot; 
 For if you do, I dare well lay a groat, 
 That you shall have the tertian fever’s pain, 
 Or some ague that may well be your bane” (Chaucer, quoted in Reiter 2000:3). 
. 
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This passage suggests that by the late 14th century people were aware of the differences 
between ‘benign tertian’ fever, the term most likely describing vivax malaria, and ague, 
which could refer to any acute febrile condition. It also demonstrates a continuing belief in 
the influence of the humours on health.  
 Franklin (1983) provides the thought-provoking insight into a possible malaria 
epidemic striking the 14th century inhabitants of Thornbury Manor, Gloucestershire. In a 
study akin to Dobson’s (1980; 1997) analyses of post-medieval parish registers, Franklin 
examines the court rolls of the Manor from between 1328 and 1352. These rolls recorded, 
for tax and tenancy purposes, the numbers of deaths each year. Although incomplete and 
selective in which cases were reported, the records reveal an unusually high death rate for 
the years 1333-34, following a long, hot summer in 1333. The tithing area within the Manor 
reporting the highest death rate was the marshland area, suggesting a local, rather than 
regional disease epidemic. This is a strikingly similar pattern to that discovered by Dobson 
in post-medieval marshland communities in south-eastern England. Later sources strongly 
suggest that this area of Gloucestershire was subject to malarial endemicity in the 17th and 
18th centuries, so it is highly likely that malaria was also present here in the 14th century 
(Dobson, 1997). This combined evidence is highly suggestive of an outbreak of epidemic 
malaria in this community, possibly with a newly introduced strain of P. vivax (or even P. 
falciparum) that may have detrimentally affected a population with a resistance to local 
strain(s). Conversely this could represent the introduction of malaria into a ‘virgin’ 
population. 
 The mid-13th to 14th centuries were a time of profound change in terms of climate, 
population, epidemiology, and more specifically for the Fenlands and marshlands, economy. 
Monastic documents suggest that the decades of the mid to late 13th century were some of 
the most tempestuous ever recorded in terms of climate (Eddison, 2000), with surviving 
records showing that the weather was particularly severe in southeast England. Numerous 
marine inundations destroyed flood defences and settlements, and salted agricultural fields, 
resulting in repeated crop failure and food shortages (Eddison, 2000). Salt production, being 
reliant on a steady supply of local labourers and dry fuel (invariably peat), would likely have 
been particularly badly affected by persistent heavy rains and flooding (Jordan, 1996). 
Unstable climatic conditions and major national epidemics of disease and famine, as well as 
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problems associated with over-grazing and rain-spoiled feed, greatly afflicted livestock 
populations. In some areas sheep flock size was reduced by two-thirds (Grant, 1988). These 
epidemics may have proven partly responsible for the Fenland and marshland economic 
decline in the 14th and 15th centuries. However, it was not only livestock that were suffering 
the ravages of disease: in 1348, the Black Death entered Britain and subsequently raged 
through country, leaving up to 50% of the human population dead (Goldberg, 1996).  
 The effects of the Black Death on Fenland/marshland populations and potential 
malarial transmission are unclear. Although local population numbers may have been 
booming by the mid-14th century, Darby (1940:152) suggests that “the Black Death did not 
produce great consequences generally” for the Lincolnshire/Cambridgeshire Fenlands. The 
Fen town of Ramsey, for instance, recorded surprisingly few losses to plague (DeWindt and 
DeWindt, 2006). There were some deleterious effects, however. For instance, loss of people 
resulted in the neglect of local watercourse management, culminating in the south 
Lincolnshire siltland town of Spalding being “in danger of being submerged by the flow of 
the sea and by the descent of fresh waters” (DeWindt and DeWindt, 2006:152). Flooding 
events such as these may have increased the available territories for anopheline mosquitoes, 
although this may have been offset by loss of human and livestock prey. Intriguingly, 
research (Wake et al., 1974; Ell, 1984) has suggested that those suffering with iron 
deficiency, a symptom of active malarial parasitism, may have had an increased resistance to 
plague. This is due to the requirement of plague organisms, such as Yersinia pestis, for 
exogenous iron for replication (Ell, 1984). Additional research by Williams et al. (1997) 
suggested a strong link between infection with P. vivax and child malnutrition, the latter of 
which would likely cause iron deficiency and increased immunity to plague. Further 
research on this possible immunity is required, particularly considering the incredible 
complexities of bodily usage and metabolism of iron, including in immunological 
mechanisms (Weiss, 2002). It does, however, provide a fascinating potential explanation for 
Darby’s assertion concerning the reduced effect of Black Death on certain Fenland 
populations.  
 Literary references to agues and fevers appeared increasingly frequently during the 
15th and 16th centuries. Shakespeare, for instance, makes numerous mentions of the 
conditions in his works, such as in the following quote from King Lear:  
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 “They told me I was everything; ‘tis a lie, I am not ague-proof” (Shakespeare 
 1800:79).  
 
The growing frequency of references to possible malaria is probably due to the increasingly 
frequent survival of such manuscripts and an advancing knowledge of epidemiology, rather 
than a growing prevalence of malaria itself. Pinello (2008:34) confidently assumes that 
“despite the extremely high population densities of the 13th and 14th centuries, this time 
period was relatively free from malaria”,  although she offers no support for this statement. 
This is an easy trap for researchers to fall into: as is often the case in archaeological and 
historical research, absence of evidence is not always evidence of absence. The increased 
survival of primary sources from the 15th century onwards seems to have influenced 
assumptions that malarial infection rates suddenly soared during this period. It is far more 
likely that malaria was already present throughout the Fens and marshlands of eastern 
England, perhaps with areas of stable endemicity that expanded in response to favourable 
demographic and climatic conditions. A short-term period of warming in the early 16th 
century, for instance, may also have stimulated an increased anopheline population density, 
hence higher malaria infection rates (Reiter, 2000). Environmental and demographic 
conditions were certainly in place for stable malaria transmission in many areas, well before 
this period of warming.  
 The year 1538 proved particularly important for those studying demography and 
population history through documentary sources. It was in this year that Oliver Cromwell 
ordered that each parish must keep records of all births, marriages and burials (Dobson, 
1997). Although sometimes incomplete and non-continuous, these extensive records allow 
researchers to track fluctuations in mortality rates over an extended period of time, hence 
aiding our understanding of population health on local and regional scales. Wrigley and 
Schofield’s (1981) and Dobson’s (1997) monumental and exhaustive syntheses on national 
and regional scales, respectively, are prime examples of the usefulness of parish registers to 
researchers of historical demography and epidemiology. The burial records of the parish 
registers are of particular interest to the malaria researcher, as they can be used to illustrate 
seasonal fluctuations in mortality which, in turn, can be compared to climatic data. 
Knowledge of the life-cycles of mosquito vectors and their parasites is applied to the historic 
data in order to infer past events of severe malaria epidemics.  
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2.4: The post-medieval period c. AD 1600-1900 
 The post-medieval period was a time of intellectual, environmental and socio-
cultural change in the Fens and marshes of eastern England, which brought an eventual end 
to sustained malaria transmission by the late 19th century. Despite these changes, late 
medieval and post-medieval perceptions of Fenland/marshland environments and their 
inhabitants remained overwhelmingly negative. John Norden, upon visiting the Essex 
marshlands in the mid-16th century, commented that he could not 
 “comende the healthfulness of it: And especiallie nere the sea coastes…and other 
 lowe places about the creeks which gave me a most cruell quarterne fever” (Norden 
 and Ellis, 1840, quoted in Dobson, 1989:3). 
 
 By the late 17th century the Fens were still perceived by outsiders to be a hostile, 
isolated place, under the constant threat of flooding (Nicholls, 2000) – a threat exacerbated 
by neglect of drainage systems following the late 16th century Dissolution of the 
Monasteries (Whyte, 2002). The Fenlanders themselves were generally viewed less than 
favourably. In 1695, William Camden described the locals: 
 “the inhabitants of this and the rest of the Fenny country…Fen-men, a sort of people 
 (much like the place) of brutish uncivilised tempers, envious of others whom they 
 call Upland men, and usually walking aloft upon a sort of stilts; they all keep to the 
 business of grazing, fishing and fowling. All this country in the winter time, and 
 sometimes for the greatest part of the year, laid under water” (Camden, 1701, quoted 
 in Whyte, 2002:41).  
 
Despite relatively successful 19th century attempts at Fenland reclamation, resulting in a 
“tamed, drained and productive landscape” (Williamson, 2006:211), external perceptions of 
the Fens remained of an unhealthy, unwholesome “region of bogs and swamps, of fever-
haunted marshes, and ague-infested lowlands” (Balfour 1891:1). The perceptions of the 
older generations of Fenlanders of their own environment were still strongly influenced by 
superstitions and legends, although attitudes of the younger generations were beginning to 
change: 
 “The people themselves are not easy to make friends with, for they are strongly 
 suspicious of strangers; but once won over, are said to be staunch and faithful. They 
 are grave, long-featured, and rather melancholy in face, touchy and reserved in 
 disposition, and intensely averse to change or innovation of any sort; many of them 
 live and die within the limits of a narrow parish, outside of which they never set foot. 
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 The younger generations are changing; but they show less disbelief in the old 
 legends than indifference to them” (Balfour, 1891:5). 
 
 The mystical and dreadful reputation of the Fenlands, particularly in relation to 
miasmas, made “men fearful of entering the Fens of Cambridgeshire, lest the Marsh 
Miasmas should shorten their lives” (Watson-William, 1827:108), while the Fen water 
“poisons the circumambient air…and sickens and frequently destroys many of the 
inhabitants” (Parkinson, 1811:21). During much of the post-medieval period agues and 
fevers were largely attributed to marshland emanations from decaying animal and vegetable 
materials, and ‘miasmic fever’ specifically attributed to the inhalation of gases released 
through the decomposition of organic matter in marshy environments, or the intake of 
‘infected’ waters (Brown, 1867; Holmes, 1891; Nicholls, 2000). In the late 17th century, Dr. 
Thomas Sydenham, often cited as the “English Hippocrates” (Dobson, 1997), commented 
that:  
 “…if one spends two or three days in a locality of marshes and lakes, the blood is in 
 the first instance impressed with a certain spirituous miasma, which produces 
 quartan ague” (Sydenham and Wallis, 1788, quoted in Creighton 1965:312-3). 
 
There is, however, tentative evidence that a link between insects and illness had been 
noticed as early as the 1690s. Merret (1695:342–3) described how “midges [mosquitoes] are 
in some places very troublesome” and that ague was “very rife, with few strangers escaping 
without a seasoning.” Sydenham also noted that fevers and agues appeared in the autumn 
months after the summer swarming of insects (Dobson, 1997), although he was still satisfied 
to attribute ague itself to a spirituous miasma. Superstitions and legends concerning the 
character of the Fens persisted well into the 19th century. Tiddy Mun, for instance, was a 
Lincolnshire bog spirit who was believed to have control over Fenland mists and waters. 
Locals were known to call upon Tiddy Mun for help during flooding episodes (Balfour, 
1891). Malaria, agues and fevers were also personified and given names such as the Bailiff 
of the Marshes and Old Johnny Axey, so high was their prevalence (Nicholls, 2000). 
 Dobson’s (1997) review of mortality records for Essex, Kent and Sussex strongly 
suggests that endemic malaria represented a significant threat to the marshland populations 
of these areas. In the twenty four parishes examined, burials outnumbered baptisms for 
nearly every decade during the 17th and 18th centuries. Wrigley and Schofield (1981) found a 
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similar rate in the Fen parish of Wyberton, Lincolnshire. Crude death rates and infant 
mortality rates in the Lincolnshire, Cambridgeshire and Norfolk Fenlands during this period 
were also consistently higher than in upland and even urban parishes (Nicholls, 2000). More 
specifically, seasonal fluctuations in burial rates often seemed to be timed with the life-
cycles of mosquito and parasite, suggesting that malaria was indeed an important factor in 
these elevated rates.  
 Although it seems that there can be little doubt that malaria was a significant 
influence on the mortality of post-medieval marshland populations, there is contention as to 
exactly how significant. Modern day temperate P. vivax strains are generally considered to 
be ‘benign’, especially when compared to the often-deadly tropical P. falciparum. For 
instance, no deaths were attributed specifically to vivax malaria during the 1969 Sri Lanka 
epidemic, in which half a million people were infected (Warrell, 2002). The impact of vivax 
malaria on morbidity and mortality in the post-medieval period has recently been heavily 
downplayed (Hutchinson, 2004; Hutchinson and Lindsay, 2006; Lindsay et al., 2010). These 
authors instead attribute Dobson’s (1997) observed seasonal fluctuations in burial rates to 
misdiagnosed cases of acute enteric and respiratory disease. There can be little doubt that 
conditions such as typhoid, leptospirosis, gastroenteric diseases, and tuberculosis greatly 
affected Fen/marsh dwellers, particularly considering the potential difficulties of procuring 
fresh, clean drinking water in these environments (Hutchinson and Lindsay, 2006). Some of 
these diseases, as previously discussed, are symptomatically similar to malaria, particularly 
in their tendency to cause cyclical paroxysm (Karunaweera et al., 2003), which may have 
resulted in automatic diagnoses of ‘ague.’ It is highly likely that patients often suffered from 
more than one disease (comorbidity), possibly being predisposed by active vivax infection 
(White and Plorde, 1991). Sydenham, for instance, wrote that: 
 “whensoever I have observed any one long labouring under one of these agues...I 
 could certainly foretell that he could not long after be taken with some dangerous 
 distemper...infants often-times after these autumnal intermittents become rickety, 
 having swollen and hard bellys being hecticall, troubled with a cough and other 
 symptoms of being in a consumption” (Sydenham and Wallis, 1788, quoted in 
 Dobson, 1997:330). 
 
 Although modern vivax malaria is assumed to be benign in that the disease itself 
rarely causes death, it still exacts a debilitating toll upon its host (Vogel, 2013a). Clinical 
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research involving patients suffering from vivax malaria demonstrates that the disease 
increases the rates of malnutrition (Williams et al., 1997), low infant birth weight (Sina, 
2002), anaemia, hepatosplenomegaly, and splenic rupture (Warrell, 2002). The debilitating 
effects of the disease also undermine the ability of individuals and communities to 
contribute productively to economies on a local, regional, and national scale (Mendis et al., 
2001; Carter and Mendis, 2002; Vogel, 2013a). Desowitz (1997:4) described P. vivax as an 
“economic” pathogen due to its repeated attacks over a long time period: “It is the 
unproductive labourer who is repeatedly feverish, aching, and anaemic”. 
  It is unknown whether past strains of P. vivax were as ‘benign’ as modern strains are 
perceived to be (although this perception has been challenged recently, as discussed in 
Section 3.5). If we assume that past English vivax malaria was indeed benign, we should 
also assume that the effects of the disease on past communities were at least as severe as 
witnessed in modern populations with access to medications. Nicholls (2000) suggests that 
past populations exposed to vivax malaria would have suffered a chronic state of ill-health. 
The increased post-medieval marshland mortality rates and reduced life expectancies 
certainly support this suggestion, particularly when considering the interaction of malaria 
with other conditions, such as enteric diseases (Mendis et al., 2001; Nicholls, 2000). Social 
status in the post-medieval period may well also have compounded the effects of P. vivax 
infection on the local populations of the Fens and marshlands. Dobson (1980, 1989) 
discusses the social inequality inherent in such populations. Affluent land owners, for 
example, could afford to live outside of the perceived ‘unhealthy’ locations and hire 
labourers to work within these areas. The poorer employees, which often included whole 
families, would have had no choice but to take on the work, thus running the risk of repeated 
exposure to malaria (Nicholls, 2000). 
 To add to the burdens of living in such an unhealthy environment, there developed a 
widespread dependence upon narcotic drugs to counteract the acute symptoms of malarial 
infection. During the 18th and 19th centuries, the Fenland districts of East Anglia exhibited 
the highest consumption rate in England of both opium and laudanum (Berridge, 1977). 
Hemp was also regularly dried and smoked. An ‘ague drop’ containing arsenic was often 
given to young children, leading to numerous child fatalities in the 19th century (Dobson, 
1997), and in Kent, narcotism was recorded as a major cause of infant mortality in the mid-
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19th century (Hunter, 1864). The doping of babies by their carers to keep them quiet seemed 
to have been a popular, albeit potentially lethal strategy (Dobson, 1997). If not dangerous 
enough by itself, opium was often “mixed with everything imaginable: mercury, hashish, 
cayenne pepper, ether, chloroform, belladonna, whiskey, wine and brandy” (Hodgson, 
2001:104). The beneficial effects of Peruvian, or Jesuit’s, bark (which contains quinine) in 
malaria therapy was known to English physicians as early as the late 17th century, but 
prohibitive expense and limited availability put the remedy out of reach of the common 
Fenlander until the late 19th century (Dobson, 1997). By this time, the shadow of malarial 
infection was withdrawing from England, leaving a need for opioid narcotics and alcohol 
based on habit, rather than necessity, particularly among the older generations:     
 “…it is only here and there that one can find traces of the poor ague-shaken, opium-
 eating creatures of earlier times. Many an old woman eats opium openly, and I fear 
 all the men who can get it will drink gin. But the days are gone by when the one or 
 the other was in constant and daily need, to still the shaking or deaden the misery 
 born of the fevermists and stagnant pools” (Balfour 1891:147). 
 
2.5: The withdrawal of English malaria  
 Partial reclamation of areas of the English Fens and marshlands had occasionally 
been attempted from the Roman period onwards. As previously discussed, the late Anglo-
Saxon/early Norman Sea Bank represented the first truly successful protective barrier, 
allowing for increasing medieval settlement and exploitation of the fertile siltlands of 
Lincolnshire and Cambridgeshire. Earlier canalisation had also improved access and trade 
routes in these areas. Further local attempts at drainage, mostly associated with the 
monasteries, took place during the medieval period, but it was not until the 17th century that 
concerted efforts to drain and reclaim the Fenlands were mounted (Williamson, 2006). 
Spurred by the General Drainage Act of 1600 and the promise of reclaimed land as a reward, 
wealthy outside businessmen employed Dutch engineers (Cornelius Vermyden being the 
most famous) to improve drainage courses throughout the Fenlands, East Anglia and 
southeast England (Cracknell, 1959; Williamson, 2006), with varying degrees of success. 
These projects were, quite understandably, often met with considerable resistance from local 
inhabitants, who perceived that the changes would destroy their traditional ways of life. For 
the most part, such protestations went unheeded, although local resistance in some instances 
forced delays well into the 18th century (Williamson, 2006).  
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 However successful these projects happened to be, certain areas of the Fens and 
marshlands remained undrained and continued to be used as pasture until the steam-driven 
revolution of the early 19th century finally conquered the most poorly drained areas. An 
excursion through the modern day Fenlands of Lincolnshire and Cambridgeshire very much 
reinforces the impression of a tamed, highly productive agricultural landscape. The modern 
Fenlands boast some of the most fertile and highest quality arable farmland in Britain. In 
some areas up to 92% of the landscape is now under arable cultivation (Cope-Faulkner et al., 
2010). The shift from the largely pastoral-based economies of the medieval and early post-
medieval periods to almost exclusively arable-based economies was accelerated by steam-
powered drainage in the early 19th century (Darby, 1956). 
 Major drainage schemes in Romney Marsh took place a little later than in the 
Fenlands of Lincolnshire, Cambridgeshire, and Norfolk. One of the most impressive projects 
was the 1804-6 cutting of the Royal Military Canal around the northern margins of the 
marsh. Where upland waters once passed through the Marsh, the Canal now diverted them 
around (Robinson, 1988; Eddison, 2000). During the 19th century the medieval Dymchurch 
Wall underwent considerable repair and strengthening and continues today to serve as an 
important defence against marine incursion (Robinson, 1988). As with the Fenlands to the 
north, the introduction of steam technology in the late 19th century and, later, diesel- and 
electric-powered drainage engines, complemented and essentially completed the task of 
drainage. Improvements in water quality in the Thames and Medway rivers, and increased 
availability of fresh water, would have reduced instances of comorbidity of vivax malaria 
and enteric diseases associated with contaminated water supplies (Hutchinson and Lindsay, 
2006). 
 So what of the effects of these dramatic post-medieval drainage schemes and shifting 
economies on the epidemiology of malaria in the Fenlands? Malaria was certainly still 
present and likely endemic in some areas by the start of the 19th century. However, hospital 
records and parish registers suggest that the disease was losing its grip on the Fen/marsh 
populations by the mid-19th century and was all but eliminated by the turn of the 20th century 
(Nicholls, 2000). This represents a startlingly rapid decline in the transmission of the 
disease. 
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 The reasons behind the withdrawal of malaria from the Fens and marshes of England 
during the 19th century are complex and multi-factorial, yet it is tempting to cite drainage as 
the direct, causative factor. Authors have, quite understandably, often made this assumption 
(Packard, 2007). However, Williamson (2006) notes that much of the siltland of 
Lincolnshire had been relatively densely populated for centuries prior to the great post-
medieval drainage schemes, yet mosquito populations would have continued to thrive due to 
the presence of stagnant water in drainage ditches and channels. Prevalence of ‘ague’ in the 
siltlands remained common through the 17th and 18th centuries. The effects of widespread, 
increasingly successful drainage schemes did influence a gradual shift from pastoral to 
heavily arable farming throughout the Fenlands and marshlands. The separation of livestock 
from human settlements, as well as the improvement of human dwellings, would have 
reduced the available over-wintering habitats of anopheline mosquitoes, thus lowering the 
vector population and infection rates below the level required for endemicity and the 
continued survival of the parasite (Carter and Mendis, 2002; Hay et al. 2004; Williamson, 
2006) and heralding the beginning of the end for malaria in Britain. By the end of the 19th 
century, when the role of mosquito vectors in the transmission of malaria was finally, 
scientifically understood, “the disease was not even of concern to the Fenlanders 
themselves” (Nicholls 2000:530).  
 The following chapter will explore the different human malaria parasites and vectors, 
concentrating on Plasmodium vivax and Anopheles atroparvus. The lifecycle and 
pathophysiology of P. vivax will be also discussed, followed by the human immune response 
to infection and the immune status of temperate populations exposed to the disease. 
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CHAPTER 3: HUMAN MALARIA: CLINICAL ASPECTS 
AND IMPLICATIONS OF INFECTION 
 
“Agues and coughs are epidemicall; 
 Hence every face presented to our view 
 Looks of a pallid or a sallow hue” 
(Anonymous author of the poem ‘The Inundation, or Life of a Fenman’, 
quoted in Dobson 1989:3) 
 
 Malaria is a eukaryotic protozoan disease caused by the introduction of Plasmodium 
parasites into the human bloodstream through the bite of an infected anopheline mosquito 
(Warrell, 2002). Over 200 species within the genus Plasmodium have been identified, four 
of which commonly infect humans. These are P. falciparum, P. vivax, P. ovale, and P. 
malariae. Malaria is widespread throughout tropical and subtropical regions and also occurs 
in many temperate areas (Warrell and Gilles, 2002). The disease is contracted by up to 250 
million people per year, killing over half a million of its victims (World Health 
Organization, 2010; 2013), and it has been estimated that between 2.6 and 3.4 billion people 
currently live at risk of infection (Hay et al., 2004; Baird, 2007). Despite an intimate 
scientific knowledge of the genomic structure and pathophysiology of human Plasmodium 
parasites, the development of an array of prophylactic drugs, and long-term global 
eradication efforts, malaria continues to persist and thrive (Doolan et al., 2009).  
This chapter will begin with an introduction to the four human malaria parasites, 
followed by a brief overview of the evolutionary origins of malaria. The main mode of 
transmission will then be discussed along with the lifecycle, pathophysiology, and supposed 
‘benign’ status of Plasmodium vivax. This is followed by a brief overview of the human 
immune response to infection and a discussion of the implications of the presence of the 
disease in both modern temperate populations and past British populations.   
 
3.1: Human malaria parasites 
 
 The primary method of malaria transmission is via the bite of an infected female 
anopheline mosquito, the only mosquito genus capable of transmitting the disease to 
humans. Infection by Plasmodium parasites can occur congenitally (e.g., Rai et al., 2013) or 
through transfusion with contaminated blood (Kitchen and Chiodini, 2006), but introduction 
62 
 
of the parasite through a mosquito vector is by far the most common method of 
transmission. Of the four human malaria parasites, P. falciparum is commonly considered to 
be the most lethal, being responsible for the majority of deaths attributed to malaria. P. 
falciparum is, therefore, also sometimes referred to as ‘malignant malaria,’ whereas P. 
vivax, for instance, is often considered ‘benign’, since it has not traditionally been associated 
with high mortality rates (Gilles, 2002). However, as discussed later, researchers (e.g., 
Mendis et al., 2001; Beg et al., 2002; Baird, 2007; Rogerson and Carter, 2008; Anstey et al., 
2009) have recently questioned the labelling of P. vivax as ‘benign’, emphasising in 
particular the neglected status of this potentially deadly disease.  
Each species of Plasmodium was historically characterised by the periodicity of 
associated fevers suffered by the infected host. These fevers result from the body’s immune 
response to the synchronised eruption of parasites from infected red blood cells, possibly in 
an attempt to raise bodily temperature above the threshold of parasitic tolerance (Gravenor 
and Kwiatkowski, 1998). P. falciparum, vivax, and malariae were known as ‘tertian’ 
malaria, since the periodic febrile paroxysm (or sudden fever) occurs every 48 hours, while 
P. ovale was referred to as ‘quartan’ since paroxysm occurs every 72 hours (Table 3.1). 
These terms are rarely used by modern researchers, who prefer to use species name as the 
identifier, since these periodicities can be complicated (or non-synchronised) by comorbidity 
or infection by multiple Plasmodium generations (Sallares, 2002). It is, of course, important 
to be familiar with the historical usage of malaria terminology if modern researchers are to 
analyse the presence of the disease in antiquity.     
 
Plasmodium species Periodicity (hours) 
P. falciparum 48 
P. vivax 48 
P. ovale 72 
P. malariae 48 
Table 3.1: Plasmodium species and the periodicity of fevers (Perez-Jorge and 
Herchline, 2014) 
 
3.1.1: Plasmodium falciparum 
 
 P. falciparum infection most commonly occurs in sub-Saharan Africa, but has been 
responsible for large-scale epidemics in India, Sri-Lanka, and Haiti (Gilles, 2002). This 
species requires sustained temperatures of at least 20°C for a minimum of twenty days for 
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successful sporogenesis (the production of sporozoites, or Plasmodium protozoa) and 
development within the mosquito vector, and is therefore mostly confined to tropical and 
subtropical latitudes (Dobson, 1997). P. falciparum malaria predominates in these areas due 
to its high rate of reproduction within the human host and the year-round presence of 
mosquito vectors (Sallares, 2002). This species of parasite is particularly dangerous as it is 
the only one that causes sequestration (or clumping) of infected red blood cells in blood 
vessels and organs, including the brain. Symptoms of falciparum malaria may include acute 
fever, vomiting, diarrhoea, splenomegaly (enlarged spleen), jaundice, anaemia, renal failure, 
hypoglycaemia, neurological impairment, cerebral and pulmonary oedema, and coma (Ellis, 
1989; Gilles, 2002). Falciparum malaria is especially dangerous to the non-immune, 
pregnant women, the unborn and young children (Molyneux, 1989; Lindsay et al., 2000).  
 
3.1.2: Plasmodium ovale 
 
 This species is less widespread and therefore less commonly encountered than P. 
falciparum or P. vivax. Ovale malaria is generally confined to sub-Saharan Africa and is 
most often found in the western region of the continent, although sporadic prevalences of 
infection have been recorded in the western Pacific region, China, and Southeast Asia 
(Gilles, 2002). The P. ovale parasite can be suppressed and out-competed by other 
Plasmodium species, although mixed infections (particularly ovale alongside falciparum) 
are relatively common. The lifecycle and pathophysiology of P. ovale are similar to that of 
P. vivax, other than the extended 72 hour period between febrile paroxysms (Table 3.1). 
Patients with ovale malaria usually suffer slightly milder symptoms and fewer relapses than 
with those with vivax malaria (Gilles, 2002). As with P. vivax, the P. ovale parasite is able to 
remain dormant within the host liver in the form of hypnozoites (or “sleeping parasites”), to 
later emerge and cause delayed disease relapses. 
 
3.1.3: Plasmodium malariae 
 
 P. malariae occupies a similar geographic range to P. falciparum, but is far less 
commonly encountered, perhaps being out-competed by the latter. As with P. ovale, P. 
malariae exhibits a similar lifecycle and pathophysiology to P. vivax. Malariae infection 
usually results in less severe sequelae than vivax malaria, although cases of severe, often 
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fatal kidney damage (nephrosis) have been reported in malariae infections (Carter and 
Mendis, 2002).  
 
3.1.4: Plasmodium vivax 
 
Plasmodium vivax is the most widely distributed species of malaria, occurring across 
tropical, subtropical, and many temperate regions of the world. It is far less commonly 
encountered in sub-Saharan Africa than P. falciparum malaria, which may be indicative of 
P. vivax being out-competed in tropical climates. Vivax malaria is particularly rare in the 
west of the African continent where much of the population lacks the Duffy blood group 
system, and are hence clinically referred to a being ‘Duffy negative’. Individuals with this 
genetic condition lack alleles controlling certain antigenic properties of red blood 
(erythrocytes) cell membranes. This confers specific immunity against erythrocytic invasion 
by P. vivax parasites (Marsh, 2002). 
 P. vivax accounts for between 80-400 million worldwide cases of malarial infection 
per year, 80-90% of which occur across the Middle East, Asia, the Western Pacific, and 
Central and South America (Mendis et al., 2001; Hay et al., 2004). The ability of the P. 
vivax parasite to survive and flourish in temperate climates means that up to 2.6 billion 
people live at risk of infection (Baird, 2007). It is this capacity that makes P. vivax the most 
likely culprit for the spread of malaria across northwest Europe and Britain in past centuries. 
P. vivax is the last species of malaria to be indigenous in Britain’s historical past (Kuhn et 
al., 2003), and hence this is the species of malaria on which this study will focus. 
 
3.2: The origins of human malaria 
 
 The Plasmodium parasite is a very ancient protozoan organism, originally thought to 
have evolved around 55 million years ago from Old World small mammal reservoirs, in 
parallel with early primates (Cockburn, 1963; Dunn, 1965). Fossil remains of anopheline 
and culex mosquitoes (vector species capable of infecting mammals and primates) have been 
recovered from Old World deposits of this period, along with associated Plasmodia parasites 
(e.g., Poinar, 2005). Recent biomolecular and genetic research has, however, extended the 
Plasmodium lineage back to approximately 200 million years ago (Rich and Ayala, 2006). 
Similar research suggests that P. falciparum is closely related to an avian malaria parasite 
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lineage that possibly diverged from mammalian parasites around 130 million years ago. The 
lines leading to modern human P. ovale, malariae, and vivax parasites likely diverged some 
100 million years ago (Carter and Mendis, 2002). 
Opinion is divided as to the exact location for the origin of P. vivax. It has been 
argued that the parasite may have had its origins in the New World (Ayala et al., 1999). 
Possible evidence for this can be seen in the modern presence of Plasmodium simium, “a 
malaria parasite of New World monkeys which appeared to be genetically, as well as 
morphologically, indistinguishable from P. vivax” (Carter, 2003:214). However, genetic 
research strongly suggests an Old World source for New World P. vivax, with P. simium 
being a likely vestige of this introduction (Li et al., 2001). Complementary phylogenetic and 
biomolecular studies suggest that southern Asia was the most likely place of P. vivax origin 
(McCutchan et al., 1996; Qari et al., 1996; Escalante et al., 1998), and its modern form 
probably diverged around three million years ago from P. cynomolgi, a parasite of Old 
World monkeys (Carter and Mendis, 2002). 
The intimate association between humans and malaria parasites can likely be traced 
to the dramatic deforestation of parts of the sub-Saharan African environment, caused by 
climatic change and agricultural expansion, and initiated around eight to ten thousand years 
ago (Packard, 2007). It has been suggested that this clearing of woodland and the subsequent 
creation of marshy land offered arboreal mosquito species a new ecological niche in which 
to breed in close proximity to human settlements (Capasso, 1998). This change has been 
implicated as resulting in the original spread of P. falciparum to humans from African 
arboreal primate reservoirs. The persistent presence of genetic red blood cell polymorphisms 
such as sickle cell anaemia, the thalassaemias, and glucose-6-phosphate dehydrogenase 
(G6PD) deficiency in many endemic malaria areas suggests long-term Plasmodium-driven 
selective pressures for such protective polymorphisms to occur and persist (Capasso, 1998; 
Hume et al., 2003; Carlton et al., 2008). 
 
3.3: The anopheline vector 
As with all species of malaria, infection of the human host with P. vivax begins with 
the inoculation of parasites into the bloodstream via the saliva of an infected female 
anopheline mosquito, while taking a blood meal from the human host. ‘Anopheles’ is a 
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genus of mosquito within the sub-family Culicinae of the order Diptera. Of the 
approximately 420 species of anopheles mosquitoes, around 70 are recognised as vectors of 
malaria parasites (Service, 1993).  Five species are common to the British Isles: A. 
algeriensis, A. claviger, A. messae, A. plumbeus, and A. atroparvus. Of these five, only the 
latter two species are thought capable of transmitting the Plasmodium parasite, and evidence 
of the role of A. plumbeus in transmission is tentative (Snow, 1998; 1999). Thus, it is A. 
atroparvus that is thought to have been the most important vector in the spread of malaria in 
past British populations. The present geographical distribution of A. atroparvus in Britain 
coincides with those areas worst affected by past episodes of malaria, such as the Fen and 
marshlands of south east and eastern England (Dobson, 1997). This suggests that A. 
atroparvus was indeed the main vector of past malarial transmission. A. atroparvus remains 
the most commonly encountered vector species throughout northern Europe today (Sinka et 
al., 2010). 
Although generally considered to prefer brackish, saline water for breeding (Snow, 
1999), A. atroparvus larval sites have also been identified in freshwater habitats, such as 
river margins, wells, and canals (Hutchinson, 2004; Sinka et al., 2010). However, it is the 
coastal salt marshes, brackish estuarine marshes, and fenlands of eastern England that 
provided (and still do, where such terrain is extant) the perfect breeding habitat. The species 
has been described as opportunistic, both zoophilic and anthropophilic in nature (Sinka et 
al., 2010). The adult female atroparvus mosquitoes semi-hibernate (overwinter) inside 
livestock shelters and human habitations, remaining in close proximity to food (Medlock 
and Vaux, 2011). The mosquito can remain infective at temperatures as low as 3ºC (Dobson, 
1980), although infectivity is reduced somewhat while overwintering (Snow, 1999). They 
can, therefore, survive harsh winters with constant access to blood-meals, emerging in 
warmer periods to return to their breeding grounds (Shute and Maryon, 1974; Hulden et al., 
2005). These combined factors provide the perfect intermediary vector for the most 
widespread of temperate malarial parasites, Plasmodium vivax. 
 
3.4: The lifecycle and pathophysiology of Plasmodium vivax 
Upon inoculation of P. vivax sporozoites (see Table 3.2 for definition of terms) into 
the human bloodstream by the anopheline vector, the introduced sporozoites travel to the 
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liver, inside which they experience several phases of reproduction, known as pre-
erythrocytic schizogony (Gilles, 2002). This process produces multiple single-nucleus 
parasite cells (schizonts), some of which remain sequestered and dormant within the liver in 
hypnozoite form. After 6-16 days of reproduction, a number of schizonts rupture, releasing 
merozoites into the bloodstream (Gilles, 2002). The merozoites attach to and invade 
erythrocytes (red blood cells), within which they reproduce asexually (erythrocytic 
schizogony), metabolising erythrocytic cytoplasm and up to 75% of endogenous 
haemoglobin in the process (Pasvol and Wilson, 1982).  
 
Schizont A cell that reproduces by schizogony 
Schizogony Asexual reproduction of Plasmodia sporozoites 
Sporozoite 
Motile, infective stage of Plasmodia that results from 
sporogeny within mosquito vector; inoculated into host 
Merozoite 
Schizont that arises from schizogony; erythrocyte-invasive form 
of the parasite; may enter either asexual or sexual phase of the 
parasite life cycle 
Trophozoite The asexual schizont of the Plasmodia parasite 
Gametocyte 
The sexual form, male or female, of Plasmodia; found in 
human erythrocytes; produce gametes upon ingestion by 
vector 
Hypnozoite 
Exo-erythrocytic 'dormant' P. vivax cell in the human liver; 
responsible for malarial relapse 
Table 3.2: Definitions of selected P. vivax life-cycle terms (Gilles, 2002) 
 
Within host erythrocytes, the merozoites become large, ring shaped trophozoites, 
which mature to form new schizonts. These eventually rupture the infected erythrocyte and 
are released back into the bloodstream. Prior to cell rupture, some schizonts differentiate 
into gametocytes (a pre-gamete cell form), which are later ingested by anopheline 
mosquitoes as they take blood meals from the infected host, after which they undergo a 
sporogenic cycle within the mosquito gut in preparation for infection of a new external host 
(Hadley, 1986; Pinello, 2008). Thus the parasite lifecycle is completed and perpetuated (see 
Figure 3.1). It is the rupturing of erythrocytes, release of schizonts, further erythrocytic 
infection and destruction, and the host immunological responses (the ‘blood stage’ of 
infection) that cause the symptoms of vivax malaria (Trampuz et al., 2003). 
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Figure 3.1: The lifecycle of Plasmodium vivax (after Mueller et al., 2009:556). 
 
The hypnozoite stage of parasitism is peculiar to both of the P. vivax and P. ovale 
organisms and does not occur in falciparum or malariae infections. Quiescence within the 
host liver allows the parasite to ‘hibernate’, thus making it less dependent on year-round 
populations of mosquito vectors to complete its lifecycle. It is this capability that gives P. 
vivax malaria an advantage over other malaria species in temperate climates, where vectors 
may not be as prevalent in colder periods of the year. The P. vivax parasite is particularly 
suited to temperate climates as it requires a relatively low temperature of 16ºC (compared to 
20ºC for P. falciparum) for at least sixteen days in order to reach maturity within the 
mosquito gut. This required average temperature is regularly reached during most summers 
in southern Britain (Dobson, 1997). The ability of both mosquito vector and parasite to 
‘hibernate’ through cold winters (the vector within human or livestock habitations, and the 
parasite within the human host) is a crucial factor in continuing and maintaining malaria 
transmission in a host population (Dobson, 1980). Research has shown that P. vivax ably 
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survives the harsh winters of northern Europe and the Korean Peninsula, for instance (Oh et 
al., 2001; Hulden and Hulden, 2011).  
The reduced virulence and ‘hibernating’ hypnozoite stage of P. vivax infection are 
likely adaptive traits borne out of a long evolutionary history of primate parasitisation 
(Anstey et al., 2009), factors which allow the P. vivax parasite to keep its host alive during 
extended sub-optimal transmission conditions (Ewald, 1994). The circumstances 
determining activation of dormant hypnozoites are not clearly understood, although recent 
research (Hulden and Hulden, 2011) suggests that the bite of non-infective anopheline 
mosquitoes may introduce specific salivary proteins into the bloodstream. These proteins 
may signal the presence of new vectors, thereby triggering hypnozoite activation and disease 
relapse. One infected bite may trigger multiple relapses within a relatively short time period. 
Relapses may also be triggered by infection with other diseases, including falciparum 
malaria (Vogel, 2013a). 
The persistent presence of hepatic hypnozoites and their capacity to cause relapse, 
sometimes many months or years following initial blood-stage infection (Ewald, 1994; Adak 
et al., 1998), can confound medical strategies of disease prevention and treatment (Baird et 
al., 2007; Price et al., 2007). This is often the case with outbreaks of temperate strains of P. 
vivax, which have a tendency to produce a primary blood-stage infection, before entering an 
extended period of hepatic dormancy host for at least 9-12 months. Intermittent relapses and 
dormancy periods are then experienced  (Adak et al., 1998; Oh et al., 2001; Price et al., 
2007). Such delayed attacks of disease have been recorded in vivax-exposed populations and 
in travellers returning from endemic temperate zones, such as parts of the Korean peninsula 
and Indian sub-continent (Ellis, 1989; Baird et al., 2007).  
 Infection by malarial parasites is generally characterised by cyclical paroxysm, 
which is defined as “an acute fever that is typically preceded by chills and rigor” 
(Karunaweera et al., 2003:188). Paroxysm is a common host reaction to many bacterial, 
viral, and parasitic infections and represents a highly complex immunological response. The 
blood stage of P. vivax infection elicits well-defined (in terms of duration), repeated cyclical 
paroxysmal episodes and is, therefore, one of the most intensely studied host immunological 
responses to parasite infection. P. vivax initiated paroxysmal episodes are usually 
characterised by chills and rigor, accompanied by the development of a high fever of up to 
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41° C within three hours of onset. Following these initial symptoms, body temperature falls 
and profuse sweating occurs, lasting for several hours until normal temperature is regained. 
Paroxysm is often accompanied by nausea, vomiting, headache, myalgia, and joint pain. The 
entire episode usually lasts from 4-8 hours, after which the patient is left physically 
exhausted (Mendis et al., 2001; Karunaweera et al., 2003).  
 Research has suggested that paroxysm and inflammatory responses associated with 
P. vivax malaria are more severe than in P. falciparum (Baird et al., 2007; Price et al., 2007; 
Anstey et al., 2009), a somewhat surprising implication given the much lower percentage of 
erythrocytic invasion and preferential targeting of young erythrocytes (reticulocytes). Hence, 
the P. vivax parasite invades only approximately 2% of total blood cells. In comparison, P. 
falciparum invades 80% of all erythrocytes (Pinello, 2008), resulting in a much higher 
parasite load. Price et al. (2007:80) suggest that this difference in symptomatic severity may 
be due to the ability of the P. vivax parasite to induce “fever at levels of parasitemia lower 
than those causing fever in P. falciparum infection…the host inflammatory response is 
activated to a greater extent during P. vivax infections, with plasma levels of fever-inducing 
cytokines being higher in vivax malaria compared with P. falciparum infections”. The exact 
role of cytokines in the immunological response in P. vivax infection is not yet clearly 
understood, although recent research has suggested that they may play a vital role in 
protecting patients from developing severe symptoms (Gonçalves et al., 2012). 
Many cases of P. vivax malaria are non-life-threatening if the infection is not 
complicated by comorbidity, or co-infection with other malaria parasites, and the patient 
receives suitable treatment. Despite this, the similarity of vivax paroxysmal symptoms to 
other infections can cause misdiagnosis, especially in imported cases where the physician is 
unfamiliar with the disease (e.g., Hänscheid et al., 2003). Since P. vivax is generally 
assumed to be non-fatal, the disease has acquired the reputation of being ‘benign’. However, 
even uncomplicated infection can occasionally result in ‘severe’ vivax malaria, 
encompassing life-threatening symptoms, some of which are remarkably similar to those 
seen in cases of P. falciparum malaria. These symptoms can include lung injury, splenic 
rupture, renal failure, cerebral malaria, acute respiratory distress syndrome (ARDS), severe 
anaemia, and haematoma (Beg et al., 2002; Baird et al., 2007). Complications of these 
symptoms by concurrent diseases/infections or nutritional deficiency increases the potential 
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lethality of severe P. vivax malaria, particularly in children (Caulfield et al., 2004). The 
similarity in symptoms between P. falciparum and severe P. vivax malaria has led to 
misdiagnosis and subsequently inadequate treatments, particularly in areas where expensive 
diagnostic equipment is not readily available. When presented with symptoms of severe 
vivax malaria, clinicians in these areas often ascribe an automatic diagnosis of P. falciparum 
(Baird, 2007), resulting in ineffective control of dormant hypnozoites. The pathophysiology 
of severe P. vivax infection is poorly understood, particularly since studies have sometimes 
failed to take into account complicating factors such as concomitant infections, access to 
treatment, individual immunity, and drug resistant parasite strains (Rogerson and Carter, 
2008; Anstey et al., 2009).   
 
3.5: The ‘benign’ status of P. vivax 
A growing awareness that P. vivax infections may be responsible for cases of severe 
and fatal malaria has prompted a renewed consideration of the assumed ‘benign’ status of 
the disease, and has stimulated calls for increased research funding (see Bassat and Alonso, 
2011). These calls have been partly driven by recent studies highlighting cases of severe P. 
vivax in Southeast Asia (Kochar et al., 2005; Barcus et al., 2007; e.g., Tjitra et al., 2008). 
Funding of malaria research has, quite understandably, been focused on P. falciparum, the 
most virulent and deadly species. Due to the perceived benign nature of P. vivax malaria, the 
disease has received “lower priority from researchers, policy makers, and funding bodies” 
(Price et al., 2007:79), attracting approximately only 3% of malaria research funding 
(Gething et al., 2012). P. vivax is also notoriously difficult to study in a laboratory setting, 
since it generally operates at low levels of parasitemia and has a more complex life cycle 
than P. falciparum. The low erythrocyte infection percentage and hypnozoite stage of P. 
vivax infection confound in-vitro study of the pathogen, and hence complicate research on 
drug resistance, mechanisms of attack, and general pathophysiology (Baird et al., 2007).  
The global burden and potential lethality of P. vivax infection combined with a lack of 
adequate research funding have led to the parasite being described as “perhaps the most 
neglected, potentially dangerous and highly prevalent infection” (Baird, 2007:533).  
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3.6: The human immune system and its response to Plasmodium infection 
 
3.6.1: The immune system 
 
Much of early 20th century malaria research was focused on the characterisation of 
certain aspects of the disease, mostly conducted through microscopic analysis of vector, 
parasite, and infected blood samples (Cox, 2010). By the mid-20th century, revolutionary 
advances in biotechnology allowed researchers to investigate the disease on a biomolecular 
level. Much of this work was driven by the search for effective vaccines (Marsh, 2002), 
some of which proved highly successful in helping to eliminate malaria, particularly in 
developed, temperate areas. With modern technological advances, understanding of the 
mechanics of the immunological response to malaria continues to grow.  
Early research on malaria immunology, such as that undertaken by Golgi and his 
contemporaries, hinted at the intricacies of the relationship between the human immune 
system and its parasitic invader (e.g., Laveran, 1891; Ross, 1910). Building upon this early 
foundation, researchers now appreciate that the human immune response to infection 
represents a complex and sophisticated coordination of processes aimed at the control and 
destruction of invading organisms, achieved without harming the host. Since a discussion of 
the full complexities of the human immune system is beyond the scope of this study, a 
simplified overview of the processes involved in the immune response will be presented, 
before considering the more specific responses to malaria infection. An understanding of the 
molecules and processes involved in the immune response to malaria infection is important 
if successful methodologies for biomolecular analysis of archaeological human remains are 
to be successfully achieved.  
The human immune system comprises two distinct, but complementary mechanisms: 
the innate and adaptive responses. The innate response forms the initial protection against 
invasion from exogenous pathogens. It is non-specific in that it produces immune factors 
that do not recognise specific pathogens. Instead, it offers generalised protection through 
recognising common pathogenic genetic patterns (Kindt et al., 2006). The adaptive response 
comprises the secondary immune defence system, which produces and utilises specialised 
immune factors to develop and build up an immunological memory. The adaptive response 
is split into two mechanisms, the humoral and cellular immune responses. Put simply, 
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humoral immunity refers to the processes by which protein antibodies are produced and bind 
to foreign molecules (or antigens), thus acting as a marker of infection. Additionally, the 
humoral response initiates the production of cytokines. The cellular immune response 
produces cytotoxic T lymphocytes which bind to and subsequently destroy foreign 
molecules (Berg et al., 2002; Riley, 2004). 
 When a new pathogen first invades its host, it will encounter the body’s pre-existent, 
innate defence mechanism. This consists of interactions between non-specific IgM 
immunoglobulins and phagocytes, the latter consisting of macrophages and neutrophils that 
ingest foreign bodies. This results in the ‘recognition’ of exogenous pathogenic microbes 
and adherence to them, thus marking them for phagocytosis. In this manner, the innate 
mechanism allows for an immediate response to pathogenic invasion. However, since the 
pre-existent, circulating phagocytes and immunoglobulins are relatively scarce within the 
bodily tissues, there may be insufficient numbers to cope with the pathogen load. In this 
situation, the macrophages initiate an inflammatory response, controlled by the release of 
certain cytokines (Wood 2001). These proteins serve a number of important functions, such 
as the activation of extra macrophages and increases to vascular permeability. They also 
promote increased blood flow to the affected area, which introduces further immune factors 
to fight the infection. Cytokines are also responsible for the increase in bodily temperature 
(fever) associated with illness, which is a protective measure aimed at limiting pathogenic 
replication. The innate immune response of phagocyte replication and pyrexia (fever) may 
be enough to kill the invading organism (Wood, 2001). 
 If the innate immune response fails to recognise or destroy a pathogen, the adaptive 
immune system is required. Lymphocytes represent the most important components of this 
system. Memory T and B lymphocytes, for instance, are crucial, as they develop long-term 
immunity to specific pathogens. B lymphocytes are particularly important since they release 
immunoglobulin antibodies (Parham, 2009). A primary role of these antibodies is to 
‘recognise’ and bind to foreign antigens. The specific binding sites on antibody molecules 
are known as ‘paratopes’, while the target sites on the pathogen are known as ‘antigenic 
epitopes’. The binding process (also called ‘opsonisation’) marks the pathogen for 
phagocytation (Figure 3.2). Most antibodies consist of two identical heavy (H) chains and 
two identical light (L) chains, each consisting of approximately 110 amino acids. These 
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chains together form a Y-shaped structure (Figure 3.2) weighing around 150kDa (Janeway, 
2001). They are considered to be relatively large biomolecules. 
 
 
Figure 3.2: Basic antibody structure and interaction with antigenic epitopes. Dark blue – 
heavy chains; light blue – light chains (adapted from Fvasconcellos, 2007). 
 
The five main classes of immunoglobulin antibodies are IgA, IgD, IgE, IgG, and 
IgM. Each class has different functions and specific paratope configurations, although they 
can have identical specificity to antigens (Wood 2001). IgG antibodies are the most 
abundant class, accounting for approximately 75% of serum immunoglobulins (Nezlin, 
1998). They consist of the classic Y-shaped heavy and light chain structure held together by 
disulphide bonds, and are mostly active in the adaptive immune response. IgGs can remain 
in the blood serum for extended periods following infection (Meulenbroek and Zeijlemaker, 
1996) and are one of the few classes of antibody that crosses the placenta, sharing maternal 
immunity with the developing foetus (Kane and Acquah, 2009). IgMs are by far the largest 
antibodies, with a molecular weight of up to 950kDa. This is due to a unique structure in 
which five pairs (a pentameric form) of heavy and light chains are linked by a heavy central 
J-chain (Figure 3.3). IgMs are non-specific and free circulating, forming a vital part of the 
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innate immune response. Their unique structure means that IgM paratopes bond very 
strongly (avidity) and to a wider range (specificity) of antigenic epitopes. IgMs also act upon 
up on certain complementary receptors to increase their avidity (Wellek et al., 1976). These 
are crucial properties in a ‘first-response’ immunological unit.  
 
 
Figure 3.3: Immunoglobulin M (IgM) structure. Blue – heavy chains; yellow – light chains; 
green - disulphide bridges; black – J chain (adapted from Fijałkowski, 2006). 
 
 
3.6.2: The immune response to Plasmodium vivax infection 
 
In this section, consideration of the immune response to vivax malaria infection is 
given initially under the assumption that the infection is the patient’s first contact with the 
parasite. It is also assumed that the patient is in relatively good health with no pre-existing 
conditions that would offer protection against or exacerbate the infection. Although this 
scenario may not prove common in the field, it is important to explore how the Plasmodium 
vivax parasite interacts with a healthy immune system with no immunological ‘memory’ of 
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malaria infection, before considering particular factors which may alter the course of the 
infection.  
The immune response to infection by Plasmodium vivax parasites begins following 
the first inoculation into the bloodstream by the anopheline vector. Due to the very short 
period of sporozoites blood stream circulation prior to hepatocytic (liver cell) invasion, the 
exact mechanism of the primary immune response to inoculation is not clearly understood. 
However, it is likely that at least some of sporozoite antigens are recognised by the innate 
immune response, which may prevent some of them from invading the liver cells (Marsh, 
2002). The main innate immune response is stimulated by the release of merozoites into the 
bloodstream by the rupture of infected hepatocytes, which usually occurs some 6-16 days 
after initial parasite inoculation. In response to the presence of numerous circulating foreign 
organisms, the immune system reacts very much as it would to any invasion by viruses, 
bacteria, or other parasites (Clark et al., 2006). As described above, the immediate response 
is the activation of innate IgM antibodies and phagocytes, and the release of cytokines in an 
inflammatory response.  
Complex parasite cell forms (e.g., merozoites) contain hundreds of antigenic 
epitopes and will therefore induce the production of further phagocytes and IgM antibodies, 
in the case of first malaria infection. If the infection is successfully controlled at this stage, 
these immune factors will remain in circulation for only a few weeks (Marsh, 2002). 
However, the adaptive immune system will be stimulated if the innate response fails to fully 
control the infection, or if the patient is later infected with a different strain; cross-strain 
protection is generally quite poor (White, 1996). 
The exact nature of the adaptive response to the presence of Plasmodium parasite 
molecules has only recently begun to be understood, particularly the roles of B- and T-
lymphocytes in antibody production and mediation. Of crucial importance are human 
leukocyte antigens (HLA). These ‘carrier’ molecules are produced by most body cells and 
determine “which antigens can elicit an immune response in any one individual” (Marsh, 
2002:68). Put simply, in the adaptive response to malaria parasite molecules, B-lymphocytes 
first recognise then absorb specific antigenic molecules. The molecule is broken down 
within the lymphocyte and its epitope is conjugated with a HLA molecule. This 
epitope/HLA complex is then transported back to the surface of the B-lymphocyte, where it 
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is recognised by a T-lymphocyte. This recognition stimulates the T-lymphocyte to produce 
specific T-helper cells, which in turn stimulate the B-lymphocyte to produce antibodies 
specific to the original antigenic epitope. This is an important stage in the development of 
immunological ‘memory’ (Marsh, 2002). 
The lifecycle of the Plasmodium vivax parasite presents unique challenges to the 
immune system upon first infection. Many of these problems are derived from the fact that 
the parasite spends the majority of its lifecycle within host cells (either hepatic or 
erythrocytic), which, in theory, offers a degree of protection against blood-borne immune 
system products. As previously mentioned, the brief time spend circulating prior to 
hepatocytic invasion allows for only a ‘transient’ innate immune response (White, 1996). 
Similarly, the merozoites and schizonts released from infected erythrocytes spend only a 
very brief exo-erythrocytic period before invading new red blood cells. Therefore, much of 
the immune response must be focused upon intracellular methods of neutralising vivax cells. 
In the liver, hepatocytes contain HLA molecules, which may allow for the production and 
presentation of surface antigens, subsequently marking the infected hepatocyte for lysis 
(Marsh 2002). Conversely, erythrocytes, in which the parasite spends the majority of its 
active life cycle, contain very few HLA molecules. To counteract this, the immune system is 
capable of recognising unique parasite-induced changes to the erythrocyte (in particular its 
cell membrane) and is thus able to mark the infected cell for destruction (Marsh, 2002). 
Research has suggested that antibody interaction with gametocytes released from infected 
erythrocytes may work to inhibit the reproductive cycle of the parasite once ingestion back 
into the anopheline mosquito vector has taken place (Mulder et al., 1994; Srikrishnaraj et al., 
1995; Lal et al., 2001).  
Erythrocytic release of merozoites and their by-products also stimulates the 
production of cytokines which, as previously mentioned, are responsible for the paroxysm 
associated with malaria infection. The exact roles of cytokines in the immune response to 
malaria are not yet fully understood, but have received considerable research focus (e.g., 
Karunaweera et al., 1992, 2003; Malaguarnera and Musumeci, 2002; Clark et al., 2006; 
Hemmer et al., 2006). It is known that the cytokine response is particularly high in vivax 
malaria infections, and may be an influence in the development of some of the potentially 
fatal severe vivax symptoms (Sina, 2002; Park et al., 2003) previously mentioned. 
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3.6.3: Immunity to temperate endemic P. vivax malaria: the Republic of Korea as a 
modern case study 
 
What is endemicity and what constitutes an endemic disease? Before discussing the 
development of immunity in endemic malarious areas, it is necessary to address these 
questions. ‘Endemic’ has been defined as “occurring frequently in a particular region or 
population”, and an endemic disease is one that is “generally or constantly found among 
people in a particular area” (Martin, 2010:242). Malaria is currently endemic in many 
tropical and sub-tropical countries. As can be seen in Figure 3.4, transmission is particularly 
intense in sub-Saharan Africa, south and Southeast Asia, and parts of South America.  
 
 
Figure 3.4: Global distribution of reported, confirmed human malaria cases in 2010 (adapted 
from World Health Organization, 2012). 
 
It is generally agreed that Plasmodium vivax was the malaria parasite prevalent in 
parts of Britain in past centuries, since the temperate climate and vector habitats would have 
been sub-optimal for survival of other human malaria parasite species (Dobson, 1997). It is 
pertinent, therefore, to explore the development and status of immunity to vivax malaria in 
modern populations inhabiting temperate areas. In doing so it may be possible to further 
understand mechanisms of immunity in past British populations. However, there are several 
important caveats to be made prior to attempting a retrospective analysis here. Firstly, the 
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status of endemicity of past malaria in Britain is unknown. It is unclear, for example, 
whether the disease was endemic for the entirety of its presence in the country, or whether 
there were short periods of endemicity, perhaps tied to climatic changes or population 
movements. As previously discussed, historical records from post-medieval south eastern 
counties certainly suggest that vivax malaria was endemic for much of the period. Prior to 
this, the existence of British malaria is disputed by some authors, who assume that the 
parasite was not present at all (e.g., Bollet, 2004; Pinello, 2008; Neginha et al., 2010), while 
others cite favourable climatic and environmental conditions for malaria transmission (e.g., 
Reiter, 2000), or medical accounts of symptoms highly suggestive of the disease (e.g., 
Franklin, 1983; Gasper, 2004). 
Secondly, the development of immunity to malaria is governed by a number of 
diverse and complex factors. These include individual health status at the time of infection, 
the presence of certain genetic factors (e.g., blood cell polymorphisms) influencing 
individual resistance, effectiveness of available treatments, transmission rate (itself being 
heavily dependent upon vector population/survivorship), and disease virulence. The latter is 
particularly important, since increased strain virulence would lead to a peak in mortality 
rates, thus increasing selective pressures. If occurring over an extended period, this may 
possibly influence the development of certain malaria-mediated genetic resistances, such as 
thalassaemia and G6PD deficiency. Although retrograde analysis from modern examples 
may not be ideal, it represents the only method of exploring the development of ‘immunity 
in action’ on the individual and population levels.   
Plasmodium vivax is the most geographically widespread malaria species, found 
throughout South America, the Indian sub-continent, Southeast Asia and the western Pacific 
islands (Mendis, 2001). As previously discussed, vivax malaria generally prevails in 
temperate areas. Due to the unique lifecycle of parasite and vector, vivax malaria can be 
described as somewhat transcending the definition of ‘endemic’ offered above. Whereas 
sub-tropical vivax fits the definition in that climatic conditions allow for year-long 
transmission, temperate strains require vectors and parasites that can survive through 
potentially unfavourable periods. In northwest Europe in antiquity, this mosquito vector was 
most likely Anopheles atroparvus, which commonly over-winters inside animal shelters and 
human habitations (Dobson, 1997). Anopheline vectors have also been observed over-
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wintering as far north as Finland (Hulden et al., 2005). This strategy gives the mosquito 
year-round access to blood meals and potential parasite hosts (Dobson, 1997). This finely 
adapted vector-parasite relationship and the ability of P. vivax to ‘hibernate’ inside the 
human host during periods unfavourable to transmission combine to make continuous 
endemicity a real possibility in temperate areas, both past and present. From the point of 
view of those studying temperate vivax malaria palaeoimmunity, it is somewhat unfortunate 
that the disease has been eliminated from most temperate areas of the World where it once 
flourished. This hinders attempts at immunological analogy between past and present 
temperate populations.  
Research on modern populations inhabiting endemic vivax malaria areas has 
generally concentrated on Indonesia, India, and the Korean peninsula. Since much of 
Indonesia and India are sub-tropical and tropical, this research is usually of less relevance to 
researchers studying vivax malaria immunity in past temperate areas. The Republic of Korea 
(ROK), however, presents a potentially more useful target. Climatically, the central areas of 
the Korean peninsula are perhaps the closest modern analogue to temperate north western 
Europe, with average summer and winter temperatures of approximately 22 to 24º and -4 to 
-2º Celsius, respectively (Korean Overseas Information Service, 1993). The low average 
winter temperatures likely account for the prevalence of vivax, rather than falciparum 
malaria here. 
After centuries of vivax malaria endemicity, The World Health Organization 
declared the ROK to be malaria-free in 1979. The disease, however, re-emerged in and 
around the Demilitarised Zone (DMZ) on the North/South Korean border in 1993 and has 
once again become established as a source of temperate malaria. Up to 80% of the re-
emerging cases occur in military personnel serving in the DMZ (Feighner et al., 1998; Oh et 
al., 2001), and a recent resurgence in cases suggests an increase in drug-resistant vivax 
strains (Jun et al., 2009). Malaria morbidity rates in the ROK rise annually in the spring and 
early summer months, which correspond to the activation of dormant hepatocytic vivax 
parasites in preparation for a short summer season of vector-mediated transmission. The 
high post-medieval mortality rates recorded in the Fens and marshlands of England suggest 
a similar pattern of infection and pathology. These record high mortality in the spring and 
autumn, which Dobson (1980) suggests correspond to deaths associated with relapse of 
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vivax malaria in the spring, and autumnal mortality influenced by primary infections 
acquired in the summer months.  
The main vector involved in the transmission of the Korean strains of vivax malaria 
is most likely Anopheles sinensis. This species is behaviourally similar to A. atroparvus in 
that they are both zoophilic (Ree et al., 1967). The species differ significantly in habitat 
preference: A. sinensis is usually confined to fresh water breeding grounds, while A. 
atroparvus generally prefers a brackish environment. A. sinensis is also far less 
anthropophilic than A. atroparvus and is not known to overwinter in human dwellings 
(Harrison and Scanlon, 1975). The predilection of A. sinensis for animal blood has been 
suggested as a possible cause of the mid-1990s surge in vivax malaria cases, which followed 
widespread crop failures and a forced reliance on livestock as a food source. It has recently 
been suggested that zooprophylaxis (the movement of livestock in order to attract zoophilic 
mosquitoes away from potential human targets) may be a more effective vivax malaria 
control than reduction of mosquito numbers (Nah et al., 2010). Behavioural differences 
between A. sinensis and A. atroparvus strongly suggest that the latter may be a more 
efficient vector of vivax malaria. If this is indeed the case, transmission of past British 
malaria may have been more intense than in modern ROK populations. 
 Korean data is particularly useful when considering the course of disease and host 
immune reactions in primary vivax infection, a situation most likely faced by non-immune 
migrants to malarious areas in the past. The investigation by Oh et al. (2001), for example, 
demonstrated an expected behaviour of vivax infection in the endemic DMZ, in that no 
relapses were reported over the winter months, with most infections acquired during the 
summer becoming evident the following spring. Long-term latency (the time between 
transmission and emergence of infection symptoms) was typically at least 10 months, 
although prophylactic treatment in the interim period may have extended this. A common 
complication of vivax infection was thrombocytopenia (abnormally low blood platelet 
count), a condition encountered in similar studies of vivax malaria (e.g., Lim et al., 1996; 
Yamaguchi et al., 1997; Kumar and Shashirekha, 2006). Symptoms of thrombocytopenia 
range from minor bruising in mild cases, to uncontrolled, potentially fatal internal 
haemorrhaging in severe, untreated cases. Non-immune patients with vivax malaria tend to 
exhibit more severe thrombocytopenia than those with other forms of malaria, although the 
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exact reasons for this are not clearly understood. Research has implicated elevated levels of 
IgG antibody and certain cytokines (e.g., Yamaguchi et al., 1997), as well as circulating 
nucleic acids (e.g., Franklin et al., 2011). 
Defoe’s 18th century account from the Essex marshes concerning the deaths of 
multiple immigrant wives gains some credibility when considering the evidence presented 
by research on modern temperate and severe P. vivax infections:  
“I took notice of the strange decay of the sex here insomuch that all along the 
 country it was very frequent to meet with men that had had from five and six wives 
 to fourteen and fifteen wives, nay and some more. I was informed that in the marshes 
 on the other side of the river over against Candy [Canvey] Island there was a farmer 
 who was then living with the five and twentieth wife, and that his son, who was then 
 about thirty-five years old, had already had about fourteen...The reason, as the merry 
 fellow told me who said he had had about a dozen and a half wives....though I found 
 afterwards that he fibbed a little...was this: that they, being bred in the marshes 
 themselves and seasoned to the place, did pretty well with it, but that they always 
 went up into the hilly country or, to speak their own language, into the uplands for a 
 wife. That when they took the young lasses out of the wholesome and fresh air they 
 were healthy, fresh and clear and well: but when they came out of their native air 
 into the marshes among the fogs and damps, there they presently changed their 
 complexion, got an ague or two, and seldom held it above half a year or a year at the 
 most” (Defoe 1722, quoted in Cracknell, 1959:25-26). 
 
The local men, having been “bred in the marshes themselves and seasoned to the place” 
(Defoe quoted in Cracknell, 1959:25), evidently had at least partial immunity (whether 
acquired or innate is unknown) to malaria infection, which may have lessened the 
debilitating effects of the relapses they must surely have suffered. The non-immune 
immigrants, however, had no such fortune. A scenario may have been that young, non-
immune women were brought into a malaria-endemic area, after which they “got an ague or 
two…and seldom held it above half a year or a year at the most” (Defoe quoted in 
Cracknell, 1959:26). Although Defoe does not specify malaria as an agent of mortality, and 
acknowledges the likely exaggeration of the account, it is highly likely that the disease 
played a significant role in the morbidity and mortality of the non-immune.  
Given the additional immunological pressures afforded by the insalubrious Fen 
environment alongside potential P. vivax infection during pregnancy, increased Fen 
mortality for females may be expected over and above that observed in the non-Fen 
83 
 
cemeteries. Short (1750, quoted in Dobson 1997:318) wrote that immigrants into 
Fen/marshland areas: 
 “run a great risk, who having been brought up, and accustomed to a clear healthy air, 
 remove to fenny, wet, sticky soils; for people born in, and inured to a bad air, bear it 
 much better, and find less sensible inconvenience from it, than such as have been 
 bred and familiarized to a good one…though burials in such places may exceed 
 births…There it is evident, that great numbers dying in infancy, are supplied by fresh 
 in-comers, who settle and marry there; and that the endemics of the place are more 
 fatal to them than the natives.”  
 
 It is well established that women from non-malarial locations or those residing in 
areas of low endemicity have limited immunity to P. vivax, and are therefore more likely to 
develop severe sequelae in response to infection (Nostern et al., 2004; ter Kuile et al., 2008). 
Infections in areas of low malaria transmission, where women have little acquired immunity, 
are believed to be much more likely to result in severe disease and death of the mother or 
foetus, when compared to populations in P. vivax-endemic areas of Africa (Desai et al., 
2007). Should pregnancy have occurred, P. vivax infection may well have been catastrophic 
for these women and their infants. Pregnancy increases the risk of both primary malaria 
infection and maternal anaemia once infected (Diagne et al., 2000). It has been suggested 
that vivax malaria infection is a significant worldwide contributor to maternal and infant 
anaemia, a condition linked to low birthweight and an associated increase in infant mortality 
(Nacher et al., 2003; Price et al., 2007).  
Should mother and infant survive the pregnancy and immediate post-partum period, 
acquired immunity to P. vivax may develop if transmission rates are high enough to sustain 
the presence of antibodies. It is known that breastfeeding confers protective immunity to the 
infant against a number of conditions, including certain respiratory and enteric diseases 
(Hanson, 1998; Oddy, 2004). Breastmilk has also been shown to contain factors that inhibit 
the growth of the P. falciparum parasite (Kassim et al., 2000). Unfortunately, the vast 
majority of studies concerning the effects of breastfeeding on infant malaria infection have 
focused on P. falciparum. Subsequently, the extent to which breastfeeding affects the impact 
of P. vivax infection on infant health remains uncertain, although the anti-inflammatory and 
immunological agents present in human milk are likely to be beneficial (Goldman et al., 
1986; Riley et al., 2001; Field, 2005). The presence of protective genetic polymorphisms 
would also offer some degree of immunity to the infant. Despite the increasing availability 
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of symptom-suppressing quinine during the late 19th century (Schute and Maryon, 1974), 
earlier patients had no recourse to effective treatments and were therefore likely at increased 
risk of suffering severe vivax malaria symptoms, such as thrombocytopenia, 
hypoproteinemia, oedema, and dramatic weight loss (Price et al., 2007).  
To further understand implications of the presence of P. vivax for past British 
populations, it is necessary to consider the numerous ways in which the parasite affects 
modern populations living with the burden of vivax malaria. Anstey et al. (2009) cite many 
factors as being important in influencing the modern burden of vivax malaria. Geographic 
location, genotypes, and socio-cultural factors (e.g., poor access to health care facilities) all 
play key roles in increasing morbidity and mortality rates associated with normal and severe 
P. vivax infections in contemporary populations (Anstey et al., 2009). Studies in Papua New 
Guinea, for instance, have demonstrated that some populations are at higher risk of 
developing severe anaemia depending on their location, and the presence of genetic 
haemoglobinopathies (Fowkes et al., 2008; Genton et al., 2008). Papuan studies have also 
shown that non-immune immigrants from non-endemic vivax affected regions displayed a 
much higher probability of developing severe vivax malaria (Genton et al., 2008) and 
associated increased mortality rates. Rogerson and Carter (2008), however, caution that the 
true mortality rate caused directly by P. vivax infection in these studies is unclear, since 
comorbidities are not taken into account. Repeated infection and relapse have been linked to 
the development of severe vivax malaria, particularly when combined with comorbidity and 
poor nutrition (Baird, 2007). Indeed, repeated vivax infections can result in serious 
symptoms such as “cachexia, spontaneous abortions, male infertility, developmental arrest, 
and impaired mental function” (Rogerson and Carter, 2008:877). 
Despite increasingly common clinical reports of severe symptoms associated with P. 
vivax infection, the disease remains a relatively rare killer in modern settings. P. vivax has 
evolved the dormant hypnozoite stage and, accordingly, the virulence of temperate strains is 
tempered in order to keep the host alive through sub-optimal transmission periods (Hulden 
and Hulden, 2005). Although individuals with uncomplicated infection occasionally develop 
severe, life-threatening symptoms, access to suitable medications can at least help to control 
the symptoms. P. vivax relapse from the dormant hypnozoite state occurs unpredictably, and 
for reasons that remain poorly understood. In modern research on Nepal, where P. vivax and 
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P. falciparum share co-endemicity, 17% of those infected with the former experienced 
relapse within six months of the initial febrile attack (Manandhar et al., 2013). Similar 
studies from India have shown relapse rates varying between 9% and 40% (Adak et al., 
1998; Gogtay et al., 2000; White, 2011), depending upon the length of follow-up study. It 
should be stated here that these relapses occurred in individuals who had undergone anti-
malarial treatment. It is likely that relapses occurred more frequently in pre-medicalised 
antiquity, with the chances of each relapse coinciding with other illnesses increasing with 
each subsequent febrile episode. For instance, Samuel Jeake (1652-1699) of Rye, Sussex, 
kept extensive diary records between 1667 and 1693, in which he chronicled 330 personal 
attacks of ague (Dobson, 1997). This averages over 12 relapses per year, and although not 
all attacks were severe or debilitating, they often resulted in lengthy episodes of ill health.  
As previously discussed, the transmission and relapse rates of P. vivax in temperate 
areas are generally quite low, especially where endemicity is sporadic. As a result, any 
partial immunity acquired after the primary attack may be lost in the extended period prior 
to the first relapse. Hence, populations in low-transmission areas do not generally achieve 
consistent levels of acquired immunity. The disease affects people in every age category and 
causes long term debilitation in terms of personal health, longevity and productivity (Mendis 
et al., 2001). Untreated vivax malaria eventually becomes a chronic condition, with the 
individual suffering consistently low-level fatigue and anaemia until the next relapse 
(Aufderheide and Rodriguez-Martin, 1998). It has been suggested that “every person in a 
moderately P. vivax-endemic area can expect to experience anywhere from 10 to 30 or more 
episodes of malaria in the course of childhood and working life” (Mendis et al., 2001:101). 
The deleterious economic impact of an endemic disease that frequently incapacitates 
working adults should not be underestimated, especially in populations already suffering 
with poor health and/or inadequate access to healthcare. 
There is uncertainty as to the exact reasons why post-medieval marshland mortality 
rates were so high. While there is little doubt that malaria played an important role, it is 
unknown whether the disease was the primary contributor. Some researchers have suggested 
that 16th and 17th century strains of P. vivax may have been more virulent than modern 
strains (e.g., Dobson, 1980; Pinello, 2008). Pinello (2008), for instance, argues that the 
possible introduction of new P. vivax strains into post-medieval Britain through increased 
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trade links may have altered indigenous parasite genotypes, causing a subsequent increase in 
virulence. Unfortunately, the exact parasite strains in operation in the past are unknown. 
While it is possible that highly virulent strains of P. vivax attributed to high seasonal 
mortality, strain-based explanatory models must remain conjectural for the present.  
It has been argued that past mortality figures cannot be wholly trusted, since the 
diagnosis of vivax malaria by physicians prior to the 20th century may have been confused 
by the similarity of malaria symptoms to other common diseases (e.g., Swellengrebel and 
Buck, 1938; Hutchinson, 2004; Hutchinson and Lindsay, 2006). For instance, water-borne 
pathogens causing cholera and other enteric conditions undoubtedly played a part in 
increasing mortality rates in unsanitary areas, where cases may have been misdiagnosed as 
malaria, or ‘ague’. Hutchinson and Lindsay (2006) discuss the deleterious effects of large-
scale raw sewage dumping into the Thames and Medway rivers on downstream, marshland 
communities, citing a mid-19th century cholera epidemic as a major cause of increased 
mortality rates in these areas. They do not, however, attempt to account for the similarly 
high post-medieval mortality rates observed in the Lincolnshire and Cambridgeshire 
Fenlands, which would surely have suffered far less from urban water contamination. They 
also assume that all P. vivax infections were benign, ignoring modern evidence for increased 
prevalence of severe vivax malaria associated with repeated infection and comorbidities in 
economically deprived areas. Further to this, they present Registrar General Reports from 
the mid to late 19th century, the time period which heralded the disappearance of malaria 
from Britain and saw a sharp decrease in malaria transmission. 
The interaction of malaria infection with other conditions and diseases is an 
important factor to consider when studying malaria-related morbidity and mortality in the 
past. Comorbidity can play an important part in the outcome of malaria infection, dependent 
on the type of concomitant condition (Sallares, 2002; Anstey et al., 2009). The syphilis 
bacteria (Treponema pallidum), for instance, cannot survive the high temperatures 
associated with malarial paroxysms (Fraser et al., 1998). Vivax malaria, therefore, provides a 
degree of protection against the development of this disease. Indeed, in the early 20th 
century, end-stage syphilis sufferers were subjects of ‘malariotherapy’, which entailed 
intentional infection with vivax malaria as a curative measure (Vogel, 2013 b). However, 
immune system compromise associated with malaria may leave the sufferer more 
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susceptible to the development of malnutrition (Williams et al., 1997), severe anaemia (Price 
et al., 2007), and infection by tuberculosis (Setzer, 2010) and typhoid (Kumar and Katiyar, 
1995), the latter of which being particularly dangerous as it can intensify the symptoms of 
malaria (Pinello, 2008). The effects of combined helminth and malaria infections (a likely 
combination in past marshland communities) are currently unknown, with modern 
epidemiological research producing conflicting results (see Mwangi et al., 2006 for a 
synthesis of such research). 
It is unlikely that one agent alone can account for the high mortality rates in 
marshland and Fen environments. Rather, a combination of many factors must have been 
responsible. As has been discussed, in areas affected by poor sanitation, poor nutrition, and 
lack of access to healthcare in the form of diagnostics, prophylactics and medical treatment, 
one may expect to encounter high morbidity and mortality rates. This is exactly the situation 
in which many marshland and Fenland populations would have found themselves in the 
past. Individuals would have been exposed to numerous viral, bacterial, and parasitic 
infections, probably suffering from more than one at once. Even if P. vivax infections were 
indeed ‘benign’, the disease has been shown to contribute to child malnutrition (Williams et 
al., 1997), severe anaemia in infants and children, and maternal anaemia (Price et al., 2007; 
Anstey et al., 2009). These conditions, perpetuated by relapses and possibly combined with 
little protective immunity, would serve to weaken individuals sufficiently that co-infection 
could prove fatal. This is discounting the consequences of widespread post-medieval 
addiction to alcohol and opiates. Research on modern populations suffering the burden of 
vivax malaria strongly suggests that past populations would indeed have found the disease 
thoroughly debilitating and commonly associated with death (Tan et al., 2008).  
Findings from the previously discussed modern Papuan studies concerning 
immigrants to endemic malarious areas may go some way to supporting the Daniel Defoe’s 
18th century account of the repeated, swift demise of extraterritorial wives taken by Essex 
marshland inhabitants (Defoe, 1722). Two points stand out in this account. Firstly, although 
the numbers are probably exaggerated, it is quite conceivable that new brides brought into a 
marshland environment would quickly fall ill after being exposed to vivax malaria and other 
diseases associated with poor sanitation. If pregnancy occurred, then the increased 
nutritional requirements of the maternal body might lead to severe anaemia, resulting in low 
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infant birthweight and high mortality rates, both of mothers and infants (Nacher et al., 2003; 
Price et al., 2007). Secondly, and as previously mentioned, the account refers to the male 
inhabitants being ‘seasoned to the place.’ This suggests that there was a level of malaria 
immunity extant in the marshland populations of Essex. This may have taken the form of 
acquired immunity, or blood cell polymorphisms that conferred immunity to malaria 
infection. The presence of acquired immunity would suggest that transmission and relapse 
occurred frequently enough to sustain anti-vivax antibodies, while the presence of genetic 
immunities would indicate that the malaria parasites were sufficiently virulent to select for 
protective polymorphisms and had been present for sufficient time to drive the selection of 
these alleles. Although not usually associated with vivax malaria outside of tropical areas, 
new cases of populations exhibiting both glucose-6-phosphate dehydrogenase (G6PD) 
deficiency and the Duffy-negative blood group system in more temperate endemic vivax 
areas have recently been recorded (Sina, 2002; Louicharoen et al., 2009). This research 
suggests that long-term exposure to vivax malaria, even in temperate climates, can influence 
the development of protective haemoglobinopathies. It is not beyond the realms of 
possibility that either acquired or genetic immunities were present in past British 
populations and it is one of the aims of this study to investigate which type of immunity, if 
any, may have been active. 
The next chapter will discuss the different methods by which malaria is most 
commonly diagnosed in clinical settings with the aim of assessing the suitability of these for 
use in detection of the disease in archaeological human remains. This will be accompanied 
by an exploration of the history of palaeopathological attempts at identifying the malaria 
either directly through, or indirectly, in skeletal material. The chapter will end with a brief 
synthesis of the evidence gathered and a proposed method for detecting vivax malaria in 
archaeological contexts. 
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CHAPTER 4: THE CLINICAL AND 
ARCHAEOLOGICAL DETECTION OF MALARIA 
 
“It was then that he had the ague. He still remembers the terrible coldness, as he sat over 
the fire with his teeth chattering, and how his mother used to put rugs round him to try to get 
him warm. Soon afterwards he would be just as hot…it was severe enough to keep him away 
from school for six months…The disease…had been in existence for very many years” 
(Wilson, 1938:1383). 
 
 The accurate diagnosis of malaria in clinical settings is the most important step in 
ensuring that appropriate treatments are administered to the patient in order to facilitate swift 
recovery from a potentially fatal disease (Chiodini and Moody, 1989). Clinical diagnosis 
usually relies on serological identification of malaria parasites, parasite products, or human 
immune-response proteins. Detection of the parasites themselves is considered 
diagnostically definitive, since malaria infection can be symptomatically similar to many 
other conditions (Gilles, 2002). Blood-slide light microscopy is therefore considered the 
‘gold standard' of diagnostic methodologies, although in certain instances misdiagnosis can 
occur (Hänscheid, 1999). It is due to these potentially catastrophic errors that biomolecular 
techniques of detecting clinical cases of malaria have gained in popularity in recent years, 
each offering alternative or supplementary strategies alongside microscopy. These are 
generally aimed at detecting the presence of the malaria parasite on a molecular level (e.g., 
Plasmodium DNA), products of the parasite released during infection, or products of the 
human immune response to infection. Some of these biomolecular techniques have been 
adapted to use with archaeological human remains, with varying degrees of success, and so 
it is therefore necessary to provide a brief overview of how each of the most-commonly 
adapted tests is used in its original, clinical setting. Traditional palaeopathological methods 
of identifying ancient disease and tracing malaria in human skeletal remains are then 
discussed, before exploring the use of biomolecular methodologies, including the potential 
advantages and drawbacks of each. Exploring and evaluating the most relevant clinical and 
palaeopathological methods are necessary steps prior to identifying the most appropriate 
analytical tests in the search for Plasmodium vivax malaria in archaeological human 
remains. 
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4.1: Clinical Detection 
 There are numerous methods employed in the effective detection and 
characterisation of malaria infection in clinical settings, ranging from basic light microscopy 
to highly specialised automated flow cytometry. This section outlines some of the most 
commonly used clinical detection methods that have the potential to be employed in 
palaeopathological or archaeological studies of malaria. 
 
4.1.1: Light microscopy 
 Microscopic detection of Plasmodium parasites was first achieved in 1880 by 
Charles Laveran, who observed active parasites within the erythrocytes of a patient suffering 
from ‘ague' (White, 1996). Simple microscopic analysis with few modifications has since 
become the standard method for the detection and diagnosis of malaria in clinical settings 
(Chipeta et al., 2009). Light microscopy is a relatively fast, inexpensive technique that 
requires little in the way of specialised equipment. The method is used to directly visualise 
erythrocytic and exo-erythrocytic parasites within a blood-smear sample, and a competent 
microscopist should be able to detect very low levels of parasitaemia (approximately 5-50 
parasites/μL of blood), as well as differentiate between Plasmodium species (Moody, 2002). 
Diagnosis of malaria based solely on symptomatic assessment can lead to mis-or over-
diagnosis, and hence ineffective treatment of the disease, particularly in situations where 
malaria is rarely encountered, such as in cases of infected travellers returning to a non-
malarious area (Chipeta et al., 2009). As has been previously mentioned, the early symptoms 
of malaria can be remarkably similar to other paroxysmal conditions, such as typhoid or 
influenza. In view of this, the World Health Organization (2010:36) suggests that 
confirmation of malaria by either microscopy or Rapid Diagnostic Test (RDT) should 
always be attempted, and that "treatment solely on the basis of clinical suspicion should only 
be considered when a parasitological diagnosis is not accessible."  
 Despite the high specificity of microscopic diagnosis, potential problems with 
sensitivity in terms of detection of low parasitaemia levels present a drawback, since such 
diagnosis is dependent on highly trained microscopists. Numerous studies (e.g., McKenzie 
et al., 2003; O’Meara et al., 2006; Zurovac et al., 2006; Ohrt et al., 2007) have demonstrated 
high inter-observer error, even among highly experienced technicians. Microscopic 
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diagnosis can be confounded by the fact that partially immune patients in endemic areas 
may exhibit no microscopically detectable parasites, particularly during periods of low 
disease transmission (Gilles 2002). The ability to detect low parasite loads is of crucial 
importance in an accurate diagnosis of active vivax malaria, which is often characterised by 
low-level parasitaemia (Anstey et al., 2009). Additional analytical techniques may therefore, 
in certain circumstances, be necessary to provide a definite diagnosis (Moody, 2002; 
Rosanas-Urgell et al., 2010).  
 Simple light microscopy cannot currently be employed in the direct detection of 
malaria in archaeological bone. However, recent research (Setzer et al., 2013) has provided a 
method of successfully visualizing preserved red blood cells (erythrocytes) in archaeological 
bone. The technique could also, theoretically, be employed to identify parasitised 
erythrocytes in infected individuals. Light microscopy could also potentially identify 
changes in bone structure caused by P. vivax infection, should such structures survive within 
the bone (see Wickramasinghe and Abdalla, 2000 for a clinical discussion of these changes 
in bone marrow). Light microscopy may well, therefore, play a useful initial role in the 
detection of ancient malaria, if the corresponding structures survive.  
 
4.1.2: Rapid diagnostic tests (RDTs) 
 Rapid Diagnostic Tests (RDTs) are a relatively recent addition to the malariologists' 
armoury and offer a fast, portable, cost-effective method of detecting malaria that require no 
specialised laboratory equipment and minimal training to use (Drakeley and Reyburn, 2009). 
Many of the commercially available test kits have recently been approved by national 
governmental agencies (e.g., The Food and Drug Administration in the USA) for use in the 
rapid diagnosis of malaria and are now becoming widely available (UNICEF, 2007). The 
introduction of RDTs has been welcomed by clinicians in remote parts of Africa, where 
laboratory facilities and experienced microscopists are not always readily available. The 
introduction of more expensive malaria treatments (e.g., artemisinin-based combination 
therapies), combined with the common practice of presumptive treatment of malaria (even 
when the patient tests negative) have prompted the need for cheap, reliable tests (Drakeley 
and Reyburn, 2009) as an alternative to microscopy. Correspondingly, many sub-Saharan 
countries now routinely employ RDTs in malaria diagnosis (Maltha et al., 2014). 
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 RDTs are immunochromatographic tests designed to detect parasite antigens in blood 
using specific monoclonal or polyclonal antibodies against the antigens. More recent 
versions are usually in the form of a cassette into which the blood sample and buffer solution 
are introduced. Target proteins are identified "by complexing them with capture antibody 
embedded in a line on a nitrocellulose strip through which a drop of blood is eluted by a few 
drops of buffer solution. The buffer solution contains a labelled antibody to complete a 
visualised complex and that also provides a second control line" (Drakeley and Reyburn, 
2009:334). Many of the early tests were designed to detect histidine-rich protein (PfHRP) of 
P. falciparum, pan-malarial Plasmodium adolase (an enzyme expressed in the blood stage of 
infection), or Plasmodium lactate dehydrogenase (pLDH), an enzyme produced by all 
malaria parasites (with different isomers, or forms, for each species) and released from 
infected erythrocytes (Piper et al., 1999; Kakkilaya, 2003). Some of the newer RDTs are a 
‘combination' style which, using the same parasite products as before, can detect either P. 
falciparum or one of the other three Plasmodium species. Drawbacks of ‘combination' RDTs 
are that they cannot specify parasite species beyond P. falciparum and cannot detect mixed 
malaria infections if P. falciparum is present. Non-combination PfHRP and pLDH tests are 
commonly used, the former being most extensively employed in Africa, where P. falciparum 
dominates, the latter in areas of high P. vivax and P. ovale prevalence (Drakeley and 
Reyburn 2009).  
 P. vivax-specific pLDH RDTs can detect a parasitaemia level of approximately 100-
200 parasites/μL of blood, whist also ‘capturing’ pLDH antigens for up to three weeks post-
infection (Kakkilaya, 2003). Although the detection limit is significantly higher than in 
microscopy, the ability to capture residual antigens gives RDTs an advantage in that the 
disease can be detected when, potentially, microscopically-observable blood-stage parasites 
no longer remain. This facility is particularly useful with diagnosing vivax malaria, since a 
positive RDT test can lead to treatment of latent hypnozoites. One problem with RDTs is 
cross-reactivity, which may result in a false positive test. PfHRP tests, for instance, are 
reported to have up to a 83% prevalence of cross-reactivity with antibodies to rheumatoid 
factor, although pLDH tests have a much lower reported prevalence of 3.3% (Bartoloni et 
al., 1998; Kakkilaya, 2003). The sensitivity of RDTs has also been called into question, 
particularly in cases of either very low or very high levels of parasitaemia, or in mixed 
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malaria infections (Mangold et al., 2005). Maltha et al. (2010), for instance, found that 
nearly 70% of vivax-specific RDTs tested using blood samples with high P. falciparum 
parasite density registered a false-positive result for vivax - a potentially life-threatening 
diagnostic mistake.  
 Although RDTs are proving to be an important and useful tool in malaria diagnosis, 
they should not be used to provide ‘stand-alone' diagnoses. Gillet et al. (2010:1) suggest that 
"the reliance on RDTs as the primary or the single tool for the diagnosis of malaria….should 
be avoided." 
 
4.1.3: Indirect/Immuno-fluorescence antibody test (IFAT)  
 The Indirect or Immuno-Fluorescence Antibody Test (IFAT) has been used in the 
diagnosis of malaria since the 1960s (e.g., Tobie and Coatney, 1961; Sodeman Jr. and 
Jeffery, 1966) and represents one of the first purely immunological approaches to malaria 
detection. Since then, IFATs have become increasingly important in malaria 
immunoserological diagnosis mainly due to their relative simplicity, replicability, low cost 
and high sensitivity (Doderer et al., 2007). The principle of the IFAT test is very similar to 
that of the more modern Enzyme Linked ImmunoSorbent Assay (ELISA) test (discussed 
later). The former can be seen as a precursor to ELISAs. In simple terms, IFATs use 
fluorescent microscopes to detect the reaction of fluorescent-conjugated antibodies with 
specific antigens, from which it is possible to determine the presence and quantity of 
specific antibodies in human blood (Collins and Skinner, 1972). As with the ELISA, IFAT 
methodologies in serology are generally based on the introduction of primary and secondary 
(the latter being fluorescent-conjugated) antibodies along with receptor blockers. These are 
interspersed with saline washes to remove non-bound proteins. Fluorescent reactions can 
then be visualised microscopically to determine the presence and quantity of the target 
antibody (Gotoh et al., 1995; Lee et al., 2011). 
 Despite the usefulness of IFATs in malaria immunoserology, ELISA may gradually 
replace this technique. ELISAs overcome the time-consuming IFAT process of multiple slide 
preparation, since their format is a pre-prepared 96 well plate containing antibody-coated 
surfaces. Attempts have been made to make the IFAT more suitable for processing high 
numbers of samples (e.g., Voller and O’Neill, 1971), but ELISAs offer a faster, more cost-
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effective alternative in situations requiring the processing of a high volume of samples. 
However, due to their high sensitivity and established methodological standards, IFATs have 
proven particularly useful in detecting P. vivax in areas of low endemicity and in 
asymptomatic patients (Lee et al., 2011). 
 
4.1.4: Polymerase Chain Reaction (PCR) 
 The Polymerase Chain Reaction (PCR) technique is designed to achieve the rapid 
amplification of unique, targeted regions of the DNA of a selected organism, resulting in the 
exponential increase in the number of these regions. These can then easily been visualised 
using electrophoretic fluorescence techniques (Gilles 2002). Since its development in the 
early 1980s, the use of the PCR technique has become increasingly prevalent in biological, 
medical, genetic, and forensic laboratory research (Bartlett and Stirling, 2003). PCR is 
routinely used in the diagnosis of cancer, viral and bacterial infections, and parasitic 
infections such as Lyme disease and malaria. The technique is recognised as "the most 
sensitive and specific method to detect malaria parasites” (Hänscheid and Grobusch, 
2002:395). PCR offers the ability to detect extremely low levels of parasitaemia (less than 5 
parasites/μL of blood) and is up to 1000 times more sensitive than microscopy (Bottius et 
al., 1996; Moody, 2002). Additionally, precise species differentiation is now achievable, 
even in cases of mixed malaria infection (Genc et al., 2010). The technique has also 
successfully been used without blood, as demonstrated by Mharakurwa et al. (2006), who 
utilised PCR to detect P. falciparum DNA in human urine and saliva samples, thus negating 
the usual requirement of infected blood samples. 
 Given these impressive facts, it would seem prudent to screen all potential malaria 
sufferers using PCR. However, this is simply not a viable option in many areas. The process 
requires sophisticated, expensive laboratory equipment and highly trained personnel, which 
limits routine, clinical analyses to all but the most developed, affluent areas. Issues with 
sample contamination, extended processing and reporting times, and protein degradation 
during transportation further ensure that the routine diagnosis of malaria using PCR remains 
beyond the scope of most clinicians working in malarious areas (Hänscheid and Grobusch, 
2002).  
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4.1.5: Radioimmunoassay (RIA) 
 This technique was first described by Yalow and Berson (1960). RIAs utilise 
radioactively-marked antibodies or antigens. These are mixed with a target blood sample 
which is assumed to contain non-radioactive versions of the same antibodies or antigens. 
Should these non-radioactive proteins be present, they displace their radioactive 
counterparts, thus freeing the radioactive marker. In the case of malaria, for instance, a 
measurement of the amount of freed marker using isotopic detectors demonstrates the 
presence of infection and level of parasitaemia. RIAs have proven to be highly sensitive in 
the detection of P. falciparum, especially in cases of low parasitaemia (Gilles 2002). 
However, their sensitivity in detecting antigens or antibodies associated with P. vivax seems 
to be less reliable (e.g., Avraham et al., 1983).  
 Much of the research utilising RIAs in malaria diagnosis took place in the 1980s 
(e.g., Mackey et al., 1980; Avraham et al., 1983; Avidor et al., 1987), yet despite the 
inherent radioactivity-related risks and requirement for special licensing and equipment, 
biomolecular research utilizing RIA techniques continues due to its relatively low cost and 
high sensitivity and specificity. However, the technique has been very much been supplanted 
by enzyme-linked immunoabsorbent assay (ELISA). This is almost certainly due to the 
prohibitive nature of utilizing radioisotopes, which severely limits the use of RIAs in field 
settings (Gilles 2002).  
 
4.1.6: Enzyme-linked immunosorbent assay (ELISA) 
 The enzyme-linked immunosorbent assay (ELISA, also referred to as Enzyme 
Immunoassay, or EIA) was developed in the 1970s as a safer alternative to the 
radioimmunoassay and a less cumbersome, time-consuming alternative to the IFAT (Doderer 
et al., 2007). In ELISA the radioactive signals are replaced by colourimetric or chromogenic 
indicators, thus eliminating the risk issues associated with RIA. ELISAs are commonly 
employed in medical diagnostic and industrial quality control applications to measure the 
presence and quantity of a particular antigen or antibody (Jordan, 2005). 
 As with most immunological tests for malaria, ELISAs were originally developed to 
detect antibodies to P. falciparum (Taylor and Voller, 1993) and suffered from poor 
sensitivity to other Plasmodium species (Doderer et al., 2007). Pan-malarial and species-
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specific ELISAs are more recent commercially available additions. Many of these more 
recent tests are still undergoing evaluative field trials to assess their quality in terms of 
specificity and sensitivity, particularly in comparison to other immunological diagnostic 
malaria tests, such as the IFAT (e.g., Doderer et al., 2007; She et al., 2007; Muerhoff et al., 
2010; Nam et al., 2010). The use of recombinant antigens, such as circumsporozoite (CSP) 
and merozoite surface (MSP) proteins, and ELISAs that can detect both immunoglobulin 
IgG and IgM antibodies, have so far proven particularly advantageous in the detection of P. 
vivax (e.g., Rodrigues et al., 2003; Doderer et al., 2007; Park et al., 2008).  
 The test is generally performed using 96-well plates, but can take a number of 
methodological forms. In malaria diagnosis, the most common forms are ‘direct’, ‘indirect' 
and ‘sandwich' ELISAs. The indirect form detects the presence of specific antigens or 
antibodies, whereas the sandwich form is used to both detect and quantify the target. The 
aim of both types is to observe a colour change within the wells that contain reactive, bound 
antigens/antibodies. A measurement of colour density and intensity reveals the presence and 
intensity of the reaction. Put simply, the direct method involves the introduction of samples 
containing antibodies conjoined with enzymes into the plate wells, each of which contain 
pre-prepared surfaces with affixed antigens: "If the antigen is present, the antibody-enzyme 
complex will bind to it, and the enzyme component of the antibody-enzyme complex will 
catalyze the reaction generating the colored product. Thus, the presence of the colored 
product indicates the presence of the antigen" (Berg et al., 2002:102). In indirect ELISAs the 
blood samples containing antibodies are introduced into the wells, followed by secondary 
enzyme-linked antibodies against human antibodies (e.g., enzyme-linked mouse-raised anti-
human antibodies). Colorimetric substrate is then added. Colour change associated with a 
bonding reaction between the introduced secondary enzyme-linked antibodies and human 
antibodies can then be recorded (Berg et al., 2002; Brown and Brown, 2011). The sandwich 
ELISA is very similar to the indirect ELISA, but utilises a different secondary enzyme-
linked antibody to the indirect test. Sandwich ELISAs are quite commonly used in malaria 
diagnosis since they provide the ability to directly measure both the presence and quantity of 
antigens (e.g., Bidwell and Voller, 1981; Chung et al., 2001; Lim et al., 2002).   
 A further type of ELISA is the competitive ELISA (C-ELISA), which is a highly 
sensitive assay designed to detect either very small antigens, or antigens present in low 
97 
 
concentrations. In C-ELISAs the sample under analysis is usually mixed with a known 
quantity of antigen which has been conjugated with an enzyme. This blend is then applied to 
a protein-binding plate coated with an antibody: "because only the conjugated form of the 
antigen allows for the colorimetric reaction to develop in the presence of the substrate, the 
maximal reading occurs when there is no antigen in the sample. The more antigen that is 
present in the sample, the lower the resulting [colorimetric] reading…the readout is 
inversely associated with the amount of antigen" (Jordan, 2005:423). C-ELISAs are not 
commonly used due to a comparatively higher workload and expertise, but they offer an 
important option when attempting to detect low concentrations of antigen (Jordan, 2005). 
 Advantages of ELISAs over other standard immunoassay tests, such as IFATs and 
RIAs, are generally cited to be in terms of higher sensitivity, comparative speed and ease of 
use, and the ability to test nearly 100 samples per plate. This latter point makes ELISAs 
especially attractive in situations that require the processing of a high volume of samples, 
hence their increasingly common use in industrial and medical applications (She et al., 
2007). The main disadvantages of ELISAs are the relatively high cost of the constituent 
materials and the requirement for both laboratory facilities and well-trained personnel (Vidal 
and Catapani, 2005). These factors may limit the use of ELISAs in malaria diagnosis, 
particularly in more remote and economically deprived areas.       
 
4.1.7: Western blot test 
 
 The Western blot (or immunoblot) test is a well-established and widely used type of 
immunological test aimed at identifying specific proteins. This is usually accomplished 
following separation by molecular weight, most commonly by polyacrylamide gel 
electrophoresis, or PAGE (Burnette, 1981). In PAGE, application of an electrical current 
induces the proteins to move through the gel, with the smallest moving fastest (thus 
separating by molecular weight). Once proteins are separated, the gel containing the proteins 
is transferred to a ‘blot', or membrane, which is usually made of nitrocellulose or 
polyvinylidene fluoride (PVDF). A separate stage, known isoelectric focusing, is sometimes 
employed prior to blotting. This is a technique used to separate proteins by electric charge, 
rather than by size (e.g., Polpanich et al., 2007). When transfer is complete, the membrane 
can be probed with an antibody to identify the presence of specific protein antigens (Towbin 
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et al., 1979; Abbas et al., 1991). The use of immunoblotting in clinical diagnosis of malaria 
is seen less frequently than other types of tests, such as the ELISA or IFA; this is possibly 
due to sample size limitations. However, the method is certainly viable (e.g., Makler and 
Hinrichs, 1993) and offers a reasonably swift and cheap alternative to other methodologies 
when bulk sampling is not required. Western blot tests in their various forms have been 
employed in the detection of ancient biomolecules in archaeological human remains (see 
section 4.4.4). 
 
4.1.8: Malaria pigment (haemozoin) detection: automated haematology 
 
 Automated haematology analysers have been utilised in the diagnosis of malaria 
since 1953 and have since proven useful tools in the early diagnosis of the disease 
(Campuzano-Zuluaga et al., 2010). Analysers were originally designed to facilitate complete 
blood counts (CBCs), a method of blood screening that is routinely used in medical and 
clinical settings alongside such methods as flow cytometry. Occasional attempts utilising 
CBCs were made to diagnose malaria through observing alterations in blood cell 
populations. However, due to the inability of the analysers to distinguish between malaria- 
and non-malaria-induced changes to blood cell count, this application was seldom used 
(Campuzano-Zuluaga et al., 2010). Recent advances in automated haematology have 
produced analysers and flow cytometers (e.g., Frita et al., 2011) which are capable of 
detecting a signature unique to infection with haematophagous organisms, including 
malaria: haemozoin.  
 Haemozoin (Hz), also known as malaria pigment, is a brown crystalline waste 
product excreted by all Plasmodium spp. parasites during the ingestion of haemoglobin in 
the erythrocytic stage of infection. Hz was first identified in 1847, although association of 
the presence of pigment with malaria infection was not achieved until the late 19th century, 
when Charles Laveran attributed it to Plasmodium parasites. In 1897 Ronald Ross observed 
the pigment within the gut of an Anopheline mosquito, and was thus the first researcher to 
identify mosquitoes as the vector for malaria infection (Sullivan, 2002). Since the 1950s the 
presence of Hz was usually detected through routine CBCs using automated analysers which 
are capable of identifying white blood cells (leucocytes) containing phagocytised pigment, 
although, as already mentioned, these machines were not designed to specifically diagnose 
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malaria (Hänscheid et al., 2001; Campuzano-Zuluaga et al., 2010). The most recent and 
advanced analysers utilise lasers to more accurately distinguish not only the presence of Hz, 
but also the Plasmodium species responsible (e.g., Noland et al., 2003; Nyunt et al., 2005). 
Despite evaluations of specificity and sensitivity yielding some conflicting results (Suh et 
al., 2003; Rathod et al., 2009), the analyses have so far proven to have high accuracy, 
particularly in cases of low parasitemia. The relatively high expense of equipment and 
laboratory expertise required for this type of analysis precludes its routine use in field 
diagnostics, but the technique has been particularly useful in diagnosing malaria in cases of 
infected travellers returning from malaria-endemic areas (Campuzano-Zuluaga et al., 2010).   
 The techniques described above represent the most commonly employed clinical 
methods of detecting and diagnosing malaria. They also have been, or have the potential to 
be, utilised in the search for the disease in past populations. 
 
4.2: Archaeological detection 
 
4.2.1: Palaeopathology and macroscopic analysis 
 
 Palaeopathology, the study of ancient disease, has a long and sometimes chequered 
history, fascinating and inspiring researchers since the first mid-18th century analyses of 
prehistoric faunal pathologies (Roberts and Manchester, 2005). Since then, the discipline has 
evolved through 19th century descriptive, rather than interpretive, analyses (Steinbock, 
1976), through 20th century large-scale population-based epidemiological and statistical 
analyses, to 21st century biomolecular-based applications. On the smallest scale, 
palaeopathological research can illuminate the health status of a single individual at the time 
of death, potentially providing information on nutrition, social status, and in rare instances, 
activity and behaviour. On a much larger scale such analyses can be vital in developing our 
understanding of pathogen antiquity, co-evolution with hosts, and the cultural and physical 
responses to the presence of disease within populations (Mitchell, 2003; Setzer, 2010).   
Evidence for disease in past societies can be gathered through inspection of historical 
documentation, artwork, and artefacts, although interpretational issues may limit the 
usefulness of these sources (Mitchell, 2011). Coprolites and preserved soft tissues can also 
provide direct evidence for disease and pathogenic processes (e.g., Aufderheide et al., 2005). 
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However, since these rarely survive in archaeological contexts, the medium of choice for 
study is usually skeletal remains, which can preserve remarkably well for extended periods 
of time in the burial environment. It is understandable, therefore, why skeletal remains have 
commanded the majority of palaeopathological research. 
 Chronic diseases can leave diagnostic markers in skeletal remains, (Roberts and 
Manchester, 2005), whereas highly virulent pathogens, such as plague, often destroy the 
host before reactionary bone remodelling occurs (Ortner, 2007). Macroscopic identification 
of such conditions is therefore rendered extremely difficult, if not impossible. Consequently, 
palaeopathological analyses of skeletal populations have traditionally focused on 
macroscopically identifiable chronic diseases (e.g., tuberculosis) in individuals that have 
survived the acute disease phase and have developed responsive bone changes in (Steinbock, 
1976; Ortner, 2003).  
 Working from a thorough knowledge of the morphological appearance of the normal 
human skeleton, a main task for the palaeopathologist is to clearly describe, record, and 
diagnose pathological lesions (Grauer, 2007) using standardised (as far as possible), 
unambiguous terminology based on clinical criteria (Roberts and Manchester, 2005).    
Macroscopic analysis of skeletal remains “serves as a starting point for virtually all 
methodological approaches” in palaeopathology, often forming a necessary prerequisite to 
supplementary biomolecular research (Grauer 2007:57). However, macroscopic diagnosis of 
disease in human remains presents many difficulties. Firstly, as already mentioned, acute 
diseases may leave no skeletal markers and therefore remain occult and undetected. The 
majority of observable disease processes in skeletal remains are the result of long-term 
chronic conditions (Roberts and Manchester, 2005). Secondly, diagnosis is usually 
dependent on good skeletal preservation, which is itself heavily dependent on multiple 
factors. These include but are not limited to: age of the buried individual (juvenile and infant 
bones often preserve relatively poorly), the effects of an individual's health upon the 
skeleton, burial customs, taphonomic and diagenetic processes in the burial environment, 
grave disturbance, care taken during excavation, and post-excavation processing. These 
factors can all serve to destroy evidence of disease processes (Mays, 2010). Thirdly, bone 
responds to disease either through destruction or proliferation of bone, or both at once. 
Consequently, different pathogens may induce similar, if not identical, osseous responses 
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(Grauer, 2007). Fourthly, many diseases have very complex aetiologies which are poorly 
understood. These include some of the most commonly observed and recognisable 
pathologies, such as osteoarthritis and cribra orbitalia (Waldron, 2009; Walker et al., 2009). 
Hence, although these diseases may be frequently recorded, extrapolations concerning their 
exact causes and subsequent impacts on health are ultimately confounded. Linked to this is 
the problem of applying clinical diagnostic criteria to dry bone for diseases where the former 
are not necessarily applicable to the latter (e.g., in diagnosing osteoarthritis) (Waldron, 
2009). 
 Finally, extrapolation of palaeopathological data to form population-wide 
interpretations of disease prevalence can be confounded by the osteological paradox (Wood 
et al., 1992). Put simply, this states that a cemetery population is not representative of the 
actual living population. For palaeopathological analyses, this may present the following 
problem: the presence of pathological lesions demonstrate that individuals survived their 
condition long enough to develop a bony response, whereas those displaying no observable 
pathologies may have died during the acute phase of a disease (Roberts and Manchester, 
2005; Pinhasi and Bourbou, 2007). This may lead to the assumption that the latter skeletons 
represent the ‘healthier’ individuals in a population, whereas they may actually represent the 
frailer portion of a population who succumbed, rather than adapted, to disease.  
Good skeletal preservation is particularly important, since patterning of bone 
changes throughout the skeleton may offer valuable diagnostic clues and aid in differential 
diagnosis (Roberts, 2009).Wherever possible, differential diagnosis should attempted: "by a 
process of gradual elimination on the basis of known patterning in modern clinical 
circumstances a most likely diagnosis may be made" (Roberts and Manchester, 2005:9). 
Differential diagnosis also benefits from accurate age and sex estimation of skeletal 
individuals, tasks that are not always straightforward (Grauer, 2007). For instance, the 
expression of certain diseases in bone may be age-dependent (e.g., β thalassaemia 
intermedia) (Lewis, 2010), or more commonly observed in a particular sex (e.g., rheumatoid 
arthritis) (Alamanos and Drosos, 2005). Despite the difficulties highlighted above, 
macroscopic methods remain some of the most commonly employed and useful diagnostic 
tools in palaeopathological analysis. 
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4.2.2: The palaeopathology of Plasmodium vivax malaria 
  
There has been little traditional palaeopathological research on vivax malaria. This 
may be surprising, given the fact that the disease undoubtedly affected so many people in the 
past. The reason for this dearth of research is, however, simple: although vivax malaria is a 
chronic condition potentially lasting many years, the disease elicits no direct osseous 
response. There are, therefore, no macroscopically observable skeletal changes that can be 
unequivocally attributed to malaria infection. The most common sequela of vivax malaria is 
haemolytic anaemia, which is likely caused by the preference of the parasite for 
reticulocytes and the repeated haemolysis of these young erythrocytes. In endemic areas, re-
infection and relapse may result in continual parasitisation and ongoing chronic anaemia 
(Collins et al., 2003). It has also been suggested that vivax malaria reduces the effectiveness 
of erythropoiesis and influences phagocytosis of non-parasitised erythrocytes 
(Wickramasinghe and Abdalla, 2000; Khan et al., 2010). These factors may help to explain 
the increased prevalence of anaemia associated with vivax malaria in comparison to 
falciparum malaria. The clinical focus tends to be on the haematological consequences of 
anaemia, rather than any effects the condition may have on the skeleton. Radiographic 
analysis has, however, suggested that certain skeletal markers may be associated with 
anaemia, and therefore may be used as a possible proxy indicator for malaria infection 
(Setzer, 2010). Two such skeletal markers that are commonly associated, rightly or wrongly, 
with anaemia in palaeopathological analyses are cribra orbitalia and porotic hyperostosis. 
 
4.2.2(i): Cribra orbitalia and porotic hyperostosis 
 
 Cribra orbitalia (CO) and porotic hyperostosis (PH) are two of the most distinctly 
recognisable pathological conditions in archaeological human skeletal remains and have 
consequently received much attention from palaeopathologists (Stuart-Macadam, 1991). 
Due to the plasticity and increased presence of haematopoietic bone within the non-adult 
skeleton, both conditions are more frequently observed in juveniles than in adults (Ortner, 
2003). CO is commonly encountered throughout Old and New World archaeological 
populations (Sullivan, 2005). It is characterised by pitting and porosity in the orbital roofs 
and usually presents bilaterally (Figure 4.1). PH is also encountered worldwide, although is 
much less frequently recorded than CO in past British populations (Walker et al., 2009; 
103 
 
Lewis, 2010). PH has been commonly recorded in Mediterranean and North American 
archaeological human remains (e.g., Angel, 1966; El-Najjar et al., 1976; Palkovich, 1987; 
Keenleyside and Panayotova, 2006) and is characterised by similar morphological changes 
to CO, but presenting as "circumscribed areas of pitting and porosity on the external surface 
of the cranial vault" (Walker et al., 2009:109) (Figure 4.2). It is often, but not exclusively, 
associated with expansion of the cranial diploë, which results in a characteristic ‘hair-on-
end' appearance when viewed radiographically (Walker et al., 2009). 
 
 
  
Figure 4.1: Bilateral cribra orbitalia (photograph by Jeff Veitch, Durham University). 
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Figure 4.2: Porotic hyperostosis evident on parietal and frontal bones (adapted from Lagia et 
al., 2007). 
 
Cribra orbitalia and PH generally receive little medical attention and are rarely 
reported in the clinical literature. Palaeopathologists have, therefore, been forced to deduce 
their aetiologies from studying skeletal material, which is hardly an ideal situation, since few 
researchers are medically trained. Despite familiarity with the macroscopically and 
radiographically observable characteristics of both conditions, palaeopathologists have yet 
to come to a consensus concerning the exact aetiological factors influencing their 
development (e.g., Walker et al., 2009; Oxenham and Cavill, 2010). The relationship (if any) 
between the conditions also remains unclear, although it is generally agreed that CO has a 
more complex aetiology than PH (Ortner, 2003). Undeterred by uncertainty concerning the 
factors influencing their development, researchers have attributed the conditions to 
numerous causes. For instance, chronic infection by parasites, especially Plasmodium 
species, has been considered an important factor in the development of CO and PH (e.g., 
Bathurst, 2005). However, before considering any possible influences of malaria infection 
on the development of CO and PH, it is useful to understand the history of research 
concerning the palaeopathological analysis of these important conditions. 
Early 20th century researchers were generally content with describing the conditions 
without in-depth consideration of their aetiologies. CO was first described in the late 19th 
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century (Steinbock, 1976), but the condition was not considered to be pathological. PH was 
initially described by Hrdlička (1914) as ‘symmetrical osteoporosis.’ It was not until 1966 
that the term ‘porotic hyperostosis’ was first coined by Angel in his research paper on 
prehistoric eastern Mediterranean populations, in which he linked the condition with skeletal 
manifestations of thalassaemia and sickle-cell anaemia related to chronic malaria infection.  
During the 1960s and 1970s a dominant explanatory paradigm for the presence of 
CO and PH in archaeological populations emerged: iron-deficiency anaemia (Walker et al., 
2009). Many of the contemporary, conflicting theories concerning the causes of iron-
deficiency anaemia were based on North American prehistoric and historic samples. 
Moseley (1965), for example, rejected earlier suppositions that PH was caused by malaria-
related thalassaemia, citing the lack of residual thalassaemic alleles in modern North 
American populations. Instead, Moseley attributed the high prevalence of prehistoric PH to 
iron-deficiency anaemia. This was followed with research by El-Najjar et al. (1976) which 
suggested a possible link between chronic iron-deficiency anaemia (characterised by a high 
prevalence of PH) and the heavily maize-based diets of prehistoric and historic Anasazi 
populations.  
Cybulski (1977) was one of the first researchers to suggest a multi-factorial aetiology 
for anaemia, opposing a single, diet-based cause. His study of historic, sedentary British 
Columbian populations demonstrated a high prevalence of CO, even though the Northwest 
coast of North America offers one of the most diverse environments in terms of marine and 
terrestrial resources. Given the varied resources and abundance of dietary iron available in 
the biosphere, Cybulski theorised that the aetiology of CO was both inherited and acquired, 
the latter being caused by parasite (or helminth) infection, the former possibly due to 
hereditary spherocytosis, a haemolytic anaemia characterised by spheration and subsequent 
haemolysis of red blood cells. Either condition would result in chronic anaemia, particularly 
in individuals with high iron requirements, such as pregnant and breast-feeding women, and 
growing children.  
 The potential importance of helminth and pathogenic infection in the development of 
anaemia, and hence CO and PH, was later highlighted by Walker (1986), Kent (1986), and 
Bathurst (2005). Walker's research suggested that marine-borne parasites and poor 
sanitation, rather than reduced dietary intake of iron, were the likely culprits for the high 
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prevalence of CO and PH among historic California Channel Island-dwelling Native 
Americans. Kent's (1986) research in the southwest of the USA suggested that anaemia 
associated with high pathogen loads derived from unsanitary living conditions, while 
Bathurst's discovery of the human intestinal parasites Diphyllobothruim spp. (fish 
tapeworm) and Ascaris lumbridoices (round worm) in Canadian Pacific coastal shell 
middens "supports the hypothesis that parasite burden may be a contributing factor to the 
incidence of anemia" (Bathurst, 2005:121).  
Studies conducted during the last decades of the 20th century show that researchers 
began to move away from single factor and reductionist theories concerning the aetiologies 
of anaemia, CO and PH, and towards more varied approaches. Stuart-Macadam (1992 a; b) 
for instance, suggested that diet may only play a minor role in the development of iron-
deficiency anaemia, and that the condition resulting in PH may actually represent an 
adaptive strategy within populations to protect against parasitic and pathogenic infection, 
since low levels of endogenous iron may inhibit the growth of invading organisms. It is via 
this mechanism that Murray et al. had earlier discovered that dietary-derived iron deficiency 
in Somali nomads prevented "the more serious consequences of potentially fatal infections 
with malaria, tuberculosis, and brucellosis to which the nomads are constantly exposed" 
(Murray et al., 1978:1115). Anaemia as a ‘healthy' adaptation proved a relatively popular 
theory, supported by researchers such as Wright and Chew (1998), although some (e.g., 
Holland and O’Brien, 1997) continued to champion a nutritional-based explanation. The 
1990s also saw an increasing appreciation of the potential effects of inherited factors on the 
development of anaemia, CO and PH, although much research (e.g., Hershkovitz et al., 
1991; Grauer, 1993; Mittler and Van Gerven, 1994; Tayles, 1996) remained split between 
either genetic inheritance or iron deficiency as causative factors, dependent upon geographic 
location of study. 
Iron deficiency as the primary cause of CO and PH was re-evaluated in the late 
1990s by Hershkovitz et al. (1997), whose research on skeletal manifestations of sickle cell 
anaemia conflicted with the commonly-held assumption that iron deficiency stimulates 
marrow expansion in order to create more haematopoietic bone, thereby increasing red 
blood cell output. They argued that such action is counter-productive, since marrow 
expansion would demand increased consumption of available nutrients, thus unnecessarily 
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stressing an already nutrient-deprived system. This viewpoint was later supported by 
histological research (Wapler et al., 2004), which demonstrated that less than half of the 
examined cases of CO exhibited the marrow hypertrophy traditionally attributed to iron 
deficiency. Ortner and Ericksen (1997) posited that CO-type manifestations in juveniles 
assumed to be caused by iron deficiency may actually be the result of sub-periosteal 
haemorrhaging associated with scurvy. They also cautioned that CO and PH may well have 
different aetiologies, even when both are observed in one individual. Peckmann (2003) even 
suggested a possible correlation between smallpox and a high prevalence of PH in 19th 
century South African communities.   
The first decade of the 21st century saw the emergence of a new explanatory model 
for CO and PH. Megaloblastic anaemia was first suggested by Fairgrieve and Molto (2000), 
who attributed the high prevalence of CO in archaeological Egyptian populations to the 
condition. As with iron-deficiency anaemia, megaloblastic anaemia is an acquired condition. 
However, the latter usually results from deficiencies in folic acid and vitamin B-12, and can 
develop due to dietary insufficiency and/or parasite infection (Sullivan, 2005). Despite this 
new development, some researchers continued to cite iron-deficiency anaemia as the 
primary cause of CO and PH (e.g., Keita, 2003; Papathanasiou, 2005; Obertová and Thurzo, 
2008). Walker et al.'s (2009) response to the continued uncertainty concerning the 
aetiological factors behind the development of CO and PH was to prepare a synthesis of the 
clinical and palaeopathological literature related to the conditions. The synthesis led them to 
agree with research suggesting that marrow hypertrophy cannot result from iron deficiency; 
rather, they cite megaloblastic and hereditary anaemias as more likely responsible for the 
development of PH and CO. The former, they suggest, may be influenced by haemolysis, 
while the latter can also being influenced by vitamin C deficiency.  
Although the long-standing iron-deficiency anaemia hypothesis has suffered a 
setback, some researchers (e.g., Oxenham and Cavill, 2010) continue to champion the 
theory. This is the state of modern thinking on the aetiologies of PH and CO: aetiological 
theories have almost come full-circle before maturation into a more integrated approach, 
from single causative factors such as Angel's malaria-induced inherited haemolytic anaemias 
and dietary-driven iron-deficiency anaemia, through iron deficiency as an adaptive strategy 
and megaloblastic anaemia. As with many palaeopathologically observable conditions, CO 
108 
 
and PH obviously have complex clinical aetiologies that are still not yet fully understood. A 
full appreciation of the complex factors contributing to their development can only be 
achieved when palaeopathologists move beyond single causative factors to analyse multiple 
lines of evidence including clinical, dietary, environmental, and socio-cultural data. This 
approach is now being taken by palaeopathologists more and more frequently.  
In terms of researching malaria in past populations, the aetiological association 
between CO, PH, and anaemia is less important. Although vivax malaria is a certain cause of 
clinical anaemia, a link between these skeletal markers and anaemia is currently tenuous. A 
more conservative stance would be to view CO and PH alongside other non-specific skeletal 
markers of stress, such as enamel hypoplasia and Harris lines (conditions discussed below). 
Facchini et al. (2004), for instance, demonstrated a positive correlation between enamel 
hypoplasia and porotic hyperostosis in Roman Ravenna, attributing the high enamel 
hypoplasia prevalence to nutritional stresses and parasitic infection, both of which would 
have been influenced by the surrounding swampy environment. The prevalence and 
distribution of non-specific stress markers can provide valuable information concerning 
health status on a population level (e.g., Facchini et al. 2004; Buckley, 2006; Gowland and 
Garnsey, 2010). Research on Anglo-Saxon Fen/marshland-associated populations (Gowland 
and Western, 2012), for instance, suggests that populations living in the type of environment 
conducive to malaria infection exhibited significantly higher prevalence rates of stress 
markers such as cribra orbitalia.  
 
4.2.4: Non-specific skeletal stress markers   
 Two of the most common palaeopathologically recorded non-specific stress markers 
in skeletal material are Harris lines and enamel hypoplasia. First clinically characterised in 
1926, Harris lines "are transverse sclerotic layers in the metaphyseal parts of long bones, 
reflecting the episodes of delayed or arrested development of the longitudinal growth of the 
bone" (Piontek et al., 2001:33). The formation of Harris lines has been clinically correlated 
with different stresses, including dietary deficiencies (e.g., Park, 1964) and general illness 
(e.g., Acheson, 1959). This correlation has inspired frequent palaeopathological study of 
Harris lines as potential indicators of episodic, non-specific periods of stress during bone 
growth in archaeological populations (Mafart, 2009). Their usefulness in this aspect is, 
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however, debated, and for the following reasons Harris lines will not be analysed in this 
study: firstly, although clinical research suggests a strong association between stresses and 
the formation of Harris lines, their predictability is low (Gindhart, 1969). For instance, they 
have been observed in ‘healthy' children, and not consistently in individuals who have 
suffered periods of high stress in childhood (Mafart, 2009). Secondly, Harris lines are 
notoriously difficult to observe in archaeological bone. Radiographic analysis is required for 
more accurate recording - equipment that is not always available to palaeopathologists. 
However, since Harris lines can also be difficult to see on radiographs, analyses may suffer 
from high inter- and intra-observer error (Grolleau-Raoux et al., 1997). Thirdly, since living 
bone continually remodels, Harris lines formed in childhood may be later remodelled and 
resorbed (Mays, 1995), and therefore undetectable. Finally, Harris line presence rarely 
correlates well with other, potentially more reliable non-specific skeletal stress markers, 
such as enamel hypoplasia (e.g., McHenry and Schulz, 1976; Alfonso et al., 2005; Mafart, 
2009).   
 Enamel hypoplasia (EH) has long been associated with non-specific episodic stresses 
during the early years of life (e.g., Sarnat and Schour, 1941). These stresses act to "depress 
the activity of the ameloblasts and to result in the production of a thin and poorly calcified 
enamel matrix, with the formation of linearly distributed pits or grooves of defective 
enamel" (Ogden, 2008:284). As with Harris lines, the exact aetiology of EH is uncertain. It 
has, however, been clinically linked to over one hundred conditions, including malnutrition, 
anaemia, parasitic infection, premature birth, low birthweight, and general illness in 
neonates and children (Duray, 1996; Lewis and Roberts, 1997; Palubeckaitė et al., 2002). 
Although minor enamel defects are frequently observed in outwardly ‘healthy' children 
(Ogden, 2008), it is generally accepted that the presence of EH is a reliable indicator of a 
stress-related interruption of amelogenesis (enamel formation) (King et al., 2005; Starling 
and Stock, 2007).  
Enamel hypoplasia has attracted much palaeopathological attention since "the nature 
of enamel means that defects cannot be remodelled and, therefore, they represent a 
permanent chronological record of a stressful incident during the first 7 years of life" (Lewis 
and Roberts, 1997:581). Working on this basis, researchers have attempted to quantify 
instances of hypoplasia, calculate age of occurrence, and determine the duration of insult of 
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each defect in ancient populations (e.g., McHenry and Schulz, 1976; Alfonso et al., 2005). 
On the surface, this sounds like the ‘perfect' pathology to study in ancient skeletal material - 
a medium that does not remodel (like bone) and usually preserves superbly well in the burial 
environment. There are, however, issues with EH analysis. For instance, many 
palaeopathological studies of EH rely on the assumption that all stages of enamel formation 
(e.g., secretion and later maturation stages) occur at set rates, which is not necessarily the 
case. Suga (1989:194), for instance, states that "the progressive mineralisation pattern is 
completely different between the matrix formation and maturation stages." Thus variation in 
the rate of amelogenesis calls into question the results of any research that does not 
recognise this. For the purpose of this study, it will only be necessary to record a basic 
presence/absence of EH. It is not important when stresses occur in the early years of an 
individual, but rather that EH is a reliable indicator of said stresses occurring at all.  
Although malaria cannot be directly attributed to EH formation, there can be little 
doubt that the infection would influence its development, particularly when comorbid with 
other conditions. Skinner and Hopwood (2004), for example, suggest that the development 
of EH in great apes is influenced by periodic episodes of malaria interacting with 
malnutrition. Interestingly, one of the malaria parasites recorded in great ape infections, P. 
silvaticum, is a relapsing type of malaria, akin to P. vivax in humans. The synergistic 
interaction of malnutrition and infectious disease has been noted as influencing EH 
development in humans (Duray, 1996). The immunosuppressive effects of malaria only 
serve to compound biological stresses by increasing the chances of co-infection with other 
diseases (Phillips, 1983). Unfortunately, recent research has suggested a lack of correlation 
between human malaria and EH development (Gowland and Garnsey, 2010; Gowland and 
Western, 2012). 
 
4.2.5: Inherited conditions 
 
 Inherited conditions represent one of a set of complex factors that dictate the 
outcome of the human host response to malarial infection, alongside host adaptive 
immunity, health status, comorbidity, and parasite virulence (Chotivanich et al., 2002). High 
frequencies of specific genetic mutations that confer a degree of protection against 
Plasmodium infection within a population suggest a long history of endemic disease 
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exposure and the "very considerable force of natural selection applied by malaria" (Sallares 
and Gomzi, 2001:211). Inherited mutations (also referred to as polymorphisms) that bestow 
protection against malaria infection can take a number of forms. Examples of such 
mutations are red blood cell (RBC) membrane abnormalities, such as a lack of the Duffy 
antigen on the RBC membranes in African populations (protecting against P. vivax infection) 
(Duffy and Fried, 2006), genetic changes in RBC shape such as in ovalocytosis (Cattani et 
al., 1987), enzyme deficiencies, such as glucose-6-phosphate dehydrogenase (G6PD) 
deficiency, and haemoglobinopathies, such as the thalassaemias and sickle cell anaemia 
(Allison, 2002; Williams, 2006).  
These inherited conditions all share a common trait in that they have, over an 
extended time period, become ‘balanced' polymorphisms, "in which the homozygote 
hematologic disadvantage is balanced by the heterozygote advantage of protection from 
malaria" (Chotivanich et al., 2002:1172). Haemoglobinopathies, such as thalassaemia, 
generally have higher frequencies in areas of the world also affected by endemic malaria, 
since they confer a degree of protection and, therefore, a selective advantage over non-
carriers (López et al., 2010). Thalassaemia is a good example of a balanced polymorphism, 
in that the homozygous disadvantage is balanced by a heterozygous resistance to malaria. 
Homozygous (thalassaemia major) sufferers usually die before reproducing, and non-carriers 
may die of malaria infection. This results in an increased frequency of surviving 
heterozygotes who pass on their increased resistance to malaria. 
The detection of inherited conditions associated with malarial infection in 
archaeological human remains is usually based on either identifying macro- and microscopic 
osseous changes, or directly testing aDNA for genetic mutations. Of course, neither of these 
techniques can definitively prove that an individual suffered from malaria, but only that their 
ancestors most likely had extended contact with endemic malaria (Sallares and Gomzi, 
2001). As with cribra orbitalia, porotic hyperostosis, and enamel hypoplasia, the detection 
of inherited polymorphisms offers a possible indirect method of tracing malaria in the 
archaeological record. 
 
4.2.5.1 The thalassaemias 
One of the most commonly observed polymorphisms in modern populations is 
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thalassaemia, the general term for a group of congenital haemolytic anaemias with high 
prevalence rates in southern and eastern Mediterranean countries, India, China, and 
Southeast Asia (Weatherall and Clegg, 1972) - areas all with a long history of malaria 
endemicity. Sufferers in other parts of the world can usually trace their ancestry to one of 
these areas. The two main types of thalassaemia result from mutation affecting specific gene 
code sites of either the α or β polypeptide chain of the haemoglobin molecule. Put simply, 
both conditions reduce the quantity of haemoglobin within RBCs, subsequently decreasing 
RBC capacity for oxygen transportation (Aufderheide and Rodriguez-Martin, 1998; 
Galanello and Cao, 2011). Low haemoglobin levels causes an increase in abnormal RBC 
production and subsequent lysis of the cells, hence promoting ‘haemolytic' anaemia. 
Subsequent expansion of the medullary cavities (marrow hypertrophy) in response to 
increased demand for RBCs is commonly observed in sufferers (Olivieri, 1999; Lewis, 
2010). Genotypic expression of α or β thalassaemia is classed as ‘major’ or ‘minor’, 
dependent upon homozygosity or heterozygosity (Olivieri, 1999; Perisano et al., 2012). A 
third class of β thalassaemia, known as β thalassaemia intermedia, can also occur.  
Both α and β thalassaemia major cause severe symptoms which often lead to 
premature death (often in infancy) of the sufferer, whereas minor expressions are much less 
severe, being either asymptomatic or causing very mild clinical symptoms, with no 
associated skeletal changes. Patients with β thalassaemia intermedia suffer mild symptoms, 
but can survive without the intensive medical treatments required by homozygotes (Parano 
et al., 1999). Skeletal changes associated with intermedia patients often worsen with 
advancing age (Taher et al., 2006), depending upon the severity of each case. Each 
genotypic expression of the thalassaemias is thought to confer some protection against 
malaria infection, although the exact underlying mechanisms of protection remain poorly 
understood (Duffy and Fried, 2006; Galanello and Cao, 2011). For instance, α thalassaemia 
seems to confer significant protection against P. falciparum malaria, yet increases 
susceptibility to P. vivax malaria infection in young children and babies (Allen et al., 1997). 
The reason for this is unclear, partly due to a poor understanding of the α thalassaemia 
phenotype and its interaction with malaria (Rees et al., 1998), but Williams et al. (1997) 
suggest that early infection with mild vivax malaria may offer cross-species protection 
against P. falciparum infection in later life. It has been suggested that in thalassaemics 
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infected with P. falciparum, parasitised blood cells are more effectively targeted by the 
immune response, thus limiting the impact of the blood-stage infection and the subsequent 
severity of the disease (Williams et al., 2002; Krause et al., 2012) . 
The correlation of endemic malaria with a high prevalence of the thalassaemias has 
been used in palaeopathological research to infer either the presence of malaria in antiquity, 
or the migration of sufferers from endemic areas, through the observation of skeletal 
changes associated with thalassaemia. Homozygous expression of α and β thalassaemia 
(major) and β thalassaemia intermedia produce osseous changes regardless of genotype (α or 
β), making differentiation of genotype from macroscopic analysis of archaeological bone 
impossible (Ortner, 2003). Palaeopathological investigations of thalassaemia in the 
archaeological record have long been based on macroscopic bone analysis, from Angel's 
(1964, 1966) seminal Mediterranean investigations to modern analyses of British (Lewis, 
2010) and Sardinian (Setzer, 2010) human remains. There have also been a handful of 
attempts to detect thalassaemia in archaeological bone using PCR (e.g., Filon et al., 1995; 
Yang, 1997; Hughey et al., 2012) and immunological (e.g., Ascenzi et al., 1991) techniques. 
However, macroscopic analyses have tended to be more successful than biomolecular 
techniques. This does not, of course, mean that macroscopic detection of thalassaemia has 
been faultless. In addition to the problems associated with all macroscopic 
palaeopathological research already discussed, early studies tended to suffer from a lack of 
comparative clinical data, relying heavily on historical analogy based on modern living 
populations, and making somewhat over-simplistic diagnoses of thalassaemia based on 
skeletal changes now known to have multi-factorial aetiologies (Hershkovitz et al., 1991; 
Lagia et al., 2007; Setzer, 2010). Despite these problems, improvements in modern medical 
understanding of the thalassaemias and a corresponding increase in comparative clinical data 
have aided palaeopathologists in establishing more standardised diagnostic criteria for 
identifying the condition in ancient human bone (Lewis, 2010). Although there remain 
issues with identifying thalassaemic sequelae in archaeological bone, recent successful 
research (e.g., Lewis, 2010; Hughey et al., 2012) suggests a more promising future for the 
detection of the condition in ancient human remains.   
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4.2.5.2: Sickle cell disease 
 
First clinically observed and characterised in the early 20th century, sickle cell 
disease is the collective term for haematopathologies resulting from the inheritance of 
haemoglobin S, a genetic variant of normal adult haemoglobin (Brozovic and Anionwu, 
1984; Allison, 2002). Sickle cell disease is the most common worldwide haematopathology, 
with up to a 15% allelic frequency, and is generally found in populations with a history of 
exposure to intense endemic P. falciparum malaria (Piel et al., 2010). Hence, the highest 
allelic frequencies are seen in sub-Saharan Africa. 
 The disease is named after the ‘sickling', or transformation of red blood cells into 
sickle shape during periods of low blood oxygenation. The two major genotypes of sickle 
cell disease are sickle cell anaemia (or SCA), resulting from the inheritance of the 
haemoglobin S gene from both parents (homozyosity), and sickle cell trait (or HbAS), 
resulting from the inheritance of one haemoglobin S gene and one normal haemoglobin A 
gene (heterozygosity) (Allison, 2002). Sickling and subsequent lysis of affected RBCs in 
homozygous carriers leads to increased blood viscosity, severe haemolytic anaemia, 
obstruction of small blood vessels, and eventual organ damage or failure. The severity of the 
disease in its homozygous state is such that the majority of untreated carriers die before they 
reach five years of age (Piel et al., 2010). Conversely, sufferers with sickle cell trait are 
usually asymptomatic and require much more extensive blood deoxygenation to trigger RBC 
sickling (Allison, 2002), although rare and serious complications such as medullary cancer, 
renal failure, thromboembolism, and neonatal death have been associated with 
heterozygosity (Tsaras et al., 2009). Although it is generally accepted that sickle cell carriers 
(SCA and HbAS) are more resistant to malaria infection, exact mechanisms behind the 
protection remain unclear, as does the degree to which heterozygosity confers protection 
(Williams et al., 2005). It has been suggested that the sickling reaction of RBCs upon 
parasitisation causes rapid haemolysis by the immune system, thus restricting the severity of 
malaria infection (Balgir, 2006). Conversely, research in India has suggested that homo- and 
heterozygous expression offer very limited protection against simultaneous falciparum and 
vivax malaria infection (Kar et al., 1990).  
The vast majority of studies of the interaction of sickle cell disease and malaria 
resistance have concentrated on populations living in endemic P. falciparum malarial areas. 
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Given the geographic concentration of sickle cell alleles, it is clear that intense P. falciparum 
transmission is a driving force behind the selection of the haemoglobin S allele. Since P. 
vivax was almost certainly the prevalent parasite in past British malarial transmission, it is 
unlikely that sickle cell disease played a significant (if any) part in the development of 
malaria resistance. Although high post-medieval mortality rates may have been malaria-
related, vivax virulence and transmission probably would have not been sufficiently intense 
to apply a selective pressure strong enough to select for sickle cell disease. Skeletal evidence 
of this condition will therefore not be sought in this study. 
 
4.2.5.3: Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
 
 G6PD deficiency is the third most common genetic polymorphism that confers a 
degree of protection against malaria infection after sickle cell disease and the thalassaemias. 
The condition affects nearly 500 million people worldwide, the majority of whom are males 
(90%) living in endemic P. falciparum malaria areas (Wajcman and Galacteros, 2004). The 
deficiency results from one, or a combination of up to 150 different mutations in the gene 
that codes for G6PD, an enzyme crucial in the removal of oxidants which damage RBCs. 
These compromised RBCs are quickly destroyed by the body (haemolysis), thus protecting 
against erythrocytic development of the malaria parasite (Sallares et al., 2004). The majority 
of sufferers are asymptomatic, only developing symptoms (acute haemolytic anaemia being 
the most common) in times of oxidative stress or when exposed to certain triggers (Ruwende 
and Hill, 1998; Mehta et al., 2000). For instance, favism is a well-known condition linked to 
G6DP deficiency and is characterised by the onset of acute haemolytic anaemia following 
the consumption of fava, or broad beans. Clinical methods to detect the condition have 
traditionally been expensive, time consuming, and require freshly collected blood samples. 
However, rapid diagnostic and ELISA methods are under evaluation (Kuwahata et al., 
2010). 
Very little research on G6PD deficiency in past populations has been carried out, 
despite the likelihood that the condition has a long history of affecting populations in 
endemic malarious areas. However, favism is well documented in antiquity, suggesting the 
latent presence of G6PD deficiency (Mehta et al., 2000). The dearth of research is likely due 
in part to a lack of comparative clinical data and to the difficulties of tracing the condition in 
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archaeological remains: there is little clinical evidence that the episodic nature of acute 
haemolytic anaemia associated with G6PD deficiency induces macroscopically observable 
changes in bone, unlike in chronic conditions such as the thalassaemias. Palaeopathological 
research on the condition has, therefore been confined to the biomolecular analysis of 
ancient DNA. For example, Sallares et al. (2003) isolated a Mediterranean variant of G6PD 
deficiency in the ancient DNA of an infant from Lugano, Italy, and, although not working 
with ancient material, Liu et al. (2002) demonstrated that genetic coding for G6PD 
mutations survive and can be amplified from archived clinical samples. The identification of 
G6PD deficiency through next generation aDNA analysis and, potentially, new rapid 
diagnostic and assay testing, offers an exciting avenue of research for indirectly tracing 
malaria in past populations. As new, more affordable and practical testing methodologies 
become available, they may well become part an important area of study in future 
palaeopathological research.  
 
4.2.6: The nature of temperate P. vivax ‘endemicity’ 
 When considering the possible development of past genetic resistance tied to 
putative P. vivax in past British populations, it is important to consider the nature of 
endemicity in the marshlands and Fens of England. Malaria epidemiology and the factors 
influencing the development of endemicity within any region are extremely complicated. 
Accordingly, the level of endemicity within a region is measured by the percentage of the 
local population infected at any one time (Hay et al., 2010). Stable malaria endemicity is 
often associated with tropical or sub-tropical areas, where the intensity of transmission is 
high and the disease maintains a constant, stable presence within local populations. Here, 
malaria endemicity is catagorised as holoendemic (>75% of population infected), 
hyperendemic (50-75%), and mesoendemic (10-50%). Areas of unstable malaria 
transmission, where less than 10% of the population are infected at any one time, are 
classified as being hypoendemic (Hay et al., 2008). As expected with the aforementioned 
research bias, these classifications are mainly based on areas dominated by P. falciparum. 
Biological differences mean that P. vivax malaria does not necessarily fit this model of 
endemicity. Temperate vivax malaria can remain latent at the hypnozoite stage for up to 14 
months following initial inoculation (Sattabongkot et al., 2004; Petersen et al., 2013), and 
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subsequent relapses can be spaced many months apart. Unlike P. falciparum malaria, which 
once cleared by the body requires a new source of infection, individuals with P. vivax often 
remain infected indefinitely unless suitable treatment is administered. This may well have 
been the situation in the past Fens and marshlands of Britain, with a large proportion of the 
population retaining the infection, but not being necessarily continuously infectious, or 
suffering from clinical illness. Transmission may have been unstable and outbreaks 
intermittent, dictated by yearly climatic fluctuations and their impact upon anopheline 
population levels, but endemicity would remain constant due the high percentage of latent 
vivax infections. The adaptation that allows P. vivax to survive and flourish in temperate 
regions of the world is a reason why authors (e.g., Knotterus, 2002; Packard, 2007) 
confidently assert that malaria was ‘endemic’ in these areas.  
Dobson’s (1997) observed seasonal fluctuations in post-medieval marshland 
mortality rates follow a typical temperate endemic P. vivax transmission pattern, similar to 
that noted by Hulden et al. (2005) in Finland. Infections initiated in late summer and autumn 
would incubate over winter, and precipitate outbreaks the following spring (hence ‘spring 
fever’) and early summer. The intensity of these outbreaks was dictated by the climate of the 
preceding summer: a hot summer would increase anopheline vector numbers, thereby 
increasing the intensity of parasite transmission. The British mortality figures are, therefore, 
highly suggestive of the presence of endemic P. vivax malaria. Endemicity and transmission 
frequency are important factors in the development of genetic resistance to malaria. If, as 
suggested by the mortality figures, P. vivax was endemic and exerting a selective pressure 
upon British Fen and marshland populations, then genetic resistance is more likely to occur. 
The emergence of haemoglobinopathies (e.g., G6PD deficiency) have recently been 
observed in temperate endemic P. vivax areas (Sina, 2002; Louicharoen et al., 2009), 
demonstrating that the disease, at least in endemic areas, can exert a significant enough 
selective pressure to drive the development of responsive genetic anaemia. However, what is 
not certain is whether the deleterious alleles developed due to spontaneous point mutations, 
or were imported into the populations from external sources (e.g., migrants from malarious 
areas). 
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4.2.7: The interaction of P. vivax malaria and thalassaemia 
Very little research has been conducted on the mechanisms of genetic resistance 
relating specifically to P. vivax. In a reflection of malaria research on a wider scale, 
concentration has been on the interaction of haemoglobinopathies with the more deadly 
malaria species, P. falciparum (e.g., Williams et al., 2002; 2005). Research investigating the 
response of thalassaemic infants exposed to both P. falciparum and P. vivax has suggested 
that thalassaemia increases the susceptibility to P. vivax infection, which confers an 
increased protection against P. falciparum infection (Williams, 2006). There has also been 
some suggestion that thalassaemia may actually increase the parasitaemia of P. vivax 
infection (e.g., O’Donnell et al., 2009), particularly in children under five years of age. This 
seems counter-intuitive, since increasing parasitaemia would increase cell haemolysis rates, 
thus elevating the risk of developing severe vivax symptoms. Price et al. (2007), however, 
suggest that severe vivax malaria is less likely to develop in infants under six months of age, 
who retain increased levels of protective foetal haemoglobin. Beyond this, however, very 
little is understood concerning the interaction of temperate P. vivax and thalassaemia 
(Douglas et al., 2012). 
 
4.2.8: Inherited conditions, P. vivax, and the palaeopathological literature 
 Considering the three genetic haematopathologies discussed earlier, it emerges that 
the most likely polymorphisms to have developed in response to putative endemic P. vivax 
malaria in past British populations are the thalassemias and G6PD deficiency. The 
development of these polymorphisms would, of course, require a very particular 
amalgamation of past circumstances. For instance, the selective pressure of the disease 
would need to have been strong enough to select for these protective genetic traits. The 
disease also would have to have been endemic within a population for a significant time 
period (at least a few hundred years, according to Carter and Mendis, 2002) for the 
polymorphism to persist and become ‘balanced', although the sporadic development of 
skeletal changes associated with genetic haemoglobinopathies is not necessarily dependent 
upon the ‘balanced’ nature of the polymorphism; it would, of course, be possible for 
detectable pathologies to develop during the balancing period. Whether these circumstances 
ever existed in Britain is currently unknown. The very low modern British prevalence of 
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thalassaemia (approximately 0.1% prevalence: Hickman et al., 1999) and G6PD deficiency 
(0% in 1962: Nkhoma et al., 2009; more recent figures unavailable) suggests that the 
mutations responsible have not persisted within in the gene pool. Whether this is due to the 
withdrawal of the selective pressure (i.e., vivax malaria) or to the fact that the conditions 
never developed is open to conjecture. Nevertheless, it worth exploring the possibility that 
such polymorphisms developed as a response to P. vivax malaria in British antiquity.  
 It was decided not to attempt to identify G6PD deficiency or sickle cell disease. 
Clinical evidence of the skeletal response to G6PD deficiency is severely lacking and the 
expense of aDNA/PCR (the standard clinical method) detection of the condition also 
precludes analysis of this disease. However, the recent development of cost-effective 
screening technologies (e.g., Kim et al., 2011) may enable future attempts at detection in 
archaeological samples. The uncertain association between P. vivax and sickle cell disease 
and the intense pressure evidently required to select for the polymorphism mean that the 
chances of it developing in British antiquity are very remote. 
This study will attempt to identify the development of thalassaemia as a possible 
indirect result of endemic malaria within past British skeletal populations excavated from 
potential malarious areas. This analysis will be based on a review of palaeopathological 
skeletal reports, since thalassaemia results in generally predictable macroscopic changes in 
the skeleton (Hershkovitz et al., 1997; Lewis, 2010), which should have been recorded in 
such reports. There has been a tendency for some diagnostic assumptions to be perpetuated 
in the palaeopathological literature (e.g., the continuance of periostitis to be attributed to 
non-specific infection caused by physiological stress) as a result of analysts relying on past 
osteological reports for diagnostic criteria, rather than attempting to access the latest 
palaeopathological interpretations and clinical literature (Grauer, 2012). Further to this, 
many human skeletal analytical reports are produced by palaeopathologists working either 
freelance or internally for contract archaeology units. The author’s experience has invariably 
been that human remains analysis in the contract environment is often chronically under-
resourced in terms of time and funds. These pressures may cause many problems, including 
insufficient pathological descriptions and poor standardisation in recording between analysts 
and reports (Roberts and Cox, 2003). Although guidelines stipulating the minimum content 
of an osteological report have been published (Brickley and McKinley, 2004) to address this 
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lack of standardisation, problems remain relevant when considering the identification of 
rarely-observed diseases in British human skeletal remains, particularly when macroscopic 
analysis alone may be insufficient for a diagnosis. The aforementioned perpetuated 
assumptions and pressures may facilitate an expectation that certain conditions simply will 
not be encountered in British skeletal populations.  
The palaeopathological diagnosis of thalassaemia in British antiquity may fall into 
this trap. A disease most commonly encountered in populations with a long history of 
exposure to endemic falciparum malaria, its palaeopathological diagnosis has usually being 
tentatively based on macroscopic observance of a combination of non-specific 
pathognomonic skeletal changes, such as cribra orbitalia, osteopenia, and porotic 
hyperostosis (Lewis, 2010). Since the latter condition is rarely observed in British 
archaeological populations (Roberts and Manchester, 2005), the assumption may follow that 
thalassaemia must be equally, if not more, rare. As previously mentioned, prevalence of 
cribra orbitalia or porotic hyperostosis was often traditionally explained by iron deficiency 
anaemia (Waldron, 2009). It is only relatively recently that aetiological reappraisals (e.g., 
Walker et al., 2009) have questioned this traditional interpretation. It is, therefore, entirely 
possible that contract analyses contemporary with the ‘iron-deficiency hypothesis’ may have 
provided this diagnosis and missed possible cases of acquired (e.g., megaloblastic) or 
hereditary anaemias (e.g., thalassaemia). Further to this, many such analyses may not 
necessarily have access to the latest advances in diagnostic techniques. 
Lewis (2010) has recently reviewed the clinical literature concerning the osseous 
sequelae of thalassaemia and identified additional diagnostic criteria that she used to identify 
probable and possible cases in child skeletons in the Romano-British assemblage from 
Poundbury Camp, Dorset. Using selected diagnostic criteria of Hershkovitz et al. (1997), 
Ortner (2003), Yochum and Rowe (2005), Lagia et al. (2007), Lewis (2010), and Perisano et 
al. (2012) this study will analyse selected palaeopathological reports in an attempt to 
determine any under-representation of thalassaemia, and whether the disease can be 
identified in skeletal populations from likely endemic malarious areas in Britain 
 
4.2.9: Skeletal evidence for thalassaemia 
Confidence with which palaeopathologists can more accurately identify sequelae that 
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may be indicative of thalassaemia in archaeological skeletal remains has recently improved 
(see Lewis, 2010). As previously mentioned, the establishment of new diagnostic criteria 
highlights the need for re-analysis of selected site reports and inhumation catalogues in an 
attempt to determine whether any published sequelae of thalassaemia could have been 
overlooked, or attributed to other conditions due to the perceived rarity of thalassaemia in 
British antiquity. It is, therefore, possible that the condition is under-represented in the 
British palaeopathological literature, due to the fact that many of these pathological analyses 
were conducted prior to the refining of diagnostic criteria. In terms of identifying 
thalassaemia in the skeletal record in a British archaeological population some key questions 
need to be addressed:  
 
1. At which British sites are we most likely to encounter thalassaemia?  
2. Which individuals are most likely to develop skeletal changes associated with             
thalassaemia?  
3. How likely are these individuals and their sequelae to be sufficiently represented 
in the archaeological record? 
 
Assuming that P. vivax exerted a significant enough selection pressure to facilitate the 
development of thalassaemia as an adaptive polymorphic response, where would we most 
likely encounter the condition? A key concern here is the effect of malarial endemicity on 
the persistence of thalassaemic alleles in the gene pool. Both α and β thalassaemia are rarely 
encountered in modern, non-endemic areas of the world, and are only usually seen in 
immigrants from endemic malarious areas (Vetter et al., 1997). The ‘malaria hypothesis’, 
first proposed by Haldane (1948) and confirmed by later research (e.g., Allison, 2002; Piel 
et al., 2010), suggests a close link between the development of haemoglobinopathies and 
endemic malaria, since natural selection increases the genetic traits which act to protect the 
carrier from malaria infection. The link is observed most commonly in association with P. 
falciparum, yet Dobson’s (1997) synthesis of post-medieval burial records suggest that the 
potential epidemiological impact of malaria on past British marshland communities should 
not be underestimated. A link between the selective pressure of vivax malaria and the 
development of haemoglobinopathies may be as valid for pre-medicalised societies as it is in 
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the modern era.  
The Fenlands and marshlands of Lincolnshire and Cambridgeshire were chosen as 
areas of interest for this study for a number of reasons. Firstly, as established in Chapter 1, 
the environmental conditions from at least the Roman period would have provided 
favourable territory for anopheline breeding. During the Roman period, the silt Fens of 
Lincolnshire and Cambridgeshire became relatively well settled (Darby, 1983), although a 
climatic deterioration towards to the end of the period seemingly resulted in the 
abandonment of some of these settlements. Total abandonment of the Fens never occurred, 
however, as people relocated to the higher ground of the Fen islands and around the Fen 
edge in order to maintain their relationship with the rich resources on offer (e.g., salt 
production, reed and peat cutting, and seasonal grazing pastures). Despite their growing 
reputation for disease and danger, the resource-rich Fens drew increasing numbers of people 
who, in the face of constant epidemiological and environmental threat, eventually tamed the 
landscape through drainage and reclamation. Consequently, Fen resource exploitation has 
been a continual phenomenon since prehistory (Oosthuizen, 2012) . 
It is not known how the fluctuating Fenland population may have affected malaria 
transmission and the potential for development of protective haemoglobinopathies. The 
malaria hypothesis suggests that those communities exposed long-term to endemic malaria 
should prove most likely to develop resistance in the form of thalassaemia, and that 
communities with discontinuous exposure are less likely to form genetic resistance. There 
exist areas within the Fens and around the Fen edge with archaeological evidence for 
continual occupation from prehistory to the modern day. These areas include the 
Cambridgeshire Fen islands of Crowland, Littleport, and Ely (Newman, 2007; Woolhouse, 
2009; Cope-Faulkner et al., 2010), and Fen edge populations such as those at Sleaford 
(Dickinson, 2004; Murphy, 2011) and in the locality of Peterborough (Evans and Hodder, 
2006). It is perhaps here, in places of continual Fen-associated occupation, that skeletal 
evidence of genetic resistance to malaria may be found, if at all. Many of these areas also 
saw influxes of migrants from continental Europe from the Roman period onwards, 
potentially introducing thalassaemic alleles into native human populations, and perhaps also 
new strains of P. vivax malaria into local anopheline populations. 
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Secondly, the choice of target populations is influenced by the results of research 
which employed spatial epidemiology to correlate prevalence rates of cribra orbitalia (CO) 
with historically recorded distributions of A. atroparvus and malaria cases (Gowland and 
Western, 2012). The intriguing link between Fen/marshland location and a high prevalence 
of CO provides perhaps the most compelling argument to date for the presence of English P. 
vivax malaria (likely in combination with comorbidities) prior to the post-medieval period. 
The study builds upon and supports previous research demonstrating higher CO prevalence 
in Mediterranean marshland populations likely exposed to endemic malaria (Gowland and 
Garnsey, 2010), and suggests that P. vivax malaria may have played an important role in 
influencing higher rates of CO in Anglo-Saxon Fenland populations. Although not 
specifically attributable to malaria infection, elevated prevalence rates of CO in Fenland 
populations may be indicative of megaloblastic anaemia associated with parasitaemia, be it 
by plasmodia, helminth, or both. Many of the sites selected for this study are classed as 
potentially ‘malarial’ by Gowland and Western. Possible inconsistencies in classification 
can be reconciled by the fact that some sites fell at the very edge of the interpolation map, 
from which the ‘malarial’ classification was taken (personal communication, Gaynor 
Western, January 2014). CO prevalence rates that vary considerably between ‘malarial’ sites 
(e.g., 3.5% and 59.5% at Castledyke South and Highfield Farm, Littleport, respectively) 
support a multifactorial aetiology for the condition, and although the research cannot 
necessarily (and does not claim to) pinpoint definite malarious sites, the correlation was 
compelling enough to suggest a malarial influence. Hence, many of these sites (at least, 
those with available skeletal reports and inventories) will provide a useful starting point for 
both the search for thalassaemia and the demographic population analysis discussed in 
Chapter 5 (sections 5.1 and 5.2). 
When considering the choice of time periods addressed in this study, the following 
question may, quite rightly, be posed: why ignore post-medieval skeletal populations from 
the areas investigated by Dobson (1997), since surely these are the most likely populations 
to have developed genetic resistance to malaria? The decision to investigate Roman, Anglo-
Saxon, and medieval samples from Lincolnshire and Cambridgeshire, rather than post-
medieval samples from Kent and Essex, is influenced by two factors. Firstly, very few post-
medieval cemetery populations from either area of the country are available for study. Post-
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medieval burial usually fell under the remit of the Anglican Church, their cemeteries and 
churchyards being considered consecrated ground (Sayer, 2011). Excavation of these burial 
grounds is a relatively rare phenomenon and excavated individuals are often subject to 
reburial, rather than curation. In rare instances (e.g., St. Peter’s Church, Barton-upon-
Humber) the cemetery population may remain archived on-site, with potential availability 
for study. Even so, Church permission is still required for destructive analysis 
(unfortunately, permission to sample a small number of Barton-upon-Humber skeletons for 
this study was denied). Consequently, there are simply an insufficient number of 
cemeteries/individuals from this period for a study of this scope.  
Secondly, the elevated post-medieval seasonal mortality rates in Lincolnshire and 
Cambridgeshire Fen parishes (West, 1974; Reynolds, 1979; Wrigley and Schofield, 1981; 
Nicholls, 2000) suggest that vivax malaria played an important epidemiological role during 
this period, and the presence of the disease here as suggested by the research of Gowland 
and Western (2012), is sufficiently compelling to challenge the assumption that malaria was 
absent from England prior to the 16th century. As previously mentioned, very little 
palaeoepidemiological research has been conducted on archaeological Fenland populations. 
This research has the potential to shed light on these relatively unstudied areas and 
populations. 
Thus, the search has been narrowed to settlements and cemetery populations likely to 
have been exposed to endemic P. vivax malaria for an extended period, such as the Fen 
islands. But who within these populations is most likely to exhibit skeletal sequelae of 
thalassaemia? This is a difficult question to address, given the idiosyncratic nature of 
phenotypic expression and the diversity of skeletal sequelae that can develop in response to 
the condition, particularly in heterozygous individuals. Differential diagnosis of 
thalassaemia can also be confounded by skeletal preservation. It is, therefore, worth 
considering how the expression of each genotype might present within the archaeological 
record, and which individuals might display the resultant phenotypic characteristics. 
In a pre-medicalised population homozygous expression of β-thalassaemia (β-
thalassaemia major) would almost certainly lead to premature death, most likely during late 
pregnancy or early infancy, due to a lack of available specialised medical treatment (Lewis, 
2010). Homozygous α-thalassemia most often results in late pregnancy death and still birth 
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due to severely compromised intrauterine oxygenation (Weatherall, 2001). Ortner 
(2003:365) suggests that skeletal changes associated with β-thalassaemia major “become 
radiologically obvious after the first year of life.” Sequelae are rarely encountered prior to 
six months of age, but marrow expansion can affect any part of the skeleton after the first 
year, with the cranium and facial bones often being the first affected (Yochum and Rowe, 
2005; Tyler et al., 2006). Untreated infants may survive the first few months of life due to 
their increased concentration of foetal haemoglobin, but when these levels decrease, severe 
haemolytic anaemia and splenomegaly occur. Should the individual survive these symptoms 
(which, in antiquity, is rather unlikely), skeletal changes in the form of marrow hyperplasia 
occur in response to inefficient production of red blood cells, and excessive production of 
the hormone erythropoietin (Weatherall, 2001). Subsequent iron sequestration can lead to 
toxicity, stroke, or cardiac failure (Olivieri, 1999). 
Since untreated homozygous β-thalassaemics rarely survive past a few months, this 
causes a potential difficulty in identifying these individuals in the archaeological record. A 
differential diagnosis of the condition would be impossible in the majority of affected 
infants, since death may occur before the development of skeletal sequelae. Lewis (2010:7), 
for instance, suggests that “in addition to the possible cases of thalassaemia intermedia [at 
Poundbury]…there may have been a greater number of children who died as the result of T-
major”. Thalassaemia major may, therefore, remain all but invisible in the archaeological 
record, regardless of how many infants were affected. Perhaps the only method of 
identifying the condition would be by observing a significantly elevated prevalence of 
perinatal and infant skeletons within a target burial population. However, this may also be 
the case within non-resistant individuals, since P. vivax infections can be particularly 
dangerous for neonates (Poespoprodjo et al., 2009), especially if any maternal immunity was 
lost during pregnancy (Whitty et al., 2005) and, therefore, not passed on to the infant. 
Skeletal changes as a consequence of thalassaemia intermedia are more likely to be 
encountered in the archaeological record (Ortner, 2003), since homozygotes are unlikely to 
survive long enough to develop diagnostic sequelae, and thalassaemia minor rarely involves 
skeletal modification (Ortner, 2003). Individuals with thalassaemia intermedia may remain 
asymptomatic until adulthood, or can display symptoms from as early as two years, 
depending upon the severity of the case. In the latter category in untreated individuals, one 
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might expect to observe growth retardation in early childhood (Taher et al., 2006). Skeletal 
changes associated with thalassaemia intermedia may include marrow hyperplasia of the 
facial bones and damage to the maxillary sinuses. Additionally, up to 40% of adults present 
with scoliosis (Yochum and Rowe, 2005).  
 
4.2.10: The effects of P. vivax infection on the foetus and neonate 
 An avenue of palaeopathological investigation that has yet to receive attention is the 
effects of vivax malaria infection on the skeletal development of the growing foetus and in 
the first few antenatal months. The burden of P. vivax malaria in pregnancy is a neglected 
area of research (Greenwood et al., 2007; Price et al., 2007; Mueller et al., 2009), with the 
majority having concentrated on P. falciparum infections in sub-Saharan Africa (Desai et al., 
2007). It has long been known that pregnant women are more susceptible to P. vivax 
infection, but it is only until relatively recently that the deleterious effects of infection on the 
mother and foetus have begun to be appreciated (Nosten et al., 2004). Although less severe 
than in P. falciparum infections, the main risks associated with P. vivax infection during 
pregnancy are maternal anaemia and significantly decreased birthweight through intrauterine 
growth restriction (IUGR) (Nosten et al., 1999; Rodriguez-Morales et al., 2006; Desai et al., 
2007). In endemic areas, malaria has been suggested to be responsible for up to 70% of 
cases of IUGR (Steketee et al., 2001). 
Exactly how malaria may influence low birthweight remains poorly understood 
(Conroy et al., 2011), especially with P. vivax parasites, which, unlike P. falciparum, do not 
cytoadhere to the placenta (Greenwood et al., 2007; Umbers et al., 2011). Also in contrast to 
P. falciparum, P. vivax infection results in more pronounced reductions in birthweight in 
subsequent (multigravida) pregnancies (Desai et al., 2007). Although miscarriage and pre-
term delivery is quite rare in cases of P. vivax infection, some women develop severe 
sequelae, such as thrombocytopenia and cerebral involvement (Rodrigues-Morales et al., 
2006). Should neonates survive the complications associated with IUGR, which include 
increased risks of diarrhoea, hypoglycaemia, immunological deficiencies, and pneumonia 
(Ashworth, 1998; Pallotto and Kilbride, 2006), they remain at high risk of developing 
dangerous symptoms of P. vivax infection, such as severe anaemia and thrombocytopenia 
(Poespoprodjo et al., 2009). One might expect a protective effect of residual maternal anti-
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malarial antibodies, yet research (Whitty et al., 2005) suggests that mothers can lose any 
previously acquired immunity during pregnancy.  
If many cases of P. vivax-affected pregnancies are carried to term, the effect of IUGR 
should be reflected in the foetal/neonate skeleton, and care must be taken when recording 
these individuals from archaeological populations inhabiting potentially malarious areas. For 
instance, cemetery populations may exhibit unusually high ratios of infant skeletons that 
may be recorded as ‘foetal’ based on bone lengths that have been reduced by IUGR. 
Cemetery populations may, therefore, contain a higher-than-expected ratios of ‘small’ 
babies. It would be challenging to infer the presence of P. vivax malaria based on gross 
infant mortality figures, given the difficulties inherent in attempting palaeodemographic 
analyses of infant mortality based on skeletal numbers (see Lewis and Gowland, 2007). 
Despite this, it may prove interesting to compare very young infant mortality ratios between 
suspected malarious and non-malarious sites and to investigate any instances of increased 
numbers of ‘small’ babies within populations. A literature search reveals no other attempts at 
identifying IUGR in in archaeological populations inhabiting potentially malarious areas. 
 
4.2.11: Palaeodemography 
 A further indirect method of potentially identifying the presence of putative English 
vivax malaria would be to perform basic palaeodemographic profiling of burial populations 
based in likely ‘malarious’ and ‘non-malarious’ areas. As previously discussed, Dobson’s 
(1997) extensive analysis of historical burial rates has provided compelling evidence for the 
impact of vivax malaria on post-medieval Kent and Essex marshland parishes. Fen-
associated parishes in Lincolnshire and Cambridgeshire have also demonstrated unusually 
high mortality rates for this period, particularly for infants (e.g., West, 1974; Reynolds, 
1979). Demographic analysis for archaeological, undocumented populations is more 
difficult, often relying on age-at-death ratios of cemetery populations to make inferences on 
any variations observed. Although cemetery data have been deemed unreliable for 
demographic analysis by some (e.g., Hollingsworth, 1969; Bocquet-Appel and Masset, 
1982), skeletal material provides an important resource for primary demographic data. 
Confounding factors to this type of analysis include possible errors or inconsistencies in 
ageing and sexing skeletal individuals, and differential preservation, deposition, and 
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recovery of skeletal remains (Hoppa and Vaupel, 2002; Chamberlain, 2006).  
With these limitations in mind, it may prove useful to compare mortality (age-at-
death) profiles from archaeological Fen/marshland and non-Fen/marshland (henceforth 
referred to as Fen and non-Fen) cemetery sites, since no such comparison has been 
performed to date. It could be hypothesised that the presence of P. vivax malaria in 
Fen/marshland environments may result in increased mortality rates for certain groups of 
individuals when compared to non-Fen/marshland populations (e.g., neonates, infants, and 
women of child-bearing age). A difficulty may, however, rise in discerning the influence of 
putative malaria from other disease factors which may have been present in the notoriously 
insalubrious Fen/marshland environs, especially given that the age groups mentioned are 
often at risk of higher mortality, regardless of environment.   
 
4.3: Biomolecular analysis and palaeopathology 
 
"So far the achievement of biomolecular archaeology in relation to malaria is only a tiny 
fraction of its potential" (Sallares and Gomzi, 2001:200). 
 
 Biomolecular analysis has its roots in the emergence of the discipline of immunology 
in the late 19th century. In 1898, for example, the reaction of antibodies and antigens was 
first observed in animal blood serum experiments (Newman et al., 1996). Since that time 
knowledge of molecular biology and immunology has increased exponentially. Given the 
increasing appreciation of the vast potential that human remains offer in furthering our 
understanding of the past, it was inevitable that biomolecular methodologies would begin to 
be employed in palaeopathological analysis. However, it is with advances in the past few 
decades that "modern instrumental chemical and biochemical techniques has provided us 
with the resources necessary for the effective recovery, detection and characterisation of 
biomolecules and their decay products in archaeological materials" (Evershed, 1993:75). 
Analysis of archaeological inorganic residues using techniques derived from chemistry and 
physics became commonplace during the mid-20th century, yet a general assumption 
remained that organic residues would not survive in the archaeological record. Radiocarbon 
dating methods developed since the 1950s using surviving bone collagen in human remains 
spurred interest in the organic biochemical information stored in ancient bone. Improving 
radiocarbon technology allowed for the discovery of carbon, and later nitrogen isotopes 
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within collagen. Since then, isotopic analysis of ancient human bone has become an 
increasingly important technique in attempting to reconstruct past dietary and migration 
patterns (Pollard, 2001). 
One of the first biomolecular applications specifically concentrating on organic 
residues in archaeological materials occurred in the late 1970s, when researchers 
successfully identified lipids surviving within ceramic vessels (Pollard, 2001). This 
pioneering research demonstrated firstly that various organic ancient biomolecules can 
indeed survive in archaeological materials, and secondly that such research had the potential 
to open up a vast resource of information previously considered inaccessible. The 
archaeological community was particularly excited by two applications of biomolecular 
research developed during the 1980s. Firstly, biochemical methodologies were employed in 
the apparently successful detection of ancient proteins in fossil material (e.g., Lowenstein, 
1981). This discovery led to a rush of research which concentrated particularly on detecting 
blood-protein residues on ancient artefacts (e.g., Loy, 1983; Newman and Julig, 1989), with 
varying degrees of success. Although the methodological validity of many of these studies 
was hotly debated (e.g., Downs and Lowenstein, 1995; Leach and Mauldin, 1995), they laid 
important groundwork in the area of ancient biomolecular detection (Malainey, 2011). 
Secondly, the mid-1980s saw the development of techniques capable of detecting and 
amplifying fragments of DNA from ancient organic material. This discovery heralded "the 
true beginning of biomolecular archaeology as a discipline in its own right" (Brown and 
Brown, 2011:9). As with ancient protein detection, immediate enthusiasm for ancient DNA 
(aDNA) analysis influenced numerous studies (e.g., Hagelberg and Clegg, 1991; Woodward 
et al., 1994; Scholz et al., 2000), many of which helped to highlight the methodological 
difficulties of obtaining valid results from degraded or contaminated samples (O’Rourke et 
al., 2000). Despite these problems continuing to limit ‘traditional’ aDNA, the technique has 
come to dominate biomolecular palaeopathology as researchers strive to develop reliable, 
replicable techniques (such as new next generation sequencing) for aDNA extraction and 
characterisation (Cooper and Poinar, 2000). This is largely due to the vast potential offered 
by surviving nucleic acids as a source of information on topics as diverse as the coevolution 
of humans and pathogens, kinship, migration, epidemiology, and genetic characterisation 
(Pinello, 2008). 
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 As the discipline of biomolecular archaeology matures and methods move onwards 
towards standardisation and replicability, new techniques of detecting human immunological 
products and pathogens in ancient osseous tissues are currently in development, such as 
high-resolution proteomic techniques for analysing archaeological bone proteins. These are 
yielding ground-breaking insights into entire ancient proteomes and disease biomarkers 
(e.g., Cappellini et al., 2011; Wadsworth and Buckley 2014). Most new methodologies are 
often expensive and, due to their novelty, may give variable and debatable results; as in any 
archaeological discipline, "with maturity and widespread application come the 
complications" (Bentley et al., 2004:365). It is only through collaborative work between 
molecular biologists and archaeologists that new methodologies can mature and become 
truly informative and reliable tools. This study should add to the growing corpus of research 
knowledge through investigation of ancient biomolecules associated with Plasmodium vivax 
infection. 
 
4.3.1: Ancient biomolecules: survival and interpretation  
 As previously mentioned, numerous biomolecules have been targeted for 
investigation of ancient human remains. These broadly fall into the categories of lipids, 
nucleic acids (e.g., DNA and RNA), collagenous proteins, and non-collagenous proteins 
(Brown and Brown, 2011). Analysis of each class of molecule presents a unique challenge to 
the biomolecular archaeologist, which must be met and overcome in order to produce 
reliable, replicable results. Before selection of the appropriate target biomolecule and the 
extraction/analytical methodology, it is important to first understand the structure and 
composition of the organic material in which the target molecule is found. Secondly, it is 
equally, if not more vital to appreciate that from the moment of death numerous complex 
processes occur within the organism which inevitably alter the properties of endogenous 
biomolecules, to a greater or lesser extent depending on multiple factors. The processes by 
which organic materials decay and degrade following death are known collectively as 
diagenesis (Smith et al., 2007). 
 Human bone matrix is comprised of approximately one third organic and two thirds 
inorganic materials. The latter is made up of mineral comprising mostly calcium phosphate 
in the form of hydroxyapatite. The organic component of bone mainly comprises collagen 
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and osteocalcin, which account for around 90% of the osseous protein content. The 
remaining 10% consists of non-collagenous proteins (NCPs), such as haemoglobin, albumin 
and immunoglobulins (Freundorfer et al., 1995; Collins et al., 2002). Many of these NCPs, 
along with cellular molecules such as DNA and lipids, are not necessarily intrinsic to the 
bone matrix itself, but are "associated with fluids and cellular components in the tissue, and 
their persistence in bone is more difficult to predict than collagen and osteocalcin" (Collins 
et al., 2002:384-5).  
 Study of bone diagenesis is a recent phenomenon, born out of the necessity for 
critical analysis of the ancient biomolecular research boom of the late 20th century. An 
understanding of the manner in which decay processes affect ancient biomolecules was 
therefore demanded in order to validate associated research. A considerable share of research 
on bone and biomolecular diagenesis has concentrated on collagen, which is understandable 
given the ubiquity of the protein and its potential application within biochemistry and 
biomolecular archaeology (e.g., Collins et al., 1995; 2002; Tuross, 2002; Dobberstein et al., 
2009; Wilson et al., 2012). The degradation of DNA has also received attention (e.g., Colson 
et al., 1997; Rollo et al., 2002; Harbeck et al., 2004; Pruvost et al., 2008). Diagenesis of non-
collagenous proteins is less well understood, although a small number of studies have 
attempted to rectify this (e.g., Masters, 1987; Freundorfer et al., 1995; Grupe and Turban-
Just, 1996; Wiechmann et al., 1999; Brandt et al., 2000).     
 Two of the main difficulties faced by biomolecular archaeologists are degradation of 
the target molecules and contamination with modern molecules (Brown and Brown, 2011). 
Contamination with modern DNA is the most common problem encountered in aDNA 
studies. However, both DNA and proteins can become contaminated and degraded soon after 
death. Upon death the breakdown of cell membranes and endogenous organelles 
immediately commences, a process known as autolysis. This destruction releases acidic 
enzymes which, in life, are contained within cell lysosomes. Reactive chemical by-products 
of decomposition are also produced. These enzymes and chemicals attack and degrade 
biomolecules and can demineralise bone (Child, 1995). Only those biomolecules which 
survive autolysis can persist in the burial environment (Brown and Brown, 2011). Microbial 
(e.g., bacterial and fungal) invasion of the bone follows inhumation. This is a much slower 
process than autolysis, but these organisms can excrete enzymes and acids to further degrade 
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bone mineral and biomolecules, increase bone porosity, and potentially introduce foreign 
proteins which may confound results of biomolecular testing (Hedges, 2002). Acids 
produced by microorganisms can also convert hydroxyapatite to brushite, a mineral that 
requires increased space, thereby resulting in cracking (Mays, 2010), which further exposes 
the internal bone structure to external diagenetic factors. Environmental processes also 
influence the breakdown of biomolecules in the archaeological record. Water and oxygen, 
for example, are highly significant diagenetic agents (Brown and Brown, 2011).  
 Diagenetic processes and the survival of ancient biomolecules in the archaeological 
record are very much mediated by the environment immediately surrounding the skeletal 
remains (Hedges and Millard, 1995). The most influential diagenetic factor is debated. It 
has, for example, been argued that hydrological action is "the most significant factor in the 
production of diagenetic change... [having] a far greater effect than age, soil content, pH or 
heat" (Cattaneo et al., 1995:271) , whereas Collins et al. (2002:386) suggest that "microbial 
deterioration is probably the most common mechanism of bone deterioration….optimized at 
near neutral pH - conditions which would otherwise protect bone". It is clear that factors as 
diverse as soil pH, geology, microbial concentration, hydrological and oxidative factors, 
temperature, humidity, post-interment disturbance, burial rituals, and individual health prior 
to burial are but a few of the variables that determine the successful endurance of 
biomolecules in the burial environment. Given the many possible variables influencing 
diagenesis and the difficulties in studying the processes ‘in action’, it is unsurprising that 
debate continues over the most important factors (Hedges, 2002). 
Despite these difficulties, research into the survival of NCPs in the burial 
environment has suggested that the acidic nature of NCPs gives them a high affinity for 
calcium sites on the hydroxyapatite within bone, which should subsequently offer a degree 
of protection following inhumation (e.g., Masters, 1987; Freundorfer et al., 1995; Grupe and 
Turban-Just, 1998; Wiechmann et al., 1999; Nielsen-Marsh and Hedges, 2000). These 
proteins should, accordingly, suffer less deterioration than collagen, which does not bind to 
the mineral content and is therefore more susceptible to hydrological and microbial agents 
(Hedges, 2002). This may be surprising, given that collagen is generally considered a more 
stable organic component of bone (Hedges and Wallace, 1978), and early research by 
Gürtler et al. (1981) isolated collagen, rather than serum proteins in archaeological samples. 
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More recent research has claimed success in detecting NCPs, including immunoglobulins, in 
archaeological bone (e.g., Cattaneo et al., 1992; Wiechmann et al., 1999; Brandt et al., 2000; 
Schmidt-Schultz and Schultz, 2004, 2007; Wadsworth and Buckley, 2014), including bone 
that has undergone post excavation treatment (washing, drying, storage, etc.) and museum 
curation (Tuross, 1991), suggesting that such processes may have less impact on the survival 
of NCPs than expected. However, many of these studies are careful to highlight the problem 
of diagenetic protein alteration: although the affinity with hydroxyapatite may lessen the 
impact of hydrological leaching, for example, it does not necessarily protect the NCPs from 
other forms of diagenetic alteration, such as microbial and enzymatic attack. 
Protein identification through immunological testing may be hampered by diagenetic 
processes which can alter the epitopic structure, molecular weight, and isoelectric points of 
the target protein (Brandt et al. 2000). Analysis is also potentially complicated by the tiny 
quantities of surviving molecules in archaeological remains; this is particularly apparent in 
the search for ancient serum proteins (including NCPs) which make up less than 10% of the 
total protein content of fresh bone. Methodologies to detect these elusive proteins must 
therefore be exceptionally sensitive, which itself may lead to cross reactions and detection of 
non-specific, degraded protein molecules or exogenous microbial proteins (Child and 
Pollard, 1992).  
The interpretation of the results of ancient protein analysis must, of course, take into 
account current limitations. Mis- and over-interpretation of data is a problem that plagued 
the discipline in its early stages, as some researchers were quick to pronounce their findings 
without a full appreciation of the "unrecognised limitations" (Brown and Brown, 2011:146) 
of the methods used in such research. This was evident in early studies which claimed to 
have successfully detected and analysed blood residues on prehistoric tools (e.g., Loy, 1983; 
Nelson et al., 1986). Negative results, controls, and the general limitations of research 
should always be reported (Gernaey et al., 2001), and appropriate caveats made when 
necessary.  
 So why, considering all of the technical challenges and pitfalls involved in ancient 
protein detection and characterisation, does such research continue? The answer to this lies 
in the information stored in ancient biomolecules which offers the researcher valuable clues 
to so many aspects of the past - information that supplements, and yet is beyond the reach of 
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traditional palaeopathological methodologies. The potential scholarly rewards for accurately 
detecting, characterising, and interpreting ancient biomolecules make the recognition and 
confrontation of the methodological challenges more than worthwhile; after all, no scientific 
field develops and progresses without addressing and overcoming inherent difficulties as 
they are met (Brown and Brown, 2011).     
 
4.3.2: Biomolecular palaeopathology 
 
"The preservation of immunoglobulins is particularly intriguing, and opens up the 
possibility that an independent record of disease states remains in the bones of many 
individuals" (Tuross, 1991:53). 
 
 Biomolecular and biochemical techniques have been used to address a variety of 
archaeological questions, ranging from the biological profiling of human skeletons using 
aDNA, to the investigation of the development of prehistoric dairying practices using 
residual protein analysis. Researchers have also been intrigued by how applications of 
biomolecular palaeopathology can be used to further our understanding of 
palaeoepidemiology and disease processes. Many applications have concentrated on 
attempting to recover bacterial and viral aDNA from archaeological material, such as 
tuberculosis (e.g., Baron et al., 1998; Braun et al., 1998; Fletcher et al., 2003; Muller et al., 
2014), syphilis (e.g., Kolman et al., 1999; Bouwman and Brown, 2005; Barnes and Thomas, 
2006), leprosy (e.g., Haas et al., 2000; Likovský et al., 2006; Schuenemann et al., 2013), 
plague (e.g., Drancourt et al., 1998; Haensch et al., 2010; Wagner et al., 2014), and typhoid 
(e.g., Papagrigorakis et al., 2006). Ancient DNA recovery has also been attempted on range 
of ancient helminths and parasites causing diseases such as toxoplasmosis (Terra et al., 
2004), trypanosomiasis (Aufderheide et al., 2005), and intestinal roundworm (Oh et al., 
2010). Many parasite aDNA studies have utilised either mummified human tissue or 
coprolites, with far fewer concentrating on bone. Biomolecular studies of ancient malaria in 
human remains are divided between the search for Plasmodium aDNA (e.g., Sallares and 
Gomzi, 2001; Chilvers, 2004; Nerlich et al., 2008; Pinello, 2008), human immunological 
reactionary products to malaria infection (e.g., Miller et al., 1994; Massa et al., 2000; 
Bianucci et al., 2008; Fornaciari et al., 2010), or both together (e.g., Setzer, 2010), in either 
skeletal or mummified tissues. Since this study will utilise immunological methodologies to 
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test for evidence of ancient Plasmodium vivax infection in archaeological bone, it is 
pertinent to explore the related research in order to form a viable sampling and testing 
methodology.   
 
4.4: Malaria and ancient biomolecules 
 
 Despite the apparent ubiquity of malaria in the ancient and modern world, the 
disease is a frustratingly difficult one to identify in the archaeological record. This is partly 
due to the absence of specific macroscopically-observable skeletal indicators directly 
associated with malaria infection. On a molecular level, PCR-based research represents the 
bulk of attempts to identify the disease in archaeological remains, through the detection of 
malaria parasite aDNA. Yet only a small handful of samples out of hundreds tested have 
yielded positive results for P. falciparum aDNA (see Sallares and Gomzi, 2001, and Nerlich 
et al., 2008 for examples). P. vivax aDNA has yet to be isolated in archaeological bone 
samples, though attempts have been made (e.g., Pinello, 2008). Reasons for this apparent 
failure are likely threefold. Firstly, P. vivax infection is characterised by low parasitaemia, 
hence there are comparatively fewer circulating parasites entering the archaeological record 
within the bone (Brown and Brown, 2011). Secondly, active blood-stage infections do not 
last a particularly long time (compared to the vivax hypnozoite stage). The target individual 
must, therefore, have been suffering from an active infection at the time of death for the 
parasites to be present in the blood stream. Thirdly, despite an intimate knowledge of the 
parasitic genome, researchers simply do not know how well P. vivax DNA survives the 
numerous diagenetic processes following host death and interment. These three factors 
conspire to make P. vivax detection an extremely difficult and potentially expensive 
endeavour when utilising ‘traditional' PCR techniques. The recent emergence of next 
generation DNA sequencing techniques (including shotgun sequencing) may prove very 
useful in the search for elusive P. vivax aDNA (e.g., Rizzi et al., 2012). Recent success in 
confirming the presence of tuberculosis (Chan et al., 2013), leprosy (Schuenemann et al., 
2013), and brucellosis (Kay et al. 2014) aDNA fragments in ancient tissue suggests a 
promising future for the detection of Plasmodium vivax aDNA. 
 A second avenue of biomolecular research that has been used to trace malaria in 
archaeological remains is the detection of antibodies to parasite antigens or parasite-derived 
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products of infection. The majority of these studies have concentrated on detecting the 
presence of P. falciparum histidine rich protein-2 (PfHPR-2) or P. falciparum lactate 
dehydrogenase (PfLDH) antigens using RDTs, ELISAs, or IFATs. PfHRP-2 is a water-
soluble protein antigen released from parasitised erythrocytes, while PfLDH is "a soluble 
enzyme found in the glycolytic pathways of the malaria parasite and is produced by sexual 
and asexual stages" (Fornaciari et al., 2010:584). These biomolecules have been detected in 
either mummified (e.g., Massa et al., 2000) or osseous (e.g., Fornaciari et al., 2010) tissues. 
As PfHRP-2 and PfLDH are specific to P. falciparum infection, the search for P. vivax 
antigens tends to concentrate on the detection of parasite lactate dehydrogenase (pLDH), an 
enzyme produced by P. vivax, ovale, and malariae parasite during the erythrocytic stage of 
infection. Moving beyond parasite antigen detection, immunological methods to trace 
products of the human immune response (i.e., immunoglobulin antibodies) to ancient 
malaria infection have also been employed. The most commonly used biomolecular tests for 
pLDH and/or ancient antibodies are discussed below. 
 
4.4.1: Rapid diagnostic tests (RDTs) 
Combination-style RDTs currently offer the cheapest and quickest method of 
detecting pLDH in clinical settings, with species-specific pLDH RDTs being much more 
expensive (UNICEF, 2007). In clinical cases, circulating pLDH antigens have been detected 
for up to three weeks post-treatment, which potentially offers a window of detection in 
archaeological human remains (if the individual died during or shortly after infection). 
Unfortunately, a literature search yields no evidence of the use of these tests in the detection 
of P. vivax in such samples. One reason for this may be that combination RDTs cannot 
currently distinguish between the non-falciparum malaria species. However, this does not 
necessarily negate their use as diagnostic tools by researchers of past British malaria: P. 
vivax was almost certainly the exclusive agent of disease in question, so positive pLDH tests 
should indicate the presence of this species, rather than P. ovale or malariae. A second 
reason may be due to the relative insensitivity of RDTs, most of which require a 
parasitaemia level of at least 100 parasites/μL of blood for detection; archaeological bone 
may contain a significantly lower (if any) concentration of surviving, detectable pLDH 
antigens. Further to this, RDT’s can only detect pLDH antigens for up to three weeks post-
137 
 
infection. As with the detection of Plasmodium aDNA, the skeletal individual tested must 
therefore have died within a short period of infection, especially since antigen levels would 
drop significantly as those three weeks progressed.  
Finally, as with all clinical immunological tests, RDTs are not designed to be used on 
ancient material. Manufacturers, quite understandably, do not test them for cross reactions 
with molecules found in association with ancient samples. One instance of RDT detection of 
ancient falciparum pLDH (Fornaciari et al., 2010) required the adoption of a significantly 
modified methodology to reach this apparently successful result. Even so, cross reactivity 
resulting in false positives are likely to remain an issue in RDT testing, particularly when 
poor controls are used, as seems to have been the case in aforementioned study. Strict 
controls, subsequent supplementary testing or protein profiling may help to resolve these 
issues, or help confirm a RDT diagnosis. Given the lack of research using RDTs to detect 
ancient P. vivax pLDH, it would be advantageous to attempt such detection using targeted 
British archaeological samples prior to the use of more sensitive tests, or as confirmatory 
tests, should positives be encountered elsewhere. 
     
4.4.2 Enzyme-linked immunosorbent assays (ELISA) 
 
 ELISAs are successfully and frequently employed in modern medical and forensic 
fields, as well as in the clinical detection of malaria (e.g., Nam et al., 2010). The use of 
ELISAs on ancient human remains to detect the presence of malaria has a similar scope to 
that of RDTs, concentrating mostly on P. falciparum antigen detection in mummified tissue 
(e.g., Massa et al., 2000). The ELISA has been reportedly used successfully in the detection 
of P. vivax in Peruvian mummified tissue (Allison et al., 2009), although this research should 
perhaps be treated with caution, as it does not seem to have been peer reviewed.  
 As with RDTs, there is no evidence that ELISAs have been employed in the 
detection of vivax malaria (either pLDH or human antibodies to vivax infection) in 
archaeological bone. The reasons for this may be similar to some of those listed above for 
RDTs, particularly concerning the cross reactivity with untested molecules. The use of 
ELISAs in ancient malaria detection may prove to be a double-edged sword for a number of 
reasons. Firstly, one ELISA kit can test up to 96 samples, meaning that after a relatively 
large initial financial outlay, they are more economical on a per-sample basis than single-
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sample RDT cartridges. Secondly, ELISAs are far more sensitive than RDTs in clinical 
applications and therefore have a greater potential to detect vivax malaria in archaeological 
samples. This increased sensitivity, however, also means a greater chance of cross reactions 
occurring with foreign biomolecules (see Brandt et al., 2002 for an example of this).  
 Despite potential drawbacks, ELISAs probably represent the immunological test of 
choice in detecting ancient vivax malaria due to high sample throughput at relatively low 
cost, the wide range of commercially available antibody/antigen combinations and high test 
sensitivity/specificity at low parasitaemia. Careful methodological design would be 
necessary to limit and characterise any possible cross contamination and false positives. 
Purification of target proteins may also prove useful prior to ELISA. This was shown in 
research by Kolman et al. (1999), who successfully purified archaeological antibodies 
(IgGs) from bone and tested them using ELISA against syphilis antigens, encountering 
positives with purified samples only. 
 
4.4.3: Radioimmunoassay (RIA) and Immunofluorescence (IFAT) 
 
 The high sensitivity of RIAs offers the potential to detect tiny quantities of surviving 
target proteins. Early attempts were made at the modification of the standard biochemical 
methodology in order to detect ancient collagen and serum proteins (e.g., Lowenstein, 1980, 
1981), although as with many early ancient biomolecular studies, diagenetic factors were 
only given cursory attention. The method is championed by Lowenstein, who has continued 
to modify the method (now known as protein radioimmunoassay, or pRIA), with apparent 
success, in a variety of archaeological and forensic applications (e.g., Lowenstein et al., 
1991, 2006). Overall, little RIA research has been conducted on ancient pathogenic 
biomolecules, including those occurring in vivax malaria infection. This is probably due 
partly to inherent methodological issues, such as risks associated with radioactivity, 
problems with cross reactivity, and reliability issues in clinical detection of vivax-associated 
proteins (e.g., Avraham et al., 1983). This study will not use RIAs due to these problems. 
 IFATs are routinely used in the clinical detection of malaria, their high sensitivity 
proving particularly useful in the diagnosis of low-parasitaemia vivax malaria and in 
asymptomatic patients (Lee et al., 2011). The tests have also been employed in pathogen 
detection in archaeological remains. Le Bailly et al. (2008), for instance, used both IFAT and 
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ELISA to detect protozoan Giardia intestinalis antigens in ancient coprolites. Bianucci et al. 
(2008) used IFAT to test the same mummified child remains that Miller et al. (1994) and 
Cerutti et al. (1999) had earlier analysed using a ParaSight™-F test (an early type of RDT). 
Conflicting results were achieved: some samples testing positive by RDT gave negative 
IFAT results. Ancient DNA analysis on the same sample has also failed to detect evidence 
for P. falciparum infection (Sallares and Gomzi, 2001). This suggests that either the RDT 
gave false positive results, or the methodologies used in the earlier studies were suspect (or 
both). IFATs are certainly more sensitive than RDTs, which increases their chance of 
detecting low quantities of antigen while also increasing the possibility of cross reactions 
(RDTs may completely miss samples with low parasitaemia). As with Western blot tests, 
IFAT methodologies in testing ancient samples are more standardised than newer techniques 
and should be considered a potentially useful tool in the detection of ancient vivax malaria, 
although as with all immunological tests, the issue of diagenetic alteration must be 
accounted for. 
 
4.4.4: SDS-PAGE and Western blot tests 
 
 SDS-PAGE and subsequent Western blotting are not frequently employed in the 
clinical detection of malaria, yet they are some of the most commonly used biomolecular 
techniques in the characterisation of ancient proteins. SDS-PAGE is designed to separate out 
proteins within a sample by molecular weight and are often used as a fore-runner to down-
stream protein identification and characterisation techniques, such as antibody/antigen 
reactivity immunoblotting (e.g., Wiechmann et al., 1999; Torres et al., 2002; Schmidt-
Schultz and Schultz, 2004, 2007), or mass spectrometry (e.g., Ostrom et al., 2000; Boros-
Major et al., 2011). SDS-PAGE and Western blot testing are relatively cheap and fast to 
perform, allowing for the testing of multiple samples at once. The methodologies involved 
in testing ancient bone samples using SDS-PAGE and Western blots are some of the more 
standardised within biomolecular archaeology. The main problem for ancient protein 
separation and analysis using electrophoresis and immunoblotting is that diagenetic 
processes may alter molecular weights and morphologies, thus giving unexpected results. 
Degradation may also obscure antibody/antigen interactions, leading to false positives or 
false negatives in Western blotting. Despite this, the general ease and standardisation of such 
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tests mean that they should certainly be considered for use when testing archaeological bone 
for proteins associated with vivax malaria infection.    
 
4.4.5: Palaeoproteomics and protein profiling 
 Palaeoproteomics refers to a collection of relatively new methods derived from 
biomolecular proteomics for studying ancient proteins. The methods are often based on the 
separation and subsequent profiling of the entire protein complex (proteome) of a given 
sample, and are hence known collectively as ‘protein profiling' techniques. Protein profiling 
offers an advantage over antigen/antibody immunological detection in that the former does 
not require the survival of functional protein epitopes, thereby avoiding the problem of cross 
reactions and false negatives/positives. In protein profiling every protein in a sample is 
isolated, from which single proteins can be selected and studied using amino acid 
characterisation (Brown and Brown, 2011). Initial profiling can be achieved by traditional 
SDS-PAGE, Western blot test (either electrophoresis or isoelectric focusing), or by various 
chromatographic methods, such as ion-exchange, gel filtration (Ó’Fágáin et al., 2011; 
Karlsson and Hirsh, 2011), and reversed phase high performance liquid chromatography 
(rpHPLC). Ostrom et al. (2000), for instance, used a combination of Western blot, RIA, and 
rpHPLC to isolate protein in archaeological bone samples. They followed this by structural 
characterisation of the protein by matrix-assisted laser desorption ionisation (MALDI), "a 
relatively new ionization technique that is capable of ionizing a large variety of compounds, 
particularly large proteins, for analysis by mass spectrometry" (Harvey, 2005:386).  
The use of MALDI mass spectrometry to recover a "sequence information from 
subpicomolar quantities of fragmented proteins and peptides" (Boros-Major et al., 2011:197) 
means that the technique is potentially an appropriate method for characterising degraded 
ancient proteins, which can subsequently be identified by matching to specific peptide 
(amino acid sequences specific to individual proteins) mass fingerprints (PMFs). Such 
analysis has recently been reported as successful in the identification of tuberculosis and 
osteogenic sarcoma proteins in archaeological human skeletal remains using MALDI 
tandem time-of-flight mass spectrometry (MALDI TOF/TOF MS) (Boros-Major et al., 
2011). These studies suggest that proteomics offers great potential in the analysis of other 
pathological organisms in future research. Caution should, however, be taken in the 
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interpretation of ancient protein profiling results: given the novelty of palaeoproteomics as a 
field of biomolecular archaeological research, procedural protocols in the profiling of 
ancient proteins are currently non-standardised and little is known about how diagenetic 
changes may alter specific PMFs (Brown and Brown, 2011). Cutting-edge methods of 
palaeoproteomics analysis using extremely sensitive nanoflow liquid chromatography 
peptide sequencing (nLC-MS) are beginning to address the problem of identifying 
diagenetic changes to ancient proteins and are opening broad new avenues of biomolecular 
investigation. These recent technological advances have opened up exciting new avenues of 
research into ancient non-collagenous proteins (e.g., Cappellini et al., 2012; Wadsworth and 
Buckley, 2014). This technology provides a potentially important method of detecting and 
characterising surviving peptides of extremely low-abundance, a category into which many 
archaeological malaria-related proteins must surely fit. However, as always, "rigorous 
scientific discipline is needed in the exploitation of new techniques" (Minnikin et al., 2010). 
Although proteomic methods could be used in the search for biomolecular evidence 
of ancient P. vivax infection, such as parasite antigenic proteins and different human 
response immunoglobulin types, the high expense currently precludes an extensive 
investigation using this technique. Proteomics could, however, provide initial positives for 
target protein identification, or important confirmatory testing should malarial positives be 
encountered in other analyses,  
 
4.4.6: Haemozoin detection 
 The detection of the Plasmodium biocrystalline waste product haemozoin as a 
marker of malaria infection is a relative newcomer to the field of clinical malariology. It is 
therefore no surprise that only one (unsuccessful) attempt has been made at such detection in 
archaeological bone (see Setzer, 2010). Given the novelty of the application in 
palaeopathological analysis, there is no published research on the effect of diagenesis on the 
survival of haemozoin in the burial environment, although insoluble biocrystals such as 
haemozoin should, theoretically, be more resistant to some diagenetic processes than 
proteins and DNA. Clinical techniques, using similar equipment to that used in protein 
profiling, or flow cytometry, may potentially be adapted for analysis of archaeological bone 
samples, and it may prove advantageous to attempt such analyses, given the potential for 
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survival of haemozoin in archaeological bone (Setzer, 2010). Histological examination of 
bone thin-sections prior to analysis may be useful as this may allow for both an evaluation 
of the state of bone preservation (as suggested by Schmidt-Schultz and Schultz, 2004 for all 
biomolecular palaeopathological studies). Thin-sectioning may also allow for direct 
microscopic visualisation of haemozoin in the ancient bone sample, particularly given the 
recent advancements in erythrocyte visualisation (Setzer et al., 2013). 
 
4.5: Summary 
 Biomolecular analysis offers vast potential in the detection and characterisation of 
ancient diseases that leave no visual evidence of their presence in human bone. This 
potential has been recognised by researchers who have continued to push the limits of 
biomolecular palaeopathological techniques in the search for disease-related biomolecules in 
archaeological remains. The discipline has matured from early, often controversial attempts 
at ancient organic residue analyses in the 1970s and 80s, to the recent use of high-resolution 
mass spectrometry technology to give a more complete protein profile from ancient organic 
samples. Each of the discussed techniques that have been employed in the detection of 
ancient biomolecules has advantages and disadvantages (see summary Table 4.1). Every 
methodology is affected, to a greater or lesser extent by uncertainties concerning the 
degradation of target biomolecules. Diagenetic processes are highly variable, dependent on 
multiple factors within the burial environment (Nielsen-Marsh and Hedges, 2000), and it is 
therefore extremely difficult to predict how each individual sample will be affected. 
Traditional aDNA and immunological methods are particularly vulnerable to biomolecular 
contamination or degeneration, which can give confounding results. Sallares and Gomzi 
(2001:199) state that "…immunological methods as applied so far to ancient malaria still 
seem to suffer from a problem with specificity. When a positive result is obtained, it is 
impossible to be sure what the antibody is actually reacting with", a difficulty common to all 
immunological tests of ancient bone for evidence of ancient pathogens. The problem is such 
that it has even been suggested that immunological tests "should only be regarded as a 
useful screening technique" and that "confirmatory studies will always be required" (Child 
and Pollard, 1992:45), sentiments echoed by Gernaey et al. (2001). Modern analytical 
techniques, such as high-resolution mass spectrometry and haemozoin detection, may be less 
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susceptible to this complication in that they avoid the cross-contamination issues associated 
with immunological testing. However, these newest techniques are not invulnerable to the 
problems of diagenesis and remain somewhat untested on ancient samples.  
 
Method 
Target 
Biomolecule 
Advantages Disadvantages References 
‘Traditional’ 
aDNA 
DNA - Human 
or parasite 
Established method;  
high sensitivity and 
specificity. Next 
generation sequencing 
looks very promising. 
Expensive;  diagenesis; 
contamination issues 
Taylor et al., 1997; 
Sallares & Gomzi, 2001;  
Chilvers, 2004;  
Pinello, 2008;   
ELISA 
Antigens/ 
Antibodies 
96 samples per test;  
high sensitivity; 
high specificity 
  
Diagenesis; 
untested on ancient P. 
vivax; 
possible cross-reactivity 
Cattaneo et al., 1992;  
Kolman et al., 1999 
Massa et al., 2000; 
Brandt et al., 2002;  
Le Bailly et al., 2008 
IFAT 
Antibodies to  
parasite  
antigens 
High sensitivity 
Cross-reactivity; 
Diagenesis 
Bianucci et al., 2008;  
Le Bailly et al., 2008 
Light  
microscopy 
Parasites/ 
infected cells 
High specificity; may 
identify poor 
preservation/diagenetic 
alternation 
Molecules not usually 
visible microscopically  
Wickramasinghe &  
Abdalla, 2000;  
Schmidt-Schultz &  
Schultz, 2004 
Haemozoin  
detection 
Haemozoin 
biocrystals 
Potentially stable/ 
insoluble biomolecule; 
high specificity and  
sensitivity 
Expensive;  
relatively untested; 
no established  
methodology 
Setzer, 2010 
Protein  
profiling 
Surviving  
protein peptides 
No false negatives;  
high sensitivity and  
specificity 
Expensive;  
relatively untested; 
no standardised  
methodologies 
Ostrom et al., 2000;  
Boros-Major et al.,  
2011;  
Cappellini et al., 2012 
RDT Parasite antigens Cheap; easy to perform 
Conflicting results; 
low sensitivity; 
diagenesis 
Miller et al., 1994; 
Fornaciari et al., 2010 
RIA 
Antibody/ 
antigen 
High sensitivity 
Questioned reliability;  
hazardous 
Gurtler et al., 1981;  
Lowenstein 1981; 
Lowenstein et al., 2006 
Western blot 
Antigens or  
antibodies 
Easy to perform; 
relatively cheap;  
established methodology 
Diagenesis; expensive if 
using high antibody 
quantities to probe 
Ascenzi et al., 1985; 
Grupe & Turban-Just, 
1998;  
Wiechmann et al., 1999; 
Torres et al., 2002; 
Schmidt-Schultz &  
Schultz, 2004 & 2007 
Table 4.1: Summary of major methodologies employed in pathogen biomolecular 
palaeopathology, with advantages and disadvantages.  
 
A possible solution may lie in a multifactorial approach to the search for ancient 
malaria in Britain, such as attempted by Setzer (2010) in her examination of Sardinian 
skeletons. Macroscopic palaeopathological analysis should form the basis of sample 
selection for biomolecular testing, followed by evaluation of the bone preservation through 
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histological analysis. Macroscopic (and possibly radiographic) identification of conditions 
that may be indirectly related to malaria infection, such as stress-induced skeletal markers 
(e.g., enamel hypoplasia), and adaptive genetic polymorphisms (e.g., the thalassaemias) 
would supply important lines of evidence upon which possible biomolecular testing would 
be based. The use of a number of targeted techniques such as these will help to identify 
sample targets of known preservation levels, thus giving the highest chance of detecting and 
characterizing P. vivax-associated biomolecules. This exploration of the most commonly 
employed methodologies in the fields of palaeopathology and biomolecular palaeopathology 
is useful in that it presents a firm base from which to choose the most appropriate 
methodologies for this study of P. vivax infection in past British populations.    
 
4.6: Protein extraction from archaeological bone 
 
“In a good preservation state, bone conserves intact collagen molecules and many, if 
not all, NCPs from recent and ancient times” (Schmidt-Schultz and Schultz, 2004). 
 
A major challenge in the detection and characterisation of archaeological bone 
proteins is the successful extraction of target proteins from the bone matrix. During life and 
after death negatively charged non-collagenous proteins (particularly glycoproteins) adsorb 
to bone hydroxyapatite, where they are afforded additional protection from diagenetic 
factors following initial decomposition by the hardly-soluble calcium-phosphate mineral 
(Wiechmann et al., 1999). The challenge lies in the successful removal of these tightly 
bound proteins from the bone matrix, and their preservation and conservation during the 
extraction process. 
 Research over recent decades has attempted to refine protein extraction techniques. 
This is likely due to an increasing appreciation of the role that diagenesis plays in the 
degradation of ancient proteins and the associated methodological difficulties in 
archaeological protein detection (Child and Pollard, 1992; Child, 1995; Collins et al., 2002). 
Increasingly, methodological refinements have turned to clinical techniques of protein 
extraction, with an emphasis on the reduction of protein degradation during the extraction 
process (Schmidt-Schultz and Schultz, 2004). Prior to this, these seems to have existed a 
latent assumption that any equilibrium reached by archaeological bone and their endogenous 
proteins with their surrounding burial environment, in terms of diagenesis, would remain in 
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place during the extraction process (i.e., the target proteins would not further degrade during 
extraction). It has, however, been suggested that mechanical grinding of bone prior to 
extraction causes the equivalent damage to collagen of 5000 years of burial (Collins and 
Galley, 1998). Clearly any processing steps taken that may reduce the likelihood of protein 
degradation should be considered. Since there remains insufficient research on the 
deleterious effects of extraction processes on surviving archaeological non-collagenous 
proteins, a move towards preventative clinically-based methodologies seems advisable.   
 
4.6.1: Selection of target biomolecule(s) 
 Identification of the most appropriate P. vivax-associated biomolecule is crucial in 
this attempt to detect the disease in archaeological bone. The choice can be quickly 
narrowed to either endogenous biomolecules (e.g., antibodies synthesised by the body in 
response to infection) or exogenous biomolecules (e.g., those introduced into the host by the 
mosquito vector, or associated with the invading parasite, such as DNA or haemozoin). 
Extraction of endogenous antibodies has advantages over and above the search for 
exogenous antigenic molecules or pathogenic aDNA. Host antibodies (mostly 
immunoglobulin G, or IgG) to vivax infection have been clinically shown to circulate and 
remain at a stable titre (serum concentration) for an extended period in the absence of 
reinfection (Wipasa et al., 2010), long after exogenous pathogenic biomolecules have been 
removed from the body. This may be one explanation for Pinello’s (2008) unsuccessful 
attempt at detecting P. vivax aDNA. If antibodies are retained in the bone, they represent a 
far more stable target for analysis than pathogenic molecules, which are, by nature, 
transitory.  
Immunoglobulin G antibodies represent the most abundant antibody class, 
accounting for approximately 75% of serum immunoglobulins in healthy individuals 
(Meulenbroek and Zeijlemaker, 1996). Non-collagenous proteins, including 
immunoglobulins, exhibit a high affinity for bone hydroxyapatite, to which they strongly 
adsorb during life (Masters, 1989; Wiechmann et al. 1999; Schmidt-Schultz and Schultz, 
2004). Clinical research has shown that adsorptive nature of hydroxyapatite can concentrate 
certain non-collagenous proteins, including immunoglobulins, to levels above that found in 
plasma. This concentration of antibodies within the bone mineral likely provides an 
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increased resistance to infection (Omelyaneko et al. 2013). IgGs should, therefore, 
concentrate within the bone mineral and have a chance of surviving the effects of diagenesis 
after death and burial, making them a potentially viable and valuable target for biomolecular 
studies of vivax malaria. Wipasa et al.’s (2010) confirmation of long-lived anti-vivax 
antibodies strengthens the case for selecting IgGs as the best target biomolecule for this 
study, since the target individual would not necessarily have to have died during, or 
immediately following, active vivax infection in order to detect the presence of the disease. 
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CHAPTER 5: MATERIALS AND METHODS 
 This chapter details and justifies the samples chosen and the various methodological 
approaches employed in the attempt to identify the presence of P. vivax malaria in British 
antiquity from skeletal remains. It firstly outlines the recently established skeletal sequelae 
of thalassaemia that may have been misidentified in pathological and skeletal reports from 
sites selected for this study, before listing these sites and justifying their inclusion. 
Following this is a brief discussion of the criteria for selecting sites for palaeodemographic 
analyses of Fen and non-Fen cemetery populations. Thirdly, the selection criteria for skeletal 
individuals and bone elements for biomolecular analyses are detailed, along with the 
methods used for initial sample preparation and histological analysis. The methods used in 
five separate protein and immunoglobulin extraction protocols and subsequent techniques 
employed in protein characterisation are then detailed. Finally, the procedures used in rapid 
testing for malaria antigens are presented. 
 
5.1: Identification of cases of genetic anaemia in skeletal reports 
 In light of the recent additional diagnostic criteria for thalassaemia in skeletal tissue 
provided by Lewis (2010), it was decided to examine selected palaeopathological reports for 
any missed or misidentified evidence of the condition. Reports from the sites selected 
(section 5.3.1) for anti-malaria antibody identification were examined, since these are the 
populations most likely to develop conditions intimately associated with exposure to malaria 
(Hume et al., 2003). As discussed in section 4.2.9, thalassaemia intermedia is the most likely 
encountered form of the disease, since homozygotes (thalassaemia major) would invariably 
die before developing diagnostic skeletal changes, and thalassaemia minor may not 
necessarily present with skeletal modifications at all (Ortner and Putschar, 1981; Lewis, 
2010). Historically, those with thalassaemia intermedia could potentially survive well into 
adulthood without medical support, exhibiting varying degrees of sequelae, which often 
worsen with age (Lagia et al., 2007; Lewis, 2010).  
Attempts have been made to identify more specific skeletal indicators of 
thalassaemia in ancient populations, beyond the ‘traditional’ non-specific markers (e.g., 
cribra orbitalia or porotic hyperostosis). Ortner and Putschar (1981:252), for instance, 
suggest that “bone lesions in thalassemia are entirely due to increased spatial demands for 
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the hyperplastic erythropoietic marrow”, which affect the crania and facial bones most 
seriously, followed by long bone epiphyses, ribs, vertebral bodies, metacarpals/tarsals, and 
phalanges. Hershkovitz et al. (1997) suggest premature epiphyseal fusion (particularly 
affecting the distal leg long bones and proximal humerus) as being pathognomonic of 
thalassaemia, while Lewis (2010) identifies costal osteomas and the ‘rib-within-rib’ 
phenomenon as likely criteria for diagnosing the condition. Unfortunately, the latter is only 
visible radiographically, and would, therefore, not necessarily be recorded during routine 
palaeopathological analyses. However, records of rib hypertrophy, or of ribs with multiple 
healing ‘fractures’ may be suggestive of thalassaemia.  
 Table 5.1 lists possible sequelae that may, in combination, be suggestive of 
thalassaemia in skeletal material. Due to the non-specific nature (e.g., scoliosis) and 
relatively high frequency (e.g., multiple rib fractures) of many of these, only individuals 
displaying two or more sequelae were marked for further analysis. In cases where a 
combination of suggestive skeletal changes was encountered in the selected 
palaeopathological reports (see section 6.1), every effort was be made to obtain appropriate 
bone samples for further macroscopic and radiographic inspection. It should be noted, 
however, that at the time of the research, the Cambridgeshire Archaeological Store 
(archive), which possesses the bulk of samples chosen for this study, was in the process of 
relocation. Consequently, access to samples of potential interest from these sites was 
precluded (other than Littleport, which is yet to be archived). 
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Sequelae 
Porotic hyperostosis 
Lateral orbit displacement 
Sunken nasal bridge 
Maxillary swelling 
Cranial diploë thickening 
‘Hair-on-end’ appearance in cranial diploë 
Osteopenia 
Sternal widening 
Premature epiphyseal plate closure 
Epiphyseal/metaphyseal widening 
Femoral fractures 
Rib osteomas 
‘Rib-within-a-rib' 
Rib cortical erosion 
Multiple rib fractures 
Scoliosis 
Table 5.1: Selected skeletal sequelae of the thalassaemias, from Ortner and Putschar (1981), 
Ortner (2003), Hershkovitz et al. (1997), Lagia et al. (2007), Lewis (2010), Yochum and 
Rowe (2005), and Perisano et al. (2012). Bold sequelae are cited as more specific for 
thalassaemia. 
 
5.2: Demographic analysis of Fen/marshland and non-Fen/marshland 
cemetery populations 
 
 As briefly discussed in section 4.2.11, palaeodemographic analysis of cemetery 
populations from potentially malarious and non-malarious areas may prove useful in the 
search for indirect evidence of P. vivax malaria. For these analyses, a number of Fen and 
non-Fen cemetery sites were selected based on the criteria defined below in section 5.2.1. 
Total and period specific mortality profiles, survivorship, and probability of death (the latter 
two after Chamberlain, 2006) were constructed, and statistical tests (chi-square and 
Kolmogorov-Smirnov) were then applied, where appropriate, in order to investigate any 
significant relationships between environment and cemetery demographics.  
 
5.2.1: Cemetery selection 
 Geographic location was of paramount importance for selecting sites, and analysis 
was dependent upon the availability of published skeletal reports containing sufficient 
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demographic detail. Fen-associated inhumation cemeteries needed to be either within the 
Fens, close to the Fen edge, or in close proximity to marshlands, river flood plains or tidal 
estuaries. The sites chosen were all associated with the historically recorded presence of 
malaria vector anopheline species (Nuttall et al., 1901), and were within an appropriate 
distance (approximately 3-12km, depending upon mosquito diet) of likely anopheline 
breeding grounds (Kaufmann and Briegel, 2004). Furthermore, many of the selected sites 
representing the Anglo-Saxon period have been identified as potentially malarious, based on 
topography and cribra orbitalia prevalence (Gowland and Western, 2012). Conversely, non-
Fen associated inhumation cemetery sites were selected based on their location away from 
anopheline breeding grounds, and with no recorded vector presence. 
A further prerequisite in terms of the type of cemetery selected was population 
density: only rural and semi-urban (e.g., Durobrivae) cemeteries were chosen. It is not valid 
to compare urban and non-urban cemetery populations, given the differential 
epidemiological pressures, which may result in markedly different mortality profiles. 
However, there is a general a dearth of urban centres associated with Fens and marshlands 
and this forced a natural reliance upon rural and semi-urban cemeteries. The selected Fen-
associated cemetery sites are listed in summary Table 5.2, while the summary in Table 5.3 
shows non-Fen associated sites. Full tables (A2.1 and A2.2) are provided in Appendix 2. 
Table 5.4 displays the total number of Fen/non-Fen individuals from each period in these 
locations.  
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Site Period Site Period 
Durobrivae, Cambs Roman Market Deeping Bypass, Cambs Anglo-Saxon 
Hoplands, Sleaford, Lincs Roman Monkton, Kent Anglo-Saxon 
Prickwillow Road, Ely Roman Quarrington, Lincs Anglo-Saxon 
The Parks, Godmanchester Roman Ramsgate, Kent Anglo-Saxon 
Watersmeet, Huntingdon Roman Rivenhall, Suffolk Anglo-Saxon 
Barton Bendish, Norfolk Anglo-Saxon Snodland, Kent Anglo-Saxon 
Baston, Lincs Anglo-Saxon St Peter's, Barton-upon-Humber, Lincs Anglo-Saxon 
Burgh Castle, Norfolk Anglo-Saxon Staunch Meadow, Suffolk Anglo-Saxon 
Caistor-on-Sea, Norfolk Anglo-Saxon Thetford, Norfolk Anglo-Saxon 
Castle Mall, Norwich Anglo-Saxon Ulwell, Dorset Anglo-Saxon 
Castledyke South, Lincs Anglo-Saxon Westfield Farm, Ely Anglo-Saxon 
Cleatham, Lincs Anglo-Saxon Orchard Lane, Huntingdon Medieval 
Edix Hill, Cambs Anglo-Saxon Rivenhall, Suffolk Medieval 
Haddenham, Cambs Anglo-Saxon St Peter's, Barton-upon-Humber, Lincs Medieval 
Highfield Farm, Littleport Anglo-Saxon Stonar, Kent Medieval 
Table 5.2: Fen sites selected for demographic analysis. 
 
Site Period Site Period 
Ancaster, Lincs Roman Empingham II, Rutland Anglo-Saxon 
Babraham Institute, Cambs Roman Filton, Bristol Anglo-Saxon 
Bainesse Farm, Catterick Roman George Street, Aylesbury Anglo-Saxon 
Baldock, Herts Roman Great Chesterford, Cambs Anglo-Saxon 
Mangiovinium, Bucks Roman Henley Wood, Berks Anglo-Saxon 
Newarke Street, Leicester Roman Mill Hill, Kent Anglo-Saxon 
Queenford Farm, Oxon Roman Norton, Cleveland Anglo-Saxon 
Rudston Villa, Yorks Roman Orpington, Kent Anglo-Saxon 
St. Albans, Herts Roman School Street, Ipswich Anglo-Saxon 
Barnstaple Castle Anglo-Saxon Sewerby, Yorks Anglo-Saxon 
Buckland, Kent Anglo-Saxon West Heslerton, Yorks Anglo-Saxon 
Castle Green, Hereford Anglo-Saxon Blackfriars Street, Carlisle Medieval 
Charlton Plantation, Wilts Anglo-Saxon Brighton Hill South, Hamps Medieval 
Coddenham, Suffolk Anglo-Saxon Corbridge, Northumberland Medieval 
Darenth Park, Kent Anglo-Saxon Wharram Percy, Yorks Medieval 
Dunton Green, Kent Anglo-Saxon 
  Table 5.3: Non-Fen sites selected for demographic analysis. 
 
Fen sites Non-Fen sites 
Period Individuals Period Individuals 
Roman 173 Roman 704 
Anglo-Saxon 1909 Anglo-Saxon 1385 
Medieval 1170 Medieval 859 
Total 3252 Total 2948 
Table 5.4: Number of Fen/non-Fen individuals from each period.  
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 As can be seen in Tables 5.2 and 5.3, there is a distinct weighting towards Anglo-
Saxon sites, particularly in the Fen category. This is, in part, an artefact of the availability of 
published site reports and skeletal inventories. It is also a reflection of the Fenland 
settlement patterns briefly discussed in Chapter 2, providing a demonstration of the 
increasing Anglo-Saxon settlement and utilisation of the Fens. The small number of Fen 
Roman sites may be as much due to burial practice as it is to a relatively limited presence in 
Fen environments (discussed in section 7.1.2(iii)). A reduced number of medieval 
cemeteries may be due to the tendency for churchyard burial in this period, and the 
associated difficulties in archaeological excavation and analysis of such populations. In both 
categories there are cemeteries that yielded large numbers of individuals. St. Peter’s Church 
in Barton-upon-Humber, for instance, accounts for 728 Anglo-Saxon and 849 medieval Fen 
burials, while Wharram Percy yielded 645 medieval non-Fen individuals. The possible 
skewing effects of these large populations were investigated by running alternate analyses 
with these two sites included and removed.   
 It should also be noted that the reports chosen for palaeodemographic analysis were 
compiled aver an extended time period (the earliest dating back to 1973) by numerous 
palaeopathologists, using a range of methods for analysing human skeletal remains. A 
problem (discussed in 7.1.2(iii)) arises when attempting to compare populations which are 
recorded using non-standardised and poorly reported methods. For instance, some reports 
chosen for this study (e.g., Waldron, 2007) explicitly state and cite the methods employed 
for biological profiling of skeletons (e.g., estimating age, sex, stature, etc.), while others 
(e.g., Anderson, 1996) offer very limited information. Robert and Cox (2003:399) collected 
data from over 30,000 British skeletons from 324 site reports, and found the reported age-at-
death data “too problematic to use in association with the palaeopathological data.” The 
methods used for biological profiling of skeletal remains have evolved over the past few 
decades in response to calls for standardisation in skeletal analysis. This has resulting in the 
introduction of texts (e.g., Buikstra and Ubelaker, 1994; Brickley and McKinley, 2004) and 
initiatives (e.g., The Global History of Health Project: http://global.sbs.ohio-state.edu/), 
which may help palaeopathologists work towards a goal of standardisation in reporting, and 
increase the ease and validity of cross-study comparisons. However, since this study will 
access reports representing a variety of non-standardised reporting methods, it is hoped that 
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the use of large sample sizes and broad age categories should mitigate for some of the issues 
arising (see age category Table 6.2, Section 6.2.1) 
 
5.3: Biomolecular testing for evidence of vivax malaria 
5.3.1: Site selection 
The primary focus of this study is the biomolecular analysis of skeletal remains to 
provide direct evidence for the presence of Plasmodium vivax malaria. A number of criteria 
needed to be met for the selection of sites that may yield individuals suitable for 
biomolecular analysis. Firstly, site location was based on the criteria for selecting Fen sites 
listed above in 5.2.1. Figures 5.1 and 5.2 shows the location of the South Lincolnshire and 
Cambridgeshire, and North Lincolnshire sites, respectively. Secondly, the chosen sites 
needed to have yielded skeletons that had been inventoried, were accessible (i.e., archived, 
or in the processes of being archived), and were sufficiently preserved for sampling. 
Permission for destructive analyses was also required for each site. Sites are listed by period. 
Each is briefly introduced and the prevalence rates of the non-specific pathologies cribra 
orbitalia, enamel hypoplasia, and porotic hyperostosis are listed, where available. Summary 
tables 5.5, 5.6, and 5.7 also display prevalences of pathologies (where available) at the end 
of each period section. Prevalence rates for skeletal pathologies are usually recorded as 
being either Crude (CPR), or True (TPR). CPR, as its name suggests, is a crude estimate of 
pathological prevalence, regardless of preservation, within a population based on the 
percentage of individuals displaying the pathology. TPR gives a more accurate 
representation of disease prevalence, since it records the number of elements preserved, 
rather than individuals, affected by a pathology, thereby controlling for skeletal 
completeness. As can be seen in Tables 5.5, 5.6, and 5.7, CPR is far more commonly 
reported. 
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Figure 5.1: Relationship of south Lincolnshire and Cambridgeshire sites to the Fens. 1 – 
Durobrivae; 2 – The Hoplands, Sleaford; 3 – Prickwillow Road, Ely; 4 – The Parks, 
Godmanchester; 5 – Baston; 6 – Edix Hill; 7 – Highfield Farm, Littleport; 8 – Haddenham; 9 
– Westfield Farm, Ely; 10 – Watersmeet and Orchard Lane, Huntingdon.  
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Figure 5.2: North Lincolnshire site locations. 1 – Castledyke, Barton-upon-Humber; 2 – 
Cleatham. 
 
 
5.3.2: Romano-British sites 
5.3.2(i): Durobrivae, Cambridgeshire 
The site of the Roman town of Durobrivae is situated in the north eastern corner of 
the modern county of Cambridgeshire to the immediate east of the village of Water Newton, 
and approximately two miles to the west of modern Peterborough (Figure 5.1). The 
Cambridgeshire Fen edge lies to the immediate east and northeast of the site. 
The town site itself remains largely unexcavated, concealed beneath pastures and 
protected from disturbance by its scheduled status. Despite this, much has been inferred 
about the history of Durobrivae and its surroundings. The foundation of the settlement likely 
occurred in the mid-1st century AD in the form of a small fort on the south bank of the River 
Nene, probably constructed to control an important early crossing point. This later became 
the point at which Ermine Street crossed the Nene (Fincham, 2004). The Fen Causeway, an 
important road running eastwards thorough the Fens into Norfolk via the raised Fen islands, 
was constructed in the late 1st century (Fincham, 2004). This represents the first known 
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major attempt to access the previously impassable central Fens, and perhaps alludes to the 
importance placed by the Romans on Fenland resources, such as salt. 
Following the withdrawal of military occupation around 100 AD, the vicus 
surrounding the fort rapidly grew along the line of Ermine Street. Its location on a navigable 
watercourse and major thoroughfare influenced the growth of Durobrivae to the extent that 
it had become an important centre for trade and industry by the late 3rd century (Fincham, 
2004). It has even been suggested that Durobrivae functioned as a civitas capital, given the 
size of the fortified settlement and importance of its pottery industry (Wacher, 1975). Given 
its location, it is likely that Durobrivae played a very important role in the market economy 
of the Fens during the 2nd and 3rd centuries. Individuals who harvested the resources of the 
central and southern Fens would have had close links to Durobrivae, possibly even setting 
up permanent domiciles around the town and working in the Fens on a seasonal basis 
(Fincham, 2004). It should be expected, then, that the population of Durobrivae would have 
been familiar with the health-related risks associated with Fen-edge occupation, particularly 
those individuals who made a living accessing the rich Fen resources.   
The cemetery of Durobrivae was located outside the southwest gate of the town 
defences, and was originally discovered in the 18th century. A major portion of the cemetery 
was excavated by Cambridgeshire County Council Archaeological Field Unit in 1999 in 
advance of disturbance by motorway maintenance work. More than 50 inhumations were 
revealed, with grave goods dating the life of the cemetery to the later 3rd to early 5th 
centuries (Casa Hatton and Wall, 1999). The individuals were generally well preserved and 
exhibited a typical range of pathologies for a semi-urban Roman population, including 
manifestations of physiological stress in the forms of cribra orbitalia (3.7% CPR) and 
enamel hypoplasia (3.7% CPR) (Duhig, 1999).  
 
5.3.2(ii): The Hoplands Business Centre, Sleaford, Lincolnshire 
The town of Sleaford is located in central Lincolnshire, approximately 30km south of 
Lincoln (Figure 5.1). With little evidence of prior prehistoric activity, Old Sleaford probably 
had its origins in the middle to late Iron Age. Its position on the navigable Slea River on the 
western edge of the resource-rich silt Fens would have been a vital factor governing the 
founding and initial growth of the settlement (Elsdon and Jones, 1997). Archaeological 
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evidence suggests that by the early Roman period, the town had increased in significance 
and prospered, possibly continuing into the Anglo-Saxon periods as an important centre for 
the production and trade of salt and pottery (Elsdon and Jones, 1997; Bradley-Lovekin, 
2005; Vince, 2006; Willis, 2006). It has, however, been suggested that Old Sleaford 
diminished in importance in the 3rd century due to the increasing success and prosperity of 
Durobrivae approximately 40km to the south (Fincham, 2004). Indeed, previous 
investigations have revealed 3rd to 4th century deposits suggestive of partial abandonment of 
Old Sleaford (Western, 2011).  
The Hoplands site is situated adjacent to a Roman road and close to the centre of the 
Iron Age and Roman settlement of Old Sleaford, which itself lies beneath the eastern part of 
the modern town. The site was excavated in 2008/2009 by Archaeological Project Services 
in advance of commercial development (Murphy, 2011). Excavations revealed part of a 
nucleated 3rd to 4th century cemetery comprising 53 graves, which yielded 54 inhumed 
individuals. The skeletal population exhibited a very high prevalence of cribra orbitalia 
(37% CPR/61.5% TPR). This is compared to a 12.5% CPR at neighbouring Ancaster 
(upland), and the general Romano-British 13.5% CPR reported by Roberts and Cox (2003). 
This may support the association of Fen locality and high cribra orbitalia prevalence 
suggested by Gowland and Western (2012). The population also displayed a high prevalence 
of enamel hypoplasia (42.6% CPR/14.2% TPR) compared to 6.7% CPR at Ancaster and a 
national average of 9.64% CPR (Western, 2011). These elevated figures suggest that the 
Hoplands population was subject to adverse conditions/environs that promoted severe 
metabolic stresses during childhood, possibly in the form of parasitic infection and vitamin 
deficiency (Western, 2011). The proximity of the Fen edge to the settlement may well have 
had a negative effect on the overall health of this population. 
 
5.3.2(iii): Prickwillow Road, Ely, Cambridgeshire 
A Roman mixed cremation/inhumation cemetery site at Prickwillow Road, Ely 
(Figure 5.1), was located approximately one kilometre north east of Ely cathedral, and was 
revealed during excavations in 1999 and 2000 (Atkins and Mudd, 2003). From the Roman 
period until successful drainage schemes in the 17th and 18th centuries, the Isle of Ely was 
completely surrounded by wetlands, with freshwater peat Fen to the south, east, and west, 
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and salt marsh to the north (Godwin, 1978; Mortimer et al., 2005). It is perhaps not 
surprising that the Isle provided a centre for human activity for centuries prior to the Anglo-
Saxon settlement at Westfield Farm. Scattered local archaeological evidence of Neolithic 
and Bronze Age activity precede an increased intensity of activity from the middle Iron Age 
to Roman period (Lucy, 2007 a). The first documentary evidence for Ely dates to the mid-
12th century and concerns the foundation of a monastery by Etheldreda in the late 7th century 
(Holton-Kreyenbuhl, 2005). 
The cemetery yielded 16 inhumed individuals (87.5% adults), dating to the 3rd to 4th 
centuries (Anderson, 2003) . Gross preservation was reported as reasonably good and the 
small population displayed a generally low pathological prevalence. No mention was made 
of cribra orbitalia, and no cases of enamel hypoplasia were reported (Anderson, 2003), 
although the recorded high prevalence of carious lesions may have obscured many 
hypoplastic defects. 
 
5.3.2(iv): The Parks, Godmanchester, Cambridgeshire 
The modern town of Godmanchester is located in the Great Ouse valley, on the 
southern bank of the River Great Ouse in the Huntingdonshire district of Cambridgeshire 
(Figure 5.1). With little archaeological evidence of permanent prehistoric settlement, it is 
likely that settlement at Godmanchester began life with the building of two consecutive 
Roman forts and associated vicus during the mid to late 1st century AD. This was quickly 
followed by the construction of Ermine Street. The site of the forts demonstrates the 
importance of the location in controlling an important river crossing along a main Roman 
route (Jones, 2003). Following military withdrawal from the area, the settlement at 
Godmanchester was re-planned and continued to grow, with archaeological evidence of 2nd 
and 3rd century buildings, late 3rd century defences, and a recently discovered 4th century 
cemetery (Green, 1975; Jones, 2003).  
The settlements of both Huntingdon and Godmanchester lie within the Great Ouse 
valley flood plain and are subsequently liable to flooding events (Huntingdonshire District 
Council, 2007), the threat of which past occupants must have been very familiar with. As 
early as 1673, Blome depicted the location of the Great Ouse valley and its proximity to the 
Fen edge to the immediate east and northeast. The threat of inundation and the health risks 
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associated with Fenland occupation would most likely have been a burden experienced by 
the occupants of the Great Ouse valley prior to the 19th century. 
 The 4th century cemetery comprised 62 relatively well preserved inhumations, with a 
moderately even sex ratio between males and females. Eighty three percent of the skeletal 
population were sufficiently well preserved to be assigned an age category, 27% of whom 
were aged less than 16 years (Brickley, 2003; Jones, 2003). Pathological analysis suggests 
that the population enjoyed reasonably good health and living conditions, although evidence 
of poor dental hygiene, rickets, non-specific infection (6.4% CPR), and anaemia in the form 
of cribra orbitalia (1.6% CPR) were also noted (Brickley, 2003). The surprisingly low 
prevalence of the latter condition may be due to the highly fragmentary nature of many of 
the extant crania. It should also be noted that enamel hypoplasia was not recorded in this 
population due to the very poor survival of dentition. 
 
5.3.2(v): Watersmeet, Huntingdon, Cambridgeshire 
Huntingdon is the administrative capital of the Huntingdonshire district of 
Cambridgeshire. Located on the north bank of the River Great Ouse (Figure 5.1), 
Huntingdon was likely founded in the Roman period as a subsidiary settlement to 
Durovigutum, or Godmanchester (described above), on the opposite south bank of the river 
(Oakey and Spoerry, 1996). The combined settlements at Huntingdon and Godmanchester 
controlled the important location where Ermine Street crossed the Great Ouse River. There 
is, unfortunately, sparse archaeological evidence for the early development of Huntingdon 
due to major modernisation and poor recording of archaeologically sensitive areas of the 
town from the 1960s to 1980s (Oakey and Spoerry, 1996). A main source of information 
concerning Roman Huntingdon comes from the numerous extra-mural cemeteries that 
escaped modernisation (Nicholson, 2006).  
The cemetery site of Watersmeet lies on the southern edge of modern Huntingdon, 
approximately 50m west of the Great Ouse. The site was excavated by Archaeological 
Solutions in 2003 prior to development, and revealed part of a mid-4th to early 5th century 
Roman cemetery, possibly associated with Whitehills villa to the immediate east (Nicholson, 
2006). The remains of 72 individuals were recovered, 78% of whom were adults. 
Preservation was generally quite poor throughout the assemblage, which severely hindered 
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analysis and interpretation. Very low prevalence rates of cribra orbitalia (1.5% CPR) and 
enamel hypoplasia (1.5% CPR) can likely be attributed to poor cranial preservation (Phillips 
2006).  
 
Site 
Cribra orbitalia 
CPR/TPR (%) 
Enamel 
hypoplasia 
CPR/TPR (%) 
Porotic hyperostosis 
CPR/TPR (%) 
Durobrivae 3.7/NR 3.7/NR 0 
Hoplands 37/61.5 42.6/14.2 0 
Prickwillow Road 0/0 0/0 0 
The Parks 1.6/NR NR 0 
Watersmeet 1.5/NR 1.5/NR 0 
British average 13.5/NR NR/9.64 NR 
Table 5.5: None-specific pathology prevalence from selected Romano British sites. NR = 
not reported. British averages taken from Roberts and Cox, 2003. 
 
 
5.3.3: Anglo-Saxon sites 
5.3.3(i): Edix Hill, Barrington, Cambridgeshire 
 Edix Hill is located close to the villages of Barrington and Orwell in the Cam valley, 
approximately 12km south-west of Cambridge, close to the edge of the south 
Cambridgeshire Fens (Figure 5.1). To the immediate south of the Hill lies the river Rhee 
floodplain, to the north, the expanse of Fens. The cemetery itself sits upon a chalk mound 
surrounded by low level clay land, which , prior to post-medieval drainage, would have been 
marshy or flooded for much of the year (Malim et al., 1998). The cemetery may have been 
associated with a settlement controlling an important crossing site of the river Rhee.  
 First discovered in the late 1860s during drainage works and coprolite (fossil) 
extraction, the cemetery underwent numerous antiquarian investigations during the 19th 
century. The location was rediscovered through metal detecting in the 1980s and partially 
excavated due to threat from ploughing (Malim et al., 1998). The cemetery dates to the 6th to 
early 7th centuries. Excavations yielded 148 skeletal individuals, including 48 males and 40 
females. Although gross preservation was relatively good, there were numerous cases of 
extensive plough damage, particularly affecting the crania (Malim et al., 1998). This may 
partly account for the absence of cribra orbitalia prevalence in this population. 
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5.3.3(ii): The ‘Three Kings’, Haddenham, Cambridgeshire 
The village of Haddenham is located approximately five miles south west of Ely, on 
the edge of the Isle of Ely (Figure 5.1). Cambridgeshire County Council Archaeology 
Section undertook salvage excavations in 1990 following the discovery of inhumations 
during development at the ‘Three Kings’ Public House in the centre of the village. The 
inhumations were dated to the early Anglo-Saxon period, the cemetery likely being 
associated with a nearby settlement (Robinson and Duhig, 1992). Excavations yielded 11 
individuals in varying states of preservation, with few pathological conditions being noted. 
A lack of cribra orbitalia may have been influenced by poor preservation of the skulls, 
many of which were reported as crushed (Robinson and Duhig, 1992). Despite an overall 
dearth of non-specific pathology, the location of the site on the very edge of the Isle of Ely 
would have exposed the population to malaria, should the disease have been present. 
 
5.3.3(iii): Highfield Farm, Littleport, Cambridgeshire 
 Littleport lies close to the eastern border of Cambridgeshire, approximately 10km 
north of Ely (Figure 5.1). Prior to 17th century drainage and land reclamation, Littleport 
would have occupied a small raised ‘island’ of land surrounded by the Cambridgeshire 
Fenlands. Highfield Farm is located to the southwest of the modern town centre, close to 
route of the main A10 road. The Farm lies close to the highpoint (approximately 20m OD) 
of the ‘island’ (Woolhouse, 2009). This elevation may explain the abundance of archaeology 
associated with Highfield Farm since the immediate area would likely have remained drier 
than its surroundings throughout its usage, which evidence suggests lasted from the 
Mesolithic through to at least the Anglo-Saxon periods (Holt, 2008; Woolhouse, 2009). The 
latter is characterised mainly by the discovery of 5th to 6th century cemetery occupying the 
aforementioned plateau of land. The cemetery was excavated in 2004 and 2005 by 
Archaeological Project Services in advance of commercial construction (Holt, 2008), 
yielding 86 inhumed individuals (61 adults, 25 sub-adults) and four cremated individuals. 
Macroscopic preservation of most skeletons was fair to good, although hydraulic action 
resulted in poor preservation of some individuals (Western, 2007). Analysis of the skeletons 
revealed high prevalences of non-specific markers of stress (Table 5.6), which may be 
suggestive of poor health associated with Fen edge habitation. 
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5.3.3(iv): Westfield Farm, Ely, Cambridgeshire 
Westfield Farm lies approximately 1.5km southwest of the modern centre of the 
small city of Ely, Cambridgeshire (Figure 5.1). Archaeological evidence suggests activity 
and occupation occurring west of Ely during the Anglo-Saxon period, including a small 
contemporary settlement and cemetery at Westfield Farm. 
The cemetery was first identified during archaeological evaluation works by 
Cambridge Archaeological Unit in early 2006 and was later excavated prior to housing 
development. The excavation uncovered 15 mostly east-west-oriented graves arranged 
around a central burial (Newman, 2007). The population demographic tended towards 
younger age-at-death ranges (Lucy, 2007 b). A full pathological report for this population 
has yet to be published (Natasha Dodwell, personal communication), hence the lack of 
disease prevalence rates in Table 5.6. The proximity of the cemetery to both freshwater Fen 
and salt marsh, and hence a variety of favourable mosquito breeding grounds, would likely 
have exposed the population to any mosquito-borne pathogens, such as vivax malaria. 
 
5.3.3(v): Castledyke South, Barton-upon-Humber, North Lincolnshire 
 The small town of Barton-upon-Humber is located on the south bank of the River 
Humber in the county of North Lincolnshire, approximately five miles southeast of Hull 
(Figure 5.2). The town lies at the interface of a marshland belt associated with the Humber 
floodplain and the rising ground of the Lincolnshire Wolds (Rodwell et al., 2007). 
Historically, Barton occupied a relatively isolated position, due in part to separation from 
nearby Ermine Street by the marshy Ancholme River Valley to the west of the town. 
Archaeological evidence suggests that the first major phase of occupation at Barton occurred 
in the early Anglo-Saxon period, possibly signifying the nucleation of small localised 
settlements (Rodwell et al., 2007). The Castledyke South Anglo-Saxon cemetery, located on 
the southern periphery of modern Barton, represents the burial ground for this population.  
Partial excavation of the cemetery, undertaken by the Archaeology Unit of 
Humberside County Council from 1975 to 1990, yielded the remains of 227 individuals. 
Stratigraphic and artefact dating suggested an intensive cemetery use-life of approximately 
two hundred years from the late 5th to early 8th centuries (Drinkall et al., 1998) . Skeletal 
preservation was generally good due to the chalk bedrock, although fragmentation was 
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frequently observed; 27% and 22% of the individuals could not be attributed a sex or age. 
Non-adults represented 23% of the interments (Boylston et al., 1998). Prevalence rates of 
enamel hypoplasia (9% TPR), and cribra orbitalia (16.6% CPR) are not exceptional for an 
Anglo-Saxon population (Boylston et al., 1998). Overall poor cranial preservation may, 
however, have contributed to an artificial reduction in prevalence of these pathologies. The 
nearby marshlands associated with the Humber tidal flats would have offered suitable 
anopheline breeding grounds in the Anglo-Saxon period. Malaria may well, therefore, have 
been a threat to pre-modern populations of the Humber Estuary environs. 
 
5.3.3(vi): Baston, Lincolnshire 
The small village of Baston is located in south Lincolnshire, close to the border with 
Cambridgeshire, approximately 60km south of Lincoln and 18km northwest of Peterborough 
(Figure 5.1). The village attests to its roots in the Roman period by its close proximity to the 
Carr Dyke and Ermine Street as it skirts the Lincolnshire Fen edge. First discovered in 1863, 
the Anglo-Saxon cemetery site lay relatively undisturbed until deep ploughing in the 1960s 
prompted recovery works by the Ministry of Public Buildings and Works. Excavations 
revealed a small 5th to 6th century mixed cremation and inhumation cemetery (Mayes et al., 
1976).  
Four inhumed individuals were recovered, each in generally good condition. Pathological 
analysis revealed enamel hypoplasia in two (50% CPR) individuals (Manchester, 1976). 
Despite the very limited number of individuals recovered at Baston, the scarcity of Anglo-
Saxon burials directly associated with the south Lincolnshire silt Fens means that this small 
population should not be ignored.    
 
5.3.3(vii): Cleatham, Kirton-in-Lindsey, Lincolnshire 
Cleatham is located approximately 1.5km north west of the town of Kirton-in-
Lindsey, North Lincolnshire (Figure 5.2). The site of the Anglo-Saxon cemetery lies on the 
edge of a limestone escarpment with the Trent River valley to the west and Ancholme River 
valley to the east. Prior to modern drainage schemes, the latter was characterised by 
marshlands, described by Balfour (1891:145) as “Cars, which were once wide swamps” 
associated with the river. Although 7km from the Ancholme itself, the Cleatham Anglo-
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Saxon population would likely have been within range of anopheline breeding grounds, and 
hence, exposed to any mosquito-borne parasites.   
Originally discovered in 1856, the cemetery was fully excavated between 1984 and 
1989 due to an increasing threat of destruction through deep ploughing. Excavation yielded 
over 1200 cremation urns and 64 inhumations, making Cleatham one of the largest Anglo-
Saxon cemeteries in England. Dating suggests that the cemetery was used throughout the 
early Anglo-Saxon period through to the later 7th century (Leahy, 2007). Since the soil 
conditions were acidic, preservation of the skeletons was highly dependent on the 
surrounding geology of each grave; burials which disturbed the limestone bedrock 
invariably displayed better preservation than those that did not. The Cleatham population 
exhibited a relatively high prevalence of cribra orbitalia (16.6% CPR).  
 
Site 
Cribra orbitalia 
CPR/TPR (%) 
Enamel 
hypoplasia 
CPR/TPR (%) 
Porotic hyperostosis 
CPR/TPR (%) 
Baston NR 50/NR 0/0 
Castledyke 16.9/NR NR/9 0/0 
Cleatham 16.6/NR NR 0/0 
Edix Hill 10.1/NR 10.8/4 0/0 
Haddenham 0/0 0/0 0/0 
Littleport 29/71 45/NR 7/4 
Westfield Farm 0* 6.6* 0/0 
British average 8/25 19/NR NR 
Table 5.6: Non-specific pathology prevalence from selected Anglo-Saxon sites. NR = not 
reported. British averages taken from Roberts and Cox (2003). *full pathological report 
pending. 
 
 
5.3.4: Medieval sites 
5.3.4(i): Orchard Lane, Huntingdon 
Prior to 10th and 11th century references to the localised Saxon and Danish 
settlements (Oakey and Spoerry, 1996), little is known concerning the early development of 
Huntingdon. The settlement had evidently entered a phase of prosperity which peaked by the 
13th century, as demonstrated by the presence of hospitals, six monastic houses, and thirteen 
parish churches. This affluence lasted until the mid-14th century decline, which has been 
attributed in part to disease epidemics and national economic turmoil (Oakey and Spoerry, 
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1996). As previously mentioned, Huntingdon lies close to the south Cambridgeshire Fens 
and within the Great Ouse floodplain (Figure 5.1). Both of these environments would likely 
have provided suitable breeding grounds for anopheline mosquitoes.  
 Orchard Lane lies within the historic medieval core of Huntingdon, running parallel 
to the river approximately 100m to the south. The site in question is located to the 
immediate south east of Orchard Lane and was excavated in 1994 by the Archaeological 
Field Unit of Cambridgeshire County Council, following the discovery of human remains 
during archaeological evaluation. Excavation revealed part of an inhumation cemetery 
dating to between the 11th and 14th centuries. The cemetery was likely associated with one of 
the now-lost medieval churches of St Clement or St Laurence (Oakey and Spoerry, 1996). 
The remains of 24 individuals were excavated, comprising 18 adult and six immature 
individuals, and an adult sex ratio of nearly 1:2 in favour of males (Duhig, 1996). The 
population exhibited a 31.3% (CPR) prevalence of enamel hypoplasia and a very high 
prevalence of cribra orbitalia (50% CPR), suggesting “that life was particularly hard for this 
group, with food shortages, parasitism, infections, or any of these in combination” (Duhig, 
1996:145).     
 
Site 
Cribra orbitalia 
CPR/TPR (%) 
Enamel hypoplasia 
CPR/TPR (%) 
Porotic hyperostosis 
CPR/TPR (%) 
Orchard Lane  50/NR 31.3/NR 0 
British average 10.8/NR 35/NR   NR 
Table 5.7: Non-specific pathology prevalence from Orchard Lane. NR = not reported. 
British averages taken from Roberts and Cox (2003). 
 
 
5.4: Selection of skeletal individuals for biomolecular analysis 
 Since it was not feasible to analyse every individual for biomolecular evidence of 
malaria, certain selection criteria needed to be in place in order to keep the sample size 
reasonable, while maximising the chances of malaria detection. Although temperate vivax 
malaria may not be as virulent as its tropical counterparts, the relapsing nature of the 
infection and lack of effective treatments would have added additional immunological 
pressures to exposed populations, particularly those already living in proximity to 
pestilential Fenland or marshy environments (Dobson, 1997). It seemed prudent, therefore, 
to initially target individuals who fell into one or more of three categories: 
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1. Those most at risk of contracting malaria; 
2. Those who might suffer more severe symptoms of the disease, such as children and 
females of child-bearing age (Anstey et al., 2009; Price et al., 2007; Williams et al., 
1997); 
3. Those with skeletal changes potentially suggestive of past malaria infection (e.g., 
cribra orbitalia, porotic hyperostosis, and enamel hypoplasia). 
Given the close proximity of the chosen sites and their inhabitants to likely anopheline 
breeding grounds, it was an unrealistic task to pinpoint individuals in the first category. 
There were, however, plenty of individuals who fitted into either the second or third 
categories. 
 Due to a lack of standardisation for age categories between skeletal reports, all 
samples selected for this study were assigned into categories (Table 5.8) based on Ubelaker 
(1989), Buikstra and Ubelaker (1994), and Scheuer et al., (2004). It should be stated here 
that individual sex was taken from pathological reports/inventories, rather than being 
assessed as part of this study. 
 
Foetal/neonate <1 month 
Infant 1-12 months 
Child 1-6 years 
Juvenile 7-12 years 
Adolescent 13-17 years 
Very young adult 18-24 years 
Young adult 25-34 years 
Middle adult 35-49 years 
Old adult 50+ years 
Adult 18+ 
Table 5.8: Age categories assigned to samples. 
 Samples chosen for this study are displayed in Appendix 2, Tables A2.3 to A2.16. A 
sufficiently large quantity of samples was taken to cover the criteria outlined above. Further 
to this, it was anticipated that at least one sample per individual would be subjected to 
testing for anti-malaria antibodies. As discussed later in section 5.6.2, it was important to 
examine all samples for histological preservation, as this provided a baseline for selecting 
the most appropriate sample(s) from each individual for testing. 
167 
 
 
5.5: Selection of bone elements 
Many archaeological biomolecular studies have utilised compact bone, since it offers 
higher resistance to diagenetic agents than trabecular bone (Brandt et al., 2002). However, it 
is logical to assume that serum proteins are most likely to concentrate in bone matrix with 
the greatest blood supply (i.e., trabecular, haematopoietic bone). Trabecular bone also has a 
higher hydroxyapatite to collagen ratio than cortical bone (Wang et al., 2005) – a potentially 
relevant consideration, given the proposed high affinity of non-collagenous proteins with 
bone mineral. Trabecular bone is, unfortunately, intrinsically more porous and potentially 
subject to increased diagenetic activity (Trueman et al., 2004). Thus, for this study, a 
balance had to be struck between using compact bone with a potentially well-protected 
matrix, and the more porous, serum-rich trabecular bone.  
When selecting bone samples for immunological testing, a balance is also required 
between choosing a large enough section of bone from an element most likely to contain 
surviving target proteins, and avoiding gratuitous sampling and destruction of the finite 
skeletal resource. Since published protein extraction protocols have required between 75mg 
and 15g of bone powder per sample (e.g. Cappellini et al., 2012; Kolman et al., 1999), a 
conservative decision was made to sample no more than 10g of bone from each individual. 
This may seem excessive, but collection of this quantity of bone would allow for further 
confirmatory testing or methodological refinement when necessary. The removal of samples 
did not compromise future osteological analysis of the skeletal populations. For instance, 
any elements displaying pathological modification or diagnostic morphologies (e.g., rib 
ends) were not selected. Any untested human bone will be returned to the archive from 
which it was taken, along with a full report of research findings. The chosen sampling 
strategy abided by the BABAO (British Association of Biological Anthropology and 
Osteoarchaeology) codes of ethics and practice concerning destructive analysis of skeletal 
material (BABAO, 2007; 2010), and the guidelines supplied by the Advisory Panel on the 
Archaeology of Burials in England (2013) . 
 Ribs and phalanges were the first choice of elements for immunological testing (after 
Wiechmann et al., 1999), since their removal does not cause excessive destruction to the 
individual skeleton, or loss to the skeletal archive. Ribs were also ideal since they retain a 
168 
 
haematopoietic function throughout life and are, therefore, always rich in blood supply 
(Rodak et al., 2012) and extracellular blood serum proteins (including immunoglobulin G, or 
IgG – the biomolecule targeted in this study). Additionally, archaeological ribs are usually 
numerous in quantity and are often fractured (post-mortem) during burial, excavation, 
analysis, and curation. A 10g sample of rib was easily encountered for many individuals 
with no sawing of larger rib elements necessary.  
Single phalanges, where present, were also chosen from each individual. Foot 
phalanges were a preferred target element, given their usual distance from the ribs in the 
grave. Although it may seem unwise to sample phalanges from adults since they, unlike ribs, 
do not retain haematopoietic marrow into adulthood, it was reasoned that the sampling of 
elements some distance apart should reduce the influence of diagenetic and taphonomic 
factors on protein survival. Critically, Wiechmann et al. (1999:384) found no significant 
differences “in terms of protein yield and quality according to sampling site” when testing 
archaeological human bone for the survival of non-collagenous proteins. In those skeletons 
without foot phalanges, hand phalanges were targeted. If no phalanges were present, cranial 
fragments were selected. It was possible to sample rib, phalanges, or cranial fragments from 
all target adult individuals. A slightly different strategy was required for many non-adult 
individuals: due the small size and often poor preservation of ribs and phalanges, 
particularly in those individuals under the age of five years, it was sometimes necessary to 
sample long bone fragments (e.g., sample HP117.2). 
 Targets selected for IgG detection (the early P1 protocols, see below) consisted of 
human bone and animal rib bone. Animal collagen was used as a control, as suggested by 
Brandt et al. (2002). The human bone consisted of unstratified, non-pathological, 
disarticulated fragments of adult and juvenile rib, phalanx, and cranium from the Hanging 
Ditch post-medieval site in Manchester (currently archived at Durham University). The 
animal rib fragments were disarticulated, unstratified archaeological bone from unspecified 
British sites dating to no earlier than the Roman period. These were curated at the Durham 
University Archaeology Department and obtained with permission of Professor Peter 
Rowley-Conwy. Collagen samples (Sigma-Aldrich®) were in the form of Type I, from 
bovine Achilles tendon. Each bone sample was histologically examined to characterise 
levels of preservation before being selected for extraction.  
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5.6: Sample preparation: bone cutting, histological analysis, and grinding 
 
To help control for the effects of diagenesis and protein degradation in their target 
samples, some studies advocate preliminary histological analysis in the form of bone 
sectioning and subsequent microscopic analysis (e.g., Hanson and Buikstra, 1987; 
Schoeninger et al., 1989; Schmidt-Schultz and Schultz, 2007). Suitable fragments from bone 
cutting were set aside for histological analysis. Nitrile gloves were worn at all stages of the 
analysis in order to minimise external contamination. 
 
5.6.1: Bone cutting 
1. Bone fragments were gently washed in distilled water and allowed to completely dry. 
 
2. Each fragment was then prepared for cutting by abrasion with a Dremel® 200 series 
drill and disposable cutting discs to carefully remove the external surface and any 
exposed surfaces (and hence surface contaminants), taking care to leave some 
cortical bone intact.  
 
3. Small samples were then cut from each bone fragment incorporating, where possible, 
both cortical and trabecular bone. At this stage small fragments were set aside for 
histological analysis.  
 
5.6.2: Histological analysis 
Histological analysis though bone sectioning characterises bone preservation and 
helps to control for diagenetic influences. Only those samples displaying good preservation 
are then usually selected for biomolecular analysis. Conflicting research on collagen 
diagenesis (Hedges et al., 1995), however, demonstrates a lack of correlation between bone 
structure and surviving collagen content; the authors suggest that collagen degradation and 
loss may occur independently of microbial attack and histological destruction. Even less is 
known about the influences of diagenetic factors on the survival of non-collagenous proteins 
(NCPs, including IgG antibodies), although their strong adherence (at least compared to 
collagen) to hydroxyapatite during life may offer increased protection from degradation 
(Masters, 1987; Schmidt-Schultz and Schultz, 2004). The work of researchers such as 
Schmidt-Schultz and Schultz potentially supports the work of Hedges et al. (1995), in that 
samples demonstrating excellent histological preservation often displayed poor collagen 
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preservation while NCPs remained comparatively intact. Since this study proposes to extract 
and detect ancient immunoglobulins (biomolecules of naturally low concentration within 
blood serum), it seemed prudent to initially target samples with good histological 
preservation (although a variety of samples were ultimately analysed to test the preferential 
NCP survival hypothesis). Prior to sample cutting, each sample was subjectively assigned a 
category of gross macroscopic preservation based on basic recording criteria suggested by 
McKinley (2004). These criteria are presented in Table 5.9. Gross and histological 
preservation are compared in section 7.2.1. 
 
Poor preservation Fair preservation Good preservation 
Heavy surface 
erosion and/or 
fissuring 
Moderate surface 
erosion and/or 
fissuring 
Limited surface 
erosion and/or 
fissuring 
Table 5.9: Basic criteria for assigning sample macroscopic preservation (based on 
McKinley, 2004). 
 
Histological analysis provides a relatively quick, cost-effective method of reducing 
the chances of contamination and cross-reactivity from exogenous, diagenetically-
introduced material. For this study all samples from each target individual were sectioned 
for histological analysis and the sample exhibiting the best preservation was selected for 
initial protein extraction protocols. The first step in preparing samples for histological 
analysis was to cut small pieces from each bone sample. To save time this was done during 
the cutting stage (detailed above in 5.6.1). Cut pieces usually measured no larger than 5 x 
4mm, although it was important to ensure sufficient length to survive the grinding/polishing 
stages of sample preparation. The bone sections were then resin impregnated under vacuum 
and polished, following the steps adapted from Hedges et al. (1995) and Millard (2001): 
 
1) In a well-ventilated area plastic moulds were coated with a releasing agent (e.g., 
silicone or anti-friction spray) and allowed to dry. 
  
2) Bone samples were fixed into each mould, transverse side down, using 
superglue. A small plastic marker was also placed and sketches made to aid in 
orientation. It was possible to place up to 20 samples in each mould, dependent 
upon sample sizes. 
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3) Resin was then prepared, consisting of Epoxy resin and Epoxy hardener (West 
System®) in a 5:1 ratio. Once well mixed, the resin was immediately added to 
each mould. The moulds were then transferred to a vacuum desiccator. 
 
4) The resins were subjected to cycles of evacuation until bubbles were removed 
and no longer formed under vacuum. This was achieved by repeatedly 
evacuating the desiccator for five to ten minutes, then allowing air into the 
chamber. When bubbles no longer formed, the samples were left under vacuum 
for one hour before being left to cure for up to 48 hours. Once completely 
hardened, the resin blocks were removed from the moulds. 
 
5) Each resin block was then subjected to wet grinding using increasing grades of 
silicone carbide paper mounted on a rotating wheel. Paper grades were 120B, 
400B, 800B, 1000B, and 2500B, each of which removed surface scratches from 
the previous grade. Blocks were cleaned ultrasonically between grades to prevent 
transfer of grit particles between papers. Light microscopy was employed to 
check for surface scratches before proceeding to the next paper grade. 
 
6) Blocks were then polished using polishing cloths mounted to a rotating wheel. 
Polishing was achieved using an ethanol-based lubricant and decreasing grades 
of diamond paste (6µm, 3µm, and 1µm). Ultrasonic cleaning and scratch analysis 
by microscope was also performed between grades. At the end of the process, the 
resin surface should be free of most scratches, rendering the samples suitable for 
microscopic histological analysis.  
 
 Microscopic histological evaluation and scoring of each resinated sample was based 
upon the Oxford Histological Index (OHI) developed by Hedges et al. (1995) and modified 
by Millard (2001). The OHI is presented in Table 5.10, below, followed by micrographic 
examples of OHI values from this study (Figures 5.3-5.8). Very subjectively, OHI 0-1 may 
compare to ‘poor’ macroscopic preservation, 1-2 to ‘fair’, and 4-5 to ‘good’ (Table 5.9). 
However, as discussed in section 7.2.1, there is rarely a correlation between macroscopic 
and microscopic preservation. 
 
 
 
 
 
 
 
172 
 
Index 
Approx. % 
of intact 
bone 
Description 
0 <5 No original features identifiable, other than Haversian canals 
1 <15 
Small areas of well-preserved bone present, or some lamellar structure 
preserved by patterns of destructive foci 
2 <50 Clear lamellate structure preserved between destructive foci 
3 >50 Clear preservation of some osteocyte lacunae 
4 >85 Only minor amounts of destructive foci, otherwise generally well preserved 
5 >95 Very well preserved, virtually indistinguishable from fresh bone 
Table 5.10: The Oxford Histological Index, summarising diagenetic changes in bone 
(Hedges et al., 1995:203; Millard, 2001). 
 
 
 
 
Figure 5.3: Micrograph displaying histology scoring 0 on the OHI. Cranium, sample 
LP5252.2. 100x magnification. Photograph by author. 
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Figure 5.4: Micrograph displaying histology scoring 1 on the OHI. Cranium, sample 
HDAS3. 100x magnification. Photograph by author. 
 
 
 
 
Figure 5.5: Micrograph displaying histology scoring 2 on the OHI. Rib, sample GM49.1. 
100x magnification. Photograph by author. 
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Figure 5.6: Micrograph displaying histology scoring 3 on the OHI. Metacarpal, sample 
HP117.2. 100x magnification. Photograph by author. 
 
 
 
 
Figure 5.7: Micrograph displaying histology scoring 4 on the OHI. Rib, sample HPA3. 100x 
magnification. Photograph by author. 
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Figure 5.8: Micrograph displaying histology scoring 5 on the OHI. Hand phalanx, sample 
PW13.3. 100x magnification. Photograph by author. 
 
 
5.6.3: Grinding 
It was decided to grind the bone samples prior to analysis since the initial protein 
extraction protocol of choice (see section 5.7.1) followed this procedure. Prior to grinding, 
each sample was immersed in liquid nitrogen. This increases the brittleness of cell 
membranes, hence promoting release of proteins during grinding, while simultaneously 
decreasing the rate of protein degradation (Wu et al., 2009). After the nitrogen had dispersed 
(the sample remaining frozen), samples were subjected to a 20 second mechanical 
dismembration at 3000rpm using a Sartorius Mikro-Dismembrator S. Trial grinds of bone 
samples without prior liquid nitrogen immersion often required up to three minutes of 
dismembration to achieve adequate powdering. The use of liquid nitrogen ensured adequate, 
efficient sample powdering without the potentially uncontrolled, damaging temperature rises 
associated with extended mechanical grinding alone (Collins and Galley, 1998; Ericsson and 
Nister, 2011). Following grinding, samples were stored at room temperature until required 
for testing. 
 
5.7: Protein and immunoglobulin G (IgG) extraction protocols 
The vast range of published protein extraction techniques is indicative of a sub-
discipline of biomolecular archaeology that is maturing in response to a growing 
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appreciation of the complexity and the challenges of extracting ancient, degraded proteins. 
While new extraction techniques continue to be published (e.g., Caputo et al., 2012), the 
choice of target protein strongly dictates the specific extraction protocol required (Cleland et 
al., 2012). With this in consideration, it should be stressed that the vast majority of published 
extraction protocols have been aimed at the retrieval of collagen for applications such as 
radiocarbon dating (e.g., Van Klinken et al., 1994; Minami et al., 2004), isotopic analyses 
(e.g., DeNiro and Weiner, 1988), and more recently, mass spectrometric peptide analysis 
(e.g., Buckley et al., 2008, 2009). Indeed, the recent synthesis by Cleland et al. (2012) 
displays a distinct lack of extractions aimed at non-collagenous proteins and, consequently, 
very few protocols have attempted to specifically extract immunoglobulins from 
archaeological bone.  
Prior to attempting to detect human antibodies to malaria in archaeological samples, 
it was necessary to first select, adapt, or design a potential methodology that was capable of 
successfully and reliably extracting and purifying IgG antibodies. This precursory stage is 
critical, since a poorly functioning extraction protocol would inhibit later testing of the 
samples. Five published protein extraction protocols were attempted in this study, which, for 
ease of referencing, were labelled P1, P2, P3, P4, and P5. The first four protocols all 
required adaptation from the original published methodologies, as explained below. 
 
5.7.1: P1: Extraction methodology adapted from Schmidt-Schultz and Schultz (2004) 
It was initially decided to follow an extraction protocol published by Schmidt-
Schultz and Schultz (2004) in which they reported successful extraction of IgGs from human 
archaeological bone and subsequent binding of these immunoreactive antibodies to antigens. 
The authors claim that their newly developed extraction method offers the best protein yield 
following solubilisation of archaeological bone matrix, and therefore a higher yield of NCPs 
(including IgGs). They argue that the high affinity of NCPs (particularly immunoglobulins) 
for hydroxyapatite means that target proteins are far more likely to be retained within the 
bone pellet matrix than released into the supernatant during extraction. They also suggest 
that sample dialysis and concentration (both commonly employed purification steps) of 
extracted material caused the loss of many NCPs. These suggestions may explain why 
earlier attempts had struggled to extract and detect IgGs: possible errors that influenced 
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Cattaneo et al. (1992), for instance, to declare that ancient IgGs represent a poor choice of 
target protein. Analysis of the bone pellet, rather than supernatant, is very rare amongst 
published protein extraction methodologies (see Cleland et al., 2012); the Schmidt-Schultz 
and Schultz research represents the only published protocol for extracting NCPs from the 
bone pellet itself. 
It quickly became apparent that this extraction required some alteration from the 
published protocol for two main reasons. Firstly, the method specified the use of 2mM of the 
serine protease inhibitor aprotinin. This represents an enormous quantity of a very expensive 
reagent, far beyond the resources available for this study, and also clearly disproportionate 
to the other inhibitors used in the published protocol. It is likely that this requirement is 
erroneous (i.e., a ‘typo’), although it is carried through to later published work (e.g., 
Schmidt-Schultz and Schultz, 2007). It was decided to omit the aprotinin due to the 
uncertainty over quantity required and, further to this, the protocol also included the serine 
protease inhibitors leupeptin and PMSF, which serve the same function as aprotinin 
(although the PMSF should ideally be solubilised in an alcohol-based solution, since it is 
water-insoluble). Secondly, the original protocol made no mention of the potential problems 
concomitant with the “abundant collagen” (Cleland et al., 2012:4) resulting from all ancient 
protein extractions from bone (Wiechmann et al., 1999). Ubiquitous degraded collagen has 
the potential to mask target proteins of smaller quantities (Wiechmann et al., 1999) and 
interfere with downstream analytical techniques, such as electrophoresis and mass 
spectrometry. Unfortunately, repeated requests to the authors for clarification on the 
aprotinin and collagen issues went unanswered. 
Three attempts at protein extraction (P1.1, 1.2, and 1.3) were made using the adapted 
Schmidt-Schultz and Schultz (2004) protocol, each one driven by results (see section 6.4.1), 
and following evolving methodology from the previous attempts.  
 
5.7.1(i): P1 samples 
The bone samples selected for P1 extractions are presented in Table 5.11. The P1.1 
samples represent histologically well preserved adult human and animal bone. Samples 
selected for extraction P1.2 represent two histologically well preserved adult human bone 
samples run in duplicate for consistency, and with the intention of choosing specific SDS-
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PAGE gel bands to analyse by mass spectrometry (see section 5.7.3(iii)). Samples chosen 
for the third protein extraction (P1.3) represent a variety of bone types and preservation 
levels. This was performed mainly to test the suggestion by Masters (1987) that the high 
affinity of non-collagenous proteins for hydroxyapatite should protect the proteins from 
diagenetic factors that may result in poor histological preservation and the loss of collagen. 
A separate set of these samples were also treated with collagenase, as detailed below 
(section 5.7.2). 
 
Sample SDS# Type HI Protocol 
HDAR1 H1 Adult rib 4 1.1 
HDAP2 H2 Adult phalanx 5 1.1 
HDAP3 H3 Adult phalanx 5 1.1 
HDAR4 H4 Adult rib 5 1.1 
AN1 A1 Animal rib 5 1.1 
AN2 A2 Animal rib 5 1.1 
AN3 A3 Animal rib 5 1.1 
AN7 A4 Animal rib 5 1.1 
HDAP3 H3 Adult phalanx 5 1.2 
HDAR4 H4 Adult rib 5 1.2 
HDJS1   Juvenile cranium 2 1.3 
HDAP5   Adult phalanx 5 1.3 
HDAS1   Adult cranium 3 1.3 
HDAP6   Adult phalanx 5 1.3 
HDAR3   Adult rib 4 1.3 
HDAP5   Adult phalanx 5 1.3 
AN2   Animal rib 5 1.3 
Table 5.11: Samples selected for P1 extractions. SDS# is the sample number assigned by 
Biological Sciences for SDS-PAGE electrophoresis. HI is histological preservation.  
 
 
5.7.2: P1.1-1.3 protein extraction protocol 
 Protein extraction methodology remained consistent throughout the three P1 
extractions:  
1. 200mg of bone powder was extracted in 1ml of buffer A (4M guanidine HCL, 
20mM NaH2PO4, 30mM Na2HPO4, and protease inhibitors 5mM benzamidine, 
1mM PMSF, 50µM leupeptin, 10mM EDTA, pH 7.6), under constant agitation at 
4°C for approximately 24 hours. Samples were then centrifuged for 30 minutes 
(10,000g) at 4°C and the supernatant discarded. 
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2. The pellet was then extracted in 1ml of buffer B (buffer A and 300mM EDTA, 
pH 7.6) at 4°C under constant agitation for approximately 24 hours. 
 
3. Chelated calcium ions were removed by washing (centrifuged at 35,000g for 20 
minutes at 4°C) three times with sterile molecular grade water. 
 
4. The extracted bone pellet was lyophilised and stored at -20°C. 
 
5. Approximately 20mg of lyophilised bone pellet was sonicated twice over ice for 
7 seconds in 2.5ml of solubilisation buffer (20mM NaH2PO4, 30mM Na2HPO4, 
and protease inhibitors 1mM benzamidine, 10mM aminocaproic acid, 10mM 
EDTA, pH 7.0). According to Schmidt-Schultz and Schultz (2004), this 
procedure should liberate approximately 10µg of protein from the bone pellet. 
 
In order to reduce the high quantity of collagen encountered in P1.1 and P1.2, which 
may mask target antibodies, a separate set of the same samples as used in P1.3 (Table 5.11) 
were treated with high purity type VII bacterial collagenase (Sigma-Aldrich®, 1335 
units/mg) following solubilisation (after Tuross and Stathoplos, 1992; Ostrom et al., 2000). 
It should be noted that the solubilisation buffer used for samples intended for collagenase 
digestion did not contain EDTA, since this acts as a collagenase inhibitor (Worthington, 
1993). The collagenase was prepared in a stock solution and then applied using the 
following steps: 
 
1. 0.1mg of collagenase was dissolved in 10ml TESCA buffer solution (50mM 
TES and 0.36mM CaCl made up to 10ml with MQ water, pH 7.4) at 37°C. 
Unused stock solution was stored at -20°C. 
 
2. 0.92ml stock solution was added to the 2.5ml solubilised sample, making a 
collagenase concentration of approximately 2.5 units to 1µg protein, or ~3.7 
units/ml (following Hummelshoj et al., 2008). 
 
3. Samples were then incubated under gentle agitation at 37°C for five hours, 
after which they were transferred to ice and immediately prepared for SDS-
PAGE. 
 
 
5.7.3: Identification of IgG antibodies from P1 extractions 
 In order to determine the presence of IgG antibodies in the extracted samples from 
the three P1 protocols, it was first necessary to identify and characterise the extracted 
proteins. The samples were thus subjected to a number of separate analytical techniques, 
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including one dimensional (1D) sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE), Western blot, enzyme-linked immunosorbent assay (ELISA), and mass 
spectrometry.  
 
5.7.3(i): P1 SDS-PAGE protocol 
Working alongside the Durham University Biological Sciences department, selected 
samples were separated by 1D SDS-PAGE. Gels were produced for all three P1 extractions, 
including the collagenase treated samples in P1.3, using the following protocol: 
 
1. Each sample was TCA (trichloroacetic acid) precipitated overnight at -20°C 
using an equal volume of 20% TCA to the sample. 
 
2. The sample was then centrifuged for 15 minutes at 4°C and the supernatant 
removed. 
 
3. Two acetone washes were performed on the supernatant by adding 
approximately 300µl of cold acetone to each sample and centrifuging at 4°C 
for 5 minutes, after which the supernatant was removed and the pellet 
allowed to air dry. 
 
4. 200µl SDS sample buffer (63mM Tris HCl, 10% Glycerol, 2% SDS, 
0.0025% Bromophenol Blue, 5% DTT, pH 6.8) was added and the sample 
boiled for 5 minutes. 
 
5. The supernatant was extracted and brought to neutral pH by adding sodium 
hydroxide (NaOH). 
 
6. 20µl of each sample was run on pre-prepared polyacrylamide gels (10% 
resolving gel, 3% stacking gel) at 100V for approximately 10 minutes, and 
then 120V until dye reached the end of the gel. 
 
7. Gels were stained overnight using Coomassie Brilliant Blue stain (40% 
methanol, 10% acetic acid, 0.025% Coomassie Brilliant Blue R-250), before 
being destained in 1% acetic acid solution.  
 
8. Gels were scanned on a conventional flatbed scanner, before being silver 
stained following the protocol described in section 5.6.2.3. 
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5.7.3(ii): P1.3 Western blots 
 
Western blot tests were performed by personnel in the Durham University Biological 
Sciences department on the two gels resulting from the P1.3 SDS-PAGE (collagenase and 
non-collagenase) protocol. In a Western blot test, the proteins from gels are transferred to a 
membrane, which can then be probed with an antibody to detect specific proteins of interest. 
These tests employed a commercially-available monoclonal mouse anti-human IgG antibody 
(Source Biosciences Lifesciences) to probe the membranes for the presence of human IgG 
heavy chains using the following protocol (supplied by Joanne Robson, Durham University 
Biological Sciences department): 
 
 Transfer: 
1. Transfer apparatus consisting of sponges, 6x filter paper, and nitrocellulose 
membrane were soaked for a few minutes in 100ml transfer buffer (2.4g tris; 
11.4g glycine) and 200ml ethanol. The gels were soaked separately in the same 
solution after careful removal of the stacking gels. 
 
2. The transfer cassettes were opened with black panel flat on the bottom tray, 
which was filled with transfer buffer. 
 
3. The transfer sandwiches were prepared by stacking the components in the 
flowing order: sponge, 3x filter paper, gel, nitrocellulose membrane, 3x filter 
paper, and sponge. The gel and membrane were placed on the cathode and anode 
sides of the cassette, respectively. The sandwiches were then firmly rolled over 
with a glass tube to remove air bubbles. 
 
4. The transfer cassettes were clamped together and placed into an electrophoresis 
tank (BioRad®), before being submerged in transfer buffer. Ultrapure water was 
added to the outer chamber. 
 
5. Blotting was achieved at 135V for one hour at 4°C. 
 
 Development: 
 
1. The membranes were removed from the cassettes and placed in a small container 
of Ponceau S stain. 
 
2. Membranes were stained with Ponceau S stain until weight markers became 
visible. Coomassie stain was then added to check successful protein transferral. 
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3. Membranes were rinsed in 100ml TBS-T (137mM sodium chloride; 2.7mM 
potassium chloride; 19mM tris; 0.5ml/l Tween 20), before being blocked 
overnight in 2% skimmed milk at 4°C. Blocking helps prevent nonspecific 
antibody/membrane binding. 
 
4. The blocking solution was rinsed off with TBS-T and membranes incubated for 
one hour in a solution of monoclonal mouse anti-human IgG (heavy chain) 
antibody at a dilution of 1:1000 (dilution following Schmidt-Schultz and Schultz, 
2004). 
 
5. The membranes were then washed three times in TBS-T for 15 minutes, five 
minutes, and five minutes, before being incubated for one hour in a solution of 
horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody (Sigma-
Aldrich®) at a dilution of 1:20000. 
 
6. The membranes were then washed three times in TBS-T for 15 minutes, five 
minutes, and five minutes. 
 
 Detection: 
 
1. Membranes were incubated in Supersignal West Pico Chemiluminescent 
substrate (Thermo Scientific®) for five minutes.  
 
2. The membranes were then transferred to Saran wrap, covered in x-ray film and 
developed in a dark room. Results were recorded at exposures of 30 seconds, one 
minute, five minutes, and eight minutes. 
 
 
5.7.3(iii): Human IgG Enzyme-linked immunosorbent assay (ELISA) 
 
 A commercially available human IgG capture ELISA kit (Molecular Innovations®, 
USA) was utilised in order to detect surviving IgG molecules in samples subjected to the 
adapted Schmidt-Schultz and Schultz protocol described above (section 5.7.2). This 
particular kit was chosen based on its ability to detect IgG quantities as low as 1ng/ml. 
Samples chosen for the ELISA represent a range of lyophilised samples from the three P1 
extractions (Table 5.11). The supplied microtitre plate was pre-coated with affinity purified 
polyclonal anti-human IgG antibody, thus increasing the chances of detecting potentially 
degraded IgG molecules. Samples selected to test for the presence of human IgGs are shown 
in Table 5.13. It was necessary to test a variety of human bone in terms of age (adult or non-
adult), element, and histological preservation. Controls in the form of final extraction buffer 
(Buffer C), bovine collagen types, and animal bone were essential. 
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 The protocol used closely followed that supplied by the manufacturer (Molecular 
Innovations, 2012), with some minor alterations due to the nature of the samples being 
tested (e.g., testing in triplicate, rather than duplicate). The assay was performed at room 
temperature, with the plate being shaken on a microtitre plate shaker (150rpm) at each step 
of the assay: 
 
1. A Tris-buffered saline (TBS) solution was made up consisting of 0.1M Tris and 
0.15M NaCl (pH 7.4), followed by a blocking buffer consisting of 3% BSA 
(bovine serum albumin) in TBS. 
 
2. The standard vial was then reconstituted with 1ml BSA blocking buffer to give a 
500ng/ml solution. Since it was expected that the archaeological samples would 
contain significantly less IgG than fresh human serum (5-12mg/ml), standards 
were prepared using the dilutions shown in Table 5.12, and samples were not 
diluted. 
 
 
IgG concentration (ng/ml) Dilution 
20 600μl (BB) + 400μl (from 50ng/ml) 
10 500μl (BB) + 500μl (from 20ng/ml) 
5 500μl (BB) + 500μl (from 10ng/ml) 
2 600μl (BB) + 400μl (from 5ng/ml) 
1 500μl (BB) + 500μl (from 2ng/ml) 
Table 5.12: Standard dilutions chosen for use in the human IgG ELISA. (BB) = blocking 
buffer. 
 
1. 100μl of each standard and sample was then added to the microtitre plate wells, 
with the well position of each being carefully recorded. The plate was then 
shaken at 150rpm for 30 minutes.  
 
2. The washing buffer was diluted to a 1:10 concentration with deionised water, and 
the microtitre wells washed three times with 300μl of wash buffer. After each 
wash, excess wash was removed by gently tapping the plate over paper towels. 
 
3. The peroxidise-conjugated antibody was then reconstituted by adding 10ml BSA 
blocking buffer and gently shaken to completely dissolve contents. 100μl of this 
was then added to all wells and the microtitre plate shaken at 150rpm for 30 
minutes. 
 
4. The wells were then washed with washing buffer as in step 2.  
 
5. 100μl of tetramethylbenzidine (TMB) substrate solution was then added to all 
wells and the plate shaken at 150rpm for 10 minutes in darkness (TMB is light 
sensitive). 
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6. The reaction was quenched by adding 50μl of 1M H2SO4 (sulphuric acid) to each 
well. 
  
7. Final absorbance values were read using a microtitre plate spectrophotometer 
(Perspective Biosystems Cytofluor® Multi-well plate reader) set at 450nm. Zero 
point was subtracted from all standards and unknowns to determine corrected 
absorbance (A450). 
 
Sample Type HI Sample Type HI 
Buffer C Buffer control - HDAR4 Adult rib 5 
Collagen 
Bovine Type 
II 
- HDAS1 Adult cranium 3 
Collagen 
Bovine Type 
III 
- HDAR2 Adult rib 5 
AN1 Animal rib 5 HDAR4 Adult rib 5 
AN2 Animal rib 5 HDAR6 Adult rib 5 
AN7 Animal rib 5 HDAP3 Adult phalanx 5 
HDAR1 Adult rib 4 HDAP5 Adult phalanx 5 
HDAR2 Adult rib 5 HDJS1 
Juvenile 
cranium 
2 
HDAR3 Adult rib 4 
   Table 5.13: Samples selected for the human IgG ELISA. HI is histological index. 
 
 
5.7.3(iv): Matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) mass 
spectrometry 
 
Bands from the SDS-PAGE analysis of samples from P1.2 were chosen and excised 
based on molecular weights closely corresponding to IgG heavy chains and light chains 
(approximately 50kDa and 25kDa, respectively). Figures 6.41 and 6.42 display the gels and 
selected bands. Bands were excised immediately following visualisation and stored at -20°C 
before being analysed by laboratory personnel at the Durham University Biological Sciences 
department, first by MALDI-TOF mass spectrometry (MS), then by nLC-MS/MS (see 
section 5.7.3(v) for the latter).  
 MALDI-TOF mass spectrometry (MS) is a fast, powerful, and sensitive protein 
fingerprinting method. Put simply, in MALDI-TOF MS, gel band samples undergo tryptic 
digestion before being dissolved into a solvent matrix. The matrix is then dried into a solid 
phase, which is ablated by short laser pulses within the mass spectrometer. This turns the 
solid phase into an ion-containing gas phase. The ions are then accelerated and allowed to 
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drift towards a detector. Their drift speed, or ‘time of flight’ is directly proportional to their 
mass. These masses are the ‘fingerprints’, which are searched against databases of known 
protein spectra (de Hoffman and Stroobant, 2007; ProTech Inc., 2011) 
Tryptic digestion of excised protein bands was performed using a ProGest robot 
(Genomic Solutions) programmed with the long trypsin digestion method as described 
immediately below. MALDI-TOF analyses were performed on a 4800 proteomic analyser 
(Applied Biosystems). All steps and analyses were carried out by laboratory personnel in the 
Biological Sciences Department of Durham University utilising the following protocols 
(Joanne Robson, personal communication, August 2013):  
 
 Tryptic digestion: 
 
1. Excised protein bands were transferred to the wells of a 96 well microtitre plate. 
This plate is designed with microscopic holes at the bottom of the wells which 
allows for positive displacement of liquids during reagent changes on the robot.  
 
2. Gel pieces were equilibrated in 50µl of 50Mm ammonium bicarbonate and 
proteins were reductively alkylated with 10mM DTT and 100mM iodoacetamide. 
 
3. Bands were then de-stained and remaining gel plugs desiccated with acetonitrile. 
 
4. Gel plugs were rehydrated with 50mM ammonium bicarbonate, containing 5% 
trypsin, and the proteins were digested for 12 hours at 37oC.  
 
5. Resulting peptides were extracted from the gel plugs with 2 x 25µl washes of 
50% acetonitrile, 0.1% triflouroacetic acid (TFA). 
 
6. Peptide extracts were lyophilised and then re-suspended in 10µl of 0.1% formic 
acid. 
 
 MALDI sample spotting: 
 
7. A saturated matrix solution of α-cyano-4-hydroxy-cinnamic acid was prepared in 
50% acetonitrile, 0.1% TFA, 10mM ammonium acetate.  
 
8. For each sample 1 µl of matrix solution was spotted on the MALDI target 
immediately followed by 1µl of sample into the matrix spot and the 
sample/matrix droplet allowed to slowly air dry. 
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 MALDI-TOF analyses: 
 
9. Analyses were first performed on all of the target spots using automated data 
acquisition and processing under the control of Applied Biosystems 4000 series 
Explorer software (version 3.5) using reflector mode, a mass range of 700-4000 
m/z, 1000 total laser shots per spectrum and a laser intensity of 3300v.  
 
10. Following acquisition the TOF-MS spectra were noise corrected, peak de-
isotoped and internally calibrated using the trypsin autolysis peaks 842.500 and 
2211.100 m/z. 
 
11. The eight most abundant precursor ions from each spectra were then selected by 
the software for fragmentation and MS-MS analyses using a 1kV CID 
fragmentation method collecting 4000 laser shots per spectra with a laser 
intensity of 3800 over the mass range. 
 
 Database searching and protein identification:  
 
12. Peak lists of ion masses were generated by GPS Explorer software version 3.6 
(Applied Biosystems) from the calibrated and de-isotoped MS and MS-MS 
spectra for each sample. Combined lists of MS-and MS-MS data were used for 
database searching with MASCOT version 2.2 (Matrix Science), against all 
entries in the NCBI database. 
 
13. Database search parameters used were; digestion enzyme trypsin, single missed 
cleavage allowed, variable modifications of carboxymethyl cysteine and oxidised 
methionine, precursor mass tolerance of 50ppm and fragment ion tolerance of 
0.2Da 
.  
 
5.7.3(v): Nanospray liquid chromatography-mass spectrometry (nLC-MS/MS) 
 
Nanospray liquid chromatography-mass spectrometry is an extremely powerful 
analytical tool which offers advantages over MALDI-TOF MS in terms of much greater 
sensitivity and reliability in protein identification. However, operationally, nLC-MS/MS is a 
much more complex task than MALDI-TOF MS. Data acquisition for the former takes also 
far longer due to the vast quantity of spectra generated (ProTech Inc., 2011). NLC-MS/MS 
has been demonstrated to be most useful for characterising whole proteomes from ancient 
bone samples (e.g., Cappellini et al., 2012). 
 Nanospray LC-MS/MS analysis was performed on the remaining tryptic digests of 
samples following the MALDI-TOF MS analysis outlined above in section 5.7.3(iv). All 
steps and analyses were carried out by laboratory personnel in the Biological Sciences 
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Department of Durham University utilising the following protocols (William Simon, 
personal communication, August 2013): 
 
1. 15µl of each sample fraction of tryptic peptide digest (see section 5.7.3(iv) for 
digestion protocol) was analysed by nLC-MS/MS using a Dionex Ultimate 3000 
nano-flow HPLC coupled to a hybrid quadrapole-TOF mass spectrometer (QStar 
Pulsar i, Applied Biosystems) fitted with a nanospray source (Protana) and a 
PicoTip silica emitter (New Objective). 
 
2. Each sample was loaded and washed on a Zorbax 300SB-C18, 5mm, 5 x 0.3mm 
trap column (Agilent) and online chromatographic separation was achieved over 
2 hours on a Zorbax 300SB-C18 capillary column (15cm x 3.5 x 75µm) with a 
linear gradient of 0-40% acetonitrile, 0.1% formic acid at a flow rate of 
200nl/minute. 
 
3. MS and MS-MS data were acquired using 1 second survey scan and 3 x 3 second 
product ion scans throughout the peptide elution. Only ions with 2+ to 4+ charge 
state and with TIC > 10 counts were selected for fragmentation. 
 
Throughout the chromatographic run the mass spectrometer cycles every 10 seconds 
between a 1.0 second survey scan (MS peptide parent ion mass) and 3 x 3.0 second MS-MS 
scans (3 peptides fragmented). This gives intact mass data and fragment ion mass data for as 
many as possible of the peptides eluting into the instrument. These combined masses are 
used in the database searches to identify and characterise proteins present in the sample 
(William Simon, personal communication, August 2013). 
 
Database searching and protein identification: 
 
1. All MS/MS data files were processed using Paragon search algorithm of Protein 
Pilot Software 4.0 (Applied Biosystems, USA) and searched against the Swiss-
Prot and/or TrEMBL databases. MS and MS/MS tolerances were set to 0.15 and 
0.1Da respectively and cleavage sites were defined as lysine and arginine with a 
single missed cleavage. 
 
 
5.7.4: P2: Extraction methodology adapted from Jiang et al. (2007) 
The protocol developed by Jiang et al. (2007) uses an exhaustive four stage 
extraction method aimed at retrieving as many proteins as possible from fresh animal bone. 
The total protein yield from each step was measured by mass spectrometric analysis. 
Although not originally aimed at archaeological bone, the exhaustive nature of the 
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extractions may prove suitable for retrieving IgGs from such material for further analysis. 
The extraction steps utilised by Jiang et al. (2007) follow a more traditional formula than 
Schmidt-Schultz and Schultz (2004), in that supernatants were collected and analysed from 
each step, rather than being discarded in favour of the bone pellet until the final 
solubilisation stage. 
 For consistency, the same cutting/grinding steps were employed as with P1. Five sets 
of samples (P2.1, P2.2, P2.3, P2.4, and P2.5) were selected for this extraction protocol. As 
with the P1 extractions detailed above, the five P2 extractions follow evolving, results-
driven methodologies; changes made in consecutive P2 extractions were designed to address 
problems encountered in each preceding extraction. Most of these problems arose due to 
difficulties of applying a protocol designed for fresh, modern bone samples to ancient, 
degraded samples. 
 In each P2 extraction (other than P2.1 – see section 5.7.4(i)), four samples were 
processed, as dictated by the immuno-affinity purification protocol subsequently chosen (see 
section 5.7.5 for details). Whereas Schmidt-Schultz and Schultz (2004) used a denaturant 
(guanidine-HCl) and chelator (EDTA) as the first extraction step, many other extraction 
methods (particularly collagen extractions) use hydrochloric acid (HCl) to initially 
demineralise the bone before denaturing and chelating. It is suggested that HCl 
demineralisation “induces ‘swelling’ of the collagen matrix and increases the ability of both 
collagen I and collagen-associated proteins [possible including cross-linked IgGs] to go into 
solution... [and] may allow for characterization of NCPs from ancient bone” (Cleland et al., 
2012:4-5).  
 
5.7.4(i): P2 samples 
 The samples chosen for the P2 extractions are show in Table 5.14. Two samples 
were chosen for P2.1 mainly to test the efficacy of the adapted Jiang et al. (2007) protocol 
and the functionality of the newly acquired thiophilic columns (see section 5.7.5). P2.2 
consisted of samples displaying high histological preservation as well as a pure bovine 
collagen control sample. The control was necessary to rule out the presence of collagen 
following thiophilic adsorption chromatography (TAC) purification (see section 5.7.5). P2.3 
samples were chosen based upon a range of histological preservations. As with P1.3, this 
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was performed to test the aforementioned suggestion by Masters (1987) concerning 
preferential NCP survival. The P2.4 and P2.5 human samples are from potentially malarious 
sites, thereby representing a range of periods (i.e., Roman and Anglo-Saxon) and 
histological preservations. An animal control sample was also included for P2.4. 
 
Sample Type HI Protocol 
HDAP5 Adult phalanx 5 2.1 
AN1 Adult rib 5 2.1 
HDAP5 Adult phalanx 5 2.2 
HDAR9 Adult rib 5 2.2 
AN2 Animal rib 5 2.2 
COLL Bovine collagen - 2.2 
HDAR2 Adult rib 5 2.3 
HDAP5 Adult phalanx 5 2.3 
HDAR3 Adult rib 4 2.3 
HDJS3 Juvenile cranium 1 2.3 
WM2316.1  Adolescent rib 5 2.4 
CD127.2  Very young adult cranium 5 2.4 
LP3845.1 Adolescent rib  0 2.4 
AN5 Animal rib  0 2.4 
HP154.1 Young adult rib 5 2.5 
LP3760.1 Juvenile rib 0 2.5 
LP4585.3 Middle adult hand phalanx 2 2.5 
OL1104.3 Young adult hand phalanx 5 2.5 
Table 5.14: Samples selected for the P2 extractions adapted Jiang et al. (2007) protocol. HI 
is histological preservation. 
 
Samples chosen for the P2 extractions were processed using an adapted Jiang et al. 
(2007) protocol. Adaptations were necessary due to the nature of the samples: Jiang and 
colleagues extracted protein from modern dog bones and therefore required additional steps 
not required with ancient samples (e.g., soft tissue removal). Additionally, Jiang and 
colleagues required the use of 1.2M and 6M HCl in the initial and final demineralisation 
stages, respectively. It has been suggested that 0.6M HCl is preferable for archaeological 
bone in order to reduce acid-hydrolysis of already degraded target proteins (Buckley et al., 
2009; Cleland et al., 2012). Bone mineral (hydroxyapatite) solubility increases as pH 
decreases, from being mostly insoluble at pH 7.5, to very soluble below pH 6 (Lindsay, 
2001). 0.6M HCl has a pH of 0.2, so should prove more than suitable for enhancing bone 
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mineral solubilisation. Although 1.2M and 6M HCl demineralisation may work well for the 
mass spectrometric peptide analysis intended by Jiang et al. (2007), these highly acidic 
conditions degrade proteins, rendering them unsuitable for the electrophoretic 
characterisation used later in this study. The P2 extractions, therefore, employed an initial 
0.6M demineralisation stage throughout. The fourth stage in P2.1 was changed to a 0.6M 
final demineralisation (adapted from published 6M HCl concentration), but this was dropped 
after P2.1, since it resulted in no spectrophotometrically measurable protein release 
following thiophilic adsorption chromatography (see 5.7.5). Benzamidine and aminocaproic 
acid were chosen as protease inhibitors, since it was felt that they would inhibit a 
sufficiently wide range of proteolytic activity likely to be encountered in archaeological 
bone. Protease inhibitors are not required during HCl demineralisation (Collins and Galley, 
1998), since proteases are unable to function under such conditions.  
After each extraction stage, supernatants were reserved for thiophilic adsorption 
chromatography (TAC), which took place immediately following each extraction stage (see 
5.7.5). Bone pellets were immediately utilised in the next extraction stage. 
 
Stage 1:  
1. 200mg of ground bone sample was incubated overnight at 4°C in 1ml 0.6M 
HCl, with occasional agitation. 
Stage 2:  
1. The bone pellet from extraction stage 1 was incubated for 24 hours at 4°C in 
1ml 100mM Tris, 6M guanidine-HCl, 5mM benzamidine, and 10mM 
aminocaproic acid, pH 8, with occasional agitation.   
Stage 3: 
1. The bone pellet from extraction stage 2 was incubated for 24 hours at 4°C in 
1ml 100mM Tris, 6M guanidine-HCl, 0.5M EDTA, 5mM benzamidine, and 
10mM aminocaproic acid, pH 8, with occasional agitation. (It should be 
noted that in extractions P2.3, P2.4, and P2.5 samples were incubated for 48 
hours at this stage, in an attempt to extract more protein). 
 
Stage 4 (only utilised in P2.1): 
 
1. The bone pellet from extraction stage 3 was incubated overnight in 1ml 0.6M 
HCl at 4°C. 
 
2. Upon careful removal of the supernatant, the bone pellets were discarded. 
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5.7.5: Purification of IgG antibodies from P2 extractions using thiophilic adsorption 
chromatography (TAC) 
 
Given the high quantity of expected proteins extracted from the phases of the 
adapted Jiang et al. (2007) technique, it was decided that an antibody purification approach 
would be necessary to separate the inevitably small quantity of IgGs from the overall protein 
yield. This is akin to the use of collagenase in the previous extraction technique. However, 
while collagenase reduces the quantity of collagen that may mask target IgG proteins, 
antibody purification should isolate target antibodies from samples, thus eliminating 
potentially interfering/masking proteins altogether.  
 Due to the generally low abundance of the target protein even in modern serum 
samples, antibody purification requires techniques that result in the highest purity yields. To 
achieve this, the most powerful purification techniques involve some type of immunoaffinity 
chromatography, in which the target antibodies are separated by interactions with a solid 
ligand (usually within a gel), based upon specific chemical or physical binding properties of 
the antibody (Thermo Scientific, 2010). Such techniques include the use of high affinity 
liquid chromatography (HPLC) over melon gel, or protein A, G, or L columns (all of which 
have a high affinity for IgGs). Kolman et al. (1999) successfully extracted IgGs from 
relatively recent archaeological bone and purified them using HPLC over protein A 
columns, prior to ELISA against syphilis antigens. Their testing of unpurified samples failed 
to produce positive antigen binding. There are, however, drawbacks to using protein 
columns, the most significant being the high cost, low sample throughput, the need for 
subsequent dialysis/cleaning steps, and potential damage to the antibodies during elution 
(Low et al., 2007; Thermo Scientific, 2010).   
 Thiophilic adsorption chromatography (TAC) was developed during the 1980s and 
has become well established as a cost-effective, gentle method of purifying IgG antibodies 
(Hardouin et al., 2007). TAC follows a similar process to most other protein column 
immunoaffinity chromatographic techniques in that target immunoglobulins are attracted to, 
or have a high affinity to, specific chemical ligands within a matrix. The chemical matrix 
structure in this case was named thiophilic gel, or T-gel (Hutchens and Porath, 1986), to 
which IgGs of all subclasses have a particularly high affinity. In anticipation of the likely 
degraded nature of the target proteins in archaeological bone and the extensive extraction 
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process of Jiang et al. (2007), it was thought prudent to attempt the gentlest IgG purification 
method available. Thiophilic purification operates at a near-neutral pH and is reliant on the 
presence of hydrophobic lyotrophic salt (e.g., potassium sulphate) as opposed to chaotropic 
salt (e.g., sodium chloride or ammonium sulphate) to promote IgG adsorption (Hardouin et 
al., 2007). The conditions serve to protect the antibodies from further degradation (Thermo 
Scientific, 2010) and also to remove many salts, which would normally require post-
extraction desalting or dialysis; it is, therefore, considered a one-step process. It is a 
relatively low-cost alternative to other IgG purification methods in that the supplied resins 
can be regenerated and reused at least ten times before exhaustion (Thermo Fisher, 2010). 
The major disadvantages of thiophilic resins are the time required for sample processing and 
the low sample through-put. 
Sample supernatants were subjected to thiophilic purification after each stage of the 
adapted Jiang et al. (2007) protocols, using a Pierce® Thiophilic Adsorption Kit (Thermo 
Scientific), which provided thiophilic columns and all necessary buffers and methodology: 
 
1. 87mg of ACS Reagent Grade crystalline potassium sulphate per ml was added to 
each 1ml sample supernatant before gentle mixing. Samples were then 
centrifuged at 10,000g for 20 minutes. 
 
2. Sample supernatants were then aspirated into separate 1.5ml tubes through 
0.45µm filters (using 5ml syringe, filter, and 20 gauge needle) and brought to pH 
8.  
 
3. Thiophilic columns and buffers were equilibrated to room temperature. Columns 
were then uncapped and allowed to drain, followed by equilibration with 12ml of 
binding buffer (flow-through fractions being discarded). 
 
4. Sample supernatants were then applied to the columns and allowed to completely 
enter the resin. 
 
5. Columns were washed with consecutive 3ml volumes of binding buffer. The 
flow-through fractions were collected after each wash, with absorbance being 
monitored at 280nm against pure binding buffer using a CamSpec M330 
spectrophotometer. This step determined when all non-bound material was 
removed from the column. 
 
6. Bound proteins were then eluted from each column using as many elution buffer 
washes as was necessary, until no further protein was measurable at 280nm 
against pure elution buffer. Fractions containing protein from this step were 
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retained and frozen at -20°C, while those containing no measurable protein were 
discarded. 
 
7. Each column was then regenerated with 12ml of 8M guanidine-HCl solution, 
before being washed with 20ml of ultrapure water. 
 
8. 6ml of storage buffer was then added to the columns, which were capped when 
3ml remained. Columns and buffers were then stored at 4°C. 
  
 It should be noted that the TAC protocol for the P2.3, 2.4, and 2.5 samples changed 
slightly in the type of 0.45µm filter used in sample preparation. The cellulose acetate filters 
used for the P2.1 and P2.2 samples were replaced with PVDF filters, which are 
demonstrated to significantly decrease the prevalence of IgG binding (Walsh and Coles, 
1980).  
 
5.7.6: Identification of IgG Antibodies from P2 Extractions and TAC Purification 
 
 Selected samples from the P2 extractions and subsequent TAC purifications were 
subjected to 1D SDS-PAGE and mass spectrometric analysis in order to identify and 
characterise any surviving IgGs. As with the Jiang et al.’s (2007) extraction protocols, 
changes in SDS-PAGE techniques were implemented as and when problems arose. 
Methodology was hampered by the dearth of published protocols aimed specifically at 
electrophoretic characterisation of ancient antibodies; this study was, therefore, required by 
trial and error to identify the most suitable SDS-PAGE techniques for the target proteins. 
Samples chosen for SDS-PAGE were generally those displaying the highest 
spectrophotometric absorbance values at 280nm following TAC. These should, 
theoretically, represent the samples with the highest concentrations of eluted IgGs. 
 
5.7.6(i): SDS-PAGE (P2.1 and P2.2) 
Working in cooperation with the Durham University Biological Sciences 
department, samples from P2.1 and P2.2 were separated by 1D SDS-PAGE (with a Bio-Rad 
Mini PROTEAN® II Electrophoresis Cell) using the following protocol, adapted from 
Laemmli (1970): 
1. Each sample was TCA (trichloroacetic acid) precipitated overnight at 20°C using 
an equal volume 20% TCA to the sample. 
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2. The samples were then centrifuged for 15 minutes at 4°C and the supernatant 
carefully removed. 
 
3. Two acetone washes were performed on the supernatants by adding 
approximately 300µl of cold acetone to each sample and centrifuging at 4°C for 
5 minutes, after which the supernatant was removed and the pellet allowed to air 
dry. 
 
4. Approximately 200µl SDS sample buffer (63mM Tris HCl, 10% Glycerol, 2% 
SDS, 5% DTT, 0.0025% Bromophenol Blue, pH 6.8) was added and the samples 
boiled for 5 minutes. 
 
5. The supernatants were extracted and brought to neutral pH by adding sodium 
hydroxide (NaOH). 
 
6. 20µl of each sample was run on pre-prepared polyacrylamide gels (10% 
resolving gel, 3% stacking gel) 100V for approximately 10 minutes, and then 
120V until dyes reached the end of the gel. See Table 5.20 for the running buffer 
recipe. 
 
7. Silver staining was achieved following the protocol described in 5.7.2.3. 
 
 
5.7.6(ii): SDS-PAGE (P2.3, P2.4, and P2.5) 
 
 Following SDS-PAGE of P2.1 and P2.2 samples, it was felt necessary to run further 
trials to optimise the protocol for visualising target archaeological IgGs using equipment 
loaned from the Biological Sciences department. The acquisition of equipment and reagents 
in-house (within the Archaeology department of Durham University) meant that it was 
possible to run many trials using multiple variations of the SDS-PAGE protocol used in P2.1 
and P2.2. Techniques presented here represent the most successful trials (from over 50 
attempts) for samples from P2.3, P2.4, and P2.5, in terms of visualizing bands possibly 
representative of IgG. A notable difference in sample preparation for electrophoresis 
occurred with the P2.5 samples. These were precipitated with trichloroacetic acid (TCA) 
rather than with acetone (see below for protocol). Acetone was used to precipitate the earlier 
P2.3 and 2.4 samples, since TCA damages the light chain receptors, thereby reducing or 
destroying any remaining functionality of already potentially degraded ancient IgGs. 
Retaining functionality would be important should immunological testing for anti-malarial 
antibodies be attempted. However, acetone precipitation resulted in large phosphate pellets, 
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the phosphate being residual from the TAC elution buffer. This became a particular problem 
when more than 1ml of sample was prepared for electrophoresis in attempts to boost protein 
concentration: increased sample resulted in larger phosphate pellets, which made 
solubilisation in SDS sample buffer extremely difficult. TCA does not precipitate salts 
alongside protein, so was preferred to acetone for the P2.5 samples. Since desalting the 
samples would likely further reduce any ancient protein yield (Schmidt-Schultz and Schultz, 
2004), it was decided to return to TCA precipitation. If IgGs were successfully visualised, an 
alternative, less destructive, yet inherently desalting precipitation method (e.g., chloroform-
methanol) may have been considered for any downstream immunological analyses. 
All in-house SDS-PAGE trials were conducted using a Bio-Rad Mini PROTEAN® II 
Electrophoresis Cell. An IgG positive control (Source Bioscience Lifesciences®) was also 
introduced at this stage in order to facilitate comparisons between gel lines and a positive 
sample. The addition of a positive control proved useful in determining the ideal gel 
concentrations, at least in terms of modern IgGs. The denaturing SDS-PAGE followed an 
adapted Laemmli (1970) methodology using gel concentrations appropriate for separating 
proteins below 100kDa in size, namely 10%, 12 %, or 15% resolving gels, and a 5% 
stacking gel (Nikolayenko et al. 2005). Tables 5.15-5.20 show recipes for these gels, along 
with the sample and running buffers. These are followed by the adapted Laemmli (1970) 
methodology employed in each of the extractions. 
 
Reagent Quantity 
dH20 4.1ml 
3M Tris, pH 8.8 1.25ml 
0.8% SDS 1.25ml 
30% acrylamide 3.33ml 
10% Ammonium persulphate (APS) 50µl 
Tetramethylethylenediamine (TEMED) 20µl 
Table 5.15: 10% resolving gel recipe for SDS-PAGE of P2.3, P2.4, and P2.5 samples. 
Makes 10ml. 
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Reagent Quantity 
dH20 3.43ml 
3M Tris, pH 8.8 1.25ml 
0.8% SDS 1.25ml 
30% acrylamide 4ml 
10% Ammonium persulphate (APS) 50µl 
Tetramethylethylenediamine (TEMED) 20µl 
Table 5.16: 12% resolving gel recipe for SDS-PAGE of P2.3, P2.4, and P2.5 samples. 
Makes 10ml. 
 
 
Reagent Quantity 
dH20 2.43ml 
3M Tris, pH 8.8 1.25ml 
0.8% SDS 1.25ml 
30% acrylamide 5ml 
10% Ammonium persulphate (APS) 50µl 
Tetramethylethylenediamine (TEMED) 20µl 
Table 5.17: 15% resolving gel recipe for SDS-PAGE of P2.3, P2.4, and P2.5 samples. 
Makes 10ml. 
 
 
Reagent Quantity 
dH20 3.105ml 
1M Tris, pH 6.8 625µl 
30% acrylamide 600µl 
0.8% SDS 625µl 
Bromophenol blue Trace 
10% Ammonium persulphate (APS) 25µl 
Tetramethylethylenediamine (TEMED) 20µl 
Table 5.18: 5% Stacking gel recipe for SDS-PAGE of P2.3, P2.4, and P2.5 samples. Makes 
5ml. 
 
 
 
 
 
 
 
 
 
 
197 
 
Reagent Quantity 
dH20 2.4ml 
0.5M Tris, pH 6.8 200µl 
Sucrose 1g 
Bicine 490mg 
2-mercaptoethanol 250µl 
SDS 150mg 
Bromophenol blue Trace 
Table 5.19: Sample buffer recipe for SDS-PAGE of P2.3, P2.4, and P2.5 samples. Makes 
3ml. 
 
Reagent Quantity 
dH20 776ml 
1M Tris, pH 8.3 16ml 
Bicine 2.64g 
10% SDS 8ml 
Table 5.20: Gel running buffer recipe for SDS-PAGE of all P2 samples. Makes 800ml. 
 
 
1. 300µl of each P2.3, and P2.4 sample was precipitated at -20°C overnight in 1.2ml 
cold acetone. For P2.5 samples, 500µl of each sample was precipitated overnight in 
an equal volume 20% TCA at 4°C. 
 
2. The P2.3 and P2.4 samples were then centrifuged for 15 minutes at 10,000g, after 
which the acetone was carefully removed and the remaining protein pellets allowed 
to air dry. For 2.5 samples, each sample was centrifuged for 15 minutes at 10,000g. 
TCA was then carefully removed and the remaining pellet washed twice in 300µl 
cold acetone, before centrifuging for 5 minutes at 10,000g. The supernatant was then 
removed and the pellet air dried for a maximum of 10 minutes. 
 
3. A 10, 12, or 15% polyacrylamide resolving gel (Tables 5.15-5.17) was made and 
allowed to polymerise.  
 
4. A 5% stacking gel (Table 5.18) was made and pipetted onto the polymerised 
resolving gel. The stacking gel was then left to polymerise with Teflon combs in 
place to create the sample wells.  
 
5. Air dried sample pellets were resuspended in 200µl sample buffer (Table 5.19: 
recipe following Wiechmann et al. (1999) for SDS concentration and Page and 
Thorpe 2002)). 
  
a. For P2.3 samples, half of the samples were incubated at 55°C for 48 hours. 
This follows the suggestion by Wiechmann et al. (1999) that extended 
heating of archaeological samples in sample buffer promotes protein 
separation. 
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b. Remaining P2.3 samples were boiled for three minutes and allowed to return 
to room temperature. All P2.4 and 2.5 samples were boiled. 
 
6. Polymerised gels were placed into running buffer (Table 5.20), before 10-20µl of 
each boiled and incubated sample was pipetted into the sample wells. 10µl of human 
IgG control sample and/or 3 µl of low range molecular weight marker and/or wide 
range molecular weight marker (Sigma-Aldrich®) were added to sample wells, 
respectively. Unused wells were filled with 10-20µl of sample buffer. 
 
7. Gels were run at 100V for approximately 10 minutes, then 150V until samples 
reached the end of the gels. 
 
 
5.7.6(iii): P2.3, P2.4, and P2.5 gel staining (Coomassie and silver) 
 
 Gels for P2.3 were visualised initially with Brilliant Blue G (Colloidal) Coomassie 
stain (Sigma-Aldrich®) following the supplied product protocol (see below). Colloidal 
Coomassie stain offers up to ten times the detection sensitivity over traditional Coomassie 
blue staining  (Neuhoff et al., 1988). If further protein visualisation was deemed necessary, 
gels were then silver stained using a ProteoSilver™ Silver Stain Kit (Sigma-Aldrich®) and 
supplied protocol (see below). Both stain types are highly sensitive and compatible with 
downstream applications, such as mass spectrometric analyses. 
 
Colloidal Coomassie Brilliant Blue G (Sigma-Aldrich®) staining: 
 The staining protocol used was as follows: 
1. After gels had completed the SDS-PAGE run, they were fixed overnight in 100ml 
40% ethanol, 10% acetic acid. 
 
2. Gels were then washed twice for 10 minutes in 100ml dH20. 
 
3. Dye working solution was prepared by taking four parts dye stock solution and 
stirring in one part methanol. Gels were left covered overnight to stain. 
 
4. Following staining, gels were washed in 1% acetic acid until the background became 
clear (wash solution was changed several times). 
 
5. Gels were recorded using a conventional flatbed scanner. Protein bands of interest 
(i.e., those potentially signifying IgG heavy or light chains) were excised and stored 
at -20° for mass spectrometric analysis. 
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Silver staining using ProteoSilver™ Plus Silver Staining Kit (Sigma-Aldrich®):  
 
 The silver staining protocol was as follows. All steps were carried out with constant 
agitation: 
 
1. Gels were fixed for 40 minutes in 100ml of a 50% ethanol, 10% acetic acid, 40% 
ultrapure H20 solution. 
 
2. Gels were then washed for 10 minutes in 100ml of a 30% ethanol solution. 
 
3. The gels were washed for 10 minutes in 200ml ultrapure water. 
 
4. The gels were then incubated for 10 minutes in 100ml of sensitiser solution (1ml 
sensitiser, 99ml ultrapure H20). 
 
5. Gels were washed twice for 10 minutes in 200ml ultrapure H20. 
 
6. The gels were then incubated for 10 minutes in 100ml silver solution (1ml silver, 
99ml ultrapure H20). 
 
7. Gels were washed in 200ml ultrapure H20 for one minute. 
 
8. Gels were then developed in 100ml developer solution (5ml developer 1, 100µl 
developer 2, 95ml ultrapure H20) until protein bands were sufficiently visualised. 
 
9. 5ml of stop solution was added and gels incubated for 5 minutes to stop 
development. 
 
10. Gels were then washed for 15 minutes in 200ml ultrapure water, and then stored in 
fresh ultrapure water. 
 
 
5.7.7: P3: Adapted Schmidt-Schultz and Schultz protocol with TAC purification 
 
Subsequent to running the P1 and P2 protocols, it was decided to prepare a further 
batch of samples (Table 5.21) using the adapted Schmidt-Schultz and Schultz methodology 
(P1), but this time collecting the supernatants from the separate extractions and subjecting 
them to TAC purification in order to remove excess collagen that may obscure IgGs. SDS-
PAGE and gel staining were then performed on post-TAC eluted samples following the 
protocols described above. Selected gel bands (see section 6.4.2(iv)) were excised and 
subjected to nLC-MS/MS analysis following the protocol described in section 5.6.3(v). It 
should be stated here that the gels shown in sections 6.4.2(iii) and 6.4.2(iv) represent testing 
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of the P3 samples prior to TAC purification, since SDS-PAGE trials failed to produce 
visible bands following TAC. A Western blot was also performed on a selection of P3 
samples (see section 5.7.10). 
 
Sample Type HI 
EH198.1 Very young adult rib 4 
CD120.2 Very young adult hand phalanx 5 
CD165.1 Child rib 5 
OL1104.2 Young adult cranium 5 
Table 5.21: Samples selected for P3 extraction. HI – histological preservation.  
 
 
5.7.8: P4: Full Jiang et al. (2007) extraction and proteomic analysis 
 
 It was decided to run one further adapted Jiang et al. (2007) protocol with the 
intention of increasing protein yield from the TAC purification and preparing eluted samples 
from each extraction stage for mass spectrometric analysis. It was hoped that the increase in 
protein (and hence IgG) yield would result in better visualisation of target IgGs in colloidal 
Coomassie stained gels, and hence provide bands suitable for proteomic analysis. 
Furthermore, mass spectrometric analysis of eluted samples should identify at which 
extraction stage IgGs were being released, if at all. Whole sample analysis (i.e., pre-TAC) 
may provide a full protein proteome, which could reveal a vast range of other surviving 
ancient biomolecules, such as were encountered in recent ground-breaking proteomic 
research on Pleistocene mammoth bone (Cappellini et al. 2012). Unfortunately whole 
sample analysis proved prohibitively expensive and was therefore beyond the limitations of 
this study. Select eluted samples (Table 5.23) were, however, analysed by nLC-MS/MS. 
 The protocol used with the P4 samples (Table 5.22) follows the published Jiang et al. 
(2007) sample preparation technique more closely than that used with the P2 samples, since 
the main intention with the P4 samples was mass spectrometric analysis of eluted samples 
from each extraction stage. Other than omitting the degreasing steps required for fresh bone, 
the only deviations from the published protocol were the choice of protease inhibitors and 
the pH of solutions used in the second and third extraction stages. As previously, it was felt 
that aminocaproic acid and benzamidine would provide sufficient protease inhibition for the 
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ancient samples, rather than the cocktail of protease inhibitors required with fresh samples. 
The pH of hydrochloric acid in the first (demineralisation) stage was altered from 1.2M to 
0.6M to reduce early hydrolysis and facilitate TAC binding. Finally, the pH of solutions was 
changed from 7.4 to 8 in preparation for the TAC following extractions, which requires the 
latter for the selective binding of only IgG. All four extraction stages and reagent 
concentrations (e.g., 6M HCl in the fourth extraction) were otherwise identical to the 
published protocol. The samples chosen represent a range of histological preservations, with 
EH156.3 (HI: 5), an exceptionally well preserved cranial section, most approximating the 
fresh cranial sample used by Jiang et al. (2007).  
 Supernatant fractions from the first three stages (approximately 3ml per sample) 
were reserved for TAC (see 5.7.5 for methodology) in order to compare quantity of bound 
‘IgGs’ resulting from the P2 and P4 extractions. The fourth stage supernatants were not 
subjected to TAC, since the high concentration of HCl would likely completely hydrolise 
and degrade proteins to the peptide level. Although peptide-level IgGs would be suitable for 
proteomic characterisation, they would not be suitable for TAC purification or SDS-PAGE 
visualisation. 
 
Sample Type HI 
EH156.3 Young adult cranium 5 
EHA4 Animal rib 4 
CD112.3 Very young adult hand phalanx 2 
CD84.2 Very young adult cranium 0 
Table 5.22: Samples selected for P4 extraction. HI – histological preservation.  
 
 The following describes the protocol followed for extraction of P4 samples. After the 
first, second, and third stages, 250µl of each sample was reserved for nLC-MS/MS analysis 
(see 5.7.9). 
 
Stage 1:  
1. 1g of ground bone sample was split into five 200mg portions in separate micro 
tubes. Each was incubated overnight at 4°C in 1ml 0.6M HCl, with occasional 
agitation. 
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Stage 2:  
1. The bone pellets from extraction stage 1 were incubated for 72 hours at 4°C in 
1ml 100mM Tris, 6M guanidine-HCl, 5mM benzamidine, and 10mM 
aminocaproic acid, pH 8, with occasional agitation. 
   
Stage 3: 
1. The bone pellet from extraction stage 2 was incubated for 72 hours at 4°C in 1ml 
100mM Tris, 6M guanidine-HCl, 0.5M EDTA, 5mM benzamidine, and 10mM 
aminocaproic acid, pH 8, with occasional agitation.  
 
Stage 4: 
1. The bone pellets from extraction stage 3 were incubated overnight in 1ml 6M 
HCl at 4°C. 
 
2. Upon careful removal of the supernatant, the bone pellets were discarded. 250µl 
of supernatant from each sample was set aside for proteomic analysis (see 5.7.8), 
while the remaining supernatant was reserved at -20°C, should further analysis 
be required. 
 
5.7.9: nLC-MS/MS analysis of post-TAC P3 and P4 samples 
 
A small number of samples (Table 5.23) representing a range of preservations and 
protein concentrations were analysed by laboratory staff at the Durham University 
Biological Science Department using nLC-MS/MS for the presence of IgG-related peptides. 
Searches for matching peptides were made on the Swiss-Prot database and a translation of 
all human DNA sequences at EMBL (European Molecular Biology Laboratory) (Adrian 
Brown, personal communication, March 2014). 
The two P3 samples were subjected to a longer separation gradient (three hours) with 
an exclusion list of 198 and 187 m/z values, respectively, in an attempt to exclude common 
keratin and collagen isoforms detected in previous runs (Adrian Brown, personal 
communication, April 2014). See section 6.4.5 for further details of this. The resulting 
peptides were searched against the human DNA sequences at EMBL (Adrian Brown, 
personal communication, April 2014).  
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Sample Protocol 
Extraction 
stage 
Protein conc. 
(mg/ml) 
CD120.2 P3 2 0.054 
CD120.2 P3 3 0.084 
CD84.2 P4 1 0.025 
CD84.2 P4 2 0.08 
CD84.2 P4 3 0.064 
EH156.3 P4 1 0.05 
EH156.3 P4 2 0.093 
EH156.3 P4 3 0.044 
Table 5.23: P3 and P4 samples analysed by nLC-MS/MS. 
 
 
5.7.10: P2, P3, and P4 Western Blot 
 
 A number of samples from the later P2, P3 and P4 extractions (Table 5.23) that were 
analysed by SDS-PAGE were also selected for Western blot analysis following the protocol 
described below (which differs slightly from the test run previously). The same primary and 
secondary antibodies were employed in this testing, since it was anticipated that the much 
lower quantities of collagen expected in these samples would significantly reduce the cross-
reactivity experienced in the P1 Western blot (see section 6.4.1(v)).  The following samples 
were selected for testing based on their likelihood to contain IgG and/or to compare results 
of other analyses (e.g., proteomic) on the same samples. 
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Sample HI Protocol 
Extraction 
Stage 
Protein 
Concentration 
(mg/ml) 
AN5 0 2.4 3rd 0.084 
LP3845.1 0 2.4 3rd 0.088 
OL1104.2 5 2.5 2nd 0.013 
HP154.1 5 2.5 3rd 0.019 
OL1104.2 5 3 3rd 0.021 
OL1104.2 5 3 3rd 0.021 
OL1104.2 5 3 Post-3rd HCl 0.021 
AN5 0 3 1st 0.054 
EH198.1 4 3 3rd 0.055 
EH198.1 4 3 3rd 0.055 
LP3845.1 0 3 1st 0.073 
CD120.2 5 3 3rd 0.084 
CD120.2 5 3 Post-3rd HCl 0.084 
CD165.1 5 3 3rd 0.112 
EH198.1 4 3 1st 0.117 
HP156.3 5 4.1 3rd 0.044 
HP156.3 5 4.1 1st 0.05 
CD84.2 0 4.1 3rd 0.064 
CD84.2 0 4.1 2nd 0.08 
HP156.3 5 4.1 2nd 0.093 
Table 5.24: P2, P3 and P4 samples selected for Western blot analysis. HI is histological 
preservation. 
 
SDS-PAGE: 
1. A gel was prepared consisting of 15% resolving and 5% stacking portions.  
 
2. 10µl of each of the twenty samples and IgG positive control were loaded and 
the gel was run at 100v until samples reached the end of the gel. The use of a 
positive control negated the need for a molecular weight marker. 
 
 
Transfer: 
1. Transfer apparatus consisting sponges, 6x filter paper, and nitrocellulose 
membrane were soaked for a few minutes in 100ml transfer buffer (2.4g tris; 
11.4g glycine) and 200ml ethanol. The gels were soaked separately in the 
same solution after careful removal of the stacking gels. 
 
2. The transfer cassettes were opened and with black panel flat on the bottom 
tray, filled with transfer buffer. 
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3. The transfer sandwiches were prepared by stacking the components in the 
flowing order: sponge, 3x filter paper, gel, nitrocellulose membrane, 3x filter 
paper, and sponge. The gel and membrane were placed on the cathode and 
anode sides of the cassette, respectively. The sandwiches were then firmly 
rolled over with a glass tube to remove air bubbles. 
 
4. The transfer cassettes were clamped together and placed into an 
electrophoresis tank (BioRad®), before being submerged in transfer buffer. 
Ultrapure water was added to the outer chamber. 
 
5. Protein transfer (blotting) was achieved at 135V for two hours at 4°C. 
 
 Development: 
1. Membranes were removed from the cassettes and placed in a small container 
of Ponceau S stain. 
 
2. Membranes were stained with Ponceau S stain until lanes became visible.  
 
3. Membranes were then rinsed in 100ml TBS-T (137mM sodium chloride; 
2.7mM potassium chloride; 19mM tris; 0.5ml/l Tween 20), before being 
blocked overnight in 2% skimmed milk at 4°C. Blocking helps prevent 
nonspecific antibody/membrane binding. 
 
4. The blocking solution was rinsed off with TBS-T and membranes incubated 
for 90 minutes in a solution of monoclonal mouse anti-human IgG (heavy 
chain) antibody at a dilution of 1:1000 (dilution following Schmidt-Schultz 
and Schultz 2004). 
 
5. The membranes were then washed three times in TBS-T for 15 minutes, five 
minutes, and five minutes, before being incubated for one hour in a solution 
of horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody 
(Sigma-Aldrich®) at a dilution of 1:20000.  
 
6. The membranes were then washed three times in TBS-T for 15 minutes, five 
minutes, and five minutes. 
 
 Detection: 
 
1. Membranes were incubated in Supersignal West Pico Chemiluminescent 
substrate (Thermo Scientific®) for five minutes.  
 
2. The membranes were then transferred to Saran wrap and covered in x-ray 
film and developed in a dark room and results recorded at exposures of one 
minute and five minutes. 
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5.7.11: P5: protein extraction following adapted Cappellini et al. (2012) protocol 
 
 Recent research (e.g., Cappellini et al. 2012) has highlighted the vast potential 
offered by high resolution proteomic methods in accessing previously unobtainable 
information concerning the survival of ancient proteins in mammalian (Pleistocene 
mammoth) bone. This included peptides associated with immunoglobulins. It was, therefore, 
considered prudent to attempt to utilise this methodology to attempt to extract IgGs from 
selected archaeological human bone samples. Samples chosen for this protocol (Table 5.25) 
represent a range of histological preservation and include animal bone samples for control 
purposes.  
 
Sample Type HI 
AN5 Animal rib 0 
LP3760.1 Juvenile rib 0 
EH133.1 Child rib 1 
HP157.2 Adult rib 2 
HP104.2 Child rib 3 
CD107.1 Very young adult rib 4 
CD120.2 Very young adult hand phalanx 5 
OL1104.2 Young adult hand phalanx 5 
HPAN5 Animal rib 5 
Table 5.25: Samples selected for P5 extraction protocol. HI – histological preservation. 
 
 
 The published extraction protocol (Cappellini et al. 2012) was followed with an 
additional 0.6M HCl demineralisation stage. This was intended to further break down the 
remaining hydroxyapatite scaffold within the bone pellets following the ammonium 
bicarbonate extraction stage, thereby increasing the chances of releasing any retained, tightly 
mineral-bound non-collagenous proteins. This protocol was incompatible with TAC, since 
the extended 75°C incubation in the second extraction stage would completely denature any 
IgGs (Vermeer and Norde, 2000). SDS-PAGE was, however, run on each sample from each 
extraction stage in order to compare gel profiles to other protocols. 
 
1. 75mg of ground bone sample was incubated overnight at 4°C in 0.5M EDTA, 
pH 8.01. 
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2. Samples were then centrifuged for 15 minutes at 17,000g. Supernatants were 
carefully collected and reserved.  
 
3. Remaining bone pellets were vortexed in 800µl of 50mM ammonium 
bicarbonate, pH 7.4 and incubated at 75°C for 24 hours. 
 
4. Samples were then centrifuged for 15 minutes at 17,000g. Supernatants were 
then collected and reserved. 
 
5. Pellets were then incubated overnight at 4°C in 0.6M HCl, before being 
centrifuged for 15 minutes at 15,000g. Supernatants were collected and the 
pellets discarded. 
  
 
5.8: Analysing histological preservation and protein yield 
 
As previously mentioned (section 5.6.2), there exists a lack of consensus concerning 
bone diagenesis and the survival of collagen, the most abundant bone protein. Less is known 
about the survival of non-collagenous proteins, although their high affinity to hydroxyapatite 
may offer preferential protection (Masters, 1987). Histological analysis can characterise 
bone preservation, providing a simple method of controlling for contamination by 
exogenous, diagenetically-introduced materials. This research intends to investigate the 
relationship between histological preservation and quantity of protein yielded from the 
different extraction protocols described above. This may provide evidence of which 
extraction protocols and stages are most suitable for each histological preservation category 
and address the question of preferential survival of the non-collagenous protein IgG. In 
order to perform these analyses, the protein yields from each wash and elution stage of the 
protocols employing TAC was measured using a CamSpec M330 spectrophotometer (at 
280nm). The resulting figures were then analysed to investigate relationships between 
histological preservation and protein yield. 
 
5.9: Malaria EIA (ELISA) 
 A commercially available anti-malaria antibody EIA (ELISA) kit was run on post-
TAC eluted samples from the P3, P4 protocols, and samples from the P5 extraction (Table 
5.25) which remained after other analyses. The Malaria Total Antibody EIA (Lab 21) 
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provided all reagents alongside a 96 well plate coated with recombinant antigens capable 
detecting IgG, IgM, and IgA antibodies to all four species of human malaria. Controls tested 
included negative and positive controls supplied with the kit, the elution buffer from P3 and 
P4, and the three buffers from P5, along with ultrapure water. Animal bone controls were 
also tested. The samples represent a variety of histological preservation. 
 
Sample Type 
 
HI              
Protocol Stage 
Protein 
conc. 
(mg/ml) 
Sample Type 
 
HI              
Protocol Stage 
Protein 
conc. 
(mg/ml) 
Negative Control  - - - - EH156.3 Human 5 4 3 0.044 
Positive Control  - - - - HP157.2 Human 2 5 1 - 
Elution 
buffer 
Control  - 3 and 4 - - CD107.1 Human 4 5 1 - 
0.5M 
EDTA 
Control  - 5 - - AN5 Animal 0 5 1 - 
50mM 
Ammonium 
bicarbonate 
Control  - 5 - - OL1104.2 Human 5 5 1 - 
0.6M HCl Control  - 5 - - HPAN5 Animal 5 5 1 - 
uH2O Control  - - - - EH133.1 Human 1 5 1 - 
EH198.1 Human 4 3 1 0.117 HP104.2 Human 3 5 1 - 
CD165.1 Human 5 3 1 0.021 HP157.3 Human 2 5 2 - 
CD120.1 Human 5 3 2 0.054 CD107.1 Human 4 5 2 - 
EH198.1 Human 4 3 3 0.055 AN5 Animal 0 5 2 - 
CD165.1 Human 5 3 3 0.112 OL1104.2 Human 5 5 2 - 
CD120.1 Human 5 3 3 0.084 HPAN5 Animal 5 5 2 - 
OL1104.2 Human 5 3 3 0.021 EH133.1 Human 1 5 2 - 
EHA4 Animal 4 4 1 0.025 HP104.2 Human 3 5 2 - 
CD84.2 Human 0 4 1 0.025 HP157.3 Human 2 5 3 - 
CD112.3 Human 2 4 1 0.034 CD107.1 Human 4 5 3 - 
EH156.3 Human 5 4 1 0.05 AN5 Animal 0 5 3 - 
EHA4 Animal 4 4 2 0.037 OL1104.2 Human 5 5 3 - 
CD84.2 Human 0 4 2 0.08 HPAN5 Animal 5 5 3 - 
CD112.3 Human 2 4 2 0.067 EH133.1 Human 1 5 3 - 
EH156.3 Human 5 4 2 0.093 HP104.2 Human 3 5 3 - 
EHA4 Animal 4 4 3 0.04 HP157.3 Human 2 5 3 - 
CD84.2 Human 0 4 3 0.064 CD107.1 Human 4 5 3 - 
Table 5.26: P3, P4, and P5 samples tested by malaria ELISA. Protein concentration is taken 
from Appendix 1, Tables A1.1-A1.7. HI is histological preservation. Stage is extraction 
stage. 
 
209 
 
The malaria ELISA was run following the protocol supplied with the kit. All controls 
and samples were tested in duplicate (apart from the negative control, which was tested three 
times) to aid in the validation of the results: 
1. All reagents and samples were brought to room temperature prior to use. 
 
2. The wash buffer was diluted to 1:20 with distilled water. 
 
3. 50µl of undiluted sample or control (in duplicate) was added to each well. The 
negative control was tested in triplicate. The plate was then shaken gently for 30 
seconds to mix. 
 
4. The plate was incubated (covered) at 37°C for 30 minutes. 
 
5. The wells were then washed five times with wash buffer, allowing 30 seconds 
soak time between each wash cycle. 
 
6. The conjugate was diluted 1:10 in conjugate buffer (50µl+ 500µl per 10 wells). 
50µl of diluted conjugate was then added to each well. 
 
7. The plate as then incubated (covered) at 37°C for 30 minutes. The wells were 
then washed five times with wash buffer, allowing 30 seconds soak time between 
each wash cycle. 
 
8. 50µl of substrate/chromogen mixture was added to each well. 
 
9. The plate was then incubated at room temperature for 30 minutes. As the 
substrate was photosensitive, the plate was protected from light during this 
incubation. 
 
10. 50µl of stop solution was added to each well. The results were read at 450nm 
(A450) using a BioTek
® Synergy H4 Hybrid Plate Reader. 
 
11. The cut-off value was calculated by taking the mean of the negative control 
values and adding 0.100. 
 
 
5.10: Rapid testing using the CareStart™ Malaria Rapydtest® 
 
 Following the apparent success of Fornaciari et al. (2010) in extracting and detecting 
P. falciparum-specific antigens using commercially-available rapid tests, it was decided to 
subject a selection of samples (Table 5.27) to similar testing in the search for any surviving 
malaria antigens. Two rounds of testing were performed utilising the CareStart™ Malaria 
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Rapydtest® VOM (Apacor), a cassette-type rapid test capable of detecting P. falciparum 
histidine-rich protein-2 (PfHRP2) and non-falciparum lactate dehydrogenase. Analysis 
requires the introduction of 5µl of sample into the sample well, followed by 90µl of assay 
buffer to the buffer well. Results are read in 20 minutes and interpreted following the 
directions in Figure 5.9. Two separate batches of CareStart™ Malaria Rapydtests® were 
required for this analysis. In the second batch of the ‘VOM’ line was replaced with a ‘2’, 
and the ‘Pf’ line was replaced with a ‘1’ (see Figures 5.9 and 5.10 for examples). Both older 
and newer styles of test were identical in function. An example of functioning tests is given 
for reference purposes in Figure 5.10 
 
 
 
Figure 5.9: Interpretation of the CareStart™ Malaria Rapydtest® (Apacor 2013). In the 
newer style of cassette, ‘VOM’ is equivalent to ‘2’, while ‘Pf’ is equivalent to ‘1’. 
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Figure 5.10: Functional CareStart™ Malaria Rapydtests®. Negative results shown 
(photograph by author).   
 
 The first round of testing was performed on samples (Table 5.27) following the 
extraction protocol of Fornaciari et al. (2010):  
1. 50mg of ground bone sample was suspended in 200µl sterile PBS and subjected 
to four 10-second liquid nitrogen freeze thaw cycles. 
 
2. The sample was then incubated for 24 hours at 4°C, before being incubated for 
30 minutes at 37°C. 
 
3. Following centrifugation for 10 minutes at 10,000 rpm, each sample supernatant 
was tested using the CareStart™ Malaria Rapydtest®. 
 
4. Samples are considered positive by the manufacturer if the appropriate lines 
develop within 20 minutes of testing. 
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Sample Type HI 
HP136.1 Adolescent rib 2 
HP154.1 Young adult rib 5 
HP227.2 Young child rib 2 
WM2291.1 Child rib 0 
CD120.2 Very young adult hand phalanx 5 
CD165.1 Child rib 5 
LP3760.1 Juvenile rib 0 
LP3687.1 Young adult rib 1 
LP3819D Very young adult dentine ? 
LP4116.1 Juvenile rib 0 
LP4585.3 Middle adult hand phalanx 2 
EH133.1 Child rib 1 
EH198.1 Very young adult rib 4 
EH584.1 Child rib 0 
OL1100.2 Child cranium 1 
OL1104.2 Young adult hand phalanx 5 
Table 5.27: Samples tested using protein extraction protocol of Fornaciari et al. (2010). HI - 
histological preservation. 
 
The second round of testing was analysed P2.5 samples (Table 5.28) after each the 
three adapted Jiang et al. (2007) extraction stages, along with collagen, and animal bone 
controls. These samples were analysed to see if detectable malaria antigens were released 
during each state of this exhaustive protein extraction protocol. Extracts from P2.5 samples 
(third extraction stage) following TAC were also subjected to rapid testing. Finally, a small 
number of samples (Table 5.28) following each of the three P5 extraction stages were 
selected for rapid testing. 
 
Sample Type HI 
HP154.1 Young adult rib 5 
LP3760.1 Juvenile rib 0 
LP4585.3 Middle adult hand phalanx 2 
OL1104.3 Young adult hand phalanx 5 
LP3819D Very young adult dentine ? 
Table 5.28: P2.5 samples subjected to rapid testing. HI – histological preservation. 
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Sample Type HI 
LP3760.1 Juvenile rib 0 
CD120.2 Very young adult hand phalanx 5 
HPAN5 Animal rib 5 
Table 5.29: P5 samples selected for rapid testing. HI – histological preservation. 
 
 
5.11: Statistical analyses 
 
 Statistical testing was performed on data resulting from the palaeodemographic 
analysis of cemetery reports from Fen/non-Fen populations (sections 4.2.11 and 5.2) in order 
to investigate the hypothesis that the presence of vivax malaria would significantly 
contribute to increased mortality in Fenland environments, and that this increase would be 
reflected in age-at-death mortality ratios. It is this comparison which forms the null 
hypothesis that age at death is independent of population location, where location is the 
dependent nominal variable, and age-at-death category is the independent nominal variable. 
Testing of the hypothesis was achieved by comparing the observed and expected age-at-
death frequencies for archaeological Fen and non-Fen cemetery populations using the chi-
square (χ2) test for independence, with an alpha-level of <0.05 and degrees of freedom (DF) 
dependent upon number of categories. Kolmogorov-Smirnov (K-S) testing was also 
performed to investigate the null hypothesis that there is no significant difference in age-at-
death distributions between Fen and non-Fen populations. K-S testing was chosen due to the 
nonparametric nature of the data and small samples sizes involved.  
 Chi-square independence testing was also performed to investigate the null 
hypothesis that histological preservation of bone samples is independent of the age-at-death 
of the sampled individual. All chi-square analyses were performed using Microsoft Excel, 
while K-S analyses were performed using the PAST (Paleontological Statistics) software 
package (Hammer et al., 2001).   
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CHAPTER 6: RESULTS 
 
 This chapter presents the results of analyses described in Chapter 5 concerning the 
presence of Plasmodium vivax malaria in the past British Fenlands. First to be presented are 
the results of the analysis of published osteological reports aimed at identifying thalassaemia 
sequelae in archaeological populations from potentially malarious areas. Results of the 
demographic analyses of selected Fen and non-Fen cemetery populations are shown, 
followed by the histological testing of bone samples selected for biomolecular analysis. 
Outcomes of the five protocols (P1 to P5) aimed at extracting immunoglobulin G (IgG) from 
archaeological human bone are then described, followed by a brief investigation of the 
histological preservation and post-thiophilic adsorption chromatography (TAC) protein 
yields. Finally, the results of the malaria EIA and rapid testing are presented.  
 
6.1: Identification of thalassaemia sequelae in skeletal reports 
 
 The results of the analysis of published osteological reports, each of which was 
examined in the light of the recently suggested skeletal sequelae of thalassaemia discussed 
in section 5.1, are presented here. The selected reports represent the sites outlined in section 
5.3. The significance of the findings in terms of possible thalassaemia is discussed in section 
7.1.  
 The identification of potentially unrecognised or misdiagnosed cases of thalassaemia 
in archaeological and palaeopathological reports is highly dependent upon the quality and 
detail of the original analysis of the skeletal material. In a number of cases, reports consisted 
of brief communications on the main pathologies encountered within populations, with very 
limited detail on individual skeletons (e.g., the Durobrivae and Baston reports). The limited 
pathological descriptions of skeletal individuals from these sites may be the result of a 
number of factors. Firstly, and as mentioned in section 4.2.8, the pressures of osteological 
analysis in a developer-funded setting may result in a short skeletal analysis included within 
a larger site report, with the intention of providing an in-depth report (often depending upon 
funding, which may not materialise) at a later date. This seems to have been the case for 
some sites in which the cemetery is not necessarily the primary focus of excavation, such as 
Durobrivae and The Parks, Godmanchester. In instances where the cemetery is the primary 
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focus, palaeopathological analyses are usually more thoroughly reported. It is these reports 
of larger cemetery sites that provided sufficient pathological detail at the individual level to 
be able to identify sequelae of interest. It is no surprise, therefore, that the majority of 
skeletons displaying pathologies consistent with possible thalassaemia (listed in Table 6.1) 
were encountered in these larger sites. These sites comprised The Hoplands, Castledyke 
South, and Highfield Farm, Littleport. It may also be the case that larger cemetery sites are 
usually analysed by highly experienced palaeopathologists, who are likely to recognise 
potential indicators of putative thalassaemia and perform additional diagnostic 
investigations, such as radiography (e.g., see Figure 6.2).  
 The level of detail of pathological analyses is, of course, dependent upon skeletal 
preservation. At certain sites, such as Watersmeet, Huntingdon and Westfield Farm, Ely, 
taphonomic processes and post-depositional disturbance resulted in fragmentation and poor 
survival of many inhumed individuals (Nicholson 2006; Lucy 2007a). Such preservation 
would hinder any diagnosis of thalassaemia, since many of the ‘specific’ sequelae 
highlighted in Table 5.1 affect elements that are inherently fragile (e.g., facial bones and 
ribs). Pathologies affecting the ribs (e.g., cortical erosion and multiple healed fractures) or 
that result in structural weakening of the bone may be difficult to distinguish in highly 
fragmented skeletal material. 
 Table 6.1 shows the possible thalassaemia sequelae identified and which sites 
yielded individuals presenting with one or more of these changes. Littleport skeleton 3760, 
an individual of approximately 8-12 years, was the only one to display more than one 
sequela (porotic hyperostosis and associated ‘hair-on-end’ appearance of the diploë). This 
individual was, therefore, subjected to further macroscopic and radiographic analysis 
(section 6.1.4). The majority of sequelae were encountered in Anglo-Saxon populations, 
which likely reflects the bias towards this time period in site selection. 
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The Parks, Godmanchester Rom 37         X 
Edix Hill A-S 198 ?         
Highfield Farm, Littleport 
A-S 3479         X 
  3745       X   
  3760 X   X     
  4095       X   
  4858       X   
L
in
co
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sh
ir
e 
Castledyke South, Barton-
upon-Humber 
A-S 15         X 
  49         X 
  73         X 
  75         X 
The Hoplands, Sleaford 
Rom 46       X   
  59         X 
  63         X 
  96       X   
  117         X 
  128         X 
  164         X 
  168         X 
  202         X 
  211   X       
Table 6.1: Summary table of sites and skeletal individuals displaying possible thalassaemia 
sequelae. Those in bold are cited as being more specific for thalassaemia (after Hershkovitz 
et al., 1997; Ortner, 2003; Lagia et al., 2007; Lewis, 2010; Yochum and Rowe, 2005; 
Perisano et al. 2012). Rom – Roman, A-S – Anglo-Saxon. 
 
  
6.1.1: Porotic hyperostosis 
 One skeleton (SK3760) from the Littleport site (Table 6.1) displayed cranial lesions 
consistent with porotic hyperostosis (Figure 6.1), with radiographic analysis confirming the 
characteristic ‘hair-on-end’ arrangement within the diploë (Figure 6.2). Skeleton 198 from 
Edix Hill (Table 6.1) also displayed cranial lesions suggestive of porotic hyperostosis, but 
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radiographic analysis conducted at the time of reporting proved inconclusive (Duhig 1998). 
Unfortunately, the burial catalogue was not sufficiently detailed to provide any further 
relevant pathological description for this individual, and the individual was unavailable for 
further study due to archive relocation. One prevalence of thickening of the cranial diploë 
was reported in the Hoplands population (Western, 2011), but no additional suggestive 
sequelae were reported in this individual.  
 
 
Figure 6.1: Porotic hyperostosis of the left parietal bone from Littleport individual 
SK3760 (photograph reproduced with permission of G. Western). 
 
 
Figure 6.2: Littleport skeleton 3760 left parietal radiograph showing distinctive diploë ‘hair-
on-end’ appearance (reproduced with permission of G. Western. Image taken by Mark 
Farmer on behalf of Reveal Imaging Ltd). 
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6.1.2: Multiple rib fractures 
 
Multiple rib fractures in individuals were the most frequently encountered 
‘thalassaemia’ sequela listed in Table 5.1. This is perhaps unsurprising, given that rib 
fractures are one of the most frequently reported traumatic lesions in the palaeopathological 
literature (Brickley, 2006). It has been argued that since rib fractures are so commonly 
observed, they are “rarely included in studies investigating trauma in past societies” 
(Brickley 2006:62). This may explain why most of the reports selected for this study failed 
to provide details of rib fractures affecting individual skeletons, instead offering population-
wide prevalence rates.  
6.1.3: Scoliosis 
 Scoliosis was reported in three individuals from Littleport and two from the 
Hoplands, Sleaford site (Table 6.1). Idiopathic scoliosis has a reported prevalence rate of 
5.2% in modern populations (Konieczny et al., 2013). Up to 40% of thalassaemic 
individuals develop non-idiopathic scoliosis (Taher et al., 2006), but the morphological 
difference between the two is very difficult to identify in archaeological skeletons, 
particularly if the vertebrae are poorly preserved. A differential diagnosis of thalassaemic 
scoliosis would rely on the presence of supportive sequelae within individuals. As 
preservation and careful analysis of each element are key to diagnosis, the condition may 
sometime be under-represented in archaeological populations. 
6.1.4: Further analysis of Littleport skeleton 3760 
 In response to the combination of skeletal sequelae suggestive of possible 
thalassaemia (Table 6.1), Littleport individual 3760 was acquired for further macroscopic 
and radiographic analysis. The latter was based on the macroscopic appearance of the extant 
elements, and with reference to the diagnostic radiography performed by Lewis (2010) on 
the Poundbury sub-adults. The skeleton was very fragmentary (less than 25% complete), 
which precluded observation of a number of criteria listed in Table 5.1 (e.g., no facial bones 
and very few vertebrae). Extant elements showed no macroscopically observable changes 
suggestive of thalassaemia. However, a selection of the fragmentary ribs was radiographed 
in order to compare to Lewis’ observed ‘rib-within-a-rib’ pathology. No evidence of this 
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was observed (Figure 6.3). None of the ribs showed macroscopic evidence of fractures, 
calluses, or cortical erosion beyond that usually associated with post-depositional damage. 
 
Figure 6.3: Radiograph of rib fragments from Littleport skeleton 3760 (radiograph by 
author). 
 
6.2: Demographic analysis of Fen and non-Fen cemetery populations 
The following presents the results from the demographic analysis of cemetery 
populations from Fen/non-Fen sites, as discussed in section 5.2. The age categories are 
defined in Table 6.2.  
 
 
 
 
 
 
 
220 
 
Foetal/neonate <1 month 
Infant 1-12 months 
Child 1-6 years 
Juvenile 7-12 years 
Adolescent 13-17 years 
Very young adult 18-24 years 
Young adult 25-34 years 
Middle adult 35-49 years 
Old adult 50+ years 
Adult 18+ 
Table 6.2: Age category definition for demographic analysis. 
 
 
6.2.1: The sites and their individuals 
 
The Fen and non-Fen sites selected for this demographic study and their respective 
number of individuals (separated into the age categories shown in Table 6.2) are presented 
in summary Tables 6.3 and 6.4. Full tables (A2.1 and A2.2) for these data are shown in 
Appendix 2.  
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          M/F M/F M/F M/F M/F   
Roman 4 3 15 18 9 2/5 17/17 18/17 18/18 5/7 173 
Anglo-Saxon 22 138 202 158 94 84/117 182/179 144/115 189/131 172/142 2069 
Medieval 25 128 136 126 63 28/38 80/62 43/16 84/44 120/177 1170 
Total 51 269 353 302 166 114/160 279/258 205/148 291/193 297/326 3412 
Table 6.3: Numbers of individuals from combined Fen sites. M/F – Males/Females. 
 
  
<
 1
 m
o
n
th
 
1
-1
2
 
m
o
n
th
s 
1
-6
 y
ea
rs
 
7
-1
2
 y
ea
rs
 
1
3
-1
7
 
y
ea
rs
 
1
8
-2
4
 
y
ea
rs
 
2
5
-3
4
 
y
ea
rs
 
3
5
-4
9
 
y
ea
rs
 
5
0
+
 
A
d
u
lt
 1
8
+
 
T
o
ta
l 
  
          
M/F M/F M/F M/F M/F   
Roman 89 32 67 50 17 20/27 59/48 71/49 53/36 45/41 704 
Anglo-Saxon 26 66 140 111 100 101/122 138/120 89/92 89/42 76/73 1385 
Medieval 51 61 157 71 42 44/30 41/27 36/33 91/50 86/39 859 
Total 166 159 364 232 159 165/179 238/195 196/174 233/128 207/153 2948 
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Table 6.4: Numbers of individuals from combined non-Fen sites. M/F – Males/Females. 
 
6.2.2: Mortality, survivorship, and probability of death 
 The data presented in Tables 6.3 and 6.4 were used to construct period-specific and 
total Fen and non-Fen mortality profiles, survivorship curves, and probability of death 
curves. The aim was to investigate differences in cemetery demographics between locations 
in order to address the question of whether such differences might support the presence of 
vivax malaria in the Fens in antiquity. Where appropriate, chi square (χ2) tests of 
independence were conducted for total Fen/non-Fen samples to test the null hypothesis that 
age-at-death is independent of Fen/non-Fen location. Kolmogorov-Smirnov (K-S) tests were 
also applied to investigate differences in Fen/non-Fen populations in terms of age-at-death 
distributions. Table 6.5 summarises the results of these tests. The demographics are first 
addressed by period, then by overall picture of total Fen/non-Fen mortality, survivorship, 
and probability of death. Given the vast quantity of information presented from these data, 
the most useful and potentially enlightening trends are emphasised here (in terms of how 
they may relate to health and the presence of putative vivax malaria). These are then 
discussed in section 7.1.2, 7.1.3, and 7.1.4. The limitations of such palaeodemographic 
analyses are addressed in section 7.1.5. 
 Mortality profiles (in the form of population percentages) for each period are 
presented for the total excavated skeletal populations in all age categories. The aged adults 
are then separated by sex in order investigate possible differential mortality based on sex. 
Survivorship (lx) and probability of death (qx) curves were calculated following the 
construction of basic life tables (after Chamberlain, 2006) based upon the raw data presented 
in Tables 6.3 and 6.4. Both types of analysis require a zero start point, so they must assume 
that all individuals are alive at birth. Survivorship curves also assume a constant decline in 
numbers between 50 and 100 years, since the final age category is 50+ and it is highly 
unlikely that a significant quantity of individuals in antiquity would live beyond 100. Both 
types also assume that populations are relatively stable in terms of fertility and mortality 
rates, a situation more likely to be encountered in pre-modern populations as instability 
“associated with demographic transitions appear to be a recent historical phenomenon” 
(Chamberlain, 2006:27). 
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6.2.2(i): The Roman period 
 Figure 6.4 suggests that overall age-at-death in the Roman period was significantly 
affected by location (χ2 p<0.01), although the significance is lost when comparing aged 
adults (Figure 6.5). K-S testing showed significance (p<0.01) for total population and aged 
adults (Figures 6.4 and 6.5). K-S testing was also performed omitting the <1 age category, 
since the Roman Fen sample is severely lacking in individuals of this age. Significance 
(p<0.01) remained the same, however. It is important to note the low Fen sample numbers 
due to the lack of excavated Roman Fen cemetery sites (Table 6.3), and the subsequent 
disparity between Fen and non-Fen sample numbers. The impact of very low numbers of 
Fen infants (<1 year old) can be been seen in Figures 6.6 and 6.7 (survivorship) and 6.8 
(probability of death), which assume that low numbers equates to low mortality. The overall 
disparity in population numbers may indeed account for the observed difference in 
survivorship between Fen and non-Fen (Figures 6.6, 6.7, and 6.9). Roman adult male and 
female mortality, survivorship, and probability of death are shown in Figures 6.5, 6.7, and 
6.7). 
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Figure 6.4: Roman Fen/non-Fen mortality profile. χ2 p= <0.01. K-S p = <0.01. Omitting <1 
category: K-S p = <0.01. n – 161 Fen, 618 non-Fen. 
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Figure 6.5: Roman male and female Fen and non-Fen mortality profile. χ2 p = 0.07. n – 55 
Fen males, 203 non-Fen males – K-S p = 0.01; 57 Fen females, 160 non-Fen females – K-S 
p = 0.01. 
225 
 
 
Figure 6.6: Roman Fen and non-Fen survivorship (lx). n – 161 Fen, 618 non-Fen. 
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Figure 6.7: Roman male and female Fen and non-Fen survivorship (lx). n – 55 Fen males, 
203 non-Fen males; 57 Fen females, 160 non-Fen females. 
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Figure 6.8: Roman Fen and non-Fen probability of death (qx). n – 162 Fen, 618 non-Fen. 
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Figure 6.9: Roman male and female Fen and non-Fen probability of death (qx). n – 55 Fen 
males, 203 non-Fen males; 57 Fen females, 160 non-Fen females. 
 
 
6.2.2(ii): The Anglo-Saxon period 
 
 The Anglo-Saxon period is represented by the largest numbers of both Fen and non-
Fen individuals (1755 and 1236 aged individuals, respectively). As with the Roman period, 
there is a correlation (χ2, p <0.01) between location and age-at-death (Figure 6.10). 
Conversely, no significance in terms of age-at-death distribution (K-S, p = 0.42) is observed 
for the Anglo-Saxon period. The relatively low numbers in the <1 year category reflects a 
general dearth of infant burials in the Anglo-Saxon period (discussed in Section 7.1.5), 
rather than being an artefact of overall low numbers such as was encountered in the Fen 
Roman sample. This period-specific trend can clearly be seen in Figures 6.10, 6.11, and 
6.15, particularly when compared to the corresponding medieval data (Figure 6.17, 6.18, 
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6.23, and 6.24). Note the relatively high mortality rates for non-Fen females aged 18-24, 
compared to their Fen counterparts (Figure 6.12). It is interesting to note that while non-Fen 
females seem to have been at particular risk of premature death (as further evidenced in 
Figures 6.14 and 6.16), Fen males display the opposite trend. 
 
 
Figure 6.10: Total Anglo-Saxon Fen and non-Fen mortality profile. χ2, p <0.01. K-S, p = 
0.42. n = 1755 Fen, 1236 non-Fen. 
 
 Figure 6.11 compares Fen and non-Fen mortality in the Anglo-Saxon period when 
the St. Peter’s Barton-upon-Humber sample is removed from the Fen population set (the 
total Fen population is included in the graph for comparison purposes). Since this sample 
accounts for 56% of the Anglo-Saxon aged Fen population, it is important to investigate any 
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skewing effect that this site has on the overall picture of Anglo-Saxon Fen mortality. The 
significance of location remains the same (χ2 p <0.01) with the St. Peter’s sample removed, 
although the K-S testing showed no significant difference (K-S p = 0.93) in age-at-death 
distribution between Fen (St. Peter’s sample removed) and non-Fen sites. A main point of 
interest here is a trend towards a larger numbers of adults (particularly in the 35-49 year 
category) in the St. Peter’s sample, perhaps suggesting that more people at this site lived into 
older age, or that younger individuals are less well represented at this cemetery. These data 
are discussed further in Section 7.1.3. 
 
 
Figure 6.11: Anglo-Saxon Fen/non-Fen mortality profiles with St. Peter’s sample removed. 
χ2, p <0.01. K-S, p = 0.93. n – 1328 Fen, 1385 non-Fen. 
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Figure 6.12: Anglo-Saxon male and female Fen and non-Fen mortality profile. χ2, p <0.01. 
n = 599 Fen males, 417 non-Fen males – K-S, p = 0.11; 542 Fen females, 376 non-Fen 
females – K-S, p = 0.53. 
232 
 
 
Figure 6.13: Anglo-Saxon Fen and non-Fen survivorship (lx). n – 1755 Fen, 1236 non-Fen. 
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Figure 6.14: Anglo-Saxon male and female Fen and non-Fen survivorship (lx). n – 599 Fen 
males, 417 non-Fen males; 542 Fen females, 376 non-Fen females. 
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Figure 6.15: Anglo-Saxon probability of death (qx). n – 1755 Fen, 1236 non-Fen. 
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Figure 6.16: Anglo-Saxon male and female Fen and non-Fen probability of death (qx). n – 
599 Fen males, 417 non-Fen males; 542 Fen females, 376 non-Fen females. 
 
 
6.2.2(iii): The medieval period 
 
 The Fen and non-Fen medieval samples are dominated by two large cemetery 
populations: St. Peter’s (Barton-upon-Humber) and Wharram Percy account for 73% and 
75% of the medieval Fen and non-Fen samples, respectively. It was important to investigate 
any skewing effect that the two largest sample might have on the tests. Consequently, the 
same statistical tests were run after removing these sites. Chi-square suggests location to be 
a significant (p<0.01) factor in age-at-death, before (Figure 6.17) and after (Figure 6.18) 
removal of these sites. Prior to removal, K-S testing shows no significance (p=0.52) in age-
at-death distribution between Fen and non-Fen. However, this reverses upon removal of the 
two largest sites, with significance emerging (p<0.01).  
 Figure 6.17 shows high infant (<1 year old) mortality at both St. Peter’s and 
Wharram Percy, with a subsequent reduction in the number of people surviving to 
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adulthood. These figures drop quite dramatically when the sites are removed (Figure 6.18). 
The peak in childhood mortality at Wharram Percy is followed by a subsequent reduction in 
the number of people surviving to adulthood. This skewing effect is evident in Figures 6.17, 
6.19, and 6.23, which show lower-than-expected percentages of aged adults. The non-Fen 
mortality profile following the removal of the Wharram Percy sample may be more 
representative of a ‘normal’ medieval non-Fen profile, particularly as concerns the effects of 
high childhood mortality on subsequent age category representation. 
 
 
Figure 6.17: Total medieval Fen and non-Fen mortality profile. χ2, p <0.01. K-S, p = 0.52. 
n = 873 Fen, 834 non-Fen. 
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Figure 6.18: Medieval Fen and non-Fen mortality profile with St. Peter’s and Wharram 
Percy samples removed. χ2, p <0.01. K-S, p <0.01. n = 321 Fen, 214 non-Fen. 
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Figure 6.19: Medieval male and female Fen and non-Fen mortality profile. χ2, p <0.01. K-S, 
p = 0.53. n = 235 Fen males, 212 non-Fen males – K-S, p = 0.10; 160 Fen females, 140 non-
Fen females – K-S, p = 0.53.   
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Figure 6.20: Total medieval Fen and non-Fen survivorship (lx). n = 873 Fen, 734 non-Fen. 
240 
 
 
Figure 6.21: Medieval Fen and non-Fen survivorship (lx) with St. Peter’s and Wharram 
Percy samples removed. n = 235 Fen, 142 non-Fen. 
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Figure 6.22: Medieval male and female Fen and non-Fen survivorship (lx). n = 235 Fen 
males, 212 non-Fen males; 160 Fen females, 140 non-Fen females. 
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Figure 6.23: Total medieval Fen and non-Fen probability of death (qx). n = 873 Fen, 734 
non-Fen. 
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Figure 6.24: Medieval Fen and non-Fen probability of death (qx) with St. Peter’s and 
Wharram Percy samples removed. n = 235 Fen, 142 non-Fen. 
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Figure 6.25: Medieval male and female Fen and non-Fen probability of death (qx). n = 235 
Fen males, 212 non-Fen males; 160 Fen females, 140 non-Fen females. 
 
 
6.2.2(iv): Total demographics 
 
 Figures 6.26-6.31 present the mortality, survivorship, and probability of death data 
for all periods combined. This is followed by Table 6.5, which summarises the results of 
statistical testing for all periods. Testing of total mortality data (Figure 6.26) shows that 
while location has a significant impact upon age-at-death (χ2 p <0.01), there is no significant 
difference between Fen and non-Fen age-at-death distributions (K-S p = 0.89). In terms of 
general observed trends in mortality, infant mortality (<1 year old) is lower than expected, 
but this may be an artefact of low Roman and Anglo-Saxon skeletal numbers (addressed in 
Section 7.1.5), or the small interval of age category in comparison to subsequent categories. 
Figure 6.26 shows that the lowest mortality occurred in the adolescent age category (13- 17 
years), and peaked in the young adult category (25-34 years). Figures 6.27 and 6.29 suggest 
that Fen and non-Fen males tended to live longer than their female counterparts, although 
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the adult age-at-death distribution does not display a significant difference (Figure 6.27). 
The poor outlook for non-Fen Roman and Anglo-Saxon females (Figures 6.9 and 6.16) is 
reflected in the survivorship (Figures 6.28 and 6.29) and probability of death (Figures 6.30 
and 6.31) charts.  
 
 
Figure 6.26: Total Fen and non-Fen populations by percentage of buried individuals in each 
age category. χ2, p <0.01. K-S, p = 0.93. Omitting <1 category: K-S, p = 0.89. n = 2789 Fen, 
2588 non-Fen. 
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Figure 6.27: Total male and female Fen and non-Fen mortality profile. χ2, p <0.01. n = 889 
Fen males, 832 non-Fen males - K-S, p = 0.53; 759 Fen females, 676 non-Fen females – K-
S, p = 0.10. 
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Figure 6.28: Total Fen and non-Fen survivorship (lx). n = 2789 Fen, 2588 non-Fen. 
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Figure 6.29: Total male and female Fen and non-Fen survivorship (lx). n = 1648 Fen males, 
832 non-Fen males; 1508 Fen females, 676 non-Fen females. 
 
249 
 
 
Figure 6.30: Total Fen and non-Fen probability of death (qx). n = 2789 Fen, 2588 non-Fen. 
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Figure 6.31: Total male and female Fen and non-Fen probability of death (qx). n = 1648 Fen 
males, 832 non-Fen males; 1508 Fen females, 676 non-Fen females. 
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Fen/non-Fen mortality 
data 
Figure 
Chi-square (a = 0.05) Kolmogorov-Smirnov (a = 0.05) 
Reject H0? Reject H0? 
Roman total 6.4 Yes Yes 
Roman males 6.5 No Yes 
Roman females 6.5 No Yes 
Anglo-Saxon total 6.10 Yes No 
Anglo-Saxon total with 
St. Peter's removed 
6.11 Yes No 
Anglo-Saxon males 6.12 Yes No 
Anglo-Saxon females 6.12 Yes No 
Medieval total 6.17 Yes No 
Medieval total with St. 
Peter's and Wharram 
Percy removed 
6.18 Yes Yes 
Medieval males 6.19 Yes No 
Medieval females 6.19 Yes No 
Total 6.26 Yes No 
Total males 6.27 Yes No 
Total females 6.27 Yes No 
Table 6.5: Summary of statistical test results on mortality profiles. H0 = null hypothesis. 
 
 
6.3: Histological analysis 
 
 Summary tables for histological analysis results are presented firstly for the control 
samples (Table 6.6) and then by period and site in Tables 6.8-6.22. Table 6.7 presents a key 
to the age category abbreviations employed in Tables 6.8-6.22. Sample percentages in each 
histological index (HI) category are included in each table to provide a summary of overall 
element preservation at each site. Summary tables for all Roman (Table 6.13) and Anglo-
Saxon (Table 6.21) data are also included for ease of comparison. The raw data for all 
summary tables are presented in Appendix 2 (Tables A2.3 to A2.16).  
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HI 0 1 2 3 4 5 
Type             
Adult rib 0 0 0 1 3 4 
Adult cranium 2 1 1 1 0 0 
Adult phalanx 0 0 1 1 0 3 
Sub-adult rib 0 1 2 0 0 0 
Sub-adult cranium 0 2 0 0 0 0 
Animal rib 1 0 0 1 2 4 
Table 6.6: Control samples in each HI category, by element type. 
 
 
Title Abbreviation Age 
Child CH 1-6 years 
Juvenile JU 7-12 years 
Adolescent AD 13-17 years 
Very young adult VYA 18-24 years 
Young adult YA 25-34 years 
Middle adult MA 35-49 years 
Old adult OA 50+ years 
Adult A 18+ years 
Table 6.7: Key to age category abbreviations used in summary Tables 6.8-6.20.  
 
 
6.3.1: Roman sites 
 
 Tables 6.8 to 6.12 display the types of element selected from each age category, and 
the histological preservation of selected samples from the Roman sites. The larger sample 
sets (e.g., The Parks, Godmanchester, The Hoplands, and Watersmeet) likely offer the best 
representations of Roman Fen histological preservation. These sites (Tables 6.9, 6.10, and 
6.12) show similar patterns in preservation levels, with the majority of samples scoring 
below 2 on the HI. This is confirmed by summary Table 6.13.  
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  HI 0 1 2 3 4 5 
Age Type             
CH Rib 0 0 2 0 0 0 
AD Rib 0 0 1 0 0 0 
AD Cranium 1 0 0 0 0 0 
VYA Rib 0 0 0 1 1 0 
MA 
Rib 0 0 0 1 0 0 
Cranium 0 0 1 0 0 0 
- Animal rib 1 0 1 0 0 0 
  
  
Total 2 0 5 2 1 0 
% of Total 20 0 50 20 10 0 
Table 6.8: Samples from the Durobrivae site in each HI category, by age and element type. 
 
 
  HI 0 1 2 3 4 5 
Age Type             
CH 
Rib 1 1 0 0 0 0 
Cranium 2 0 0 0 0 0 
JU 
Rib 3 1 4 0 0 0 
Cranium 0 0 1 0 0 0 
Hand phalanx 3 1 0 0 0 0 
AD Cranium 0 0 0 0 1 0 
VYA 
Rib 3 0 0 1 0 0 
Cranium 3 1 0 0 0 0 
Hand phalanx 1 0 0 0 0 1 
- Animal rib 2 1 1 0 0 0 
  
  
Total 18 5 6 1 1 1 
% of Total 56 16 19 3 3 3 
Table 6.9: Samples from The Parks, Godmanchester site in each HI category, by age and 
element type. 
 
 
 
 
 
 
 
 
 
 
 
 
254 
 
  HI 0 1 2 3 4 5 
Age Type             
CH Rib 2 0 1 1 1 0 
AD 
Rib 1 1 1 0 0 0 
Foot phalanx 0 0 0 0 1 0 
Hand phalanx 0 3 0 0 1 0 
VYA 
Rib 1 0 0 0 0 0 
Foot phalanx 0 1 0 0 0 0 
Hand phalanx 0 1 0 0 0 0 
YA 
Rib 3 0 1 0 0 1 
Foot phalanx 2 0 0 0 0 1 
Hand phalanx 0 0 0 0 0 2 
-  Animal rib 1 2 0 1 0 5 
  
  
Total 10 8 3 2 3 9 
% of Total 29 23 9 6 9 26 
Table 6.10: Samples from The Hoplands site in each HI category, by age and element type.  
 
 
  HI 0 1 2 3 4 5 
Age Type             
YA 
Rib 0 0 0 1 1 0 
Hand phalanx 0 0 0 0 0 1 
  
Total 0 0 0 1 1 1 
% of Total 0 0 0 33 33 33 
Table 6.11: Samples from the Prickwillow Road, Ely site in each HI category, by age and 
element type. 
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  HI 0 1 2 3 4 5 
Age Type             
CH Rib 2 2 0 0 0 0 
JU 
Rib 1 0 0 1 0 0 
Cranium 0 0 1 0 0 0 
Foot phalanx 1 0 0 0 0 0 
AD 
Rib 0 0 1 0 0 0 
Foot phalanx 0 0 0 0 0 1 
YA 
Rib 2 0 0 2 0 0 
Cranium 1 0 0 0 0 0 
Hand phalanx 1 0 0 0 0 2 
  Animal rib 2 0 1 0 0 0 
  
Total 11 2 3 3 1 3 
% of Total 48 9 13 13 4 13 
Table 6.12: Samples from the Watersmeet, Huntingdon site in each category, by age and 
element type. 
 
 
HI 0 1 2 3 4 5 
Type             
Rib 20 5 11 8 4 1 
Cranium 7 1 3 0 1 0 
Foot phalanx 3 1 0 0 1 2 
Hand phalanx 5 5 0 0 1 6 
Total 35 12 14 8 7 9 
% of total 41 14 16 9 8 11 
Table 6.13: Summary of element histological preservation from Roman sites (human 
samples). 
 
 
6.3.2: Anglo-Saxon sites 
 
 Tables 6.14 to 6.20 show the element types selected from each age category, and the 
histological preservation of selected samples from the Anglo-Saxon sites. As with the 
Roman sites, the trend in preservation is towards the lower HI categories, although there is 
greater variation between sites. For example, Castledyke South (Table 6.15) and Edix Hill 
(Table 6.17) display a greater proportion of well-preserved samples levels than Cleatham 
(Table 6.16) and Littleport (Table 6.19), which are generally poorly preserved. However, as 
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seen with the Roman samples, overall preservation (Table 6.21) is heavily weighted towards 
the lower HI categories. 
 
  HI 0 1 2 3 4 5 
Age Type             
VYA 
Rib 0 1 0 0 0 0 
Hand phalanx 0 0 1 0 0 0 
  Animal rib 1 2 0 0 0 0 
  
Total 1 3 1 0 0 0 
% of Total 20 60 20 0 0 0 
Table 6.14: Samples from the Baston site in each HI category, by age and element type. 
 
 
  HI 0 1 2 3 4 5 
Age Type             
CH 
Rib 2 0 1 1 0 1 
Cranium 2 1 0 1 1 0 
JU 
Rib 1 2 0 1 1 0 
Cranium 2 2 0 1 0 0 
Foot phalanx 0 0 1 0 0 0 
AD 
Rib 0 0 1 1 0 0 
Cranium 0 0 0 1 1 0 
Hand phalanx 0 0 0 0 0 1 
VYA 
Rib 2 5 3 0 2 0 
Cranium 3 2 0 1 1 1 
Foot phalanx 2 1 0 0 0 0 
Hand phalanx 0 0 1 0 0 1 
 - Animal rib 4 0 1 0 0 0 
  
Total 18 13 8 7 6 4 
% of Total 32 23 14 13 11 7 
Table 6.15: Samples from the Castledyke South, Barton-upon-Humber site in each HI 
category, by age and element type. 
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  HI 0 1 2 3 4 5 
Age Type             
CH Cranium 0 0 0 1 0 0 
JU Cranium 1 0 0 0 0 0 
AD 
Rib 3 1 0 0 0 0 
Cranium 1 3 0 0 0 0 
Hand phalanx 2 1 0 0 0 0 
YA 
Rib 2 1 0 0 1 0 
Cranium 3 1 0 0 0 0 
  
Total 12 7 0 1 1 0 
% of Total 57 33 0 5 5 0 
Table 6.16: Samples from the Cleatham site in each HI category, by age and element type. 
 
 
  HI 0 1 2 3 4 5 
Age Type             
CH 
Rib 1 1 0 0 0 0 
Cranium 1 0 1 0 0 0 
JU 
Rib 0 0 0 2 0 0 
Cranium 1 0 0 0 1 0 
Hand phalanx 0 1 0 0 0 0 
AD Cranium 0 0 1 0 0 0 
  Hand phalanx 0 0 0 1 0 0 
VYA 
Rib 2 0 0 0 1 0 
Cranium 0 0 1 1 0 0 
Foot phalanx 0 2 0 0 1 0 
Hand phalanx 0 0 0 0 1 0 
YA 
Rib 1 0 0 1 0 0 
Cranium 0 0 0 0 0 1 
Foot phalanx 1 0 0 0 0 0 
Hand phalanx 0 0 1 0 0 0 
  Animal rib 1 0 1 0 0 0 
  
Total 8 4 5 5 4 1 
% of Total 30 15 19 19 15 4 
Table 6.17: Samples from the Edix Hill site in each HI category, by age and element type. 
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  HI 0 1 2 3 4 5 
Age Type             
? 
Rib 0 0 0 0 1 0 
Cranium 1 0 0 0 0 0 
  
Total 1 0 0 0 1 0 
% of Total 50 0 0 0 50 0 
Table 6.18: Samples from the Haddenham site in each HI category, by age and element type. 
 
 
  HI 0 1 2 3 4 5 
Age Type             
CH 
Rib 3 0 0 0 0 0 
Cranium 3 1 1 0 0 0 
AD 
Rib 5 1 1 0 0 0 
Cranium 4 2 1 0 0 0 
Foot phalanx 1 0 2 0 0 0 
JU 
Rib 5 1 0 0 0 0 
Cranium 5 0 0 0 0 0 
Foot phalanx 0 1 0 0 0 0 
Hand phalanx 0 1 0 0 0 0 
YA 
Rib 3 3 0 0 0 0 
Cranium 1 3 0 0 0 0 
Foot phalanx 1 0 3 0 0 0 
Hand phalanx 1 0 0 1 0 0 
MA 
Rib 1 1 1 0 0 0 
Cranium 2 1 0 0 0 0 
Foot phalanx 0 0 0 1 0 0 
Hand phalanx 1 0 1 0 0 0 
A 
Rib 1 0 0 0 0 0 
Cranium 0 0 1 0 0 0 
Hand phalanx 1 0 0 0 0 0 
  Animal rib 0 0 0 2 0 0 
  
Total 38 15 11 4 0 0 
% of Total 56 22 16 6 0 0 
Table 6.19: Samples from the Littleport site in each HI category, by age and element type. 
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  HI 0 1 2 3 4 5 
Age Type             
CH Rib 2 1 0 0 0 0 
JU Rib 1 1 0 0 0 0 
AD 
Rib 0 1 0 0 0 0 
Foot phalanx 0 0 2 0 0 0 
YA 
Rib 0 0 1 0 0 0 
Hand phalanx 0 1 0 0 0 0 
  
Total 3 4 3 0 0 0 
% of Total 30 40 30 0 0 0 
Table 6.20: Samples from the Westfield Farm, Ely site in each HI category, by age and 
element type. 
 
 
HI 0 1 2 3 4 5 
Type             
Rib 35 20 8 6 6 1 
Cranium 30 16 6 6 4 2 
Foot phalanx 5 4 8 1 1 0 
Hand phalanx 5 4 4 2 1 2 
Total 75 44 26 15 12 5 
% of total 42 25 15 8 7 3 
Table 6.21: Summary of element histological preservation from Anglo-Saxon sites (human 
samples). 
 
 
6.3.3: Medieval site 
 
 Table 6.22 shows results of the histological analysis of the Orchard Lane, 
Huntingdon. The pattern of preservation is similar to that seen in the earlier Roman and 
Anglo-Saxon periods, with poorer preserved samples dominating. 
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  HI 0 1 2 3 4 5 
Age Type             
CH 
Rib 1 1 0 0 0 0 
Cranium 0 2 0 0 0 0 
JU 
Rib 0 0 0 0 1 0 
Cranium 0 1 0 0 0 0 
Hand phalanx 0 1 0 0 0 1 
AD Rib 1 0 0 0 0 0 
  Hand phalanx 0 0 0 0 1 0 
VYA 
Rib 2 0 0 0 0 0 
Cranium 2 0 0 0 0 0 
Hand phalanx 0 1 0 0 0 0 
YA 
Rib 0 0 1 0 0 0 
Cranium 0 1 0 0 0 0 
Hand phalanx 0 0 0 0 0 1 
  Animal rib 0 0 2 0 0 0 
  
Total 6 7 3 0 2 2 
% of Total 30 35 15 0 10 10 
Table 6.22: Samples from the Orchard Lane, Huntingdon site in each HI category, by age 
and element type. 
 
 
6.3.4: Summary analysis 
 
 Figure 6.32 demonstrates the trend towards poor preservation as observed in the 
summary tables presented above. Table 6.23 and Figure 6.33 suggest differential 
preservation between element types, with ribs and cranial samples tending towards poorer 
microscopic preservation. This is discussed further in Section 7.2. 
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Figure 6.32: Percentage of bone samples in each category of histological preservation. 
 
 
HI Rib Cranium Hand Phalanx Foot Phalanx 
0 54 50 28 28 
1 18 24 23 25 
2 6 10 13 32 
3 12 6 8 4 
4 8 8 8 4 
5 2 2 20 7 
Table 6.23: Percentages of bone types in each HI category. 
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Figure 6.33: Percentage of bone elements in each HI category. 
 
 Figure 6.34 compares overall histological preservation between the Roman and 
Anglo-Saxon sites. The medieval site was omitted here due to limited sample size. The χ2 
test (p<0.01) rejects the null hypothesis that histological preservation is independent of 
period. 
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Figure 6.34: Element percentage in each HI category by period. χ2, p <0.01. 
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Figure 6.35: Element percentage in each HI category by age group (see Table 6.7 for 
category abbreviations). χ2 , p = 0.19. 
 
 Figure 6.35 displays histological preservation levels in each age category 
(abbreviations defined in Table 6.7). The χ2 test (p<0.19) suggests that age-at-death is 
independent of histological preservation. 
 
 
6.4: Protein and immunoglobulin G (IgG) extraction protocols 
 
 This section presents the results from the five protein extraction, purification, and 
characterisation protocols (P1-P5) detailed in section 5.7. For SDS-PAGE analyses, only the 
most ‘successful’ gels in terms of their potential for IgG identification are presented here. 
Schmidt-Schultz and Schultz (2004) identified likely archaeological IgG heavy chain bands 
at around 60kDa molecular weight bands in very well preserved samples (Figures 6.36 and 
6.37). It was, therefore, expected that IgG heavy chain bands in the samples chosen here 
would approximate similar weights, and it was assumed that light chains would appear as 
bands at around 25kDa.  
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6.4.1: P1: Extraction methodology adapted from Schmidt-Schultz and Schultz (2004) 
6.4.1(i): P1.1 SDS-PAGE gels 
 Figures 6.38, 6.39, and 6.40 show the Coomassie and silver stained gels for samples 
resulting from the P1.1 and P1.2 extractions. Samples chosen for these SDS-PAGE tests (see 
Table 5.11 for explanation of sample abbreviations) were all well preserved, in order to 
compare results to those achieved by Schmidt-Schultz and Schultz (2004) in Figures 6.36 
and 6.37. Inserted arrows in Figures 6.38-6.40 illustrate the approximate molecular weight 
of IgG heavy chains (c. 60kDa). 
 
Figure 6.36: Silver stained SDS-PAGE gel showing six ancient samples with molecular 
weight ladder on the right. KD = molecular weight. Arrow indicates expected IgG heavy 
chain bands, as shown in Figure 6.37 (adapted from Schmidt-Schultz and Schultz 2004:33). 
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Figure 6.37: Schmidt-Schultz and Schultz (2004:34) confirmation of IgG heavy chains at 
approximately 60kDa by Western blot. 
 
 Examination of the silver stained gel (Figure 6.39) shows considerable smearing of 
proteins above approximately 37kDa, resulting in very poor band resolution when compared 
to Schmidt-Schultz and Schultz’s ancient samples (Figure 6.36). Excessive smearing of 
ancient samples on SDS-PAGE gels often results from degraded proteins and is discussed in 
section 7.3. The poor resolution of Coomassie bands (Figure 6.38) and silver stained bands 
(Figure 6.39) around 60kDa (top arrows) made selection and excision of potential IgG heavy 
chain bands impossible, although Figure 6.39 displays possible bands corresponding to IgG 
light chains (c. 25kDa). 
 
 
Figure 6.38: P1.1 Coomassie stained SDS-PAGE gel. MW is molecular weight marker 
(kDa). H1 – HDAR1; H2 – HDAP2; H3 – HDAP3; H4 – HDAR4; A1 – AN1; A2 – AN2; 
A3 – AN3; A4 – AN7 (see Table 5.11). Gel/samples prepared as in section 5.7.3(i). Arrow 
indicates expected bands for IgG heavy chains.  
267 
 
 
Figure 6.39: P1.1 silver stained SDS-PAGE gel. MW is molecular weight marker (kDa). H1 
– HDAR1; H2 – HDAP2; H3 – HDAP3; H4 – ADAR4; A1 – AN1; A2 – AN2; A3 – AN3; 
A4 – AN7 (see Table 5.10). Gel/samples prepared as in section 5.7.3(i). Top arrow indicates 
expected bands for IgG heavy chain; bottom arrow indicates expected bands for IgG light 
chains.  
 
 
6.4.1(ii): P1.2 SDS-PAGE gels 
 
 A further set of samples (Table 5.11) were tested in an attempt to reduce the 
excessive smearing encountered in the P1.1 gels. Figure 6.40 shows slight improvement in 
band clarity in the Coomassie stained gel, with possible IgG heavy chain bands present (see 
arrow). The silver stained gel, however, demonstrated the same obscuring smear above 
approximately 30kDa, although clarity improved below this, with potential IgG light chain 
bands visible (Figure 6.40, bottom right arrow). 
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Figure 6.40: P1.2 SDS-PAGE gels following Coomassie (left) and silver (right) staining. 
MW is molecular weight marker (kDa). H3 – HDAP3; H4 – HDAR4 (see Table 5.11). 
Gels/samples prepared as in sections 5.7.3(i). Top arrows indicate expected bands for IgG 
heavy chains; bottom white arrow indicates expected bands for IgG light chains. 
 
 
6.4.1(iii): P1.2 SDS-PAGE gel bands selected for proteomic analysis, and proteomic 
results 
  
 The slightly improved Coomassie stained band clarity in Figure 6.41 and the 
potential silver stained light chain bands in Figure 6.42 allowed for selection of promising 
bands for proteomic analysis. The chosen bands were assigned numbers by the Biological 
Sciences personnel (bands 2, 5, and 7 from gel in Figure 6.41, and 9, 10, and 11 from gel in 
Figure 6.42). Those chosen in Figure 6.41 (2, 5, and 7) approximate the IgG heavy chain 
bands identified by Schmidt-Schultz and Schultz (2004). It was assumed that IgG light 
chains might present around 25kDa, given the evidently well-preserved heavy chains 
identified by Schmidt-Schultz and Schultz. Since they did not attempt to identify light 
chains, three clear bands (bands 9, 10, and 11) around and slightly above 25kDa were 
excised for proteomic analysis (Figure 6.42). 
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Figure 6.41: P1.2 Coomassie stained SDS-PAGE gel bands (2, 5, and 7) excised for 
proteomic analysis. H3 – HDAP3; H4 – HDAR4 (see Table 5.11). 
 
 
 
Figure 6.42: P1.2 silver stained SDS-PAGE gel bands (9, 10, and 11) excised for proteomic 
analysis. H3 – HDAP3; H4 – HDAR4 (see Table 5.11). 
 
 MALDI analysis results tested negative for any protein. Laboratory personnel were 
unsure of the reasons behind this failure (Joanne Robson, personal communication, 
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September 2012). The samples were subsequently analysed by nanospray LC-MS/MS, the 
results of which are presented in Table 6.24. No human proteins beyond collagen (other than 
exogenous contaminating keratin) were detected when matched against the Swiss-Prot 
database.  
 
Gel band Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
2 Pro alpha 1 collagen 38.3 81 
5 Pro alpha 1 collagen 47.8 67 
7 Pro alpha 1 collagen 42 64 
9 Alpha type 2 collagen 33 30 
10 Alpha 1 type 1 collagen 29.4 29 
11 Pro alpha 1 collagen 24.4 26 
Table 6.24: Results of P1.2 nLC-MS/MS analysis, showing most prevalent proteins and 
sequence coverage. Swiss-Prot database. Gel bands as in Figures 6.41 and 6.42. 
 
 
6.4.1(iv): P1.3 SDS-PAGE gels 
 
Analysis of the P1.2 SDS-PAGE gels and proteomic results demonstrated the 
requirement for the removal of smearing collagen, which may mask non-collagenous 
proteins (NCPs) of lower abundance, including IgG. Selected samples (Table 5.11) were 
tested in duplicate, with one batch (Figure 6.44) treated with collagenase prior to SDS-
PAGE, and one batch (Figure 6.43) left untreated. This allowed for direct comparison 
between gels and assessment of the efficacy of the collagenase treatment. As can be seen, 
the collagenase treatment was partially successful in reducing smearing for some samples 
(compare AP3, AR6, and AN4), yet unsuccessful for others (compare AR3, AP5, and AN2).  
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Figure 6.43: P1.3 Coomassie stained SDS-PAGE gel, non-collagenase treated. Samples as in 
Table 5.11. MW is molecular weight (kDa). Gel/samples prepared as in 5.7.3(i). Arrow 
indicates expected bands for IgG heavy chains. 
 
 
 
 
Figure 6.44: P1.3 Coomassie stained SDS-PAGE gel following collagenase treatment. 
Samples as in Table 5.11. MW is molecular weight (kDa). Gel/samples prepared as in 
5.7.3(i) and 5.7.2. Arrow indicates expected bands for IgG heavy chains. 
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6.4.1(v): Western blot 
 In an attempt to directly detect the presence of IgG heavy chains, the P1.3 
collagenase and non-collagenase treated gels (Figures 6.43 and 6.44) were subjected to a 
Western blot analysis (see section 5.7.3(ii)). This was performed by probing transferred 
protein bands with a monoclonal mouse anti-human IgG (Fc chain) antibody and secondary 
anti-mouse IgG conjugated antibody. Both gels were exposed for 10, 30, 60 seconds, and 
eight minutes following transfer of proteins. A comparison of the membranes (Figures 6.45-
6.51) to Schmidt-Schultz and Schultz’s (2004) positive Western blot results (Figure 6.37), 
fails to show any correlation with their ‘positive’ for IgG heavy chains at approximately 
60kDA. The appearance of bands above the expected molecular weight range for IgG heavy 
chains (see Figure 6.46 for an example of this) should be treated with caution, as they likely 
represent non-specific cross reactivity. Bands below 60kDa may, however, represent 
degraded IgG Fc chains (see Figure 6.46 for an example, indicated by the white arrow). 
 Figures 6.45, 6.46, and 6.47 show the non-collagenase treated membranes at 10, 30, 
and 60 second exposures, respectively. The left side of this membrane was damaged during 
the protocol; the lane representing JS1 is, therefore, not present here. Cross-reactivity is 
shown at all exposure stages, becoming increasingly evident over time. The eight minute 
exposure of the non-collagenase treated membrane is not shown, due to over-exposure and 
subsequent loss of clarity. A possible positive for degraded IgG heavy chain can be seen on 
Figures 6.46 and 6.47 (marked by a white arrow).  
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Figure 6.45: Western blot of non-collagenase-treated P1.3 SDS-PAGE gel, exposed for 10 
seconds. MW – molecular weight markers. 
 
 
 
Figure 6.46: Western blot of non-collagenase-treated P1.3 SDS-PAGE gel, exposed for 30 
seconds. Arrow indicates possible positive for human IgG. MW – molecular weight 
markers. 
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Figure 6.47: Western blot of non-collagenase-treated P1.3 SDS-PAGE gel, exposed for 60 
seconds. Arrow indicates possible positive for human IgG. MW – molecular weight 
markers. 
 
 Figures 6.48, 6.49, and 6.50 display the collagenase-treated membrane at 10 seconds, 
30 seconds, 60 seconds, and eight minute exposure times, respectively. Far less cross-
reactivity is observed here. The possible IgG heavy chain positive is marked by white 
arrows. This band is discussed in section 7.3.1(ii), as is the appearance of a band in Figure 
6.50 adjacent to the 29kDa molecular weight (MW) marker. Very faint bands at 
approximately 25kDa (Figure 6.50) for samples AR6, AR3, and AP5 may tentatively 
suggest the presence of IgG light chains. Their appearance, however, would be the result of 
cross-reactivity, given the heavy-chain specificity of the primary antibody and anti-mouse 
IgG specificity of the secondary antibody. 
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Figure 6.48: Western blot of collagenase-treated P1.3 SDS-PAGE gel, exposed for 10 
seconds. Arrow indicates possible positive for human IgG. MW – molecular weight 
markers. 
 
 
 
Figure 6.49: Western blot of collagenase-treated P1.3 SDS-PAGE gel, exposed for 30 
seconds. Arrow indicates possible positive for human IgG. MW – molecular weight 
markers. 
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Figure 6.50: Western blot of collagenase-treated P1.3 SDS-PAGE gel, exposed for 60 
seconds. Arrows indicates possible positive for human IgG. MW – molecular weight 
markers. 
 
 
 
Figure 6.51: Western blot of collagenase-treated P1.3 SDS-PAGE gel, exposed for eight 
minutes. Arrow indicates possible positive for human IgG. MW – molecular weight 
markers. 
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6.4.1(vi): P1 human IgG ELISA 
 
 Two types of enzyme-linked immunosorbent assays (ELISAs) were employed as 
part of this study. The first was a human IgG capture ELISA that analysed samples resulting 
from the P1.1 extraction protocol alongside a variety of standards and controls (Table 6.25). 
These controls included bovine collagen, animal bone, and buffers. Table 6.25 suggests that 
IgGs were detected at extremely low concentrations, with the highest concentration in 
sample HDAR3 (4.79ng/ml). Note that many of the results fall close to the ELISA detection 
limit of 1ng/ml. These results are discussed in section 7.3.1(iii). The test functioned 
correctly, as evidenced by the standards. 
 
Sample Type 
IgG quantity 
(ng/ml) 
Sample Type 
IgG quantity 
(ng/ml) 
Standard (1ng/ml) Standard 1 AN7 Animal rib 3.43 
Standard (2ng/ml) Standard 2 HDAR1 Adult rib 2.07 
Standard (5ng/ml) Standard 5 HDAR2 Adult rib 4.47 
Standard 
(10ng/ml) 
Standard 10 HDAR3 Adult rib 4.79 
Standard 
(20ng/ml) 
Standard 20 HDAR4 Adult rib 2.18 
Buffer C Buffer control 2.8 HDAS1 Adult cranium 1.97 
Collagen Bovine Type I 0.61 HDAR6 Adult rib 1.76 
Collagen Bovine Type III 3.53 HDAP3 Adult phalanx 1.66 
AN1 Animal rib 1.97 HDAP5 Adult phalanx -0.22 
AN2 Animal rib 2.5 HDJS1 
Juvenile 
cranium 
0.82 
Table 6.25: Results from P1 human IgG ELISA described in section 5.7.3(iii). 
 
 
6.4.2: P2 extraction methodology adapted from Jiang et al. (2007) 
 
 This section presents the results of the P2 extractions following the adapted Jiang et 
al. (2007) protocol outlined in section 5.7.4. Samples selected for the P2 extractions are 
shown in Table 5.14. Results of thiophilic adsorption chromatography (TAC) purifications 
for all P4 extractions are show in summary Tables 6.26 to 6.29. Each table displays the total 
spectrophotometric absorbance values at 280nm for each sample at each extraction stage, 
which equates to the approximated mg/ml concentration of the tested sample. Full results 
tables for these TAC tests are shown in Appendix 1. The SDS-PAGE gels corresponding to 
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each P2 extraction are displayed immediately following the appropriate table. Samples with 
higher protein concentrations (post-TAC) were usually selected for SDS-PAGE analysis, 
since it was assumed that these were the most likely to result in clearer IgG bands. 
 
6.4.2(i): P2.1 thiophilic adsorption results and SDS-PAGE gels 
 
 Table 6.26 displays the TAC results from the P2.1 extractions. Total resin-retained 
eluted protein concentrations (mg/ml) from the TAC resins for each sample at each 
extraction stage (stages described in section 5.7.4(i)) are shown. Note the extremely low 
totals, with the highest total (HDAP5 stage 1) approximating only 38µg/ml, and the absence 
of retained protein from the fourth extraction stage.  
 
Sample HI 
Stage 1  
(mg/ml) 
Stage 2  
(mg/ml) 
Stage 3  
(mg/ml) 
Stage 4  
(mg/ml) 
HDAP5 5 0.038 0 0.025 0 
AN1 5 0.004 0.004 0.007 0 
Table 6.26: Summary of P2.1 TAC showing total protein (mg/ml) eluted from each 
extraction stage. HI – histological index. Samples described in Table 5.14. 
 
 Figure 6.52 shows the SDS-PAGE gel (sliver stained) with selected samples from the 
P2.1 TAC. The white arrow indicates the expected molecular weight of extracted IgG heavy 
chains. The gel shows a cluster of bands for most samples between approximately 45 and 
66kDa. No further analytical action (e.g., excision for proteomics) was taken on this gel due 
to the extremely low protein concentrations. 
 
 
 
279 
 
 
Figure 6.52: P2.1 SDS-PAGE silver stained gel. 1, 2, and 3 – HDAP5, 1st stage; 4, 5, and 6 – 
HDAP5, 3rd stage; 7 – AN1, 1st stage; 8 – AN1, 3rd stage. See Table 5.14 for sample 
descriptions. MW is molecular weight (kDa). Gel/samples prepared as in sections 5.7.4(i) 
and 5.7.3(i). Arrow indicates expected bands for IgG heavy chains. 
 
 
6.4.2(ii): P2.2 thiophilic adsorption results and SDS-PAGE gels 
 
 In an attempt to increase protein yield, a wider range of samples were extracted and 
subjected to TAC (Table 6.27) and SDS-PAGE (Figure 6.53). Once again, however, silver 
staining was required due to the low protein concentrations resulting from the TAC. Bands 
were not, therefore, excised for further analysis. Note the retention and elution of protein 
from the collagen control sample (Table 6.27), and appearance of lanes around 50-60kDa on 
the corresponding gel lanes (7 and 8). This demonstrates non-specific binding of collagen by 
the TAC resins; matching bands for the other samples (lanes 1-6) are suggestive of similar 
collagen binding in these archaeological samples. 
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Sample HI 
Stage 1 
(mg/ml) 
Stage 2  
(mg/ml) 
Stage 3 
(mg/ml) 
HDAR9 5 0 0.103 0.027 
HDAP5 5 0.137 0.085 0.022 
HDAN2 5 0.006 0.072 0.009 
Collagen - 0.003 0.062 0 
Table 6.27: Summary of P2.2 TAC showing total protein (mg/ml) eluted from each 
extraction stage. HI – histological index. Samples described in Table 5.14. 
 
 
 
 
Figure 6.53: P2.2 silver stained SDS-PAGE gel. MW is molecular weight marker (kDa). 1 - 
HDAP3, 2nd stage; 2 - HDAP9, 2nd stage; 3 – AN2, 2nd stage; 4 – HDAR9, 3rd stage; 5 – 
HDAP3, 3rd stage; 6 – AN2, 1st stage; 7 – Collagen, 1st stage; 8 – Collagen, 2nd stage. See 
Table 5.14 for sample descriptions. Gel/samples prepared as in sections 5.7.4(i) and 5.7.3(i). 
Arrow indicates expected bands for IgG heavy chains. 
. 
 
6.4.2(iii): P2.3 thiophilic adsorption results and SDS-PAGE gels 
 
 Results of the TAC test for P2.3 extraction samples are shown in Table 6.28. Sample 
HDJS3 was included here to investigate the effect of poor histological preservation (HI) on 
protein yield (discussed later in section 6.5) and TAC retention. Table 6.28 suggests that HI 
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had little impact on the concentration of proteins eluted from the TAC resins, which 
remained very low, regardless of sample preservation. 
 
Sample HI 
Stage 1 
(mg/ml) 
Stage 2 
(mg/ml) 
Stage 3 
(mg/ml) 
HDAP5 5 0.1 0 0.041 
HDAR2 5 0.001 0.005 0.026 
HDAR3 4 0.004 0.018 0.026 
HDJS3 1 0.04 0.003 0.055 
Table 6.28: Summary of P2.3 TAC showing total protein (mg/ml) eluted from each 
extraction stage. HI – histological index. Samples described in Table 5.14. 
 
 The SDS-PAGE gel for selected P2.3 samples is shown in Figure 6.54. A positive 
fresh IgG control was included at this stage in order to help identify potential ancient IgG 
bands. The gel shows the positive heavy chains at approximately 50kDa (lower than 
Schmidt-Schultz and Schultz’s ancient Fc chains at 60kDa, interestingly) and light chains 
very faintly at approximately 25kDa. A comparison of the extended heating (advocated by 
Wiechmann et al., 1999) and traditional short boil steps during sample preparation was 
attempted with three P2.3 post-TAC samples. It can be seen that the latter approach resulted 
in more intense bands. Potential matches to the positive heavy chains can be seen in all 
samples, particularly the boiled versions. 
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Figure 6.54: P2.3 SDS-PAGE silver stained gel. MW is molecular weight (kDa), with 
positive control. Samples described in Table 5.14. 
 
 
6.4.2(iv): P2.3 gel bands selected for proteomic analysis, and proteomic results 
 
 Selected bands potentially matching the IgG positive control were excised for 
proteomic analysis (Figure 6.55). Bands from the strongest non-boiled sample (AP5 48hr) 
and its boiled counterpart (AP5) were tested to compare results, and IgG positive control 
bands were selected to test the efficacy of proteomic analysis of silver stained bands. 
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Figure 6.55: P2.3 gel bands excised for proteomic analysis. 
 
 Unfortunately neither MALDI nor nLC-MS/MS analysis yielded reportable results 
for analyses of the excised gel bands, including the IgG positive controls. This was likely in 
part due to the extremely low protein quantity being visualised in post-Coomassie silver 
staining and potential interference with residual acrylamide (William Simon, personal 
communication, July 2013). 
 
6.4.2(v): P2.4 thiophilic adsorption results and SDS-PAGE gels 
 
 Table 6.29 shows that the P2.4 samples resulted in noticeably higher TAC elution 
concentrations than in previous samples. An absence of protein from the stage 2 extractions 
is likely representative of human error, rather than a problem with the extraction or TAC 
methodology. This increase in protein concentration allowed for band visualisation by 
colloidal Coomassie staining (Figure 6.56), thereby increasing the chance of successful 
proteomic analysis of selected bands (Figure 6.57). 
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Sample HI 
Stage 1 
mg/ml) 
Stage 2 
(mg/ml) 
Stage 3 
(mg/ml) 
WM2316.1 5 0.083 0 0.022 
CD127.2 5 0.077 0 0.01 
LP3845.1 0 0.073 0 0.088 
AN5 0 0.054 0 0.084 
Table 6.29: Summary of P2.4 TAC showing total protein (mg/ml) eluted from each 
extraction stage. HI – histological index. Samples described in Table 5.14. 
 
 Figure 6.56 shows faint bands potentially matching the IgG positive control heavy 
chains at around 50kDa (see arrow) for most of the ancient samples (lanes 1-7). The gel also 
shows the effectiveness of acetone precipitation on fresh IgGs (compare lanes 8 and 9). 
 
 
 
Figure 6.56: P2.4 SDS-PAGE. Colloidal Coomassie stained gel. 1 – WM2316.1, 1st stage; 2 
– CD127.2, 1st stage; 3 – LP3845.1, 1st stage; 4 – LP3845.1, 3rd stage; 5 – AN5, 1st stage; 6 – 
AN5, 3rd stage; 7 – HDAR3 (from P2.3); 8 – IgG positive control (not precipitated); 9 – IgG 
positive control (acetone precipitated); MW – Molecular weight marker (kDa). Samples 
described in Table 5.14. Gel/samples prepared as in section 5.7.6(ii). Arrow indicates 
expected bands for IgG heavy chains. 
 
 
6.4.2(vi): P2.4 gel bands selected for proteomic analysis, and proteomic results 
 
 Bands of potential interest matching the IgG positive control (including the control 
itself) were excised for proteomic analysis (Figure 6.57).  
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Figure 6.57: P2.4 gel bands excised for proteomic analysis, including the IgG positive 
control (band 9). 
 
 The results of proteomic analysis of the selected bands are presented in Tables 6.30 
(MALDI) and 6.31 (nanospray LC-MS/MS). Both analyses showed only contaminating 
exogenous keratin for the ancient samples (LP3845 and AN5), but successfully identified 
the positive controls. Best matches to databases of sequenced proteins (NCBI for MALDI 
and Swiss-Prot for nLC-MS/MS) are shown. Put simply, protein score (Table 6.30) is the 
number of successful matches for each identified protein, and sequence coverage (Table 
6.31) is the percentage of a peptide sequence that match a known the sequence of a known 
protein.  
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Sample Best Match Protein Score 
LP3845.1, 1st stage Keratin 5 [Homo sapiens] 52 
LP3845.1, 3rd stage No result No result 
AN5, 1st stage Predicted: similar to keratin 10 [Pan troglodytes] 86 
AN5, 3rd stage No result No result 
IgG heavy chain, 
positive control 
Immunoglobulin gamma 2 heavy chain constant 
region [Homo sapiens] 107 
IgG light chain, 
positive control 
Chain A, crystal structure Fab fragment of 
monoclonal IgG [Homo sapiens] 86 
Table 6.30: Results from MALDI analyses of excised P2.4 gel bands. NCBI database. 
 
 
Sample Name 
Sequence 
Coverage (%) 
LP3845.1, 1st stage Keratin type 1, cytoskeletal 9 [Homo sapiens] 6.3 
LP3845.1, 3rd stage 
Keratin type I, cytoskeletal 10 [Homo sapiens] 16.4 
Keratin type I, cytoskeletal 9 [Homo sapiens] 7.5 
Keratin type 2, cytoskeletal 1 [Homo sapiens] 9 
AN5, 1st stage 
Keratin type I, cytoskeletal 10 [Homo sapiens] 16.4 
Keratin type 2, cytoskeletal 1 [Canis familiaris] 6.8 
Keratin type I, cytoskeletal 9 [Homo sapiens] 7.4 
AN5, 3rd stage No result No result 
IgG heavy chain, positive 
control 
Ig gamma-3 chain C region [Homo sapiens] 19.9 
Keratin type I, cytoskeletal 10 [Homo sapiens] 8.9 
Keratin type I, cytoskeletal 9 [Homo sapiens] 9.3 
Keratin type II, cytoskeletal 2 [Homo sapiens] 8.6 
Ig alpha-1 chain C region [Gorilla gorilla] 7.9 
Ig gamma-2 chain C region [Homo sapiens] 22.4 
Ig gamma-1 chain C region [Homo sapiens] 22.7 
Ig heavy chain V-I region [Homo sapiens] 15.4 
Ig heavy chain V-III region [Homo sapiens] 16.7 
Keratin type II, cytoskeletal 1 [Canis familiaris] 11.3 
IgG light chain, positive 
control 
Ig kappa chain C region [Homo sapiens] 35.8 
Ig kappa chain V-II region [Homo sapiens] 25.6 
Ig gamma-1 chain C region [Homo sapiens] 11.2 
Ig lambda chain V-I region [Homo sapiens] 19.2 
Ig lambda chain V-I region [Homo sapiens] 20.2 
Ig kappa chain V region [Oryctolagus cuniculus] 14.8 
Ig lambda chain V-I region [Homo sapiens] 16.5 
Ig kappa chain V-III region [Homo sapiens] 23.5 
Ig lambda chain V-II region [Homo sapiens] 11.7 
Table 6.31: Results of nLC-MS/MS analyses of excised P2.4 gel bands. Swiss-Prot 
database. Peptide numbers were not supplied. 
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6.4.2(vii): P2.5 thiophilic adsorption results and SDS-PAGE gels 
 
 Table 6.32 shows the total eluted protein concentrations (mg/ml) from TAC testing 
of the P2.5 samples described in Table 5.14, and Figure 6.58 displays the corresponding 
colloidal Coomassie stained SDS-PAGE gel. As mentioned in section 5.7.6(ii), these 
samples were precipitated in TCA, rather than acetone, since the latter resulted in large 
phosphate pellets which were difficult to solubilise in SDS sample buffer. No bands clearly 
matching the IgG control are present in Figure 6.58, although possible heavy chain matches 
are observable for all samples in the silver stained version (Figure 6.59). 
 
Sample HI 
Stage 1 
(mg/ml) 
Stage 2 
(mg/ml) 
Stage 3 
(mg/ml) 
HP154.1 5 0.023 0.053 0.025 
LP3760.1 0 0.007 0.01 0.016 
LP4585.3 2 0.007 0 0.006 
OL1104.2 5 0 0.013 0.015 
Table 6.32: Summary of P2.5 TAC showing total protein (mg/ml) eluted from each 
extraction stage. HI – histological index. Samples described in Table 5.14. 
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Figure 6.58: P2.5 SDS-PAGE. Colloidal Coomassie stained gel. 1 – HP154.1, 1st stage; 2 – 
HP154.1, 2nd stage; 3 – OL1104.2, 2nd stage; 4 – HP154.1, 3rd stage; 5 – LP4585.3, 3rd stage; 
6 – 3819D, 3rd stage; 7 – OL1104.2, 3rd stage; 8 – Blank sample buffer; 9 – IgG positive 
control; 10 – Molecular weight marker (kDa). Samples described in Table 5.14. Gel/samples 
prepared as in section 5.7.6(ii). Arrow indicates expected bands for IgG heavy chains. 
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Figure 6.59: P2.5 SDS-PAGE. Silver stained gel. 1 – HP154.1, 1st stage; 2 – HP154.1, 2nd 
stage; 3 – OL1104.2, 2nd stage; 4 – HP154.1, 3rd stage; 5 – LP4585.3, 3rd stage; 6 – 3819D, 
3rd stage; 7 – OL1104.2, 3rd stage; 8 – Blank sample buffer; 9 – IgG positive control; 10 – 
Molecular weight marker (kDa). Samples described in Table 5.14. Gel/samples prepared as 
in section 5.7.6(ii). Arrow indicates expected bands for IgG heavy chains. 
 
 
6.4.2(viii): P2.5 gel bands selected for proteomic analysis, and proteomic results 
 
 Figure 6.60 displays the possible heavy chain bands from the P2.5 gel (Figure 6.59) 
selected for proteomic analysis. Unfortunately, no protein was detected in either MALDI or 
nLC-MS/MS analyses of the seven gel bands. 
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Figure 6.60: P2.5 gel bands excised for proteomic analysis. Samples as in Figure 6.59. 
 
 
6.4.3: P3 extraction methodology adapted from Schmidt-Schultz and Schultz (2004), 
followed by thiophilic adsorption 
 
 The four well-preserved samples described in Table 5.21 were subjected to the 
adapted P1 extraction methodology followed by TAC. This was performed to remove 
degraded collagen which caused intense smearing of many P1 SDS-PAGE lanes, potentially 
masking lower abundance IgGs.  
 
6.4.3(i): P3 thiophilic adsorption results and SDS-PAGE gel 
 
 Table 6.33 displays the total protein concentration (mg/ml) from each extraction 
stage for the selected samples. Although still relatively low concentrations, they compare 
favourably to most of the P2 samples subjected to TAC.  
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Sample HI 
Stage 1 
(mg/ml) 
Stage 2 
(mg/ml) 
Stage 3 
(mg/ml) 
EH198.1 4 0.117 0.105 0.055 
CD120.2 5 0.055 0.054 0.084 
CD165.1 5 0.021 0.103 0.112 
OL1104.2 5 0.024 0.024 0.021 
Table 6.33: Summary of P3 TAC showing total protein (mg/ml) eluted from each extraction 
stage. HI – histological index. Samples described in Table 5.21. 
 
Repeated SDS-PAGE analyses of these samples post-TAC unfortunately resulted in 
no Coomassie-stained bands suggestive of IgG. Consequently, extracted samples that had 
not been subjected to TAC were instead analysed by SDS-PAGE. The resulting gel is shown 
in Figure 6.61. As expected, the sample lanes show significant smearing, since collagen was 
not removed prior to testing. 
 
 
Figure 6.61: P3 SDS-PAGE. Colloidal Coomassie stained gel. All samples post 3rd stage. 1 – 
EH198.1; 2 – EH198.1; 3 – CD120.2; 4 – CD120.2; 5- OL1104.2; 6 – OL1104.2; 7 – 
CD165.1; 8 – CD165.1; 9 – Blank sample buffer; 10 – IgG positive control. Samples 
described in Table 5.14. Arrow indicates expected bands for IgG heavy chains. 
 
6.4.3(ii): P3 gel bands selected for proteomic analysis, and proteomic results  
 
 Faint bands potentially representing IgG Fc chains were excised from the P3 gel 
(Figure 6.62) for nLC-MS/MS analysis. Given the nature of the samples (not subjected to 
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TAC), it is unsurprising that collagen was the dominant protein identified in the bands 
(Table 6.34), followed by exogenous keratin. No endogenous NCPs were identified. 
 
 
Figure 6.62: P3 gel bands excised for proteomic analysis. Samples as in Figure 6.61. 
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Sample Name 
Sequence 
Coverage (%) 
EH198.1 
Collagen alpha-2(I) chain [Homo sapiens] 34.5 
Collagen alpha-1(I) chain [Homo sapiens] 29.1 
Keratin type II, cytoskeletal 1 [Homo sapiens] 27.8 
Keratin, type I, cytoskeletal 14 [Homo sapiens] 35.6 
Keratin type I, cytoskeletal 9 [Homo sapiens] 22.5 
Keratin type II, cytoskeletal 6C [Homo sapiens] 32.6 
Keratin type I, cytoskeletal 10 [Homo sapiens] 11.8 
Keratin type I, cytoskeletal 16 [Homo sapiens] 31.1 
Keratin type II, cytoskeletal 5 [Homo sapiens] 15.8 
CD120.2 lane 
3 upper 
Collagen alpha-1(I) chain [Homo sapiens] 48.4 
Collagen alpha-2(I) chain [Homo sapiens] 55.9 
Keratin type II, cytoskeletal 1 [Homo sapiens] 10.7 
Collagen alpha-2(I) chain [Rattus norvegicus] 44.5 
CD120.2 lane 
4 upper 
Collagen alpha-1(I) chain [Homo sapiens] 62.6 
Collagen alpha-2(I) chain [Homo sapiens] 72.8 
Keratin 1 [Homo sapiens] 15.1 
Collagen type I, alpha 1 [Homo sapiens] 62.5 
CD120.2 lane 
3 lower 
Collagen alpha-1(I) chain [Homo sapiens] 51 
Collagen alpha-2(I) chain [Homo sapiens] 57.8 
Keratin type II, cytoskeletal 1 [Homo sapiens] 12.4 
Collagen alpha-2(I) chain [Canis familiaris] 41.8 
CD120.2 lane 
4 lower 
Collagen alpha-2(I) chain [Homo sapiens] 32.7 
Keratin type II, cytoskeletal 1 [Homo sapiens] 23.4 
Keratin, type I cytoskeletal 10 OS=Homo sapiens 11.8 
Keratin type I, cytoskeletal 9 [Homo sapiens] 16.7 
Keratin type II, cytoskeletal 2 [Homo sapiens] 13 
Table 6.34: Results of nLC-MS/MS analysis of excised P3 gel bands. Swiss-Prot database. 
 
 
6.4.4: P4 full Jiang et al. (2007) extraction, SDS-PAGE, and proteomic analysis 
 
 A further batch of samples (Table 5.22) were selected for extraction in an attempt to 
increase protein yield following an adapted Jiang et al. (2007) protocol similar to that 
employed for the P2 samples (see section 5.7.8 for details). These samples represented a 
range of preservation levels.  
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6.4.4(i): P4 thiophilic adsorption results 
 Despite the comparatively adequate protein concentrations shown in Table 6.35, 
repeated attempts at SDS-PAGE analysis failed to provide any Coomassie stained bands 
suggestive of IgG. 
 
Sample HI 
Stage 1 
(mg/ml) 
Stage 2 
(mg/ml) 
Stage 3 
(mg/ml) 
CD84.2 0 0.025 0.08 0.064 
CD112.3 2 0.034 0.067 0.059 
EHA4 4 0.025 0.037 0.04 
EH156.3 5 0.05 0.093 0.044 
Table 6.35: Summary of P4 TAC showing total protein (mg/ml) eluted from each extraction 
stage. HI – histological index. Samples described in Table 5.21. 
 
 
6.4.5: nLC-MS/MS analysis of P3 and P4 samples 
 
 This section presents the results of nLC-MS/MS analysis of selected P3 and P4 post-
TAC samples (section 5.7.8; Table 5.23) in Tables 6.36 to 6.46. Peptide matches were made 
by searching the Swiss-Prot and TrEMBL (human genome) databases. Only proteins for 
which more than one peptide scored over 95% confidence are included in the tables. The 
number of successfully identified peptides is shown in the Peptides (95%) column. Sequence 
coverage represents the percentage of each unique protein sequence identified. For full 
analyses, see Appendix 3. The extracted NCPs of interest (namely the endogenous NCPs 
and soil-associated, infiltrating proteins) are discussed in sections 7.3.3(ii) and 7.3.3(iii). 
 Tables 6.36 and 6.37 show pre- and post-exclusion analysis for sample CD120.2 (2nd 
extraction stage). As explained in section 5.7.8, the post-exclusion samples were subjected 
to a longer separation gradient with lists excluding the collagen and keratin sequences 
encountered in the pre-exclusion analysis. The aim of this was to instruct the mass 
spectrometer to ‘ignore’ these high-abundance proteins to reveal lower abundance non-
collagenous, non-contaminating proteins. Tables 6.36 and 6.37 suggest that this process was 
partially successful for this sample in that all collagen was excluded, and two previously 
masked NCPs (terminal uridylyltransferase 4; Ankyrin repeat and SOCS box protein 18) 
were detected post-exclusion.  
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Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD120.2 
2nd stage 
5 
Collagen alpha-2(I) chain [Homo sapiens] 58.9 24 
Collagen, type I, alpha 1 [Homo sapiens] 51.3 19 
Keratin, type I cytoskeletal 9 [Homo sapiens] 26.6 6 
Keratin 1 [Homo sapiens] 25 5 
Keratin, type I cytoskeletal 10 [Homo sapiens] 32 3 
Keratin, type II cytoskeletal 2 [Homo sapiens] 20.5 2 
Dermcidin [Homo sapiens] 29.1 2 
Table 6.36: P3 sample CD120.2, 2nd extraction stage, nLC-MS/MS analysis, pre-exclusion. 
TrEMBL database.  
 
 
Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD120.2 
2nd stage 
5 
Keratin, type I cytoskeletal 10 [Homo sapiens] 25.9 3 
Keratin, type II cytoskeletal 2 [Homo sapiens] 24.4 2 
Dermcidin [Homo sapiens] 25.5 1 
Terminal uridylyltransferase 4 [Homo sapiens] 8.7 1 
Table 6.37: P3 sample CD120.2, 2nd extraction stage, nLC-MS/MS analysis, post-exclusion. 
TrEMBL database. Bold entries are endogenous non-collagenous proteins. 
 
 Tables 6.38 and 6.39 show results of analysis of P3 sample CD120.2 (3rd extraction 
stage), pre- and post-exclusion, respectively. Once again, endogenous NCPs (shown in bold) 
were revealed following exclusion. 
 
Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD120.2 
 3rd stage 
5 
Collagen alpha-2(I) chain [Homo sapiens] 25.8 15 
Keratin 1 [Homo sapiens] 25.49 12 
Keratin, type I cytoskeletal 9 [Homo sapiens] 19.21 10 
Collagen, type I, alpha 1 [Homo sapiens] 14.53 7 
Keratin, type II cytoskeletal 2 [Homo sapiens] 18.74 8 
Keratin, type I cytoskeletal 10 [Homo sapiens] 13.25 6 
Keratin, type I cytoskeletal 15 [Homo sapiens] 4.97 2 
Keratin 1 [Homo sapiens] 25.49 12 
Dermcidin [Homo sapiens] 2 1 
Table 6.38: P3 sample CD120.2, 3rd extraction stage, nLC-MS/MS analysis, pre-exclusion. 
TrEMBL database. 
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Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD120.2 
 3rd stage 
5  
Keratin, type I cytoskeletal 10 [Homo sapiens] 31.5 7 
Keratin, type I cytoskeletal 9 [Homo sapiens] 21.3 3 
Keratin 1 [Homo sapiens] 15.4 2 
Collagen, type I, alpha 1 [Homo sapiens] 28.5 2 
Keratin, type II cytoskeletal 2 [Homo sapiens] 22.4 1 
Terminal uridylyltransferase 4 [Homo sapiens] 6.5 1 
Dermcidin [Homo sapiens] 10 1 
Ankyrin repeat and SOCS box protein 18 [Homo 
sapiens] 
9.2 1 
Table 6.40: P3 sample CD120.2, 3rd extraction stage, nLC-MS/MS analysis, post-exclusion. 
TrEMBL database. Bold entries are endogenous non-collagenous proteins. 
 
 Two post-TAC P4 samples displaying different histological preservation levels were 
analysed for comparative protein data. These samples were not subjected to nLC-MS/MS 
analysis with exclusion lists due to the extended time required to create such lists. However, 
the apparent success of this step with the P3 samples suggests that exclusion should be 
considered for future analyses. 
 Tables 6.41, 6.42, and 6.43 display the proteins detected in sample CD84.2 (HI: 0) 
from the first, second, and third extraction stages, respectively. The first extraction stage 
(Table 6.41) revealed collagen, exogenous contaminating proteins, and two bacterial 
proteins likely introduced into the bone by soil infiltration (environmental contamination). 
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Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD84.2 
1st stage 
0 
Collagen alpha-1(I) chain [Homo sapiens] 72.4 105 
Collagen alpha-1(I) chain [Homo sapiens] 66.3 89 
Collagen, type I, alpha 1 [Homo sapiens]  69.9 71 
Collagen alpha-2(I) chain [Homo sapiens] 77.1 63 
Collagen alpha-2(I) chain [Homo sapiens] 70.3 62 
Keratin, type I cytoskeletal 9 [Homo sapiens] 31.1 11 
Keratin, type I cytoskeletal 9 [Homo sapiens] 29.5 10 
Keratin 1 [Homo sapiens] 30.4 10 
Keratin, type I cytoskeletal 10 [Homo sapiens] 34.2 5 
Keratin, type I cytoskeletal 10 [Homo sapiens] 23.5 5 
Keratin, type II cytoskeletal 2 [Homo sapiens] 14.6 2 
Keratin, type II cytoskeletal 2 [Homo sapiens] 8.1 2 
Dermcidin [Homo sapiens] 27.3 1 
MUC19 variant 12 [Homo sapiens] 2.6 1 
L-glutamine:scyllo-inosose aminotransferase [Streptomyces 
griseus] 
13.2 1 
Probable tRNA sulfurtransferase [Lactobacillus casei] 10.6 1 
Table 6.41: P4 sample CD84.2, 1st extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. 
 
 Analysis of the second extraction stage of sample CD84.2 (Table 6.42) revealed a 
number of endogenous NCPs, shown in bold. 
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Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
CD84.2 
2nd 
stage 
0 
Collagen alpha-2(I) chain [Homo sapiens] 79.8 95 
Collagen alpha-1(I) chain [Homo sapiens] 75.9 93 
Collagen alpha-1(I) chain [Homo sapiens] 61.7 87 
Collagen alpha-2(I) chain [Homo sapiens] 74.2 86 
Collagen, type I, alpha 1 [Homo sapiens] 74 67 
Protein S100-A7 [Homo sapiens] 30.7 2 
Keratin, type II cytoskeletal 1 [Homo sapiens] 5.9 2 
Protein S100-A7 [Homo sapiens] 30.7 2 
Keratin 1 [Homo sapiens] 22 2 
Vitronectin [Homo sapiens] 4.2 1 
Cystatin-A [Homo sapiens] 28.6 1 
Protein pelota homolog [Methanocaldococcus jannaschii] 9.2 1 
Chondroadherin [Homo sapiens] 20.3 1 
Vitronectin [Homo sapiens] 7.9 1 
Pigment epithelium-derived factor [Homo sapiens] 9.8 1 
Cystatin-A protein [Homo sapiens] 38.8 1 
Keratin, type I cytoskeletal 10 [Homo sapiens] 14.2 1 
Table 6.42: P4 sample CD84.2, 2nd extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. Bold entries are endogenous non-collagenous proteins. 
 
 Table 6.43 shows the proteins detected in sample CD84.2, third extraction stage. The 
endogenous NCPs are again shown in bold. Note that the detected NCPs from both second 
and third extraction stages are represented by only one peptide. 
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Sample HI Name 
Sequence 
Coverage 
(%) 
Peptides 
(95%) 
CD84.2 
3rd stage 
0 
Collagen alpha-1(I) chain [Homo sapiens] 70.4 97 
Collagen alpha-1(I) chain [Homo sapiens] 66 93 
Collagen alpha-2(I) chain [Homo sapiens] 76.2 73 
Collagen alpha-2(I) chain [Homo sapiens ] 72.5 72 
Collagen, type I, alpha 1 [Homo sapiens] 67.6 65 
Keratin, type II cytoskeletal 1 [Homo sapiens] 35.7 23 
Keratin 1 [Homo sapiens] 39.3 23 
Keratin, type I cytoskeletal 9 [Homo sapiens] 34.8 14 
Keratin, type I cytoskeletal 9 [Homo sapiens] 34.3 13 
Keratin, type I cytoskeletal 10 [Homo sapiens] 28.3 13 
Keratin, type I cytoskeletal 10 [Homo sapiens] 35.8 13 
Keratin, type II cytoskeletal 2 [Homo sapiens] 35.5 12 
Keratin, type II cytoskeletal 2 [Homo sapiens] 37.2 12 
Keratin, type II cytoskeletal 6B [Homo sapiens] 20.9 6 
Keratin, type II cytoskeletal 6B [Homo sapiens] 30.5 5 
Keratin, type I cytoskeletal [Homo sapiens] 18.6 3 
Keratin, type II cytoskeletal 5 [Homo sapiens] 22.2 3 
Keratin, type I cytoskeletal 14 [Homo sapiens] 18.4 2 
Chondroadherin [Homo sapiens] 14.8 2 
Vitronectin [Homo sapiens] 8.2 1 
Hornerin [Homo sapiens] 6.7 1 
Pigment epithelium-derived factor [Homo sapiens] 10.3 1 
Dermcidin [Homo sapiens] 10 1 
Biglycan [Homo sapiens] 4.6 1 
Prothrombin [Homo sapiens] 12.9 1 
Vitronectin [Homo sapiens] 12.3 1 
Biglycan preproprotein variant (Fragment) [Homo 
sapiens] 
9.8 1 
Hornerin [Homo sapiens] 12.2 1 
Pigment epithelium-derived factor [Homo sapiens] 12.2 1 
Dermcidin [Homo sapiens] 17.3 1 
Table 6.43: P4 sample CD84.2, 3rd extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. Bold entries are endogenous non-collagenous proteins. 
 
 
 Tables 6.44, 6.45, and 6.46 display the results of nLC-MS/MS analysis of post-TAC 
P4 sample EH156.3 (HI: 5). Analysis of the first extraction stage revealed one endogenous 
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NCP (protein argonaute-4), which is represented by a single peptide (Table 6.44), along with 
a number of soil-associated infiltrating bacterial proteins. Cronobacter sakazakii is a 
pathogenic bacteria, the unusual presence of which is discussed further in section 7.3.3(iii). 
 
Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
EH156.3 
1st stage 
5 
Collagen alpha-1(I) chain [Homo sapiens] 77.7 148 
Collagen alpha-1(I) chain [Homo sapiens] 73.8 129 
Collagen alpha-2(I) chain [Homo sapiens] 83.4 117 
Collagen alpha-2(I) chain [Homo sapiens] 77.8 97 
Collagen, type I, alpha 1 [Homo sapiens] 76.9 93 
cDNA FLJ56576, highly similar to Collagen alpha-2(I) 
chain [Homo sapiens] 
94.1 14 
Collagen alpha-1(II) chain [Homo sapiens] 79.1 9 
Collagen alpha-6(IV) chain [Homo sapiens] 79.2 1 
Collagen, type XI, alpha 1 [Homo sapiens] 56 1 
Keratin 1 [Homo sapiens] 17.2 1 
Protein argonaute-4 [Homo sapiens] 7.9 1 
Keratin, type II cytoskeletal 1 [Homo sapiens] 5.7 1 
Collagen alpha-1(XXVIII) chain [Homo sapiens] 34 1 
HTH-type transcriptional regulator MalT [Cronobacter 
sakazakii] 
3.6 1 
Dihydroxy-acid dehydratase [Methanosarcina barkeri] 8.5 1 
Diflavin flavoprotein A 1 [Synechocystis sp.] 6.3 1 
DNA polymerase catalytic subunit [Equine herpesvirus 1] 6.1 1 
Table 6.44: P4 sample EH156.3, 1st extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. 
 
 Table 6.45 shows the range of proteins identified in the second P4 extraction stage of 
sample EH156.3. Although collagen once again dominates, two endogenous NCPs were 
detected. The two non-human proteins, representing highly exotic bacterial species 
Trichodesmium erythraeum and Halorubrum lacusprofundi, were identified through the 
Swiss-Prot database. Their ‘presence’ is discussed in section 7.3.3(iii). 
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Sample HI Name 
Sequence 
Coverage (%) 
Peptides 
(95%) 
EH156.3 
2nd 
stage 
5 
Collagen alpha-2(I) chain [Homo sapiens] 81.7 146 
Collagen alpha-1(I) chain [Homo sapiens] 77.3 143 
Collagen alpha-1(I) chain [Homo sapiens] 72.3 123 
Collagen alpha-2(I) chain [Homo sapiens ] 78.8 122 
Collagen, type I, alpha 1 [Homo sapiens] 76.5 96 
Collagen alpha-1(II) chain [Homo sapiens] 76.3 6 
Collagen alpha-1(II) chain [Homo sapiens] 65.4 5 
Keratin, type II cytoskeletal 1 [Homo sapiens] 8.01 4 
Keratin 1 [Homo sapiens] 20 4 
Keratin, type I cytoskeletal 9 [Homo sapiens] 7.2 1 
Imidazoleglycerol-phosphate dehydratase [Trichodesmium erythraeum] 5.2 1 
30S ribosomal protein S3Ae [Halorubrum lacusprofundi] 7.9 1 
Protein AHNAK2 [Homo sapiens] 11.1 1 
Keratin, type I cytoskeletal 9 [Homo sapiens] 14.1 1 
cDNA, FLJ94754, highly similar to Homo sapiens potassium 
inwardly-rectifying channel, subfamily J, member 2 (KCNJ2), 
mRNA [Homo sapiens] 
11.2 1 
Table 6.45: P4 sample EH156.3, 2nd extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. 
 
 The largest quantity of endogenous NCPs was detected in the third extraction of 
sample EH156.3 (Table 6.46). This sample was also the only one to contain NCPs 
represented by multiple peptides 
 
Sample HI Name 
Sequence 
Coverage 
(%) 
Peptides 
(95%) 
EH156.3 3rd 
stage 
5 
Collagen alpha-1(I) chain [Homo sapiens] 76.4 117 
Collagen alpha-1(I) chain [Homo sapiens] 68.4 104 
Collagen alpha-2(I) chain [Homo sapiens] 79.5 100 
Collagen alpha-2(I) chain [Homo sapiens] 78.3 94 
Collagen, type I, alpha 1 [Homo sapiens] 73.1 78 
Keratin, type II cytoskeletal 1 [Homo sapiens] 16.6 7 
Keratin 1 [Homo sapiens] 20.5 7 
Pigment epithelium-derived factor [Homo sapiens] 18.7 6 
Pigment epithelium-derived factor [Homo sapiens] 24.6 6 
Collagen alpha-1(II) chain [Homo sapiens] 74.8 6 
Collagen alpha-1(II) chain [Homo sapiens ] 6.77 5 
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Chondroadherin [Homo sapiens] 19.8 4 
Biglycan preproprotein variant (Fragment) [Homo sapiens] 24.7 4 
Matrix Gla protein [Homo sapiens] 36.9 4 
Biglycan [Homo sapiens] 6.12 3 
Vitronectin [Homo sapiens] 6 3 
Keratin, type II cytoskeletal 6B [Homo sapiens] 5.7 3 
Vitronectin [Homo sapiens] 21.5 3 
Keratin, type II cytoskeletal 6B [Homo sapiens] 21.3 3 
Keratin, type I cytoskeletal 10 [Homo sapiens] 4.92 2 
Keratin, type I cytoskeletal 10 [Homo sapiens] 12.2 2 
Chondroadherin [Homo sapiens ] 28.7 2 
Prothrombin [Homo sapiens] 17.8 2 
cDNA FLJ55606, highly similar to Alpha-2-HS-
glycoprotein [Homo sapiens] 
18.5 2 
Keratin, type I cytoskeletal 9 [Homo sapiens] 9.6 1 
Alpha-2-HS-glycoprotein [Homo sapiens] 14.4 1 
Keratin, type II cytoskeletal 2 [Homo sapiens] 11.9 1 
Osteomodulin [Homo sapiens] 4.3 1 
Lumican [Homo sapiens] 1.7 1 
Dermatopontin [Homo sapiens] 9.5 1 
Keratin, type I cytoskeletal 9 [Homo sapiens] 20.7 1 
cDNA, FLJ93532, highly similar to osteomodulin, mRNA 
[Homo sapiens] 
8.8 1 
Collagen alpha-2(V) chain [Homo sapiens] 61.5 1 
Keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 18.5 1 
Lumican variant (Fragment) [Homo sapiens] 5.6 1 
Keratin, type I cytoskeletal 17 [Homo sapiens] 20.8 1 
Table 6.46: P4 sample EH156.3, 3rd extraction stage, nLC-MS/MS analysis. Swiss-Prot and 
TrEMBL databases. Bold entries are endogenous non-collagenous proteins. 
 
 
6.4.5(i): TAC-retained collagen 
 Nanospray LC-MS/MS analysis of the P3 (CD120.2, HI: 5) and P4 post-TAC eluted 
samples CD84.2 (HI: 0) and EH156.3 (HI: 5) offers insights into the different extant 
isoforms of collagen non-specifically retained on the thiophilic resins (see sections 7.3.3(ii) 
and 7.3.3(iii) for details of retained non-human proteins and human NCPs). Tables 6.47-6.49 
present a summary of the collagen isoforms identified in the three post-TAC samples, along 
with their sequence coverage and number of peptides confidently identified. It should be 
303 
 
recalled that the collagen has non-specifically bound to the thiophilic resin in very low 
concentrations, and may not be representative of the entire collagen content of the pre-TAC 
samples (e.g., for sample CD84.2 3rd stage extraction, the post-TAC protein concentration 
was 0.064mg/ml, compared to 5.61mg/ml pre-TAC). Note the large differences in collagen 
isoform diversity, average sequence coverage, and identified peptides between the P3 (pre-
exclusion) and P4 samples. 
Stage Protein Sequence Coverage (%) Peptides (95%) 
2 pre 
Collagen alpha-2(I) chain 58.9 24 
Collagen, type I, alpha 1 51.3 19 
Average 55.1 22 
3 pre 
Collagen alpha-2(I) chain 25.8 15 
Collagen, type I, alpha 1 14.5 7 
Average 20.2 11 
3 post Collagen, type I, alpha 1 28.5 2 
Table 6.47: Collagen from post-TAC P3 sample CD120.2, 2nd and 3rd extraction stages. Pre 
– pre exclusion; post – post exclusion. 
 
Stage Protein Sequence Coverage (%) Peptides (95%) 
1 
Collagen alpha-2(I) chain 77.1 63 
Collagen alpha-1(I) chain 72.4 105 
Collagen, type I, alpha 1 69.9 71 
Average 73.1 80 
2 
Collagen alpha-2(I) chain 79.8 95 
Collagen alpha-1(I) chain 75.9 93 
Collagen, type I, alpha 1 74 67 
Average 76.6 85 
3 
Collagen alpha-2(I) chain 76.2 73 
Collagen alpha-1(I) chain 70.4 97 
Collagen, type I, alpha 1 67.6 65 
Average 71.4 78 
Table 6.48: Collagen from P4 post-TAC sample CD84.2 (HI: 0). Stage – extraction stage. 
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Stage Protein Sequence Coverage (%) Peptides (95%) 
1 
Collagen alpha-2(I) chain 83.4 117 
Collagen alpha-1(I) chain 77.7 148 
Collagen, type I, alpha 1  76.9 93 
Collagen alpha-1(II) chain 79.1 9 
Collagen alpha-6(IV) chain 79.2 1 
Collagen, type XI, alpha 1 56 1 
Average 75.4 62 
2 
Collagen alpha-2(I) chain 81.7 146 
Collagen alpha-1(I) chain 77.3 143 
Collagen, type I, alpha 1 76.5 96 
Collagen alpha-1(II) chain 76.3 6 
Average 78.0 98 
3 
Collagen alpha-2(I) chain 79.5 100 
Collagen alpha-1(I) chain 76.4 117 
Collagen, type I, alpha 1 73.1 78 
Collagen alpha-1(II) chain 74.8 6 
Collagen alpha-2(V) chain 61.5 1 
Average 73.1 60 
Table 6.49: Collagen isoforms from P4 post-TAC sample EH156.3 (HI: 5). Stage – 
extraction stage. 
 
6.4.6: P2, P3, and P4 Western blot 
 
 The Western blot test run on selected P2, P3, and P4 samples following the protocol 
described in section 5.7.9 failed to produce any positive results, even for the positive IgG 
control; exposures at one and five minutes showed only background ‘noise’, and are 
therefore not presented here. Possible reasons for this failure are discussed in section 7.35. 
 
6.4.7: P5: protein extraction following adapted Cappellini et al. (2012) protocol and 
SDS-PAGE gels 
  
 The results (SDS-PAGE gels) of samples extracted (Table 5.25) following the P5 
adapted Cappellini et al. (2012) outlined in section 5.7.10 are presented in this section. The 
IgG positive control was also included in these gels (lane 10). Figures 6.63, 6.64, and 6.65 
represent SDS-PAGE analysis of the three extraction stages. No clear bands suggestive of 
IgG were identified by colloidal Coomassie staining and smearing is evident on all gels. A 
possible match to IgG heavy chain can be seen in Figure 6.63, lane 9. However, the 
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extended development period (shown by yellowing of the gel) suggests extremely low 
protein concentration, and consequently the band was not excised for proteomic analysis.  
 
 
Figure 6.63: P5 first extraction stage SDS-PAGE silver stained gel. 1 – AN5; 2 – LP3760.1; 
3 - EH133.1; 4 – HP157.3; 5 – HP104.2; 6 – CD107.1; 7 – CD120.2; 8 – OL1104.2; 9 – 
HPAN5; 10 – IgG positive control. Samples described in Table 5.25. Arrow indicates 
expected bands for IgG heavy chains. 
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Figure 6.64: P5 second extraction stage SDS-PAGE silver stained gel. 1 – AN5; 2 – 
LP3760.1; 3 – EH133.1; 4 – HP157.3; 5 – HP104.2; 6 – CD107.1; 7 – CD120.2; 8 – 
OL1104.2; 9 – HPAN5; 10 – IgG positive control. Samples described in Table 5.25. Arrow 
indicates expected bands for IgG heavy chains. 
 
 
 
Figure 6.65: P5 third extraction stage SDS-PAGE colloidal Coomassie stained gel. 1 – AN5; 
2 – LP3760.1; 3 – EH133.1; 4 – HP157.3; 5 – HP104.2; 6 – CD107.1; 7 – CD120.2; 8 – 
OL1104.2; 9 – HPAN5; 10 – IgG positive control. Samples described in Table 5.25. Arrow 
indicates expected bands for IgG heavy chains. 
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6.5: Histological preservation and protein yield 
 
 Protocols P2 and P4 provided protein yields from thiophilic adsorption 
chromatography for a range of histological preservations, while P3 (Table 6.50) 
concentrated on well preserved (HI 4 and 5) samples only. P2 and P4 cannot be directly 
compared to P3, since the extraction stages differ methodologically. Figures 6.66 and 6.67 
show average P2 protein yields and the dependence of protein yield on histological 
preservation. 
 
 
Figure 6.66: Average protein yields from each P2 extraction stage following TAC. 
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Figure 6.67: P2 TAC bulk protein yield (mg/ml) and histological preservation. 
 
 Figure 6.68 suggests that the P2 TAC elution yield was less dependent upon 
histological preservation than the bulk protein yield seen in Figure 6.67. A similar pattern to 
this is seen in the P4 bulk and elution yields (Figures 6.70 and 6.71). 
 
 
 
Figure 6.68: P2 TAC elution yield (µg/ml) and histological preservation. 
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 Tables 6.50 and 6.51 display the total and average P3 TAC yield by extraction stage 
and histological preservation, respectively.  
 
Sample EH198.1 CD120.2 CD165.1 OL1104.2 
Type Rib Hand phalanx Rib Cranium 
HI 4 5 5 5 
Total protein yield (mg/ml) 4.55 6.71 5.17 2.34 
Table 6.50: Total post-TAC protein yield for P3 samples. HI – histological 
preservation. 
 
  HI: 4 HI: 5 
1st stage 1.713 1.300 
2nd stage 1.818 1.995 
3rd stage 1.014 1.445 
Table 6.51: Average P3 extraction stage TAC protein yields (mg/ml) and histological 
preservation. 
 
 Figure 6.69 shows the total bulk protein yields from the four P4 samples of varying 
histological preservation. Note the general decrease in yield as preservation levels increase. 
This dependence upon histological integrity is shown in Figure 6.70, although as previously 
stated, the eluted yield (Figure 6.71) does not follow this pattern. 
 
 
Figure 6.69: Total protein yields (mg/ml) from P4 TAC. 
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Figure 6.70: P4 TAC bulk protein yield (mg/ml) and histological preservation. 
 
 
 
Figure 6.71: P4 TAC elution yield (µg/ml) and histological preservation. 
 
 Figures 6.72 and 6.73 display the average P2 and P4 TAC protein yields and their 
relationship to histological preservation, while Table 6.52 shows the total post-TAC protein 
yields for the P2 and P4 samples. The figures and table confirm the general trend towards 
better preservation and lower protein yields. 
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Figure 6.72: Histological preservation and average TAC protein yields (mg/ml) from each 
extraction stage (P2 and P4 combined). 
  
 
 
Figure 6.73: Average P2 and P4 TAC bulk protein yields (combined) and histological 
preservation. 
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Sample Type Period HI 
Total protein yield 
(mg/ml) 
CD84.2 Cranium A-S 0 12.44 
LP3760.1 Rib A-S 0 8.27 
HDAN5 Rib PM 0 8.57 
HDJS4 Cranium PM 1 2.70 
CD112.3 Hand phalanx A-S 2 13.58 
LP4585.3 Hand phalanx A-S 2 5.65 
EHA4 Rib A-S 4 8.89 
HDAR3 Rib PM 4 2.80 
EH156.3 Cranium A-S 5 8.97 
OL1104.2 Hand phalanx M 5 1.71 
HP154.1 Rib R 5 3.01 
CD127.2 Cranium A-S 5 3.21 
WM2316.1 Rib R 5 1.21 
HDAR2 Rib PM 5 2.43 
HDAR3 Rib PM 5 2.96 
HDAP5 Hand phalanx PM 5 5.53 
Table 6.52: Total post-TAC protein yield for P2 and P4 samples. HI – histological 
preservation; R- Roman; A-S – Anglo-Saxon; M – medieval; PM – post medieval. 
Tables 6.53 and 6.54 show average protein yields and histological preservation by 
element type for P2/P4 and P3, respectively. Note the usually high yield from the cranial 
sample (HI: 5) in Table 6.53. 
  HI: 0 HI: 1 HI: 2 HI: 4 HI: 5 
Rib 9.14 -  -  2.80 2.40 
Cranium 13.44 2.70 -  -  8.97 
Hand Phalanx  - -  9.62 -  3.62 
Table 6.53: Average TAC protein yields (mg/ml) from P2 and P4 extractions by histological 
preservation (HI) and element type. 
 
 
  HI: 4 HI: 5 
Rib 4.55 5.17 
Hand Phalanx -  4.52 
Table 6.54: Average TAC protein yields (mg/ml) from P3 extractions by histological 
preservation (HI) and element type. 
 
 The following Tables (6.55 and 6.56) show average TAC elution yields for the P2/P4 
and P3 extractions. Note the higher P3 elution yields and general lack of correlation between 
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yield and preservation in the P2 and P4 samples. However, Table 6.55 shows that the 
average P2/P4 elution yield percentages of the total protein yields are higher in the better 
preserved samples. This is not necessarily the case for the P3 samples (Table 6.56). 
 
  HI: 0 HI: 1 HI: 2 HI: 4 HI: 5 
Rib 97  - -  94 89 
Cranium 169 33  -  - 122 
Hand Phalanx  - -  88  - 26 
Table 6.55: Average TAC elution yields (µg/ml) from P2 and P4 extractions by histological 
preservation (HI) and element type. 
 
 
  HI: 4 HI: 5 
Rib 277 236 
Hand Phalanx -  131 
Table 6.56: Average TAC elution yields (µg/ml) from P3 extractions by histological 
preservation (HI) and element type.  
 
 
  HI: 0 HI: 1 HI: 2 HI: 4 HI: 5 
Rib 1.0 -  -  3.4 4.1 
Cranium 1.3 1.2 -   - 2.1 
Hand Phalanx -  -  0.7 -  1.1 
Table 6.57: Average TAC elution yield percentages of total protein for P2 and P4 
extractions, by histological preservation (HI) and element type. 
 
 
  HI: 4 HI: 5 
Rib 6.1 4.6 
Hand Phalanx  - 2.9 
Table 6.58: Average TAC elution yield percentages of total protein for P3 extractions, by 
histological preservation (HI) and element type. 
 
 Finally, Table 6.59 shows average total TAC protein yields (mg/ml), average eluted 
yields (µg/ml), and average eluted percentage of total yield, by element type. The data 
suggests that although rib samples on average yielded the least total protein, they displayed 
the highest average eluted percentage. Note that this is likely due to the inclusion of the P3 
ribs samples (see Table 6.58) in the data. 
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  Total Yield (mg/ml) Eluted Yield (µg/ml) Elution % of Total 
Rib 4.56 152 3.9 
Cranium 7.08 111 1.6 
Hand Phalanx 5.57 94 1.9 
Table 6.59: Average total TAC protein yields (mg/ml), average eluted yields (µg/ml), and 
average eluted percentage of total yield, by element type. 
 
 
6.6: Malaria EIA (ELISA) 
 
 The results of the anti-malaria antibody EIA (ELISA) described in section 5.9 are 
presented here (Table 6.60). Samples and controls with an A450 value less than the cut-off 
(0.382) are considered negative, while samples just below the cut-off should be interpreted 
with caution. The samples and controls were run in duplicate, with the average absorbance 
at A450 reported. The negative control was read three times, with average absorbance 
measuring 0.282. The cut off value was calculated by adding 0.100 to the average negative 
control absorbance, as directed by the manufacturer. Note the false positive (in duplicate) 
recorded for the animal sample HPAN5. 
 
Sample Type HI Protocol Stage Protein conc.  Read 1 Read 2 Average Abs 
Positive Control - - - - 2.639 2.530 2.585 
Elution buffer Control - 3 and 4 - - 0.257 0.194 0.226 
0.5M EDTA Control - 5 - - 0.201 0.279 0.240 
50mM ammonium 
bicarbonate 
Control - 5 - - 0.218 0.248 0.233 
0.6M HCl Control - 5 - - 0.267 0.387 0.327 
uH20 Control - - 
 
- 0.217 0.402 0.310 
EH198.1 Human 4 3 1 0.117 0.343 0.213 0.278 
CD165.1 Human 5 3 1 0.021 0.232 0.268 0.250 
CD120.1 Human 5 3 2 0.054 0.185 0.219 0.202 
EH198.1 Human 4 3 3 0.055 0.255 0.268 0.262 
CD165.1 Human 5 3 3 0.112 0.358 0.570 0.464 
CD120.1 Human 5 3 3 0.084 0.173 0.192 0.183 
OL1104.2 Human 5 3 3 0.021 0.185 0.187 0.186 
EHA4 Animal 0 4 1 0.025 0.314 0.235 0.275 
CD84.2 Human 0 4 1 0.025 0.224 0.346 0.285 
CD112.3 Human 2 4 1 0.034 0.372 0.263 0.318 
EH156.3 Human 5 4 1 0.05 0.231 0.220 0.226 
EHA4 Animal 4 4 2 0.037 0.180 0.172 0.176 
CD84.2 Human 0 4 2 0.08 0.186 0.188 0.187 
CD112.3 Human 2 4 2 0.067 0.208 0.208 0.208 
EH156.3 Human 5 4 2 0.093 0.181 0.192 0.187 
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EHA4 Animal 4 4 3 0.04 0.228 0.175 0.202 
CD84.2 Human 0 4 3 0.064 0.179 0.161 0.170 
CD112.3 Human 2 4 3 0.059 0.202 2.080 1.141 
EH156.3 Human 5 4 3 0.044 0.839 0.169 0.504 
HP157.2 Human 2 5 1 - 0.148 0.099 0.124 
CD107.1 Human 4 5 1 - 0.119 0.212 0.166 
AN5 Animal 0 5 1 - 0.207 0.200 0.204 
OL1104.2 Human 5 5 1 - 0.193 0.190 0.192 
HPAN5 Animal 5 5 1 - 0.202 1.562 0.882 
EH133.1 Human 1 5 1 - 0.396 0.319 0.358 
HP104.2 Human 3 5 1 - 0.183 0.195 0.189 
HP157.2 Human 2 5 2 - 0.217 0.226 0.222 
CD107.1 Human 4 5 2 - 0.099 0.157 0.128 
AN5 Animal 0 5 2 - 0.433 0.201 0.317 
OL1104.2 Human 5 5 2 - 0.252 1.067 0.660 
HPAN5 Animal 5 5 2 - 0.696 0.521 0.609 
EH133.1 Human 1 5 2 - 0.316 0.347 0.332 
HP104.2 Human 3 5 2 - 0.290 0.265 0.278 
HP157.2 Human 2 5 3 - 0.243 0.360 0.302 
CD107.1 Human 4 5 3 - 0.311 0.337 0.324 
AN5 Animal 0 5 3 - 0.274 0.378 0.326 
OL1104.2 Human 5 5 3 - 0.332 0.266 0.299 
HPAN5 Animal 5 5 3 - 0.244 0.337 0.291 
EH133.1 Human 1 5 3 - 0.281 0.205 0.243 
HP104.2 Human 3 5 3 - 0.262 0.232 0.247 
Table 6.60: Results of malaria ELISA. HI is histological preservation. Stage is extraction 
stage. Protein concentration in mg/ml. Abs is absorbance. Cut of value is 0.382. Positive 
samples when read at A450 in bold. 
 
 
6.7: Rapid testing using the CareStart™ Malaria Rapydtest® 
 
 As a part of the suite of analyses attempting to detect malaria-associated 
biomolecules in archaeological human, selected samples (Tables 5.27, 5.28, and 5.29) were 
subjected to rapid testing using the CareStart™ Malaria Rapydtest® (Apacor). This cassette-
type RDT is capable of detecting malaria parasite antigens in the form of P. falciparum 
histidine-rich protein-2 (PfHRP2) and the non-falciparum enzyme lactate dehydrogenase in 
clinically-derived serum samples. One set of samples were tested following the published 
Fornaciari et al. (2010) protocol, while others tested represent samples from the P2.5 and P5 
extractions. Figures for all tested samples are presented in Appendix 2 (Figures A2.1 to 
2.14). 
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 All samples subjected to rapid testing, regardless of protocol followed, registered as 
having worked correctly through appearance of the control line. Samples tested using the 
Fornaciari et al. (2010) protocol (Table 5.27) were the most likely to show true positives, 
rather than cross-reactivity potentially associated with the collagen control (see Figure 
A2.11) or any chemical reagents used in the P2.5 and P5 extractions. Unfortunately, no 
positives were identified from the samples tested following the Fornaciari et al. (2010) 
protocol. Neither were positives registered for any of the P5 samples at any of the three 
extraction stages. Although neither the Fornaciari et al. (2010) protocol samples, nor the P5 
samples produced positive results, a number of the P2.5 tests did so (Table 6.61). These 
‘positives’ are discussed in section 7.6. 
 
  HI Stage 1 Stage 2 Stage 3 
Appendix 2 figure 
reference 
HP154.1 5 VOM - - A2.7 
LP4585.3 2 VOM/Pf VOM/Pf - A2.7; A2.8 
LP3760.1 0 VOM/Pf - - A2.7; A2.8 
LP3819D ? VOM VOM - A2.7 
Collagen - - VOM - A2.11 
Table 6.61: P2.5 rapid test positives. VOM – P. vivax, P. malariae, or P. ovale; VOM/Pf – 
mixed infection. HI – histological preservation. LP3819D – dentine sample.  
 
 This chapter has presented the results of the numerous lines of enquiry employed in 
the search for direct and indirect evidence of Plasmodium vivax in past British populations. 
The following chapter will critically interpret the data presented here, with reference to the 
limitations of each methodology chosen, and will attempt to identify possible research 
avenues for future investigations of past malaria through human remains analysis.  
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CHAPTER 7: DISCUSSION 
 
 This chapter discusses the evidence acquired during this study concerning the 
presence of putative P. vivax malaria in British antiquity. This research has attempted to 
identify indirect and direct evidence of the disease through analysis of palaeopathological 
reports, demographic burial profiles, and endogenous (antibody) and exogenous (antigenic) 
ancient biomolecules associated with malaria infection.  
 
7.1 Indirect evidence for P. vivax malaria 
 Indirect evidence for ancient Plasmodium vivax in the Lincolnshire and 
Cambridgeshire Fens was sought through examination of published archaeological and 
pathological reports in attempts to identify previously unrecognised skeletal sequelae of 
thalassaemia, following the recent publication of new diagnostic criteria (Lewis, 2010). A 
palaeodemographic analysis of cemetery populations was also undertaken in order to 
identify possible differences in mortality rates based on Fen/non-Fen site location. 
7.1.1: Thalassaemia in the past British Fens 
 As discussed in section 4.2.8, the establishment and consolidation of thalassaemia 
would require the amalgamation of a very particular set of circumstances in the presence of 
a strong selective pressure. The development of skeletal sequelae of thalassaemia would rely 
upon either a spontaneous point mutation, a deletion of non-coding parts of the genes 
responsible for α or β globin chain synthesis (Min-Oo and Gros, 2005), or the introduction 
of such genes through inheritance from an exogenous carrier into the population. Although 
any of these scenarios is possible, external introduction of the deleterious genes into the 
gene pool by heterozygous carriers is probably more likely to occur, since individuals 
affected by point mutations or deletions would need to survive and reproduce in order to 
pass on the defective genes; the presence of fellow carriers in the population for the 
transmission of genes to the subsequent generation would also be required. The influx of 
new genes with the Roman legions, for instance, may have introduced thalassaemia in to the 
gene pool of Poundbury Camp, Dorset, resulting in the first possible skeletal sequelae of 
thalassaemia to be encountered in the British archaeological record (Lewis, 2010). 
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 For thalassaemia to become widespread within a past population, the newly 
introduced alleles would need to persist and become ‘balanced’. This is a state in which the 
frequency of affected alleles is equilibrated due to the increased fitness of the heterozygote 
over the homozygote. Since thalassaemia minor and, to a lesser extent, intermedia sufferers 
are more likely to survive to reproduce, the affected alleles can persist within a gene pool 
and become equilibrated by the process of natural selection (Carter and Mendis, 2002). Even 
if P. vivax were exerting a strong enough selection pressure to drive the development of this 
particular haemoglobinopathy in Fenland populations, there may not have been sufficient 
time from the introduction of the required alleles to achieve polymorphic balancing and 
regular skeletal manifestation within the Roman and early Anglo-Saxon cemetery 
populations evaluated in this study (if it can be assumed that both malaria and thalassaemia 
were introduced into the British Isles during the former period). Futuer physical re-
evaluation of a large skeletal sample from a Fen/marshland cemetery with a long use-life 
(e.g., potentially St. Peter’s Church, Barton-upon-Humber) may be the best strategy in 
identifying the development of thalassaemia over time.  
 
7.1.1(i): The archaeological record 
 As outlined in section 4.2.9, the most likely type of thalassaemia to be encountered 
in the archaeological record is the heterozygous form known as thalassaemia intermedia 
(Ortner, 2003). The disease is idiosyncratic in its expression, with a range of clinical 
outcomes depending upon severity. Since symptoms generally worsen with age (Taher et al., 
2006), it could be expected that older individuals would display multiple skeletal sequelae, 
should they survive into adulthood without treatment. Survivability into adulthood is, of 
course, dependent upon the severity of symptoms. Lewis (2010) identified three possible 
cases of thalassaemia intermedia in older Poundbury children, although it remains uncertain 
as to whether their deaths were directly influenced by their condition. Had her reanalysis 
included the adults, she may well have observed an increased prevalence of skeletal changes 
suggestive of thalassaemia intermedia.  
 Regardless of the age of individuals, a differential diagnosis of thalassaemia would 
require the presence of at least two skeletal changes, if not more. Unfortunately, no 
individuals from the selected site reports in this study displayed more than one sequela that 
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might be indicative of thalassaemia. What follows is a discussion of the different sequelae 
listed in Table 5.1 and identified in Table 6.1 that were encountered in the reports. It should 
be recalled here that only individuals displaying two or more skeletal changes suggestive of 
thalassaemia were considered for further investigation, and that most of the Cambridgeshire 
samples were unavailable for further analysis due to archive relocation. 
 
7.1.1(ii): Porotic hyperostosis, multiple rib fractures, and scoliosis  
The Littleport skeleton displaying radiographically-confirmed porotic hyperostosis 
(section 6.11) represents the only positively identified case of this condition in any site 
selected for this study. Due to the rarity of the condition in British archaeological 
populations and its geographical association with potentially endemic malaria, a thorough 
macroscopic analysis of the surviving skeletal elements was performed with the intention of 
identifying other pathological changes that might be indicative of thalassaemia. This was 
accompanied by radiographic analysis of ribs in order to identify any of Lewis’ (2010) 
diagnostic rib-within-a-rib features. Unfortunately, no further sequelae of interest were 
identified. Analysis was, however, highly restricted due to poor overall preservation and 
lack of many elements prone to developing thalassaemic sequelae.   
Multiple rib fractures were the most commonly reported pathology suggestive of 
thalassaemia. Multiple pathological bone fractures in thalassaemic patients usually result 
from cortical thinning and medullary expansion (Ahmad et al., 2011). Such fractures are 
more frequently observed in homozygous thalassaemics; it is rarer to encounter them with 
thalassaemia intermedia (Haidar et al., 2010), but the fact that they do occasionally appear 
warranted their inclusion as a suggestive sequela. In suspected archaeological thalassaemia 
cases, radiography of ribs may be used to identify the ‘rib-within-rib’ feature encountered by 
Lewis (2010) at Poundbury. This would, of course, be contingent upon adequate 
preservation of ribs. No individuals in this study who exhibited multiple rib fractures 
displayed other sequelae suggestive of thalassaemia. They were not, therefore, targeted for 
further analyses. 
The Hoplands site displays a 13% crude prevalence rate (CPR) of rib fractures, with 
seven individuals exhibiting multiple fractures (Western, 2011). This is considerably higher 
than any other study site, as well as the Romano-British average CPR of 2.9% (Roberts and 
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Cox, 2003), although it is more comparable to the 9.4% CPR seen at the Roman cemetery at 
Jesus Lane, Cambridge (Alexander et al., 2004; Western, 2011). Unfortunately, the absence 
of other supportive ‘thalassaemia’ sequelae in any of the Hoplands individuals displaying 
multiple rib fractures precludes possible diagnoses of genetic anaemia. The same pattern is 
evident at the Castledyke South site, with four individuals (2% CPR) displaying multiple rib 
fractures (Bolyston et al., 1998) with no further supportive skeletal changes reported. The 
elevated Hoplands figure may represent more rigorous reporting of rib fractures on the 
individual level, or better rib preservation at this site. Without further physical skeletal 
analysis, both of these scenarios currently offer more likely explanations than thalassaemia. 
A further possible cause of multiple rib fractures can see seen at the Castledyke site, 
where two out of the four individuals were aged over 45 years. The fractures in these 
individuals may be associated with osteoporosis (Ortner, 2003). Osteoporotic rib fractures in 
modern European populations occur commonly in both men and women, with an estimated 
prevalence of over 3% (Ismail et al., 2006), yet it can be difficult to diagnose in skeletal 
material due to the challenge of distinguishing between pathological bone loss and post-
mortem deterioration (Boylston et al., 1998). It is, of course, possible that multiple healed 
rib fractures are simply evidence of a series of traumatic events over an extended life period. 
Taher et al. (2006) report that up to 40% of individuals affected by thalassaemia 
intermedia develop scoliosis. Research on the relationship between the two has 
demonstrated that the development of the condition in thalassaemics follows a different 
trajectory than in idiopathic scoliosis, reflecting the haematological abnormalities 
characteristic of thalassaemia. It would be difficult to be specific about the precise aetiology 
of scoliosis in archaeological cases, although thalassaemic scoliosis is often associated with 
retarded skeletal maturation (Korovessis et al., 1996; Papanastasiou et al., 2002). A 
differential diagnosis of thalassaemic scoliosis would rely on supportive sequelae within 
individuals. It is potentially interesting that scoliosis is recorded at the Littleport (three 
individuals, 8.8% TPR/4.9% CPR) and The Hoplands (2 individuals, 5.9% TPR) sites, both 
of which are situated in areas of the Fenland that may have experienced continuous malaria 
endemicity (as discussed in section 4.2.6). 
Idiopathic scoliosis has a true prevalence rate (TPR) of up to 5.2% in modern 
adolescents, exhibiting a female to male ratio to up to 3:1, which increases with advancing 
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age (Konieczny et al., 2013). Post-medieval scoliosis prevalence (CPR) is a suggested 
0.34% (Roberts and Cox, 2003). An explanation for this low prevalence may lie in the 
palaeopathological diagnosis of the condition, which benefits from a well preserved 
vertebral column. If preservation allows, each vertebrae should be carefully examined for 
abnormal morphology, since the conformation of the vertebral column is difficult to 
accurately reconstruct in dry bone (Ortner, 2003). As preservation and careful analysis of 
each element are key to diagnosis, the condition may sometimes be under-represented in 
archaeological populations. The Littleport site yielded three adult scoliotic individuals (8.8% 
TPR/4.9% CPR), two females and one male. Assuming that past populations exhibited 
similar patterns to modern, it could very tentatively be suggested that the Littleport 
prevalence rate may be suggestive of non-idiopathic scoliosis, despite an original differential 
diagnosis of developmental/idiopathic aetiologies (Western, 2007). Once again, the 
individuals affected by scoliosis at both The Hoplands and Littleport sites displayed no other 
sequelae suggestive of thalassaemia. 
 
7.1.1(iii): Summary 
 The analysis of skeletal reports from the Fen sites revealed scant evidence for 
thalassaemia in these populations. There are a number of possible reasons for this: 
1. Malaria was not present in the Fenlands during the periods under investigation; 
2. Malaria was present, but any selective pressure was insufficient to drive the 
development of thalassaemia. For instance, fluctuating endemicity or 
transmission may not have stimulated the development of the condition; 
3. Thalassaemia was present, but most sufferers (i.e., individuals with thalassaemia 
major or minor) would be undetectable in the archaeological record. 
The first point forms the basis of this entire study, and is the reason for investigating 
thalassaemia, population demographics, and biomolecular malaria markers. The further 
possible reasons were explored through report analysis and, where necessary, supplementary 
physical examination of the individuals of interest. Skeletal evidence for thalassaemia in the 
past British Fens provides a far from conclusive answer to the presence of this disease. It 
may not be coincidental that some populations most likely to have experienced extended 
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malaria endemicity exhibited higher frequencies of putative thalassaemia sequelae, yet the 
lack of multiple indicators within individuals precludes any convincing differential 
diagnoses. A more in-depth investigation would require a full re-examination of archived 
skeletal populations, searching specifically for the presence of suggestive sequelae, rather 
than relying on skeletal reports which may be insufficiently detailed. This type of analysis 
would be akin to that performed by Lewis (2010) on the Poundbury non-adult skeletons, and 
supported by radiography of suspected cases. 
The likelihood of encountering evidence of thalassaemia in skeletal material from 
British antiquity was very low from the outset. Many of the skeletal changes listed in Table 
5.1 either affect elements which are inherently fragile and at high risk of post-mortem 
fragmentation, or affect the bone in such a manner as to increase its susceptibility to 
diagenesis and damage. Elevated neonate and infant mortality resulting from thalassaemia 
major within a population is difficult to assess, given the generally poor representation of 
this age group in Fenland cemeteries (see section 7.1.5 for a discussion of this bias). 
Methodological improvements in ancient DNA analysis may provide confirmatory evidence 
of thalassaemic genotypes in ancient Fenland skeletal material. Such research has recently 
been undertaken on Bronze Age Minoan (Cretan) populations (Hughey et al., 2012), which 
successfully identified genetic markers of heterozygous beta thalassaemia in one ancient 
individual. This showed a similar average frequency to modern Cretans. This type of 
investigation builds upon previous attempts to identify archaeological thalassaemia (e.g., 
Yang, 1997), and suggests that next generation aDNA sequencing techniques may prove 
extremely useful in the identification of ancient thalassaemia. New aDNA technology may 
yet prove extremely useful in identifying polymorphic traits suggestive of malaria resistance 
in archaeological populations which elicit no direct osseous response. These may include 
protective conditions, such as the Duffy-negative blood system and G6PD deficiency 
recently documented in populations exposed to endemic temperate vivax malaria (Sina, 
2002; Louicharoen et al., 2009). 
Although this small analysis of putative thalassaemia skeletal sequelae cannot 
support the presence of malaria in the ancient Fens, it does not, of course, prove that the 
polymorphism was not present. Highly tentative evidence from sites such as Littleport and 
The Hoplands may be suggestive of the disease, but secondary analysis of sequelae through 
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published reports remains insufficient for diagnosis at this time. Vivax malaria may have 
been present and indeed endemic in the past Fenlands, but may not have driven the specific 
development of thalassaemia as a protective mechanism. The emergence of thalassaemia 
tends to be associated with falciparum-endemic areas and it may be the case that vivax 
malaria (particularly temperate strains) exerts insufficient selective pressure. Conversely, it 
may reflect the lack of research on ‘benign’ P. vivax addressed in section 3.5. Research on 
the evolution of population-specific protective haemoglobinopathies has tended to 
concentrate on P. falciparum, with far less known concerning the interaction of P. vivax and 
genetic resistance (Louicharoen et al., 2009). The situation is complicated by the presence of 
both falciparum and vivax malaria in many areas where emerging protective polymorphisms 
have been recorded, such as Southeast Asia.  
It may be the case that Defoe’s (1722) reported ‘seasoning’ of male marshland 
inhabitants may be reflective of an acquired, rather than genetic, immunity to vivax malaria. 
As discussed in the next section, demographic analysis of Fen and non-Fen populations may 
suggest that Fen populations were indeed ‘seasoned’ to their environments. The malaria 
hypothesis suggests that populations exposed to long-term endemic malaria are the most 
likely to develop genetic resistance to the disease, rather than populations exposed 
intermittently. The lack of evidence for thalassaemia in past Fenland populations may 
support acquired immunity as the dominant form of resistance. It may also suggest that vivax 
malaria transmission was discontinuous or, if endemic, lacked the selective pressure 
required to drive the development of protective polymorphisms. This assumes, of course, 
that conditions such as G6PD deficiency were not present. As mentioned previously, 
technological developments may soon allow for detection of this polymorphism in 
archaeological contexts. 
This study of the palaeopathological evidence has not been able to confirm the 
presence of thalassaemia in the past British Fenlands, yet it has added to a limited corpus of 
knowledge concerning Fen health. It also offers a base from which to expand research into 
any acquired immunity of haemoglobinopathies that may have developed in response to 
vivax malaria in past Fenland populations.   
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7.1.2: Cemetery population demography 
Before discussing the results of the small Fen/non-Fen palaeodemographic study 
outlined in section 5.2, it is important to recall the type of mortality profile that might be 
expected in a population affected by P. vivax. As discussed in sections 4.2.10 and 4.2.11, the 
groups most at risk of developing severe illness and potentially dying from P. vivax (likely 
combined with comorbidity) are the very young and pregnant women (Nosten et al., 2004). 
In terms of age categories for this study, these would include neonates (0-1 month old), 
infants (1-12 months), young children (1-6 years), and adolescent to young adult females 
(13-34 years). Thirty four years is, of course, is an arbitrary cut-off point. It assumes that the 
majority of pregnancies would occur prior to 35 years of age and that the reduced number of 
pregnancies occurring in middle adulthood (35-49 years) are unlikely to affect the overall 
mortality profile of a population. If vivax malaria were a significant contributor to mortality 
in past Fen/marshland communities it should, theoretically, be reflected in elevated numbers 
of cemetery burials in comparison to non-Fen cemeteries, over and above those observed in 
non-Fen populations. General trends in mortality, survivorship, and force of mortality (also 
known as probability of death) are discussed, followed by an analysis of how these trends 
coalesce to form overall patterns of Fen and non-Fen demography. Consideration of the 
extent to which these trends inform us about the presence of vivax malaria in the Fens will 
be given throughout the interpretation. Finally, the limitations of such demographic analyses 
are addressed. 
 
7.1.2(i): Fen/non-Fen mortality, survivorship (lx), and probability of death (qx) 
 When examining the mortality profiles for the Roman period, it is important to note 
the low Fen sample numbers due to the lack of excavated Roman Fen cemetery sites (Table 
6.3). This is especially noticeable for the <1 year old categories and may be representative of 
a particular Roman burial custom in which “infants rarely received proper burial” (Sallares 
et al., 2004:319), instead being interred within settlements rather than in designated, 
organised cemeteries outside of settlement boundaries (Toynbee, 1971; Scott, 1990). The 
majority of non-Fen Roman individuals in the <1 year categories came from the Ancaster 
and Baldock sites (See Appendix 2, Table A2.2). The former was a small Roman town with 
likely communal burial areas, in which many of the infants were buried in groups (Cox, 
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1989). This suggests the presence of organised burial plots for infants, rather than ad-hoc 
burial within a settlement or domicile, such as was observed at the Rudston Villa site (Stead, 
1980; Bayley 1980a). The disproportionate number of <1 year olds at Baldock may be 
suggestive of differential burial practice, or biased cemetery sampling. The non-Fen <1 year 
old mortality profile (Figure 6.4) may be more representative of a typical rural Roman 
profile, since the bulk of these individuals originated from two such cemeteries. The 
generally low Fen and non-Fen infant numbers may suggest that rural Roman infant burial 
was indeed less organised, with the mortality profile (Figure 6.4) perhaps representative of 
rural infant burial practices, regardless of Fen/non-Fen location.  
 The higher prevalence of Fen adults (Figures 6.4 and 6.5), particularly in the 50+ 
year category may indicate that more of these groups survived to an older age, thus 
potentially supporting higher pre-adult mortality in the non-Fen Roman locations. The 
survivorship data (Figures 6.6 and 6.7) support this hypothesis. However, as mentioned in 
section 6.2.2(i), the difference in sample numbers between Fen and non-Fen could 
potentially skew the data and subsequent interpretation for the Roman period. Chi-square 
testing (p<0.01) shows location to be a significant influence on age-at-death, while the 
Roman period is the only one for which the K-S null hypothesis can be rejected, with a 
significant difference (p <0.01) in total age-at-death (Figure 6.4) and adult age-at-death 
(Figure 6.5) mortality distributions by location. The K-S test perhaps offers a more reliable 
indicator of distribution than χ2 here, since the former is more suited to analysing the small 
Fen samples size. The selected Fen Roman cemeteries are all relatively small, the largest 
(The Parks, Godmanchester) yielding only 52 aged individuals, whereas non-Fen Ancaster 
yielded over 300.  
 Figure 6.5 shows that non-Fen females make up the highest proportion of burials in 
the 18-24 year age category, with corresponding poor survivorship (Figure 6.7) and highest 
probability of death (Figure 6.9). The subsequent proportional fall in non-Fen females in the 
50+ category suggests that this group was particularly at risk during the Roman period, a 
trend that continued into the Anglo-Saxon period. That the Fen populations show better 
survivorship and lower probability of death may be indicative of populations adapting to 
high-stress environments, with the survivors living longer than their non-Fen 
contemporaries. This theory is discussed further in section 7.14. 
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 Demographic analysis of the Anglo-Saxon data suggests that this period was 
particularly difficult for the non-Fen groups, with females experiencing the highest 
probability of death and lowest survivorship (Figures 6.14 and 6.16). Given the post-
medieval reports of elevated female immigrant deaths in marshland environments discussed 
in section 3.6.3, it might be expected that the number of very young adult and young adult 
female Fen burials would exceed that of non-Fen burials in the same age categories. 
Demographic analysis, however, may tentatively suggest the opposite. The very young adult 
female category (ages 18-24), for instance, exhibited higher non-Fen burial probability of 
death for the Roman and Anglo-Saxon periods, with the latter showing the greatest 
differences by location (Figures 6.9 and 6.16). Of course, even if the 18th century reports 
were entirely accurate, such a phenomenon may not be reflected in the burial record. 
 It is difficult to pinpoint exact reasons for this pattern, and there are likely to be 
multiple factors influencing the data. For instance, ongoing research (Ellen Kendall, 
personal communication, March 2014) tentatively suggests that Anglo-Saxon Fen-associated 
populations, including those at Littleport, may have adopted a practice of extended 
breastfeeding as an adaptive strategy to the harsh environment. This biocultural behaviour 
has been observed in developing countries, where poor health and growth in childhood 
influenced the extension of breastfeeding (e.g., Marquis et al., 1997; Simonden et al., 2001). 
If this practice was widespread in the Anglo-Saxon Fens, it may help to explain the overall 
improved Fen survivorship. Unfortunately, the lack of individuals in the <1 year old 
categories confounds comparisons of Fen/non-Fen infant survivorship. However, since more 
Fen individuals seem to have survived for longer, it may be suggestive of lower infant 
mortality. It is also possible that an adapted breastfeeding and weaning practice reduced the 
probability of death for Fen females compared to their non-Fen counterparts, given that 
extended breastfeeding reduces fertility and promotes natural birth spacing through 
lactational amenorrhoea (Tommaselli et al., 2000). Since increased frequency of pregnancy 
and birth would have directly correlated with maternal morbidity and mortality (Lewis, 
1998; Norton, 2005), it follows that a practice which reduced this frequency may have 
reduced mortality. At this point and without further research, this conclusion must remain 
conjectural, yet is highlights a possible line of evidence that may illuminate our 
understanding of Fen health and cultural practices in the undocumented past. 
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 The difficulties of traversing the “wide wilderness” of “vast fens and swamps” 
(Felix, quoted in Darby, 1940:8-9) would have meant near isolation for many Anglo-Saxon 
Fen island populations, such as Ely, which Bede recorded as only being accessible by boat 
in the 8th century (Darby, 1940). Whether such isolation served as a protective measure 
against the external pressures of conflict and disease is open to question. It is possible, for 
instance, that reduced mobility and migration may have led to Defoe’s ‘seasoning’ 
mentioned in section 3.6.3, potentially producing a baseline population-wide resistance to 
local immunological threats. The rich, year-round resource availability in the Fens may also 
have ensured an adequate nutritional status, although this may have been offset by increased 
parasitism, such as was suggested for the Littleport and earlier Hoplands samples (Western, 
2007; 2010).   
 Analysis following removal of the St. Peter’s Anglo-Saxon individuals (Figure 6.11), 
which make up 56% of the total Anglo-Saxon Fen sample set, suggests a lower probability 
of death prior to 35 years at the St. Peter’s site. This may be evidenced in the increased 
number of buried 25-49 year olds when including the St. Peter’s individuals. Consideration 
of the large St. Peter’s population and its influence on the Anglo-Saxon and medieval Fen 
demographic patterns introduces a potential problem of differential burial customs. The St. 
Peter’s data set represents the only Fen sample associated with a church. Although many of 
the earliest burials may pre-date the extant early 11th century church, it is possible that the 
10th century Christian cemetery was associated with a precursory chapel on the site 
(Rodwell and Atkins, 2011). The influence of the Church on later Anglo-Saxon burial 
customs is difficult to ascertain (Geake, 2003). It is unknown, for instance, whether Anglo-
Saxon burial in direct association with the church was reserved for certain members of the 
local community (as was common in later medieval intra-mural church burials), or whether 
all who died locally were buried here. Certainly, the large numbers of infants at St. Peter’s 
compared to other Fen sites suggests that the unique location allowed a focal point for burial 
and subsequent preservation of an age group often under-represented in the Anglo-Saxon 
period. This may, therefore, represent a more normalised pattern of infant mortality than is 
observed in most other Anglo-Saxon sites. In terms of tracing the presence of Plasmodium 
vivax in the Roman and Anglo-Saxon Fens though palaeodemographic analysis, there are no 
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obvious signs of its existence, although mortality and survivorship data suggest a picture of 
adaptation to the environment 
 An indirect indicator of putative P. vivax presence in the medieval Fens may be 
suggested by comparing data derived from infant burials at the St. Peter’s Church and 
Wharram Percy sites, data which potentially suggests the effects of intrauterine growth 
restriction (IUGR) at the Fen site. As mentioned in section 4.2.10, a causative link has been 
suggested between malaria and up to 70% of clinically observed cases of IUGR (Steketee et 
al., 2001). P. vivax infection during pregnancy is a well-established, though poorly 
understood cause of IUGR and low birth-weight (Nostern et al., 1999; Rodriguez-Morales et 
al., 2006; Desai et al., 2007). An estimated 18 million babies of low birth-weight are born 
every year as a result of either pre-term birth or IUGR, the latter being responsible for 
approximately 2% of neonatal deaths (Lawn et al., 2005). Given the modern statistics, we 
should perhaps expect to observe IUGR in archaeological populations exposed to malaria. 
 The average femoral (diaphyseal) lengths of one year olds were 126mm at Wharram 
Percy (Mays, 1999) and approximately 75mm at St. Peter’s (Waldron, 2007). The St. Peter’s 
population exhibits evidence for adequate nutrition and an “unremarkable” disease load 
(Waldron, 2007:129), whereas health and nutrition at Wharram Percy was suggested to 
approximate that of poor 19th century urban communities (Mays, 2007). The relatively high 
child mortality rate observed at Wharram Percy (and evidenced in Figures 6.17 and 6.18) is 
likely a direct indicator of the poor nutritional status and high disease load of the population 
as a whole (Mays, 2007). The average 12 month old femoral length at Wharram Percy is 
comparable to other British archaeological populations (Mays, 2007), suggesting that low 
birth weight/size was not a major problem at this site. Since malnutrition in developing 
countries has been shown to influence the development of IUGR in up to 24% of 
pregnancies (Villar et al., 1986), one may expect to observe a higher prevalence of ‘small’ 
infants in a chronically under-nourished population. This is, however, not the case at 
Wharram Percy. There seems to be another as yet unidentified factor that influenced the 
high prevalence of small babies at St. Peter’s. The strong correlation of vivax malaria 
infection with the development of IUGR provides a possible explanation for the increased 
prevalence of small infants at St. Peter’s. It should, however, be acknowledged that IUGR 
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can be caused by numerous factors beyond vivax malaria and malnutrition, such as 
infectious disease, diabetes, and maternal high blood pressure.  
 The comparison of infant size, as determined by average femoral (diaphyseal) length, 
at Wharram Percy and St. Peter’s Church may offer tentative support for the presence of P. 
vivax-associated IUGR at the latter site. The latter population certainly exhibits a large 
proportion of smaller-than-expected children (Waldron, 2007), a pattern that may reflect the 
norm in modern endemic vivax malaria areas (Nosten et al., 1999). Alternately, the 
diachronicity of the small baby trend from the Anglo-Saxon to later medieval periods may 
point to a population-specific genetic trait. It could also be argued that the small St. Peter’s 
babies may suggest an unusually high prevalence of premature birth, although the use of 
multiple age indicators in their recording makes this a less likely scenario (Waldron, 2007). 
An important caveat must be made here regarding the St. Peter’s population percentages in 
the 0-1 year (1.6% average) and 1-5 (14.2% average) year old categories. Waldron 
(2007:37) suggests that the unusually low number of 0-1 year olds may have been “an 
artefact, and some of those placed in the succeeding age group probably belong to this 
earlier stage”. An unspecified number of 0-1 year olds mistakenly placed in the 1-5 year old 
category would skew analyses of femoral lengths and increase the impression of a cohort of 
smaller one year olds. 
Mays (1999) suggests that the average age for cessation of breastfeeding at Wharram 
Percy was approximately 18 months, based on measurements of nitrogen isotopes. Although 
no such study has been performed on the Barton population, a possible adaptive 
breastfeeding strategy (mentioned above) may have been in place here; if babies at St. 
Peter’s were born small and sickly, it may have influenced the practice of delaying full 
weaning in order to extend the immunological and nutritional benefits of breastfeeding. At 
Wharram Percy, the cessation of breastfeeding at an average of 18 months was correlated 
with a slowing of growth (Mays, 2007) and potentially increased child mortality. 
Breastfeeding and weaning practices may help to explain why average growth in the St. 
Peter’s and Wharram Percy children differed so dramatically at one year, but reached near 
parity by the age of five. Isotopic study of the Barton skeletons would be required to support 
such hypotheses. It should, of course, be remembered that the growth profiles at both sites 
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are based upon children who died, and are therefore not necessarily representative of the 
healthy children who survived to adulthood (Mays, 2007; Waldron, 2007).  
 
7.1.2(ii): General trends and summary 
 
 The total mortality profile (Figure 6.26) reflects a pattern that might be expected for 
antiquity, with peaks in childhood (1-6 years) and young adulthood (25-34), and remaining 
consistently high into middle and old adulthood (35+). The lowest mortality for both Fen 
and non-Fen sites was seen in the adolescent (13-17) age group. The survivorship and 
probability of death profiles suggest that very young (18-24 years) adult females were more 
at risk of dying than their male counterparts, which, given the risks associated with 
pregnancy, is to be expected. Increased male survivorship is commonly observed in pre-
modern populations (Berin et al., 1989). The pattern is apparent for all periods, other than in 
the medieval non-Fen sample (Figure 6.25). 
 The significant difference (p <0.01) between total Fen/non-Fen populations shown in 
Figures 6.26 suggests that location is significant in influencing age-at-death, although it was 
surprising to find that many of the target categories expected to show higher Fen mortality 
(the <1, 1-6, and 18-24 categories, for example) actually displayed the opposite relationship, 
with higher percentages in the non-Fen cemeteries. These percentages are not necessarily 
representative of the overall death rates in these populations; Figures 6.28 and 6.30 suggest 
that the overall survivorship and probability of death for Fen and non-Fen populations are 
similar, despite the apparent significance of location in determining the age-at-death. When 
examining mortality and survivorship by period, however, the picture that emerges from this 
small study seems to be of one adaptation to the environment, particularly in the Roman and 
Anglo-Saxon Fens. In these periods Fen population demographics consistently suggest a 
lower probability of death and better survivorship than for their non-Fen counterparts. It is 
likely that the Fen environment was as unwholesome as was frequently reported from the 
later literature, yet the populations seemed to be ‘coping’ with this constant challenge to 
their health. The high prevalence of Anglo-Saxon cribra orbitalia in Fen-associated 
populations (Gowland and Western, 2012) may be an indicator of this adaptation to a high-
stress environment. It is, of course, very possible that vivax malaria played a part in the 
health status of Fen existence. However, it has not been possible through demographic 
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analysis to isolate vivax malaria from the epidemiological milieu that surely existed in the 
Roman and Anglo-Saxon Fens. 
 Health status in the Fens seems to have declined somewhat in the medieval period 
compared to the non-Fen populations, possibly due to new external pressures that were 
undoubtedly introduced during this period. As discussed in section 2.3, the 13th and 14th 
centuries were a time of upheaval in terms of climatic decline and disease epidemics. Since 
these factors would affect Fen and non-Fen alike, why would the former populations seem to 
suffer worse in terms of mortality? Defoe’s 18th century accounts of marshland locals being 
‘seasoned to the place’ (see section 3.6.3) is suggestive of adaptation to an inherently 
unhealthy environment, a state that perhaps existed in the Anglo-Saxon period (as evidenced 
by high cribra prevalence). Something may have occurred during the medieval period which 
upset this balance. Could it possibly be that vivax malaria made its appearance in the Fens at 
this time, adding further immunological stress to an already burdened, but coping, 
population? Perhaps increased instability resulting from a combination of environmental, 
demographic, and epidemiological changes had a greater impact upon Fen populations. It 
may be useful for future research to analyse the prevalence of medieval Fen non-specific 
stress markers, such as cribra orbitalia, to compare to the Anglo-Saxon data of Gowland 
and Western (2012). This type of analysis may reveal changing patterns in any possible 
adaptations. An analysis of post-medieval Fen and non-Fen demographics may also help to 
support Defoe’s observations by investigating any possible return to adaptation in the Fens 
following medieval upheaval. 
 What does this limited analysis of Fen and non-Fen cemetery sites suggest 
concerning the presence of P. vivax malaria from the Roman to medieval periods? The 
overall demography shows no obviously higher Fen mortality rates in the expected groups 
most liable to succumb to infection. Location and the immediate environment may have had 
a significant influence on mortality for past and modern populations, as demonstrated in this 
study and others (e.g., Bull and Morton, 1978; Hertz et al., 1994; Lewis and Gowland, 
2007). However, diachronic mortality and its representation within an attritional cemetery 
population certainly cannot be attributed to one extrinsic factor. Mortality is affected by a 
myriad of factors, geographical location being but one. 
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This is probably reflected by the fact that while cemetery location is a significant factor in 
mortality, there remains no significant difference between Fen and non-Fen in the 
distribution of age-at-death categories. Plasmodium vivax malaria would have to 
significantly influence mortality in select groups over an extended period for it to be evident 
in the mortality rates and profiles of an attritional Fen cemetery. The threat to life posed by 
comorbid P. vivax infection is well established, particularly in younger patients (Baird, 
2007; Caulfield et al., 2004). Comorbidity almost certainly helps to explain the elevated 
post-medieval burial rates recorded in the marshland and Fenland parishes of eastern and 
south-eastern Britain (West, 1974; Wrigley and Schofield, 1981; Dobson, 1997), but 
unfortunately, such patterns may not be so readily observable in an attritional archaeological 
cemetery.  
 Although potentially interesting patterns in Fen and non-Fen mortality and 
survivorship have been revealed, the limited palaeodemographic analysis performed in this 
study cannot directly support the presence of vivax malaria in the Fens. The ‘small’ infant 
phenomenon encountered at St. Peter’s Church may suggest an increased occurrence of 
IUGR, which is consistent with, but not evidence for, the long-term presence of P. vivax. 
Unfortunately, no other Fen site has yet yielded sufficient quantities of infant skeletons for 
any possible association between location and reduced infant size to be determined. While is 
highly likely that vivax malaria played an important part in the health status of past Fen 
inhabitants, it has not been possible through the analyses performed here to demonstrate the 
presence of the disease. 
 
7.1.2(iii): Limitations 
Appendix 2 Tables A2.1 and A2.2 show that 320 Fen and 325 non-Fen < 1 year old 
individuals were excavated from the selected sites, representing 9.8% and 11% of total 
cemetery populations, respectively. These figures may seem somewhat low, given the high 
infant mortality rates uniformly assumed for past societies. Here they probably, at least in 
part, represent the poor survival of inherently fragile bone, while also reflecting the large 
number of Anglo-Saxon cemeteries included in the study (a sampling bias first addressed in 
section 5.2), since it is unusual for Anglo-Saxon cemeteries to yield an expected number of 
foetal, neonate, and infant burials (Crawford, 1993). The under-representation of neonates 
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and infants in the archaeological record is a well-documented phenomenon, and forms an 
important source of sample biasing in palaeodemography (Hoppa and Vaupel, 2002; 
Chamberlain, 2006). While the problem is particularly acute for the Anglo-Saxon period 
(e.g., Figures 6.10, 6.11, 6.13, and 6.15), the Great Chesterford and St. Peter’s (Barton-
upon-Humber) cemeteries may represent more normalised Anglo-Saxon infant burial 
patterns (Inskip, 2008), as may the recent and ongoing (full demographic details yet to be 
published) excavations at Oakington, Cambridgeshire (Sayer et al., 2011).    
This bias in the archaeological record is certainly reflected in many of the sites 
selected for this study (e.g., Figures 6.4 and 6.10; Tables 6.3 and 6.4), and may reflect poor 
bone preservation, or differential burial practice (Inskip, 2008). The former should, 
theoretically, be applicable to many lowland Fen-associated sites, where repeated exposure 
to constantly fluctuating groundwater levels may accelerate bone diagenesis (Jans et al., 
2002). It has been argued that the acidity of peat soils may have a protective effect on buried 
bone in terms of reducing microbial attack (Manifold, 2012). Yet, there remains a 
demonstrated correlation between decreasing soil pH and bone deterioration (Gordon and 
Buikstra, 1981). Acidic soils may, at the very least, have a demineralising effect upon bone, 
thereby increasing the vulnerability to non-microbial diagenetic factors. In the most extreme 
cases, soil acidity can completely dissolve the mineral content of bone (Forbes, 2008). It 
would, of course, be foolish to assume that all Fen-associated sites have the same geology 
and would, therefore, display the same preservation patterns. Fen-edge sites, such as The 
Hoplands and Edix Hill, are likely to have different soil types to the Fen islands of Littleport 
and Ely, which would likely differ to the estuarine soils of Barton-upon-Humber. The same 
can also be said of the non-Fen sites, which represent a variety of different locations and, 
consequently, different geologies/soil types spread throughout Britain. As addressed in 
section 4.3.1, bone diagenesis and deterioration is influenced by a multitude of extrinsic and 
intrinsic factors which can result in differential intra-site and even intra-grave skeletal 
preservation.  
A higher quantity of infants from Fen cemeteries may be expected due to increased 
mortality associated with living in unsanitary conditions (i.e., associated with the 
‘insalubrious’ Fens). Post-medieval parish registers, for instance, show that 25% of infants 
born in Ely died in their first year, with only half surviving to 15 years of age (Dobson, 
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1997:167). Such high infant mortality patterns are observed in modern developing countries, 
where infant mortality rates can exceed that for neonates (Saunders and Barrans, 1999; Hill 
and Amouzou, 2006). This pattern, however, is not shown in this study. The reduced 
quantity of foetal/neonate bones in all sites from all periods are likely suggestive of a 
combination of many factors, including preservation bias and period-specific burial customs, 
such as those mentioned earlier for the Roman period. 
An important limitation which affects most, if not all, palaeodemographic research 
based on cemetery populations, is the fact that the excavated skeletal series are rarely 
representative of the actual burial record (Wood et al., 1992; Waldron, 1994), for numerous 
reasons. These include, for example, differential burial practices and taphonomy, such as 
may have adversely affected the number of infant skeletons in the Fen populations analysed 
here. A further example would be an attritional cemetery (particularly if associated with a 
church), which might expect to receive many hundreds, if not thousands of burials over its 
use-life. This would result inevitably in the disturbance of earlier graves by later burials and 
a subsequent abundance of disarticulated remains upon excavation. It is also rare for modern 
commercial archaeological projects to be excavate entire cemeteries, since this would be 
extremely time consuming and expensive for the developer. A cemetery excavation would 
usually yield inhumed individuals only from areas under threat of destruction, thus leading 
to a biased sample. Even for sites that were not necessarily under threat of immediate 
development, such as St Peter’s Church and Wharram Percy, the actual quantity of skeletons 
excavated would represent a fraction of the total number of burials in these locations. Bell 
and Beresford (1987), for instance, suggest that there may have been up to 10,000 burials in 
the Wharram Percy churchyard, yet excavations yielded less than a tenth of this figure 
(Mays, 2007). Reported mortality figures for this study are, therefore, actually prevalence 
rates of individuals from the excavated burial sample, rather than true mortality figures for 
the entire population. Any interpretations concerning cemetery populations must 
acknowledge these sample biases. Waldron (1991:24) neatly summarised the problem faced 
by palaeodemographers: 
“The underlying assumption that is inherent in any attempt to use a death assemblage 
 to predict something about the living is that the dead population is representative – or 
 at least typical – of the live population. Given all the non-random events that 
 surround death and burial, not to mention preservation and recovery, this is at best an 
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 approximation, and at worst the two (the live and the dead) bear no epidemiological 
 relation to each other whatsoever…” 
 
The reliability of palaeodemographic reconstruction and interpretation is based upon 
accurate assessments of biological data (e.g., individual age and sex) in skeletal populations 
(White and Folkens, 2005). The accuracy of methods used to age adult skeletons has long 
been debated. Many of the commonly used ageing techniques in palaeopathology are based 
upon skeletal individuals of known age (Roberts and Manchester, 2005). The assumption is, 
therefore, that growth and deterioration, and the development of skeletal age ‘markers’, are 
universal processes. The application of ageing criteria derived from (often modern) skeletal 
individuals of known age to archaeological populations, therefore, fails to account for the 
complex variation of factors that influence ageing (Schmitt et al., 2002). In a reflection of 
the numerous methods available and the difficulties inherent in ageing adult skeletons, they 
are often attributed an age range based upon a variety of morphological changes (e.g., 
degeneration of joint surfaces in the pelvis, or dental attrition) (Roberts and Manchester, 
2005). Given the difficulties of accurately ageing adult skeletons, it is vital that 
palaeopathologists detail their choice of analytical methods. However, as previously 
mentioned (Section 5.2.1), the range of lack of standards used for ageing immature and adult 
skeletons and the poor reporting of methods employed can impact upon the reliability of 
demographic analyses (Ubelaker, 2008). This study relied upon extant skeletal reports and 
was therefore dependent upon analyses performed by numerous people over an extended 
time period; some of these were compiled before the need for standardised recording 
techniques became apparent. Although some reports (e.g., at St. Peter’s Church) made clear 
their use of multiple age indicators in an attempt to improve accuracy, many of the earlier 
reports (e.g., Anderson, 1996) in particular failed to specify exact methods used for age 
estimation. An ideal scenario would have been to reassess each skeleton in each report using 
standardised ageing criteria. As this was not possible for this small study, individuals were 
assigned an age category, where possible. The use of relatively broad age categories should 
have mitigated some of the issues associated with non-standardised ageing methodologies. 
The large overall sample sizes used in this study would have helped reduce some of the 
issues associated with poor ageing standardisation between reports. 
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The male and female adults who could not be placed into an age category must be 
considered when interpreting the adult percentages. Over 19% and 13% of Fen and non-Fen 
males and females, respectively, were recorded only as ‘adult’ (i.e., over 18 years of age). 
This could have significant implications for interpretations of the burial percentages, since 
these individuals could potentially fit into any of the adult age categories. These adults were 
not included in the mortality profiles, but the fact that up to a fifth of the excavated adult 
population is missing may lead to erroneous interpretations and conclusions based on the 
remaining aged individuals, especially if the unaged adults were biased towards one 
particular age group.  
The sex of adolescent skeletons can be difficult to estimate due to a lack of sexually 
dimorphic characteristics (Roberts and Manchester, 2005). This means that both males and 
females are represented in the 12-17 year age category for this study. Although one of the 
smaller categories in terms of percentage of burial population (4.9% Fen, 5.4% non-Fen), 
the lack of sex differentiation has implications for comparing adolescent female mortality 
rates by location. This represents the age range in which adolescents reach sexual maturity, 
and there may, therefore, be an expected increase in pregnancy-related mortality in this 
group. 
Although the Barton-upon-Humber site may offer the first evidence for intrauterine 
growth restriction in an archaeological population, IUGR as a result of P. vivax infection 
would be very difficult to identify, since the target skeletal demographic (i.e., neonates and 
infants) are groups with notoriously high mortality rates in all periods of antiquity. In order 
to potentially support the presence of P. vivax, observation of a phenomenon of 
comparatively ‘small’ neonates and infants in other Fen cemeteries would be required. A 
physical reappraisal (in the form of femoral measurements) of other cemetery populations 
with sufficient numbers of burials is required to support a possible link between Fen 
environment and small infants. Even then, the prevalence may not necessarily be attributable 
to P. vivax, since the unsanitary conditions associated with Fen environments may influence 
the development of IUGR. Early childhood catch-up growth in survivors of IUGR may also 
confound attempts at identification past the infant stage.  
It should be remembered that since the main focus of this research project was the 
identification of biomolecular malaria markers, time permitted only a relatively small and 
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basic palaeodemographic study, rather than an exhaustive investigation. The resulting 
evidence deserves a thorough analysis over and above the search for indirect indicators of 
malaria. Such analysis was, unfortunately, beyond the scope for this study. Nevertheless, it 
has provided a useful starting point for further interpretation and possible demographic 
analyses of archaeological populations from Fen environs. Further cemeteries, such as 
Oakington in Cambridgeshire (Sayer et al., 2011) and Cuxon in Kent (Powers and 
Langthorne, 2006), have since been identified that could be included in any future 
comparisons of Fen and non-Fen demographics.  
 
7.2: Histological preservation and implications for protein extraction 
This section discusses the observed relationship between microscopic preservation 
and macroscopic preservation, before exploring the implications of histological preservation 
for extracted protein yield and preservation. Differential protein yields from element types 
are also discussed here.  
 
7.2.1: Histological and macroscopic preservation 
 
 It is well established that bone diagenesis often occurs independently on the 
macroscopic and microscopic levels, and that external preservation state may provide no 
indication of histological preservation (Jans et al., 2002; Mays, 2010). The samples selected 
for this study support this, with numerous examples of externally well preserved samples 
displaying very poor histological preservation. This was particularly noticeable with the 
Highfield Farm, Littleport samples (Table 6.19), for which, as expected, poor macroscopic 
preservation often correlated with lower Histological Index (HI) scores (71% scored 0 or 1). 
However, 53% of samples displaying good macroscopic preservation also scored 0 or 1 on 
the HI, whereas only 12% scored 4 or 5. This complements earlier research by Hanson and 
Buikstra (1987), which demonstrated that the preservation of microscopic bone structure 
was often independent of the gross, cortical preservation.  
 As mentioned above (section 7.1.2(iii)), low-lying Fen-associated cemeteries may be 
more frequently exposed to fluctuating ground-water levels than non-Fen upland sites. 
Hydrological action is an important factor in bone deterioration, and has even been 
suggested to be the most significant extrinsic agent of diagenesis (Cattaneo et al., 1995). The 
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Littleport site provides a good example of the discrepancy between gross and microscopic 
preservation, and is a site where cyclical exposure to fluctuating ground-water was cited as 
being an important diagenetic agent, alongside generally shallow burial and root action 
(Western, 2007). At this site, macroscopic skeletal preservation was judged to be overall fair 
to good (Figure 7.1). Histological analysis, however, demonstrated that the sampled 
Littleport elements were generally very poorly preserved, with 82% of all samples being 
scored as 0-1 on the HI (Table 7.1). 
 
 
Figure 7.1: Observed macroscopic preservation of skeletal remains from Highfield Farm, 
Littleport (data reproduced with permission of G. Western). 
 
 
 
 
 
 
 
 
 
 
 
339 
 
OHI Rib Cranium 
Hand 
Phalanx 
Foot 
Phalanx 
0 30 25 4 2 
1 8 9 2 2 
2 3 3 2 6 
3 0 0 2 1 
4 0 0 0 0 
5 0 0 0 0 
Table 7.1: Percentages of Littleport bon elements in each HI (histological preservation) 
category. 
 
 This study suggests that the underlying geology may be an important factor in 
histological bone preservation. The Edix Hill cemetery, for example, is located on a chalk 
knoll surrounded by clay lowlands (Malim and Hines, 1998). Overall, the histological bone 
preservation at this site was the highest of any selected for this research. Histological and 
proteomic analysis of sample EH156.3, for instance, demonstrated good preservation of both 
collagen and microscopic bone structure, which suggests optimal local conditions. 
Conversely, as discussed above, microscopic bone preservation at the Littleport site, which 
is situated on a clay and silt island (Holt, 2008), was exceptionally poor. This pattern of poor 
preservation is mirrored at Westfield Farm, which is situated on the south western extremity 
of Ely Island, on a geology of sand, silt, and clay (Newman, 2007). 
 One variable that may prove useful in the prediction of microscopic sample 
preservation is element type. Table 6.23 and Figure 6.33 suggest that, in this study, hand 
phalanges had the best chance of being well preserved (28% scored 4-5 on the OHI), 
whereas ribs and cranial samples displayed overall much poorer preservation (10% scored 4-
5 on the OHI). This pattern is likely due to three main factors, the first being cortical 
thickness, the second being element size, and the third being anatomical position and 
location within the grave. Cortical thickness of each element type became apparent during 
sample cutting, when the cortex was exposed in cross section. Hand and foot phalanges 
displayed the thickest cortices, followed by the cranium (vault), and ribs. This is broadly 
reflected in the overall histological preservation of each element type (Table 6.23; Figure 
6.33). Anatomical position and location within the grave may serve to protect hand 
phalanges (which in the author’s experience tend to survive preferentially over foot 
phalanges), since they are often less prominent and therefore less prone to post-mortem 
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damage than the ribs or skull. Their small size may also help to protect them from 
mechanical damage. 
These factors do not mean that all the phalanges were well preserved; 51% and 53% 
of hand and foot phalanges scored 0-1 on the OHI, respectively. They merely suggest that 
these elements seem to have a better chance of resisting diagenesis when compared to the 
other element types investigated in this study. Although these elements tend to be less 
frequently retrieved from the burial context, their increased histological preservation 
somewhat contradicts previous experimental research, which has demonstrated that small 
bones are less resistant to diagenesis (e.g., Von Endt and Ortner, 1984; Waldron, 1987c). It 
should be stated, however, that ‘preservation’ and rates of diagenesis can be measured in 
more ways than through macroscopic and microscopic analysis. Von Endt and Ortner 
(1984), for instance, measured artificially induced diagenesis rates through analysis of extant 
nitrogen in bone. In addition, the size of bones may be less influential than the age of the 
individual represented; small elements (e.g., phalanges) from sub-adults could be more 
prone to diagenesis than their adult counterparts, for instance. Purely in terms of 
macroscopic preservation, Bello and Andrews (2006) found that hand and foot phalanges 
were often well preserved, likely on account of their cortical thickness and reduced 
medullary cavity size – a suggestion supported by this research. Although always small in 
size, the hand and foot phalanges chosen in this study were often whole, closed systems, 
whereas cranial and rib samples were always fragmented. This increases exposure of the 
internal structures to diagenetic factors, so elements less prone to fragmentation should 
suffer less degradation. 
 As discussed in section 4.3.1, diagenesis and bone degradation are multifactorial 
processes and it cannot be assumed that macroscopic preservation or element type will 
correlate with microscopic preservation. While cortical thickness is an important factor in 
diagenetic resistance, the nature of the burial and the position of elements within the grave 
may also influence their microscopic degradation. The shallowness of burials at many sites, 
including Cleatham, Westfield Farm, and Littleport, increased the possibility of post-mortem 
damage, thus lowering the resistance of elements to extrinsic diagenetic influences. It is 
perhaps unsurprising that the rib and cranial samples displayed the poorest preservation of 
all elements, given their usual prominent positions and often fragmented state in the grave.  
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It might be expected that older samples would display poorer histological 
preservation, since they were exposed to taphonomic processes for longer. A comparison of 
percentages of elements in each OHI category from the Roman and Anglo-Saxon sites, 
however, shows the inverse is true for this set of samples. Figure 6.34 demonstrates that the 
Roman samples display a significantly (χ2 <0.01) better overall level of preservation than the 
Anglo-Saxon samples. This suggests that microscopic preservation is independent of time 
since burial, at least for these samples. This conclusion is in line with other studies which 
have shown little correlation between preservation and burial period (e.g., Hedges et al., 
1995). Histological preservation is also shown to be statistically independent (χ2 p = 0.19) of 
the age category of the individual from which the elements were sampled (Figure 6.35), a 
conclusion which supports Manifold’s (2013) research on sub-adult bone preservation. 
These results may be used to support an argument that the immediate burial 
environment and its associated taphonomic processes have more fundamental effects on 
bone diagenesis than either the historical age of the bone, or the age-at-death of the 
individual from which the sample is taken. Pathological processes (e.g., conditions that may 
weaken the bone structure) may well contribute to the degradation of bone, but this was 
controlled for here through the selection of non-pathological bone samples. This could not, 
of course, guarantee a lack of pathology – it could only control for macroscopically 
observable pathological conditions. 
7.2.2: Histological preservation and implications for protein extraction, yield, and 
preservation 
The use of thiophilic adsorption chromatography (TAC) in this study has permitted 
the accurate recording of total and eluted protein yields from each P2, P3, and P4 extraction 
stage through spectrophotometry (yields read at 280nm). It has, therefore, been possible to 
compare protein yields from samples of differing histological preservation following a 
variety of extraction techniques, and to investigate correlations between histological 
preservation and protein yield. Protein yield and archaeological bone preservation have been 
previously investigated in association with collagen extraction for isotopic study or 
radiocarbon dating (e.g., Schoeninger et al., 1989; Pfeiffer and Varney, 2000), where the 
yield is measured by the percentage of extracted collagen, by the surviving carbon to 
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nitrogen ratios, or by the amino acid profile of the extracted proteins. This study represents 
the first to assess protein yields following immunoaffinity chromatography. 
Spectrophotometry cannot, of course, characterise the type or integrity of the extracted 
proteins; this would require analysis through mass spectrometry. It can, however, 
demonstrate which protocols and associated extraction stages are more efficient at releasing 
proteins from samples of differing histological preservation. 
An immediate limitation to this approach is that not all of the HI categories are 
equally represented in the samples subjected to TAC (Table 7.2). For example, only one 
sample with an HI score of 1 was tested (sample HDJS4 in P2.3), while no samples with an 
HI score of 3 were investigated. Samples were often chosen to maximise the chance of 
investigating the hypothesis that non-collagenous proteins are preferentially retained over 
collagen in poorly preserved bone (after Masters, 1987). In order to efficiently evaluate this 
hypothesis, it was considered prudent to select the majority of samples from polar ends of 
the HI scale. Unfortunately, the very low throughput and extended time demands of 
subjecting three-stage extraction protocols to TAC meant that only a very limited number of 
total samples could be investigated. 
HI TAC samples 
0 5 
1 1 
2 2 
3 0 
4 3 
5 11 
Table 7.2: Number of samples in each HI (histological preservation) category subjected to 
TAC. 
When examining the graphs presented in Section 6.5, it should be recalled that yields 
from TAC elutions (measured in µg/ml) are those which result from the elution stage of the 
TAC protocol (e.g., Figures 6.68 and 6.71), which is the stage intended to elute bound IgGs 
from the columns. This should not be confused with total or average protein yields (e.g., 
Figures 6.66, 6.69, and 6.72), which include the yields from wash steps and elutions 
(measured in mg/ml). 
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Figures 6.66, 6.67, 6.69, 6.70, 6.72, 6.73, and Table 6.52 demonstrate a general 
pattern of P2 and P4 decreasing total and average protein yields as histological preservation 
increases. The only exception to this is the sample HDJS4 (HI: 1) extracted in P2.3, which 
produced unexpectedly low total and elution protein yields in comparison to other samples 
of relatively low HI. Although this sample seems to be an outlier in terms of fitting the 
overall observed yield pattern, the quantity of eluted protein is comparable to other samples 
of low preservation (Figures 6.67 and 6.68). The overall pattern observed in the P2 and P4 
extractions supports Pfeiffer and Varney’s (2000) finding that poorly preserved bone 
produces the highest protein yields. The P3 extractions do not entirely support this finding 
(Tables 6.54 and 6.56), since the best preserved samples released more protein in the second 
and third extraction stages. This may be due to the fact that only four samples were tested 
here, and all were well preserved (HI 4 or 5). The increased P3 second stage yields compare 
to the P2 and P4 third stage, and can be explained by the use of guanidine-HCl and EDTA at 
these stages. An elevated P3 third stage protein yield for sample CD120.2 (HI: 5) may 
indicate a correlation between increased protein retention and histological preservation. 
Further testing of a greater range of samples using the P3 protocol is necessary to clarify the 
reasons for this somewhat unexpected yield pattern. 
The general correlation of increasing protein yield with decreasing histological 
preservation suggests that less chemical intervention is required to disassociate extant 
collagen fibrils from poorly preserved bioapatite matrix. Further to this, the integrity of the 
collagen itself is likely to be diminished in these cases of poor preservation, resulting in 
increasing protein yield early in the extraction process. These suppositions are supported by 
Tables 6.44 and 6.45, which suggest a slight decrease in collagen integrity from all P4 
extraction stages in poorly preserved bone. This was assessed by comparing peptide 
numbers and sequence coverage through nLC-MS/MS analysis (section 6.4.5(i)). The 
investigation of correlations between histological preservation and protein yield suggests 
that screening of sample preservation should form an important precursor in sample 
selection if well preserved endogenous protein is a requirement for analysis. This is 
evidenced in Tables 6.39 (sample CD84.2, HI: 0) and 6.42 (sample EH156.3, HI: 5), which 
suggest a correlation between histological preservation and both NCP quantity and integrity. 
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7.2.3: Protein yield and quality by element type 
Wiechmann et al. (1999) observed no significant difference in protein quality or 
quantity between extracts from the femur, rib, and phalanges, although no attempt was made 
to characterise the preservation status of their samples prior to extraction. It is difficult to 
make direct comparisons of protein yield and quality between this and Wiechmann et al.’s 
(1999) research, since the extraction methodologies differ quite significantly. The latter used 
a one-stage extraction (guanidine-HCl) followed by dialysis and, in some instances, 
ultracentrifugation. These final steps are intended to desalt, concentrate and remove small 
molecular components (e.g., heavily degraded collagen). This study used at least two 
extraction stages (depending upon the protocol followed) on bone of known microscopic 
preservation status and measured bulk protein yield from TAC purification. Thus, all non-
resin-bound protein is being recorded in the yield, including the proteins which would be 
removed if following the methodology of Wiechmann et al. (1999).   
It is interesting to note the differences in collagen and NCP quantity and integrity 
from P3 sample CD120.2 (hand phalanx, HI: 5) and P4 sample EH156.3 (cranium, HI: 5), as 
characterised by nLC-MS/MS analysis of TAC resin-bound proteins. Tables 6.45 and 7.4 
suggest that well preserved cranial samples subjected to the P4 extraction protocol released 
collagen and NCPs in higher quantities and of higher quality, as shown by the increased 
diversity of resin-bound proteins, higher sequence coverages, and greater numbers of 
uniquely identified peptides. Tables 6.43 and 7.4 suggest that the same element type yields 
far less protein following the P3 protocol. When the results from all protocols and samples 
are averaged and histological preservation is disregarded (Table 6.55), the difference in total 
protein yield by element is small, a finding which may support the conclusion of 
Wiechmann et al. (1999). 
Variation in the average elution percentage of total protein yields by element is 
interesting, in that ribs seem to display an inverse relationship between the two (Tables 6.53 
and 6.54): they produced low protein yields, yet the highest resin-bound yields, particularly 
when following the P3 extraction protocol (Tables 6.49 to 6.52). It may be the case that 
well-preserved ribs represent the best target element for IgG extraction due their life-long 
haematopoietic function and the increased binding of extracted rib proteins to the TAC 
resins. However, given the observed propensity for non-specific collagen and NCP binding, 
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proteomic analysis of pre- and post-TAC rib samples would be required to confirm this 
hypothesis.  
Hand phalanx samples CD112.3 (HI: 2) and LP4585.3 (HI: 2) demonstrate the 
influence of variables beyond element type and histological preservation, when assessing 
total protein yield (Table 6.52). Despite the similarity in microscopic preservation level, the 
Littleport sample (LP4585.3) yielded less than half the protein of its Castledyke 
contemporary (CD112.3). It is possible, then, that site location and local diagenetic factors 
may explain this disparity. Many Littleport samples, for instance, exhibited infiltration of an 
unidentified yellowish substance, which either destroyed or obscured much of the extant 
bone matrix. While Tables 6.52 and 6.59 suggest that protein yield is dependent upon both 
histological preservation and the choice of extraction protocol, the above example of 
CD112.3 and LP4585.3 shows that histological preservation may be useful in predicting 
yields and quality of extracting proteins, but should not be completely relied upon. 
Proteomic analysis of pre-TAC samples and their post-TAC elutions from all selected 
element types representing all histological preservation levels would potentially demonstrate 
which element represents the best target for NCP extraction.  
7.2.4: Protein preservation 
 The importance of characterising the preservation of bone samples by histological 
analysis prior to protein extraction has been well established (e.g., Schoeninger et al., 1989; 
Schmidt-Schultz and Schultz, 2004). Histological preservation may be an important 
precursor in screening out contamination, but does it necessarily indicate which samples are 
more likely to provide the purest, most well-preserved protein yield? Although it may 
logically follow that histological preservation would provide a useful indication of the level 
of protein integrity, previous research on archaeological bone has demonstrated a distinct 
lack of correlation between histological integrity and the preservation of collagen, in 
particular (Pfeiffer and Varney, 2000). Nanospray LC-MS/MS analysis of a small number of 
excised P3 SDS-PAGE gel bands (Figures 6.61 and 6.62; Table 6.34) and P3 and P4 post-
TAC samples (section 6.4.5) has provided interesting evidence that may be used to compare 
between studies and extraction techniques.  
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 Three useful proteomic indicators of ancient protein survival and preservation are 
observed peptide number, confidence intervals, and peptide sequence coverage (De 
Hoffman and Stroobant, 2007). The first and second are, respectively, measures of how 
many peptides unique to individual proteins have been detected, and the level of confidence 
(e.g., 95%) that these peptides have been accurately identified. The sequence coverage (i.e., 
the percentage of peptide sequences that match a known protein sequence) resulting from 
proteomic analysis of samples with known histological preservation can provide a general 
indication of protein integrity. Accomplishing a 70% peptide sequence coverage is 
considered to represent a successful analysis using modern samples (De Hoffman and 
Stroobant, 2007), but there are a number of reasons why achieving a high peptide sequence 
coverage presents a significant challenge. Poor detection resulting in low coverage may be 
due to limited (e.g., <5000Da) or excessive size of peptides, which may cause them to either 
be lost from the LC column, or lost through adsorption or ineffective elution to and from 
gels or tubes (Wu et al., 2005). These problems would be exacerbated by peptide 
fragmentation, which may itself render the peptides ‘unreadable’ by the mass spectrometer 
(De Hoffman and Stroobant, 2007). Proteins of extremely low abundance in the sample may 
also be ‘masked’ by those of greater abundance. While samples can be analysed against 
exclusion lists in order to characterise proteins present in smaller quantities, this can be an 
extremely time consuming process (Adrian Brown, personal communication, March 2014), 
and was only attempted on two P3 post-TAC samples (see section 6.4.5). 
 It may be expected that confidently-identified peptides recovered from 
archaeological bone would be extremely small in number, with sequence coverage falling 
well below 70% due to protein diagenesis and fragmentation over an extended burial period. 
However, advances in proteomic technologies and extraction methodologies have provided 
extensive peptide sequences for ancient mammalian collagen (e.g., Buckley et al., 2010; 
2011), the most abundant protein in bone, and a variety of non-collagenous proteins (e.g., 
Solazzo et al., 2008; Cappellini et al., 2012). NLC-MS/MS analysis of selected excised gel 
bands and post-TAC elutions (section 6.4.3(ii) and 6.4.5) in this study revealed collagen, 
keratin (the latter the result of extrinsic contamination), and a small quantity of non-
collagenous (not including IgG, unfortunately) and non-human proteins. Proteomic analysis 
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may offer useful clues to the type and extent of degradation in samples of differential 
histological preservation. 
7.2.5: Collagen preservation in SDS-PAGE band samples 
 Proteomic analysis suggests that collagen from gel band sample CD120.2 (HI 5) 
suffered less degradation than in EH198.1 (HI 4), providing at their highest a 72.8% and 
34.5% sequence coverage, respectively (Table 6.34). The spectra from one CD120.2 gel 
band (Figure 7.2) with a relatively high coverage of 62.2% shows limited evidence of 
degradation/modification through deamidation, a spontaneous chemical reaction which 
removes an amide group, hence modifying protein functionality (Robinson, 2002). Here, 
deamidation has affected the amino-acid asparagine (N), which represents an extremely 
common non-enzymatic protein modification (Yang and Zubarev, 2010). Full modifications 
for all analysed samples can be seen in Appendix 3. 
MFSFVDLRLLLLLAATALLTHGQEEGQVEGQDEDIPPITCVQNGLRYHDRDVWKPEPCRICV
CDNGKVLCDDVICDETKNCPGAEVPEGECCPVCPDGSESPTDQETTGVEGPKGDTGPRGPRG
PAGPPGRDGIPGQPGLPGPPGPPGPPGPPGLGGNFAPQLSYGYDEKSTGGISVPGPMGPSGPRG
LPGPPGAPGPQGFQGPPGEPGEPGASGPMGPRGPPGPPGKNGDDGEAGKPGRPGERGPPGPQ
GARGLPGTAGLPGMKGHRGFSGLDGAKGDAGPAGPKGEPGSPGENGAPGQMGPRGLPGER
GRPGAPGPAGARGNDGATGAAGPPGPTGPAGPPGFPGAVGAKGEAGPQGPRGSEGPQGV
RGEPGPPGPAGAAGPAGNPGADGQPGAKGANGAPGIAGAPGFPGARGPSGPQGPGGPP
GPKGNSGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGLPGPPGE
RGGPGSRGFPGADGVAGPKGPAGERGSPGPAGPKGSPGEAGRPGEAGLPGAKGLTGSPGSP
GPDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGVPGPPGAV
GPAGKDGEAGAQGPPGPAGPAGERGEQGPAGSPGFQGLPGPAGPPGEAGKPGEQGVPGDL
GAPGPSGARGERGFPGERGVQGPPGPAGPRGANGAPGNDGAKGDAGAPGAPGSQGAPGLQ
GMPGERGAAGLPGPKGDRGDAGPKGADGSPGKDGVRGLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGEPGDAGAKGDAGPPGPAGP
AGPPGPIGNVGAPGAKGARGSAGPPGATGFPGAAGRVGPPGPSGNAGPPGPPGPAGKE
GGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGPAGAPGTPGPQGIAGQRGVVGL
PGQRGERGFPGLPGPSGEPGKQGPSGASGERGPPGPMGPPGLAGPPGESGREGAPGAEGS
PGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGPTGPVGPVG
ARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSGLQGPPGPPGSPGEQGPSGASGPAGPRG
PPGSAGAPGKDGLNGLPGPIGPPGPRGRTGDAGPVGPPGPPGPPGPPGPPSAGFDFSFLPQP
PQEKAHDGGRYYRADDANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCRDLKMC
HSDWKSGEYWIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKDKRHVW
FGESMTDGFQFEYGGQGSDPADVAIQLTFLRLMSTEASQNITYHCKNSVAYMDQQTGNLKK
ALLLQGSNEIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKTSRLPIIDVAPLDVGAP
DQEFGFDVGPVCFL 
Figure 7.2: Complete sequence of human collagen alpha-1 chain with peptides 
identified by nLC-MS/MS analysis of P3 sample CD120.2 lane 4 upper gel band 
(62.2% coverage). Bold text - high-confidence matched peptides; italic text - 
medium confidence; underlined text – low-confidence; N – asparagine deamidation. 
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The six gel bands analysed from P1.2 (Figures 6.41 and 6.42; Table 6.24) show an 
average collagen peptide sequence coverage of only 35.8%, despite the samples HDAR3 
and HDAR4 displaying HI scores of 4 and 5, respectively. The disparity in coverage 
between P1.2 and P3 may be the result of slightly different precipitation and sample 
preparation methods prior to SDS-PAGE, or it may be indicative of poor correlation 
between histological preservation and collagen integrity. Correspondingly low collagen 
peptide sequence coverage in the P3 post-TAC sample (Table 6.47) may support the former 
suggestion, since it represents the same sample (CD120.2) as shown above in Figure 7.2. 
Low sequence coverage from gel bands may also be the result of selecting bands 
representing proteins of specific molecular weights. Bands that possibly correspond to IgG 
fragments, for example, would also include any other proteins of that weight, including 
collagen fragments in various states of degradation.  
 
7.2.6: Collagen and histological preservation in the P3 and P4 post-TAC samples 
 When assessing the impact of histological preservation on protein survival in this 
study, it should be recalled that P3 and P4 samples analysed by nLC-MS/MS represent post-
TAC elutions. The protein yields from these elutions represent a fraction of the total pre-
TAC yields, since the resins are designed to extract IgGs. Consequently, any non-IgG 
proteins present in the elutions have been bound non-selectively. It is uncertain exactly how 
these non-selectively bound proteins relate to the non-bound fractions, and why they were 
preferentially bound over others. It may be the result of protein degradation or unspecified 
interactions of buffer reagents which may increase the binding on non-IgG proteins (see 
sections 7.3.3 for further discussion of this).  
 Tables 6.47–6.49 (section 6.4.5(i)) display the characteristics of the resin-bound 
collagen from post-TAC P3 and P4 samples. Elutions from the P3 second stage were 
analysed due to the demonstrated elevated protein yield observed in extraction stages 
incorporating guanidine-HCl solublisation (see Table 6.50). Summary Table 7.3, and Tables 
6.47-6.49 show that the P3 sample yielded a less diverse number of resin-bound collagen 
isoforms than P4 sample EH156.3, despite their comparative high level of histological 
preservation. Indeed, more diversity was seen in CD84.2 (HI: 0) than in CD120.2 (HI: 5). 
This may suggest that P4 is the more effective protocol for collagen extraction, perhaps in 
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part due to the absence of the HCl demineralisation stage in the P3 protocol. As discussed in 
section 7.7.5, HCl demineralisation increases the solubility of collagen (Cleland et al., 2012) 
and may induce a greater collagen yield in later extraction stages. The number of peptides 
and their sequence coverages are also much lower for the P3 sample. It is difficult to 
ascertain the reasons behind the relative lack of extracted collagen and its apparently poorer 
quality in the P3 sample. The two main variables here are bone element type and extraction 
protocol. It may be the case that the thick cortex of the CD120.2 (hand phalanx) required 
more intense chemical treatment (due to less efficient homogenisation) than provided by the 
P3 protocol in order to release well-preserved collagen, although it may be expected that 
sonication would be more than sufficient to release retained collagen. Conversely, the 
difference in collagen preservation between P3 and P4 may be an artifact of the non-specific 
TAC binding, perhaps related to differential impact of extraction techniques and reagents 
upon both the thiophilic resin and surviving collagen molecules. 
 In general, increased histological preservation seems to correlate with the retention 
of a greater diversity of collagen isoforms, although their successful acquisition may be just 
as dependent upon the inclusion of a demineralisation extraction stage. Full proteome 
analysis of pre-TAC samples would allow for a deeper investigation into the effects of 
histological preservation on the retention of collagen in bone. 
Sample CD120.2 EH156.3 CD84.2 
Histological Index 5 5 0 
Period Anglo-Saxon Anglo-Saxon Anglo-Saxon 
Location Castledyke Edix Hill Castledyke 
Element Hand phalanx Cranium Cranium 
Age Very young adult Young adult Very young adult 
Protocol P3 P4 P4 
Collagen isoforms 2 4 3 
Average SC/P 30.1/16 75.2/77 74/82 
Identified NCPs 2 12 6 
Table 7.3: Comparison of variables and extracted peptide characteristics for nLC-MS/MS 
analysed post-TAC P3 and P4 samples. SC/P – sequence coverage (%)/peptides (95% 
confidence). NCPs represent only endogenous human proteins. 
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7.2.7: Non-collagenous protein (NCP) preservation 
 Table 7.4 demonstrates differences in the quantity of resin-bound NCPs between 
extraction protocols and histological preservation. NLC-MS/MS analyses suggests that bone 
displaying higher preservation (i.e., EH156.3, HI: 5) yields NCPs in greater quantity (Tables 
7.7 and 7.8) and of better integrity (Table 7.4). The apparent lack of resin-bound collagen 
and NCPs from P3 sample CD120.2 (HI: 5) may suggest that this relationship is partially 
dependent upon the choice of extraction protocol. Possible reasons for differential collagen 
and NCP binding between protocols are explored in section 7.3.3. The observed correlation 
between protein quantity/quality suggests that well-preserved bone represents the best target 
for future NCP extractions, despite the fact that the NCPs characterised here (Table 7.4) 
represent TAC resin-bound proteins, rather than the full range of pre-TAC proteins. Firm 
conclusions based on these observations are difficult, however, due to the small sample 
numbers subjected to proteomic analysis. 
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CD120.2 (HI: 5) CD84.2 (HI: 0) EH156.3 (HI:5) 
 
P3 P4 P4 
Protein 
Sequence 
Coverage 
(%) 
Peptides 
(95%) 
Sequence 
Coverage 
(%) 
Peptides 
(95%) 
Sequence 
Coverage 
(%) 
Peptides 
(95%) 
Terminal 
uridylyltransferase 4 
6.5 1 - - - - 
Ankyrin repeat and 
SOCS box protein 18 
9.2 1 - - - - 
Vitronectin - - 12.1 1 21.5 3 
Chondroadherin - - 14.8 2 28.7 2 
Pigment epithelium-
derived factor 
- - 12.2 1 21.5 3 
Biglycan - - 4.6 1 6.1 3 
Prothrombin - - 12.9 1 17.8 2 
Cystatin-A - - 38.8 1 - - 
Protein argonaute-4 - - - - 7.9 1 
Protein AHNAK2 - - - - 11.1 1 
Alpha-2-HS-
glycoprotein 
- - - - 14.4 1 
Osteomodulin - - - - 4.3 1 
Lumican - - - - 5.6 1 
Matrix Gla protein - - - - 36.9 4 
Dermatopontin - - - - 9.5 1 
Table 7.4: Comparison of extracted endogenous human NCP sequence coverage and peptide 
numbers for P3 and P4 post-TAC samples.  
 Further proteomic analysis of bones exhibiting a full range of histological 
preservations is required here to investigate a possible correlation between histological 
preservation and protein degradation. The extremely limited evidence presented may 
tentatively suggest that bone displaying better histological preservation may yield protein of 
higher quantity and integrity. This would be a logical conclusion if increased peptide 
sequence coverage is indicative of protein integrity, yet would contradict previous research 
(e.g., Pfeiffer and Varney, 2000), which failed to find a correlation between histological and 
protein preservation. It must, however, be stressed that the two studies used different 
methods of extracting protein and assessing preservation. An aim of Pfeiffer and Varney’s 
(2000) research was to investigate whether histological preservation might be used to select 
bone samples suitable for palaeodietary isotopic analysis. They therefore used a technique 
designed for maximum retrieval of collagen and assessed protein integrity through 
examination of remaining carbon and nitrogen elemental values and amino-acid profiles (the 
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latter characterised by High Performance Liquid Chromatography). This study used 
extraction techniques designed to either maximise the extraction of non-collagenous protein 
(e.g., P1 and P3), or to extract as much protein as possible (e.g., P2 and P4). Integrity here 
was assessed though nLC-MS/MS analysis and identification of surviving protein peptide 
sequences. Direct comparison of conclusions between studies is, therefore, difficult. 
7.3: Protein and immunoglobulin extraction and characterisation 
protocols 
 
 This section considers the different protein and immunoglobulin extraction protocols 
(P1-P5) and the subsequent protein characterisation methods employed in this study in terms 
of their effectiveness in extracting and characterising archaeological IgGs. 
 
7.3.1: P1: adapted Schmidt-Schultz and Schultz (2004) extraction protocol 
 
 The first method employed to extract IgGs from archaeological bone (section 5.7.1) 
was based closely on a protocol developed by Schmidt-Schultz and Schultz (2004). This 
method was aimed specifically at disrupting the tight interaction between the bone mineral 
scaffold and non-collagenous proteins (NCP) through a process of 
demineralisation/chelation and denaturation designed to loosen the mineral scaffold and 
remove proteins not bound to the bioapatite. The final bone pellet solublisation stage 
destroys the scaffold, thus releasing remaining mineral-bound NCPs (Schmidt-Schultz and 
Schultz, 2004). The three-stage protocol discards supernatants following the first two stages 
and retains the final supernatant following bone pellet solublisation. This approach does, of 
course, rely upon the assumption that NCPs of interest are retained in the bone pellet until 
the final extraction stage. This research offered a highly promising method of extracting 
well-preserved IgGs from archaeological human bone. If successfully reproducible, the 
protocol could have been used to extract IgGs from target samples. These immunoglobulins 
could then have then been tested for reactivity and then against malaria antigens in order to 
detect the presence of the disease in past populations. 
 As mentioned in section 5.7.1, the method almost immediately required changing in 
terms of the specific protease inhibitors employed. Not only was the reported quantity of 
aprotinin clearly disproportionate, the authors also suspended PMSF in the aqueous 
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extraction buffers. PMSF is mostly insoluble in an aqueous solution, so its inhibitory 
properties would likely be severely negated without first dissolving it in a suitable medium 
(e.g., isopropanol). Perhaps more importantly, there was the distinct lack of strategy in the 
published protocol to account for the collagen invariably released during the solublisation. 
The presence of degraded collagen was confirmed through proteomic analysis and Western 
blots for the P1.2 and P1.3 samples, respectively (see below), even though the authors state 
that highly defined laboratory conditions are required to “produce collagen fragments larger 
than 10 kDa” (Schmidt-Schultz and Schultz, 2007:96). The copious quantities of degraded 
collagen resulting from all extractions in this study served to mask proteins of lower 
concentration and to cross-react with antibodies used in both the P1 Western Blot and IgG 
ELISA analyses. Cross-reactivity with collagen would almost certainly have occurred in the 
Western blots performed by Schmidt-Schultz and Schultz (2004; 2007), yet none was 
reported. It is, therefore, impossible to fully evaluate the efficacy of the Schmidt-Schultz and 
Schultz protocol without more in-depth reporting of their strategies for avoiding the 
extensive collagen cross-reactivity encountered when attempting to replicate their research. 
No method attempted here was able to reproduce the results of Schmidt-Schultz and Schultz 
(2004). 
 The SDS-PAGE gels analysing the P1.1 and P1.2 samples were affected quite 
strongly by smearing (Figures 6.39 and 6.40). This was particularly pronounced for the P1.2 
gels, where only faint bands were visible through the smearing. Smearing is a relatively 
common problem in SDS-PAGE analysis, sometimes resulting from errors in gel 
preparation or over-loading of wells. It can also be caused through interference by residual 
chemicals used in sample preparation, such as EDTA (Cleland et al., 2012). EDTA is likely 
to be partly responsible for the smearing evident on the P1.1 and P1.2 gels, since it was 
required in the final solubilisation buffer. There may also have been residual EDTA in the 
lyophilised bone pellets prior to solubilisation, since removal of the chemical can require 
more than 15 washes (Cleland et al., 2012); the Schmidt-Schultz and Schultz (2004) 
protocol used only three washes. EDTA would also probably persist through SDS-PAGE 
sample preparation, since it is likely to precipitate alongside the proteins in TCA 
precipitation. Omission of EDTA from the final solublisation buffer and perhaps switching 
to HCl demineralisation may reduce any EDTA-associated smearing in future. However, as 
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discussed later, HCl demineralisation may not be suitable to extraction targeting 
archaeological IgGs. 
  Schmidt-Schultz and Schultz (2007) suggest that SDS-PAGE smearing from 
archaeological samples is the result of poorly-solubilised proteins failing to produce sharp 
bands. This may not, however, be completely accurate, since their solublisation protocol was 
exactly followed for the P1.2 samples, yet still resulted in significant smearing. Fragmented 
collagen has also been shown to increase smearing on SDS-PAGE gels of clinical samples 
(e.g., Acil et al., 2007; 2013), and research on collagen diagenesis by Dobberstein et al. 
(2009) encountered smearing in the oldest of their tested bone samples. The authors suggest 
that the smearing may be associated with the specific cleavage method employed, or partial 
hydrolysis of the collagen. It is possible that the mechanical grinding used in sample 
preparation throughout this study and by Schmidt-Schultz and Schultz (2004) had a 
significant degradation effect on the extant collagen, perhaps resulting in the increased 
smearing seen in the SDS-PAGE gels. This intense smearing was the reason for the use of 
collagenase in the subsequent P1.3 samples. 
 Bacterial collagenase was used in the P1.3 samples to remove the excess, interfering 
collagen that was extracted and characterised in P1.1 and P.1.2, and to reduce its potential 
masking effect on any low abundance NCPs (section 5.7.2). Research by Tuross and 
Stathoplos (1992) and Ostrom et al. (2001:1046) demonstrated significant reductions in gel 
lane smearing through the removal of “weakly staining collagenous degradation products”. 
Figures 6.43 and 6.44 suggest that collagen digestion was rather less successful for the P1.3 
samples. This failure to completely remove smearing was perhaps due to an insufficient 
collagenase concentration. The concentration used here was based on digestion of modern 
collagen (Hummelshoj et al., 2008), since figures were not explicitly stated by either Ostrom 
et al. (2001), or Tuross and Stathoplos (1992).  
 Collagenase digestion seems to have been differentially successful, depending upon 
the sample (Figures 6.43 and 6.44). The enzyme was particularly effective for samples AR6 
and AN4, for example, but far less so for AP5 and AN2. It was initially thought that this 
may be an artifact of the preservation of collagen, in that the collagenase may be 
preferentially removing the poorly preserved protein, thus resulting in the reduction of 
smearing. However, if better microscopic bone preservation correlates with less degraded 
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collagen, the histological preservation of these four samples does not support this initial 
theory (AR6 = HI: 5; AN4 = HI:3; AP5 = HI:5; AN2 = HI:5). The reasons behind the 
protein banding and smearing for AP5 and AN2 following collagenase treatment are 
unclear, since the banding pattern certainly seems to match other samples which responded 
well to collagenase digestion. Residual EDTA may have reduced the effectiveness of the 
collagenase, since it acts as a collagenase inhibitor (Worthington, 1993). 
  It is interesting that in Western blot testing, non-collagenase treated AP5 and AN2 
cross-reacted strongly with the secondary antibody, while their collagenase digested 
counterparts did not (Figures 6.45–6.51). Unfortunately, these gels were not silver stained. 
This process would have provided further band resolution, particularly in lanes where much 
of the smearing had been removed by collagenase. It may also have allowed for visualisation 
of the putative IgG positive discussed in section 7.3.1(ii). 
Examination of the collagenase and non-collagenase Western blot membranes 
(Figures 6.45-6.51) shows that cross-reactions were ubiquitous with the latter samples, 
whereas very little evidence of cross-reactivity was seen with the former samples. This 
implies that, although the smearing often appeared slightly reduced on the SDS-PAGE gels, 
the main agents of cross-reactivity were actually removed by the collagenase. This 
subsequently suggests a correlation in reactivity between the secondary polyclonal antibody 
and highly degraded collagen, the latter of which was removed by collagenase treatment. 
 
7.3.1(i): P1.2 MALDI-TOF and nLC-MS/MS analyses 
 
 Sections 5.7.3(iv) and 5.7.3(v) outline the methodologies used in the proteomic 
analysis of selected P1.2 gels bands (gels and bands shown in sections 6.4.1(ii) and 
6.4.1(iii)). Peptide ‘fingerprinting’ by MALDI-TOF was the first analytical method 
attempted for these gel band samples, followed by nLC-MS/MS. Unfortunately, neither 
method successfully detected IgGs (section 6.4.1(iii)) in any of the six excised gel bands, 
The MALDI failed to detect any proteins (for possible reasons, see section 7.4.4, below), 
while the nLC-MS/MS analysis revealed collagen as the most prevalent protein in the bands 
(Table 6.24). The sequence coverage for these samples was somewhat low (the highest 
being 47.8%), thus demonstrating the degraded nature of the collagen fragments 
inadvertently excised in the gel bands. 
356 
 
In hindsight, the selected bands were probably not representative of the expected 
molecular weights of potentially degraded IgG heavy and light chains. The choice of bands 
for proteomic analyses was based on Schmidt-Schultz and Schultz’s (2004; 2007) apparently 
successful Western blot analyses (Figure 6.37), which detected ancient IgG heavy chains 
with a molecular weight akin to modern, fresh samples (around 60kDa). It was assumed that 
following their published extraction protocol and using of well-preserved samples would 
produce gel bands of a similar weight. Western blot analysis (section 7.3.1(ii)) for later P1.3 
samples supplied a possible positive for heavy chain IgG at around 40kDa (the disparity 
between this and the published analyses in terms of molecular weights is addressed in 
section 7.3.1(ii)). It was perhaps naïve to expect to be able to select bands analogous to the 
IgG chains apparently detected by Schmidt-Schultz and Schultz (2004), given the poor band 
definition and obvious smearing encountered in each gel lane. A more targeted approach to 
selecting gel bands possibly representing IgGs was required for proteomic analysis. This led 
to the inclusion of positive IgG controls in later SDS-PAGE analyses and excision of 
possible matching bands.  
 
7.3.1(ii): P1.3 Western blot   
 
The analysis of collagenase treated and non-collagenase treated samples allowed for 
a direct comparison by elucidating the effects of degraded collagen on potential masking of 
target proteins and cross-reactivity with the primary and secondary antibodies employed in 
the Western blot. Nitrocellulose membranes were exposed for periods of 10, 30, 60 seconds, 
and eight minutes, with x-ray records taken at each exposure stage. The results of the eight 
minute exposure of the non-collagenase treated samples were discounted due to over-
exposure and subsequent poor band resolution.  
The analysis yielded one possible positive for collagenase treated sample (HD)AP3 
(Figures 6.48-6.51), which had an appearance very similar to the heavy chain IgG bands 
(Figure 6.37) identified by Schmidt-Schultz and Schultz (2004). The difference here, 
though, is that the band is suggestive of a protein fragment with a weight of approximately 
40kDa, rather than the 55-60kDa detected by Schmidt-Schultz and Schultz (2004). This 
reduced molecular weight may be due to protein degradation in a sample of sub-optimal 
preservation: AP3 displayed a histological preservation score of 4, while the samples tested 
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by Schmidt-Schultz and Schultz (2004) were all very well preserved. It is unlikely that 
collagenase could have degraded the protein, since it seems to be present at the same 
molecular weight in the non-treated samples (Figures 6.46 and 6.47). Harper (1980) suggests 
that non-collagenous proteins should not be affected by collagenase, although Ostrom et al. 
(2001) experienced degradation of their target NCP, osteocalcin, and Wadsworth and 
Buckley (2014) lost NCPs during collagenase treatment. Clearly, any enzymatic effect on 
potentially degraded archaeological IgGs is unpredictable and cannot be completely ruled 
out. It is, of course, possible that the protein detected does not represent an IgG Fc chain at 
all, but rather a non-specific primary antibody/antigen binding. An example of this is the 
appearance of a band on the molecular weight marker chain at 29kDa (Figures 6.49 and 
6.50). A commonly-used marker protein at this weight is bovine carbonic anhydrase, which 
has here likely cross-reacted with the primary antibody. However, the appearance of a clear 
band at a credible molecular weight (around 40 kDa) is suggestive of the presence of human 
IgG, and represents the most likely ‘positive’ from all of the P1.3 samples. Its appearance in 
both collagenase and non-collagenase treated samples over all exposure times suggests that 
the ‘positive’ was not the product of non-specific antibody binding to collagen. Very faint 
bands at approximately 25kDa on the collagenase 60 second exposure membrane for 
samples AR6, AR3, and AP5 (Figure 6.50) may tentatively suggest the presence of IgG light 
chains. Their appearance, however, would be the result of cross-reactivity, given the heavy-
chain specificity of the primary antibody and anti-mouse IgG specificity of the secondary 
antibody. 
A potential positive for sample HDAP3 prompts the question of why no further 
‘positives’ from the other samples were encountered, particularly for those of similar 
histological preservation. It is possible that the Western blot methodology used can account 
for this dearth. Milk powder, rather than bovine serum albumin (BSA), may have been too 
strong of a blocking agent. If this was the case, it would have inhibited many primary 
antibody interactions with target IgGs (as well as potentially introducing bovine IgGs into 
the experiment). The alternative blocker, BSA, was, however, likely to cross-react with the 
primary antibody. Although BSA contributes a small percentage of protein in milk powder, 
the high concentration in analytical grade BSA would greatly increase the chances of cross-
reactivity (Dr. Stephen Chivasa, personal communication, April 2014). It is for this latter 
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reason that milk powder was again chosen for the Western blots on the selected P2, P3, and 
P4 samples (section 5.7.10). Also, since the type of blocking buffer used by Schmidt-Schultz 
and Schultz (2004) was not specified, the use of milk powder followed clinical examples of 
human IgG heavy chain detection (e.g., Shiguekawa et al., 2000).  
A further answer for the lack of positives may lie in the choice of a monoclonal 
primary antibody, which has specificity for a single target epitope. It may be the case that 
the ‘positive’ encountered in sample HDAP3 represents the only survival of the target 
epitope in all tested samples. The use of a polyclonal primary antibody with specificity to 
multiple IgG epitopes would increase the chances of detection, but would also 
correspondingly increase the likelihood of the type of nonspecific cross-reactions. However, 
the detection here of a potential IgG heavy chain using a monoclonal antibody increases the 
possibility that this is indeed a true positive. This may be in part why Schmidt-Schultz and 
Schultz (2004; 2007) detected IgG in all of their ancient samples; although not explicitly 
stated, it is likely that they employed a polyclonal primary antibody to increase the changes 
of positive interactions. Unfortunately, they do not explain how they interpreted any cross-
reactions, although they are likely to have encountered them. They also only present cropped 
images of the ‘positives’ resulting from their Western blot analyses, rather than the entire 
membranes. A final reason for the lack of positives in the current study may be simply that 
IgGs were not present in the samples, and the HDAP3 ‘positive’ was merely a cross-reaction 
with an unidentified protein. 
The IgG ELISA (section 6.4.1(vi), Table 6.25) suggests an IgG concentration of 
approximately 1.66ng/ml for sample HDAP3. HDAR3 measured over 4ng/ml, yet the latter 
exhibited no apparent IgG in Western blot analysis. The reason for this disparity is unclear, 
but may be indicative of differential or incomplete protein transfer from gel to nitrocellulose 
membrane, or a possible false positive in the ELISA. It may also suggest that the HDAP3 
‘positive’ on the Western Blot is an aberration. If these ‘positives’ are to be believed, it may 
be suggestive of differential levels of IgG in different bone elements (HDAP3 being an adult 
phalanx, HDAR3 being adult rib), although this simplistic conclusion would neglect a 
variety of other variables affecting IgG survival in bone.  
The HDAP3 ‘positive’ may be supported by silver staining of the P1.1 gel (Figure 
6.39), which displays a possible band at approximately 40kDa. HDAP3 was also analysed 
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by SDS-PAGE in protocols P1.2 (Figure 6.40) and P2.2 (Figure 6.53). The former gel 
(Figure 6.40) does not display the same band around 40kDa, although the high quantity of 
smearing collagen may have obscured any IgG. The silver stained version (Figure 6.26), 
however, shows a clearer band at this weight. The P2.2 gel shows a very faint band around 
40kDa (Figure 6.37), but this may match a band at the same weight in the collagen control 
samples on the same gel. Proteomic analysis was attempted on a band excised from the P1.2 
gel (section 6.4.1(iii)), but not on the band shown in the P1.3 Western blot, which was 
performed subsequent to P1.2.  
 The analysis of collagenase and non-collagenase treated samples has allowed for 
loose characterisation through cross-reactivity of the collagen yield from the P1.3 extraction. 
The non-collagenase treated samples demonstrate beyond doubt that the vast majority of 
cross-reactivity is caused by the interaction of antibody with degraded collagen, although 
there are a number of other possible reasons for the increased number of bands detected for 
the non-collagenase treated samples. These include insufficient protein blocking, 
contamination during equipment preparation, or over-exposure of the film (as encountered 
here with exposure over 60 seconds). The most likely reasons here, though, are non-specific 
binding of the secondary antibody (a HRP-conjugated polyclonal anti-mouse IgG antibody) 
with degraded collagen, or too high of a secondary antibody concentration. The latter 
problem would be easiest to address by further dilution of the secondary antibody from 
1:20000 used here, to 1:40000 suggested by Schmidt-Schultz and Schultz (2004). 1:20000 
was used in this analysis to ensure sufficient conjugation with the primary antibody, but the 
concentration may have increased the prevalence of non-specific cross-reaction, particularly 
for the non-collagenase treated samples. This could be countered, although probably not 
completely ameliorated, by the use of a monoclonal secondary conjugated antibody at lower 
concentration. The monoclonal nature of the primary antibody should reduce the chances of 
cross-reactions with non-specific proteins at this stage, but at the risk of failing to detect 
IgGs with specific epitopes degraded beyond a detectable limit. Even with a monoclonal 
primary antibody, the possibility of such nonspecific interactions should not be discounted. 
The analysis of samples that have been subjected to antibody purification (e.g., thiophilic 
adsorption chromatography) should also improve detection by removing the majority of 
interfering collagen.  
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7.3.1(iii): P1 human IgG ELISA 
 Results for the P1 IgG ELISA (section 6.4.1(vi)) suggest that IgGs were detected at 
extremely low concentrations, with the highest concentration in sample HDAR3 
(4.79ng/ml). This is, as expected, far below the level of normal human serum IgG, which 
ranges from 5-12mg/ml (Stoop et al., 1969). Unfortunately, these results were almost 
certainly affected by cross-reactivity. The polyclonal antibodies used to detect the numerous 
subclasses of human IgG may have resulted in the positives observed in the bovine collagen 
type III (3.53ng/ml) and animal bone sample AN7 (Table 6.25). The degraded nature of the 
samples may also have caused non-specific reactions with the ELISA antibodies. The fact 
that the blank third stage P1 buffer solution tested positive for human IgG (2.8ng/ml) is 
suggestive of exogenous contamination during sample preparation or testing (potentially 
from the standards, which were in close proximity to the blank buffer on the multi-well 
plate). Given the strong likelihood of non-specific cross reactions and exogenous 
contamination, positive results for any of the human samples should be considered with 
extreme caution. IgGs may well have been detected, but their positive detection cannot be 
separated from potential false positives resulting from contamination or cross-reactivity. 
 
7.3.2: P2 and P4: adapted Jiang et al. (2007) protocols and thiophilic adsorption 
chromatography (TAC) 
 
 The chosen protocol for the P2 samples was based on Jiang et al.’s (2007) multi-
stage protein extraction from fresh bone. It was felt that the exhaustive nature of these 
extractions would increase the chances of retrieving IgGs from archaeological bone samples 
if combined with an additional immunoglobulin purification stage. As described in section 
5.7.4, the published methodology required minor alteration due to the disparity in sample 
type and downstream analytical applications. The fresh bone samples analysed by Jiang et 
al. (2007) required, for example, the initial removal of soft tissue and two strong acid (1.2M 
and 6M HCl) demineralisation steps. Their intention was to characterise proteins extracted 
from each stage by mass spectrometry, and they were therefore unconcerned if their 
extracted proteins were reduced to the peptide level, since this would be suitable for MS 
analysis. For this study, a more gentle demineralisation was required (in line with other 
archaeological protocols) in order to avoid hydrolysis of target IgGs and allow for their 
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purification using TAC. As explained in 5.7.4, the methodology changed slightly with each 
subsequent P2 extraction to mitigate for issues arising from the application of a protocol 
designed for fresh bone samples to ancient bone. 
 A strength of the Jiang et al. (2007) protocol over the Schmidt-Schultz and Schultz 
(2004) protocol is in the analysis of supernatants following each extraction stage.  
It was hoped that the characterisation of proteins from each stage, rather than from a final 
pellet solublisation alone, would increase the chances of detecting target IgGs that may be 
released at any point during the extraction. Although Schmidt-Schultz and Schultz (2004; 
2007) supposedly detected IgG following solublisation, they report no analysis of 
supernatants from their first two extraction stages. This is somewhat of a surprise, 
considering the research of Termine et al. (1981), which demonstrated that two thirds of 
mineral-bound NCP are released by extraction and solublisation with guanidine-HCl (the 
second stage employed by Schmidt-Schultz and Schultz). Given the uncertainty over at 
exactly which stage degraded IgGs might be extracted, it was felt prudent to analyse 
supernatants from each P2 and P4 extraction stage. 
 The Jiang et al. (2007) extraction methodology includes a precursory step designed 
to induce the solubilisation of mineral-bound proteins and start the release of proteins. HCl 
is a commonly used demineralising agent that increases bone matrix porosity, thus exposing 
and releasing mineral-bound protein (Cleland et al., 2012). Schmidt-Schultz and Schultz 
(2004) instead employed EDTA as the prime demineralizing agent. Both EDTA and HCl are 
effective demineralisers, each offering positives and negatives in terms of protein extraction 
and conservation. HCl demineralisation is much faster, negates the need for toxic protease 
inhibitors, and offers a ‘cleaner’ extraction. It is, therefore, ideal for downstream analysis 
such as mass spectrometry. The acidic conditions, however, increase the chances of target 
protein degradation or hydrolysis (Jiang et al., 2007; Cleland et al., 2012). Using EDTA 
takes far longer, but is a much gentler method of demineralisation (Cho et al., 2010). EDTA 
is also less compatible with many downstream applications and samples usually require 
extensive washing to remove it prior to analysis. The potential smearing effects of residual 
EDTA on SDS-PAGE gels can be seen in the P1 extractions (Figures 6.38-6.42), suggesting 
that the three washes advised by Schmidt-Schultz and Schultz (2004) were likely 
insufficient for complete EDTA removal, at least for these samples. The use of thiophilic 
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resins for the P2 and P4 protocols negated the requirement for EDTA removal from the 
second and third extraction stages, since the chemical should not be retained in the resins.    
 As can be seen in Figures 6.66, 6.69, and 6.72, total and average P2 and P4 protein 
yield increased with each subsequent extraction, which reflects the cumulative effects of 
chemical weakening of the bioapatite and release of mineral-associated proteins by 
HCl/EDTA demineralisation and chelation, and by guanidine-HCl denaturing and 
solubilisation. This pattern is demonstrated regardless of histological preservation, although 
poorer preservation generally correlated with higher protein yield for all extraction stages. 
The pattern is to be expected, as it should require less chemical intervention to release 
proteins (particularly degraded collagen) from samples displaying poorly preserved bone 
microstructure.  
 Figures 6.52-6.60 display the most ‘successful’ P2 post-TAC SDS-PAGE gels in 
terms of the visualisation of bands potentially corresponding to ancient IgG heavy and light 
chain fragments. Bands felt most likely to represent IgG fragments were excised and 
subjected to proteomic analysis, a choice facilitated by the introduction of a modern IgG 
control in P2.3. Unfortunately, no IgGs were detected in any of the excised bands, other than 
the control IgG bands excised from the P2.4 gel (see Figure 6.57, and Tables 6.29, and 
6.30). Possible reasons for this failure are numerous, and are discussed in sections 7.3.3, 
7.4.2, and 7.4.3. 
 
7.3.3: TAC and non-specific protein binding 
 
 Thiophilic adsorption chromatography should, theoretically, be an optimal method 
for purifying IgGs. TAC offers a highly selective environment for retrieval of target 
immunoglobulins, yet avoids the harsh elution (and hence potentially degrading) conditions 
associated with, for example, traditional protein A columns. This study represents the first to 
attempt to apply TAC immunoaffinity to ancient samples. As with all modern analytical 
techniques adapted for archaeological samples, this does introduces a degree of uncertainty 
as to the effectiveness of the method. It was crucial, therefore, to analyse the elutions in 
order to both identify any eluted IgGs and to evaluate the method in terms of non-selective 
protein binding. 
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Protocol Total TAC Protein Yield (mg/ml) TAC Elution Protein % 
P2 64.653 1.6 
P3 18.764 4.1 
P4 44.876 1.4 
Table 7.5: Comparing total TAC protein yield and TAC elution protein percentage between 
protocols. 
 
 Spectrophotometric measurements of eluted protein concentrations were initially 
very promising. The very low percentage of eluted proteins (Table 7.5) suggested that the 
resins were binding very small amounts of protein, perhaps in quantities to be expected for 
archaeological IgGs. However, as described in sections 6.4.1(iii), 6.4.2(vi), and 6.4.3(ii), 
proteomic analysis of SDS-PAGE gel bands from eluted samples proved fruitless in terms of 
IgGs, revealing only collagen and exogenous keratin. This confirmed that the TAC resins 
were retaining other proteins, which was initially suggested by the appearance of gel bands 
for pure collagen samples (e.g., P2.2, Figure 6.53) and bands of higher molecular weight 
than those of the modern IgG positive controls (e.g., P2.3 and P2.4, Figures 6.54 and 6.56). 
Upon consideration of the likely degraded nature of any IgG and the subsequent difficulties 
in isolating appropriate gel bands for further analysis, it was decided to subject a selection of 
eluted samples to proteomic analysis. This should have allowed for characterisation of all 
proteins within each given elution and bypass any issues of potential IgG loss during SDS-
PAGE analysis. nLC-MS/MS analysis of P3 and P4 post-TAC eluted samples demonstrates 
that the TAC resins did indeed retain a quantity of proteins other than the intended IgG 
target, while confirming that no IgG (at a detectable level) was successfully extracted or 
purified from these samples. 
. This non-specific adsorption is perhaps unsurprising, given the degraded nature of 
the proteins in question and the use of an application that is unintended for archaeological 
samples. It is unlikely, for instance, that TAC resins have been tested against the range of 
degraded proteins or extraction reagents used in this study. An example of the latter may be 
seen in the reaction of 1st stage extracted (in 0.6M HCl) samples and the subsequent 
difficulty of sample introduction into the resins. Successful TAC requires samples to be 
above pH 8 to help prevent binding of proteins other than IgG. When these demineralised 
samples were brought from their acidic condition to pH 8, they became very viscous and 
proved difficult to introduce into the resins. This problem is unlikely to be encountered 
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when using modern, clinical samples. Further to this, the use of the denaturant guanidine-
HCl may adversely affect the binding of protein during TAC (a potential problem discussed 
in section 7.7.6). The extent to which these unconventional conditions affected binding is 
uncertain, but it highlights the potential difficulties in using non-standard samples and 
reagents in clinical applications. Since whole proteomes were not studied here, comparisons 
of protein content with other archaeological proteome studies (e.g., Cappellini et al., 2012; 
Wadsworth and Buckley 2014) are difficult. 
 
7.3.3(i): TAC-retained collagen 
 It is immediately clear from the Tables 6.47, 6.48, and 6.49 that the largest variety of 
collagen isoforms was detected in sample EH156.3. Their presence likely corresponds to the 
preservation level of this sample (HI: 5), since only three isoforms were identified in sample 
CD84.2 (HI: 0). Despite this difference, sequence coverage for both samples is surprisingly 
high, regardless of histological preservation. This may suggest that certain collagen isoforms 
resist diagenesis and when they do persist, it is in a relatively well-preserved state, even in 
poorly preserved bone, as previously suggested by Dobberstein et al (2009). 
 It is uncertain why the apparent variety and quality of collagen extracted from the P3 
sample (CD120.2, HI: 5) is considerably lower than for the P4 samples. For unspecified 
reasons, higher quality collagen (and NCPs, see 7.3.3(ii) below) of more varied type was 
retained from the P4 extractions. It is possible that the higher quality collagen was extracted 
in the first P3 stage (not subjected to proteomic analysis) and is therefore not represented 
here. It is also possible that the P3 extraction conditions resulted in increased degradation of 
collagen; the third stage sonication, for instance, may be partly responsible for the low 
sequence coverage and peptide identifications seen in Table 7.3. The apparently poorer P3 
collagen quality and lack of isoform variety may, of course, be an artifact of non-specific 
binding to the thiophilic resin, but exactly why poorly preserved collagen is retained here, 
rather than for the P4 samples, remains unknown. 
 
7.3.3(ii): TAC-retained non-collagenous proteins (NCPs) 
 Despite the lack of IgGs purified in the TAC columns, nLC-MS/MS analysis of the 
P3 and P4 elutions offers glimpses of the types of extant NCPs extracted from each stage. It 
365 
 
also facilitates characterisation of NCPs released from the bones that display differing 
histological preservation. Summary Tables 7.6-7.8 show the range of NCPs (not including 
exogenous keratin) detected at the second and third extraction stages of P3 for sample 
CD120.2 (HI: 5), and all P4 extraction stage for samples CD84.2 (HI: 0) and EH156.3 
(HI:5). Information concerning the location and function of each protein was taken from the 
National Center for Biotechnology Information database (NCBI, 2014). Full results of these 
analyses are shown in Appendix 3. It should once again be recalled that these represent 
NCPs that have bound non-specifically to the TAC resin, rather than an entire bone 
proteome. Any differences in extracted protein types between CD84.2 and EH156.3 cannot 
be attributed to methodology or element type, since both were young adult cranial vault 
fragments which were prepared, extracted and analysed using exactly the same techniques. 
The only variables here are histological preservation and diagenetic factors specific to the 
sites. Many of the NCPs in this study were identified based upon one peptide (Tables 6.41-
6.64). Jiang et al. (2007) only considered identifications based on more than two peptides to 
represent confident protein matches, since this would reduce the chances of false positives. 
 
Name Location Function Stage 
Dermcidin Epidermis Immune  2nd pre 
Dermcidin Epidermis Immune  2nd post 
Terminal uridylyltransferase 4  Cellular 
 Gene 
silencing 
2nd post 
Dermcidin Epidermis Immune  3rd pre 
Terminal uridylyltransferase 4  Cellular 
  Gene 
silencing 
3rd post 
Dermcidin  Epidermis Immune  3rd post 
Ankyrin repeat and SOCS box protein 18 Cellular 
 Protein 
modification 
3rd post 
Table 7.6: Type and function of non-collagenous human proteins extracted from P3 sample 
CD120.2 (HI: 5), 2nd and 3rd extraction stages, pre-and post-exclusion. Bold entries are 
likely exogenous contaminants. 
 
 
 
 
 
 
 
 
366 
 
Name Location Function Stage 
Dermcidin Epidermis Immune 1st 
MUC19 variant 12 ECM Mucosal 1st 
Vitronectin Plasma Multifunctional 2nd 
Cystatin-A Intra/extra cellular Protease inhibition 2nd 
Protein S100-A7 Cellular/epidermis Regulation/immune 2nd 
Chondroadherin Cartilage Mediation 2nd 
Pigment epithelium-derived factor ECM Multifunctional 2nd 
Dermcidin Epidermis Immune 3rd 
Vitronectin Plasma Multifunctional 3rd 
Chondroadherin Cartilage Mediation 3rd 
Pigment epithelium-derived factor ECM Multifunctional 3rd 
Hornerin Epidermis Immune 3rd 
Biglycan ECM Bone mineralisation 3rd 
Prothrombin Plasma Coagulation 3rd 
Biglycan preproprotein variant (Fragment) ECM Bone mineralisation  3rd 
Table 7.7: Non-collagenous human proteins extracted from sample CD84.2 (HI: 0), their 
types and functions, and extraction stage. Bold entries are likely exogenous contaminants. 
ECM – extra cellular matrix. 
 
 
Name Location Function Stage 
Protein argonaute-4 Cell cytoplasm Gene silencing 1st 
Protein AHNAK2 Cell nucleus 
Interacts with DYSF, a 
skeletal muscle protein 
2nd 
cDNA, FLJ94754, highly similar to Homo sapiens potassium 
inwardly-rectifying channel, subfamily J, member 2 (KCNJ2), 
mRNA 
Cell membrane Channel 2nd 
Pigment epithelium-derived factor ECM Multifunctional 3rd 
Biglycan ECM Bone mineralisation 3rd 
Vitronectin Plasma/ECM Multifunctional 3rd 
Chondroadherin Cartilage Mediation 3rd 
Alpha-2-HS-glycoprotein Plasma Multifunctional 3rd 
Osteomodulin ECM Biomineralisation 3rd 
Lumican ECM Multifunctional 3rd 
Biglycan preproprotein variant (Fragment) ECM  Bone mineralisation 3rd 
Matrix Gla protein ECM Calcification inhibition 3rd 
Prothrombin Plasma Coagulation 3rd 
cDNA FLJ55606, highly similar to Alpha-2-HS-glycoprotein Plasma Multifunctional 3rd 
Dermatopontin ECM ECM interactions 3rd 
cDNA, FLJ93532, highly similar to Homo sapiens 
osteomodulin, mRNA 
ECM Biomineralisation 3rd 
Table 7.8: Endogenous non-collagenous human proteins extracted from sample EH156.3 
(HI: 5), their types and functions, and extraction stage. ECM – extra cellular matrix. 
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 Before considering any implications of the extraction of these NCPs, possible 
reasons why these particular proteins bound to the TAC resins should be explored. Protein 
extraction and proteomic analyses of ancient mammalian bones (e.g., Buckley et al., 2011; 
Cappellini et al., 2012; Wadsworth and Buckley, 2014) have indicated the survival of a vast 
range of NCPs in samples from differing periods and from multiple environments. The 
range of NCPs extracted and characterised in this study must represent a small fraction of 
the whole extracted protein content, a product of non-specific binding in the search for IgG. 
It is likely that some of these NCPs were retained due to their close association with 
collagen. Biglycan, vitronectin, chondroadherin, and lumican, for instance, all bind to, 
interact with, or form complexes with collagen (Schvartz et al., 1999; Mansson et al., 2001; 
Wiberg et al., 2002; Nitokovic et al., 2008). Their presence could be explained by cross-
linkage or complexing with resin-bound collagen, and by their release during trypsin 
digestion prior to mass spectrometry. The complexing of collagen with other organic 
molecules seems to be a common diagenetic phenomenon that can mask lower-abundance 
proteins from detection (Brandt et al., 2002). Their extremely small size (often only one 
peptide) and any potential masking effects of cross-linked collagen may help to explain the 
difficulties experienced in NCP detection by SDS-PAGE, Western blot, or ELISA.  
 Hardouin et al. (2007) reported non-specific TAC binding of alpha-2-HS-
glycoprotein (A2HSG) in modern serum samples, so it is perhaps unsurprising to find it 
here. Interestingly, they also found significant TAC binding of serum albumin. Its absence 
here is, therefore, somewhat unexpected, given its relatively high abundance in serum, 
affinity for hydroxyapatite, apparent affinity for thiophilic resin, and common appearance in 
other proteomic analyses (Xu et al., 2009). Albumin was the second most prevalent NCP 
detected by Jiang et al. (2007), and was extracted and characterised in ancient samples using 
the same extraction method (Wadsworth and Buckley, 2014). Finally, the proteins 
dermcidin, hornerin, MUC19 variant 12, and S100-A7 are potentially exogenously derived, 
likely introduced during sample preparation. Although their degraded state and level of 
modification (see Appendix 3) may support endogenicity, their association with epidermal 
or mucosal cells means that external contamination cannot be ruled out. Indeed, their 
degradation in itself may provide a reason for their binding to the TAC resins.  
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 The small range of NCPs characterised here is similar to the much larger proteome 
extracted by Wadsworth and Buckley (2014) following the Jiang et al. (2007) protocol, in 
that the majority of identified peptides represent extracellular matrix (ECM) proteins. The 
two P4 samples yielded peptides of 13 distinct NCPs, six of which are found in the ECM, 
and three found in blood serum. No bone-specific NCPs were retained on the TAC resins, 
although several that are functionally associated with bone (e.g., biglycan, osteomodulin, 
vitronectin, and A2HSG) were detected. Wadsworth and Buckley (2014) suggest that 
archaeological serum and ECM proteins may be easier to extract and detect than bone-
specific proteins due to their higher abundance, their affinity to hydroxyapatite, and possible 
post-mortem adsorption to bone surfaces. Future proteome analysis of pre-TAC samples 
CD120.2, CD84.2 and EH156.3 should provide a much more extensive picture of the range 
of NCPs extant in these samples. These analyses exceeded the timeframe for this project, but 
are planned for future investigation. 
 The relative lack of collagen in the P3 sample may offer an explanation for a 
corresponding dearth of NCPs, if the latter are being indeed preferentially retained on the 
resins due to cross-linking or complexing with collagen. Alternatively, the extracted P3 
NCPs may have been less degraded than their P4 counterparts, and thus resisted cross-
linkage with collagen and non-specific resin binding. A majority of NCPs in the P3 sample 
may also have been released in the first extraction stage (not subjected to nLC-MS/MS 
analysis), which, in terms of reagents used, corresponds most closely to P2 and P4 third 
stage.  
 The research has been unable to support Masters’ (1987) hypothesis concerning the 
preferential survival of NCPs due to their affinity with hydroxyapatite (section 1.2, research 
question 2) for two main reasons. Firstly, the choice analysis of TAC purified samples 
precluded an assessment of full bone sample proteomes. Secondly, and perhaps most 
interestingly, is the complete absence of osteocalcin from any samples. Osteocalcin 
represents the most abundant non-collagenous protein in human bone, and has a very high 
affinity for hydroxyapatite (Smith et al., 2005); if any NCP should be expected to 
preferentially survive diagenesis, it is osteocalcin. Although the protein data here represents 
non-specific TAC binding, it should perhaps be expected that osteocalcin should be present. 
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Its absence may call into question Masters’ (1987) original supposition (Matthew Collins, 
personal communication, October 2014). 
  
7.3.3(iii): TAC-retained non-human proteins 
 A small quantity of non-human peptides were detected through nLC-MS/MS 
analysis of post-TAC P4 samples and the matching of resulting peptide sequences to the 
Swiss-Prot database. This approach was useful for the identification of exogenous proteins, 
such as those from soil bacteria, that may have infiltrated the bone samples during 
diagenesis, or even proteins associated with exogenous pathogens. A problem with this 
approach is that reliable protein identification relies upon peptide matching to species with 
known genomes. When extracted peptide sequences are searched against a genomic 
database, a ‘best fit’ result may be given (Lubec and Afjehi-Sadat, 2007). Identification can, 
therefore, prove somewhat ambiguous, particularly when peptide sequences are extremely 
limited in number, or highly modified. This explains the detection of organismal proteins of 
unlikely presence in archaeological human bone. An example of this is a homolog protein 
matched to Methanocaldococcus jannaschii (Table 6.42), a eukaryotic organism only found 
in extreme environments, such as ocean floor hypothermal vents (Bult et al., 1996). Another 
peptide was matched to Trichodesmium erythraeum (Table 6.45), a tropical ocean-dwelling 
species of cyanobacteria, while Halorubrum lacusprofundi (Table 6.45) can only be found 
in one Antarctic lake (Ng et al., 2000). These results clearly represent ‘best fit’ matches for 
the peptides on the Swiss-Prot database, since they are highly unlikely to be associated with 
archaeological human remains. 
 Proteins from organisms whose association with inhumed bone is more credible 
include species from localised environmental sources which have infiltrated the samples 
through taphonomic and diagenetic action. Table 7.9 displays these organisms and their 
likely sources. All are from P4 samples, and all were detected in the first extraction (HCl 
demineralisation) stage elutions. Their release at this early stage suggests that they were not 
mineral bound, potentially supporting an exogenous source. Two species, Streptomyces 
griseus, and Caenorhabditis elegans, are known as a soil-dwelling microorganisms (Wood, 
1998; Ohnishi et al., 2008). Synechocystis sp. cyanobacteria was likely introduced into the 
bone by groundwater infiltration, while the Lactobacillus casei, Methanosarcina barkeri, 
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and Equine herpesvirus are associated with livestock (Kaneko and Tabata, 1997; Cai et al., 
2009; Telford et al., 1992; Grigoriev et al., 2012). The presence of all these can be credibly 
explained by extrinsic environmental contamination. 
 Cronobacter sakazakii is a pathogenic bacterium that can cause wound and urinary 
tract infections in human adults, and can be particularly dangerous to neonates, the elderly, 
and the immunocompromised. These bacteria are regarded as ubiquitous, very hardy, 
opportunistic pathogens, but their exact source in the environment remains unknown (Healy 
et al., 2010). Although its presence in the soil cannot be ruled out, Cronobacter sakazakii 
may tentatively represent the only detected non-human protein that was present in the ante-
mortem bone, if individual CD120 was infected at the time of death. 
  When interpreting the presence of these TAC-retained non-human proteins, it should 
be acknowledged that they all are represented by a single peptide, many of which exhibit 
very low sequence coverages (e.g., only 3.6% for the Cronobacter). As Baldwin (2004:2) 
states, “the greater the number of peptides being matched to any one protein and the greater 
the sequence coverage, the greater the probability of a correct identification”, although it is 
possible that archaeological proteins and their species can be correctly identified based on 
single peptides (e.g., Buckley et al., 2010). Although only peptides with a 95% confidence 
match to known genomic sequences are considered here, previous studies (e.g., Jiang et al., 
2007; Cappellini et al., 2012) have discounted protein identifications based upon single 
peptides. If the species identified here are accurate, then their retention was likely due to 
non-selective binding, or cross-linkage to other proteins. They may be representative of a 
fraction of the non-human proteins from the pre-TAC samples. Proteomic analysis of the 
pre-TAC samples may have yielded evidence supporting positive species identifications in 
the form of multiple proteins from single organisms. 
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Species Type Source SC/Pep Sample Protocol/Stage 
Streptomyces griseus Bacterium Soil 13.2/1 CD84.2 P4/1
st 
Lactobacillus casei Bacterium Livestock? 10.6/1 CD84.2 P4/1
st 
Caenorhabditis elegans Non-parasitic roundworm Soil 3.3/1 CD84.2 P4/3
rd 
Synechocystis sp. Cyanobacteria Freshwater 6.3/1 EH156.3 P4/1
st 
Equine herpesvirus 1 Viral pathogen Livestock 6.1/1 EH156.3 P4/1
st 
Cronobacter sakazakii Bacterial pathogen ? 3.6/1 EH156.3 P4/1
st 
Methanosarcina barkeri Archaea Livestock 8.5/1 EH156.3 P4/1
st 
Table 7.9: Credible non-human microorganisms detected by nLC-MS/MS in post-TAC P4 
samples CD84.2 and EH156.3. SC/Pep – Sequence coverage (%)/Peptide number (95% 
confidence). 
 
 
7.3.4: P3: adapted Schmidt-Schultz and Schultz protocol with TAC purification 
 The P3 methodology followed the same extraction protocol as P1 with the addition 
of TAC intended to purify target IgGs and reduce potential masking by more abundant 
proteins (e.g., degraded collagen). As mentioned in section 5.7.6, multiple SDS-PAGE trials 
failed to produce sufficiently visible, resolved colloidal Coomassie-stained bands in post-
TAC P3 samples. At this stage, the aim was to produce such bands, since previous 
proteomic analysis of P2 silver stained bands had invariably proven unsuccessful due to 
insufficient protein concentration. Smearing in gels (pre-TAC P3 samples) suggests the 
extraction of a quantity of degraded collagen in the 3rd P3 stage, a supposition supported by 
post-TAC proteomic analysis of sample CD120.2 (Table 6.36-6.40). As previously 
mentioned, smearing due to degraded collagen is commonly experienced in SDS-PAGE 
analyses of ancient samples (Wadsworth and Buckley, 2014).  However, if poor band 
resolution and smearing is also due to insufficiently separated and solubilised proteins, as 
suggested by Schmidt-Schultz and Schultz (2004), it suggests possible issues with the 
extraction and detection methodology. Keratin also proved to be a significant contaminant 
for P3 bands and samples subjected to proteomic analysis (Table 6.34), far more so than for 
the P2 and P4 samples. This is surprising, considering that the same measures were taken to 
minimise external contamination for all samples in all protocols (e.g., the use nitrile gloves, 
fume cupboard, fresh reagents). The reasons for this elevated quantity of keratin remain 
unclear. 
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7.3.5: P2, P3, and P4 Western blot 
 
 A Western blot test was run on selected P2, P3, and P4 samples following TAC, 
precipitation, and SDS-PAGE. The protocol differed slightly from the Western blot 
described, reported and discussed in sections 5.7.3(ii), 6.4.1(v), and 7.3.1(ii), respectively. 
This later Western blot test (section 5.7.9) employed a longer primary antibody incubation 
time and initial exposure time due to the lower concentration of protein in these post-TAC 
samples. Unfortunately, the test failed to produce any results other than background 
staining/contamination after a five minute exposure. That the positive IgG control failed to 
be detected may suggest a problem with protein transfer to the nitrocellulose membrane. It is 
possible that the small gel pore size in the 15% gel slowed the transfer of proteins and they 
were therefore not given sufficient time to completely transfer to the membrane. The very 
low concentration of protein in these post-TAC samples is also a likely reason behind the 
negative result. In hindsight, the use of a positive control in lieu of a molecular weight 
ladder in this test was a mistake, since the markers would have been of sufficient 
concentration to demonstrate the effectiveness of transfer from a 15% gel; it is unlikely that 
the samples and the IgG positive control were at high enough concentrations (only 10µl per 
sample well) to survive the unavoidable loss of proteins during transfer. The milk powder 
blocking may also have been overwhelming for the inevitably low signal anticipated for 
these low-concentration samples (Dr. Stephen Chivasa, personal communication, April 
2014).  
 Finally, the type of membrane used in the test may have had an effect upon the 
result. Nitrocellulose membranes represent the cheapest and most commonly employed type. 
Alternatively, polyvinylidene difluoride (PVDF) membranes can be used. These offer a 
higher binding capacity and sensitivity, but at a higher cost. Nitrocellulose membranes 
usually have a pore size of 0.45µm pore size, which is makes them less suitable for 
transferring proteins smaller than around 20kDa. It is possible that highly degraded 
archaeological IgGs might ‘escape’ through these larger pores during transfer, although this 
would not explain the non-detection of the positive control in this test.  
 Future Western blotting of post-TAC samples would benefit from attempting to 
increase protein concentration within the samples. This should be followed by comparing 
blots from 10%, 12%, and 15% gels, all with a molecular weight ladder and a positive 
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control in place. A comparison of results using different membrane types (nitrocellulose and 
PVDF) with differing pore sizes would also be informative. It is evident from both Western 
blot tests attempted in the study that the characterisation of degraded ancient proteins in this, 
as in all other attempted methods, presents a considerable challenge which requires 
systematic trial-and-error testing.  
 
7.3.6: P5: adapted Cappellini et al. (2012) extraction protocol 
 
 The final extraction method attempted in this study was an adaptation of the 
groundbreaking protocol of Cappellini et al. (2012). This research successfully extracted 
non-collagenous proteins (NCPs), including IgG-related peptides from Pleistocene 
mammoth bones from permafrost and temperate environments. These proteins were 
identified through highly sensitive nanospray ESI-LC-MS/MS analysis following a simple 
extraction protocol, and protein concentration through the use of custom-made C-18 stage 
tips. This latter step was important in its novelty: the stage tips provided a rapid and simple 
method of concentrating peptides, while also removing potentially interfering salts from the 
final extraction buffer. Crucially, the mass spectrometric analysis demonstrated the presence 
of three peptides related to immunoglobulin G, as shown in the constructed human STRING 
network of orthologous mammoth proteins (Cappellini et al., 2012). That the Wadsworth 
and Buckley (2014) and Jiang et al. (2007) extractions and analyses failed to detect 
immunoglobulin-related peptides suggests that the Cappellini et al. (2012) extraction 
protocol may be better suited to their specific extraction.  
 A potential difficulty in replicating this research using the human bone in this study 
is that Cappellini et al.’s (2012) most successful extractions, in terms of recovering peptides, 
were made on Siberian samples. These permafrost-preserved samples yielded up to three 
times the protein of bones from temperate settings, thus confirming the importance of 
temperature in protein diagenesis and loss. Their research indicates that IgG may not 
preserve particularly well in mammalian remains from temperate regions, although it should 
be remembered that their samples were considerably older than the samples selected for this 
study.  
 A further complication in applying the Cappellini et al. (2012) protocol was that this 
study aimed to extract immunoreactive IgGs from archaeological bone in order to test them 
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against malaria antigens. As mentioned in section 5.7.11, the published protocol was not 
suitable for the gentle extraction of IgG, since the heating stage would completely denature 
the target protein, thus rendering the samples incompatible with TAC purification. 
Adaptation of the Cappellini et al. (2012) protocol in order to maximise the recovery of IgGs 
may require a lower second stage incubation temperature, possibly for a longer duration, to 
avoid heat-induced denaturing. Wiechmann et al. (1999) advocate the heating of samples at 
55°C for 48 hours in order to facilitate the separation of ancient proteins, although this is 
during sample preparation for SDS-PAGE, rather than during extraction. However, since 
Vermeer and Norde (2000) demonstrated that whole IgGs quickly denature above 60°C, 
Wiechmann et al.’s (2000) 55°C incubation seems close to the limit of IgG stability, 
especially since the thermal stability of degraded, archaeological IgGs is unknown. Analysis 
of extractions following incubation at different temperatures may help to establish an 
optimal temperature for releasing IgGs into solution. 
 The high concentration of degraded collagen resulting from this extraction was, as 
expected, evident in the P5 SDS-PAGE gels (Figures 6.63-6.65). These display significant 
smearing for all extraction stages, which serves to obscure many bands of potential interest. 
Cappellini et al. (2012) encountered a masking of lower abundance proteins by collagen 
smearing in their 1D SDS-PAGE gels. They suggest that their results may be improved by 
the removal of collagen prior to analysis. Since collagenase has been demonstrated to 
deplete the NCP content of archaeological samples (Wadsworth and Buckley, 2014), the 
removal of excess collagen though immunoaffinity chromatography may remain the best 
solution for future analyses. 
 
7.4: Observations on archaeological IgG purification and characterisation methods 
 
 As expected from examination of published attempts to extract and characterise non-
collagenous biomolecules from ancient human remains (e.g., Grupe and Turban-Just, 1996; 
Wiechmann et al., 1999), all clinically-derived techniques require adaptation to account for 
the inevitably degraded nature of archaeological proteins. This is reflected in the 
adjustments made throughout the extraction protocols in this study. Although IgG was not 
conclusively identified in any samples in this study, results from attempts to purify, detect, 
and characterise them offer insights into the reasons behind this failure. 
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7.4.1: Thiophilic adsorption chromatography (TAC) 
 
 The failure of this study to successfully purify archaeological IgGs may call into 
question the efficacy of TAC for this purpose, despite its high affinity for the protein and 
gentle elution conditions. There a number of reasons why TAC may have been unsuccessful. 
Firstly, TAC is untested for use with archaeological samples. Despite its high affinity for 
fresh IgG, their ancient counterparts may be too degraded or altered during extraction to 
bind to the thiophilic support. The non-specific binding of collagen and certain NCPs is 
unsurprising, considering that Hardouin et al. (2007) experienced similar interactions in 
fresh biological samples. Non-specific binding may have been increased by the degraded 
nature of the extracted proteins, with the presence of single-peptide NCPs perhaps indicating 
their complexing/cross-linkage with resin-bound collagen. It may be encouraging that the 
eluted yields of resin-bound non-specific proteins were always extremely small, since a low 
protein concentration may reduce potential masking of target IgGs.  
 Secondly, the extraction buffers and their reagents may not be fully compatible with 
the resins. An example of this is guanidine-HCl (GuHCl), a chaotropic salt which may 
adversely affect the binding of IgG to the thiophilic support. The strong denaturing effect of 
GuHCl may also have caused extracted IgGs to aggregate with other proteins, thus negating 
their affinity to the resin. Once again, TAC manufacturers are unlikely to have tested the 
efficacy of thiophilic resins in the presence of the numerous chemical reagents used in this 
study. Future investigations could test the effect of these reagent used here on thiophilic 
resin IgG retention by testing solutions containing known IgG concentrations. 
 Thirdly, and perhaps most tellingly, is the complete lack of IgG-related peptides in 
any post-TAC sample analysed by nLC-MS/MS. This may suggest either an insufficient 
protein concentration for detection on the MS equipment (discussed in section 7.4.4), or that 
the chosen extraction protocols failed to release extant IgGs, resulting in no purification via 
TAC. The presence of IgG-related peptides in pre-TAC samples could, in future 
experiments, be assessed by mass spectrometry in order to screen out negatives prior to TAC 
purification. 
 
 
 
376 
 
7.4.2: SDS-PAGE 
 SDS-PAGE is a standard analytical tool employed in many fields, including 
biochemistry, genetics, and molecular biology. The early SDS-PAGE gels in this study (for 
P1, P2.1, and P2.2) were run by laboratory personnel in the Biological Sciences Department 
at Durham University following standard procedures used for modern samples (see sections 
5.7.3(i) and 5.7.6). As can be seen in sections 6.4.1 and 6.4.2, resulting gels all display a 
significant level of smearing. This is particularly evident on the P1 silver stained gels. Such 
smearing serves to obscure bands that may potentially represent low abundance NCPs, such 
as IgGs, and is likely indicative of the high concentration of degraded collagen in these 
samples. It is possible that the highly acidic nature of the 20% trichloroacetic acid (TCA) 
precipitation exacerbated this smearing by further degrading large collagen molecules into 
smaller fragments. The low precipitation temperature (-20°C) may reduce the hydrolysis of 
collagen in fresh samples, but the effect on ancient degraded collagen is uncertain here. 
These early gels also display strongly concentrated bands at the interface between stacking 
and resolving phases. There are a number of reasons why this apparent failure of proteins to 
enter the resolving gel may occur. These include:  
1. Single proteins or aggregated protein complexes are too large to enter the gel. 
This can be solved by decreasing the concentration of polyacrylamide to create 
gels with large pores, thus allowing entry of larger molecules. However, this 
increases the risk of losing proteins of smaller molecular weight from the gel.   
2. Membrane-associated proteins, which may include certain collagen isoforms 
(e.g., Hagg et al., 1998), stack together with other proteins during 
electrophoresis, yet fail to enter the gel or fail to resolve into distinct bands 
(Hames, 1998). 
3. Human error in hand-casting of gels. For instance, incorrect buffer pH can 
prevent many proteins from entering the resolving gel. This use of precast gels 
would provide a solution to this, although they are an expensive option. 
4. The obstruction of proteins from entering the gel or efficiently migrating by 
“large and cross-linked organic substances in the extract, such as degraded 
collagen, mucopolysaccharides, and humic substances” (Wiechmann et al., 
377 
 
1999:391). The presence of these substances is difficult to mitigate, although the 
extended heating of ancient samples in buffer, as advocated by Wiechmann et al. 
(1999), may reduce this problem. 
 Following the P1, P2.1, and P2.2 gels, it was decided to run further SDS-PAGE 
analyses in-house. This allowed for greater flexibility in terms of trialing different sample 
preparation techniques and buffer/gel recipes in order to optimise the protocol for 
characterising ancient IgGs. The introduction of a modern positive control was crucial at this 
stage, since it allowed for evaluation of the effects of different preparatory techniques on 
reduced IgGs. As mentioned in Section 4.4.4, SDS-PAGE has quite frequently been 
employed in attempts to separate and characterise ancient proteins, and therefore offers a 
level of standardisation unusual for most clinical protocols that have been adapted for 
archaeological studies. The choice of appropriate preparation and gel production 
methodologies can depend upon the target protein of interest. No published archaeological 
studies using SDS-PAGE have specifically attempted to identify only IgG, although 
Schmidt-Schultz and Schultz’s (2004) protocol was apparently successful in detecting the 
protein (Figure 6.36).  
 The first stage of SDS-PAGE protein characterisation is sample preparation prior to 
introduction into the gel, which usually consists of precipitation and subsequent denaturation 
of proteins in appropriate reagents and buffers. Commonly used reagents that precipitate a 
wide variety of proteins include trichloroacetic acid (TCA), acetone, or high-salt reagents 
(e.g., ammonium sulphate). Although the latter is commonly employed in the clinical 
precipitation of IgG, often resulting in high yields (Page and Thorpe, 2002), it was not 
attempted in this study due to the comparative technical difficulty of the methodology, the 
potential interference of residual salt with downstream analysis, and the success of Schmidt-
Schultz and Schultz (2004) in identifying IgG through SDS-PAGE (following TCA 
precipitation) and Western blot. As the use of a modern positive control in this study 
demonstrated that both acetone and TCA precipitation resulted in detectable IgG, it was 
assumed, perhaps naively, that either method would also work for ancient IgGs. It would, 
however, be useful to attempt ammonium sulphate precipitation in future attempts to 
characterise ancient IgGs through SDS-PAGE. 
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 Protein precipitation is a complex phenomenon which relies on the aggregation of 
proteins by hydrophobic interaction with the chosen solution. Formation of a protein pellet 
through aggregation, which can be subsequently solubilised into SDS sample buffer, 
requires a sufficiently high sample protein concentration (Hames, 1982). Samples of low 
protein concentration (e.g., the post-TAC samples in this study) may not efficiently form 
pellets, resulting in loss of protein. Chemicals within the sample may also aggregate along 
with any protein, such as was encountered with acetone precipitation of post-TAC samples. 
This inevitably resulted in large phosphate pellets, which were very difficult to solubilise in 
SDS sample buffer, thus resulting in a decreased quantity of pelletised proteins. 
Precipitation, therefore, inevitably leads to a certain degree of protein loss. The process has 
been described as ‘inefficient’ for degraded archaeological proteins by Cappellini et al. 
(2012), who avoided it in favour of stage tip purification. Precipitation may not, therefore, 
represent the most efficient method of concentrating low-abundance archaeological proteins 
(e.g., NCPs), since loss of even a small portion of these would detrimentally affect efforts to 
characterise them. This inefficiency may provide a reason for the lack of IgGs detected 
through SDS-PAGE or Western blot in this study. 
 The second stage for SDS-PAGE is preparation of an appropriate sample buffer into 
which the precipitated protein pellet can be solubilised. Most published archaeological SDS-
PAGE protocols follow a recipe based on Laemmli (1970), which includes a reducing agent 
(usually DTT or mercaptoethanol), glycerol, tris, and SDS (e.g., Freundorfer et al., 1995; 
Grupe and Turban-Just, 1996; Wiechmann et al., 1999; Brandt et al., 2000; Ostrom et al., 
2000). Many employ a higher concentration of SDS in order to increase denaturation of 
potentially cross-linked proteins. For this study, it was decided to use and adapt a sample 
buffer recipe constructed by Page and Thorpe (2002), which is optimised for SDS-PAGE 
characterisation of fresh IgGs, and adapt it by increasing the concentration of SDS in line 
with archaeological protocols. This adapted buffer used bicine and sucrose, rather than 
glycerol, since it reportedly results in clearer resolution of IgG light chains (Page and 
Thorpe, 2002). A number of archaeological protocols use iodoacetamide in their sample 
buffers. This powerful cysteine inhibitor helps to maintain the reduced state of proteins 
following boiling of samples in SDS buffer. Although not used in this study due its absence 
in the Page and Thorpe (2002) recipe, further trials with archaeological samples could 
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include iodoacetamide to assess its efficacy and allow for comparisons between 
methodologies. 
 Wiechmann et al. (1999) advocate the extended heating of samples (at 55°C for 48 
hours) in SDS buffer in order to destroy products of decomposition, such as protein cross-
links, and to free proteins that might be encapsulated by humic substances. They suggest 
that the traditional method of boiling samples for a short period fails to result in adequate 
separation of ancient proteins. A comparison of the extended heating and traditional short 
boil approaches was attempted with three P2.3 post-TAC samples (section 5.7.6(ii)). 
Although the gel required silver staining for visualisation (section 6.4.2(iii), Figure 6.54), it 
clearly shows that the quick-boiled sample produced stronger bands. This suggests an 
increase in protein loss for the samples exposed to longer heating, possibly due to heat-
associated degradation or associated increase in protease activity. Since proteomic analysis 
failed to identify any peptides in the excised bands (Figure 6.55), it is difficult to assess 
exactly how Wiechmann et al.’s (1999) extended heating might affect archaeological NCPs. 
The apparent loss of proteins through extended heating and the success of Schmidt-Schultz 
and Schulz (2004) in characterising IgGs after traditional sample boiling influenced the 
decision to continue with the traditional method. 
 After multiple trials utilizing slightly different precipitation techniques and buffer/gel 
recipes, it was found that acetone precipitation followed by introduction into a 5% 
stacking/15% resolving gel resulted in the clearest bands for IgG (positive control) heavy 
and light chains. However, as the acetone precipitation proved incompatible with post-TAC 
eluted samples (due to high salt content), 8% TCA precipitation was instead adopted (after 
Schmidt-Schultz and Schultz, 2004). The majority of post-P2.2 gels presented in chapter 6 
used 8% TCA precipitation and a 15% resolving gel. This configuration generally resulted 
in the clearest bands of both the positive control and resolved ancient proteins.  
 The main problem encountered using SDS-PAGE in this study was the difficulty in 
producing a high enough protein yield for visualisation using Coomassie staining. Attempts 
at proteomic analysis (e.g., section 6.4.2(iv)) of silver stained bands often proved fruitless 
due to the extremely low concentration of proteins in post-Coomassie silver stained bands. It 
is likely that the low protein concentration in the eluted TAC samples is mostly responsible 
for this problem, although the inevitable loss of protein associated with inefficient 
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precipitation and loss and degradation during gel electrophoresis surely contributed. The 
latter may be suggested by nLC-MS/MS results (Table 6.31) showing relatively low peptide 
sequence coverage of the excised P2.4 IgG positive control bands; one might expect these 
fresh antibodies to show less degradation and greater sequence coverage, although the IgG 
fractions did remain at the expected molecular weights (approximately 50 and 25 kDa). The 
fact that modern IgG subjected to SDS-PAGE showed this much peptide fragmentation may 
indicate that the method (at least as attempted here) is somewhat unsuitable for visualizing 
already-degraded archaeological IgG. 
 The problem of matching degraded IgG fractions to their modern IgG counterparts 
was shown in a lack of successful detection using proteomic analysis of selected gel bands. 
Following Schmidt-Schultz and Schultz’s (2004) supposed detection of ancient IgGs at a 
molecular weight approximating 55-60kDa, it was assumed that proteomic analysis of 
excised bands at or around this weight range would produce positive results. It is, however, 
more likely that any extracted IgGs would survive in a degraded state of uncertain molecular 
weight. This would confound attempts to identify them in excised bands matching a positive 
control, as can be seen in this study by the detection of keratin or collagen at weights 
matching the IgG positive control. If ancient IgG was present in these bands, then it was 
probably either masked by more abundant proteins, or at too low a concentration for 
proteomic detection.   
 The experience gained in attempting to tailor a methodology for successful SDS-
PAGE characterisation of ancient IgGs has led to the conclusion that the technique is 
probably not entirely suitable for detecting these extremely low-abundance proteins. This is 
mainly due to the difficulties in concentrating the target proteins to a suitable level for 
visualisation and downstream analysis, combined with the inevitable protein loss during 
sample preparation and electrophoresis, and uncertainties concerning the molecular weight 
of degraded target proteins. Masking by more abundant proteins, such as collagen, is also a 
potential issue. A possible way forward for SDS-PAGE of archaeological IgGs would be in 
combination with Western blotting and subsequent proteomic analysis of any positive 
acquired, if an initially sufficient protein concentration could be achieved. 
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7.4.3: Western blot 
 
 Western blotting, like SDS-PAGE, is a commonplace analytical technique in many 
modern biological fields, and although employed less frequently for archaeological samples, 
it can potentially detect very low abundance proteins not necessarily visible by post-SDS-
PAGE gel staining. The use of conjugated antibodies to interact with target proteins 
increases detection sensitivity far above that of traditional gel staining. The process is also 
reasonably straightforward, with few changes to established techniques required to adapt 
standardised Western blotting protocols to archaeological samples. The most important of 
these adaptations is in the choice of primary and secondary antibodies, which should be 
dictated by the nature of the target protein, taking into account the likely presence of 
potential sources of cross-reactivity in the samples.  
 On the surface, Western blotting should provide the ideal technique for detection of 
ancient IgGs, since it should allow for detection of degraded fractions of unknown 
molecular weight, thus eliminating a major problem with SDS-PAGE characterisation, 
discussed above. This assumes, of course, that IgGs have been successfully extracted, 
precipitated, electrophoresed, transferred during blotting, and detected by the primary 
antibody. Unfortunately, these numerous stages present a myriad of opportunities for protein 
loss and degradation beyond detectability, and it is perhaps not surprising that only one 
potential positive was detected in this study (section 6.4.1(v)). As discussed above (section 
7.3.1(ii)), this single detection represents the most likely true positive from any other 
presented here. The gel was not retained by the Biological Sciences department for further 
analysis, which is unfortunate since this early sample (from P1.3) may have been of 
sufficiently high concentration for proteomic confirmation. Later Western blotting of P2, P3, 
and P4 post-TAC samples failed to yield any positives (section 6.4.6), possibly due to 
inefficient transfer of proteins from a high percentage gel, or protein degradation beyond the 
point of antibody interaction. 
   
7.4.4: Proteomics 
 Recent proteomic technological advances and methodological refinements have 
produced new insights into the vast range of NCPs extant in archaeological mammalian 
bone (e.g., Cappellini et al., 2012; Wadsworth and Buckley, 2014). However, attempts at 
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characterising ancient bone proteomes have had varied success in terms of detecting IgG-
related peptides. As previously mentioned, the detection of specific NCPs is heavily 
dependent upon the choice of extraction and purification methodologies. The technology 
utilised in their accurate detection and characterisation is of no less importance. These 
factors can both be seen in Table 7.12 (section 7.7) which summarises protocols which have 
reportedly extracted and detected archaeological IgG. Wadsworth and Buckley (2014) 
analysed archaeological bone proteomes using equipment of similar specification to that 
used in this study (see section 5.7.3(v)),  following the Jiang et al. (2007) extraction and 
sample preparation protocols. The failure of the three studies to detect IgGs suggests that the 
extraction or purification methods used were unsuited to the task and/or that the MS 
equipment used was insufficiently sensitive to detect the target peptides. Cappellini et al. 
(2012) identified IgG-related peptides using MS equipment of higher resolution and 
sensitivity, following a relatively simple extraction protocol and purification by customised 
C-18 tips. Despite the apparent identification of NCPs based on single peptides in this study, 
the MS equipment employed may not have been appropriately sensitive to detect fragmented 
IgG peptides in post-TAC samples (Adrian Brown, personal communication, April 2014). 
As can be seen in Appendix 3, most single-peptide protein identifications required a 
sequence of at least eight amino acids. It is possible that IgGs were fragmented into smaller 
sequences and were not identified by the MS equipment. 
 This study has shown that MALDI-TOF may not be an ideal method for detecting 
low-abundance proteins in ancient samples, particularly when excised SDS-PAGE bands are 
analysed. As can be seen in Table 6.30, which shows the results of MALDI analysis of 
selected colloidal Coomassie-stained P2.4 gel bands, the analysis failed to detect any 
peptides in two of the six tests. This is likely due to the low concentration of proteins in the 
bands, other than the IgG positive controls. MALDI analysis also failed to detect any 
proteins in excised silver stained bands from post-TAC samples. Since MALDI uses 
extremely small samples sizes and usually requires at least 10 peptides for identification, 
many excised gel bands evidently contained insufficient proteins for detection (particularly 
of NCPs, many of which were identified by nLC-MS/MS based on far fewer peptides than 
required for MALDI). This likely explains the failure of MALDI to identify proteins in the 
excised bands from the P1.2 (section 6.4.1(iii)) and P2.3 (Section 6.4.2(iv)) gels. SDS-
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PAGE gel band analysis may not, therefore, represent the most ideal format for detecting 
ancient proteins.  
 As mentioned in section 7.2.4, it is possible to create exclusion lists following nLC-
MS/MS. These are lists of peptides resulting from sample analysis which are ignored by the 
MS equipment during subsequent analyses of the same samples, thus increasing the chance 
of detecting low-abundance proteins. The creation of such lists is extremely time-
consuming, especially for samples which contain many different protein isoforms (slightly 
different forms of the same protein), each of which requires manual entry onto the list. This 
was attempted for P3 post-TAC sample CD120.2 (Tables 6.36-6.40), and proved relatively 
effective in ‘screening out’ much of the collagen (Table 6.47) and improving the detection 
of NCPs (Table 7.6). Considering the failure of the Jiang et al. (2007) protocol to detect 
IgG-related peptides from fresh bone, and the time constraints of the project, it was decided 
not to create exclusion lists and reanalyse the six P4 samples. 
 High resolution proteomic analysis may provide the first proof that IgGs survive 
within a chosen sample. With a known positive, extraction methodology could be refined in 
an attempt to isolate IgGs without reducing them to the peptide level. This is the goal for 
studies such as this, which require the extraction of immunoreactive IgGs to test against 
pathogenic antigens. Prior proteomic confirmation of the presence of IgG would also aid in 
the verification of any positive immunological results. 
7.5: Malaria ELISA  
 The second ELISA to be run in this study was the Malaria Total Antibody EIA (Lab 
21), which is designed to detect IgM, IgA, and IgG antibodies to all human malaria species. 
Selected samples from the P3, P4, and P5 protocols were tested, alongside controls in the 
form of protocol buffers, ultrapure water, and animal bone samples (Table 6.60). The P3 and 
P4 samples were TAC elutions with known protein concentrations. Samples were run in 
duplicate with average absorbance above 0.382 indicating a positive reaction. Before 
assessing the results, it should be stated that that the manufacturer guidelines suggest that 
negative readings should be less than 0.080 (with a maximum cut-off value of 0.180) for the 
test be considered valid. Table 6.60 shows that in this case, both negative control readings 
were significantly higher than recommended, giving a cut-off of 0.382. As none of the 
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buffer controls and a vast majority of the samples registered lower than the recommended 
maximum cut-off value (0.180), it is possible that the established cut-off value remains valid 
for this test. However, in light of the potentially high cut-off value, caution should be taken 
when interpreting the results.  
 Table 7.10 shows that a small number of positives were recorded for this ELISA. 
While it is potentially encouraging that the vast majority of positives are from human 
samples, the occurrence of a positive for an animal control (HPAN5) suggests the presence 
of an interfering contaminant that has cross-reacted with the anti-malaria antibodies. 
Placental mammalian antibody structure shows little variation across the clade, so it may be 
the case that extracted antibodies in sample HPAN5 have degraded or been modified into a 
form that cross-reacted with the test antigens. The human samples most likely to have 
produced true positives are CD165.1 and EH133.1 (Table 7.10), since the duplicates are 
relatively close in value. The other human positives demonstrate a large difference between 
duplicates (e.g., CD112.2), suggesting either contamination or cross-reactivity. This 
demonstrates the importance of running ancient samples at least in duplicate to help rule out 
false positives. Since both EH133.1 and CD165.1 present values close to the cut-off, 
however, the ‘true’ positives should be treated with caution. 
Sample Type HI Protocol Stage 
Protein conc. 
(mg/ml) 
First 
Read 
Second 
Read 
Average 
Absorbance 
Positive Control - - - - 2.639 2.53 2.585 
CD165.1 Human 5 3 3 0.112 0.358 0.57 0.464 
CD112.3 Human 2 4 3 0.059 0.202 2.08 1.141 
EH156.3 Human 5 4 3 0.044 0.839 0.169 0.504 
EH133.1 Human 1 5 1 - 0.396 0.319 0.358 
OL1104.2 Human 5 5 2 - 0.252 1.067 0.66 
HPAN5 Animal 5 5 2 - 0.696 0.521 0.609 
Table 7.10: Positive results from malaria ELISA. HI - histological preservation. Stage is 
extraction stage. Cut off value is 0.382. Positive samples when read at A450 in bold. 
 
The type of ELISA employed here may be more suitable for use with ancient 
samples than the IgG ELISA discussed above. The use of a secondary polyclonal antibody 
in the earlier IgG test (Figure 7.3) increases the IgG binding capacity, as the antibody is 
capable of recognizing many epitopes on the bound sample IgGs. Yet this would also 
increase the prevalence of reactions with non-specific molecules in the degraded sample 
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(Brandt et al., 2002). The malaria sandwich ELISA does not rely on a secondary polyclonal 
antibody (Figure 7.4) to detect the bound sample IgGs, thus theoretically reducing the 
chances of cross-reactivity. The well plates are coated with antigens, which should 
specifically bind to antibodies in the samples, which in turn should also bind specifically to 
the conjugated secondary malaria antigens. However, the potential for nonspecific binding 
of the antigens to other proteins present in the samples should not be discounted. Degraded 
collagen, for instance, is capable of forming complexes with other proteins, or humic 
substances. These complexes can either confound antibody/antigen reactions by blocking 
epitope/paratope interactions, or can cause nonspecific cross-reactions (Brandt et al., 2002). 
Either possibility cannot be ruled out in this instance. The human ‘positives’ encountered 
here for CD165.1 and EH133.1 could be supported by future independent ELISA and 
analysis of different skeletal elements. 
 
Figure 7.3: IgG ELISA. Unreacted material is removed by washing between stages. 
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Figure 7.4: Malaria sandwich ELISA. Unreacted material is removed by washing 
between stages. 
 
7.6: Malaria rapid testing 
 The lack of any positive rapid test results from the Fornaciari et al. (2010) protocol 
and P5 samples most likely suggests that the malaria antigen was not present in any of these 
samples, and that reagents used in these protocols do not induce cross reactions with this 
particular RDT. However, if the antigen was present, its concentration may have been too 
low to register a positive. Since RDTs are designed to be used on modern, fresh serum 
samples, they only require relatively low sensitivity levels. Surviving antigens in 
archaeological bone may not be of a high enough concentration to be detected by rapid 
testing. 
 The positive P2.5 results (see Table 6.61) may tentatively suggest evidence of 
malaria infection in the selected individuals. These results must, however, be considered 
with extreme caution. Cross contamination resulting in false positives must first be ruled 
out. These may arise from a number of sources which interact unexpectedly with the RDT 
antibodies. These sources may include the chemical reagents used in the preparation of 
samples, degraded endogenous and exogenous biomolecules, or extrinsic soil-based 
components that have infiltrated the bone (Brown and Brown, 2011). As with all clinical 
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immunological tests, RDTs are not designed to be used to detect ancient, degraded proteins. 
Neither are they evaluated for cross reactivity against biomolecules found in association 
with ancient samples, or against the range of chemical reagents used in archaeological 
protein extraction (Brandt et al., 2002). The polyclonal nature of the RDT antibodies used to 
detect multiple species of malaria may only serve to increase the likelihood of cross-reaction 
with non-specific targets. It should also be stated that none of the ‘positives’ encountered 
here developed within the manufacturer-specified 20 minutes following testing, with many 
of them taking up to 24 hours to register positive. By manufacturer standards, none of the 
results should be considered true positives. The extended development time of the positives 
may, of course, be an artifact of low antigenic (be they specific or non-specific reactions) 
concentration. 
 
  
Fornaciari et al. 
(2010) 
P2.5 P5 
Stage 1 
Phosphate 
buffered saline 
0.6M HCL 0.5M EDTA 
Stage 2 - 
100mM Tris; 6M guanidine-HCl; 5mM 
benzamidine; 10mM aminocaproic acid 
50mM ammonium 
bicarbonate 
Stage 3 - 
100mM Tris; 6M guanidine-HCl; 0.5M 
EDTA; 5mM benzamidine; 10mM 
aminocaproic acid 
0.6M HCl 
Table 7.11: Comparison of reagents used in the three RDT protocols. Stage – extraction 
stage. 
 
 The first potential source of cross-reactivity to be ruled out is chemical. Table 7.11 
summarises the reagents used in each protocol. As Table 6.61 and Appendix 2 Figures A2.7 
and A2.8 demonstrate, P2.5 positives only resulted in samples from the first and second 
extraction stages. The first stage utilised only 0.6M HCl to demineralise the samples. It is 
interesting that a number of the samples from this stage produced positives, while none from 
the P5 third stage (also 0.6M HCl) samples reacted positively (Figure A2.9). This suggests 
that HCl is not a source of reactivity. The fact that reactivity is sporadic between samples 
from the first and second extractions suggests that that none of the reagents caused cross-
reactivity, as does the lack of positives recorded for the third extraction stage and for the 
post-TAC P2.5 samples (Figure A2.10). This latter group were very unlikely to register as 
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positive, since any extant antigen should not bind to the thiophilic resin, and would therefore 
not be eluted from the columns. 
 Could these intermittent reactions recorded in the first two P2.5 extraction stages be 
suggestive of true malaria positives, despite their delay in development far beyond the 
recommended 20 minutes? LP3819D, a sample of powdered dentine, is interesting. Dentine 
is slightly more highly mineralised than bone (Goldberg et al., 2011) and may potentially 
afford increased protection to any surviving malaria antigens over bone samples.  
Unfortunately, histological preservation was not assessed for this sample. The nature of the 
positives for the Littleport samples and the collagen control sample may, however, be 
suggestive of cross-reactivity. None of the Littleport samples produced positive results 
outside of the P2.5 protocol. Given the lack of corresponding positives, it is more likely that 
an unidentified contaminant present in the bone was released during first two P2.5 extraction 
stages that was perhaps not released in the other two protocols. This may be the very same 
substance as mentioned in section 7.2.3. A similar contamination scenario could explain 
why sample HP154.1 failed to test positive in the Fornaciari et al. (2010) protocol tests, yet 
registered positive following the P2.5 protocol. 
 Positive reactions showing mixed malaria infections for the LP3760.1 and LP4585.3 
samples (Table 7.11) also point to cross-reactivity, since it is rather implausible that these 
individuals would have died while infected with both tropical P. falciparum and temperate 
vivax malaria. As the collagen control tested using the Fornaciari et al. (2010) protocol 
failed to elicit a false positive, it seems unlikely that the positives encountered in the P2.5 
tests can be attributed to cross-reactivity with intact collagen. It is somewhat surprising, 
then, that the collagen control sample (Figure A2.11) from the second P2.5 stage tested 
positive. It is possible that the test reacted specifically to well-preserved bovine collagen, 
rather than the degraded human collagen. Beyond this possibility, it remains unclear why 
this cross reaction occurred. 
A positive rapid test result here would require the survival of circulating antigenic 
biomolecules in the bone samples. In order for the tests to detect Plasmodium vivax 
infection, survival of the vivax-specific lactate dehydrogenase enzyme (LDH) in the bone 
samples would be necessary. No published research has investigated the extent to which this 
enzyme may persist in archaeological bone, if at all. Unlike anti-malaria antibodies, LDH 
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does not persist in the body following the clearance of parasites (Iqbal et al., 2004). The 
patient would, therefore, have to have perished during, or within approximately three weeks 
(Kakkilaya, 2003) of, infection for the antigens to remain in the circulatory system upon 
burial. While it is possible that at least some of the positives encountered in the P2.5 rapid 
tests represent true malaria infections (LP3819D being the most likely), the chances of 
sampling an individual with surviving LDH are remote. Clinical immunological tests that 
depend upon antigen/antibody interactions should be supported by secondary, confirmatory 
testing in order to verify claims of positive reactions (Child and Pollard, 1992; Brandt et al., 
2002). Proteomic testing of the positive samples encountered here are planned for the near 
future, since it was beyond the timeframe for this project. 
 
 
7.7: Archaeological IgG as a target biomolecule: combining past and 
present for a brighter future 
 
 Do the results of this study and the history of research aimed at extracting 
archaeological IgGs support Cattaneo et al.’s (1992) conclusion that ancient IgG represents a 
poor choice for biomolecular analysis? Their early research is one of the few published 
attempts at specifically extracting immunoreactive immunoglobulins from archaeological 
bone, and their conclusion may have led to a dearth of similar research until Kolman et al.’s 
(1999) and Schmidt-Schultz and Schultz’s (2004) apparently successful extraction and 
detection of IgGs. A comparison of the Cattaneo et al. (1992) methodology with more recent 
attempts at extracting IgGs highlights the evolution of the technique and offers potential 
lessons for such future extractions (Table 7.12). It also provides insights into the likely 
reasons why Cattaneo et al. (1992) struggled to isolate IgG from their samples. Their 
cellulose-based filtration stage, for instance, probably bound and removed many extracted 
IgGs before detection (see Walsh and Coles, 1980). Even prior to this, mechanical sample 
grinding and extraction without protease inhibitors may have severely degraded extant IgGs. 
Their methodology also seems to assume that diagenesis would affect their target molecules 
(albumin and IgG) equally, and that their chosen extraction methodology was suitable for 
both types. Subsequent research into diagenesis, protein survival and extraction techniques 
has led to a growing appreciation of the importance of adapting methodologies depending 
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upon the choice of specific protein target (Cleland et al., 2012). Table 7.12 compares four 
techniques that have reportedly extracted and detected IgGs or IgG-related peptides and a 
proposed new methodology based upon the published research, and this current study 
(discussed below, section 7.8). 
 
  
Cattaneo et 
al., 1992 
Kolman et 
al., 1999 
Schmidt-
Schultz and 
Schultz, 2004 
Cappellini et 
al., 2012 
2014 
Elements tested 
Vertebral 
body 
Femur 
Long 
bones/cranium 
Femur Various 
Histology No No Yes No Yes 
Sample size 10g 15g 1g 75mg 100mg 
Grinding Mechanical Mechanical 
Mechanical 
under nitrogen 
Hand 
powdered 
Hand powdered 
under nitrogen 
Low temperature Partly Yes Yes Partly Partly 
Demineralisation EDTA EDTA EDTA EDTA EDTA 
Solublisation No No 
Guanidine; 
sonication 
Ammonium 
bicarbonate 
Ammonium 
bicarbonate; 
sonication 
Protease 
inhibition 
No No Yes No Yes 
Dialysis Yes Yes No No No 
Purification 
Cellulose 
filter 
Filtration; 
HPLC; 
protein A 
No 
In house C-18 
stage tips 
Stage tips; thiophilic 
adsorption 
Characterisation ELISA ELISA Immunological nLC-MS/MS 
Immunological; 
proteomic 
Table 7.12: Comparison of techniques reported to have extracted and detected 
archaeological IgGs. 2014 – this thesis: detailed in section 7.8. 
 
7.7.1: Element selection 
 Table 7.12 shows that studies attempting to extract archaeological IgGs have tested a 
variety of bone elements. Many studies favoured long bones, such as the femur, due to their 
inherently thicker cortices and inferred resistance to diagenesis. Others, such as Cattaneo et 
al. (1992) tested blood-rich haematopoietic vertebral bodies in the anticipation that these 
would contain higher concentrations of IgG. These elements, however, often display thinner 
cortices, rendering them potentially more vulnerable to diagenetic degradation. The TAC 
purifications performed in this study may support the research of Wiechmann et al. 
(1999:384), who found there to be no significant differences [between elements]…in terms 
of protein yield and quality”, since there is little observable difference in gross protein yields 
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between element types. Based on TAC elutions and nLC-MS/MS analysis of samples in this 
study, cranial bone may at first appear to present a good target for IgG extraction, yet both 
this and the Jiang et al. (2007) research failed to detect IgG-related peptides from cranial 
samples. However, since Schmidt-Schultz and Schultz (2004) apparently detected ancient 
IgGs in cranial bone, the failure may be methodologically-based, perhaps influenced by HCl 
hydrolysis, inefficient purification, or insufficiently sensitive detection equipment.  
 Upon consideration of the different elements tested in reported IgG extractions, and 
non-standardisation of extraction and detection methods used, it would seem prudent that 
future IgG extractions test a range of bone elements. Crucially, the microscopic preservation 
of the elements should first be assessed: this study has supported Schmidt-Schultz and 
Schultz’s (2004) research by indicating that that increased quantities of higher quality NCPs 
can be obtained from well-preserved bone. It is likely, therefore, that microscopic 
preservation may be a more reliable predictor of NCP survival (including IgG) than bone 
element type alone. Unfortunately, beyond histological analysis, little can be done to predict 
the preservation state of archaeological IgGs, if, indeed, they survive at all.  
7.7.2: Histological preservation 
 While not a necessary precondition for the successful extraction of archaeological 
IgGs, histological analysis provides important information concerning the state of sample 
preservation prior to analysis. It helps to control for the selection of well-preserved samples 
that are less likely to be damaged by microbial attack. Characterisation of microscopic 
preservation would, for instance, have further supported Kolman et al.’s (1999) positive 
antibody/antigen reactions by ruling out extensive microbial damage and reducing the 
chances of cross-contamination with diagenetically introduced contaminants. It may also 
have allowed them to target samples displaying better preservation, potentially allowing 
them to destroy far less than their 15g of bone per sample. Histological analysis also allows 
for comparison of proteomes and protein yields extracted from different bone elements 
displaying different levels of preservation. It could, therefore, provide an important base 
from which to select samples. 
 The observed inverse relationship between protein yield and histological 
preservation in this study suggests that the chosen protein extraction methodology should 
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reflect sample preservation. It is likely that samples displaying the best preservation may 
require more intensive extractions to disrupt the bone matrix and release proteins of interest. 
However, if the end goal is to identify and characterise target protein(s) by methods that 
require well preserved molecules (e.g., immunological testing), then all care should be taken 
not to further degrade proteins during the extraction process. The extraction protocol could 
potentially be modified by increasing the duration of exposure to chemical reagents, rather 
than the relative strengths of the reagents. It seems prudent that further research should first 
identify the target proteins in well-preserved bone before applying the successful extraction 
method to more poorly preserved samples. This study made the mistake of attempting to 
extract and characterise IgGs from samples displaying a range of preservations before 
positively identifying them in any samples; it was naïvely assumed that following of 
published extraction protocols (P1, in particular) would result in successful IgG extraction. 
7.7.3: Sample preparation and size 
 The choice of initial sample preparatory steps and methods of preparing samples for 
extraction are important precursors in the subsequent extraction, detection, and 
characterisation of NCPs. Many of the earlier studies homogenised samples to increase the 
surface area exposed to reagents during the extraction process. While grinding certainly 
increases protein yield, it is known to significantly degrade collagen (Collins and Galley, 
1998). Crucially, Jiang et al. (2007) found that bone homogenisation releases large 
quantities of collagen, which may obscure lower-abundance proteins. Although IgG was 
detected in ground bone samples by Cattaneo et al. (1992) and Kolman et al. (1999), the 
effects of grinding on NCP quantity and quality are unknown. The rise in temperatures 
particularly associated with mechanical homogenisation may be adversely detrimental to 
IgG survival. Hand grinding (such as performed by Cappellini et al. 2012) may prove less 
damaging, especially if performed following immersion in liquid nitrogen, which is shown 
to promote the release of proteins while decreasing the rate of degradation (Wu et al., 2009).  
 Table 7.12 suggests a general trend over time towards testing smaller samples. 
Whereas earlier research used up to 15g of powdered bone (Kolman et al., 1999), the latest 
proteomic studies (e.g., Cappellini et al., 2012; Wadsworth and Buckley, 2014) require less 
than 100mg of sample. This change reflects both the early choice of extraction and 
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characterisation methods, and the recent technological advancements which require only 
tiny samples for protein identification. The early attempts at IgG detection understandably 
used larger quantities of sample, since their target protein was likely to be present in 
extremely low abundance, and detection methods were less sensitive than in their more 
modern analytical counterparts. Cattaneo et al.’s (1992) ELISA, for instance, had a detection 
limit of 10ng. If the IgG ELISA results from this study were accurate, the highest detected 
IgG yield was less than 5ng. Thus, if IgGs are normally this low in abundance in 
archaeological samples, it may indicate why Cattaneo et al.’s results were limited by their 
choice of analytical test. Subsequent improvements in extraction techniques which saw 
increases in protein yield and purity (e.g., Brand et al., 2002; Schmidt-Schultz and Schultz, 
2004), permitted the use of smaller samples, thus easing pressure on a finite skeletal 
resource.   
 Considering the difficulties encountered in this study in extracting IgGs from 
archaeological material, it is difficult to propose exactly what sample size might be 
appropriate for their successful extraction. It may ultimately depend upon the choice of 
characterisation method. Proteomic identification, for instance, has been shown to require 
much less initial sample than immunological detection (Table 7.12). It seems advisable to 
test a range of sample sizes, depending upon the availability of laboratory equipment 
suitable for extraction. For example, larger samples usually require larger receptacles, which 
subsequently require equipment capable of receiving them (e.g., refrigerated centrifugation 
of 15ml, rather than 1.5ml test tubes). This equipment availability was a major factor in 
dictating sample sizes in this study. The future proposed extraction protocol (see section 7.8) 
suggests the distribution of numerous 120mg sample fractions between tubes, depending 
upon availability of processing equipment. The use of numerous fractions from the sample 
should increase the overall yield of extracted proteins and allow sufficient material for 
numerous downstream analyses (Cleland et al., 2012), thus maximizing the chances of 
ancient IgG detection. 
7.7.4: Extraction temperatures 
 The temperature at which protein extraction take places is a further variable to take 
into consideration when proposing a method for archaeological IgG extraction. All of the 
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published studies in Table 7.12 perform the demineralisation stage at 4°C in order to slow 
protein degradation. However, analysis of the research suggests a transition to low 
temperature sample processing throughout the extraction and most of the characterisation 
stages. This change may be related to an increasing effort to follow clinical protein 
extraction practices and a growing appreciation of the potential range of proteolytic 
biomolecules (both extrinsic and intrinsic) that may survive in bone alongside target NCPs. 
Given the relationship between elevated temperature and protein degradation, it seems wise 
for any future IgG extractions to keep samples at a low temperature throughout processing 
and testing to prevent further deterioration of already degraded archaeological IgGs. 
7.7.5: Demineralisation 
 The most commonly employed agents of bone demineralisation in biomolecular 
archaeological studies are EDTA and HCl. Both have benefits and drawbacks. In 
comparison to HCl demineralisation, EDTA provides a more gentle method. However, it 
takes much longer, requiring the presence of protease inhibitors and extensive desalting of 
samples. Despite HCl demineralisation leading to the ‘purest’ and cleanest archaeological 
protein extractions (Cleland et al., 2012), no protocol employing this method has resulted in 
detectable IgGs. HCl demineralisation is optimised for the extraction of acid-soluble 
collagen and collagen-associated proteins through the dissolution of the inorganic bone 
content and induction of “‘swelling’ of the collagen matrix [which] increases the ability of 
both collagen I and collagen-associated proteins to go into solution” (Cleland et al., 2012:4). 
Although 0.6M HCl is proposed to reduce protein hydrolysis and degradation during 
demineralisation, the low pH (approximately 0.2) may make the method unsuitable for 
extractions specifically aimed at IgGs. Vermeer and Norde (2000) demonstrated that IgG 
denaturation is proportional to decreasing pH, with significant denaturation occurring at pH 
3.5 at 20°C. Smejkal et al. (2007) experienced significant protein loss in the 55-60kDa range 
(approximating IgG heavy chain molecular mass) following HCl demineralisation of fresh 
ostrich cortical bone. While most HCl demineralisations of archaeological bone take place at 
4°C in order to reduce protein degradation, the harsh acidic conditions may help to explain 
why no IgGs have been detected following this demineralisation technique.    
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 EDTA demineralisation is more time consuming than HCl, but the reaction is not 
dependent upon pH: the former reagent removes calcium from the bioapatite by chelation, 
rather than dissolution, meaning that the pH of the extraction solution can be regulated. This 
is potentially crucial for IgG extraction. The length of time required for EDTA 
demineralisation and the gentle conditions require extraction at low temperature in the 
presence of protease inhibitors. Increased temperature has been demonstrated to 
significantly accelerate demineralisation rate (e.g., Cho et al., 2010), but this may not be 
advisable for extracting already-degraded IgGs. It is difficult to determine the effect of HCl 
demineralisation on the quantity and quality of NCPs, since studies employing the method 
have tended to assess the yield and purity of extracted collagen. It may be significant that no 
research (either on modern or ancient bone) that has used HCl demineralisation has 
subsequently reported the presence of extracted IgGs or IgG-related peptides: all of the 
published protocols that reported the presence of extracted IgGs in Table 7.12 used EDTA, 
as did Delmas et al. (1984) in their extraction of the protein from modern bovine bones. 
While HCl and EDTA have been shown to selectively extract certain NCPs from modern 
bone, “EDTA solutions at neutral pH were as efficient as the strongest acid in dissociating 
the mineral phase” (Gerstenfeld et al., 1994:231). It seems prudent, therefore, for future 
NCP extractions to employ EDTA demineralisation, given the gentle nature of the process in 
comparison to HCl, and the apparent success of the reagent in extraction IgGs from both 
modern and archaeological bone. 
7.7.6: Solubilisation 
The solubilisation of proteins is commonly performed with archaeological samples, 
often following demineralisation. The decision as to exactly which agent of solubilisation to 
employ may have important consequences on the outcome of extractions targeting 
archaeological IgG. The most commonly employed reagents are guanidine-HCl (GuHCl) or 
ammonium bicarbonate, both of which effectively solubilise proteins following the removal 
of bone mineral (Cleland et al., 2012). The former is an extremely strong denaturant, which 
solubilises protein through denaturation. This usually does not represent a problem, since 
many proteins can refold back into a functional unit following solubilisation. However, the 
oligomeric nature of IgGs means that they often fail to refold, which can result in 
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irreversible aggregation with other proteins and loss of functionality (Maede et al., 1996). 
Although IgG has been detected following extractions which included GuHCl denaturing 
(e.g., Schmidt-Schultz and Schultz, 2004), the omission of a denaturant may result in an 
increased IgG yield, particularly following purification. Purification following GuHCl 
denaturation may not be effective, since the inherent affinity of the IgG for the chosen 
ligand may not survive in a denatured state. This may help to explain why Kolman et al. 
(1999) managed to extract immunoreactive antibodies, although their choice of protein A 
columns required a low pH (3.0-3.5) elution, which may have reduced their IgG yield 
through acid-induced degradation or denaturation. 
 The choice of downstream purification or analytical techniques should influence the 
choice of solublisation agent. Thiophilic adsorption, the purification technique advocated 
here, relies on the presence of non-chaotropic salts (e.g., potassium sulphate) to increase 
efficient immunoglobulin binding to the thiophilic support (Thermo Scientific, 2011). 
GuHCl is a strong chaotropic salt, and its presence in solutions may adversely affect the 
binding efficiency of the thiophilic resins, depending upon the interaction of GuHCl with 
water molecules. GuHCl also reduces the efficiency of tryptic digestion in sample 
preparation for mass spectrometry analysis (Proc et al., 2010), and samples therefore require 
an additional GuHCl-removal step if this type of analytical approach is chosen. It is for these 
reasons that ammonium bicarbonate has been proposed as the solublisation agent of choice 
when attempting to extract archaeological IgG from bone (section 7.8). However, it may 
prove useful to be run a tandem extraction using GuHCl, in order to assess both resulting 
extractions for the presence of IgG. 
 Schmidt-Schultz and Schultz (2004) advocate the use of sample sonication as an 
additional solubilisation step, claiming that it results in a more efficient release of strongly 
mineral-bound NCPs. nLC-MS/MS analysis of P3 sample CD120.2 (post-sonication) does 
not necessarily support this step, since it produced only two cellular NCPs (Table 6.40). Its 
effectiveness cannot be fully evaluated, however, because of the post-TAC nature of the 
sample tested; many non-resin-bound NCPs would have been lost during TAC purification. 
Sonication has been included in the proposed protocol (section 7.8) in order to more 
accurately assess its efficacy. 
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7.7.7: Dialysis 
 Dialysis during (e.g., Kolman et al., 1999), or following (e.g., Cattaneo et al., 1992) 
extractions is an extended process undertaken to remove contaminants, such as excess salts 
or residual EDTA from samples, in preparation for downstream analyses. Dialysis is 
particularly effective for samples containing high salt concentrations and for removing 
interfering contaminants that might precipitate along with proteins during sample 
preparation (Cleland et al., 2012). The process is, however, time consuming and introduces 
an extra preparatory stage, which may increase the loss of target proteins, particularly if they 
have a tendency to adsorb to any of the dialysis equipment or filters. Schmidt-Schultz and 
Schultz (2004) advise against dialysis due to this latter concern. Contaminant removal 
through dialysis or washing was not required for samples subjected to thiophilic adsorption, 
since contaminants should wash away during the TAC process. The resulting elutions in 
sodium phosphate buffer, however, may require desalting, depending upon chosen 
downstream analytical protocol.  
7.7.8: Purification 
 
 In a process similar to dialysis, protein purification techniques following extraction 
are often designed to both remove contaminants and high abundance proteins from samples, 
thereby purifying the target protein(s). This step is particularly important when target 
proteins, such as immunoglobulins, are naturally of low abundance. All of the published 
extraction protocols in Table 7.12 use some form of protein purification, other than Schmidt-
Schultz and Schultz (2004), who state that the use of purification or concentration 
techniques results in loss of NCPs. While this is likely true to an extent, the authors offer no 
solution for eliminating the ubiquitous NCP-masking collagen inevitably extracted alongside 
any NCPs. Kolman et al. (1999) demonstrate the importance of IgG purification by 
comparing extracted IgG reactivity in purified and unpurified samples. They found that the 
latter failed to produce immunological confirmation of IgG, whereas the purified samples 
reacted positively. This suggests that IgG is susceptible to masking by more abundant 
proteins, such as collagen or albumin. 
 TAC purification in this study resulted in the non-specific binding of a small quantity 
of collagen and possibly cross-linked non-collagenous proteins (not including IgG). This is 
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likely due to the failure of the preceding stages (P2 and P4 in particular) for extracting IgG 
from the bone samples, rather than a failure of the TAC to purify the target protein. TAC 
represents a gentle, highly specific method of purifying immunoglobulins and further 
extractions are required from archaeological bone to truly test the efficacy of thiophilic 
binding of degraded target IgGs. It would be useful to analyse pre-TAC samples using high-
resolution nLC-MS/MS to identify samples containing IgG-related peptides. Positive 
samples could then be subjected to TAC to assess the suitability of the purification method. 
Alternatively, the HPLC/protein A purification method employed by Kolman et al. (1999) 
could be attempted, with the results compared to matching samples that have been TAC 
purified. If proteome analysis (perhaps prior to TAC) is to be performed, it may be advisable 
to follow the C18 stage tip purification and concentration method of Cappellini et al. (2012). 
Bona et al., (2014) also used stage tips to concentrate proteins in their apparent detection of 
protein biomarkers specific to osteogenic sarcoma in archaeological bone. That they also 
detected heavily degraded IgG heavy chains (around 12kDa) may support the potential of 
using stage tips in future analyses. 
 
7.7.9: Detection and characterisation 
 
 The choice of final IgG detection technique is crucial in developing a suitable 
extraction methodology. A purely proteomic approach, for instance, does not require the 
extraction of functional, immunoreactive IgGs for identification. It also benefits from the 
use of compatible extraction reagents, since additional sample clean-up steps may result in 
the loss of target IgGs. Extraction for proteomic analysis also requires only a very small 
initial bone sample quantity. 
When considering Cappellini et al.’s (2012) success in detecting ancient IgGs using 
high-resolution nLC/MS-MS, it should be remembered that they analysed Pleistocene 
mammoth bone from both polar and temperate regions. Unsurprisingly, the samples 
preserved in permafrost produced more detectable IgG-related peptides of better 
preservation compared to the temperate samples (Table 7.13). However, their innovative 
purification and concentration technique and use of high-resolution proteomics offers hope 
for future analysis of archaeological samples, since it demonstrates that the proteins can 
survive extended periods in temperate conditions. Their success also shows that newly 
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developed, highly sensitive technology can characterise ancient proteins of extremely low 
concentration – proteins that may previously have been present, but undetectable by less 
sensitive techniques (a problem discussed by Tran et al., 2011). 
 
 
Burial 
environment 
Protein 
Sequence 
coverage (%) 
Unique 
peptides 
Permafrost PREDICTED: IgG heavy chain 8.8 3 
Permafrost PREDICTED: IgG heavy chain 10.4 3 
Temperate PREDICTED: IgG heavy chain 5.6 2 
Table 7.13: Mammoth IgG-related peptides from permafrost and temperate samples 
(Cappellini et al., 2012). 
 
 Theoretically, more recent bone should yield greater quantities of IgG than 
Cappellini et al.’s (2012) mammoth samples. However, their research suggests that, should 
IgGs be present, they will likely be at extremely low abundance and of potentially poor 
quality. It is, therefore, crucial to first identify extracted IgGs by the most sensitive, 
accurate, and reliable methods available. At the current time, high-resolution proteomics 
seems the best method to achieve this. Once IgG-containing samples are identified, testing 
using other characterisation methods (e.g., ELISA or Western blot) can be considered. 
 
7.8: A proposed protocol for future ancient IgG extractions 
Bearing in mind the problems encountered in this study, the experience gained from 
attempting to extract archaeological IgGs, and a reanalysis of published protocols that have 
reportedly extracted them, a new protocol (summarised in Table 7.12) has been devised for 
future IgG extractions. It represents a combination of extraction stages from Schmidt-
Schultz and Schultz (2004) and Cappellini et al. (2012), both of which reported successful 
extraction of IgGs or IgG-related peptides. This protocol is adapted specifically for the 
extraction of any extant IgGs from well-preserved samples, with an emphasis on reducing 
possible further damage to already degraded target proteins. The extraction will result in 
three separate supernatant fractions which could potentially be subjected to numerous 
analyses to investigate IgG presence. This is one reason for preparing multiple samples from 
one bone of known histological preservation. Fractions could potentially be purified using 
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stage tips and characterised by nLC-MS/MS in order to identify IgG-containing samples. 
Corresponding fractions could then be subjected to TAC to evaluate the effectiveness of this 
purification method on samples with known IgG content. 
1. Select bone of known good histological preservation. 
 
2. Clean bone surfaces, as in section 5.6.1. Immerse bone in liquid nitrogen. 
 
3. Wrap bone sample in clean aluminium foil and powder with a hammer. This 
should offer more control over any excessive heating associated with mechanical 
grinding, and possibly reduce NCP degradation. It should also result in lower 
quantities of extracted collagen. 
 
4. Take multiple 100mg bone sample into microtubes and suspend in 1.5ml of 0.5M 
EDTA (pH 8) in the presence of protease inhibitors for 48 hours at 4°C, with 
gentle agitation. 
 
5. Centrifuge for 15 minutes in a microcentrifuge at maximum speed (e.g., 17,000g) 
at below 8°C. Retain supernatant (Fraction A) at -20°C. 
 
6. Wash bone pellet twice in 0.75ml of analytical grade water, then suspend in 
1.2ml of 50mM ammonium bicarbonate, in the presence of protease inhibitors, 
pH 7.4. 
 
7. Incubate sample for 48 hours at 45°C with gentle agitation. 
 
8. Centrifuge sample for 15 minutes in a microcentrifuge at maximum speed (e.g., 
17,000g) below 8°C. Retain supernatant (Fraction B) at -20°C. 
 
9. Wash pellet twice in 0.75ml of analytical grade water then lyophilise. 
 
10. Take 20mg of lyophilised bone pellet and suspend in 1.5ml solubilisation buffer 
(20mM NaH2PO4, 30mM Na2HPO4, and protease inhibitors 1mM benzamidine, 
10mM aminocaproic acid, 10mM EDTA, pH 7.4). 
 
11. Sonicate sample in twice over ice for 7 seconds. Centrifuge for 15 minutes in a 
bench top microcentrifuge at maximum speed (e.g., 17,000g) below 8°C. Retain 
supernatant (Fraction C) and bone pellets at -20°C. 
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 Protein purification: 
1. As mentioned above, C-18 stage tip purification following the Cappellini et al. 
(2012) protocol could be employed at this point to prepare sample fractions for 
nLC-MS/MS analysis. 
 
 IgG purification by TAC: 
1. Add 87mg reagent grade crystalline potassium sulphate per ml of sample 
fractions, before gentle mixing.  
 
2. Centrifuge sample at 10,000g for 20 minutes below 8°C. Carefully remove 
supernatant through 0.45µm low-protein binding filters (using 5ml syringe, filter, 
and 20 gauge needle). Bring aspirated supernatant to pH8.  
 
3. Equilibrate thiophilic columns and buffers to room temperature. Uncap columns 
and allow to drain. Equilibrate with 12ml of binding buffer, discarding the flow-
through fractions. 
 
4. Apply sample supernatants to the columns and allow to completely enter the 
resin. 
 
5. Wash columns with consecutive 3ml volumes of binding buffer. Collect flow-
through fractions after each wash and monitor absorbance of each at 280nm 
against pure binding buffer using a spectrophotometer. This step will determine 
when all non-bound material is removed from the column. 
 
6. Elute bound proteins from each column using as many elution buffer washes as is 
necessary, until no further protein is measurable at 280nm against pure elution 
buffer. Retain eluted fractions containing protein at -20°C. Discard fractions 
containing no measurable protein. 
 
7. Lyophilise retained protein-containing fractions (expect the tubes to contain a 
high quantity is dried phosphate). The remaining protein pellet can then be 
resuspended in a buffer appropriate for chosen downstream analytical technique. 
Alternatively, the samples could be desalted prior to lyophilisation. 
 
 If this protocol proves successful in extracting IgGs from archaeological 
bone, the integrity of the proteins will be investigated through high resolution mass 
spectrometry. This would provide some idea of the potential functionality of the 
extracted IgGs. In the case of poorly preserved proteins, the extraction technique 
could be altered to see if preservation is being negatively affected during the 
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extraction process. Should preservation be adequate, the next stage would be to 
assess the functionality (or immunoreactivity) of the isolated IgGs. Immunoreactivity 
could potentially be assessed by employing a human IgG ELISA or Western blot. If 
immunoreactive IgGs are detected, then they will be tested against P. vivax antigens 
to assess the original thesis hypothesis concerning the presence of malaria in the past 
English Fens.  
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CHAPTER 8: CONCLUSIONS 
 
8.1: Summary of research findings  
 The aim of this study was to detect the presence of temperate Plasmodium vivax 
malaria in the past English Fens (from the Roman to late medieval periods) through a variety 
of indirect and direct methods. P. vivax is known to have affected post-medieval marshland 
populations in south east England, but its presence has yet to be confirmed prior to this. This 
is despite the existence of favourable environmental and demographic conditions for many 
preceding centuries. These conditions were particularly suitable for endemic vivax malaria 
in the Fens of Lincolnshire and Cambridgeshire, yet very little palaeoepidemiological 
research has concentrated in these areas. The reservations of some researchers concerning 
the presence of malaria in England prior to the post-medieval period are likely based on a 
lack of documentary sources pertaining to the disease, beyond vague symptomatic 
descriptions. There are, however, few justifiable reasons why P. vivax malaria should not 
have been present before the 16th century. The results of this study in relation to the research 
questions posed in Section 1.2 can be summarised thus: 
 
 1.  This research was unable to extract or detect extracted antibodies from 
 archaeological human bone. Consequently, it cannot assess the proposal that ancient 
 P. vivax malaria can be detected through testing of extracted anti-malarial antibodies.  
 2.  The failure to extract IgGs suggests that the methods of extraction and detection 
 were insufficient, or that IgG is not preferentially retained in bone, or both.
 However, the study has confirmed that bone of higher histological preservation 
 yields a more diverse range of NCPs. The lack of osteocalcin may indicate that NCPs 
 do not preferentially survive in archaeological bone due to a high affinity to 
 hydroxyapatite.   
 3.  Analysis of published skeletal reported revealed no evidence of genetic anaemia 
 in the form of β thalassaemia in the small Fen-associated sample (through analysis of 
 published reports). This suggests that P. vivax, if present, did not exert sufficient 
 selective pressure to drive the development of thalassaemia, or that the nature of the 
 disease and poor skeletal preservation precluded its manifestation in the 
 archaeological record. 
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 4.  Palaeodemographic comparison of Fen/non-Fen populations through analysis of 
 published skeletal reports could not support the presence of P. vivax. However, 
 analysis of mortality patterns did suggest evidence of ‘healthy adaptation’ to the Fen 
 environment, which supports earlier research (Gowland and Western, 2012). One 
 Fen population also displayed possible evidence for intra-uterine growth restriction, 
 a condition strongly linked with endemic P. vivax. 
 
 The first indirect method of tracing P. vivax malaria entailed the analysis of 
osteoarchaeological reports in order to identify putative sequelae of the haemoglobinopathy 
β thalassaemia in populations from potentially malarious areas (third research question). 
This analysis followed recent refining of diagnostic criteria for identifying the condition in 
skeletal remains (Lewis, 2010). Identification of this disease in past Fen populations would 
suggest that malaria supplied a significant enough selective pressure to drive the selection of 
genetic resistance. One individual from the Littleport site displayed two possible changes 
associated with thalassaemia (porotic hyperostosis and ‘hair-on-end’ diplöic arrangement), 
but further macroscopic and radiographic analysis yielded no further suggestive pathologies 
(see sections 6.1.1 and 6.1.4). Unfortunately, an overall lack of reported sequelae cannot 
currently support the presence of thalassaemia in the past in the English Fens. Nor can it 
support, by proxy, the hypothesised malarial selective pressure. It may be more likely that 
genetic resistance in the form of G6PD deficiency would have developed in response to 
long-term P. vivax exposure, such as has been recently observed in Southeast Asia 
(Louicharoen et al., 2009). While macroscopic identification of this condition in 
archaeological bone remains impossible, recent developments in aDNA technology may 
prove useful in identifying preserved genomic markers of G6PD deficiency.  
 There can be little doubt that the past Fens and marshlands of England presented 
significant epidemiological and environmental challenges to their inhabitants. Post-medieval 
parish registers from eastern and south eastern England, for instance, clearly demonstrate the 
significant health burden placed upon marshland-associated populations, which suffered 
considerably higher mortality rates than their upland counterparts (Dobson, 1997). The year-
round resources offered by these locations were, however, worth the risk associated with 
their continual utilisation. The seasonal pattern to this increased mortality is highly 
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suggestive of endemic P. vivax malaria, likely comorbid with other diseases ubiquitous to 
what were inherently unhealthy environments. Although until recently considered a ‘benign’ 
infection in comparison to its tropical cousin P. falciparum, vivax malaria in modern settings 
is well known to increase morbidity and mortality in the most vulnerable groups, namely 
infants and mothers. In pre-medicalised antiquity, P. vivax infection would have been 
chronic and debilitating, and would have added to the plethora of diseases and conditions 
that served to increase infant and maternal mortality. It was the intention of this study to 
investigate whether P. vivax presence could be inferred from comparing the mortality 
patterns of Fen and non-Fen cemetery populations, with particular emphasis on these most 
vulnerable groups (fourth research question). 
  Despite the acknowledged limitations of cemetery population-based 
palaeodemographic analyses, some interesting, and somewhat unexpected patterns emerged 
concerning Fen/non-Fen survivorship and probability of death. Statistical analysis showed 
that location was a significant factor influencing age-at-death and it was expected that Fen-
associated populations would show lower survivorship and increased force of mortality 
compared to their non-Fen counterparts. The opposite relationship was, however, observed 
in most of the ‘vulnerable’ groups for all but the medieval period, with Roman and Anglo-
Saxon Fen populations seemingly coping better with their environments. Although 
unexpected, this pattern may suggest that these relatively isolated populations had adapted to 
the constant epidemiological pressures of their unwholesome locations. The observed 
increased prevalence of cribra orbitalia in Anglo-Saxon marshland-associated populations 
(Gowland and Western, 2012) may support such a ‘healthy adaptation’ hypothesis. It is 
possible that an acquired, rather than genetic immunity to malaria was present here. It is 
unknown why this pattern reverses in the later medieval period. The economic boom and 
favourable climatic conditions of the 12th and 13th centuries certainly saw an exponential 
increase in Fen population and subsequent exploitation. It could, theoretically, be the case 
that this expansion (including migrants unadapted to the Fens) increased contact with either 
local parasite vectors or new, externally introduced pathogens. The latter could, of course, 
include malaria.  
 Perhaps tellingly in terms of identifying vivax malaria through increased mortality 
rates, demographic analysis showed no significant difference in Fen/non-Fen age-at-death 
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category distribution, where it might be expected that vivax malaria would increase Fen 
mortality in certain vulnerable groups. It remains uncertain whether P. vivax, if present at 
all, provided a force of mortality significant enough to be inferable through analysis of 
cemetery demography. One potential indirect indicator, however, was observed in the St. 
Peter’s, Barton-upon-Humber population, which showed an unusually high prevalence of 
small infants (as recorded though femoral diaphyseal measurement). This may be a potential 
indicator of intrauterine growth restriction (IUGR), a condition strongly linked to endemic 
P. vivax malaria in modern populations. IUGR does have alternative aetiologies that cannot 
be discounted here. However, its putative presence has not before been documented in 
archaeological populations, and its strong association with vivax malaria presents an 
intriguing possible link to the disease affecting an otherwise apparently ‘healthy’ population. 
The further research required to substantiate this would, unfortunately, be complicated by an 
overall dearth of infant burials from Fen contexts. Although the palaeodemographic analysis 
attempted in this study has been unable to confidently identify the presence of P. vivax 
malaria as a driver of mortality, it has offered a hitherto unforeseen glimpse of the health 
status of past Fenlanders, a group potentially well adapted to the epidemiological pressures 
associated with life in ‘demon-haunted’ (Colgrave, 1956:78, translating Felix), miasmic 
wilderness of the pre-modern Fens.  
 Direct evidence of P. vivax malaria was sought though the biomolecular analysis of 
human skeletal remains from potentially malarious areas of the Lincolnshire and 
Cambridgeshire Fens (first research question). Since published attempts at detecting 
pathogenic P. vivax-related molecules had failed, it was hypothesised that the extraction and 
detection of biomolecules associated with the human immune response to P. vivax infection 
would prove more successful. The biomolecule of choice was immunoglobulin G (IgG), the 
most abundant serum antibody, which has been clinically shown to circulate long after 
infection (and associated pathogenic molecules) has been cleared from the body (Wipasa et 
al., 2010). It was hypothesized that the extraction of functional anti-malaria antibodies from 
archaeological bone would offer a direct method of detecting the presence of the disease in 
past populations. 
 The inherent stability of IgGs and their naturally negative charge should influence 
strong adsorption to bioapatite following death, thereby providing increased protection 
407 
 
against diagenetic factors. Theoretically then, IgG should persist in well-preserved 
archaeological bone. Each collected bone sample was initially subjected to histological 
analysis in order to characterise the level of preservation. This provided an important 
baseline for selecting samples for protein extraction, and provided useful information 
regarding the relationships between histological preservation and the quantity and integrity 
of proteins yielded.  
 Numerous protein extraction and characterisation techniques were attempted in this 
research, each based on published protein extraction techniques using either archaeological 
(e.g., Schmidt-Schultz and Schultz, 2004) or modern (e.g., Jiang et al., 2007) bone. This 
study was also the first to attempt to purify archaeological IgGs using thiophilic adsorption 
chromatography (TAC). This technique was introduced to eliminate collagen, which was 
responsible for masking of lower abundance proteins, a phenomenon confirmed by 
proteomic analysis. Although no IgG was identified in the TAC-purified samples, nLC-
MS/MS analysis of post-TAC elutions demonstrated non-specific binding of collagen and a 
small quantity of endogenous and exogenous NCPs, along with one possibly from a 
pathogenic organism (Cronobacter sakazakii). Since many of these protein identifications 
were based upon single peptides, further testing of pre-TAC samples is required for more 
secure identifications. The study also found that Schmidt-Schultz and Schultz’s (2004) 
‘successful’ extraction and detection of archaeological IgG could be not reproduced, which 
may call into question the authenticity of this published research; future work based on this 
research should regard the reported findings with extreme caution. 
 The research was unable to fully support Masters’ (1987) theory that non-
collagenous proteins (NCPs) are preferentially retained in archaeological bone due to a high 
affinity with hydroxyapatite (second research question), since the nature of the proteomic 
analyses (nLC-MS/MS of post-thiophilic resin samples) did not allow for a full evaluation of 
entire sample proteomes. Many of the identified NCPs may have been cross-linked to 
collagen, rather than associated with bone mineral. Also, the lack of expected osteocalcin in 
any analysed sample calls into question the original hypothesis concerning preferential NCP 
survival. The study did, however, support earlier research (Schmidt-Schultz and Schultz, 
2004) by indicating that increased quantities of higher quality NCPs can be obtained from 
well-preserved bone, thus demonstrating the importance of histological screening of samples 
408 
 
prior to analysis. The observed inverse relationship between protein yield and histological 
preservation also suggests that the chosen protein extraction methodology should reflect 
sample preservation. It is likely, for instance, that samples displaying the best preservation 
may require more intensive extractions to disrupt the bone matrix and release proteins of 
interest. This research joins other studies (e.g., Cappellini et al., 2012) in supporting Cleland 
et al.’s (2012) suggestion that extraction and purification methods should be tailored to the 
specific target protein. Consequently, the experience gained during this research has led to 
the proposal of a protocol specifically aimed at specific extraction of archaeological IgGs. 
This protocol will be implemented in the near future, alongside investigations into the 
diagenesis and retention of IgGs in modern mammalian bone. 
  
8.2: Summary of limitations 
The main limitations of this research can be summarised thus: 
 1.  Assessment of the first research question was limited by the inability to extract 
 IgG from archaeological bone following published protocols.  
 2.  Although a range of NCPs were characterised and the relationship between high
 histological preservation and NCP yield was confirmed, the nature of the analyses 
 (nLC-MS/MS on eluted TAC samples) meant that full proteomes were not revealed. 
 High resolution mass spectrometry of pre-elution samples would be required for this. 
 3.  Evidence for genetic anaemia in associated with P. vivax was limited by the 
 reliance on sufficiently detailed reporting of suggestive sequelae in skeletal reports, 
 and the small sample size in terms of cemetery sites. Limitations also included the 
 likely poor representation of thalassaemia in the archaeological record, and current 
 difficulties in detecting G6PD deficiency (a condition more likely to be associated 
 with P. vivax than β thalassaemia) in skeletal samples. 
4.  Palaeodemographic analysis of mortality and survivorship patterns is inherently 
limited by the lack of correlation between living and cemetery populations in terms 
of demographic structure. Furthermore, many recent palaeodemographic studies 
have reassessed skeletal assemblages using statistically-based methods in an attempt 
to both standardise and increase the accuracy of ageing adult skeletons. The large 
sample sizes analysed in this study and time-constraints precluded the reassessment 
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of reported skeletal populations, each of which would have originally been recorded 
using different criteria. 
 
8.3: Future research directions 
 Despite the limitations inherent in such analyses, the paleodemographic element of 
this study revealed interesting and unexpected patterns in Fen mortality, as well as possible 
evidence for IUGR at the St. Peter’s, Barton-upon-Humber site. Since this research relied 
completely on skeletal reports produced by many palaeopathologists over a number of 
decades, the lack of standardisation in recording limits the usefulness of interpretations 
based upon this data. The potential insights into past Fen health and adaptation suggested 
here warrants deeper investigation, perhaps incorporating reassessment of skeletal 
populations using a standardised recording criteria. This would be particularly useful for the 
St. Peter’s Barton-upon-Humber population, since there remains uncertainty concerning the 
possible under-ageing of infants. This presents a possible confounding factor for the 
presence of IUGR that only a reassessment of these individuals could address.   
 This study has confirmed the lack of a standardised methodology for extracting IgGs 
from archaeological bone. It is, therefore, recommended that future attempts should first 
extract IgGs from modern mammalian bone, perhaps through trialing a number of different 
techniques (including the methods proposed in Section 7.8) and monitoring the presence of 
IgGs in each extract. Fresh bone samples could also be buried and tested sequentially over 
time to assess the degradation of IgGs. The successful extraction of immunoreactive IgGs 
from archaeological bone offers enormous potential in the detection and characterisation of 
past disease, either through the confirmation of a suspected diagnosis, or the identification of 
latent conditions. The challenge, as highlighted by this study, remains the extraction, 
detection, and the ultimate utilisation of an incredibly elusive biomolecule that offers such 
high potential for palaeopathology. Although this study was unsuccessful in extracting 
archaeological IgGs, it has explored and advanced new methodologies in their extraction, 
purification, and characterisation. The resulting newly-proposed technique for retrieving IgG 
from archaeological bone can now be implemented. It is hoped that this new methodology, 
in combination with high-resolution proteomic analysis, will ultimately lead to a successful, 
replicable technique of ancient, reactive IgG isolation.   
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Appendix 1: Thiophilic adsorption chromotography (TAC) 
results 
 
 Appendix 1 presents in full results of the thiophilic adsorption chromotography 
(TAC) tests performed on P2, P3, and P4 samples. All rinse and elution figures are mg/ml. 
HI is histological preservation. 
 
P2.1 
 
Sampl
e 
HI Wash 
1st 
stage 
rinse 
1st 
stage 
elution 
2nd 
stage 
rinse 
2nd stage 
elution 
3rd 
stage 
rinse 
3rd 
stage 
elution 
4th 
stage 
rinse 
4th 
stage 
elution 
HDAP
5 
5 1 1.16 0.01 1.22 0 1.27 0.01 0.23 0 
    2 0.13 0.01 0.08 0 0.67 0.004 0.24 0 
    3 0 0.01 0.04 0 0.03 0.01 0 0 
    4 0 0.008 0.03 -  0 0.001 0 -  
    5 0 0 0 - 0 0 0 -  
    6  - 0 0 - 0 0 -  -  
    7  - 0 0 - -  0 -  -  
AN1 5 1 0.04 0.007 2.45 0 0 0 0 0 
    2 0 0.002 0.45 0.006 0.007 0 0 0 
    3 0 0.004 0 0 0 0 0 0 
    4 0 0 0 0 0 -  -  -  
    5 -  0 0 0 0 -  -  -  
    6 -  0 -  -  -  -  -  -  
Table A1.1: P2 TAC results. 
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P2.2 
 
Sample HI Wash 
1st 
stage 
rinse 
1st stage 
elution 
2nd 
stage 
rinse 
2nd stage 
elution 
3rd 
stage 
rinse 
3rd stage 
elution 
HDAR9 5 1 0.188 0 0.625 0.01 1.424 0.01 
    2 0 0 0.071 0.015 0.474 0.013 
    3 0 0 0.015 0.024 0.018 0.004 
    4 0 -  0 0.035 0.007 0 
    5 -  -  0 0.019 0.007 0 
    6 -  -  0 0 0 0 
    7 -  -  -  0 0 -  
    8 -  -  -  0 0 -  
HDAP3 5 1 0.006 0.137 0.207 0.01 0.171 0.004 
    2 0.038 0 0.052 0.013 0.796 0.014 
    3 0.006 0 0.02 0.032 0.011 0.004 
    4 0 0 0.013 0.016 0.003 0 
    5 0 -  0.002 0.014 0.003 0 
    6 0 -  0 0 0 0 
    7 -  -  0 0 0 -  
    8 -  -  0 0 0 -  
AN2 5 1 0.024 0.06 0.58 0.009 2.954 0 
    2 0.045 0 0.434 0.021 0.202 0.009 
    3 0 0 0.025 0.009 0.011 0 
    4 0 0 0.003 0.007 0.003 0 
    5 0 -  0.003 0.01 0.007 0 
    6 -  -  0 0.016 0 -  
    7 -  -  0 0 0 -  
    8 -  -  0 0 0 -  
    9 -  -    0 -  -  
COLLAGEN - 1 0 0.003 0.078 0.016 0.097 0 
    2 0 0 0.047 0.017 0.248 0 
    3 0 0 0.001 0.015 0.003 0 
    4 -  0 0 0.014 0 -  
    5 -  -  0 0 0 -  
    6 -  -  0 0 0 -  
    7 -  -  -  0 -  -  
Table A1.2: P2 TAC results 
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P2.3 
 
Sample HI Wash 
1st 
stage 
rinse 
1st stage 
elution 
2nd 
stage 
rinse 
2nd stage 
elution 
3rd 
stage 
rinse 
3rd stage 
elution 
HDAP5 5 1 0.45 0.08 0.344 0 0.798 0.01 
  
2 0.876 0.02 0.07 0 0.303 0.02 
  
3 0.768 0 0.037 0 0.011 0.01 
  
4 0.084 0 0.003 - 0.005 0.001 
  
5 0.035 0 0 - 0 0 
  
6 0 - 0 - 0 0 
  
7 0 - 0 - 0 0 
  
8 0 - - - - - 
HDAR2 5 1 0.37 0 0.513 0 0.257 0.023 
  
2 0.405 0 0.668 0.005 0.062 0 
  
3 0.027 0 0.05 0 0 0.003 
  
4 0.007 0.001 0.011 0 0.017 0 
  
5 0.003 0 0.002 0 0.004 0 
  
6 0 0 0 - 0 0 
  
7 0 0 0 - 0 - 
  
8 0 - 0 - 0 - 
HDAR3 4 1 0.209 0 0.438 0.004 0.937 0.027 
  
2 0.375 0.004 0.272 0.01 0.373 0.007 
  
3 0.051 0 0.017 0.004 0 0.006 
  
4 0.01 0 0.007 0 0.008 0.004 
  
5 0.004 0 0.003 0 0.005 0.011 
  
6 0 - 0 0 0 0.01 
  
7 0 - 0 - 0 0.007 
  
8 0 - 0 - 0 0 
  
9 - - - - - 0 
  10 - - - - - 0 
HDJS3 1 1 0.211 0.022 0.641 0.003 1.274 0.024 
  
2 0.167 0.014 0.111 0 0.122 0.018 
  
3 0.084 0.004 0.009 0 0.003 0.007 
  
4 0.024 0 0.003 0 0 0.006 
  
5 0.015 0 0.001 - 0 0 
  
6 0 0 0 - 0 0 
  
7 0 - 0 - - 0 
  
8 0 - 0 - - - 
Table A1.3: P3 TAC results. 
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P2.4 
 
Sample HI Wash 
1st stage 
rinse 
1st stage 
elution 
2nd stage 
rinse 
2nd stage 
elution 
3rd stage 
rinse 
3rd stage 
elution 
WM2316.1 5 1 0.065 0.01 0.184 0 0.624 0.002 
    2 0.033 0.021 0.066 0 0.119 0.016 
    3 0.008 0.01 0 0 0 0.004 
    4 0.007 0.009 0 -  0 0 
    5 0.01 0.01 0 -  0 0 
    6 0.008 0   -  -  0 
    7 0.005 0 -  -  -  -  
    8 0 0 -  -  -  -  
    9 0 -  -  -  -  -  
    10 0 -  -  -  -  -  
CD127.2 5 1 0.029 0.011 0.2 0 1.16 0 
    2 0.064 0.012 0.076 0 1.5 0.009 
    3 0.009 0.014 0 0 0.056 0 
    4 0 0.006 0 -  0.027 0.001 
    5 0 0.003 0 -  0.018 0 
    6 0 0 -  -  0.014 0 
    7 -  0 -  -  0 0 
    8 -  0 -  -  0 -  
    9 -  -  -  -  0 -  
LP3845.1 0 1 0.017 0.012 2.469 0 3 0.006 
    2 0.223 0.011 0.346 0 2.8 0.012 
    3 0.013 0.019 0.825 0 0.077 0.009 
    4 0.009 0.013 0.038 -  0.019 0.037 
    5 0.006 0.018 0 -  0.011 0.024 
    6 0.004 0 0 -  0 0 
    7 0 0 0 -  0 0 
    8 0 0 -  -  0 0 
    9 0 -  -  -  -  -  
AN5 0 1 0.043 0.013 0.202 0 2.73 0.039 
    2 0.254 0.013 0.42 0 2.76 0.021 
    3 0.026 0.006 0 0 0.012 0.018 
    4 0.004 0.007 0 -  0 0.005 
    5 0 0.006 0 -  0 0.001 
    6 0 0.009 -  -  0 0 
    7 0 0 -  -  -  0 
    8 -  0 -  -  -  0 
    9 -  0 -  -  -  -  
Table A1.4: P2.4 TAC results. 
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P2.5 
 
Sample HI Wash 
1st stage 
rinse 
1st stage 
elution 
2nd stage 
rinse 
2nd stage 
elution 
3rd stage 
rinse 
3rd stage 
elution 
HP154.1 5 1 0.071 0.023 0.336 0 2.325 0.005 
    2 0.023 0.018 0.075 0.005 0.053 0.013 
    3 0.002 0 0 0 0 0.001 
    4 0.008 0 0 0.001 0 0 
    5 0 0 0  0.025 0 0 
    6 0 -  -  0.011 -  0 
    7 0 -  -  0.011 -  -  
    8 -  -  -  0 -  -  
    9 -  -  -  0 -  -  
    10 -  -  -  0 -  -  
LP3760.1 0 1 1.596 0.007 1.083 0.01 3 0.016 
    2 0.842 0 0.451 0 0.664 0 
    3 0.22 0 0.086 0 0.108 0 
    4 0.075 0 0.04 0 0 0 
    5 0.041 -  0.026 -  0 -  
    6 0.006 -  0 -  0 -  
    7 0 -  0 -  -  -  
    8 0 -  0 -  -  -  
    9 0 -  -  -  -  -  
LP4585.3 2 1 0.285 0 1.46 0 2.98 0.005 
    2 0.213 0 0.267 0 0.374 0.01 
    3 0.032 0 0.004 0 0 0 
    4 0.006 -  0 -  0 0 
    5 0.011 -  0 -  0 0 
    6 0.004 -  0 -  -  -  
    7 0 -  -  -  -  -  
    8 0 -  -  -  -  -  
    9 0 -  -  -  -  -  
OL1104.2 5 1 0 0.002 0.148 0 1.388 0.007 
    2 0 0 0.115 0 0.03 0.008 
    3 0 0 0 0.004 0 0 
    4 0 0 0 0.005 0 0 
    5 0 -  0 0.004 0 0 
    6 -  -  -  0 -  -  
    7 -  -  -  0 -  -  
    8 -  -  -  0 -  -  
Table A1.5: P2.5 TAC results. 
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P3 
 
Sample HI Wash 
1st 
stage 
rinse 
1st stage 
elution 
2nd 
stage 
rinse 
2nd stage 
elution 
3rd 
stage 
rinse 
3rd stage 
elution 
EH198.1 4 1 1.172 0.038 1.414 0.038 0.869 0.011 
  
2 0.424 0.039 0.204 0.034 0.053 0.016 
  
3 0 0.016 0 0.026 0.02 0.013 
  
4 0 0.024 0 0.007 0.017 0.005 
  
5 0 0 0 0 0 0.01 
  
6 - 0 - 0 0 0 
  
7 - 0 - 0 0 0 
  
8 - - - - - 0 
CD120.2 5 1 1.243 0.009 2.526 0.015 1.33 0.009 
  
2 0.741 0.043 0.173 0.025 0.369 0.022 
  
3 0.011 0.003 0.051 0.014 0.037 0.014 
  
4 0.003 0 0.03 0 0 0.004 
  
5 0 0 0 0 0 0.007 
  
6 0 0 0 0 0 0.02 
  
7 0 - 0 - - 0.008 
  
8 - - - - - 0 
  
9 - - - - - 0 
  
10 - - - - - 0 
CD165.1 5 1 1.188 0.008 1.802 0.048 1.432 0.018 
  
2 0.123 0.007 0.132 0.038 0.196 0.039 
  
3 0.002 0.006 0.027 0.017 0.004 0.022 
  
4 0.012 0 0.019 0 0.001 0.016 
  
5 0 0 0 0 0 0.017 
  
6 0 0 0 0 0 0 
  
7 0 - 0 - 0 0 
  
8 - - - - - 0 
OL1104.2 5 1 0.302 0.008 0.837 0.009 0.749 0.005 
  
2 0.171 0.009 0.094 0.008 0 0.007 
  
3 0.004 0.007 0.073 0.007 0 0.002 
  
4 0 0 0.039 0 0 0 
  
5 0 0 0 0 - 0.007 
  
6 0 0 0 0 - 0 
  
7 - 0 0 - - 0 
  
8 - - - - - 0 
Table A1.6: P3 TAC results. 
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P4 
 
Sample HI Wash 
1st 
stage 
rinse 
1st stage 
elution 
2nd 
stage 
rinse 
2nd stage 
elution 
3rd 
stage 
rinse 
3rd stage 
elution 
CD84.2 0 1 1.175 0.012 2.942 0.031 3.129 0.028 
  
2 1.831 0.006 0.972 0.024 2.267 0.023 
  
3 0.463 0.007 0 0.017 0.092 0.01 
  
4 0.126 0 0 0.008 0.055 0.003 
  
5 0.077 0 0 0 0.028 0 
  
6 0.038 0 - 0 0.027 0 
  
7 0.033 - - 0 0.012 0 
  
8 0 - - - 0 - 
  
9 0 - - - 0 - 
  
10 0 - - - 0 - 
CD112.3 2 1 0.981 0.021 2.948 0.027 3.17 0.015 
  
2 1.64 0.013 1.359 0.025 2.785 0.028 
  
3 0.278 0 0.054 0.015 0.093 0.012 
  
4 0.045 0 0.003 - 0.042 0.004 
  
5 0.015 0 0 - 0.009 0 
  
6 0 - 0 - 0 0 
  
7 0 - 0 - 0 0 
  
8 0 - 
 
- 0 - 
EHA4 4 1 0.926 0.006 2.194 0.014 3.032 0.013 
  
2 0.522 0.011 0.59 0.01 1.323 0.02 
  
3 0.073 0.008 0 0.008 0.086 0.007 
  
4 0.004 0 0 0.005 0.023 0 
  
5 0 0 0 0 0.014 0 
  
6 0 0 - 0 0 0 
  
7 0 - - 0 0 - 
  
8 - - - - 0 - 
EH156.3 5 1 1.494 0.012 2.003 0.025 2.742 0.004 
  
2 0.707 0.017 0.833 0.033 0.743 0.025 
  
3 0.161 0.021 0 0.021 0.034 0.01 
  
4 0.038 0 0 0.014 0.007 0.005 
  
5 0.015 0 0 0 0 0 
  
6 0.005 0 - 0 0 0 
  
7 0 - - 0 0 0 
  
8 0 - - - - - 
  
9 0 - - - - - 
Table A1.7: P4 TAC results. 
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Appendix 2: Palaeodemography, histology, and rapid test data 
 
 Appendix 2 presents complete tables showing the Fen (Table A2.1) and non-Fen 
(Table A2.2) sites selected for palaeodemographic analysis. These tables include the 
numbers of individuals in each age category and the reference for the osteological report 
associated with each site. This is followed by full results of histological analysis of the 
individuals selected for biomolecular analysis (Tables A2.3-2.16); individual sample 
numbers, element type, and associated histological preservation (or HI) is shown for each 
site. Finally, Figures A2.1-2.14 display the photographed results of malaria rapid testing 
(photographs by author). 
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Durobrivae, 
Cambs 
Rom 0 0 2 3 1 0 0 0 1 2 3 1 0 2 1 
Duhig 
1999 
Hoplands, 
Sleaford, Lincs 
Rom 2 0 5 2 3 0 1 4 5 7 7 3 5 0 0 
Western 
2011 
Prickwillow 
Road, Ely 
Rom 0 0 2 0 0 0 1 1 2 3 2 4 0 0 1 
Anderson 
2003 
The Parks, 
Godmanchester 
Rom 0 0 3 9 5 2 3 8 4 0 0 8 7 2 1 
Brickley 
2003 
Watersmeet, 
Huntingdon 
Rom 2 3 3 4 0 0 0 4 5 6 5 2 6 1 4 
Phillips 
2006 
Barton Bendish, 
Norfolk 
A-S 0 3 14 6 0 4 2 10 4 9 2 5 1 3 5 
Stroud 
1984 
Baston, Lincs A-S 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 
Manchester 
1976 
Burgh Castle, 
Norfolk 
A-S 0 1 9 9 11 8 7 9 13 29 17 24 13 7 13 
Anderson 
and Birkett 
1989 
Caistor-on-Sea, 
Norfolk 
A-S 0 7 6 12 7 0 9 5 5 6 6 15 17 4 1 
Anderson 
1991 
Castle Mall, 
Norwich 
A-S 3 4 9 6 3 3 10 2 5 10 17 3 2 3 2 
Anderson 
1996 
Castledyke 
South, Lincs 
A-S 0 1 15 13 13 5 14 11 13 8 18 13 17 12 6 
Drinkall 
and 
Foreman 
1998 
Cleatham, Lincs A-S 0 1 4 2 0 2 4 12 8 3 4 4 0 3 2 
Leahy 
2007 
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Edix Hill, 
Cambs 
A-S 1 2 13 8 14 12 7 7 18 7 6 11 5 8 2 
Duhig 
1998 
Haddenham, 
Cambs 
A-S 0 0 0 3 0 2 0 0 0 0 0 0 0 1 3 
Robinson 
and Duhig 
1992 
Highfield Farm, 
Littleport 
A-S 3 1 3 7 6 2 4 5 4 6 6 0 5 0 0 
Western 
2007 
Market Deeping 
Bypass, Cambs 
A-S 0 1 1 1 0 1 1 3 3 1 0 2 0 0 2 
Gowland 
2000 
Monkton, Kent A-S 0 0 1 0 0 1 1 2 1 2 1 0 0 7 2 
Richardson 
2005 
Quarrington, 
Lincs 
A-S 0 0 2 1 2 1 3 3 0 1 0 1 0 1 0 
Dickinson 
2004 
Ramsgate, Kent A-S 0 6 8 6 3 4 7 12 7 10 6 1 1 8 7 
Richardson 
2005 
Rivenhall, 
Suffolk 
A-S 0 2 4 4 3 2 1 6 3 2 1 2 2 20 12 
O'Connor 
1993 
Snodland, Kent A-S 0 0 2 0 2 1 2 9 6 5 2 0 1 1 0 
Richardson 
2005 
St Peter's, 
Barton-upon-
Humber, Lincs 
A-S 9 92 80 45 14 18 26 65 65 16 4 91 50 83 70 
Waldron 
2007 
Staunch 
Meadow, 
Suffolk 
A-S 6 10 9 12 9 11 13 13 12 15 13 9 8 8 8 
Anderson 
1990 
Thetford, 
Norfolk 
A-S 0 7 20 13 5 2 2 3 5 9 6 4 5 2 3 
Stroud 
1993 
Ulwell, Dorset A-S 0 0 1 9 0 4 3 2 6 3 3 4 4 1 3 
Waldron 
1987a 
Westfield Farm, 
Ely 
A-S 0 0 1 1 2 1 0 3 1 2 2 0 0 0 1 
Hills and 
Dodwell 
2007 
Orchard Lane, 
Huntingdon 
Med 0 1 10 5 3 4 3 
  
2 2 0 3 2 5 4 
Duhig 
1996 
Rivenhall, 
Suffolk 
Med 0 2 14 16 4 3 6 3 3 3 3 14 6 32 31 
O'Connor 
1993 
St Peter's, 
Barton-upon-
Humber, Lincs 
Med 8 116 88 92 56 16 27 61 51 27 5 59 32 76 135 
Waldron 
2007 
Stonar, Kent Med 17 9 24 13 0 5 2 16 6 11 8 8 4 7 7 
Bayley and 
Eley 1975 
Table A2.1: Numbers of individuals from Fen sites. Rom - Roman; A-S – Anglo-Saxon; 
Med – Medieval.  
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Ancaster, Lincs Rom 34 6 19 22 11 8 11 42 16 33 19 13 14 33 23 Cox 1989 
Babraham 
Institute, Cambs 
Rom 0 2 5 2 1 0 0 1 2 15 9 0 0 2 3 
Armour et 
al. 2007 
Bainesse Farm, 
Catterick 
Rom 0 0 1 5 1 2 0 1 1 3 2 3 2 0 2 
Waldron 
1985 
Baldock, Herts Rom 25 9 1 0 0 3 0 1 0 0 1 0 2 2 1 
Henderson 
1982 
Mangiovinium, 
Bucks 
Rom 1 7 1 0 0 0 1 1 2 1 3 0 2 4 3 
Henderson 
1981 
Newarke Street, 
Leicester 
Rom 1 1 1 5 0 0 4 2 4 1 1 5 1 1 1 
Cooper 
1996 
Queenford Farm, 
Oxon 
Rom 11 3 33 15 3 6 7 9 23 17 14 32 15 3 8 
Chambers 
et al. 1987 
Rudston Villa, 
Yorks 
Rom 10 3 6 1 0 0 2 2 0 1 0 0 0 0 0 
Bayley 
1980a 
St. Albans, Herts Rom 7 1 0 0 1 1 2 0 0 0 0 0 0 0 0 
Keepax 
1973 
Barnstaple Castle A-S 0 5 9 4 1 5 10 12 4 2 6 0 0 5 4 
Bayley 
1976 
Buckland, Kent A-S 1 1 19 21 20 10 22 33 41 23 25 31 13 19 13 
Richardson 
2005 
Castle Green, 
Hereford 
A-S 5 10 8 0 0 6 4 6 4 12 0 3 0 5 9 
Bayley 
1980b 
Charlton 
Plantation, Wilts 
A-S 0 0 3 3 3 2 2 4 2 2 4 3 1 0 1 
Henderson 
1983a 
Coddenham, 
Suffolk 
A-S 0 0 9 2 2 3 2 3 0 2 1 2 1 3 4 
Anderson 
2011 
Darenth Park, 
Kent 
A-S 0 0 2 0 1 1 0 0 2 1 2 0 0 0 0 
Richardson 
2005 
Dunton Green, 
kent 
A-S 0 0 18 10 9 7 12 16 4 4 2 12 4 4 2 
Richardson 
2005 
Empingham II, 
Rutland 
A-S 0 2 20 17 15 18 16 11 10 6 6 1 2 6 3 Mays 1990 
Filton, Bristol A-S 2 0 2 5 3 3 4 1 2 0 5 3 1 4 2 
Caffell and 
Holst 2005 
George Street, 
Aylesbury 
A-S 0 0 0 1 1 1 1 1 2 0 0 2 0 6 6 
Henderson 
1983b 
Great 
Chesterford, 
Cambs 
A-S 17 38 11 10 2 7 9 7 10 8 17 8 6 5 1 
Inskip 
2008 
Henley Wood, 
Berks 
A-S 0 4 2 4 3 8 6 9 5 4 3 2 0 1 2 
Bayley 
1973 
Mill Hill, Kent A-S 0 0 7 6 11 5 6 2 0 5 4 6 7 2 2 
Richardson 
2005 
Norton, 
Cleveland 
A-S 0 2 11 10 14 16 14 12 10 4 3 2 2 0 0 
Marlow 
1992 
476 
 
Orpington, Kent A-S 0 0 3 1 1 1 5 5 5 5 4 2 0 1 5 
Richardson 
2005 
School Street, 
Ipswich 
A-S 0 2 4 8 4 5 6 8 5 3 8 11 1 8 8 Mays 1989 
Sewerby, Yorks A-S 0 0 1 3 2 1 1 3 5 4 1 1 1 3 3 
Bayley 
1974 
West Heslerton, 
Yorks 
A-S 1 2 11 6 8 2 2 5 9 4 1 0 3 4 8 Cox 1990 
Blackfriars 
Street, Carlisle 
Med 0 1 9 3 7 15 7 14 7 5 10 11 5 45 22 
Henderson 
1984 
Brighton Hill 
South, Hamps 
Med 3 6 16 2 0 0 0 1 1 6 3 4 1 2 2 
Waldron 
1987b 
Corbridge, 
Northumberland 
Med 0 1 1 0 0 1 0 0 0 1 1 1 0 0 0 Holst 2006 
Wharram Percy, 
Yorks 
Med 48 53 131 66 35 28 23 26 19 24 19 75 44 39 15 Mays 2007 
Table A2.2: Numbers of individuals from non-Fen sites. Rom - Roman; A-S – Anglo-Saxon; 
Med – Medieval. 
 
 
Sample Type HI Sample Type HI 
HDAR1 Adult rib 4 HDAP3 Adult phalanx 5 
HDAR2 Adult rib 5 HDAP4 Adult phalanx 5 
HDAR3 Adult rib 4 HDAP5 Adult phalanx 5 
HDAR4 Adult rib 5 HDJR1 Sub-adult rib 1 
HDAR5 Adult rib 4 HDJR2 Sub-adult rib 2 
HDAR6 Adult rib 5 HDJR3 Sub-adult rib 2 
HDAR7 Adult rib 2 HDJS1 Sub-adult cranium 2 
HDAR8 Adult rib 1 HDJS2 Sub-adult cranium 1 
HDAR9 Adult rib 5 HDJS3 Sub-adult cranium 1 
HDAR10 Adult rib 3 AN1 Animal rib 5 
HDAS1 Adult cranium 3 AN2 Animal rib 5 
HDAS2 Adult cranium 0 AN3 Animal rib 4 
HDAS3 Adult cranium 2 AN4 Animal rib 3 
HDAS4 Adult cranium 1 AN5 Animal rib 0 
HDAS5 Adult cranium 0 AN6 Animal rib 4 
HDAP1 Adult phalanx 2 AN7 Animal rib 5 
HDAP2 Adult phalanx 3 AN8 Animal rib 5 
Table A2.3: Control sample (Hanging Ditch site) histological index (HI). 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
DU2.1 Adolescent ? Rib Good 2 
DU2.2 Adolescent ? Cranium Good 0 
DU4.1 Child ? Rib Fair 2 
DU4.2 Child ? Rib Fair 2 
DU536.1 Middle adult Female Rib Fair 3 
DU536.2 Middle adult Female Cranium Fair 2 
DU601 Very young adult ? Rib Good 3 
DU661 Very young adult ? Rib Fair 4 
DUA2 Animal N/A Rib Fair 0 
DUA3 Animal N/A Rib Fair 2 
Table A2.4: Histological index (HI) and observed macroscopic condition of bone samples 
from the Durobrivae Roman site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
GM12.1 Juvenile ? Rib Fair 1 
GM12.2 Juvenile ? Rib Fair 0 
GM18.1 Very young adult Female Rib Fair 0 
GM18.2 Very young adult Female Hand phalanx Fair 0 
GM18.3 Very young adult Female Cranium Fair 0 
GM20.1 Juvenile ? Rib Fair 0 
GM20.2 Juvenile ? Hand phalanx Fair 0 
GM23.1 Child ? Rib Fair 1 
GM23.2 Child ? Cranium Fair 0 
GM25.1 Very young adult Female Rib Fair 0 
GM25.2 Very young adult Female Foot phalanx Fair 0 
GM25.3 Very young adult Female Cranium Good 0 
GM29.1 Child ? Rib Fair 0 
GM29.2 Child ? Cranium Good 0 
GM32.1 Very young adult Female Rib Fair 3 
GM32.2 Very young adult Female Hand phalanx Good 5 
GM32.3 Very young adult Female Cranium Good 1 
GM39.1 Juvenile ? Rib Good 3 
GM39.2 Juvenile ? Rib Good 2 
GM4.1 Juvenile ? Rib Fair 2 
GM4.2 Juvenile ? Hand phalanx Fair 1 
GM4.3 Juvenile ? Cranium Good 2 
GM42.1 Juvenile ? Rib Good 0 
GM42.2 Juvenile ? Hand phalanx Good 0 
GM49.1 Juvenile ? Rib Fair 2 
GM49.2 Juvenile ? Hand phalanx Fair 0 
GM51.1 Juvenile ? Rib Fair 3 
GM51.2 Juvenile ? Rib Fair 2 
GM58 Adolescent Female? Cranium Good 4 
GM59.1 Very young adult ? Rib Good 0 
GM59.2 Very young adult ? Foot phalanx Good 1 
GM59.3 Very young adult ? Cranium Good 0 
GMA1 Animal N/A Rib Fair 0 
GMA2 Animal N/A Rib Fair 2 
GMA4 Animal N/A Rib Fair 1 
GMA5 Animal N/A Rib Good 0 
Table A2.5: Histological index (HI) and observed macroscopic condition of bone samples 
from The Parks, Godmanchester Roman site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
HP23.2 Young adult Female? Foot phalanx Good 0 
HP23.2 Young adult Female? Foot phalanx Good 0 
HP104.1 Child ? Rib Fair 4 
HP104.2 Child ? Rib Fair 3 
HP113.1 Adolescent ? Rib Good 1 
HP113.2 Adolescent ? Hand phalanx Good 1 
HP117.1 Child ? Rib Good 0 
HP136.1 Adolescent ? Rib Good 2 
HP136.2 Adolescent ? Hand phalanx Good 1 
HP136.3 Adolescent ? Hand phalanx Good 1 
HP154.1 Young adult Female Rib Good 5 
HP154.2 Young adult Female Hand phalanx Good 5 
HP154.3 Young adult Female Hand phalanx Good 5 
HP157.1 Young adult Female? Rib Good 0 
HP157.2 Young adult Female? Rib Fair 2 
HP179.1 Adolescent ? Rib Good 0 
HP179.2 Adolescent ? Hand phalanx Good 4 
HP179.3 Adolescent ? Foot phalanx Good 4 
HP214.1 Very young adult Female Rib Good 0 
HP214.2 Very young adult Female Hand phalanx Good 1 
HP214.3 Very young adult Female Foot phalanx Good 1 
HP217.1 Young adult Female Rib Good 0 
HP222.1 Young adult Female Rib Good 0 
HP222.2 Young adult Female Foot phalanx Good 5 
HP227.1 Child ? Rib Good 0 
HP227.2 Child ? Rib Good 2 
HPA1 Animal N/A Rib Good 3 
HPA2 Animal N/A Rib Good 1 
HPA3 Animal N/A Rib Good 5 
HPA4 Animal N/A Rib Good 0 
HPA5 Animal N/A Rib Good 1 
Table A2.6: Histological index (HI) and observed macroscopic condition of bone samples 
from the Hoplands, Sleaford Roman site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
PW13.1 Young adult Female Rib Good 3 
PW13.2 Young adult Female Rib Good 4 
PW13.3 Young adult Female Hand phalanx Good 5 
PWA1 N/A Animal Rib Good 1 
PWA2 N/A Animal Rib Fair 1 
Table A2.7: Histological index (HI) and observed macroscopic condition of bone samples 
from the Prickwillow Road, Ely Roman site. 
 
 
Sample Age Sex Element 
Macroscopic 
Condition HI 
WM2104.1 Young adult Female Rib Fair 3 
WM2104.2 Young adult Female Hand phalanx Fair 0 
WM2125.1 Child ? Rib Fair 1 
WM2125.2 Child ? Rib Fair 1 
WM2221.1 Young adult Female? Rib Fair 3 
WM2221.2 Young adult Female? Hand phalanx Fair 5 
WM2244.1 Young adult Female Rib Fair 0 
WM2244.2 Young adult Female Hand phalanx Fair 5 
WM2283.1 Young adult Female Rib Good 0 
WM2283.2 Young adult Female Cranium Good 0 
WM2291.1 Juvenile ? Rib Good 0 
WM2291.2 Juvenile ? Foot phalanx Good 0 
WM2291.3 Juvenile ? Cranium Good 2 
WM2293.1 Juvenile ? Rib Fair 3 
WM2293.2 Juvenile ? Cranium Fair 0 
WM2297.1 Child ? Rib Fair 0 
WM2297.2 Child ? Rib Fair 0 
WM2316.1 Adolescent ? Rib Fair 2 
WM2316.2 Adolescent/ ? Foot phalanx Fair 5 
WMA1 Animal N/A Rib Good 2 
WMA3 Animal N/A Rib Fair 0 
WMA4 Animal N/A Rib Fair 0 
Table A2.8: Histological index (HI) and observed macroscopic condition of bone samples 
from the Watersmeet, Huntingdon Roman site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
BS54.1 Very young adult Female Rib Fair 1 
BS54.2 Very young adult Female Hand phalanx Fair 2 
BSA1 Animal N/A Rib Fair 0 
BSA2 Animal N/A Rib Good 1 
BSA3 Animal N/A Rib Good 1 
Table A2.9: Histological index (HI) and observed macroscopic condition of bone samples 
from the Baston Anglo-Saxon site. 
 
 
Sample Age Sex Element 
Macroscopic 
Condition HI 
CD14.1 Juvenile ? Rib Poor 1 
CD14.2 Juvenile ? Cranium Fair 0 
CD16.1 Child ? Rib Poor 3 
CD16.2 Child ? Cranium Fair 0 
CD20 Juvenile ? Cranium Poor 1 
CD28.1 Juvenile ? Rib Fair 4 
CD32.1 Juvenile ? Rib Good 1 
CD32.2 Juvenile ? Cranium Fair 5 
CD34.1 Juvenile ? Rib Good 3 
CD34.2 Juvenile ? Cranium Good 0 
CD34.3 Juvenile ? Foot phalanx Fair 2 
CD37.1 Juvenile ? Cranium Poor 3 
CD61.1 Child ? Rib Poor 0 
CD61.2 Child ? Cranium Fair 0 
CD68.1 Child ? Rib Fair 0 
CD68.2 Child ? Cranium Fair 3 
CD76.1 Juvenile ? Rib Good 0 
CD76.2 Juvenile ? Cranium Good 1 
CD77.1 Adolescent ? Rib Poor 3 
CD77.2 Adolescent ? Cranium Poor 3 
CD84.1 Very young adult Female Rib Fair 1 
CD84.2 Very young adult Female Cranium Good 0 
CD84.3 Very young adult Female Foot phalanx Good 1 
CD88.1 Very young adult Female Rib Good 1 
CD96.1 Very young adult Female Rib Fair 0 
CD96.2 Very young adult Female Rib Fair 1 
CD107.1 Very young adult Female Rib Poor 4 
CD107.2 Very young adult Female Cranium Poor 3 
CD112.1 Very young adult Female Rib Good 1 
CD112.2 Very young adult Female Cranium Good 1 
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CD112.3 Very young adult Female Hand phalanx Good 2 
CD120.1 Very young adult Female Rib Fair 0 
CD120.2 Very young adult Female Hand phalanx Good 5 
CD127.1 Very young adult Female Rib Fair 4 
CD127.2 Very young adult Female Cranium Poor 5 
CD134.1 Very young adult Female Rib Fair 2 
CD134.2 Very young adult Female Foot phalanx Fair 0 
CD155.1 Very young adult Female Rib Good 2 
CD155.2 Very young adult Female Cranium Fair 1 
CD156.1 Adolescent ? Rib Fair 2 
CD156.2 Adolescent ? Cranium Poor 4 
CD156.3 Adolescent ? Hand phalanx Fair 5 
CD164.1 Very young adult Female? Rib Fair 1 
CD164.2 Very young adult Female? Cranium Poor 4 
CD165.1 Child ? Rib Good 5 
CD165.2 Child ? Cranium Fair 4 
CD172.1 Child ? Rib Good 2 
CD172.2 Child ? Cranium Good 1 
CD183.1 Very young adult Female Rib Fair 2 
CD183.2 Very young adult Female Cranium Good 0 
CD183.3 Very young adult Female Foot phalanx Good 0 
CDA1 Animal N/A Rib Good 0 
CDA2 Animal N/A Rib Good 0 
CDA3 Animal N/A Rib Good 0 
CDA4 Animal N/A Rib Good 2 
CDA5 Animal N/A Rib Good 0 
Table A2.10: Histological index (HI) and observed macroscopic condition of bone samples 
from the Castledyke South Anglo-Saxon site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
CL11.1 Young adult Female Rib Fair 4 
CL11.2 Young adult Female Cranium Poor 0 
CL13.1 Adolescent Female Rib Poor 0 
CL13.2 Adolescent Female Cranium Poor 0 
CL13.3 Adolescent Female Hand phalanx Poor 0 
CL26.1 Young adult Female Rib Poor 0 
CL26.2 Young adult Female Cranium Fair 0 
CL27.1 Adolescent Male Rib Fair 0 
CL27.2 Adolescent Male Cranium Fair 1 
CL27.3 Adolescent Male Hand phalanx Good 1 
CL28.1 Adolescent Male Rib Poor 0 
CL28.2 Adolescent Male Cranium Poor 1 
CL28.3 Adolescent Male Hand phalanx Fair 0 
CL35.1 Child ? Cranium Poor 3 
CL50.1 Young adult Female Rib Fair 1 
CL50.2 Young adult Female Cranium Poor 1 
CL54.1 Young adult Female Rib Poor 0 
CL54.2 Young adult Female Cranium Fair 0 
CL58 Juvenile ? Cranium Poor 0 
CL61.1 Adolescent Female Rib Fair 1 
CL61.2 Adolescent Female Cranium Poor 1 
Table A2.11: Histological index (HI) and observed macroscopic condition of bone samples 
from the Cleatham Anglo-Saxon site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
EH19.1 Very young adult Male Rib Fair 0 
EH19.2 Very young adult Male Foot phalanx Good 4 
EH45.1 Very young adult Female Cranium Good 3 
EH45.2 Very young adult Female Hand phalanx Good 4 
EH119.1 Young adult Female Rib Fair 0 
EH119.2 Young adult Female Hand phalanx Fair 2 
EH128.1 Adolescent Female Cranium Fair 2 
EH128.2 Adolescent Female Hand phalanx Fair 3 
EH133.1 Child ? Rib Good 1 
EH133.2 Child ? Cranium Good 2 
EH156.1 Young adult Female Rib Poor 3 
EH156.2 Young adult Female Foot phalanx Fair 0 
EH156.3 Young adult Female Cranium Fair 5 
EH172.1 Juvenile ? Rib Fair 3 
EH172.2 Juvenile ? Cranium Good 0 
EH198.1 Very young adult Male Rib Fair 4 
EH198.2 Very young adult Male Foot phalanx Good 1 
EH436.1 Very young adult Female Rib Good 0 
EH436.2 Very young adult Female Foot phalanx Good 1 
EH436.3 Very young adult Female Cranium Good 2 
EH584.1 Child ? Rib Good 0 
EH584.2 Child ? Cranium Good 0 
EH586.1 Juvenile ? Rib Fair 3 
EH586.2 Juvenile ? Hand phalanx Fair 1 
EH586.3 Juvenile ? Cranium Fair 4 
EHA1 Animal N/A Rib Fair 0 
EHA2 Animal N/A Rib Fair 2 
Table A2.12: Histological index (HI) and observed macroscopic condition of bone samples 
from the Edix Hill Anglo-Saxon site. 
 
 
Sample Age Sex Element 
Macroscopic 
Condition HI 
HA5.1 ? ? Rib Fair 4 
HA5.2 ? ? Cranium Fair 0 
Table A2.13: Histological index (HI) and observed macroscopic condition of bone samples 
from the Haddenham Anglo-Saxon site. 
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Sample Age Sex Element 
Macroscopic 
Condition HI 
LP3311.1 Juvenile ? Rib Good 0 
LP3311.2 Juvenile ? Cranium Good 0 
LP3687.1 Young adult Female Rib Fair 1 
LP3687.2 Young adult Female Foot phalanx Fair 2 
LP3690.1 Young adult ? Rib Good 0 
LP3690.2 Young adult ? Cranium Good 1 
LP3690.3 Young adult ? Hand phalanx Good 0 
LP3745.1 Young adult Female Rib Good 1 
LP3745.2 Young adult Female Cranium Good 0 
LP3745.3 Young adult Female Foot phalanx Fair 2 
LP3760.1 Juvenile ? Rib Good 0 
LP3760.2 Juvenile ? Cranium Good 0 
LP3770.1 Child ? Rib Fair 0 
LP3770.2 Child ? Cranium Fair 0 
LP3819.1 Adult Female? Rib Fair 0 
LP3819.2 Adult Female? Cranium Fair 2 
LP3819.3 Adult Female? Hand phalanx Fair 0 
LP3845.1 Adolescent ? Rib Fair 0 
LP3845.2 Adolescent ? Cranium Fair 0 
LP4037.1 Child ? Cranium Fair 2 
LP4037.2 Child ? Cranium Fair 1 
LP4046.1 Adolescent ? Rib Good 1 
LP4046.2 Adolescent ? Cranium Fair 2 
LP4046.3 Adolescent ? Foot phalanx Good 0 
LP4067.1 Middle adult Female Rib Fair 2 
LP4067.2 Middle adult Female Cranium Fair 1 
LP4067.3 Middle adult Female Foot phalanx Fair 3 
LP4085.1 Young adult Female? Rib Good 0 
LP4085.2 Young adult Female? Foot phalanx Fair 2 
LP4092.1 Young adult Male? Rib Good 1 
LP4092.2 Young adult Male? Cranium Fair 1 
LP4092.3 Young adult Male? Hand phalanx Fair 3 
LP4112.1 Adolescent ? Rib Fair 2 
LP4112.2 Adolescent ? Cranium Good 0 
LP4116.1 Juvenile ? Rib Good 0 
LP4116.2 Juvenile ? Cranium Good 0 
LP4116.3 Juvenile ? Foot phalanx Fair 1 
LP4144.1 Juvenile ? Rib Fair 0 
LP4144.2 Juvenile ? Hand phalanx Fair 1 
LP4155.1 Juvenile ? Cranium Fair 0 
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LP4156.1 Adolescent ? Rib Fair 0 
LP4156.2 Adolescent ? Cranium Good 0 
LP4167.1 Juvenile ? Rib Fair 0 
LP4167.2 Juvenile ? Rib Fair 1 
LP4174.1 Adolescent ? Rib Fair 0 
LP4174.2 Adolescent ? Cranium Good 1 
LP4174.3 Adolescent ? Foot phalanx Fair 2 
LP4371.1 Adolescent ? Rib Poor 0 
LP4371.2 Adolescent ? Cranium Fair 0 
LP4373.1 Young adult Female? Rib Fair 0 
LP4373.2 Young adult Female? Cranium Good 1 
LP4373.3 Young adult Female? Foot phalanx Fair 0 
LP4395.1 Middle adult Female Rib Good 0 
LP4395.2 Middle adult Female Cranium Good 0 
LP4395.3 Middle adult Female Hand phalanx Good 0 
LP4494.1 Juvenile ? Cranium Fair 0 
LP4585.1 Middle adult Female? Rib Good 1 
LP4585.2 Middle adult Female? Cranium Good 0 
LP4585.3 Middle adult Female? Hand phalanx Good 2 
LP4751.1 Adolescent ? Rib Fair 0 
LP4751.2 Adolescent ? Cranium Fair 1 
LP4751.3 Adolescent ? Foot phalanx Fair 2 
LP4848.1 Child ? Rib Good 0 
LP4848.2 Child ? Cranium Good 0 
LP5252.1 Child ? Rib Fair 0 
LP5252.2 Child ? Cranium Fair 0 
LPA1 Animal N/A Rib Fair 3 
LPA3 Animal N/A Rib Fair 3 
Table A2.14: Histological index (HI) and observed macroscopic condition of bone samples 
from the Highfield Farm, Littleport Anglo-Saxon site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
487 
 
Sample Age Sex Element 
Macroscopic 
Condition HI 
WF25.2 Young adult Female Hand phalanx Poor 1 
WF28.1 Adolescent ? Rib Poor 1 
WF45.2 Adolescent Female? Foot phalanx Poor 2 
WF51.1 Juvenile ? Rib Poor 0 
WF57.2 Child ? Rib Poor 0 
WF57.3 Child ? Rib Poor 0 
WF25.1 Young adult Female? Rib Poor 2 
WF28.2 Adolescent ? Foot phalanx Poor 2 
WF45.1 Adolescent Female? Rib Poor 2 
WF51.2 Juvenile ? Rib Poor 1 
WF57.1 Child ? Rib Poor 1 
Table A2.15: Histological index (HI) and observed macroscopic condition of bone samples 
from the Westfield Farm, Ely Anglo-Saxon site. 
 
 
Sample Age Sex Element 
Macroscopic 
Condition HI 
OL1071.1 Adolescent Female? Rib Fair 0 
OL1071.2 Adolescent Female? Hand phalanx Good 4 
OL1072.1 Very young adult Female Rib Good 0 
OL1072.2 Very young adult Female Hand phalanx Good 1 
OL1072.3 Very young adult Female Cranium Good 0 
OL1094.1 Juvenile ? Rib Fair 4 
OL1094.2 Juvenile ? Hand phalanx Fair 1 
OL1094.3 Juvenile ? Cranium Fair 1 
OL1100.1 Child ? Rib Good 0 
OL1100.2 Child ? Cranium Good 1 
OL1104.1 Young adult Female Rib Fair 2 
OL1104.2 Young adult Female Hand phalanx Fair 5 
OL1104.3 Young adult Female Cranium Fair 1 
OL1123.2 Juvenile ? Hand phalanx Fair 5 
OL1125.1 Child ? Rib Good 1 
OL1125.2 Child ? Cranium Good 1 
OL1130.1 Very young adult Female Rib Fair 0 
OL1130.2 Very young adult Female Cranium Fair 0 
OLA1 Animal N/A Rib Good 2 
OLA2 Animal N/A Rib Fair 2 
Table A2.16: Histological index (HI) and observed macroscopic condition of bone samples 
from the Orchard Lane, Huntingdon medieval site. 
 
 
488 
 
Rapid testing using the CareStart™ Malaria Rapydtest® 
 
Fornaciari et al. (2010) protocol: 
 
 
Figure A2.1: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
CON – control line; VOM or 2 – P. vivax, P. malariae, or P. ovale; Pf or 1 – P. 
falciparum. 
 
 
Figure A2.2: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
CON – control line; 2 – P. vivax, P. malariae, or P. ovale; 1 – P. falciparum. 
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Figure A2.3: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
CON – control line; VOM or 2 – P. vivax, P. malariae, or P. ovale; Pf or 1 – P. 
falciparum. 
 
 
Figure A2.4: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
CON – control line; 2 – P. vivax, P. malariae, or P. ovale; 1 – P. falciparum. 
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Figure A2.5: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
CON – control line; 2 – P. vivax, P. malariae, or P. ovale; 1 – P. falciparum. 
 
 
Figure A2.6: Malaria rapid test results following Fornaciari et al. (2010) protocol. 
Collagen control. CON – control line; 2 – P. vivax, P. malariae, or P. ovale; 1 – P. 
falciparum. 
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P2.5 samples 
 
 
Figure A2.7: Malaria rapid test results from P2.5 samples, 1st extraction stage. CON 
– control line; VOM – P. vivax, P. malariae, or P. ovale; Pf – P. falciparum. 
 
 
 
Figure A2.8: Malaria rapid test results from P2.5 samples, 2nd extraction stage. CON 
– control line; VOM – P. vivax, P. malariae, or P. ovale; Pf – P. falciparum. 
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Figure A2.9: Malaria rapid test results from P2.5 samples, 3rd extraction stage. CON 
– control line; VOM – P. vivax, P. malariae, or P. ovale; Pf – P. falciparum. 
 
 
 
Figure A2.10: Malaria rapid test results from P2.5 samples following thiophilic 
chromatography adsorption. CON – control line; VOM – P. vivax, P. malariae, or P. 
ovale; Pf – P. falciparum. 
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Figure A2.11: Malaria rapid test results for adapted Jiang et al. protocol using 
collagen (COLL) and animal bone (AN5) controls. CON – control line; VOM – P. 
vivax, P. malariae, or P. ovale; Pf – P. falciparum. 
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 P5 samples 
 
 
Figure A2.12: Malaria rapid test results for adapted P5 Cappellini et al. protocol, 1st 
extraction. HPAN5 – control animal sample. CON – control line; 2 – P. vivax, P. 
malariae, or P. ovale; 1 – P. falciparum. 
 
 
 
Figure A2.13: Malaria rapid test results for adapted P5 Cappellini et al. protocol, 2nd 
extraction. HPAN5 – control animal sample. CON – control line; 2 – P. vivax, P. 
malariae, or P. ovale; 1 – P. falciparum. 
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Figure A2.14: Malaria rapid test results for adapted P5 Cappellini et al. protocol, 3rd 
extraction. HPAN5 – control animal sample. CON – control line; 2 – P. vivax, P. 
malariae, or P. ovale; 1 – P. falciparum. 
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Appendix 3: nLCMS/MS proteomic results 
 
 Appendix 3 presents in-depth information on the results of nLC-MS/MS analysis of 
post-TAC elutions from the P3 and P4 protocols (section 6.45). Groups identified with 95% 
confidence and above (for human non-contaminating proteins, and non-human proteins of 
interest) are shown, with modifications and cleavages, where present. Trypsin is a remnant 
from pre-analysis digestion. 
 
Table column title key: 
 
N – Protein group 
SC – Sequence coverage (%) 
Prec MW – Precursor molecular weight  
 
CD120.2, P3 2nd extraction, pre-exclusion, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 58.9 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  24 
2 51.3 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
19 
3 26.6 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  6 
4 25 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  5 
5 32 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  3 
6 20.5 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2  2 
7 29.1 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  2 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GETGPSGPVGPAGAVGPR     1561.8 
GIPGPVGAAGATGAR Oxidation(P)@5   1266.6 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@8 
  1253.6 
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GLPGVAGAVGEPGPLGIAGPP
GAR 
Oxidation(P)@3; Oxidation(P)@14; 
Oxidation(P)@21 
  2114.1 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1619.7 
GPPGAAGAPGPQGFQGPAGE
PGEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@11; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1844.9 
EGPVGLPGIDGR Oxidation(P)@7 
cleaved R-
P@C-term 
1181.6 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@11   1200.6 
GENGVVGPTGPVGAAGPAGP
NGPPGPAGSR 
Deamidated(N)@21; 
Oxidation(P)@24 
  2567.2 
 
Group 2: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
GDAGPPGPAGPAGPPGPIGNVG
APGAK 
Oxidation(P)@8; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGRPGEVGPPGPPGPAG
EK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.1 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGESG
PSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15 missed K-G@18 2868.4 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@5; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
SGDRGETGPAGPAGPVGPVGA
R 
  missed R-G@4 1961.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
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CD120.2, P3 2nd extraction, post-exclusion, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 25.9 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  3 
2 24.4 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 
SV=2  
2 
3 25.5 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  1 
4 8.7 Terminal uridylyltransferase 4 OS=Homo sapiens GN=ZCCHC11 PE=1 SV=3  1 
 
 
Group 4: Terminal uridylyltransferase 4 
 
Sequence Modifications Cleavages Prec MW 
MDDFQLKGIVEEKF
VK 
Oxidation(M)@1; Lys-
>Allysine(K)@7 
missed K-G@7; missed K-F@13 1939.9 
 
 
CD120.2, P3 3nd extraction, pre-exclusion, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 44.6 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  15 
2 35.9 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  12 
3 30.3 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  10 
4 40.9 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
7 
5 27.1 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2  8 
6 25 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  6 
7 22.4 Keratin, type I cytoskeletal 15 OS=Homo sapiens GN=KRT15 PE=1 SV=3  2 
8 32.8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  12 
9 10 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  1 
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Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GETGPSGPVGPAGAVGPR     1561.8 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLPGVAGAVGEPGPLGIAGPPG
AR 
Oxidation(P)@3; Oxidation(P)@14; 
Oxidation(P)@21 
  2114.1 
GPPGAAGAPGPQGFQGPAGEPG
EPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 
cleaved L-
L@N-term 
1238.7 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
 
 
Group 4: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
GETGPAGPAGPVGPVGAR     1545.8 
GFSGLQGPPGPPGSPGEQGPS
GASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.7 
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CD120.2, P3 3nd extraction, post-exclusion, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 31.5 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  7 
2 21.3 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  3 
3 15.4 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  2 
4 28.5 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
2 
5 22.4 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2  1 
6 25.2 
cDNA FLJ16494 fis, clone CTONG3004576, highly similar to Keratin, type I 
cytoskeletal 15 OS=Homo sapiens PE=2 SV=1  
1 
7 6.5 Terminal uridylyltransferase 4 OS=Homo sapiens GN=ZCCHC11 PE=1 SV=3  1 
8 10 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  1 
9 6.1 
Protein LOC100652824 (Fragment) OS=Homo sapiens GN=LOC100652824 PE=2 
SV=1  
1 
10 9.2 Ankyrin repeat and SOCS box protein 18 OS=Homo sapiens GN=ASB18 PE=2 SV=2  1 
 
Group 4: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
SGDRGETGPAGPAGPVGPVGAR   missed R-G@4 1961.0 
 
Group 7: Terminal uridylyltransferase 4 
 
Sequence Modifications Cleavages Prec MW 
MDDFQLKGIVEEK
FVK 
Dioxidation(M)@1; Dehydrated(D)@2; 
Deamidated(Q)@5 
missed K-G@7; missed K-F@13 1939.9 
 
Group 9: Protein LOC100652824 (Fragment) 
 
Sequence Modifications Cleavages Prec MW 
EGKVYGQAEAAIGK   
missed K-
V@3 
1419.7 
 
Group 10: Ankyrin repeat and SOCS box protein 18 
 
Sequence Modifications Cleavages Prec MW 
GAHVDARNGRGETALSAACGAAR   missed R-N@7; missed R-G@10 2210.1 
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CD84.2, P4 1st extraction, Swiss-Prot database 
 
N SC Name 
Peptides 
(95%) 
1 70.3 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 62 
2 66.3 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 89 
3 31.1 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 11 
4 25.6 Keratin, type II cytoskeletal 1 OS=Pan troglodytes GN=KRT1 PE=1 SV=1 10 
5 28.6 Trypsin OS=Sus scrofa PE=1 SV=1 14 
6 23.5 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 5 
7 67.2 Collagen alpha-1(I) chain OS=Rattus norvegicus GN=Col1a1 PE=1 SV=5 52 
8 8.1 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 
SV=2 
2 
10 66.1 Collagen alpha-1(I) chain OS=Bos taurus GN=COL1A1 PE=1 SV=3 67 
11 62.2 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 26 
12 69.7 Collagen alpha-2(I) chain OS=Mammut americanum PE=1 SV=3 23 
13 13.2 
L-glutamine:scyllo-inosose aminotransferase OS=Streptomyces griseus GN=stsC 
PE=1 SV=1 
1 
14 58.8 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 20 
15 59.5 Collagen alpha-1(II) chain OS=Rattus norvegicus GN=Col2a1 PE=1 SV=2 4 
16 10.6 
Probable tRNA sulfurtransferase OS=Lactobacillus casei (strain ATCC 334) 
GN=thiI PE=3 SV=1 
1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages 
Prec 
MW 
EGPVGLPGIDGR Oxidation(P)@7 
cleaved R-
P@C-term 
1181.6 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEAG
AAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 
missed R-
G@18 
2726.4 
GAPGPDGNNGAQGPPGPQGVQG
GK 
Oxidation(P)@3; Deamidated(N)@9; 
Deamidated(Q)@12; Oxidation(P)@15 
  2147 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPNG
PPGPAGSR 
Deamidated(N)@3; Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GESGNKGEPGSAGPQGPPGPSGE
EGK 
Oxidation(P)@9; Oxidation(P)@18 
missed K-
G@6 
2395.1 
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GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANGL
TGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQPG
AK 
Deamidated(N)@9; Deamidated(Q)@20; 
Oxidation(P)@21 
  2052 
GHNGLDGLK Deamidated(N)@3   910.5 
GHNGLQGLPGIAGHHGDQGAPG
SVGPAGPR 
Deamidated(N)@3; Oxidation(H)@15; 
Oxidation(P)@21 
  2800.3 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPGA
R 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@21 
  2114.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(M)@15 
  1782.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGF Oxidation(P)@3; Oxidation(P)@9 
cleaved F-
Q@C-term 
1211.6 
GPPGAAGAPGPQGFQGPAGEPGE
PGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPSGPPGPDGNKGEPGVVGAVG
TAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-
G@12 
3212.5 
GPSGPQGIR     867.5 
GSDGSVGPVGPAGPIGSAGPPGF
PGAPGPK 
Oxidation(P)@21; Oxidation(P)@24; 
Oxidation(P)@27 
  2588.2 
HGNRGETGPSGPVGPAGAVGPR   
missed R-
G@4 
2025.9 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 
cleaved L-
L@N-term 
1238.6 
PGPIGPAGAR Oxidation(P)@1 
cleaved R-
P@N-term 
907.5 
PGPVGAAGATGAR Oxidation(P)@1 
cleaved I-
P@N-term 
1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved L-
P@N-term 
1082.5 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 
cleaved F-
Q@N-term 
1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-
G@1 
1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
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Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER     1689.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GDAGPPGPAGPAGPPGPIGN
VGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@5; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Oxidation(P)@21 
  2149.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPGP
VGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.1 
GETGPAGRPGEVGPPGPPGP
AGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGP
SGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12   2688.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGE
SGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GNDGATGAAGPPGPTGPAG
PPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK 
Oxidation(M)@6; Oxidation(P)@9; 
Oxidation(P)@11 
  1192.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGI
AGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
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GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPPG
AR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPAG
K 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
 
Group 13: Streptomyces griseus 
 
Sequence Modifications Cleavages 
Prec 
MW 
LSELGMTAQATAPGTTARAYYRYL
VR 
Deamidated(Q)@
9 
missed R-A@18; missed R-
Y@22 
2860.3 
 
Group 16: Lactobacillus casei 
 
Sequence Modifications Cleavages Prec MW 
LNGNVTRALHEFPNLTIRPK Deamidated(N)@4 missed R-A@7 2290.2 
 
 
CD84.2, P4 1st extraction, TrEMBL database 
 
N SC Name 
Peptides 
95% 
1 77.1 
Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 
SV=7  
63 
2 72.4 
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 
SV=5  
105 
3 29.5 
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3  
10 
4 30.4 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  10 
5 34.2 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6  
5 
6 14.6 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2  
2 
7 69.9 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens 
GN=COL1A1 PE=4 SV=1  
71 
8 27.3 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  1 
9 2.6 MUC19 variant 12 OS=Homo sapiens GN=MUC19 PE=2 SV=1  1 
505 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 
cleaved R-P@C-
term 
1181.6 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEAG
AAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQG
GK 
Oxidation(P)@3; Deamidated(N)@9; 
Deamidated(Q)@12; Oxidation(P)@15 
  2147.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPNG
PPGPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GESGNKGEPGSAGPQGPPGPSGE
EGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.1 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANGL
TGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQPG
AK 
Deamidated(N)@9; 
Deamidated(Q)@20; Oxidation(P)@21 
  2051.9 
GEVGPAGPNGFAGPAGAAGQPG
AKGER 
Deamidated(N)@9; Oxidation(P)@21; 
Oxidation(K)@24 
missed K-G@24 2409.2 
GHNGLDGLK Deamidated(N)@3   910.5 
GHNGLQGLPGIAGHHGDQGAPG
SVGPAGPR 
Deamidated(N)@3; Oxidation(H)@15; 
Oxidation(P)@21 
  2800.3 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPGA
R 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@14; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(M)@15 
  1766.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGF Oxidation(P)@3; Oxidation(P)@9 
cleaved F-Q@C-
term 
1211.6 
GPPGAAGAPGPQGFQGPAGEPGE
PGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR Oxidation(P)@3; Oxidation(P)@9;   1751.8 
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Deamidated(N)@12; Oxidation(P)@15 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPSGPPGPDGNKGEPGVVGAVG
TAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GSDGSVGPVGPAGPIGSAGPPGF
PGAPGPK 
Oxidation(P)@21; Oxidation(P)@24; 
Oxidation(P)@27 
  2588.2 
HGNRGETGPSGPVGPAGAVGPR   missed R-G@4 2025.9 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 
cleaved L-L@N-
term 
1238.7 
PGPIGPAGAR Oxidation(P)@1 
cleaved R-P@N-
term 
907.5 
PGPVGAAGATGAR Oxidation(P)@1 
cleaved I-P@N-
term 
1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved L-P@N-
term 
1082.5 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 
cleaved F-Q@N-
term 
1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1828.9 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@5; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@5; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
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GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGP
SGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12   2688.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@9   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGSAGAPGKDGLNGLPG
PIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(R)@27 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@5   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@13; Dioxidation(P)@19 
  2057.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
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CD84.2, P4 2nd extraction, Swiss-Prot database 
 
N SC Name 
Peptides 
(95%) 
1 74.2 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 86 
2 61.7 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 87 
3 37.2 Trypsin OS=Sus scrofa PE=1 SV=1 12 
4 59.5 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 28 
5 55.3 Collagen alpha-1(I) chain OS=Mus musculus GN=Col1a1 PE=1 SV=4 48 
6 67 Collagen alpha-2(I) chain OS=Bos taurus GN=COL1A2 PE=1 SV=2 32 
7 30.7 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 2 
8 5.9 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 2 
9 64.7 Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=1 SV=3 25 
10 54.6 Collagen alpha-1(I) chain OS=Cynops pyrrhogaster GN=COL1A1 PE=2 SV=1 3 
11 59.4 Collagen alpha-1(II) chain OS=Mus musculus GN=Col2a1 PE=1 SV=2 4 
12 15 Chondroadherin OS=Bos taurus GN=CHAD PE=1 SV=1 1 
13 82.5 Collagen alpha-1(I) chain OS=Mammut americanum GN=COL1A1 PE=1 SV=4 51 
14 62.4 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 30 
15 5.8 Pigment epithelium-derived factor OS=Bos taurus GN=SERPINF1 PE=1 SV=1 1 
16 4.2 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 1 
17 28.6 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 1 
18 13.5 Keratin, type I cytoskeletal 10 OS=Mus musculus GN=Krt10 PE=1 SV=3 1 
19 27.4 Collagen alpha-1(X) chain OS=Bos taurus GN=COL10A1 PE=2 SV=1 1 
20 9.2 
Protein pelota homolog OS=Methanocaldococcus jannaschii (strain ATCC 43067 / 
DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) GN=pelA PE=3 SV=1 
1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@13   2071.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGE
AGAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQ
GGK 
Oxidation(P)@5; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR     1546.8 
GENGVVGPTGPVGAAGPAGPN
GPPGPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
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GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGVVGAVGTAGPSGPSGLP
GER 
Oxidation(P)@3; Oxidation(P)@21   2136.0 
GEQGPPGPPGFQGLPGPSGPAG
EVGKPGER 
Formyl@N-term; Oxidation(P)@17; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPSG
EEGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.0 
GESGNKGEPGSAGPQGPPGPSG
EEGKR 
Oxidation(P)@9; Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2551.1 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; 
Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQP
GAK 
Deamidated(N)@9; 
Oxidation(P)@21 
  2051.0 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHNGLDGLK Deamidated(N)@3   910.4 
GHNGLQGLPGIAGHHGDQGAP
GSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPG
AR 
Oxidation(P)@3; Oxidation(P)@14; 
Oxidation(P)@21 
  2114.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@17 
  1766.8 
GPNGEAGSAGPPGPPGLR Oxidation(P)@12; Oxidation(P)@15   1618.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.3 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1750.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.7 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@8; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GSDGSVGPVGPAGPIGSAGPPG
FPGAPGPK 
Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@27 
  2588.2 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Oxidation(P)@3; Oxidation(H)@18   2283.1 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.7 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
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PGPVGAAGATGAR Oxidation(P)@1 cleaved I-P@N-term 1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 cleaved F-Q@N-term 1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; 
Oxidation(P)@13; Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
GHAGLAGAR     808.4 
GPSGEAGTAGPPGTPGPQGLLG
APGILGLPGSR 
Oxidation(P)@15; 
Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.4 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2213.9 
GDAGPPGPAGPAGPPGPIGN
VGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEQGPSGASGPAGPR   
cleaved P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184 
GETGPAGRPGEVGPPGPPGP
AGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
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GFSGLQGPPGPPGSPGEQGP
SGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGTAGLPGMK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(M)@11 
  1145.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKGE
SGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GNDGATGAAGPPGPTGPAG
PPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPSGPQGPGGPPGPK Oxidation(P)@2; Oxidation(P)@12   1317.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2056 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GVVGLPGQR Oxidation(P)@6   897.5 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@9   1257.6 
 
Group 16: Vitronectin 
 
Sequence Modifications Cleavages Prec MW 
FEDGVLDPDYPR     1421.6 
 
Group 17: Cystatin 
 
Sequence Modifications Cleavages Prec MW 
SLPGQNEDLVLTGYQVDK     1975 
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CD84.2, P4 2nd extraction, TrEMBL database 
N SC Name 
Peptides 
(95%) 
1 79.8 
Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 
SV=7  
95 
2 75.9 
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 
SV=5  
93 
3 74 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens 
GN=COL1A1 PE=4 SV=1  
67 
4 30.7 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4  2 
5 22 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  2 
6 20.3 Chondroadherin OS=Homo sapiens GN=CHAD PE=2 SV=2  1 
7 7.9 Vitronectin OS=Homo sapiens GN=VTN PE=2 SV=1  1 
8 9.8 
Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 
PE=1 SV=4  
1 
9 38.8 CSTA protein OS=Homo sapiens GN=CSTA PE=2 SV=1  1 
10 14.2 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6  
1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@13   2071.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGE
AGAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGV
QGGK 
Oxidation(P)@5; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGP
NGPPGPAGSR 
Deamidated(N)@3; Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGVVGAVGTAGPSGPSGLP
GER 
Oxidation(P)@3; Oxidation(P)@21   2136.0 
GEQGPPGPPGFQGLPGPSGPA
GEVGKPGER 
Formyl@N-term; Oxidation(P)@17; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPS
GEEGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.1 
GESGNKGEPGSAGPQGPPGPS Oxidation(P)@9; Oxidation(P)@18 missed K-G@6; 2551.1 
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GEEGKR missed K-R@26 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQ
PGAK 
Cation:Na(E)@2; Oxidation(P)@8; 
Deamidated(N)@9; Oxidation(P)@21 
  2088.9 
GEVGPAGPNGFAGPAGAAGQ
PGAKGER 
Deamidated(N)@9; Deamidated(Q)@20; 
Oxidation(P)@21; Oxidation(K)@24 
missed K-G@24 2410.1 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHNGLDGLK Deamidated(N)@3   910.5 
GHNGLQGLPGIAGHHGDQGA
PGSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@8 
  1253.6 
GLPGVAGAVGEPGPLGIAGPP
GAR 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@12; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@17 
  1766.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.3 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@9; Deamidated(N)@12; 
Oxidation(P)@15 
  1735.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GSDGSVGPVGPAGPIGSAGPP
GFPGAPGPK 
Oxidation(P)@21; Oxidation(P)@24; 
Oxidation(P)@27 
  2588.3 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Oxidation(P)@3; Oxidation(H)@18   2283.2 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.7 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGPVGAAGATGAR Oxidation(P)@1 cleaved I-P@N-term 1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 cleaved F-Q@N-term 1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
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GHAGLAGAR     808.4 
GPSGEAGTAGPPGTPGPQGLL
GAPGILGLPGSR 
Oxidation(P)@15; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.4 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGP
SGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLPGTAGLPGMK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(M)@11 
  1145.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
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GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGSAGAPGKDGLNGLPG
PIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@20; Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@2; Oxidation(P)@12   1317.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
 
Group 3: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications 
Cleavage
s 
Prec MW 
GETGPAGPAGPVGPVGAR     1545.8 
SGDRGETGPAGPAGPVGPVGAR   
missed R-
G@4 
1961.0 
DGEAGAQGPPGPAGPAGER     1689.8 
DGEAGAQGPPGPAGPAGER 
Cation:K(E)@3; 
Oxidation(P)@10 
  1743.7 
DGEAGAQGPPGPAGPAGER 
Deamidated(Q)@7; 
Oxidation(P)@10 
  1706.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@13; 
Oxidation(P)@15; Cation:K@C-
term 
  1583.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@13 
  1561.8 
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DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@13; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@13; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@13; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
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GDAGAPGAPGSQGAPGLQGMPGER 
Oxidation(P)@6; 
Oxidation(P)@9; 
Oxidation(P)@15; 
Dioxidation(M)@20 
  2214.0 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Cation:K(D)@2; Oxidation(P)@8; 
Oxidation(P)@17; 
Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Oxidation(P)@6; 
Oxidation(P)@15; 
Deamidated(N)@20; 
Oxidation(P)@24 
  2281.1 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Oxidation(P)@6; 
Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPGAPGPVGPAG
K 
Oxidation(P)@11; 
Oxidation(P)@21 
missed R-
G@3 
2480.2 
GDRGETGPAGPPGAPGAPGAPGPVGPAG
K 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@18; 
Oxidation(P)@21 
missed R-
G@3 
2512.2 
GDRGETGPAGPPGAPGAPGAPGPVGPAG
K 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@21 
missed R-
G@3 
2496.2 
GDRGETGPAGPPGAPGAPGAPGPVGPAG
K 
Oxidation(P)@12; 
Oxidation(P)@18; 
Oxidation(P)@21 
missed R-
G@3 
2496.2 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15; 
Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15; 
Oxidation(P)@21 
  2149.0 
GEQGPSGASGPAGPR   
cleaved 
P-G@N-
term 
1323.6 
GEQGPSGASGPAGPR   
cleaved 
P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1546.8 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@18 
  2184.0 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
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GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@5; 
Oxidation(P)@15; 
Oxidation(P)@18; 
Oxidation(P)@20 
  2231.0 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; 
Cation:K(E)@11; 
Oxidation(P)@15; 
Oxidation(P)@20 
  2253.0 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; 
Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@11; 
Oxidation(P)@12 
  2688.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@11; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@11; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Cation:K(E)@17 
  2742.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@12; 
Oxidation(P)@15 
  2688.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@9; 
Oxidation(P)@12 
  2688.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGP
R 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Cation:Na(E)@17 
  2726.2 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDK 
Oxidation(P)@9; 
Oxidation(P)@15 
  1589.8 
GLTGPIGPPGPAGAPGDK 
Oxidation(P)@9; 
Oxidation(P)@15 
  1589.8 
GLTGPIGPPGPAGAPGDKGESGPSGPAGP
TGAR 
Oxidation(P)@9 
missed K-
G@18 
2852.4 
GLTGPIGPPGPAGAPGDKGESGPSGPAGP
TGAR 
Oxidation(P)@9; 
Oxidation(P)@15 
missed K-
G@18 
2868.4 
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GLTGPIGPPGPAGAPGDKGESGPSGPAGP
TGAR 
Oxidation(P)@9; 
Oxidation(P)@15 
missed K-
G@18 
2868.4 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6 
  1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(P)@15 
  1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@2; Lys-
>Allysine(K)@11; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2452.3 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@3; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@3; 
Deamidated(N)@15; 
Oxidation(P)@20; 
Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@3; 
Dioxidation(P)@9; 
Deamidated(N)@15; 
Dioxidation(P)@23 
  2470.2 
GSAGPPGATGFPGAAGR 
Oxidation(P)@6; 
Oxidation(P)@12 
  1458.7 
GSAGPPGATGFPGAAGR 
Oxidation(P)@6; 
Oxidation(P)@12 
  1458.7 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(D)@6; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Deamidated(Q)@23 
  2121.0 
GSPGADGPAGAPGTPGPQGIAGQR Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12 
  2104.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12; 
  2105.0 
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Deamidated(Q)@23 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR 
Deamidated(Q)@3; 
Oxidation(P)@6 
  1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6   897.5 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@10 
cleaved 
R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@10 
cleaved 
R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@10; 
Oxidation(K)@16 
cleaved 
R-P@N-
term 
1505.7 
SGDRGETGPAGPAGPVGPVGAR   
missed R-
G@4 
1961.0 
SGDRGETGPAGPAGPVGPVGAR   
missed R-
G@4 
1961.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Deamidated(N)@9; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GEPGPPGPAGAAGPAGNPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@18; 
Oxidation(P)@24 
  2315.1 
GEPGPTGLPGPPGER 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; 
Oxidation(P)@12 
  1846.9 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; 
Oxidation(P)@12 
missed K-
R@20 
2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(N)@9; 
  1742.7 
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Oxidation(P)@12 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFSGLDGAK Dehydrated(S)@3   832.4 
GLPGPPGAPGPQGF 
Oxidation(P)@3; 
Oxidation(P)@6; Oxidation(P)@9 
cleaved 
F-Q@C-
term 
1295.6 
GLPGTAGLPGMK 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(M)@11 
  1145.6 
GNDGATGAAGPPGPTGPAGPPGFPGAVG
AK 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPSGPQGPGGPPGPK 
Oxidation(P)@2; 
Oxidation(P)@12 
  1317.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
PGADGVAGPK Oxidation(P)@1 
cleaved 
F-P@N-
term 
883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@13 
cleaved 
S-P@N-
term 
1510.8 
PGPVGVQGPPGPAGEEGKR 
Oxidation(P)@1; 
Oxidation(P)@10 
cleaved 
E-P@N-
term; 
missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@18; 
Oxidation(P)@19 
  2056.0 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.7 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Pro->pyro-
Glu(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1583.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GEPGPPGPAGAAGPAGNPGADGQPGAK Oxidation(P)@5;   2315.0 
522 
 
Oxidation(P)@6; 
Oxidation(P)@18; 
Oxidation(P)@24 
GEPGPTGLPGPPGER 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK 
Pro->pyro-Glu(P)@3; 
Oxidation(P)@12 
  1844.9 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; 
Oxidation(P)@12 
missed K-
R@20 
2003.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GNDGATGAAGPPGPTGPAGPPGFPGAVG
AK 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPSGPQGPGGPPGPK 
Deamidated(Q)@6; 
Oxidation(P)@12 
  1302.6 
GPSGPQGPGGPPGPK 
Deamidated(Q)@6; 
Oxidation(P)@12 
  1302.6 
GPSGPQGPGGPPGPK 
Deamidated(Q)@6; 
Oxidation(P)@12; 
Oxidation(P)@14 
  1318.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK 
Oxidation(P)@8; 
Oxidation(P)@12 
  1317.6 
GPSGPQGPGGPPGPK 
Oxidation(P)@8; 
Oxidation(P)@12 
  1317.7 
GQAGVMGFPGPK 
Deamidated(Q)@2; 
Oxidation(M)@6; 
Oxidation(P)@9 
  1177.6 
GQAGVMGFPGPK 
Oxidation(M)@6; 
Oxidation(P)@9 
  1176.6 
GQAGVMGFPGPK 
Oxidation(M)@6; 
Oxidation(P)@9 
  1176.6 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Deamidated(Q)@9; 
Dioxidation(P)@16; 
Oxidation(P)@19 
  2057.0 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@18; 
Oxidation(P)@19 
  2056.0 
 
Group 6: Chondroadherin 
 
Sequence Modifications Cleavages Prec MW 
FSDGAFLGVTTLK     1354.7 
 
 
 
 
523 
 
Group 7: Vitronectin 
 
Sequence Modifications Cleavages Prec MW 
FEDGVLDPDYPR     1421.4 
 
Group 8: Pigment epithelium-derived factor 
 
Sequence Modifications Cleavages Prec MW 
DTDTGALLFIGK     1249.6 
DTDTGALLFIGK     1249.7 
 
Group 9: CSTA protein 
 
Sequence Modifications Cleavages Prec MW 
SLPGQNEDLVLTGYQVDK     1975 
 
 
CD84.2 P4 3rd extraction, Swiss-prot database 
 
N SC Name 
Peptides 
(95%) 
1 72.5 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 72 
2 66 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 93 
3 35.7 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 23 
4 34.3 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 13 
5 28.3 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
13 
6 35.5 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 
PE=1 SV=2 
12 
7 44.6 Trypsin OS=Sus scrofa PE=1 SV=1 14 
8 60 Collagen alpha-2(I) chain OS=Bos taurus GN=COL1A2 PE=1 SV=2 30 
9 64.3 Collagen alpha-1(I) chain OS=Bos taurus GN=COL1A1 PE=1 SV=3 75 
10 64.9 Collagen alpha-1(I) chain OS=Rattus norvegicus GN=Col1a1 PE=1 SV=5 56 
11 6.9 Chondroadherin OS=Bos taurus GN=CHAD PE=1 SV=1 2 
12 54.9 Collagen alpha-1(II) chain OS=Bos taurus GN=COL2A1 PE=1 SV=4 5 
13 20.9 
Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
6 
14 18.4 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
2 
15 52.3 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 23 
16 8.2 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 1 
17 49.6 Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=1 SV=3 22 
18 19.9 
Keratin, type II cytoskeletal 2 epidermal OS=Canis familiaris GN=KRT2 
PE=2 SV=1 
6 
19 66.3 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 24 
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20 6.7 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 1 
21 10.3 
Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 
PE=1 SV=4 
1 
22 10 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 1 
23 4.6 Biglycan OS=Homo sapiens GN=BGN PE=1 SV=2 1 
24 12.9 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 1 
25 3.3 
Suppressor of presenilin protein 4 OS=Caenorhabditis elegans GN=spr-4 
PE=4 SV=2 
1 
26 54.5 Collagen alpha-1(I) chain OS=Gallus gallus GN=COL1A1 PE=1 SV=3 37 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGE
AGAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGV
QGGK 
Oxidation(P)@3; Deamidated(N)@8; 
Deamidated(N)@9; Oxidation(P)@15 
  2147.0 
GAPGPHGPVGPAGK Oxidation(P)@3 
cleaved A-G@N-
term 
1213.6 
GDGGPPGMTGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1532.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPN
GPPGPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGPLGIAGPPGAR Oxidation(P)@3; Oxidation(P)@12 
cleaved V-G@N-
term 
1376.7 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEQGPPGPPGFQGLPGPSGPAG
EVGKPGER 
Formyl@N-term; Deamidated(Q)@12; 
Oxidation(P)@15; Oxidation(P)@27 
  2870.3 
GESGNKGEPGSAGPQGPPGPS
GEEGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.0 
GESGNKGEPGSAGPQGPPGPS
GEEGKR 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2552.1 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQP
GAK 
Deamidated(N)@9; 
Deamidated(Q)@20; Oxidation(P)@21 
  2052.0 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHNGLQGLPGIAGHHGDQGAP
GSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
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GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPP
GAR 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@14; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.5 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@17 
  1782.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@9; Deamidated(N)@12; 
Oxidation(P)@15 
  1735.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GSDGSVGPVGPAGPIGSAGPPG
FPGAPGPK 
Oxidation(P)@21; Oxidation(P)@24; 
Oxidation(P)@27 
  2588.2 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Pro->pyro-Glu(P)@3; 
Deamidated(N)@5; Oxidation(P)@17 
  2282.1 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
PGPHGPVGPAGK Oxidation(P)@1 cleaved A-P@N-term 1085.6 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
GPSGPQGIR     867.4 
PGAPGPK Oxidation(P)@1; Oxidation(P)@4 cleaved F-P@N-term 654.3 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@18   2071.1 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAGPP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPGAP Oxidation(P)@12; Oxidation(P)@15; missed R-G@3 2512.2 
526 
 
GPVGPAGK Oxidation(P)@18; Oxidation(P)@21 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
GEPGPPGPAGAAGPAGNPGAD
GQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2003.9 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPGPA
GEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGESG
PSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
TGPPGPAGQDGRPGPPGPPGA
R 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
527 
 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
GVVGLPGQR Oxidation(P)@6   897.5 
 
Group 16: Vitronectin 
 
Sequence Modifications Cleavages Prec MW 
FEDGVLDPDYPR     1421.6 
 
Group 21: Pigment epithelium-derived factor 
 
Sequence Modifications Cleavages Prec MW 
DTDTGALLFIGK     1249.7 
 
Group 23: Biglycan 
 
Sequence Modifications Cleavages Prec MW 
VPSGLPDLK     924.5 
Group 24: Prothrombin 
 
Sequence Modifications Cleavages Prec MW 
ELLESYIDGR     1193.6 
 
Group 25: Caenorhabditis elegans 
 
Sequence Modifications Cleavages Prec MW 
KGDSIPPGVK   missed K-G@1 996.5 
 
 
CD84.2, P4 3rd extraction, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 76.2 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  73 
2 70.4 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5  97 
3 39.3 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  23 
4 34.8 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  14 
5 35.8 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  13 
6 37.2 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 
SV=2  
12 
7 18.6 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4  3 
8 67.6 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
65 
9 14.8 Chondroadherin OS=Homo sapiens GN=CHAD PE=2 SV=2  2 
10 30.5 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5  5 
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11 12.3 Vitronectin OS=Homo sapiens GN=VTN PE=2 SV=1  1 
12 9.8 Biglycan preproprotein variant (Fragment) OS=Homo sapiens PE=2 SV=1  1 
13 22.2 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3  3 
14 12.2 Hornerin OS=Homo sapiens GN=HRNR PE=2 SV=1  1 
15 12.2 Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=4  1 
16 17.3 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2  1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGE
AGAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQ
GGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GAPGPHGPVGPAGK Oxidation(P)@5 cleaved A-G@N-term 1213.6 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPN
GPPGPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GESGNKGEPGSAGPQGPPGPSG
EEGK 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6 2396.0 
GESGNKGEPGSAGPQGPPGPSG
EEGKR 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2552.1 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; 
Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQP
GAK 
Deamidated(N)@9; 
Oxidation(P)@21 
  2051.0 
GEVGPAGPNGFAGPAGAAGQP
GAKGER 
Deamidated(N)@9; 
Oxidation(P)@21; Oxidation(K)@24 
missed K-G@24 2409.1 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHNGLQGLPGIAGHHGDQGAP
GSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
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GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPG
AR 
Oxidation(P)@3; Oxidation(P)@14; 
Oxidation(P)@21 
  2114.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.5 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(M)@15 
  1782.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; 
Oxidation(P)@12; Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.3 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GSDGSVGPVGPAGPIGSAGPPG
FPGAPGPK 
Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@27 
  2588.2 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Deamidated(N)@5; Methyl(I)@6; 
Oxidation(H)@18 
  2282.1 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
PGPHGPVGPAGK Oxidation(P)@1 cleaved A-P@N-term 1085.6 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; 
Oxidation(P)@13; Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1828.9 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
AGRPGEAGLPGAK Oxidation(P)@4; Oxidation(P)@10 cleaved E-A@N-term 1211.6 
DGEAGAQGPPGPAGPAGER     1689.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GDAGAPGAPGSQGAPGLQGM
PGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPGAP
GPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
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GEPGPPGPAGAAGPAGNPGAD
GQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2003.9 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2168.0 
GETGPAGRPGEVGPPGPPGPA
GEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGES
GPSGPAGPTGAR 
Oxidation(P)@9 missed K-G@18 2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGSAGAPGKDGLNGLPGPI
GPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
TGPPGPAGQDGRPGPPGPPGA Oxidation(P)@4; Oxidation(P)@13;   2056.0 
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R Oxidation(P)@16; Oxidation(P)@19 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
GAPGDRGEPGPPGPAGFAGPP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
 
Group 8: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@9; 
Oxidation(P)@15 
  1545.8 
GAPGDRGEPGPPGPAGFAGPP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.8 
DGEAGAQGPPGPAGPAGER Cation:K(E)@3; Oxidation(P)@10   1743.7 
GVVGLPGQR Oxidation(P)@6   897.5 
GFSGLDGAK     850.4 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
TGPPGPAGQDGRPGPPGPPGA
R 
Oxidation(P)@4; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@19 
  2056.0 
GETGPAGPAGPVGPVGAR     1545.8 
SGDRGETGPAGPAGPVGPVGA
R 
  missed R-G@4 1961.0 
AGRPGEAGLPGAK Oxidation(P)@4; Oxidation(P)@10 
cleaved E-
A@N-term 
1211.6 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-
G@N-term 
1397.7 
GEPGPPGPAGAAGPAGNPGAD
GQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2003.9 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFSGLDGAK Dehydrated(S)@3   832.4 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-
Q@C-term 
1295.6 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSPGEAGRPGEAGLPGAK Oxidation(P)@3; Oxidation(P)@9;   1654.8 
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Oxidation(P)@15 
PGADGVAGPK Oxidation(P)@1 
cleaved F-
P@N-term 
883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-
P@N-term 
1510.7 
TGPPGPAGQDGRPGPPGPPGA
R 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
DGEAGAQGPPGPAGPAGER     1689.8 
DGEAGAQGPPGPAGPAGER Deamidated(Q)@7; Oxidation(P)@10   1706.7 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Dioxidation(P)@15; 
Cation:K@C-term 
  1583.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
GDAGAPGAPGSQGAPGLQGM
PGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Cation:K(D)@2; Oxidation(P)@15; 
Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPGAP
GPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
GDRGETGPAGPPGAPGAPGAP
GPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GDRGETGPAGPPGAPGAPGAP
GPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
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GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Oxidation(P)@21 
  2149.0 
GESGPSGPAGPTGAR     1296.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR Pro->pyro-Glu(P)@11   1559.8 
GETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2168.0 
GETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPGPA
GEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPGPA
GEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@8   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12   2688.3 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.2 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGES
GPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Cation:K(D)@17 
missed K-
G@18 
2906.3 
GLTGPIGPPGPAGAPGDKGES
GPSGPAGPTGAR 
Oxidation(P)@9 
missed K-
G@18 
2852.4 
GLTGPIGPPGPAGAPGDKGES
GPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 
missed K-
G@18 
2868.4 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(M)@6   1815.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(P)@9;   1831.8 
534 
 
Oxidation(P)@15 
GPPGSAGAPGKDGLNGLPGPI
GPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2454.2 
GPPGSAGAPGKDGLNGLPGPI
GPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2454.2 
GSAGPPGATGFPGAAGR 
Methyl(S)@2; Oxidation(P)@6; 
Oxidation(P)@12 
  1472.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-
P@N-term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-
P@N-term 
1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-
P@N-term 
1035.5 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-
P@N-term 
1035.5 
SGDRGETGPAGPAGPVGPVGA
R 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGPVGA
R 
  missed R-G@4 1961.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GEPGPPGPAGAAGPAGNPGAD
GQPGAK 
Dioxidation(P)@6; Oxidation(P)@18; 
Deamidated(Q)@23; Oxidation(P)@24 
  2316.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGKR Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@9   1257.6 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
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GPSGPQGPGGPPGPK 
Methyl(Q)@6; Oxidation(P)@8; 
Oxidation(P)@12 
  1331.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@5; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@5; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-
P@N-term 
1510.7 
TGPPGPAGQDGRPGPPGPPGA
R 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@15; Dioxidation(P)@19 
  2057.0 
 
Group 9: Chondroadherin 
 
Sequence Modifications Cleavages Prec MW 
FSDGAFLGVTTLK     1354.7 
SIPDNAFQSFGR Deamidated(N)@5   1338.6 
 
Group 11: Vitronectin 
 
Sequence Modifications Cleavages Prec MW 
FEDGVLDPDYPR     1421.6 
 
Group 12: Biglycan preproprotein variant (fragment) 
 
Sequence Modifications Cleavages Prec MW 
VPSGLPDLK     924.5 
 
Group 15: Pigment epithelium-derived factor 
 
Sequence Modifications Cleavages Prec MW 
DTDTGALLFIGK     1249.7 
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EH156.3, P4 1st extraction, Swiss-Prot database 
N SC Name 
Peptides 
(95%) 
1 77.8 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 97 
2 73.8 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 129 
3 33.3 Trypsin OS=Sus scrofa PE=1 SV=1 6 
4 70.5 Collagen alpha-1(I) chain OS=Mus musculus GN=Col1a1 PE=1 SV=4 65 
5 67.7 Collagen alpha-1(II) chain OS=Bos taurus GN=COL2A1 PE=1 SV=4 8 
6 75.2 Collagen alpha-2(I) chain OS=Bos taurus GN=COL1A2 PE=1 SV=2 35 
7 69.3 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 26 
8 72.7 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 38 
9 71.1 Collagen alpha-1(I) chain OS=Gallus gallus GN=COL1A1 PE=1 SV=3 43 
10 5.7 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 1 
11 88.8 Collagen alpha-2(I) chain OS=Mammut americanum PE=1 SV=3 35 
12 66.3 Collagen alpha-1(II) chain OS=Mus musculus GN=Col2a1 PE=1 SV=2 8 
13 74.1 Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=1 SV=3 25 
14 34 Collagen alpha-1(XXVIII) chain OS=Homo sapiens GN=COL28A1 PE=2 SV=2 1 
15 52 Collagen alpha-1(XIX) chain OS=Homo sapiens GN=COL19A1 PE=1 SV=3 0 
16 3.6 
HTH-type transcriptional regulator MalT OS=Cronobacter sakazakii (strain ATCC 
BAA-894) GN=malT PE=3 SV=1 
1 
17 8.5 
Dihydroxy-acid dehydratase OS=Methanosarcina barkeri (strain Fusaro / DSM 804) 
GN=ilvD PE=3 SV=1 
1 
18 6.3 
Diflavin flavoprotein A 1 OS=Synechocystis sp. (strain PCC 6803 / Kazusa) GN=dfa1 
PE=1 SV=1 
1 
19 6.1 
DNA polymerase catalytic subunit OS=Equine herpesvirus 1 (strain V592) GN=30 
PE=3 SV=1 
1 
20 58.5 Collagen alpha-1(X) chain OS=Bos taurus GN=COL10A1 PE=2 SV=1 1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7   2055.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEA
GAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.4 
GAPGPDGNNGAQGPPGPQGVQ
GGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPN Deamidated(N)@3;   2568.2 
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GPPGPAGSR Deamidated(N)@21; Oxidation(P)@24 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.8 
GEPGNIGFPGPK 
Oxidation(P)@3; Deamidated(N)@5; 
Oxidation(P)@9 
  1201.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGVVGAVGTAGPSGPSGLP
GER 
Oxidation(P)@3; Oxidation(P)@21   2136.1 
GESGNKGEPGSAGPQGPPGPSG
EEGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.1 
GESGNKGEPGSAGPQGPPGPSG
EEGKR 
Oxidation(P)@9; Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2551.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.3 
GEVGPAGPNGFAGPAGAAGQP
GAK 
Deamidated(N)@9; 
Deamidated(Q)@20; Oxidation(P)@21 
  2052.0 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHAGLAGAR     808.4 
GHNGLDGLK Deamidated(N)@3   910.5 
GHNGLDGLKGQPGAPGVK 
Deamidated(N)@3; 
Deamidated(Q)@11; Oxidation(P)@12; 
Oxidation(P)@15 
missed K-G@9 1734.9 
GHNGLQGLPGIAGHHGDQGAP
GSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
GLPGLKGHNGLQGLPGIAGHH
GDQGAPGSVGPAGPR 
Oxidation(P)@3; Oxidation(H)@8; 
Oxidation(P)@15; Oxidation(P)@27 
missed K-G@6 3397.8 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPG
AR 
Oxidation(P)@3; Cation:K(E)@11; 
Oxidation(P)@12; Oxidation(P)@21 
  2152.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1766.8 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Cation:K(E)@23; Oxidation(P)@24 
  2980.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPQGHQGPAGPPGPPGPPGPPG
VSGGGYDFGYDGDFY 
Oxidation(P)@14; Oxidation(P)@17; 
Oxidation(P)@20; Oxidation(P)@21 
cleaved Y-R@C-term 3572.6 
GPQGHQGPAGPPGPPGPPGPPG
VSGGGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
  3728.7 
GPSGEAGTAGPPGTPGPQGLLG
APGILGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAV Oxidation(P)@6; Oxidation(P)@15; missed K-G@12 3212.6 
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GTAGPSGPSGLPGER Oxidation(P)@33 
GPSGPQGIRGDKGEPGEK Oxidation(P)@15 
missed R-G@9; 
missed K-G@12 
1780.9 
GPTGDPGKNGDKGHAGLAGA
R 
Oxidation(P)@6; Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1949.0 
GSDGSVGPVGPAGPIGSAGPPG
FPGAPGPK 
Oxidation(P)@21; Oxidation(P)@27   2572.3 
GVGLGPGPMGLMGPR Oxidation(M)@9   1410.7 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Oxidation(P)@3; Oxidation(P)@15   2283.2 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.7 
PGNIGFPGPK Oxidation(P)@1; Oxidation(P)@7 cleaved E-P@N-term 1014.5 
PGNIGPVGAAGAPGPHGPVGP
AGK 
Oxidation(P)@1; Oxidation(H)@16 cleaved Y-P@N-term 2063.1 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGPVGAAGATGAR Oxidation(P)@1 cleaved I-P@N-term 1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 cleaved F-Q@N-term 1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1828.9 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-term 1017.5 
GVVGPQGAR     839.5 
PGAPGPKGEIGAVGNAGPAGP
AGPR 
  
cleaved F-P@N-
term; missed K-G@7 
2148.1 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications  Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10  
 
1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
 
 
1561.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
 
 
1584.8 
GAPGDRGEPGPPGPAGFAGPP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
 
missed R-G@6 2702.3 
GDAGAPGAPGSQGAPGLQGM
PGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
 
 
2198.0 
GDAGPAGPKGEPGSPGENGAP
GQMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; Dioxidation(M)@24 
 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Cation:Na(D)@2; Oxidation(P)@8; 
Oxidation(P)@15; Oxidation(P)@24 
 
 
2302.1 
GDRGETGPAGPPGAPGAPGAP
GPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 
 
missed R-G@3 2480.2 
539 
 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
 cleaved P-G@N-
term 
1397.7 
GEPGDAGAKGDAGPPGPAGP
AGPPGPIGNVGAPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(P)@24; Oxidation(P)@33 
 
missed K-G@9 3078.5 
GEPGPPGPAGAAGPAGNPGAD
GQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
 
 
2315.1 
GEPGPPGPAGFAGPPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Oxidation(P)@21 
 
 
2149.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
 
 
1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Oxidation(P)@12  
 
1846.9 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
 
 
1742.7 
GESGPSGPAGPTGAR    
 
1296.6 
GETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
 
 
2168.1 
GETGPAGRPGEVGPPGPPGPA
GEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
 
 
2215.0 
GFPGADGVAGPK Oxidation(P)@3  
 
1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6  
 
1327.6 
GFPGLPGPSGEPGKQGPSGAS
GER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(Q)@15 
 
missed K-Q@14 2255.0 
GFSGLDGAK    
 
850.4 
GFSGLQGPPGPPGSPGEQGPSG
ASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
 
 
2704.3 
GISVPGPMGPSGPR Oxidation(M)@8 
 cleaved G-G@N-
term 
1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
 cleaved F-Q@C-
term 
1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15  
 
1589.8 
GLTGPIGPPGPAGAPGDKGES
GPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 
 
missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6  
 
1241.6 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
 
 
2547.2 
GNDGATGAAGPPGPTGPAGPP
GFPGAVGAKGEAGPQGPR 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@35 
 
missed K-G@30 3412.7 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(M)@6  
 
1815.9 
GPPGPPGKNGDDGEAGKPGRP
GER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
 
missed K-N@8 2347.1 
GPSGPQGPGGPPGPK Oxidation(P)@12  
 
1301.6 
GQAGVMGFPGPK Oxidation(P)@11  
 
1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12  
 
1458.7 
GSPGADGPAGAPGTPGPQGIA
GQR 
Oxidation(P)@12; Oxidation(P)@15 
 
 
2104.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
 
 
1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3  
 
1175.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6  
 
1105.6 
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PGADGVAGPK Oxidation(P)@1 
 cleaved F-P@N-
term 
883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
 cleaved S-P@N-
term 
1510.8 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
 cleaved R-P@N-
term 
1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 
 cleaved F-P@N-
term 
1123.6 
PGPMGPSGPR Oxidation(M)@4 
 cleaved V-P@N-
term 
967.5 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
 cleaved V-P@N-
term 
1035.5 
PGPPGKNGDDGEAGKPGRPGE
R 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@19 
 cleaved P-P@N-
term; missed K-
N@6 
2193.1 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
 cleaved E-P@N-
term 
1278.6 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
 cleaved E-P@N-
term; missed K-
R@18 
1816.9 
PPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@2; Oxidation(P)@11; 
Oxidation(P)@14; Oxidation(P)@17 
 cleaved G-P@N-
term 
1897.9 
SGDRGETGPAGPTGPVGPVGA
R 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
 
missed R-G@4 1998.9 
SGPQGPGGPPGPK Oxidation(P)@10 
 cleaved P-S@N-
term 
1147.6 
STGGISVPGPMGPSGPR Oxidation(P)@8  
 
1568.8 
TGPPGPAGQDGRPGPPGPPGA
R 
Oxidation(P)@4; Oxidation(P)@15; 
Oxidation(P)@16; Oxidation(P)@19 
 
 
2056.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
 
 
1827.9 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8  
 
898.5 
AGRPGEAGLPGAK Oxidation(P)@4; Oxidation(P)@10 
 cleaved E-A@N-
term 
1211.6 
GAAGLPGPKGDRGDAGPK Oxidation(P)@6; Oxidation(P)@17 
 missed K-G@9; 
missed R-G@12 
1651.9 
GAAGLPGPK Oxidation(P)@6  
 
782.4 
 
Group 14: Collagen alpha-1(XXVIII) chain 
 
Sequence Modifications Cleavages Prec MW 
GEPGPPGPYGSPGAPGIGQQGIK 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(Q)@20 
  2145 
 
Group 16: Cronobacter sakazakii 
 
Sequence Modifications Cleavages Prec MW 
EQLLEIGSQQLAFTHQEAR Deamidated(Q)@10; Deamidated(Q)@16   2199 
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Group 17: Methanosarcina barkeri 
 
Sequence Modifications Cleavages Prec MW 
APNRSLLKATGVTDSEMR Oxidation(M)@17 missed R-S@4; missed K-A@8 1961 
 
Group 18: Synechocystis sp. 
 
Sequence Modifications Cleavages Prec MW 
VAKAEGLTAVHHR   missed K-A@3 1387.8 
 
Group 19: Equine herpesvirus 1 
 
Sequence Modifications Cleavages Prec MW 
EAGVVNSMRGTAQNPVVTKT
ARPQPK 
Glu->pyro-Glu@N-term; 
Deamidated(N)@14 
missed R-G@9; missed K-T@19 2718.3 
 
EH156.3, P4 1st extraction, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 83.4 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  117 
2 77.7 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5  148 
3 76.9 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
93 
4 65.8 Collagen alpha-1(XIX) chain OS=Homo sapiens GN=COL19A1 PE=1 SV=3  0 
5 79.1 Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3  9 
6 79.2 Collagen alpha-6(IV) chain OS=Homo sapiens GN=COL4A6 PE=2 SV=3  1 
7 56 
Collagen, type XI, alpha 1, isoform CRA_c OS=Homo sapiens GN=COL11A1 
PE=4 SV=1  
1 
8 17.2 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  1 
9 94.1 
cDNA FLJ56576, highly similar to Collagen alpha-2(I) chain OS=Homo sapiens 
PE=2 SV=1  
14 
10 7.9 Protein argonaute-4 OS=Homo sapiens GN=AGO4 PE=1 SV=2  1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7   2055.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEAGA
AGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
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GAPGPDGNNGAQGPPGPQGVQGGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPNGPP
GPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12 
  1700.8 
GEPGNIGFPGPK 
Oxidation(P)@3; Deamidated(N)@5; 
Oxidation(P)@9 
  1201.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGVVGAVGTAGPSGPSGLPGER Oxidation(P)@3; Oxidation(P)@21   2136.0 
GESGNKGEPGSAGPQGPPGPSGEEG
K 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6 2396.1 
GESGNKGEPGSAGPQGPPGPSGEEG
KR 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2552.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANGLTG
AK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; 
Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQPGAK 
Deamidated(N)@9; 
Deamidated(Q)@20; 
Oxidation(P)@21 
  2052.0 
GEVGPAGPNGFAGPAGAAGQPGAK
GER 
Deamidated(N)@9; 
Oxidation(P)@21; Oxidation(K)@24 
missed K-G@24 2409.1 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GFPGTPGLPGFKGIR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9; Carbamyl(K)@12 
missed K-G@12 1590.8 
GHAGLAGAR     808.5 
GHNGLDGLK Deamidated(N)@3   910.5 
GHNGLDGLKGQPGAPGVK 
Deamidated(N)@3; 
Deamidated(Q)@11; 
Oxidation(P)@12; Oxidation(P)@15 
missed K-G@9 1734.9 
GHNGLQGLPGIAGHHGDQGAPGSV
GPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
GLPGLKGHNGLQGLPGIAGHHGDQ
GAPGSVGPAGPR 
Oxidation(P)@3; Oxidation(H)@8; 
Oxidation(P)@15; Oxidation(P)@27 
missed K-G@6 3397.7 
GLPGSPGNIGPAGK 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@8 
  1253.6 
GLPGVAGAVGEPGPLGIAGPPGAR 
Oxidation(P)@3; Oxidation(P)@14; 
Oxidation(P)@21 
  2114.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR Deamidated(N)@3; Oxidation(P)@9;   1766.8 
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Oxidation(P)@12 
GPNGEAGSAGPPGPPGLR 
Deamidated(N)@3; 
Oxidation(P)@12; Oxidation(P)@15 
  1619.8 
GPPGAAGAPGPQGFQGPAGEPGEPG
QTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.3 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFY 
Deamidated(Q)@6; 
Dioxidation(P)@21; 
Cation:K(D)@29; Oxidation(F)@30 
cleaved Y-R@C-term 3595.5 
GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
  3728.6 
GPSGEAGTAGPPGTPGPQGLLGAPG
ILGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAVGTA
GPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GPSGPQGIRGDKGEPGEK Oxidation(P)@15 
missed R-G@9; 
missed K-G@12 
1780.9 
GPTGDPGKNGDKGHAGLAGAR Oxidation(P)@6; Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1949.0 
GSDGSVGPVGPAGPIGSAGPPGFPG
APGPK 
Oxidation(P)@21; Oxidation(P)@24; 
Oxidation(P)@27 
  2588.2 
GSDGSVGPVGPAGPIGSAGPPGFPG
APGPKGEIGAVGNAGPAGPAGPR 
Myristoyl(K)@30 missed K-G@30 4280.1 
GVGLGPGPMGLMGPR     1391.7 
GYPGNIGPVGAAGAPGPHGPVGPA
GK 
Oxidation(P)@3; Oxidation(P)@15   2283.2 
HGNRGETGPSGPVGPAGAVGPR Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.7 
PGNIGFPGPK Oxidation(P)@1; Oxidation(P)@7 cleaved E-P@N-term 1014.5 
PGNIGPVGAAGAPGPHGPVGPAGK Oxidation(P)@1; Oxidation(H)@16 cleaved Y-P@N-term 2063.1 
PGPIGPAGAR Oxidation(P)@1 cleaved R-P@N-term 907.5 
PGPVGAAGATGAR Oxidation(P)@1 cleaved I-P@N-term 1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.6 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-term 1017.6 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 cleaved F-Q@N-term 1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; 
Oxidation(P)@13; Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.7 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1828.9 
GVVGPQGAR     839.5 
PGAPGPKGEIGAVGNAGPAGPAGPR   
cleaved F-P@N-
term; missed K-G@7 
2148.0 
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Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
AGRPGEAGLPGAK Oxidation(P)@4; Oxidation(P)@10 
cleaved E-A@N-
term 
1211.7 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
GAAGLPGPKGDRGDAGPK Oxidation(P)@6; Oxidation(P)@17 
missed K-G@9; 
missed R-G@12 
1651.9 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GAPGDRGEPGPPGPAGFAGPPGAD
GQPGAK 
Dioxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
GDAGAPGAPGSQGAPGLQGMPGE
R 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2213.9 
GDAGPAGPKGEPGSPGENGAPGQ
MGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIGNVGAP
GAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPGAPGPV
GPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
GEPGDAGAKGDAGPPGPAGPAGPP
GPIGNVGAPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(P)@24; Oxidation(P)@33 
missed K-G@9 3078.4 
GEPGPPGPAGAAGPAGNPGADGQP
GAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Cation:K(E)@17   1868.9 
GEPGPVGVQGPPGPAGEEGKR Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Dioxidation(P)@6; Deamidated(N)@9; 
Oxidation(P)@12; Deamidated(Q)@14 
  1743.7 
GEQGPAGSPGFQGLPGPAGPPGEA
GKPGEQGVPGDLGAPGPSGAR 
Oxidation(P)@9; Deamidated(Q)@30; 
Phospho(D)@35 
  4112.9 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPGPVGPA
GK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.7 
GFPGLPGPSGEPGKQGPSGASGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(Q)@15 
missed K-Q@14 2255.0 
GFSGLDGAK     850.4 
GFSGLQGPPGPPGSPGEQGPSGASG
PAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
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GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGPPGAPGPQGFQGPPGEPGEPG
ASGPMGPR 
Dioxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGESGPSG
PAGPTGAR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPPGFP
GAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GNDGATGAAGPPGPTGPAGPPGFP
GAVGAKGEAGPQGPR 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(K)@30 
missed K-G@30 3412.6 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9 
  1831.9 
GPPGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@21 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLPGPIGPP
GPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGPAGPKGSPGEAGRPGEAGLP
GAK 
Oxidation(P)@3; Oxidation(K)@9; 
Dioxidation(P)@18; Oxidation(P)@24 
missed K-G@9 2435.2 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.8 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 
cleaved F-P@N-
term 
1123.6 
PGPMGPSGPR Oxidation(M)@4 
cleaved V-P@N-
term 
967.5 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.6 
PGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@19 
cleaved P-P@N-
term; missed K-
N@6 
2193.1 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-
term 
1278.6 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
SGDRGETGPAGPTGPVGPVGAR 
Carboxy(D)@3; Dehydrated(T)@7; 
Dehydrated(T)@13 
missed R-G@4 1999.0 
546 
 
SGPQGPGGPPGPK Oxidation(P)@10 
cleaved P-S@N-
term 
1147.6 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
GAAGLPGPK Oxidation(P)@6   782.5 
 
Group 3: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
GAAGLPGPK Oxidation(P)@6   782.5 
GISVPGPMGPSGPR   
cleaved G-G@N-
term 
1307.7 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAKGEAGPQGPR 
Oxidation(P)@17; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@38 
missed K-G@30 3412.5 
GPPGPPGKNGDDGEAGKPGRPG
ER 
Oxidation(P)@3; Ubiquitination 
GG(K)@8; Deamidated(N)@9; 
Oxidation(P)@18 
missed K-N@8 2445.0 
GETGPAGPAGPVGPVGAR     1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
GFPGLPGPSGEPGK Oxidation(P)@12   1311.6 
GETGPAGPAGPVGPVGAR     1545.8 
SGDRGETGPAGPAGPVGPVGAR   missed R-G@4 1961.0 
AGRPGEAGLPGAK Oxidation(P)@4; Oxidation(P)@10 
cleaved E-A@N-
term 
1211.7 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GDAGPAGPKGEPGSPGENGAPG
QMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2509.1 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
GEPGPPGPAGAAGPAGNPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Cation:K(E)@17   1868.9 
GEPGPVGVQGPPGPAGEEGKR Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Dioxidation(P)@6; Deamidated(N)@9; 
Oxidation(P)@12; Deamidated(Q)@14 
  1743.7 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFSGLDGAK     850.4 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
GLPGPPGAPGPQGF Oxidation(P)@3; Oxidation(P)@6; cleaved F-Q@C- 1295.6 
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Oxidation(P)@9 term 
GLPGPPGAPGPQGFQGPPGEPGE
PGASGPMGPR 
Dioxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAKGEAGPQGPR 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(K)@30 
missed K-G@30 3412.6 
GPPGPPGKNGDDGEAGKPGRPG
ER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@21 
missed K-N@8 2347.1 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGPAGPKGSPGEAGRPGEAG
LPGAK 
Oxidation(P)@3; Oxidation(K)@9; 
Dioxidation(P)@18; Oxidation(P)@24 
missed K-G@9 2435.2 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.8 
PGPMGPSGPR Oxidation(M)@4 
cleaved V-P@N-
term 
967.5 
PGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@19 
cleaved P-P@N-
term; missed K-
N@6 
2193.1 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-
term 
1278.6 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
SGDRGETGPAGPTGPVGPVGAR 
Carboxy(D)@3; Dehydrated(T)@7; 
Dehydrated(T)@13 
missed R-G@4 1999.0 
SGPQGPGGPPGPK Oxidation(P)@10 
cleaved P-S@N-
term 
1147.6 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2056.0 
GAPGERGETGPPGPAGFAGPPG
ADGQPGAK 
Methyl(E)@5; Oxidation(P)@12; 
Dioxidation(P)@21; Deamidated(Q)@26 
missed R-G@6 2719.2 
KGEPGPAGPQGAPGPAGEEGK Oxidation(P)@4; Dehydrated(E)@18 
cleaved P-K@N-
term; missed K-
G@1 
1884.8 
DGEAGAQGPPGPAGPAGER     1689.8 
DGEAGAQGPPGPAGPAGER Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGEAGAQGPPGPAGPAGER Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
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DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Oxidation(P)@7; Oxidation(P)@12; 
Oxidation(P)@13 
  1560.8 
GAAGLPGPKGDRGDAGPK Oxidation(P)@6; Oxidation(P)@17 
missed K-G@9; 
missed R-G@12 
1651.9 
GAPGDRGEPGPPGPAGFAGPPG
ADGQPGAK 
Dioxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
GAPGDRGEPGPPGPAGFAGPPG
ADGQPGAK 
Oxidation(D)@5; Dioxidation(P)@12; 
Oxidation(P)@21; Deamidated(Q)@26 
missed R-G@6 2703.2 
GAPGDRGEPGPPGPAGFAGPPG
ADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GDAGAPGAPGSQGAPGLQGMP
GER 
Delta:H(2)C(2)@N-term; 
Carboxy(D)@2; Oxidation(P)@15; 
Oxidation(P)@21 
  2236.0 
GDAGAPGAPGSQGAPGLQGMP
GER 
Oxidation(P)@6; Oxidation(P)@9; 
Deamidated(Q)@18; 
Dioxidation(M)@20 
  2198.9 
GDAGAPGAPGSQGAPGLQGMP
GER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2213.9 
GDAGAPGAPGSQGAPGLQGMP
GER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPPGPAGPAGPPGPIGNVG
APGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIGNVG
APGAK 
Cation:Na(D)@2; Oxidation(P)@8; 
Oxidation(P)@15; Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIGNVG
APGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDAGPPGPAGPAGPPGPIGNVG
APGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
GDRGETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
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GDRGETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GDRGETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEPGDAGAKGDAGPPGPAGPAG
PPGPIGNVGAPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(P)@24; Oxidation(P)@33 
missed K-G@9 3078.4 
GEPGPPGPAGFAGPPGADGQPG
AK 
Dioxidation(P)@6; Oxidation(P)@15; 
Deamidated(Q)@20; Oxidation(P)@21 
  2149.9 
GEPGPPGPAGFAGPPGADGQPG
AK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPPGPAGFAGPPGADGQPG
AK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADGQPG
AK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Oxidation(P)@21 
  2149.0 
GEQGPAGSPGFQGLPGPAGPPGE
AGKPGEQGVPGDLGAPGPSGAR 
Oxidation(P)@9; Deamidated(Q)@30; 
Phospho(D)@35 
  4112.9 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPPGAPGAPGAPGPVG
PAGK 
Oxidation(P)@9; Oxidation(P)@12   2152.0 
GETGPAGPPGAPGAPGAPGPVG
PAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGPPGAPGAPGAPGPVG
PAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
GETGPAGPPGAPGAPGAPGPVG
PAGK 
Oxidation(P)@9; Oxidation(P)@15   2152.1 
GETGPAGRPGEVGPPGPPGPAGE
K 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GETGPAGRPGEVGPPGPPGPAGE
K 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPGPAGE
K 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(K)@24 
  2231.1 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@12   1327.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@12   1327.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@8 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.7 
GFPGLPGPSGEPGKQGPSGASGE
R 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(Q)@15 
missed K-Q@14 2255.0 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Deamidated(Q)@6; Oxidation(P)@9; 
Oxidation(P)@15 
  2689.3 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@11; Oxidation(P)@12   2688.3 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15; Cation:K(E)@17 
  2742.2 
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GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQGPSGA
SGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.2 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGAR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGAR 
Oxidation(P)@11; Cation:K(D)@17 missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGAR 
Oxidation(P)@15; Cation:K(D)@17; 
Oxidation(K)@18 
missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGPIGPPGPAGAPGDKGESGP
SGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9 
  1831.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESGR Oxidation(P)@3; Oxidation(P)@9   1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPPGSAGAPGKDGLNGLPGPIGP
PGPR 
Dioxidation(K)@11; 
Deamidated(N)@15; Oxidation(P)@18; 
Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLPGPIGP
PGPR 
Dioxidation(P)@9; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLPGPIGP
PGPR 
Oxidation(P)@2; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLPGPIGP
PGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLPGPIGP
PGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@12; Oxidation(P)@15   2104.0 
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GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQGIAG
QR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.7 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.5 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 
cleaved F-P@N-
term 
1123.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.6 
PGPPGAVGPAGK Oxidation(P)@4 
cleaved V-P@N-
term 
1019.6 
SGDRGETGPAGPAGPVGPVGAR   missed R-G@4 1961.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1827.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGERGETGPPGPAGFAGPPG
ADGQPGAK 
Methyl(E)@8; Oxidation(P)@12; 
Oxidation(P)@21; Deamidated(Q)@26 
missed R-G@6 2703.2 
GEPGPPGPAGAAGPAGNPGADG Dioxidation(P)@8; Oxidation(P)@18;   2316.1 
552 
 
QPGAK Deamidated(Q)@23; Oxidation(P)@24 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.8 
GEPGPVGVQGPPGPAGEEGK Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GFPGADGVAGPK Oxidation(P)@3   1087.6 
GFPGADGVAGPK Oxidation(P)@3   1087.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@9   1257.6 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAK 
Cation:K(D)@3; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@24 
  2585.2 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAK 
Cation:Na(D)@3; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2569.2 
GNDGATGAAGPPGPTGPAGPPG
FPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
GPPGPPGKNGDDGEAGKPGRPG
ER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Dioxidation(P)@21 
missed K-N@8 2363.1 
GPPGPPGKNGDDGEAGKPGRPG
ER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.7 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.7 
GPSGPQGPGGPPGPK Oxidation(P)@2; Oxidation(P)@12   1317.7 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.5 
STGGISVPGPMGPSGPR     1552.8 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
STGGISVPGPMGPSGPR Oxidation(P)@8   1568.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Dioxidation(P)@16; Oxidation(P)@19 
  2057.0 
TGPPGPAGQDGRPGPPGPPGAR Oxidation(P)@4; Oxidation(P)@15;   2056.0 
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Oxidation(P)@16; Oxidation(P)@19 
 
Group 5: Collagen alpha-1(II) chain 
 
Sequence Modifications Cleavages 
Prec 
MW 
GAAGLPGPK Oxidation(P)@6   782.5 
GISVPGPMGPSGPR   cleaved G-G@N-term 1307.7 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK
GEAGPQGPR 
Oxidation(P)@17; 
Oxidation(P)@21; 
Oxidation(P)@24; 
Oxidation(P)@38 
missed K-G@30 3412.5 
GPPGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@3; 
Ubiquitination 
GG(K)@8; 
Deamidated(N)@9; 
Oxidation(P)@18 
missed K-N@8 2445.0 
GETGPAGPAGPVGPVGAR     1545.8 
GFPGLPGPSGEPGK Oxidation(P)@12   1311.6 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@13; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@13; 
Oxidation(P)@15 
  1561.8 
GAPGERGETGPPGPAGFAGPPGADGQPGAK 
Methyl(E)@5; 
Oxidation(P)@12; 
Dioxidation(P)@21; 
Deamidated(Q)@26 
missed R-G@6 2719.2 
KGEPGPAGPQGAPGPAGEEGK 
Oxidation(P)@4; 
Dehydrated(E)@18 
cleaved P-K@N-term; 
missed K-G@1 
1884.8 
GAPGERGETGPPGPAGFAGPPGADGQPGAK 
Methyl(E)@8; 
Oxidation(P)@12; 
Oxidation(P)@21; 
Deamidated(Q)@26 
missed R-G@6 2703.2 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@12 
  1327.7 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@12 
  1327.7 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@6 
  1327.7 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@6 
  1327.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@8 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.7 
PGLPGPSGEPGK 
Oxidation(P)@1; 
Oxidation(P)@4 
cleaved F-P@N-term 1123.6 
AGRPGEAGLPGAK Oxidation(P)@4; cleaved E-A@N-term 1211.7 
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Oxidation(P)@10 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.7 
GAAGLPGPKGDRGDAGPK 
Oxidation(P)@6; 
Oxidation(P)@17 
missed K-G@9; 
missed R-G@12 
1651.9 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.7 
GAPGDRGEPGPPGPAGFAGPPGADGQPGAK 
Dioxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@21; 
Oxidation(P)@27 
missed R-G@6 2718.2 
GDAGAPGAPGSQGAPGLQGMPGER 
Oxidation(P)@6; 
Oxidation(P)@9; 
Oxidation(P)@15; 
Dioxidation(M)@20 
  2213.9 
GDAGPAGPKGEPGSPGENGAPGQMGPR 
Oxidation(P)@12; 
Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Oxidation(P)@6; 
Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEAGRPGEAGLPGAK 
Oxidation(P)@6; 
Oxidation(P)@12 
cleaved P-G@N-term 1397.7 
GEPGDAGAKGDAGPPGPAGPAGPPGPIGNV
GAPGAK 
Oxidation(P)@3; 
Oxidation(P)@15; 
Oxidation(P)@24; 
Oxidation(P)@33 
missed K-G@9 3078.4 
GEPGPPGPAGAAGPAGNPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@18; 
Oxidation(P)@24 
  2315.0 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15; 
Deamidated(Q)@20 
  2134.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; 
Cation:K(E)@17 
  1868.9 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; 
Oxidation(P)@12 
missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Dioxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12; 
  1743.7 
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Deamidated(Q)@14 
GEQGPAGSPGFQGLPGPAGPPGEAGKPGEQ
GVPGDLGAPGPSGAR 
Oxidation(P)@9; 
Deamidated(Q)@30; 
Phospho(D)@35 
  4112.9 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; 
Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGKQGPSGASGER 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(Q)@15 
missed K-Q@14 2255.0 
GFSGLDGAK     850.4 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Cation:Na(E)@17 
  2726.2 
GISVPGPMGPSGPR Oxidation(M)@8 cleaved G-G@N-term 1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLPGPPGAPGPQGFQGPPGEPGEPGASGPMG
PR 
Dioxidation(P)@6; 
Oxidation(P)@9; 
Oxidation(P)@21; 
Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK 
Oxidation(P)@9; 
Oxidation(P)@15 
  1589.8 
GLTGPIGPPGPAGAPGDKGESGPSGPAGPTG
AR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK
GEAGPQGPR 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24; 
Oxidation(K)@30 
missed K-G@30 3412.6 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@9 
  1831.9 
GPPGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@21 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@3; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2454.2 
556 
 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK 
Oxidation(M)@6; 
Oxidation(P)@9 
  1176.6 
GSAGPPGATGFPGAAGR 
Oxidation(P)@6; 
Oxidation(P)@12 
  1458.7 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGPAGPKGSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; 
Oxidation(K)@9; 
Dioxidation(P)@18; 
Oxidation(P)@24 
missed K-G@9 2435.2 
GVPGPPGAVGPAGK 
Oxidation(P)@3; 
Oxidation(P)@6 
  1191.6 
GVQGPPGPAGPR 
Deamidated(Q)@3; 
Oxidation(P)@6 
  1105.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPMGPSGPR Oxidation(M)@4 cleaved V-P@N-term 967.5 
PGPPGAVGPAGK 
Oxidation(P)@1; 
Oxidation(P)@4 
cleaved V-P@N-term 1035.6 
PGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@1; 
Oxidation(P)@4; 
Deamidated(N)@7; 
Oxidation(P)@19 
cleaved P-P@N-term; 
missed K-N@6 
2193.1 
PGPTGLPGPPGER 
Oxidation(P)@1; 
Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-term 1278.6 
PGPVGVQGPPGPAGEEGKR 
Oxidation(P)@1; 
Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
SGDRGETGPAGPAGPVGPVGAR   missed R-G@4 1961.0 
SGDRGETGPAGPTGPVGPVGAR 
Carboxy(D)@3; 
Dehydrated(T)@7; 
Dehydrated(T)@13 
missed R-G@4 1999.0 
SGPQGPGGPPGPK Oxidation(P)@10 cleaved P-S@N-term 1147.6 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@18; 
Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Deamidated(N)@9; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1812.9 
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DGEAGAQGPPGPAGPAGER     1689.8 
DGEAGAQGPPGPAGPAGER 
Cation:K(E)@3; 
Oxidation(P)@10 
  1743.7 
DGEAGAQGPPGPAGPAGER 
Deamidated(Q)@7; 
Oxidation(P)@10 
  1706.8 
DGEAGAQGPPGPAGPAGER Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; 
Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Oxidation(P)@7; 
Oxidation(P)@12; 
  1560.8 
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Oxidation(P)@13 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; 
Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(D)@5; 
Dioxidation(P)@12; 
Oxidation(P)@21; 
Deamidated(Q)@26 
missed R-G@6 2703.2 
GAPGDRGEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(D)@5; 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@21 
missed R-G@6 2702.2 
GDAGAPGAPGSQGAPGLQGMPGER 
Delta:H(2)C(2)@N-
term; Carboxy(D)@2; 
Oxidation(P)@15; 
Oxidation(P)@21 
  2236.0 
GDAGAPGAPGSQGAPGLQGMPGER 
Oxidation(P)@6; 
Oxidation(P)@9; 
Deamidated(Q)@18; 
Dioxidation(M)@20 
  2198.9 
GDAGAPGAPGSQGAPGLQGMPGER 
Oxidation(P)@6; 
Oxidation(P)@9; 
Oxidation(P)@15; 
Oxidation(P)@21 
  2198.0 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Cation:K(D)@2; 
Oxidation(P)@11; 
Oxidation(P)@15; 
Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Cation:Na(D)@2; 
Oxidation(P)@8; 
Oxidation(P)@15; 
Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIGNVGAPGAK 
Oxidation(P)@6; 
Oxidation(P)@15; 
Deamidated(N)@20; 
Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@18; 
Oxidation(P)@21 
missed R-G@3 2512.2 
GDRGETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@12; 
Oxidation(P)@15; 
Oxidation(P)@18; 
missed R-G@3 2512.2 
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Oxidation(P)@21 
GDRGETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@12; 
Oxidation(P)@18 
missed R-G@3 2480.2 
GEPGPPGPAGAAGPAGNPGADGQPGAK 
Dioxidation(P)@8; 
Oxidation(P)@18; 
Deamidated(Q)@23; 
Oxidation(P)@24 
  2316.1 
GEPGPPGPAGFAGPPGADGQPGAK 
Dioxidation(P)@6; 
Oxidation(P)@15; 
Deamidated(Q)@20; 
Oxidation(P)@21 
  2149.9 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPPGPAGFAGPPGADGQPGAK 
Oxidation(P)@3; 
Oxidation(P)@6; 
Oxidation(P)@15; 
Oxidation(P)@21 
  2149.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; 
Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.8 
GEPGPVGVQGPPGPAGEEGK 
Oxidation(P)@3; 
Oxidation(P)@12 
  1846.8 
GEPGPVGVQGPPGPAGEEGKR 
Oxidation(P)@3; 
Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12 
  1742.7 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@12 
  2152.0 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
GETGPAGPPGAPGAPGAPGPVGPAGK 
Oxidation(P)@9; 
Oxidation(P)@15 
  2152.1 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; 
Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GETGPAGRPGEVGPPGPPGPAGEK 
Oxidation(P)@9; 
Oxidation(P)@15; 
Oxidation(P)@18; 
Oxidation(K)@24 
  2231.1 
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GFPGADGVAGPK Oxidation(P)@3   1087.6 
GFPGADGVAGPK Oxidation(P)@3   1087.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Deamidated(Q)@6; 
Oxidation(P)@9; 
Oxidation(P)@15 
  2689.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@11; 
Oxidation(P)@12 
  2688.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@11; 
Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@11; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Cation:K(E)@17 
  2742.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Cation:Na(E)@17 
  2710.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQGPSGASGPAGPR 
Oxidation(P)@9; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Deamidated(Q)@18 
  2705.2 
GLTGPIGPPGPAGAPGDKGESGPSGPAGPTG
AR 
Oxidation(P)@11; 
Cation:K(D)@17 
missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKGESGPSGPAGPTG
AR 
Oxidation(P)@15; 
Cation:K(D)@17; 
Oxidation(K)@18 
missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKGESGPSGPAGPTG
AR 
Oxidation(P)@9; 
Oxidation(P)@15 
missed K-G@18 2868.4 
GLTGPIGPPGPAGAPGDKGESGPSGPAGPTG
AR 
Oxidation(P)@9; 
Oxidation(P)@15 
missed K-G@18 2868.4 
GLTGSPGSPGPDGK 
Oxidation(P)@6; 
Oxidation(P)@9 
  1257.6 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK 
Cation:K(D)@3; 
Oxidation(P)@12; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2585.2 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK 
Cation:Na(D)@3; 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2569.2 
GNDGATGAAGPPGPTGPAGPPGFPGAVGAK 
Deamidated(N)@2; 
Oxidation(P)@14; 
Oxidation(P)@21; 
Oxidation(P)@24 
  2548.2 
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GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6 
  1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(M)@6; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(P)@15 
  1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(P)@9 
  1815.9 
GPPGPMGPPGLAGPPGESGR 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPPGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(N)@9; 
Dioxidation(P)@21 
missed K-N@8 2363.1 
GPPGPPGKNGDDGEAGKPGRPGER 
Oxidation(P)@3; 
Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Dioxidation(K)@11; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Dioxidation(P)@9; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@2; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLPGPIGPPGPR 
Oxidation(P)@3; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK 
Deamidated(Q)@6; 
Oxidation(P)@12 
  1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.7 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.7 
GPSGPQGPGGPPGPK 
Oxidation(P)@2; 
Oxidation(P)@12 
  1317.7 
GPSGPQGPGGPPGPK 
Oxidation(P)@8; 
Oxidation(P)@12 
  1317.6 
GPSGPQGPGGPPGPK 
Oxidation(P)@8; 
Oxidation(P)@12 
  1317.6 
GQAGVMGFPGPK 
Deamidated(Q)@2; 
Oxidation(M)@6 
  1161.6 
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GQAGVMGFPGPK 
Oxidation(M)@6; 
Oxidation(P)@9 
  1176.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSAGPPGATGFPGAAGR 
Oxidation(P)@6; 
Oxidation(P)@12 
  1458.7 
GSPGADGPAGAPGTPGPQGIAGQR Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@12; 
Deamidated(Q)@23 
  2089.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@12; 
Oxidation(P)@15 
  2104.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12 
  2104.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQGIAGQR 
Oxidation(P)@3; 
Oxidation(P)@12; 
Oxidation(P)@15; 
Deamidated(Q)@23 
  2121.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; 
Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVPGPPGAVGPAGK 
Oxidation(P)@3; 
Oxidation(P)@6 
  1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.7 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.5 
GVVGLPGQR 
Oxidation(P)@6; 
Deamidated(Q)@8 
  898.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.5 
PGPPGAVGPAGK 
Oxidation(P)@1; 
Oxidation(P)@4 
cleaved V-P@N-term 1035.6 
PGPPGAVGPAGK Oxidation(P)@4 cleaved V-P@N-term 1019.6 
SGDRGETGPAGPAGPVGPVGAR   missed R-G@4 1961.0 
STGGISVPGPMGPSGPR     1552.8 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
STGGISVPGPMGPSGPR Oxidation(P)@8   1568.8 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Deamidated(Q)@9; 
Dioxidation(P)@16; 
Oxidation(P)@19 
  2057.0 
TGPPGPAGQDGRPGPPGPPGAR 
Oxidation(P)@4; 
Oxidation(P)@15; 
Oxidation(P)@16; 
Oxidation(P)@19 
  2056.0 
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VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@3; 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1827.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Deamidated(N)@9; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPAGK 
Oxidation(P)@4; 
Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
 
Group 6: Collagen alpha-6(IV) 
 
Sequence Modifications Cleavages Prec MW 
VGPPGDPGFPGMKGKAGPR 
Oxidation(P)@4; 
Methyl(D)@6 
missed K-G@13; missed K-A@15 1850.8 
 
Group 7: Collagen, type XI, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
EGRQGEKGAKGE
AGAEGP 
Deamidated(R)@3 
cleaved A-E@N-term; cleaved P-P@C-term; missed 
R-Q@3; missed K-G@7; missed K-G@10 
1727.7 
 
Group 9: cDNA FLJ56576, highly similar to Collagen alpha-2(I) 
 
Sequence Modifications Cleavages Prec MW 
TGIGAPRTRNT   cleaved T-S@C-term; missed R-T@7; missed R-N@9 1142.6 
 
Group 10: Protein argonaute-4 
 
Sequence Modifications Cleavages Prec MW 
RPGLGTVGKPIR Deamidated(R)@1; Oxidation(P)@2   1266.6 
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EH156.3, P4 2nd extraction, Swiss-Prot database 
 
N SC Name 
Peptides 
(95%) 
1 78.8 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 122 
2 72.3 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 123 
3 70.5 Collagen alpha-1(I) chain OS=Rattus norvegicus GN=Col1a1 PE=1 SV=5 68 
4 8.7 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 4 
5 19.9 Trypsin OS=Sus scrofa PE=1 SV=1 6 
6 71.3 Collagen alpha-2(I) chain OS=Bos taurus GN=COL1A2 PE=1 SV=2 41 
7 58.2 Collagen alpha-1(I) chain OS=Cynops pyrrhogaster GN=COL1A1 PE=2 SV=1 6 
8 68.7 Collagen alpha-1(I) chain OS=Gallus gallus GN=COL1A1 PE=1 SV=3 42 
9 71.2 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 35 
10 46.2 Collagen alpha-2(IV) chain OS=Caenorhabditis elegans GN=let-2 PE=1 SV=2 1 
11 71.7 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 44 
12 94.3 Collagen alpha-1(I) chain OS=Mammut americanum GN=COL1A1 PE=1 SV=4 69 
13 80.9 Collagen alpha-2(I) chain OS=Mammut americanum PE=1 SV=3 40 
14 65.4 Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3 5 
15 7.2 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 1 
16 5.2 
Imidazoleglycerol-phosphate dehydratase OS=Trichodesmium erythraeum 
(strain IMS101) GN=hisB PE=3 SV=1 
1 
17 7.9 
30S ribosomal protein S3Ae OS=Halorubrum lacusprofundi (strain ATCC 49239 
/ DSM 5036 / JCM 8891 / ACAM 34) GN=rps3ae PE=3 SV=1 
1 
18 3.3 
Inward rectifier potassium channel 2 OS=Canis familiaris GN=KCNJ2 PE=2 
SV=1 
1 
19 6 
Receptor tyrosine-protein kinase erbB-3 OS=Mus musculus GN=Erbb3 PE=1 
SV=2 
1 
20 63.1 Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=1 SV=3 32 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@13   2071.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEA
GAAGPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQ
GGK 
Oxidation(P)@3; Cation:K(D)@6; 
Deamidated(N)@9; Oxidation(P)@15 
  2183.9 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPN Deamidated(N)@3;   2568.2 
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GPPGPAGSR Deamidated(N)@21; 
Oxidation(P)@24 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK 
Oxidation(P)@3; Deamidated(N)@5; 
Oxidation(P)@9 
  1201.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGSAGPQGPPGPSGEEGKR Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 1978.9 
GEPGVVGAVGTAGPSGPSGLPG
ER 
Oxidation(P)@3; Oxidation(P)@21   2136.0 
GEQGPPGPPGFQGLPGPSGPAG
EVGKPGER 
Formyl@N-term; Oxidation(P)@17; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPSG
EEGK 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6 2396.1 
GESGNKGEPGSAGPQGPPGPSG
EEGKR 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2552.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANG
LTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; 
Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQP
GAK 
Deamidated(N)@9; 
Deamidated(Q)@20; 
Oxidation(P)@21 
  2052.0 
GFPGTPGLPGFK Oxidation(P)@3; Oxidation(P)@9   1205.6 
GHAGLAGAR     808.4 
GHNGLQGLPGIAGHHGDQGAP
GSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.6 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
GLPGSPGNIGPAGK 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@8 
  1253.6 
GLPGVAGAVGEPGPLGIAGPPG
AR 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@14; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1766.8 
GPNGEAGSAGPPGPPGLR Oxidation(P)@12; Oxidation(P)@15   1618.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@9; Deamidated(N)@12; 
Oxidation(P)@15 
  1735.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.8 
GPQGHQGPAGPPGPPGPPGPPG
VSGGGYDFGYDGDFY 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@20; Oxidation(P)@21 
cleaved Y-R@C-term 3572.6 
GPQGHQGPAGPPGPPGPPGPPG
VSGGGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@20; Oxidation(P)@21 
  3728.6 
GPSGEAGTAGPPGTPGPQGLLG
APGILGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.6 
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GPSGPQGIR     867.5 
GPTGDPGKNGDKGHAGLAGAR Oxidation(P)@6; Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1948.9 
GSDGSVGPVGPAGPIGSAGPPG
FPGAPGPK 
Oxidation(P)@20; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@27 
  2604.3 
GVGLGPGPMGLMGPR Oxidation(M)@9   1410.7 
GVVGPQGAR     839.5 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Oxidation(P)@3; Deamidated(N)@5; 
Oxidation(H)@18 
  2284.1 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.7 
PGNIGFPGPK Oxidation(P)@1; Oxidation(P)@7 cleaved E-P@N-term 1014.5 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGPVGAAGATGAR Oxidation(P)@1 cleaved I-P@N-term 1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-term 1017.5 
PGVAGAVGEPGPLGIAGPPGAR 
Oxidation(P)@1; Cation:K(E)@9; 
Oxidation(P)@19 
cleaved L-P@N-term 1966.0 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 cleaved F-Q@N-term 1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.8 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
GAPGPDGNNGAQGP 
Deamidated(N)@8; 
Deamidated(N)@9 
cleaved P-P@C-term 1209.5 
PGAPGPKGEIGAVGNAGPAGPA
GPR 
  
cleaved F-P@N-
term; missed K-G@7 
2147.6 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGER Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAG
PPGADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPPGPAGPAGPPGPIGN
VGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
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GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1741.7 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGPTGPVGPVGAR 
Formyl@N-term; Dehydrated(T)@3; 
Dehydrated(T)@9 
  1567.8 
GETGPAGRPGEVGPPGPPGP
AGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQGP
SGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GISVPGPMGPSGPR Oxidation(M)@8 cleaved G-G@N-term 1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKGE
SGPSGPAGPTGAR 
Oxidation(P)@9 missed K-G@18 2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPAG
PPGFPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGPPGKNGDDGEAGKPG
RPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.5 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
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PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEQGPSGASGPAGPR Oxidation(P)@1 cleaved S-P@N-term 1436.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 cleaved F-P@N-term 1123.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-term 1278.6 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
QGPPGEPGEPGASGPMGPR 
Oxidation(P)@4; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(M)@16 
cleaved F-Q@N-term 1837.8 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
SGDRGETGPAGPTGPVGPV
GAR 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
missed R-G@4 1998.9 
 
Group 14: Collagen alpha-1(II) chain 
 
Sequence Modifications Cleavages Prec MW 
TGPPGPAGQDGRPGPAGPP
GAR 
Oxidation(P)@4; Carbamyl(R)@12; 
Oxidation(P)@18; Oxidation(P)@19 
  2057.0 
DGLNGLPGPIGPPGPR Oxidation(P)@7; Oxidation(P)@15   1544.8 
GPSGPQGPGGPPGPK Oxidation(P)@12; Cation:K@C-term   1339.6 
GFSGLDGAK     850.4 
GFSGLDGAK     850.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15; Cation:K(E)@17 
  2742.2 
SGDRGETGPAGPTGPVGPV
GAR 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
missed R-G@4 1998.9 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Cation:K(D)@3; Oxidation(P)@20; 
Oxidation(P)@21; Oxidation(P)@24 
  2585.2 
GEAGPQGARGSEGPQGVR 
Oxidation(P)@5; Deamidated(Q)@6; 
Oxidation(P)@14; Deamidated(Q)@15 
missed R-G@9 1742.7 
PGERGAAGLPGAK Oxidation(P)@1; Oxidation(P)@10 
cleaved M-P@N-term; 
missed R-G@4 
1211.6 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GAPGERGETGPPGPAGFAG
PPGADGQPGAK 
Pro->pyro-Glu(P)@3; 
Oxidation(P)@12; Oxidation(P)@21; 
Deamidated(Q)@26 
missed R-G@6 2703.2 
GFPGLPGPSGEPGK Oxidation(P)@3   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.7 
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GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 cleaved F-P@N-term 1123.6 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
GEPGPAGVQGPPGPAGEE
GK 
Carbamyl@N-term; Oxidation(P)@12   1845.9 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1741.7 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPIGPAGAR Pro->pyro-Glu(P)@14   1545.7 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGPTGPVGPVGAR 
Formyl@N-term; Dehydrated(T)@3; 
Dehydrated(T)@9 
  1567.8 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GISVPGPMGPSGPR Oxidation(M)@8 cleaved G-G@N-term 1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9 missed K-G@18 2852.4 
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GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGSPGKDGLNGLPG
PIGPPGPR 
Deamidated(N)@15; Oxidation(P)@18; 
Oxidation(P)@23; Oxidation(P)@24 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.5 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEQGPSGASGPAGPR Oxidation(P)@1 cleaved S-P@N-term 1436.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-term 1278.6 
PGPVGVQGPPGPAGEEGK
R 
Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
QGPPGEPGEPGASGPMGPR 
Oxidation(P)@4; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(M)@16 
cleaved F-Q@N-term 1837.8 
SGDRGETGPAGPAGPAGP
AGVR 
Pro->pyro-Glu(P)@15; Pro->pyro-
Glu(P)@18 
missed R-G@4 1961.0 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
DGEAGAQGPPGPAGPAGE
R 
    1689.8 
DGEAGAQGPPGPAGPAGE
R 
Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
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DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@15; 
Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@15; Cation:K(D)@18 
  2170.9 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.9 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12; 
Cation:Na(E)@17 
  1868.9 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
572 
 
GETGPAGPAGPIGPAGAR Pro->pyro-Glu(P)@14   1545.8 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.1 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@18   2152.1 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@5; Oxidation(P)@15; 
Oxidation(P)@17 
  2215.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@20 
  2231.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Cation:K(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15; 
Cation:Na(E)@17 
  2710.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15; 
Deamidated(Q)@18 
  2689.3 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Cation:K(D)@17 
missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Cation:Na(E)@20 
missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Lys->Allysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Lys->Allysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@11; 
Oxidation(P)@15 
missed K-G@18 2884.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@9   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9 
  1831.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.9 
GPPGPMGPPGLAGPPGESG Oxidation(P)@3; Oxidation(P)@15   1815.9 
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R 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9   1815.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@21 
missed K-N@8 2347.1 
GPPGSAGSPGKDGLNGLPG
PIGPPGPR 
Deamidated(N)@15; Oxidation(P)@18; 
Oxidation(P)@23; Oxidation(P)@24 
  2454.2 
GPPGSAGSPGKDGLNGLPG
PIGPPGPR 
Deamidated(N)@15; Oxidation(P)@18; 
Oxidation(P)@23; Oxidation(P)@24 
  2454.2 
GPSGPQGPGGPPGPK Cation:K@C-term   1323.6 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Oxidation(P)@15   2104.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@18; 
Deamidated(Q)@23 
  2106.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
PGEVGPPGPPGPAGEK Oxidation(P)@1; Oxidation(P)@7; cleaved R-P@N-term 1489.7 
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Oxidation(P)@10 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@12 
cleaved R-P@N-term 1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2055.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
 
 
EH156.3, P4 2nd extraction, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 81.7 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  146 
2 77.3 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5  143 
3 20 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  4 
4 76.5 Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 SV=1  96 
5 76.3 Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3  6 
6 11.1 Protein AHNAK2 OS=Homo sapiens GN=AHNAK2 PE=1 SV=2  1 
7 14.1 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  1 
8 11.2 
cDNA, FLJ94754, highly similar to Homo sapiens potassium inwardly-rectifying channel, 
subfamily J, member 2 (KCNJ2), mRNA OS=Homo sapiens PE=2 SV=1  
1 
9 56.7 Collagen alpha-2(XI) chain OS=Homo sapiens GN=COL11A2 PE=2 SV=1  0 
10 48.4 Collagen alpha-4(IV) chain OS=Homo sapiens GN=COL4A4 PE=1 SV=3  0 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 
cleaved R-P@C-
term 
1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@13   2071.1 
ENGVVGPTGPVGAAGPAGPNGPPGP
AGSR 
Phospho(T)@8; Deamidated(N)@20; 
Oxidation(P)@25 
cleaved G-E@N-
term 
2590.2 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEAGAA
GPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQGGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@14 
  2146.0 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPNGPPG Deamidated(N)@3;   2568.2 
575 
 
PAGSR Deamidated(N)@21; 
Oxidation(P)@24 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEPGSAGPQGPPGPSGEEGKR Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 1978.9 
GEPGVVGAVGTAGPSGPSGLPGER Oxidation(P)@3; Oxidation(P)@21   2136.0 
GEQGPPGPPGFQGLPGPSGPAGEVG
KPGER 
Formyl@N-term; Oxidation(P)@17; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPSGEEG
K 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6 2396.0 
GESGNKGEPGSAGPQGPPGPSGEEG
KR 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2552.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANGLTG
AK 
Oxidation(P)@6; 
Dioxidation(P)@18; 
Deamidated(N)@21; 
Oxidation(K)@27 
  2434.2 
GEVGPAGPNGFAGPAGAAGQPGAK 
Deamidated(N)@9; 
Deamidated(Q)@20; 
Oxidation(P)@21 
  2051.9 
GEVGPAGPNGFAGPAGAAGQPGAK
GER 
Deamidated(N)@9; 
Oxidation(P)@21; Oxidation(K)@24 
missed K-G@24 2409.1 
GFPGTPGLPGFK Oxidation(P)@3; Oxidation(P)@9   1205.6 
GHAGLAGAR     808.4 
GHNGLQGLPGIAGHHGDQGAPGSV
GPAGPR 
Deamidated(N)@3; 
Deamidated(Q)@6; Oxidation(P)@9; 
Oxidation(P)@21 
  2801.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.7 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.8 
GLPGLKGHNGLQGLPGIAGHHGDQG
APGSVGPAGPR 
Dioxidation(P)@3; 
Deamidated(N)@9; 
Oxidation(H)@21; Oxidation(P)@27 
missed K-G@6 3397.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPGAR 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@14; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR Oxidation(P)@9; Oxidation(P)@12   1765.8 
GPNGEAGSAGPPGPPGLR Oxidation(P)@12; Oxidation(P)@15   1618.8 
GPPGAAGAPGPQGFQGPAGEPGEPG
QTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.3 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1735.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.7 
GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFY 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@18; Cation:K(D)@29 
cleaved Y-R@C-
term 
3594.5 
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GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@20; Oxidation(P)@21 
  3728.5 
GPSGEAGTAGPPGTPGPQGLLGAPGI
LGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAVGTAG
PSGPSGLPGER 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@33 
missed K-G@12 3212.5 
GPSGPQGIR     867.5 
GPTGDPGKNGDKGHAGLAGAR Oxidation(P)@6; Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1949.0 
GSDGSVGPVGPAGPIGSAGPPGFPGA
PGPK 
Oxidation(P)@20; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(P)@27 
  2604.3 
GSDGSVGPVGPAGPIGSAGPPGFPGA
PGPKGEIGAVGNAGPAGPAGPR 
Biotin(K)@30 missed K-G@30 4295.1 
GVGLGPGPMGLMGPR Oxidation(M)@9   1410.7 
GVVGPQGAR     839.5 
GYPGNIGPVGAAGAPGPHGPVGPAG
K 
Oxidation(P)@3; Oxidation(P)@15   2283.1 
HGNRGETGPSGPVGPAGAVGPR Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 
cleaved L-L@N-
term 
1238.7 
PGNIGFPGPK 
Oxidation(P)@1; Deamidated(N)@3; 
Oxidation(P)@7 
cleaved E-P@N-
term 
1015.5 
PGPIGPAGAR Oxidation(P)@1 
cleaved R-P@N-
term 
907.5 
PGPVGAAGATGAR Oxidation(P)@1 
cleaved I-P@N-
term 
1096.6 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved L-P@N-
term 
1082.5 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-
term 
1017.5 
PGVAGAVGEPGPLGIAGPPGAR 
Oxidation(P)@1; Cation:K(E)@9; 
Oxidation(P)@19 
cleaved L-P@N-
term 
1966.0 
QGPAGEPGEPGQTGPAGAR Oxidation(P)@7; Oxidation(P)@10 
cleaved F-Q@N-
term 
1764.8 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; 
Oxidation(P)@13; Oxidation(P)@16 
missed R-G@1 1775.8 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1828.9 
VGLPGIDGRPGPIGPAGAR 
Cation:Cu[I](D)@7; 
Oxidation(P)@10 
cleaved P-V@N-
term 
1833.9 
GFPGTPGLPGFKGIR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9; Carbamyl(K)@12 
missed K-G@12 1590.8 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
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GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Dioxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; 
Dioxidation(M)@20 
  2213.9 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Dioxidation(P)@12; 
Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2525.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; 
Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1741.7 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(R)@8; Oxidation(P)@15; 
Oxidation(P)@17 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GISVPGPMGPSGPR Oxidation(M)@8 cleaved G-G@N-term 1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
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GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; 
Deamidated(N)@15; 
Oxidation(P)@18; 
Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.6 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(K)@18 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
NGLPGPIGPPGPRGR 
Deamidated(N)@1; Oxidation(P)@4; 
Oxidation(P)@10; Oxidation(P)@12 
cleaved L-N@N-term; 
missed R-G@13 
1489.7 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEQGPSGASGPAGPR Oxidation(P)@1 cleaved S-P@N-term 1436.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 cleaved F-P@N-term 1123.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPPGKNGDDGEAGKPGR
PGER 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@16 
cleaved P-P@N-term; 
missed K-N@6 
2193.0 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-term 1278.6 
PGPVGVQGPPGPAGEEGK
R 
Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
QGPPGEPGEPGASGPMGPR 
Oxidation(P)@4; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(M)@16 
cleaved F-Q@N-term 1837.8 
QGPPGPAGPR Oxidation(P)@4 cleaved V-Q@N-term 948.5 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GFPGPKGAAGEPGK 
Oxidation(P)@3; Oxidation(P)@5; 
Carbamyl(K)@14 
cleaved M-G@N-term; 
missed K-G@6 
1343.6 
SGDRGETGPAGPTGPVGPV
GAR 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
missed R-G@4 1998.9 
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Group 4: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGEAGAQGPPGPAGPAGE
R 
    1689.8 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.7 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Dioxidation(P)@15; Deamidated(R)@16 
  1562.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Dioxidation(P)@15 
  1577.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR Deamidated(N)@4; Oxidation(P)@7;   1561.8 
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Oxidation(P)@12; Oxidation(P)@15 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Dioxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GAPGERGETGPPGPAGFAG
PPGADGQPGAK 
Methyl(E)@8; Oxidation(P)@12; 
Oxidation(P)@21; Deamidated(Q)@26 
missed R-G@6 2703.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2213.9 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2197.9 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Dioxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; Dioxidation(M)@24 
missed K-G@9 2525.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@15; 
Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 cleaved P-G@N-term 1397.7 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Dioxidation(P)@8; Oxidation(P)@18; 
Deamidated(Q)@23; Oxidation(P)@24 
  2316.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Dioxidation(P)@6; Oxidation(P)@15; 
Deamidated(Q)@20; Oxidation(P)@21 
  2149.9 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@15; Cation:K(D)@18 
  2170.9 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.8 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12; 
Cation:Na(E)@17 
  1868.9 
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GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1741.7 
GEQGPSGASGPAGPR   cleaved P-G@N-term 1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR Cation:Na(E)@2   1567.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.7 
GETGPAGPAGPVGPVGAR     1545.7 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1544.8 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@18   2152.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(K)@24 
  2231.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(R)@8; Oxidation(P)@15; 
Oxidation(P)@17 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3   1311.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Cation:K(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15; 
Deamidated(Q)@18 
  2689.2 
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GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Dioxidation(P)@15; 
Cation:K(E)@17 
  2742.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GISVPGPMGPSGPR Oxidation(M)@8 cleaved G-G@N-term 1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-term 1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Cation:Na(E)@20 
missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Carboxy(D)@17; Delta:H(2)C(2)(K)@18 missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9 missed K-G@18 2852.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(K)@18 
missed K-G@18 2884.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(K)@30 
  2563.2 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESG Oxidation(P)@3; Oxidation(M)@6;   1831.8 
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R Oxidation(P)@15 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Dioxidation(P)@21 
missed K-N@8 2363.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@21 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Dioxidation(K)@11; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2454.2 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.6 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@18; Deamidated(Q)@23 
  2106.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Oxidation(P)@15   2104.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(D)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
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GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(K)@18 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
GVVGLPGQR Oxidation(P)@6   897.5 
NGLPGPIGPPGPRGR 
Deamidated(N)@1; Oxidation(P)@4; 
Oxidation(P)@10; Oxidation(P)@12 
cleaved L-N@N-term; 
missed R-G@13 
1489.7 
PGADGVAGPK Oxidation(P)@1 cleaved F-P@N-term 883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-term 1510.8 
PGEQGPSGASGPAGPR Oxidation(P)@1 cleaved S-P@N-term 1436.7 
PGERGAAGIAGPK Oxidation(R)@4; Oxidation(P)@12 
cleaved M-P@N-term; 
missed R-G@4 
1211.6 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(K)@16 
cleaved R-P@N-term 1505.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-term 1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(K)@16 
cleaved R-P@N-term 1505.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@12 
cleaved R-P@N-term 1489.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 cleaved F-P@N-term 1123.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved V-P@N-term 1035.5 
PGPPGKNGDDGEAGKPGR
PGER 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@16 
cleaved P-P@N-term; 
missed K-N@6 
2193.0 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-term 1278.6 
PGPVGVQGPPGPAGEEGK
R 
Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-term; 
missed K-R@18 
1816.9 
QGPPGEPGEPGASGPMGPR 
Oxidation(P)@4; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(M)@16 
cleaved F-Q@N-term 1837.8 
QGPPGPAGPR Oxidation(P)@4 cleaved V-Q@N-term 948.5 
SGDRGETGPAGPAGPVGP
VGAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGP
VGAR 
  missed R-G@4 1961.0 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@15; Dioxidation(P)@19 
  2056.9 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
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TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2055.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGPKGAAGEPGK 
Oxidation(P)@3; Oxidation(P)@5; 
Carbamyl(K)@14 
cleaved M-G@N-term; 
missed K-G@6 
1343.6 
GFSGLDGAK     850.4 
SGDRGETGPAGPTGPVGPV
GAR 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
missed R-G@4 1998.9 
DGLNGLPGPIGPPGPR Oxidation(P)@7; Oxidation(P)@15   1544.8 
GFSGLDGAK     850.4 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Cation:K(D)@3; Oxidation(P)@20; 
Oxidation(P)@21; Oxidation(P)@24 
  2585.1 
GPSGPQGPGGPPGPK Oxidation(P)@12; Cation:K@C-term   1339.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Cation:Na(E)@2; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@18 
  2190.0 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Cation:Na(D)@3; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2569.2 
 
Group 5: Collagen alpha-1(II) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGEAGAQGPPGPAGPAGE
R 
    1689.8 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.7 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Dioxidation(P)@15; Deamidated(R)@16 
  1562.7 
DGLNGLPGPIGPPGPR Deamidated(N)@4; Oxidation(P)@7;   1545.8 
586 
 
Oxidation(P)@15 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Dioxidation(P)@15 
  1577.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.7 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Dioxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
GAPGDRGEPGPPGPAGFA
GPPGADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.2 
GAPGERGETGPPGPAGFAG
PPGADGQPGAK 
Methyl(E)@8; Oxidation(P)@12; 
Oxidation(P)@21; Deamidated(Q)@26 
missed R-G@6 2703.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2197.9 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2213.9 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Dioxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; Dioxidation(M)@24 
missed K-G@9 2525.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@15; 
Oxidation(P)@24 
  2302.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
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GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GDRGETGPAGPPGAPGAP
GAPGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Dioxidation(P)@8; Oxidation(P)@18; 
Deamidated(Q)@23; Oxidation(P)@24 
  2316.0 
GEPGPPGPAGAAGPAGNP
GADGQPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@15; Cation:K(D)@18 
  2170.9 
GEPGPPGPAGFAGPPGADG
QPGAK 
Dioxidation(P)@6; Oxidation(P)@15; 
Deamidated(Q)@20; Oxidation(P)@21 
  2149.9 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12; 
Cation:Na(E)@17 
  1868.9 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Oxidation(P)@12   1846.8 
GEPGPVGVQGPPGPAGEE
GK 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
  1847.8 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGPVGVQGPPGPAGEE
GKR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1741.7 
GEQGPSGASGPAGPR   
cleaved P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1544.8 
GETGPAGPAGPVGPVGAR Cation:Na(E)@2   1567.8 
GETGPAGPAGPVGPVGAR     1545.7 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.7 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@18   2152.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(R)@8; Oxidation(P)@15; 
Oxidation(P)@17 
  2215.0 
GETGPAGRPGEVGPPGPPG Oxidation(P)@9; Oxidation(P)@15;   2215.1 
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PAGEK Oxidation(P)@18 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(K)@24 
  2231.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Cation:K(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15; 
Deamidated(Q)@18 
  2689.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Dioxidation(P)@15; 
Cation:K(E)@17 
  2742.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.2 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Carboxy(D)@17; Delta:H(2)C(2)(K)@18 missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(K)@18 
missed K-G@18 2884.4 
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GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@9 missed K-G@18 2852.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15; 
Cation:Na(E)@20 
missed K-G@18 2890.4 
GLTGSPGSPGPDGK Oxidation(P)@6   1241.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Deamidated(N)@2; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2548.2 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24; Oxidation(K)@30 
  2563.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Dioxidation(P)@21 
missed K-N@8 2363.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@21 
missed K-N@8 2347.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Dioxidation(K)@11; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@24 
  2454.2 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
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GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GQAGVMGFPGPK Oxidation(P)@9   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(D)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@18; Deamidated(Q)@23 
  2106.0 
GSPGADGPAGAPGTPGPQ
GIAGQR 
Oxidation(P)@12; Oxidation(P)@15   2104.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@15; 
Oxidation(K)@18 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
GVVGLPGQR Oxidation(P)@6   897.5 
NGLPGPIGPPGPRGR 
Deamidated(N)@1; Oxidation(P)@4; 
Oxidation(P)@10; Oxidation(P)@12 
cleaved L-N@N-
term; missed R-
G@13 
1489.7 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.5 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.8 
PGEQGPSGASGPAGPR Oxidation(P)@1 
cleaved S-P@N-
term 
1436.7 
PGERGAAGIAGPK Oxidation(R)@4; Oxidation(P)@12 
cleaved M-P@N-
term; missed R-
G@4 
1211.6 
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PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(K)@16 
cleaved R-P@N-
term 
1505.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@12 
cleaved R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(K)@16 
cleaved R-P@N-
term 
1505.7 
PGLPGPSGEPGK Oxidation(P)@1; Oxidation(P)@4 
cleaved F-P@N-
term 
1123.6 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.5 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.5 
PGPPGKNGDDGEAGKPGR
PGER 
Oxidation(P)@1; Oxidation(P)@4; 
Deamidated(N)@7; Oxidation(P)@16 
cleaved P-P@N-
term; missed K-
N@6 
2193.0 
PGPTGLPGPPGER 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved E-P@N-
term 
1278.6 
PGPVGVQGPPGPAGEEGK
R 
Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
QGPPGEPGEPGASGPMGPR 
Oxidation(P)@4; Oxidation(P)@7; 
Oxidation(P)@10; Oxidation(M)@16 
cleaved F-Q@N-
term 
1837.8 
QGPPGPAGPR Oxidation(P)@4 
cleaved V-Q@N-
term 
948.5 
SGDRGETGPAGPAGPVGP
VGAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGP
VGAR 
  missed R-G@4 1961.0 
STGGISVPGPMGPSGPR     1552.8 
STGGISVPGPMGPSGPR Oxidation(M)@11   1568.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@18; Oxidation(P)@19 
  2055.9 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@15; Dioxidation(P)@19 
  2056.9 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGPKGAAGEPGK 
Oxidation(P)@3; Oxidation(P)@5; 
Carbamyl(K)@14 
cleaved M-G@N-
term; missed K-
G@6 
1343.6 
GFSGLDGAK     850.4 
SGDRGETGPAGPTGPVGPV
GAR 
Delta:H(2)C(2)@N-term; 
Dehydrated(T)@13 
missed R-G@4 1998.9 
DGLNGLPGPIGPPGPR Oxidation(P)@7; Oxidation(P)@15   1544.8 
GFSGLDGAK     850.4 
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GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Cation:K(D)@3; Oxidation(P)@20; 
Oxidation(P)@21; Oxidation(P)@24 
  2585.1 
GPSGPQGPGGPPGPK Oxidation(P)@12; Cation:K@C-term   1339.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Cation:Na(E)@2; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@18 
  2190.0 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Cation:Na(D)@3; Oxidation(P)@14; 
Oxidation(P)@21; Oxidation(P)@24 
  2569.2 
 
Group 6: Protein AHNAK2 
 
Sequence Modifications Cleavages Prec MW 
GLQEDAPGRQGS
AGR 
Deamidated(Q)@10; 
Dehydrated(S)@12 
cleaved F-G@N-term; missed R-Q@9 1480.7 
 
Group 8: cDNA, FLJ94754, highly similar to Homo sapiens potassium inwardly-
rectifying channel 
 
Sequence Modifications Cleavages Prec MW 
LATMAVANGFGNGK     1349.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
593 
 
EH156.3, P4 3rd extraction, Swiss-Prot database 
 
N SC Name 
Peptides 
(95%) 
1 78.3 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 94 
2 68.4 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 104 
3 16.6 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 7 
4 18.7 Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=4 6 
5 37.2 Trypsin OS=Sus scrofa PE=1 SV=1 9 
6 20.1 Biglycan OS=Homo sapiens GN=BGN PE=1 SV=2 3 
7 12.6 Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 3 
8 68.2 Collagen alpha-2(I) chain OS=Canis familiaris GN=COL1A2 PE=2 SV=2 30 
9 9.4 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 2 
10 58.8 Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3 5 
11 24.3 Matrix Gla protein OS=Sus scrofa GN=MGP PE=2 SV=1 2 
12 64.1 Collagen alpha-1(I) chain OS=Rattus norvegicus GN=Col1a1 PE=1 SV=5 58 
13 19.8 Chondroadherin OS=Homo sapiens GN=CHAD PE=2 SV=2 4 
14 12.5 Prothrombin OS=Pongo abelii GN=F2 PE=2 SV=1 2 
15 81 Collagen alpha-1(I) chain OS=Mammut americanum GN=COL1A1 PE=1 SV=4 60 
16 9.6 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 1 
17 16.9 Dermatopontin OS=Mus musculus GN=Dpt PE=2 SV=1 1 
18 64.6 Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=2 SV=2 28 
19 14.4 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 1 
20 11.9 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 1 
21 59 Collagen alpha-1(I) chain OS=Gallus gallus GN=COL1A1 PE=1 SV=3 39 
22 4.3 Osteomodulin OS=Homo sapiens GN=OMD PE=1 SV=1 1 
23 68.8 Collagen alpha-2(I) chain OS=Bos taurus GN=COL1A2 PE=1 SV=2 31 
24 75.5 Collagen alpha-2(I) chain OS=Mammut americanum PE=1 SV=3 29 
25 10.1 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 3 
26 10.9 Lumican OS=Homo sapiens GN=LUM PE=1 SV=2 1 
27 13.8 Keratin, type I cytoskeletal 17 OS=Bos taurus GN=KRT17 PE=2 SV=1 1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPI 
Oxidation(P)@7; Dehydrated(D)@10; 
Oxidation(P)@13 
cleaved I-G@C-term 1543.8 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7   2055.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGE Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
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AGAAGPAGPAGPR 
GAPGPDGNNGAQGPPGPQGV
QGGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GAPGPHGPVGPAGK Oxidation(P)@3 
cleaved A-G@N-
term 
1213.6 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
GEAGAAGPAGPAGPR     1234.5 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGP
NGPPGPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; Oxidation(P)@24 
  2568.2 
GEPGAPGENGTPGQTGAR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1700.7 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEQGPPGPPGFQGLPGPSGPA
GEVGKPGER 
Pro->pyro-Glu(P)@8; Pro->pyro-
Glu(P)@9; Oxidation(P)@20; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPS
GEEGK 
Oxidation(P)@9; Oxidation(P)@18 missed K-G@6 2395.1 
GESGNKGEPGSAGPQGPPGPS
GEEGKR 
Oxidation(P)@9; Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2551.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGAN
GLTGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQ
PGAK 
Deamidated(N)@9; 
Deamidated(Q)@20; Oxidation(P)@21 
  2052.0 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GHNGLQGLPGIAGHHGDQGA
PGSVGPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.4 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.6 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGLKGHNGLQGLPGIAGHH
GDQGAPGSVGPAGPR 
Oxidation(P)@3; Oxidation(H)@8; 
Oxidation(P)@15; Oxidation(P)@27 
missed K-G@6 3396.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPP
GAR 
Oxidation(P)@3; Cation:Na(E)@11; 
Oxidation(P)@12; Oxidation(P)@21 
  2136.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1766.8 
GPNGEAGSAGPPGPPGLR Oxidation(P)@12; Oxidation(P)@15   1618.8 
GPPGAAGAPGPQGFQGPAGEP
GEPGQTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@3; Oxidation(P)@9; 
Deamidated(N)@12; Oxidation(P)@15 
  1751.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.7 
GPQGHQGPAGPPGPPGPPGPP
GVSGGGYDFGYDGDFY 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@18; Oxidation(P)@20 
cleaved Y-R@C-term 3572.5 
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GPQGHQGPAGPPGPPGPPGPP
GVSGGGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@17; Oxidation(P)@21 
  3728.6 
GPSGEAGTAGPPGTPGPQGLL
GAPGILGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAV
GTAGPSGPSGLPGER 
Oxidation(P)@8; Oxidation(P)@15 missed K-G@12 3196.6 
GPTGDPGKNGDKGHAGLAGA
R 
Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1932.9 
GSDGSVGPVGPAGPIGSAGPP
GFPGAPGPK 
Oxidation(P)@21; Oxidation(P)@27   2572.2 
GVGLGPGPMGLMGPR Oxidation(M)@9   1410.7 
GYPGNIGPVGAAGAPGPHGPV
GPAGK 
Oxidation(P)@3; Oxidation(P)@15   2283.1 
HGNRGETGPSGPVGPAGAVGP
R 
Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.6 
PGAPGPKGEIGAVGNAGPAGP
AGPR 
  
cleaved F-P@N-
term; missed K-G@7 
2148.1 
PGNIGFPGPK Oxidation(P)@1; Oxidation(P)@7 cleaved E-P@N-term 1014.5 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-term 1017.5 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; Oxidation(P)@13; 
Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
GHNGLDGLK Deamidated(N)@3   910.4 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAG
PPGADGQPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.3 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPG Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
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APGPVGPAGK 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-
G@N-term 
1397.7 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-
R@20 
2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEQGPSGASGPAGPR   
cleaved P-
G@N-term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.1 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-
Q@C-term 
1295.6 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11 
missed K-
G@18 
2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@11   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
PGADGVAGPK Oxidation(P)@1 
cleaved F-
P@N-term 
883.4 
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PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-
P@N-term 
1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-
P@N-term 
1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-
P@N-term 
1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-
P@N-term; 
missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
 
Group 4: Pigment epithelium-derived factor 
 
Sequence Modifications Cleavages Prec MW 
DTDTGALLFIGK 
  
1249.6 
LAAAVSNFGYDLYR Deamidated(N)@7 
 
1559.8 
TSLEDFYLDEER 
  
1515.7 
TVQAVLTVPK 
  
1054.6 
DTDTGALLFIGK 
  
1249.7 
DTDTGALLFIGK Cation:Na(D)@3 
 
1271.6 
LAAAVSNFGYDLYR 
  
1560.8 
 
Group 6: Biglycan 
 
Sequence Modifications Cleavages Prec MW 
LGLGHNQIR Deamidated(N)@6   1007.6 
PVPYWEVQPATFR   cleaved N-P@N-term 1588.8 
VPSGLPDLK     924.5 
VPSGLPDLK     924.5 
VPSGLPDLK     924.5 
 
Group 7: Vitronectin 
 
Conf Sequence Modifications Cleavages Prec MW 
99 DVWGIEGPIDAAFTR     1645.8 
99 FEDGVLDPDYPR     1421.6 
99 RVDTVDPPYPR   missed R-V@1 1313.7 
99 FEDGVLDPDYPR     1421.7 
99 FEDGVLDPDYPR     1421.6 
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Group 10: Collagen alpha-1(II) chain 
 
Sequence Modifications Cleavages Prec MW 
GAPGERGETGPPGPAGFAGPP
GADGQPGAK 
Pro->pyro-Glu(P)@3; Oxidation(P)@12; 
Oxidation(P)@21; Oxidation(P)@27 
missed R-G@6 2718.2 
 
Group 13: Chondroadherin 
 
Sequence Modifications Cleavages Prec MW 
FSDGAFLGVTTLK     1350.7 
SIPDNAFQSFGR Deamidated(N)@5   1338.6 
FSDGAFLGVTTLK     1354.7 
FSDGAFLGVTTLK     1354.7 
FSDGAFLGVTTLK     1354.7 
SIPDNAFQSFGR Deamidated(N)@5; Deamidated(Q)@8   1339.6 
SIPDNAFQSFGR Deamidated(Q)@8   1338.6 
 
Group 19: Alpha-2-HS-glycoprotein 
 
Sequence Modifications Cleavages Prec MW 
HTLNQIDEVK Deamidated(N)@4   1196.6 
HTLNQIDEVK Deamidated(N)@4   1196.6 
 
Group 22: Osteomodulin 
 
Sequence Modifications Cleavages Prec MW 
LLLGYNEISK Deamidated(N)@6   1149.629 
LLLGYNEISK Deamidated(N)@6   1149.636 
 
Group 26: Lumican 
 
Sequence Modifications Cleavages Prec MW 
FNALQYLR Deamidated(N)@2   1024.5 
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EH156.2, P4 3rd extraction, TrEMBL database 
 
N SC Name 
Peptides 
(95%) 
1 79.5 Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7  100 
2 76.4 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5  117 
3 20.5 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1  7 
4 24.6 Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 SV=4  6 
5 24.7 Biglycan preproprotein variant (Fragment) OS=Homo sapiens PE=2 SV=1  4 
6 21.5 Vitronectin OS=Homo sapiens GN=VTN PE=2 SV=1  3 
7 36.9 Matrix Gla protein OS=Homo sapiens GN=MGP PE=1 SV=2  4 
8 12.2 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6  2 
9 73.1 
Collagen, type I, alpha 1, isoform CRA_a OS=Homo sapiens GN=COL1A1 PE=4 
SV=1  
78 
10 28.7 Chondroadherin OS=Homo sapiens GN=CHAD PE=2 SV=2  2 
11 17.8 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2  2 
12 74.8 Collagen alpha-1(II) chain OS=Homo sapiens GN=COL2A1 PE=1 SV=3  6 
13 18.5 
cDNA FLJ55606, highly similar to Alpha-2-HS-glycoprotein OS=Homo sapiens PE=2 
SV=1  
2 
14 9.5 Dermatopontin OS=Homo sapiens GN=DPT PE=2 SV=2  1 
15 20.7 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3  1 
16 8.8 
cDNA, FLJ93532, highly similar to Homo sapiens osteomodulin (OMD), mRNA 
OS=Homo sapiens PE=2 SV=1  
1 
17 61.5 Collagen alpha-2(V) chain OS=Homo sapiens GN=COL5A2 PE=1 SV=3  1 
18 18.5 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2  1 
19 5.6 Lumican variant (Fragment) OS=Homo sapiens PE=2 SV=1  1 
20 21.3 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5  3 
21 11.3 Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=2 SV=1  0 
22 20.8 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2  1 
 
Group 1: Collagen alpha-2(I) chain 
 
Sequence Modifications Cleavages Prec MW 
EGPVGLPGIDGR Oxidation(P)@7 cleaved R-P@C-term 1181.6 
EGPVGLPGIDGRPGPIGPAGAR Oxidation(P)@7; Oxidation(P)@15   2071.1 
GAAGLPGVAGAPGLPGPR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@17 
  1561.8 
GAPGAVGAPGPAGATGDR Oxidation(P)@3; Oxidation(P)@9   1509.7 
GAPGAVGAPGPAGATGDRGEAGAA
GPAGPAGPR 
Oxidation(P)@3; Oxidation(P)@9 missed R-G@18 2726.3 
GAPGPDGNNGAQGPPGPQGVQGGK 
Oxidation(P)@3; Deamidated(N)@9; 
Oxidation(P)@15 
  2146.0 
GAPGPHGPVGPAGK Oxidation(H)@6 
cleaved A-G@N-
term 
1213.6 
GDGGPPGMTGFPGAAGR 
Oxidation(P)@6; Oxidation(M)@8; 
Oxidation(P)@12 
  1548.7 
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GEAGAAGPAGPAGPR     1234.6 
GEIGAVGNAGPAGPAGPR Deamidated(N)@8   1547.8 
GENGVVGPTGPVGAAGPAGPNGPP
GPAGSR 
Deamidated(N)@3; 
Deamidated(N)@21; 
Oxidation(P)@24 
  2568.2 
GEPGNIGFPGPK Oxidation(P)@3; Oxidation(P)@9   1200.6 
GEPGSAGPQGPPGPSGEEGK Oxidation(P)@3; Oxidation(P)@12   1822.8 
GEQGPPGPPGFQGLPGPSGPAGEVG
KPGER 
Pro->pyro-Glu(P)@8; Pro->pyro-
Glu(P)@9; Oxidation(P)@20; 
Oxidation(P)@27 
  2869.3 
GESGNKGEPGSAGPQGPPGPSGEEG
K 
Deamidated(N)@5; Oxidation(P)@9; 
Oxidation(P)@18 
missed K-G@6 2396.0 
GESGNKGEPGSAGPQGPPGPSGEEG
KR 
Oxidation(P)@9; Oxidation(P)@18 
missed K-G@6; 
missed K-R@26 
2551.2 
GETGPSGPVGPAGAVGPR     1561.8 
GEVGLPGLSGPVGPPGNPGANGLTG
AK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@18; 
Deamidated(N)@21 
  2418.2 
GEVGPAGPNGFAGPAGAAGQPGAK 
Deamidated(N)@9; 
Deamidated(Q)@20; 
Oxidation(P)@21 
  2052.0 
GEVGPAGPNGFAGPAGAAGQPGAK
GER 
Deamidated(N)@9; 
Oxidation(P)@21; Oxidation(K)@24 
missed K-G@24 2409.1 
GFPGTPGLPGFK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
  1221.6 
GFPGTPGLPGFKGIR 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9; Carbamyl(K)@12 
missed K-G@12 1590.8 
GHNGLDGLK Deamidated(N)@3   910.4 
GHNGLQGLPGIAGHHGDQGAPGSV
GPAGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@21 
  2800.3 
GIPGPVGAAGATGAR Oxidation(P)@3   1266.6 
GLHGEFGLPGPAGPR Oxidation(P)@9   1476.7 
GLPGSPGNIGPAGK Oxidation(P)@3; Oxidation(P)@6   1252.6 
GLPGVAGAVGEPGPLGIAGPPGAR 
Oxidation(P)@3; Cation:K(E)@11; 
Oxidation(P)@12; Oxidation(P)@21 
  2152.1 
GLVGEPGPAGSK Oxidation(P)@6   1083.6 
GPAGPSGPAGKDGR Carbamyl(K)@11   1265.6 
GPNGDAGRPGEPGLMGPR 
Deamidated(N)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1766.8 
GPNGEAGSAGPPGPPGLR Oxidation(P)@12; Oxidation(P)@15   1618.8 
GPPGAAGAPGPQGFQGPAGEPGEPG
QTGPAGAR 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@21; Oxidation(P)@24 
  2958.4 
GPPGAVGSPGVNGAPGEAGR 
Oxidation(P)@9; 
Deamidated(N)@12; 
Oxidation(P)@15 
  1735.8 
GPPGESGAAGPTGPIGSR Oxidation(P)@3   1579.7 
GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFY 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@18; Oxidation(P)@20 
cleaved Y-R@C-term 3572.5 
GPQGHQGPAGPPGPPGPPGPPGVSG
GGYDFGYDGDFYR 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@17; Oxidation(P)@21 
  3728.6 
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GPSGEAGTAGPPGTPGPQGLLGAPG
ILGLPGSR 
Oxidation(P)@12; Oxidation(P)@17; 
Oxidation(P)@24; Oxidation(P)@30 
  2956.5 
GPSGPPGPDGNKGEPGVVGAVGTA
GPSGPSGLPGER 
Oxidation(P)@8; Oxidation(N)@11 missed K-G@12 3196.6 
GPSGPQGIR     867.5 
GPTGDPGKNGDKGHAGLAGAR Deamidated(N)@9 
missed K-N@8; 
missed K-G@12 
1932.9 
GSDGSVGPVGPAGPIGSAGPPGFPG
APGPK 
Oxidation(P)@21; Oxidation(P)@27   2572.2 
GSDGSVGPVGPAGPIGSAGPPGFPG
APGPKGEIGAVGNAGPAGPAGPR 
Biotin(K)@30; Deamidated(N)@38 missed K-G@30 4296.1 
GVGLGPGPMGLMGPR Oxidation(M)@9   1410.7 
GYPGNIGPVGAAGAPGPHGPVGPA
GK 
Oxidation(P)@3; Deamidated(N)@5; 
Oxidation(H)@18 
  2284.1 
HGNRGETGPSGPVGPAGAVGPR Deamidated(N)@3 missed R-G@4 2027.0 
LGAPGILGLPGSR Oxidation(P)@4; Oxidation(P)@10 cleaved L-L@N-term 1238.6 
PGNIGFPGPK Oxidation(P)@1; Oxidation(P)@7 cleaved E-P@N-term 1014.5 
PGPIGPAGAR   cleaved R-P@N-term 891.5 
PGSPGNIGPAGK Oxidation(P)@1; Oxidation(P)@4 cleaved L-P@N-term 1082.5 
PGTPGLPGFK 
Oxidation(P)@1; Oxidation(P)@4; 
Oxidation(P)@7 
cleaved F-P@N-term 1017.5 
RGPNGEAGSAGPPGPPGLR 
Deamidated(N)@4; 
Oxidation(P)@13; Oxidation(P)@16 
missed R-G@1 1775.9 
TGEVGAVGPPGFAGEK Oxidation(P)@10   1487.7 
TGHPGTVGPAGIR Oxidation(P)@4   1234.6 
TGPPGPSGISGPPGPPGPAGK 
Oxidation(P)@3; Oxidation(P)@4; 
Oxidation(P)@13; Oxidation(P)@16 
  1844.9 
 
Group 2: Collagen alpha-1(I) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAG
PPGADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.3 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPAGPKGEPGSPGENG
APGQMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
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GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEQGPSGASGPAGPR   
cleaved P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@9; 
Dioxidation(P)@18; Oxidation(P)@24 
  3099.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@11   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLPG
PIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
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PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
GLPGTAGLPGMKGHR 
Oxidation(P)@9; Oxidation(M)@11; 
Formyl(K)@12; Deamidated(R)@15 
missed K-G@12 1508.7 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
 
Group 4: Pigment epithelium-derived factor 
 
Sequence Modifications Cleavages Prec MW 
DTDTGALLFIGK     1249.6 
LAAAVSNFGYDLYR Deamidated(N)@7   1559.8 
TSLEDFYLDEER     1515.7 
TVQAVLTVPK     1054.6 
DTDTGALLFIGK     1249.7 
DTDTGALLFIGK Cation:Na(D)@3   1271.6 
LAAAVSNFGYDLYR     1560.8 
 
Group 5: Biglycan preproprotein variant (fragment) 
 
Sequence Modifications Cleavages Prec MW 
LGLGHNQIR Deamidated(N)@6   1007.6 
PLENSGFEPGAFDGLK Deamidated(N)@4 cleaved N-P@N-term 1677.8 
PVPYWEVQPATFR   cleaved N-P@N-term 1588.8 
VPSGLPDLK     924.5 
VPSGLPDLK     924.5 
VPSGLPDLK     924.5 
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Group 6: Vitronectin 
 
Sequence Modifications Cleavages Prec MW 
DVWGIEGPIDAAFTR     1645.8 
FEDGVLDPDYPR     1421.6 
RVDTVDPPYPR   missed R-V@1 1313.7 
FEDGVLDPDYPR     1421.7 
FEDGVLDPDYPR     1421.6 
 
Group 7: Matrix Gla protein 
 
Sequence Modifications Cleavages Prec MW 
RNANTFISPQQR Deamidated(N)@2; Deamidated(N)@4 missed R-N@1 1432.7 
YAMVYGYNAAYNR Deamidated(N)@8; Deamidated(N)@12   1556.7 
NANTFISPQQR Deamidated(N)@1; Deamidated(N)@3   1276.6 
YAMVYGYNAAYNR 
Oxidation(M)@3; Deamidated(N)@8; 
Deamidated(N)@12 
  1572.7 
 
Group 9: Collagen, type I, alpha 1, isoform CRA 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGEAGAQGPPGPAGPAGE
R 
    1689.8 
DGEAGAQGPPGPAGPAGE
R 
Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
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DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAG
PPGADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.3 
GAPGERGETGPPGPAGFAG
PPGADGQPGAK 
Pro->pyro-Glu(P)@3; 
Oxidation(P)@12; Oxidation(P)@21; 
Oxidation(P)@27 
missed R-G@6 2718.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Dioxidation(P)@9; 
Deamidated(Q)@12; Oxidation(P)@15; 
Dioxidation(M)@20 
  2215.0 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Dioxidation(P)@6; Oxidation(P)@18; 
Deamidated(Q)@23; Oxidation(P)@24 
  2316.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
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GEPGPPGPAGFAGPPGADG
QPGAK 
Dioxidation(P)@6; Oxidation(P)@15; 
Deamidated(Q)@20; Oxidation(P)@21 
  2150.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Dioxidation(M)@15 
  1758.7 
GEQGPSGASGPAGPR   
cleaved P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.1 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@15   2152.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Cation:Na(E)@2; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@18 
  2190.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3; Cation:K(D)@6   1125.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFSGLDGAK     850.4 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.3 
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GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Acetyl(S)@3; Carboxy(E)@17   2742.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12   2688.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Cation:K(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Oxidation(P)@3; Dioxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Dioxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3099.4 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@9; 
Dioxidation(P)@18; Oxidation(P)@24 
  3099.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(D)@17; Oxidation(K)@18; 
Cation:Na(E)@20 
missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Delta:H(2)C(2)@N-term; 
Carboxy(D)@17 
missed K-G@18 2906.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@11   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
608 
 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Dioxidation(P)@3; 
Deamidated(N)@15; Oxidation(P)@18; 
Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Dioxidation(P)@18; 
Dioxidation(P)@23 
  2470.2 
GPSGPQGPGGPPGPK Oxidation(P)@12; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@2; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
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GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@15; Dioxidation(P)@19 
  2057.0 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GESGPSGPAGPTGAR     1296.6 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPSGLAGPKGANGDPGRP
GEPGLPGAR 
Oxidation(N)@12; Cation:Na(D)@14; 
Oxidation(P)@15 
missed K-G@9 2492.2 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Dioxidation(P)@12 
  1561.8 
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GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFSGLDGAK     850.4 
GLPGTAGLPGMKGHR 
Oxidation(P)@9; Oxidation(M)@11; 
Formyl(K)@12; Deamidated(R)@15 
missed K-G@12 1508.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@8   1327.6 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
 
Group 10: Chondroadherin 
 
Sequence Modifications Cleavages Prec MW 
FSDGAFLGVTTLK     1350.7 
SIPDNAFQSFGR Deamidated(N)@5   1338.6 
FSDGAFLGVTTLK     1354.7 
FSDGAFLGVTTLK     1354.7 
FSDGAFLGVTTLK     1354.7 
SIPDNAFQSFGR Deamidated(N)@5   1338.6 
 
Group 11: Prothrombin 
 
Sequence Modifications Cleavages Prec MW 
ELLESYIDGR     1193.6 
ETAASLLQAGYK     1250.6 
ELLESYIDGR     1193.6 
ELLESYIDGR     1193.6 
 
Group 12: Collagen alpha-1 (II) chain 
 
Sequence Modifications Cleavages Prec MW 
DGEAGAQGPPGPAGPAGE
R 
    1689.8 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Oxidation(P)@10   1705.8 
DGEAGAQGPPGPAGPAGE
R 
Deamidated(Q)@7; Oxidation(P)@10   1706.8 
DGEAGAQGPPGPAGPAGE
R 
Cation:K(E)@3; Oxidation(P)@10   1743.7 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
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DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@15 
  1545.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@15 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.8 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@12; Oxidation(P)@13 
  1561.7 
GAAGLPGPK Oxidation(P)@6   782.4 
GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GANGAPGIAGAPGFPGAR 
Oxidation(P)@6; Oxidation(P)@12; 
Oxidation(P)@15 
  1584.8 
GAPGDRGEPGPPGPAGFAG
PPGADGQPGAK 
Oxidation(D)@5; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@21 
missed R-G@6 2702.3 
GAPGERGETGPPGPAGFAG
PPGADGQPGAK 
Pro->pyro-Glu(P)@3; 
Oxidation(P)@12; Oxidation(P)@21; 
Oxidation(P)@27 
missed R-G@6 2718.2 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Dioxidation(M)@20 
  2214.0 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Dioxidation(P)@9; 
Deamidated(Q)@12; Oxidation(P)@15; 
Dioxidation(M)@20 
  2215.0 
GDAGAPGAPGSQGAPGLQ
GMPGER 
Oxidation(P)@6; Oxidation(P)@9; 
Oxidation(P)@15; Oxidation(P)@21 
  2198.0 
GDAGPAGPKGEPGSPGEN
GAPGQMGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Deamidated(N)@18; 
Dioxidation(M)@24 
missed K-G@9 2509.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Cation:K(D)@2; Oxidation(P)@11; 
Oxidation(P)@15; Oxidation(P)@24 
  2318.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Oxidation(P)@24 
  2280.1 
GDAGPPGPAGPAGPPGPIG
NVGAPGAK 
Oxidation(P)@6; Oxidation(P)@15; 
Deamidated(N)@20; Oxidation(P)@24 
  2281.1 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@18 missed R-G@3 2480.2 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@18; Oxidation(P)@21 
missed R-G@3 2512.2 
GDRGETGPAGPPGAPGAPG
APGPVGPAGK 
Oxidation(P)@12; Oxidation(P)@15; 
Oxidation(P)@21 
missed R-G@3 2496.2 
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GEAGRPGEAGLPGAK Oxidation(P)@6; Oxidation(P)@12 
cleaved P-G@N-
term 
1397.7 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Dioxidation(P)@6; Oxidation(P)@18; 
Deamidated(Q)@23; Oxidation(P)@24 
  2316.0 
GEPGPPGPAGAAGPAGNPG
ADGQPGAK 
Oxidation(P)@3; Oxidation(P)@8; 
Oxidation(P)@18; Oxidation(P)@24 
  2315.1 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15; Deamidated(Q)@20 
  2134.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Dioxidation(P)@6; Oxidation(P)@15; 
Deamidated(Q)@20; Oxidation(P)@21 
  2150.0 
GEPGPPGPAGFAGPPGADG
QPGAK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@15 
  2133.0 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPTGLPGPPGER 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@12 
  1464.7 
GEPGPVGVQGPPGPAGEEG
K 
Oxidation(P)@3; Oxidation(P)@12   1846.9 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Deamidated(Q)@9; 
Oxidation(P)@12 
missed K-R@20 2004.0 
GEPGPVGVQGPPGPAGEEG
KR 
Oxidation(P)@3; Oxidation(P)@12 missed K-R@20 2003.0 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; 
Dioxidation(M)@15 
  1758.7 
GEPGSPGENGAPGQMGPR 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@12 
  1742.7 
GEQGPSGASGPAGPR   
cleaved P-G@N-
term 
1323.6 
GESGPSGPAGPTGAR     1296.6 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPAGPVGPVGAR     1545.8 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@18 
  2168.1 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Cation:Na(E)@2; Oxidation(P)@9; 
Oxidation(P)@12; Oxidation(P)@18 
  2190.0 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Oxidation(P)@18 
  2184.1 
GETGPAGPPGAPGAPGAPG
PVGPAGK 
Oxidation(P)@9; Oxidation(P)@15   2152.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.0 
GETGPAGRPGEVGPPGPPG
PAGEK 
Oxidation(P)@9; Oxidation(P)@15; 
Oxidation(P)@18 
  2215.1 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3   1087.5 
GFPGADGVAGPK Oxidation(P)@3; Cation:K(D)@6   1125.5 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@6   1327.6 
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GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFPGLPGPSGEPGK Oxidation(P)@6   1311.6 
GFSGLDGAK Dehydrated(S)@3   832.4 
GFSGLDGAK     850.4 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@11; Oxidation(P)@12   2688.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@18 
  2705.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@12; Oxidation(P)@15; 
Cation:K(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15; Cation:Na(E)@17 
  2726.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Acetyl(S)@3; Carboxy(E)@17   2742.2 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@15   2688.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Oxidation(P)@12; 
Oxidation(P)@15 
  2704.3 
GFSGLQGPPGPPGSPGEQG
PSGASGPAGPR 
Oxidation(P)@9; Cation:K(E)@17   2710.2 
GLPGPPGAPGPQGF 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@9 
cleaved F-Q@C-
term 
1295.6 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Dioxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3099.4 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Dioxidation(P)@5; Oxidation(P)@9; 
Dioxidation(P)@18; Oxidation(P)@24 
  3099.4 
GLPGPPGAPGPQGFQGPPG
EPGEPGASGPMGPR 
Oxidation(P)@3; Dioxidation(P)@11; 
Oxidation(P)@21; Oxidation(P)@24 
  3083.4 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9; Oxidation(P)@15   1589.8 
GLTGPIGPPGPAGAPGDK Oxidation(P)@9   1573.8 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11; Oxidation(P)@15 missed K-G@18 2868.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(D)@17; Oxidation(K)@18; 
Cation:Na(E)@20 
missed K-G@18 2890.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@11 missed K-G@18 2852.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Oxidation(P)@15; Lys-
>Hydroxyallysine(K)@18 
missed K-G@18 2867.4 
GLTGPIGPPGPAGAPGDKG
ESGPSGPAGPTGAR 
Delta:H(2)C(2)@N-term; 
Carboxy(D)@17 
missed K-G@18 2906.4 
GLTGSPGSPGPDGK Oxidation(P)@6; Oxidation(P)@11   1257.6 
GNDGATGAAGPPGPTGPA
GPPGFPGAVGAK 
Oxidation(P)@14; Oxidation(P)@21; 
Oxidation(P)@24 
  2547.2 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@15   1815.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.9 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@15 
  1831.8 
GPPGPMGPPGLAGPPGESG Oxidation(P)@3; Oxidation(M)@6   1815.9 
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R 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1831.9 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGPPGKNGDDGEAGKP
GRPGER 
Oxidation(P)@3; Oxidation(P)@6; 
Deamidated(N)@9; Oxidation(P)@18 
missed K-N@8 2347.1 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Dioxidation(P)@3; 
Deamidated(N)@15; Oxidation(P)@18; 
Dioxidation(P)@24 
  2470.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Dioxidation(P)@18; 
Dioxidation(P)@23 
  2470.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPPGSAGAPGKDGLNGLP
GPIGPPGPR 
Oxidation(P)@3; Deamidated(N)@15; 
Oxidation(P)@18; Dioxidation(P)@23 
  2454.2 
GPSGPQGPGGPPGPK Deamidated(Q)@6; Oxidation(P)@12   1302.6 
GPSGPQGPGGPPGPK Oxidation(P)@12; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@2; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@14   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@8; Oxidation(P)@12   1317.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GPSGPQGPGGPPGPK Oxidation(P)@12   1301.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Oxidation(M)@6; Oxidation(P)@9   1176.6 
GQAGVMGFPGPK Oxidation(P)@11   1160.6 
GQAGVMGFPGPK Deamidated(Q)@2; Oxidation(M)@6   1161.6 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSAGPPGATGFPGAAGR Oxidation(P)@6; Oxidation(P)@12   1458.7 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12; Deamidated(Q)@23   2089.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Deamidated(Q)@23 
  2105.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@12   2088.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15 
  2120.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12   2104.0 
GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Cation:Na(D)@6; 
Oxidation(P)@12 
  2126.0 
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GSPGADGPAGAPGTPGPQG
IAGQR 
Oxidation(P)@3; Oxidation(P)@12; 
Oxidation(P)@15; Deamidated(Q)@23 
  2121.0 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GSPGEAGRPGEAGLPGAK 
Oxidation(P)@3; Oxidation(P)@9; 
Oxidation(P)@15 
  1654.8 
GVPGPPGAVGPAGK Oxidation(P)@3   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@6   1175.6 
GVPGPPGAVGPAGK Oxidation(P)@3; Oxidation(P)@6   1191.6 
GVQGPPGPAGPR Deamidated(Q)@3; Oxidation(P)@6   1105.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVQGPPGPAGPR Oxidation(P)@6   1104.6 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6   897.5 
GVVGLPGQR Oxidation(P)@6; Deamidated(Q)@8   898.5 
PGADGVAGPK Oxidation(P)@1 
cleaved F-P@N-
term 
883.4 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEAGRPGEAGLPGAK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@13 
cleaved S-P@N-
term 
1510.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGEVGPPGPPGPAGEK 
Oxidation(P)@1; Oxidation(P)@7; 
Oxidation(P)@10 
cleaved R-P@N-
term 
1489.7 
PGPPGAVGPAGK Oxidation(P)@1; Oxidation(P)@4 
cleaved V-P@N-
term 
1035.5 
PGPVGVQGPPGPAGEEGKR Oxidation(P)@1; Oxidation(P)@10 
cleaved E-P@N-
term; missed K-
R@18 
1816.9 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
SGDRGETGPAGPAGPVGPV
GAR 
  missed R-G@4 1961.0 
STGGISVPGPMGPSGPR     1552.8 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Deamidated(Q)@9; 
Oxidation(P)@15; Dioxidation(P)@19 
  2057.0 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
TGPPGPAGQDGRPGPPGPP
GAR 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16; Oxidation(P)@19 
  2056.0 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Deamidated(N)@9; 
Oxidation(P)@13; Oxidation(P)@16 
  1812.9 
VGPPGPSGNAGPPGPPGPA
GK 
Oxidation(P)@4; Oxidation(P)@13; 
Oxidation(P)@16 
  1811.9 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Oxidation(P)@13; Oxidation(P)@15 
  1561.8 
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GANGAPGIAGAPGFPGAR 
Deamidated(N)@3; Oxidation(P)@6; 
Oxidation(P)@12; Oxidation(P)@15 
  1585.8 
GESGPSGPAGPTGAR     1296.6 
GPPGPMGPPGLAGPPGESG
R 
Oxidation(P)@3; Oxidation(M)@6; 
Oxidation(P)@9; Oxidation(P)@15 
  1847.8 
GPSGLAGPKGANGDPGRP
GEPGLPGAR 
Oxidation(N)@12; Cation:Na(D)@14; 
Oxidation(P)@15 
missed K-G@9 2492.2 
DGLNGLPGPIGPPGPR 
Deamidated(N)@4; Oxidation(P)@7; 
Dioxidation(P)@12 
  1561.8 
GFPGLPGPSGEPGK 
Oxidation(P)@3; Oxidation(P)@6; 
Oxidation(P)@12 
  1343.6 
GFSGLDGAK     850.4 
GLPGTAGLPGMKGHR 
Oxidation(P)@9; Oxidation(M)@11; 
Formyl(K)@12; Deamidated(R)@15 
missed K-G@12 1508.7 
GFPGLPGPSGEPGK Oxidation(P)@3; Oxidation(P)@8   1327.6 
GISVPGPMGPSGPR Oxidation(M)@8 
cleaved G-G@N-
term 
1323.7 
 
Group 13: cDNA FLJ55606, highly similar to Alpha-2-HS-glycoprotein 
 
Sequence Modifications Cleavages Prec MW 
HTLNQIDEVK Deamidated(N)@4   1196.6 
SNFQLEEISR Deamidated(N)@2; Deamidated(Q)@4 cleaved G-S@N-term 1223.6 
HTLNQIDEVK Deamidated(N)@4   1196.6 
 
Group 14: Dermatopontin 
 
Sequence Modifications Cleavages Prec MW 
GATTTFSAVER     1138.6 
 
Group 16: cDNA, FLJ93532, highly similar to Homo sapiens osteomodulin 
 
Sequence Modifications Cleavages Prec MW 
LLLGYNEISK Deamidated(N)@6   1149.6 
LLLGYNEISK Deamidated(N)@6   1149.6 
 
Group 17: Collagen alpha-1 (XII) chain 
 
Sequence Modifications Cleavages Prec MW 
PLGAPGEDGRPGPPGSIGIR   cleaved G-P@N-term 1898.9 
 
Group 19: Lumican variant (fragment) 
 
Sequence Modifications Cleavages Prec MW 
FNALQYLR Deamidated(N)@2   1024.5 
 
